<SEC-DOCUMENT>0001104659-21-098238.txt : 20210730
<SEC-HEADER>0001104659-21-098238.hdr.sgml : 20210730
<ACCEPTANCE-DATETIME>20210730160613
ACCESSION NUMBER:		0001104659-21-098238
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20210730
DATE AS OF CHANGE:		20210730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAXCYTE, INC.
		CENTRAL INDEX KEY:			0001287098
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				522210438
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257810
		FILM NUMBER:		211132575

	BUSINESS ADDRESS:	
		STREET 1:		22 FIRSTFIELD ROAD
		STREET 2:		SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		301-517-5556

	MAIL ADDRESS:	
		STREET 1:		22 FIRSTFIELD ROAD
		STREET 2:		SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MAXCYTE INC
		DATE OF NAME CHANGE:	20040415
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>tm2113965-12_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<html>
  <head>
    <title>tm2113965-12_424b4 - block - 30.3126561s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">

          <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">&#8202;Filed Pursuant to Rule 424(b)4</font>&#8203;</div>


          <div style="text-align:right; width:456pt; line-height:10pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">&#8202;Registration Statement No. 333-257810</font>&#8203;</div>


          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-size:14pt;">
            <font style="letter-spacing:-0.035pt;">13,500,000 Shares</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
          </div>

        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lg_maxcyte-4c.jpg" alt="[MISSING IMAGE: lg_maxcyte-4c.jpg]" height="45" width="304" >
        </div>
        <div style="margin-top:11pt; text-align:center; width:456pt; line-height:16pt;font-size:14pt;">
          <font style="letter-spacing:-0.035pt;">COMMON STOCK</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:17.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:10pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">This is the U.S. initial public offering of shares of common stock of MaxCyte, Inc. We are offering 13,500,000 shares of our common stock at a public offering price of $13.00 per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for our common stock in the United States. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#8220;MXCT.&#8221; Our common stock trades on AIM, a market operated by the London Stock Exchange, under the symbols &#8220;MXCT&#8221; and &#8220;MXCN.&#8221; We will apply to list the shares of common stock being offered by this prospectus on the AIM market. The last reported sale price of our common stock on the AIM market on July&#160;29, 2021 was &#163;9.40 per share, or approximately $13.12 per share based on the last reported exchange rate for British pounds sterling of &#163;1.00 = $1.3959 on July&#160;29, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:13pt;font-weight:bold;font-size:11pt;">
          <font style="letter-spacing:-0.122pt;">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; beginning on page </font><font style="letter-spacing:-0.1221pt;"><a href="#tRIFA">12</a></font><font style="letter-spacing:-0.122pt;"> to read about factors you should consider before buying our common stock.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.22pt;"> </font>
        </div>
        <div style="margin-top:16.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <table style="width:456pt;height:53.5pt;margin-top:7.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:343.82pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Per Share </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:343.82pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Public offering price </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">13.00 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">175,500,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:343.82pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">0.91 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">12,285,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:343.82pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Proceeds, before expenses, to MaxCyte, Inc. </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">12.09 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">163,215,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">See the section titled &#8220;Underwriting&#8221; for additional information regarding compensation payable to the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have granted the underwriters an option for a period of 30&#160;days from the date of this prospectus to purchase up to an additional 2,025,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The underwriters expect to deliver the shares of common stock to purchasers on or about August 3, 2021.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Joint Book-Running Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:6pt; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.178pt;">Cowen </font><font style="margin-left:107.75pt;letter-spacing:-0.178pt;">&#8199;&#8199;&#8199;&#8199;&#8199;Stifel </font><font style="float:right;letter-spacing:-0.178pt;">William Blair</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Co-Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:6pt; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.155pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;BTIG </font><font style="float:right;"><font style="letter-spacing:-0.155pt;">Stephens Inc.&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
          </font>
        </div>
        <div style="margin-top:17.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:10pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Prospectus dated July 29, 2021.</font>
          </div>

      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:365.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:435.94pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:-0.025pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tPRSU">1</a></font> <a href="#tPRSU"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:-0.025pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tRIFA">12</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:-0.025pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSNRF">52</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMIAO"><font style="letter-spacing:-0.025pt;">MARKET, INDUSTRY AND OTHER DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMIAO">54</a></font> <a href="#tMIAO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:-0.025pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tUOP">55</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:-0.025pt;">DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDIPO">56</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:-0.025pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCAP">57</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:-0.025pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDIL">58</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSCFD"><font style="letter-spacing:-0.025pt;">SELECTED CONSOLIDATED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSCFD">60</a></font> <a href="#tSCFD"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:435.94pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:-0.025pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMDAA">61</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:-0.025pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tBUS">83</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:-0.025pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMAN">114</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:-0.025pt;">EXECUTIVE COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tEXCO">121</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:-0.025pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCRAR">134</a></font> <a href="#tCRAR"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRST"><font style="letter-spacing:-0.025pt;">PRINCIPAL STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tPRST">136</a></font> <a href="#tPRST"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:-0.025pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tDOCS">138</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEFF"><font style="letter-spacing:-0.025pt;">SHARES ELIGIBLE FOR FUTURE SALE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tSEFF">142</a></font> <a href="#tSEFF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:-0.025pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tMUFI">144</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUND"><font style="letter-spacing:-0.025pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tUND">148</a></font> <a href="#tUND"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:-0.025pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tLEMA">155</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:-0.025pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tEXP">155</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:-0.025pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tWYCF">155</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:435.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fIFS"><font style="letter-spacing:-0.025pt;">INDEX TO FINANCIAL STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fIFS">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:1.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 36.842%; margin-right: 36.842%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:19pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">None of us or any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. None of us nor any of the underwriters take responsibility for, or can provide any assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only under circumstances and in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For investors outside the United States: None of us or any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering and the possession and distribution of this prospectus outside of the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Any discrepancies included in this prospectus between totals and the sums of the percentages and dollar amounts presented are due to rounding.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.111pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;font-style:italic;">This summary highlights selected information included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections titled &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business,&#8221; and our financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless the context otherwise requires, all references in this prospectus to &#8220;MaxCyte,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to MaxCyte, Inc. and its consolidated subsidiary.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Our Mission</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We believe in the vast potential of next-generation cell therapies to have a meaningful impact on the millions of patients worldwide who, despite medical advancement, live with unmet medical needs across a variety of diseases. Our aim is to be the premier cell engineering platform technology to support the development of advanced therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have sought to leverage or repurpose cell functions and/or machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has led to a revolution in biological research and resulted in numerous biological discoveries. Living human cells can also be engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">, or outside the body, where they are repaired or reprogrammed to fight disease. In this case, the engineered cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. Over the past few&#160;years, the success of multiple U.S. Food and Drug Administration, or FDA, approved cell therapies providing long-lasting amelioration of symptoms or presence of disease has catalyzed tremendous investment&#8201;&#8212;&#8201;leading to exponential growth in cell-based therapies being evaluated for therapeutic applications. According to the Alliance for Regenerative Medicine, the combination of gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the American Society of Gene and Cell Therapy, or ASGCT, there are now more than 3,400 gene, cell and RNA therapies in development globally, with gene therapy including genetically-modified chimeric antigen receptor T cells, or CAR-Ts, accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; portfolio of proprietary related processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of June&#160;30, 2021, we have placed more than 400 of our electroporation instruments worldwide. During the year ended December 31, 2020, we sold a total of 70 instruments and leased an additional 16 instruments to our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We believe our ExPERT platform offers a compelling value proposition to our academic and biopharmaceutical customers due to: (i)&#160;the ability to use our technology to deliver almost any molecule into almost any cell type, including hard-to-transfect human primary cells, while maintaining high cell viability and function; (ii)&#160;the capacity to introduce larger and more diverse payloads compared to other intracellular delivery technologies, such as viral vectors; and (iii)&#160;the flexibility to scale up from research to current good manufacturing practices, or cGMP, manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform is being used in the clinic to support the development of next-generation cell therapy approaches to treat human disease. Following the successful clinical development leading to FDA approvals of CAR-T cell therapies in blood-based cancer, developers have focused on improving efficacy, lowering the cost of manufacturing and/or expanding engineered cell therapies into new indications, such as solid tumors. To address these goals, the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy industry has trended towards developing more complex therapies that require sophisticated engineering and gene manipulation as well as the use of different starting cell types.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We believe we are well positioned in this market given the manufacturing supply constraints and payload size limitations of other delivery methods, such as viral vectors. Given our value proposition in non-viral delivery, we have established strategic relationships in the form of Strategic Platform Licenses, or SPLs, with a growing number of leading cell therapy developers as they work to bring next-generation cell therapies into and through the clinic and advance those candidates to potential commercialization. These SPLs provide us with the ability to secure downstream program-related pre-commercial milestones and, in most cases, commercial sales-based payments. In addition, from our SPL customers, we receive both annual research and clinical license fees as well as payments from sales of our proprietary disposables as recurring revenue streams.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have entered into 13 SPLs with commercial cell therapy developers, which include: CRISPR/</font>&#8203;<font style="letter-spacing:-0.025pt;">Casebia Therapeutics; CRISPR Therapeutics; Kite Pharma (now Gilead); Precision Biosciences; Editas Medicine; VOR Biopharma; KSQ; Allogene Therapeutics; Caribou Biosciences; Apeiron Biologics; Celularity; and Myeloid Therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">In addition to SPLs, we provide some customers, which could be academic institutions or commercial entities, with access to our instruments through licenses for research-only purposes, without the rights or ability to produce material for clinical use, or for use in the clinical evaluation and development of a therapeutic product intended for human use. We refer to these agreements as research licenses and clinical licenses, respectively. When referring to clinical agreements we sometimes include SPLs along with the clinical licenses, as the licenses granted cover ongoing or contemplated future clinical development programs being conducted by our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Under these SPLs and other license agreements with our customers, in exchange for an annual license fee per instrument, we provide our customers with non-exclusive access to our:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">cGMP-compatible platform, which enables early-optimization and scale-up from preclinical research into clinical development using our intellectual property portfolio;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">FDA Master File and equivalent foreign Technical Files, which may accelerate and streamline development and reduce regulatory risk in the creation and development of our partners&#8217; therapeutic drug candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">experienced commercial team of sales personnel and application scientists who work directly with our customers to solve cell engineering problems; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">continuous know-how and cell engineering process improvements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Of the over 75 clinical program licenses associated with our existing SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared investigational new drug application, or IND. Our 13 SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments if all of the licensed programs were to achieve regulatory approvals. In addition, under the SPLs, we typically have the potential to receive significant, sales-based commercial payments for approved products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">For the year ended December 31, 2020, one cell therapy company with which we have entered in to an SPL accounted for 15% of our total revenue, and our six largest SPL customers accounted for an aggregate of approximately 40% of our total revenue for the year through a combination of instrument license fees, milestones realized and processing assembly revenue.</font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our current strategic partners have demonstrated success progressing next-generation cell therapies through the clinic, which has provided growing validation supporting our ability to facilitate complex cell engineering in a clinical setting. Further, our platform is supported by an FDA Master File. A Master File is a submission to the FDA with confidential detailed information about our products, methods, processes and data, which can be referenced by our customers to support their own regulatory filings, which we believe has the potential to reduce certain risks and challenges in connection with our customers&#8217; regulatory submissions and development timelines. Outside of the United States, similar Technical Files are in place or being pursued to support our customers&#8217; regulatory processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We aim to build a large, diversified portfolio of SPLs that enable us to participate in the economics of the near-term and long-term success of our partners&#8217; drug candidates. We estimate that the total addressable market opportunity for our ExPERT platform, based on the potential for current SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies as described in more detail under &#8220;Business&#8201;&#8212;&#8201;Our Market Opportunity.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Our Competitive Strengths</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">We believe our industry leadership position and continued growth will be driven by the following competitive strengths:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Our proprietary technology platform unlocks the significant potential of advanced therapeutics</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We have built our ExPERT platform to advance the growing demands for non-viral delivery and next-generation cell and gene engineering approaches. Our platform technology enables delivery of almost any molecule into almost any cell type. We believe our platform leads the industry in performance (measured by consistency, efficiency, viability, flexibility and scale). Our platform is further supported by a robust intellectual property portfolio with 50 issued patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Comprehensive, high-performance transfection platform</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We believe our ExPERT platform offers a unique value proposition given the flexibility to scale up from research to cGMP manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less. Our long-term internal engineering expertise is supplemented by our customer focused approach&#8201;&#8212;&#8201;with a growing application scientist team working with our customers across increasingly diverse applications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Positioned as a leader in the large and growing next-generation cell therapy market with the ability to capitalize on rising demand for non-viral approaches.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We believe we are well positioned to capture increased market share within the large and growing next- generation cell therapy market. Since the FDA approved the first engineered CAR-T cell therapies to treat cancer in 2017, the number of cell therapy candidates being evaluated pre-clinically and clinically has grown exponentially. We expect growth to continue given the remaining high unmet medical need in cancer and other chronic conditions and predict increased investments in cell therapy product development across a variety of human diseases. We expect to grow our market share given the high performance of our platform and regulatory support through our FDA Master File as well as the ongoing shift to non-viral delivery as the industry has trended towards developing advanced cell-based therapies with complex engineering strategies to improve efficacy, reduce time to patient treatment and expand into new indications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Innovative partnership business model focused on value creation and shared success</font><font style="letter-spacing:-0.025pt;">. Our SPLs allow us to participate in the value creation of our customers&#8217; programs via pre-commercial milestones and in nearly all cases commercial sales-based payments. We intend to continue to build a portfolio of strategic partnerships with cell therapy developers, which provide us with a growing, diversified source of potential downstream revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">In addition to the high performance and flexibility of the ExPERT platform, we believe our partnership model further reduces clinical risk and development timelines for our cell therapy partners. By entering into an SPL with us, for example, our partners gain access to our FDA Master File to support their IND-enabling studies and potentially shorten clinical development. Our FDA Master File was originally established in 2002 and has been continuously updated as platform improvements are implemented to support different applications and cell types. The FDA Master File and equivalent Technical Files in other countries can be referenced by our partners to support their own regulatory submissions with the goal of accelerating regulatory submissions processes for our partners. To date, our FDA Master File and Technical Files have been referenced by our customers in over 30 clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">First-mover advantage has yielded broad-based adoption, with commercial model supported by top-tier customers.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model is supported by more than 20&#160;years of investment and experience and has enabled us to cultivate long-standing and collaborative relationships with our significant and growing customer base. From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base includes large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue. We now have 13 SPLs with commercial cell therapy developers, which together provide licenses for over 75 programs, of which currently more than 15% have advanced into clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Recurring revenue model provides high visibility, with drivers of potential long-term upside.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model enables us to generate substantial revenue from five sources: sales of instruments and disposables to new customers; additional sales of instruments and disposables to our existing installed base; annual instrument license fees from cell therapy customers; pre-commercial milestones under SPLs; and future potential commercial sales-based payments under SPLs. We generate high recurring revenue from our ExPERT instrumentation licenses and disposable sales, which provides visibility into future near-term revenue. Over the last three&#160;years, annual renewals of instrument licenses were greater than 80% on average&#8201;&#8212;&#8201;and for our SPLs were near 100%. In addition to recurring revenue, we have the potential to receive meaningful pre-commercial and commercial payments under SPLs if our customers are successful in advancing programs through the clinic and into the commercial stage. In aggregate, we have the potential to receive over $950&#160;million in pre-commercial milestone payments under our current SPLs, if all of the covered programs were to receive regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Founder-led leadership team and workforce with deep domain knowledge.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our management team combines strong and broad subject matter expertise with a demonstrated history of commercial and operational execution. Moreover, our workforce has deep domain knowledge across a range of scientific, engineering, regulatory and business disciplines. We have supplemented our diverse technical experience by assembling a deep operational team with expertise in manufacturing, legal, sales, marketing, customer service and finance. We believe the team we have assembled with talent from multiple disciplines and a science- and customer-focused culture represents a significant competitive advantage for us. As of March 31, 2021, of our 65 full-time employees, 45 have advanced degrees, including 19 with Ph.D. degrees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Our Growth Strategies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The key elements of our growth strategy include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Establish ExPERT as the standard of non-viral delivery technology in the rapidly growing cell therapy market</font><font style="font-weight:bold;letter-spacing:-0.111pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We are committed to continued investment in technology and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">scientific innovation to maintain our market leadership position. We believe that the adaptability of, and continuous improvement in, our single-use disposable product portfolio via recent product launches exemplifies our partnership with our customers to meet varying processing volume requirements, for example. We plan to further invest in our current platform and potentially introduce new instruments and processing assemblies, or PAs, that allow us to meet the evolving needs of customers and move into new applications to better serve high-growth segments of the cell therapy market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Drive customer adoption and accelerate revenue growth through execution and expansion of our strategic marketing initiatives.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We aim to accelerate our revenue growth by investing in our sales and application scientist teams to fuel growth in our underlying ExPERT platform and foster and develop new customer and SPL opportunities. We also see opportunity for geographic expansion, particularly in Asia, and the potential to further penetrate non-commercial customer accounts, including translational academic centers globally, which we believe will represent &#8220;hotspots&#8221; driving innovation that favor non-viral extracellular delivery technology. Finally, we expect to continue to cultivate academic collaborations and grow our application scientist team to gain exposure to and experience with up and coming cell and gene engineering approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Increase our number of SPLs.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We plan to continue to pursue SPLs with target customers, including leading biopharmaceutical companies focused on cell therapies. We believe that there are a substantial number of potential SPL opportunities in the market and have seen a commensurate increase in our SPL discussions over the past several&#160;years. Given growth in the cell therapy pipeline and increased investment in the space, we estimate that the number of potential SPLs for us will increase from approximately 50 today, based on our estimate of the companies that are currently developing engineered cell therapies, to almost 140 by 2026, based on our estimates of growth in the cell therapy pipeline, growth in the number of therapeutic delivery entrants into the market and ongoing shift to non-viral delivery. We plan to aggressively pursue these opportunities and establish new SPLs by increasing business development activities and demonstrating our technological advantages over alternative methods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Commercialize our VLX Large-Scale Transfection System under the ExPERT brand to expand our capabilities into additional attractive market verticals, including large-scale bioprocessing and cell therapy applications.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our VLX Large-Scale Transfection System provides the ability to transfect up to approximately 200&#160;billion cells, or ten times the number of cells and/or volume of the GTx/STx, in less than 30 minutes. The VLX has been sold to a limited number of customers for specific large-scale applications in a first generation design. We plan to align the current design of the VLX with the design, capabilities and branding of our ExPERT instruments, as well as make specific product enhancements that would be unique to the VLX. As part of this initiative, the VLX will be rebranded under the ExPERT brand as the &#8220;VLx.&#8221; We believe that improving the design of the VLX and commercializing it under the ExPERT brand with an updated state-of-the art design, adding an on-board user interface, and developing associated cGMP compatible large-scale disposables and software protocols, would allow us to enter into large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins, including monoclonal antibodies&#8201;&#8212;&#8201;as well as facilitate further scale up in allogeneic (or donor-derived) cell therapy approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Enhance manufacturing and research and development capabilities by investing in capacity as well as automation and process development.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We intend to expand our manufacturing infrastructure. We plan to invest in our capacity to support increased demand for our instruments and disposables as our customers move further through the clinic and toward commercialization. We also plan to invest in the automation and final assembly of our PAs for greater control and for enhanced flexibility as our partners expand the use of our technology. Additionally, we plan to expand our research and development capabilities by investing in process development via expanding laboratory space, increasing capital investment in laboratory equipment and supplies and growing our scientific team&#8201;&#8212;&#8201;to continue to align our capabilities with the requirements of our customers and potentially support new product development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:0.970000000000027pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-style:italic;font-weight:bold;">Opportunistically pursue strategic investments, partnerships and acquisitions.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our revenue growth to date has been organically driven by the addition of customers to our growing installed base of ExPERT users and expansion of our product offerings to those customers. We may consider opportunistic investments, partnerships and acquisitions that we believe will complement our product platform, allowing us to enter new markets and applications to enhance our growth profile. We also intend to establish new industry partnerships, enabling us to remain at the forefront of cell engineering trends and continue to collaborate with customers to accelerate the development and commercialization of new medicines.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Risk Factors Summary</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are more fully described in the section titled &#8220;Risk Factors.&#8221; These risks include, among others:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We have incurred significant losses since our inception, we expect to incur losses for the foreseeable future and we may never achieve or maintain profitability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We are highly dependent on a limited number of product offerings that require a substantial sales cycle and as a result we are prone to quarterly fluctuations in revenue. If we fail to maintain significant market acceptance in existing markets or fail to successfully increase our penetration in new and expanding markets, we will not generate expected revenue and our prospects may be harmed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We operate in a highly competitive market characterized by rapid technological change, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. Our success depends, in part, on our ability to maintain a competitive position in the development of technologies, enhancements and products for use by our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our business currently depends significantly on research and development spending by biopharmaceutical companies and academic institutions, a reduction in which could limit demand for our products and adversely affect our business and operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We must develop new products, as well as enhancements to existing products, and adapt to rapid and significant technological change to remain competitive.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">If we cannot maintain and expand current partnerships and enter into new partnerships, including internationally, that generate marketed licensed products, our business could be adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We depend on continued supply of components and raw materials for our ExPERT instruments and PAs from third-party suppliers, and if shortages of these components or raw materials arise, we may not be able to secure enough components to build new products to meet customer demand or we may be forced to pay higher prices for these components. As such, we must also accurately forecast customer demand for our products and manage our inventory.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Our FDA Master File, and equivalent Technical Files in foreign jurisdictions, are an important part of our strategic offering which allows our partners to expedite their cellular therapies into and through the clinic. Delays in filing or obtaining, or our inability to obtain or retain, acceptance of such filings in individual countries could negatively impact the progress of our partners if they intend to run clinical trials in such countries, and as a result, could negatively affect our reputation and revenues or require disclosure of confidential information to our partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">We may need additional funding beyond the proceeds of this offering and may be unable to raise capital when needed, which would force us to delay, reduce, eliminate or abandon our commercialization efforts or product development programs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">The COVID-19 pandemic has had and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners and our customers operate.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">Upon the completion of this offering, our common stock will be traded on two separate stock markets and investors seeking to take advantage of price differences between such markets may create unexpected volatility in our share price; in addition, investors may not be able to easily move shares for trading between such markets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Our Corporate Information</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We were incorporated under the laws of the State of Delaware in July&#160;1998 under the name Theramed, Inc. On December&#160;31, 2001, we changed our name to MaxCyte, Inc. Our principal executive offices are located at 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878, and our telephone number is (301) 944-1700. Our website address is www.maxcyte.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Trademarks and Service Marks</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We have proprietary rights to a number of trademarks used in this prospectus which are important to our business. &#8220;MaxCyte,&#8221; &#8220;ExPERT,&#8221; &#8220;CARMA,&#8221; &#8220;Flow Electroporation,&#8221; &#8220;ATx,&#8221; &#8220;STx,&#8221; &#8220;GTx,&#8221; &#8220;VLX Large-Scale Transfection System&#8221; and our other registered and common law trade names, trademarks and service marks are the property of MaxCyte, Inc. Other trade names, trademarks and service marks used in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.111pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may take advantage of certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until those standards apply to private companies. We have elected to use the extended transition period under the JOBS Act. Accordingly, our financial statements may not be comparable to the financial statements of public companies that comply with such new or revised accounting standards. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.111pt;">THE OFFERING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Common stock offered by us </font>
            </div>
          </div>

            <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">13,500,000 shares</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Option to purchase additional shares of common stock offered by us </font>
            </div>
          </div>

            <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">We have granted the underwriters an option, exercisable for 30&#160;days after the date of this prospectus, to purchase up to an additional 2,025,000 shares from us. See the section of this prospectus titled &#8220;Underwriting.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Common stock to be outstanding after this </font>
              <br >
              <font style="letter-spacing:-0.025pt;">offering </font>
            </div>
          </div>

            <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">98,189,559 shares (100,214,559 shares if the option to purchase additional shares from us is exercised in full).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
            </div>

          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Use of proceeds </font>
            </div>
          </div>

            <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">We estimate that our net proceeds from the sale of our common stock that we are offering will be approximately $160.2 million (or approximately $184.7 million if the underwriters&#8217; option to purchase additional shares of our common stock from us is exercised in full) after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font>
            </div>

          <div style="margin-left:145pt; margin-top:8pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The principal purposes of this offering are to obtain additional capital to increase our financial flexibility, to support our operations and growth, to create a public market for our common stock in the United States and to enable access to the U.S. public equity markets for us and our stockholders. However, we currently intend to use the net proceeds we receive from this offering for research and development initiatives, to expand our manufacturing capabilities and invest in manufacturing automation, to expand our sales and marketing, business development and field application scientist teams, and for working capital and general corporate purposes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:145pt; margin-top:8pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">See the section titled &#8220;Use of Proceeds&#8221; for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">You should carefully read the section titled &#8220;Risk Factors&#8221; beginning on page&#160;12 and the other information included in this prospectus for a discussion of facts that you should consider before deciding to invest in shares of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Nasdaq Global Select Market symbol </font>
              </div>
            </div>

          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8220;MXCT&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:-0.025pt;">AIM trading symbols </font>
            </div>
          </div>
          <div style="margin-left:145pt; margin-top:-12pt; width:311pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#8220;MXCT&#8221;, &#8220;MXCN&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on 84,689,559 shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">12,071,923 shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our Long-Term Incentive Plan, or our LTIP, with a weighted average exercise price of $4.41 per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">4,131,667 shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">71,168 shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of $&#163;1.09081 ($1.50477 based on the exchange rate of &#163;1.00 to $1.3795, the exchange rate on March&#160;31, 2021) per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">In addition, unless we specifically state otherwise, the information in this prospectus assumes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us in this offering; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">no exercise of the outstanding stock options and warrant described above. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:19pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.111pt;">SUMMARY CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The summary consolidated statement of operations data for the&#160;years ended December&#160;31, 2019 and 2020 and the summary consolidated balance sheet data as of December&#160;31, 2020 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary consolidated statement of operations data for the three months ended March 31, 2020 and 2021 and the summary consolidated balance sheet data as of March 31, 2021 have been derived from our unaudited interim financial statements included elsewhere in this prospectus. You should read the financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results to be expected for any period in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <table style="width:416pt;height:330pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:149.07pt;text-align:left;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Years Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Three Months Ended March&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">2019 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">2021 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:1.917pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.111pt;">Consolidated Statement of Operations Data:</font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,620,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8199;5,742,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8199;6,494,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Costs of goods sold </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">2,499,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">659,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">693,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Gross profit </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,121,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,083,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,801,800</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <font style="letter-spacing:-0.025pt;">Operating expenses: </font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">17,601,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,244,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,077,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">7,852,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,050,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,789,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">6,088,200</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,776,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">3,308,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">31,541,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">8,071,300</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,174,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Operating loss </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(2,988,300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(6,373,100<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <font style="letter-spacing:-0.025pt;">Other income (expense): </font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(116,300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(742,300<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Interest and other income </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">206,100</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">65,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">42,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">9,800</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total other income (expense) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(73,600<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(732,500<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:149.07pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Net loss </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:1.417pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">Net loss per share, basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(0.09<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">Weighted-average common shares outstanding, basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">56,397,524</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">57,403,583</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">81,004,081</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

            <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
                <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.09pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                  <div style="white-space:nowrap; text-align:center;">
                    <font style="letter-spacing:-0.089pt;">As of March&#160;31, 2021 </font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
                <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                  <div style="white-space:nowrap; text-align:center;">
                    <font style="letter-spacing:-0.089pt;">Actual </font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                  <div style="white-space:nowrap; text-align:center;">
                    <font style="letter-spacing:-0.089pt;">As Adjusted(1)</font>
                  </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.25pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <font style="letter-spacing:-0.111pt;">Consolidated Balance Sheet Data:</font>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">78,703,700</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">238,918,700 </td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Working capital(2) </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">77,015,100</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">237,230,100</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Total assets </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">95,007,800</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">255,222,800</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Total liabilities </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">13,722,200</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">13,722,200</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">182,766,600</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">342,846,600</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
                <td style="padding:3.5pt 0pt 0.5pt 0pt; width:273.09pt;text-align:left;">
                  <div style="white-space:nowrap;">
                    <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
                  </div>
                </td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt; width:1pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">81,285,600</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
                <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">241,500,600</td>
                <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
            </table>

        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt;">
            <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>

            <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;">(1)</font>
              <br >
            </div>
            <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
              <font style="letter-spacing:-0.025pt;">The as adjusted balance sheet data gives effect to our receipt of estimated net proceeds from the sale of 13,500,000 shares of common stock that we are offering at a public offering price of $13.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
            </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;">(2)</font>
              <br >
            </div>
            <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
              <font style="letter-spacing:-0.025pt;">Working capital is defined as current assets less current liabilities.</font>
            </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">RISK FACTORS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">An investment in our common stock involves a high degree of risk. You should consider carefully the following risks and other information contained in this prospectus before you decide whether to buy our common stock. If any of the events contemplated by the following discussion of risks should occur, our business, results of operations, financial condition and growth prospects could suffer significantly. As a result, the market price of our common stock could decline, and you may lose all or part of the money you paid to buy our common stock. The risks below are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this prospectus.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to Our Business and Growth Strategy</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We are a cell engineering and life sciences company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have limited product offerings approved for commercial sale and may never achieve or maintain profitability.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are a cell engineering and life sciences company focused on advancing the discovery, development and commercialization of next-generation cell-based medicines. The biopharmaceutical development industry, where the majority of our customers operate, is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since inception and have financed our operations principally through private financings and sales of our securities in our initial public offering on AIM, a market operated by the London Stock Exchange, in March&#160;2016. We have historically relied on sales and licensing of our ATx, STx and GTx instruments, as well as sales of our portfolio of single-use disposable processing assemblies, or PAs, for nearly all of our revenue. We may be unable to sell or license our instruments to new customers and existing customers may cease or reduce their utilization of our instruments or fail to renew licenses of our instruments. Our net losses were $12.9&#160;million and $11.8&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and for the three months ended March 31, 2021, we had a net loss of $7.1 million. As of March&#160;31, 2021, we had an accumulated deficit of $102.3&#160;million. Our losses have resulted principally from expenses incurred for the research and clinical development of our proprietary cell therapy CARMA platform clinical candidate MCY-M11 and, to a lesser extent, our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms and from sales and marketing costs, manufacturing expenses, management and administrative costs and other expenses that we have incurred while building our business infrastructure.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We concluded clinical activities associated with CARMA in the first half of 2021. We expect our expenses and operating losses, excluding CARMA, will continue to increase substantially for the foreseeable future as we expand our research and development efforts, expand the capabilities of our cell engineering platforms and operate as a public company in the United States. We anticipate that our expenses will increase substantially as we:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue to advance our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms and develop new technologies related to our platform;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">acquire and license technologies aligned with our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand our operational, financial and management systems and increase personnel, including personnel to support our research and development, manufacturing and commercialization efforts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continue to develop, perfect and defend our intellectual property portfolio; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">incur additional legal, accounting and other expenses in operating our business, including the additional costs associated with operating as a public company in the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have devoted a significant portion of our financial resources and efforts to building our organization, developing our </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell engineering platforms, acquiring technology, building out our manufacturing capabilities, organizing and staffing the company, business planning, establishing our intellectual property portfolio, raising capital, securing license and partnership arrangements with customers and providing general and administrative support for these operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">To become and remain profitable, we must succeed in realizing meaningful pre-commercial milestone payments from our current SPLs and potentially secure future commercial partnership, licensing or collaboration arrangements for use of our cell engineering platforms and similar arrangements for future platforms in development that have not yet been partnered. This will require us to be successful in a range of challenging activities, including continuing to develop our technology and products, accessing, developing and advancing manufacturing capacity, advancing our sales and marketing capabilities and commercializing and selling our products. We may never succeed in any or all of these activities and, even if we do, we may never generate a level of revenue that is sufficient to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our financial results, including profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our financial results, the value of our shares of common stock could be materially adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are highly dependent on a limited number of product offerings. Our revenue has been primarily generated from the sale and licensing of our ATx, STx and GTx instruments, as well as sales of single-use disposable PAs, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform and family of instruments&#8201;&#8212;&#8201;the ATx, STx and GTx, representing next-generation technology for complex cellular engineering, was commercially launched in April&#160;2019. Sales and licensing of ExPERT technology systems and related instruments together accounted for 50% and 51% of our revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively. We expect that, for at least the foreseeable future, sales and licensing of our ExPERT technology systems will continue to account for a substantial portion of our revenue. The sales cycle for our cell engineering instruments is complex and can take up to 12&#160;months or longer to complete. Material, one-time milestones earned as Strategic Platform License, or SPL, customers achieve clinical progress may also, from time to time be a significant portion of our revenue, are not in our control, are unpredictable and because of the early-stage nature of the cell therapy clinical development, may contribute materially to the volatility of our revenue. As a result of our lengthy and unpredictable sales cycle, we will be prone to quarterly fluctuations in our revenue. Quarterly fluctuations may make it difficult for us to predict our future operating results. Consequently, comparisons of our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As a result of variability and unpredictability, we may also fail to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall short of the expectations of analysts or investors or any guidance we may provide, or if the guidance we provide falls short of the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance we may have provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may be unable to successfully execute on our growth strategy.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We intend to grow our business and market opportunity by continuing to invest in technology and scientific innovation, broadening our distribution capabilities to expand our installed base of ExPERT products, pursuing SPLs with target customers, commercializing our VLX Large-Scale Transfection System under the ExPERT brand, expanding our commercial infrastructure and considering opportunistic investments, partnerships and acquisitions, among other initiatives. Each of these growth strategies will require considerable time and resources, and we may not be successful in executing on any or all of these strategies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">One of the components of our growth strategy is to develop and commercialize our novel VLX platform for large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins. The VLX has been sold to a limited number of customers for specific large-scale applications in a first-generation design. We intend to align the current design of the VLX with the design, capabilities and branding of our ExPERT instruments (the STx, ATx and GTx) as well as to make specific product enhancements unique to the VLX to enable expansion into new applications such as large-scale bioprocessing and large-scale cell therapy. To improve the VLX platform and successfully penetrate new markets, we will be required to invest significant time, resources and capital investment in the development, production and launch of the VLX platform, which could divert our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">resources from other parts of our business and growth strategy. In addition, the success of the redesigned ExPERT VLx, including new engineering modifications to the platform, may depend in part on the availability, compatibility and capability of appropriate technologies upstream and downstream of electroporation to support potential large-scale applications enabled by the VLX platform and willingness of customers to adopt the ExPERT VLx for new applications. Further, we could encounter delays and setbacks in the launch of the ExPERT VLx platform, including implementing engineering modifications necessary for certain large-scale applications, resulting in delayed acceptance by future customers and partners of such a large-scale system. In addition, the sales and implementation cycles of customers for such a large-scale platform may require more time than originally assumed, which could delay or negatively impact forecasted revenues.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Another component of our growth strategy is expanding our SPL model, through which we build collaborative relationships with our customers as we facilitate their efforts to bring critical cell-based medicines to the market. Even if we are able to enter into additional future SPL arrangements and similar arrangements for future therapeutic products that have not yet been partnered, there can be no assurance that any of the therapeutic products that are being or might be developed by our partners using our technology will continue to advance through clinical development, receive regulatory approvals or be successfully developed into commercially viable products. As a result, we may suffer setbacks in increasing awareness and adoption of our products in addition to the material impact on our financial results as a result of milestones not being realized and leased instruments being returned. Further, setbacks in the clinical trials of our current or future partners, such as serious adverse events, including patient deaths, could significantly impact capital available to customers and our ability to enter into future SPL agreements with new therapeutic product companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our growth strategy also involves expanding our international operations. In addition to risks associated with international operations in general, we will also need to navigate complex foreign regulatory requirements with which we may not be familiar or have experience. To operate successfully in or obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety, efficacy, manufacturing, clinical trials, commercial sales, pricing and distribution of our products. Although our partners have repeatedly been able to reference our FDA Master File in the United States and our Technical Files in some other countries in the course of clinical development of their therapeutic products, we cannot ensure that we will obtain or establish a regulatory Technical File in other countries. If we fail to establish a regulatory Technical File in any jurisdiction, this could make customers in such jurisdictions less likely to adopt our instruments, and the geographic market for our products could be limited.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe there are several opportunities to grow our sales and product line. However, we have limited financial and managerial resources, and we may forego or delay pursuit of growth opportunities that later prove to have greater value to our business. Our resource allocation decisions may cause us to fail to capitalize on viable opportunities, and we could spend resources on strategies that are not ultimately successful.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">The estimates of market opportunity and forecasts of market growth included in this prospectus or that we develop internally may prove to be inaccurate, and even if the markets in which we compete are as large as we estimate or achieve their forecasted growth, our business could fail to grow at projected rates, if at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Market opportunity estimates and growth forecasts included in this prospectus, including those we have generated ourselves, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The variables that go into the calculation of our market opportunity are subject to change over time, and there is no guarantee that any particular number or&#160;percentage of customers covered by our market opportunity estimates will purchase our products at all or generate any particular level of revenue for us. Any expansion in our market depends on a number of factors, including the cost and perceived value associated with our products and those of our competitors. Even if the markets in which we compete meet the size estimates and growth forecast in this prospectus, our business could fail to grow at projected rates, if at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. Accordingly, the forecasts of market size and growth included in this prospectus should not be taken as indicative of our future growth.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We rely on assumptions and estimates and data to calculate certain of our key metrics, and real or perceived inaccuracies in such metrics may harm our reputation and negatively affect our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to our financial results, our management regularly reviews a number of operating and financial metrics, including a breakdown of product and leased revenue into instrument sales, PAs, and leased revenue (recurring revenue), product placements, cumulative product placements, revenue by customer market (cell therapy and drug discovery), and status or number of installed instruments, SPLs, program licenses (research, clinical and SPL) and potential pre-commercial milestones, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As both the industry in which we operate and our businesses continue to evolve, so too might the metrics by which we evaluate our businesses. In addition, while the calculation of the metrics we use is based on what we believe to be reasonable estimates, our internal tools are not independently verified by a third party and have a number of limitations and, furthermore, our methodologies for tracking these metrics may change over time, for example, the industry breakdown of our customer revenue. Accordingly, investors should not place undue reliance on these metrics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our future success is dependent upon our ability to increase penetration in our existing markets and expand into adjacent markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customer base includes biopharmaceutical and biotechnology companies and academic institutions focused on cell-based therapeutics. Our success will depend in part upon our ability to increase our market penetration by expanding sales to existing customers and acquiring new customers and partnerships within our existing markets, and our ability to market new products and applications to existing and new customers as we develop such products and applications. Attracting new customers and introducing new products and applications require substantial time and expense. For example, it may be difficult to identify, engage and market to customers who are unfamiliar with our current products. We cannot guarantee that we will be able to further penetrate our existing markets or that these markets will be able to sustain our current and future product and service offerings. Any failure to increase penetration in our existing markets would adversely affect our ability to improve our operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success will also depend on our ability to further expand into adjacent markets, such as penetrating non-commercial customer opportunities, including translational academic centers. Our failure to further expand in adjacent markets and attract new customers could adversely affect our ability to improve our operating results.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Due to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, technology offerings and partnerships, and there can be no assurance that we will expend our resources successfully or in a way that results in meaningful revenue or capitalizes on potential new markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our platform has potential applications across a wide range of markets and we have targeted certain markets in which we believe we have a higher probability of success or revenue opportunity or for which the path to commercialize products and realizing or achieving revenue is shorter. For example, we believe our products have applications in markets for engineered cell therapies in immuno-oncology and inherited disorders. We seek to continue to prioritize opportunities and allocate our resources among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets for our technology. However, due to the significant resources required for the development for new markets, we must make decisions regarding which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular markets or workflows may not lead to the development of any viable product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain markets may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. In particular, if we are unable to develop additional relevant products and applications for markets such as cell therapy or large-scale bio-processing, it could slow or stop our business growth and negatively impact our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our business is dependent on adoption of our products by biopharmaceutical companies and academic institutions for their research and development activities focused on cell-based therapeutics. If biopharmaceutical companies and academic institutions are unwilling to change current practices to adopt our products it will negatively affect our business, financial condition, prospects and results of operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our primary strategy to grow our revenue is to market our products across key stakeholders in cell-based therapeutics, such as biopharmaceutical companies and academic institutions. Most of our potential customers already use expensive research systems in their laboratories and may be reluctant to replace those systems. While the number of customers using our products has increased in recent&#160;years, many biopharmaceutical companies and academic institutions have not yet adopted our products, and such institutions and companies may choose not to adopt our products for a number of reasons, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inability to convince potential customers that our products are an attractive alternative to existing technologies and reluctance of potential customers to replace those existing technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inadequate recruiting or training of talented sales force and field application scientists in existing and new markets to facilitate outreach and further adoption and awareness of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">lack of experience of potential customers with our products for cell engineering;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">perceived inadequacy of evidence supporting benefits or cost-effectiveness of our products over existing alternatives or negative publicity regarding cell engineering technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">liability risks generally associated with the use of new products and processes;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the time and training required for potential customers to use and validate our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a decrease or delay in the research and development activities using our products as a result of the COVID-19 pandemic;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">competing products and alternatives; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">introduction of other novel alternative products for cell engineering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, our customers may experience a change of control or otherwise consolidate with other biopharmaceutical companies and academic institutions. If as a result of such change of control, our customers choose or are forced to adopt other products, or otherwise reduce their use of our products, our ability to execute our growth strategy will be impaired and it will negatively affect our business, financial condition, prospects and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that educating notable industry key opinion leaders, or KOLs, and representatives of biopharmaceutical companies and academic institutions about the merits and benefits of our products for Flow Electroporation and cell engineering is one of the key elements of increasing the adoption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adoption of our products will be slowed, our ability to execute our growth strategy will be impaired, and it will negatively affect our business, financial condition, prospects and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may be unable to compete successfully against our existing or future competitors.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We operate in a highly competitive market characterized by rapid technological change, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. We currently compete with both established and early-stage life sciences technologies companies that design, manufacture and market electroporation and other non-viral cell engineering technology based on efficacy, price, ease of use, reimbursement and customer support services.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends, in part, on our ability to maintain a competitive position in the development of technologies, enhancements and products for use by our customers. Many of the companies developing or marketing competing or alternative products have competitive advantages when compared to us, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">greater financial and human resources for product development, sales and marketing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">greater domestic and international name recognition and more product familiarity among users;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader and more established relationships with pharmaceutical companies and academic institutions;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader product lines and the ability to offer lower prices or rebates, integrate technologies more successfully to offer better workflow solutions, bundle products to offer greater discounts or incentives or offer more attractive milestone and partnership terms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader intellectual property protection for their technology and products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">broader and more established domestic and international sales and marketing and distribution networks; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">more experience in conducting research and development, manufacturing and preparing regulatory submissions, both in the United States and in foreign jurisdictions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We primarily compete against products marketed by Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc. and Harvard Bioscience, Inc. (BTX).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to already marketed products, we also face competition from products that are or could be under development and that target the same applications as our products or applications that we may address in the future. Such product candidates may be developed by the above-mentioned entities and others, including life sciences tools companies, biotechnology companies, pharmaceutical companies, private and public research institutions and academic institutions or may come about as the result of consolidation in our industry. Our competitors may develop and patent processes or products earlier than we can, obtain regulatory clearance or approvals for competing products more rapidly than we can and develop more effective and/or less expensive products or technologies that render our technology or products obsolete or non-competitive. Despite the steps we have taken to maintain and protect our intellectual property, competitors may nevertheless attempt to, or succeed in, developing similar electroporation technology, including Flow Electroporation. We also compete with other organizations in recruiting and retaining qualified scientific and management personnel. If our competitors are more successful than us in these matters, we may be unable to compete successfully against our existing or future competitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our business currently depends significantly on research and development spending by biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A portion of our revenue is derived from sales to biopharmaceutical companies and academic institutions. Much of their funding is, in turn, provided by public and private financings, including investments from venture capital funds and, for public companies, the capital markets. In the near term, we expect that a portion of our revenue will continue to be derived from sales to biopharmaceutical companies and academic institutions. Accordingly, the spending policies and practices of these customers&#8201;&#8212;&#8201;which have been impacted by the COVID-19 pandemic and may additionally be impacted by other factors&#8201;&#8212;&#8201;could have a significant effect on the demand for our products. In addition, the demand for our products may depend upon the research and development budgets of these customers, which are impacted by factors beyond our control, such as:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">macroeconomic conditions and the political climate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">investor confidence in the biopharmaceutical industry and the amount of capital such investors provide to our potential customers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reduced pricing of approved therapeutics;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">scientists&#8217; and customers&#8217; opinions of the utility of new products or services;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the regulatory environment;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">differences in budgetary cycles;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">competitor product offerings or pricing;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">merger and acquisition activity within the industry;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market-driven pressures to consolidate operations and reduce costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market acceptance of relatively new technologies, such as ours;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">clinical trial or milestone failures that impact our customers&#8217; ability to raise capital; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">inability to sustain capital requirements or bankruptcy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, while the majority of our revenues are derived from biopharmaceutical customers, various state, federal and foreign agencies that provide grants and other funding may be subject to stringent budgetary constraints that could result in spending reductions, reduced grant making, reduced allocations or budget cutbacks, which could jeopardize the ability of these customers, or the customers to whom they provide funding, to purchase our products. For example, congressional appropriations to the National Institutes of Health, or NIH, have generally increased year-over-year in recent&#160;years, but the NIH also experiences occasional year-over-year decreases in appropriations. There is no guarantee that NIH appropriations will not decrease or cease in the future. A decrease in the amount of, or delay in the approval of, appropriations to NIH or other similar United States or foreign organizations, such as the Medical Research Council in the United Kingdom, could result in fewer grants benefiting life sciences research. These reductions or delays could also result in a decrease in the aggregate amount of grants awarded for life sciences research or the redirection of existing funding to other projects or priorities, any of which in turn could cause our customers and potential customers to reduce or delay purchases or licensing of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our operating results may fluctuate substantially due to the potential changes in our customers&#39; resources as described above. Any decrease in our customers&#8217; budgets or expenditures, or in the size, scope or frequency of their capital or operating expenditures, could materially and adversely affect our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our current research and development efforts may not produce significant revenue for several&#160;years, if at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Developing our products is expensive, and the investment in product development may involve a long payback cycle. Our investment in research and development may not result in the data we hope to develop to support marketing of our products or in marketable products or may result in products that take longer to generate revenue, or generate less revenue, than we anticipate. For the year ended December&#160;31, 2020 and the three months ended March&#160;31, 2021, our research and development expenses were $17.7&#160;million and $6.1 million, respectively, or approximately 68% and 94%, respectively, of our total revenue, These amounts included $11.1 million and $3.9 million, respectively, of investment in our CARMA platform including the clinical investment in our wholly-owned cell therapy candidate, MCY-M11. Our future plans include significant investments in research and development of product opportunities for expansion of our products and new application areas for our products. We believe that we must continue to dedicate a significant amount of resources to our research and development efforts to maintain our competitive position. However, we may not receive significant revenue from these investments for several&#160;years, if at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our international operations may raise additional risks, which could have an adverse effect on our operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">International customers have typically accounted for a meaningful portion of our revenue. For the year ended December 31, 2020, approximately 27% of our revenue was derived from international customers, with the most significant markets being Switzerland and the United Kingdom. We expect our international revenue and operations will continue to expand in the future. Our international operations are subject to a variety of risks that we do not face in the United States, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the difficulty of increased travel, infrastructure and legal compliance costs associated with developing international revenue;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">difficulties in enforcing contracts, collecting accounts receivable and longer payment cycles, especially in emerging markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general economic conditions in the countries in which we operate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">additional withholding taxes or other taxes on our foreign income, and tariffs or other restrictions on foreign trade or investment;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">compliance with privacy and data security requirements in foreign jurisdictions in which we operate;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">imposition of, or unexpected adverse changes in, foreign laws or regulatory requirements, many of which differ from those in the United States;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">costs and delays associated with developing products or technology in multiple languages, such as the software embedded in our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">compliance with foreign technical standards;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">increased length of time for shipping and acceptance of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">increased exposure to foreign currency exchange rate risk;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">uncertainties related to the political and economic environments, including related to the recent withdrawal of the United Kingdom from the European Union;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reduced protection for intellectual property rights in some countries, particularly China; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">political unrest, war, incidents of terrorism, or responses to such events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As we continue to expand our business globally, our success will depend, in large part, on our ability to anticipate and effectively manage these and other risks associated with our international operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our overall success in international markets depends, in part, on our ability to succeed in differing legal, regulatory, economic, social and political conditions. We may not be successful in developing and implementing policies and strategies that will be effective in managing these risks in each country where we do business. Our failure to manage these risks successfully could harm our international operations, reduce our international sales and increase our costs, thus adversely affecting our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we fail to offer high-quality customer service, our business and reputation could suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We differentiate ourselves from our competition through our commitment to an exceptional customer experience. Accordingly, high-quality customer service is important for the growth of our business and any failure to maintain such standards of customer service, or a related market perception, could affect our ability to sell products to existing and prospective customers. The number of our customers has grown significantly and such growth, as well as any future growth, will put additional pressure on our field application scientists and customer service organization. We may be unable to hire qualified staff quickly enough or to the extent necessary to accommodate increases in demand. Providing an exceptional customer experience requires significant time and resources from our customer service team. Therefore, failure to scale our customer service organization adequately may adversely impact our business results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Customers utilize our service teams and online content for help with a variety of topics, including how to use our products efficiently, how to integrate our products into existing workflows, and how to resolve technical, analysis and operational issues if and when they arise. While we have developed significant resources for remote training and customer service, including our virtual product demonstration process, if our customers do not adopt these resources, we may be required to increase the staffing of our customer service team, which would increase our costs. Also, as our business scales, we may need to engage third-party customer service providers, which could increase our costs and negatively impact the quality of the customer experience if such third parties are unable to provide service levels equivalent to ours.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, as we continue to grow our operations and reach a global customer base, we need to be able to provide efficient customer service that meets our customers&#8217; needs globally at scale. In geographies where we sell through distributors, we often rely on those distributors to provide customer service. If these third-party distributors do not provide a high-quality customer experience, our business operations and reputation may suffer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we cannot maintain and expand current partnerships and enter into new partnerships that generate marketed licensed products, our business could be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We do not have our own pipeline of therapeutic candidates, and instead we focus our efforts on the development of our cell engineering offerings, including our ExPERT platform. Our partners then use our instruments and PAs for cell engineering to develop their own therapeutic candidates without our direct involvement. As a result, our success depends on our ability to expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners&#8217; satisfaction with our products, competitive offerings of other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">companies, our partners&#8217; ability to successfully develop, secure regulatory approval for and commercialize therapeutic candidates using our products, our partners&#8217; internal priorities (including fluctuations in research and developments budgets), our partners&#8217; resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction, as well as severe adverse events in cell therapy trials regardless of association with our partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to factors beyond our control, such as our partners&#8217; inability to successfully develop or commercialize their therapeutic candidates. In such circumstances, we would not generate any substantial revenues from such a collaboration in the form of milestone payments, royalties or otherwise. Speculation in the industry about our existing or potential partnerships can be a catalyst for adverse speculation about us which can adversely affect our reputation and our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Further, our customers are subject to the extensive risks and uncertainties that apply to product candidates in this area including those associated with preclinical and clinical research and development and related regulatory and Institutional Review Board authorization and oversight, manufacturing challenges and compliance standards, the data requirements and review process for seeking marketing authorization, and the potential for safety and efficacy concerns to emerge at any stage of product development and even after approval.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If the quality or delivery of our products does not meet our customers&#8217; expectations and needs relative to their regulatory obligations, our reputation could suffer and ultimately our sales and financial results could be negatively impacted.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our customers operate in a highly regulated industry. In the course of conducting our business, our customers will expect us to adequately address any quality issues suspected to be associated with our products, including defects in our engineering, design, manufacturing and delivery processes, as well as defects in third-party components included in our products. The occurrence of defects in our products may increase as we continue to introduce new products and as we rapidly scale up manufacturing to meet potentially increased customer demand. Although we have established internal procedures designed to reduce the risks of product quality issues that may arise, there can be no assurance that we will be able to eliminate or mitigate occurrences of these issues and associated potential liabilities. In addition, identifying the root cause of quality issues may be difficult, which increases the time needed to address quality issues as they arise and increases the risk that similar problems could recur. Finding solutions to quality issues can be expensive and we may incur significant costs or lost revenue in connection with, for example, shipment holds, product recalls or other service obligations. In addition, quality issues can impair our relationships with new or existing customers and adversely affect our brand image, and our reputation could suffer, which could adversely affect our business, financial condition, results of operations, cash flows and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The failure of our partners to meet their contractual obligations to us could adversely affect our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of therapeutic candidates produced using our instruments and PAs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">data security risk as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of their clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our partners have significant discretion in determining when and whether to make announcements about the status of their programs that use our technology, including their preclinical and clinical programs, such as setbacks or terminations, and timelines for advancing therapeutic candidates developed using our platform. We do not plan to disclose the development status and progress of individual therapeutic candidates of our partners. Our partners may wish to report such information more or less frequently than we prefer or may not wish to report such information at all. In addition, if partners choose to announce a collaboration with us or their progress, there is no guarantee that we will concurrently recognize any fees or that such announcement will be indicative of future fees to us, as such fees are not due to us until our partner reaches certain specific activities or clinical progress events, for example investigational new drug, or IND, submissions or start of pivotal trials. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our partners may not achieve projected development and regulatory milestones and other anticipated key events in the expected timelines or at all, or may discontinue some or all of their programs, which could have an adverse impact on our business and could cause the price of our common stock to decline.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Certain of our partners have also made public statements regarding their expectations for the development of programs under partnership with us and they and other partners may in the future make additional statements about their goals and expectations for the progress of their programs and/or their partnerships with us. The actual timing of these events and any resultant revenue to us can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; therapeutic discovery and development programs and the numerous uncertainties inherent in the development of therapeutics. As a result, there can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect, or at all. In addition, we have very little visibility into, or advance notice of, any changes in our partners&#8217; development timelines and expectations, which means that we may not be able to swiftly react and adapt to changed expectations related to the achievement and payment of milestones under our agreements. If our partners fail to achieve one or more of these milestones or other key events as we or they expect, our business could be materially adversely affected and the price of our common stock could decline.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Biopharmaceutical drug and therapeutics development is inherently uncertain, and it is possible that none of the drug or therapeutic candidates discovered using our platform that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We offer our cell engineering platform to partners who are engaged in drug and therapeutics discovery and development. These partners include large pharmaceutical companies, biotechnology companies of all sizes and non-profit and academic institutions. While we receive early payments generated through sales of our ExPERT instruments and PAs and recurring revenue through the annual licenses of the ExPERT instrument to our partners, we estimate that the vast majority of the economic value of the SPLs that we enter into with our partners is in the downstream payments that are payable if certain milestones are met or approved products are sold. As a result, our future growth is dependent on the ability of our partners to successfully develop and commercialize therapies discovered or produced using our platform. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">derivatively through the activities of our partners. There can be no assurance that our partners will successfully develop, secure marketing approvals for and commercialize any drug or therapeutic candidates discovered or produced with our instruments. As a result, we may not realize the intended benefits of our partnerships. Since 2017, we have entered into 13 SPLs resulting in a growing number of clinical milestone payments, but we have not yet had a licensed program receive regulatory marketing approval.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, our partners may not successfully develop any drug or therapeutic candidates with our platform, or our partners may choose to discontinue the development of these drug candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, manufacturing challenges, commercialization potential, production limitations or prioritization of their resources. For product candidates of the type expected to be developed using our technology, there is the potential they could create a safety risk to patients and can also limit product efficacy. It is possible that none of these drug or therapeutic candidates will ever receive regulatory approval and, even if approved, such drug candidates may never be successfully commercialized resulting in clinical progress milestones and commercial sales-based payments not being earned.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Regulatory authorities have substantial discretion in the review and approval process and may refuse to accept any application or may decide that our partners&#8217; data are insufficient to support progression to further stages of preclinical or clinical development or for marketing approval and require additional preclinical, clinical or other studies. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the product candidate (including cell therapies, for which development is inherently challenging), the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Application of the legal and regulatory standards for approval, and the type and amount of clinical data and data supporting Chemistry, Manufacturing and Control necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that any product candidates our partners may seek to develop in the future will never obtain the appropriate, necessary regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, even if these drug or therapeutic candidates receive regulatory approval in the United States, our partners may never obtain approval or commercialize such drugs outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved drugs or therapeutics may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Third-party payers may opt to implement efficacy-based payment mechanisms over a multi-year period, which could impact potential product sales in any given year. Likewise, our partners have to make decisions about which clinical stage and pre-clinical drug and therapeutic candidates to develop and advance, and our partners may not have the resources to invest in all of the drug or therapeutic candidates that are produced using our platform, or clinical data and other development considerations may not support the advancement of one or more drug candidates developed using our platform. Decision-making about which drug or therapeutic candidates to prioritize involves inherent uncertainty, and our partners&#8217; development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one or more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug or therapeutic candidate that utilizes our platform. If one of our SPL customers terminates its agreement with us, we may find it more difficult to attract new partners.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our partners, and therefore our potential financial outcomes under our agreements, are also subject to inherent industry-wide FDA and other regulatory risk. The number of new drug applications and biologics license applications approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of new drug applications and biologics license applications approved by the FDA, the industry would contract and our business would be materially harmed. Furthermore, regulatory agencies may introduce new submission requirements or implement new </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">regulations for cell and gene therapies which could result in extended timelines for our partners, creating uncertainty or delays in achieving milestones. Such delays in these milestones will materially affect our ability to forecast and receive milestone payments outlined in our license agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our partners&#8217; failure to effectively advance, market and sell suitable drug and therapeutic candidates developed using our platform could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common stock to decline. In addition to the inherent uncertainty in drug development addressed above, our ability to forecast our future revenues may be limited.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the year ended December&#160;31, 2020, one cell therapy company with which we have entered into an SPL accounted for 15% of our total revenue, and our six largest such customers accounted for an aggregate of approximately 40% of our total revenue for the year through a combination of instrument license fees, milestones realized and processing assembly revenue. These partnerships cover a large number of programs under contract, and therefore represent a large portion of potential downstream value. In addition, our partnership agreements are typically terminable at will. As a result, if we fail to maintain our relationships with our partners or if any of our partners discontinue their programs or transition to alternative cell engineering technologies, our future results of operations could be materially and adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Similarly, in recent periods, a portion of our revenue has been derived from milestone payments from a limited number of SPL customers. Accordingly, we are more dependent on the success of a limited number of our customers&#8217; programs than we would be if our revenue was derived more broadly from many customer contracts. The loss of any of our large customers, or significant delays or discontinuations in our customers&#8217; programs, would have an adverse effect on our ability to generate revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our customers&#8217; products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval, which could cause our future results of operations to be materially and adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Serious adverse events or undesirable side effects caused by our customers&#8217; products or product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the European Medicines Agency or other authorities. Results of our customers&#8217; clinical trials could reveal a high and unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If unacceptable side effects or deaths arise in the development of our customers&#8217; product candidates, the Institutional Review Boards at the institutions in which their studies are conducted, the FDA or any comparable foreign regulatory authority could suspend or terminate our customers&#8217; clinical trials or the FDA or other regulatory authorities could order them to cease clinical trials or deny approval of their product candidates for any or all targeted indications. Undesirable side effects or deaths in clinical trials with our customers&#8217; product candidates may cause the FDA or comparable foreign regulatory authorities to place a clinical hold on the associated clinical trials, to require additional studies, or otherwise to delay or deny approval of our customers&#8217; product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences could negatively impact the availability of capital for the broader cell therapy development market, reduce the demand for our products and harm our business, financial condition and prospects significantly.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may continue to pursue collaborations or licensing arrangements, joint ventures, strategic alliances, partnerships or other strategic investment or arrangements, which may fail to produce anticipated benefits and adversely affect our operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We may continue to pursue opportunities for collaboration, out-license, joint ventures, acquisitions of products, assets or technology, strategic alliances, or partnerships that we believe would advance </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">our development. We may consider pursuing growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities. Proposing, negotiating and implementing these opportunities may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not be able to identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have limited experience with respect to these business development activities. Management and integration of a licensing arrangement, collaboration, joint venture or other strategic arrangement may disrupt our current operations, decrease our profitability, result in significant expenses, or divert management resources that otherwise would be available for our existing business. We may not realize the anticipated benefits of any such transaction or arrangement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, partners, collaborators, or other parties to such transactions or arrangements may fail to fully perform their obligations or meet our expectations or cooperate with us satisfactorily for various reasons and subject us to potential risks, including the followings:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties have significant discretion in determining the efforts and resources that they will apply to a transaction or arrangement;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties could independently develop, or develop with third parties, services and products that compete directly or indirectly with our product candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may stop, delay or discontinue clinical trials as well as repeat clinical trials or conduct new clinical trials by using our intellectual property or proprietary information;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disputes may arise between us and partners, collaborators, or other parties that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable services and products; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">partners, collaborators, or other parties may own or co-own intellectual properties covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual properties.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Any such transactions or arrangements may also require actions, consents, approval, waiver, participation or involvement of various degrees from third parties, such as regulators, government authorities, creditors, licensors or licensees, related individuals, suppliers, distributors, shareholders or other stakeholders or interested parties. There is no assurance that such third parties will be cooperative as we desire, or at all, in which case we may be unable to carry out the relevant transactions or arrangements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may engage in future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our financial condition and operating results.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the future, we may acquire companies, assets or technologies in an effort to complement our existing offerings to enhance our market position. We have not made any acquisitions to date and we currently have no plans, proposals or arrangements with respect to any acquisition. Should we choose to pursue an acquisition in the future, we may not be able to find suitable acquisition candidates and we may not be able to complete acquisitions on favorable terms, if at all. Any future acquisitions we make could subject us to a number of risks, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the purchase price we pay could significantly deplete our cash reserves, impair our future operating flexibility or result in dilution to our existing stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may find that the acquired company, assets or technology does not further improve our financial and strategic position as planned;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may find that we overpaid for the company, asset or technology, or that the economic conditions underlying our acquisition have changed;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty integrating the operations and personnel of the acquired company;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty retaining the employees with the technical skills needed to enhance and provide services with respect to the acquired assets or technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the acquisition may be viewed negatively by customers, financial markets, or investors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have difficulty incorporating the acquired technologies or products with our existing products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may encounter difficulty entering and competing in new product or geographic markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may encounter a competitive response, including price competition or intellectual property litigation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may have product liability, customer liability or intellectual property liability associated with the sale of the acquired company&#8217;s products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may be subject to litigation by terminated employees or third parties;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may incur debt and restructuring charges;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we may acquire goodwill and other intangible assets that are subject to impairment tests, which could result in future impairment charges;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ongoing business and management&#8217;s attention may be disrupted or diverted by transition or integration issues and the complexity of managing geographically or culturally diverse enterprises; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our due diligence process may fail to identify significant existing issues with the target company&#8217;s product quality, product architecture, financial disclosures, accounting practices, internal controls, legal contingencies, intellectual property and other matters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Any acquisitions may not generate sufficient revenue to offset the associated costs of the transactions or may result in other adverse effects, which could have a material adverse effect on our business, operating results, and financial condition. In addition, negotiations for acquisitions, collaborations or investments that are not ultimately consummated could result in significant diversion of management time, as well as substantial out-of-pocket costs, any of which could have a material adverse effect on our business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to the Supply and Manufacturing of Our Products</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We depend on continued supply of components and raw materials for our ExPERT instruments and PAs from third-party suppliers, and if shortages of these components or raw materials arise, we may not be able to secure enough components to build new products to meet customer demand or we may be forced to pay higher prices for these components.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely on a limited number of suppliers for certain key components utilized in the assembly of our ExPERT instruments and manufacture of our PAs and buffer, and in some cases, such as certain instrument components, for example CPU chips or PA electrodes, we rely on a single supplier for a particular component, subassembly or consumable. Approximately 47% of our inventory held at December 31, 2020 was purchased from one supplier. Although in many cases we use standard components in our products, in some cases, components may only be purchased from a limited number of suppliers or a single supplier. Identifying and qualifying alternate sources may take time and involve additional expense, and there is no guarantee that current suppliers or alternate sources will timely deliver materials that meet our needs. If our customers experience a shortage or delay in delivery of our ExPERT instruments, PAs or buffers our business could be materially and adversely impacted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Neither we nor our contract manufacturers enter into long-term supply contracts for these components, and none of our third-party suppliers is obligated to supply products to us for any specific period or in any specific quantities, except as may be provided for in submitted and accepted purchase orders. We are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. Our industry has experienced component shortages </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">and delivery delays in the past, and we may experience shortages or delays of critical components in the future as a result of strong demand in the industry, high demand in unrelated industries (e.g. shortages of electronic components due to digitization in the automotive industry), or other factors. Many of the other components required to build our ExPERT instruments are also occasionally in short supply. Therefore, if shortages or delays arise, we may not be able to timely secure enough components at reasonable prices or of acceptable quality to build new products, resulting in an inability to meet customer demand or our own operating goals, which could adversely affect our customer relationships, business, operating results and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Many of the components that we use are part of the global supply chain and may be manufactured overseas. Therefore, our access to, or ability to acquire, components may be impacted by trade disputes or importation restrictions resulting from such trade disputes between governments. These disputes may result in increased tariffs, duties or taxes that will increase the cost of the components and we may have to increase the price of our products, or incur an impact on our margins, both of which can materially affect customer demand and resulting revenues.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, damage to a manufacturing facility or other property of any of our suppliers or their distribution channels due to fire, flood or other natural disaster or casualty event may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We have limited experience manufacturing our PAs and if we move manufacturing of our PAs in-house in the future and are unable to manufacture our PAs in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have limited experience manufacturing our products. We do not currently manufacture our PAs in-house but may choose to do so in the future. To manufacture our PAs in the quantities that we believe will be required to meet the currently anticipated market demand, we will need to increase manufacturing capacity, which will involve significant challenges and may require additional quality controls. We may not successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If there is a disruption to our manufacturing operations, we will have no other means of producing our products until we resolve such issues with our manufacturing facilities, develop alternative manufacturing facilities, or contract with third-party manufacturers capable of producing our PAs. Additionally, any damage to or destruction of our manufacturing facilities or equipment may significantly impair our ability to supply PAs on a timely basis. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our PAs, changes to labor costs or less favorable terms with third-party suppliers. There can be no assurance that we will not encounter such problems in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If we are unable to manufacture PAs consistently and in sufficient quantities to meet anticipated customer demand, our business, financial condition, results of operations and prospects would be harmed. If we choose to scale the commercial production of our PA and increase our manufacturing capacity, we may encounter quality issues that could result in product defects, errors or recalls. Manufacturing delays related to quality control could negatively impact our ability to bring our PAs to market, harm our reputation and decrease our revenue. Any defects, errors or recalls could be expensive and generate negative publicity, which could impair our ability to market or sell our PAs, and adversely affect our results of operations. Our inability, or that of our suppliers, to find and retain the necessary qualified employees to achieve our manufacturing goals would also negatively impact our ability to meet customer needs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have historically sourced and for the foreseeable future will continue to source components for our PAs from a limited number of manufacturers and, in some cases, sole source manufacturers. With respect to our PA manufacturers, we are neither a major customer, nor do we have long-term supply contracts. These manufacturers may therefore give other customers&#8217; needs higher priority than ours, and we may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms. While we are in the process of qualifying additional manufacturers, qualifications can take many&#160;months. If we were to lose one or more of our sole or single source manufacturers and suppliers, it would take significant time and effort to qualify alternative suppliers, if </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">available. Moreover, in the event that we transition to a new manufacturer, particularly from any of our single source manufacturers, doing so could be time-consuming and expensive, may result in interruptions in our ability to supply our products to the market and could affect the performance of our PAs, resulting in increased costs and negative customer perception and could have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">To ensure adequate supply of our instruments, PAs and other products, we must forecast the inventory needs of our current and prospective customers and manufacture our products based on our estimates of future demand. Our ability to accurately forecast demand for our products could be negatively affected by many factors, many of which are beyond our control, including our failure to accurately manage our expansion strategy, product introductions or failures by competitors, an increase or decrease in customer demand for our products or for products of our competitors, the availability of capital for our customers, our failure to accurately forecast the success of our customers&#8217; therapeutic products, market acceptance of new products, changes in general market conditions, including as a result of the COVID-19 pandemic, seasonal demands, regulatory matters or strengthening or weakening of general economic conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We seek to maintain sufficient levels of inventory of our instruments and other products to protect ourselves from supply interruptions. We rely in part on our commercial team and distributors to supply forecasts of anticipated product orders in their respective territories. If we fail to accurately estimate customer demand for our products, our inventory forecasts may be inaccurate, resulting in shortages or excesses of inventory. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which could negatively impact our business, prospects, financial condition and results of operations. Conversely, if we underestimate customer demand for our products, we may not be able to deliver products in a timely manner or at all, and this could result in reduced revenue and damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, we may not have adequate manufacturing capacity to meet such demand, and additional supplies may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, all of which would negatively affect our business, financial condition and results of operations. If we are unable to meet customer demand, we could lose our existing customers or lose our ability to acquire new customers, which would also negatively impact our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to Our Product Sales</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our offerings include products such as instruments, single-use disposables and the provision of support services to our customers with the goal to support the advancement of our customers&#8217; cell-therapies and/or drug discovery activities. We aim to collectively provide our customers with a single, integrated platform to discover, develop and manufacture safer, more targeted and increasingly complex cell-based therapies, designed for integration into customers&#8217; current good manufacturing practices environments. We cannot guarantee that the market for our current products will continue to generate significant or consistent demand. Demand for our current products could be significantly diminished by competitive technologies or products that replace them or render them obsolete or less desirable. Accordingly, we must continue to invest in research and development to develop competitive products. Restrictions resulting from the COVID-19 pandemic have had a negative impact on the work of some of our, and our customers&#8217;, research and development programs due to limitations on in-person lab work.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our future success depends on our ability to anticipate our customers&#8217; needs and develop new products and enhance current products to address those needs. Introduction of new products and product enhancements will require that we effectively transfer production processes from research and development to manufacturing and coordinate our efforts with those of our suppliers to achieve the desired level of production. If we fail to transfer production processes effectively, develop product </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">enhancements or introduce new products or enabling services in sufficient quantities to meet the needs of our customers, or effectively coordinate with our suppliers, our sales may be reduced and our business would be harmed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The commercial success of all of our products will depend upon their acceptance by the life science and biopharmaceutical industries. Some of the products that we are developing are based upon new technologies or approaches. As a result, there can be no assurance that these new products, even if successfully developed and introduced, will be accepted by customers. If customers do not adopt our new products, services and technologies, our results of operations may suffer and, as a result, the market price of our common stock may decline.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors, make strategic and operational decisions to prioritize certain markets, technology offerings or partnerships, and develop and capitalize on markets, technologies or partnerships, our business could suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We currently sell and license our products primarily in the cell therapy market, which is characterized by significant enhancements and evolving industry and regulatory standards and a high degree of regulatory scrutiny. As a result, our customers&#8217; needs are rapidly evolving. If we do not appropriately innovate and offer our customers comprehensive solutions and otherwise invest in new technologies, our offerings may become less desirable in the markets we serve, and our customers could move to new technologies offered by our competitors or make products themselves. Without the timely introduction of new instruments, single-use disposables software, services, enhancements and new product integrations with electroporation, our offerings may become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new products and applications to further drive adoption of our platform. To the extent we fail to timely introduce new and innovative products, offer enhancements to our existing products, adequately predict our customers&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our products have potential applications across a wide range of markets and we have targeted certain markets in which we believe our technology has significant advantages, or for which we believe we have a higher probability of success or significant revenue opportunity. For example, we are committed to developing our platform&#8217;s applications within the life sciences market, including research, discovery, development, and manufacturing of next-generation autologous and allogeneic cell-based therapeutics, as well as drug discovery, including protein production for biological therapeutics, viral vectors, vaccines and for the discovery of small molecule drugs. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between advancing near-term opportunities and exploring additional markets and uses for our technology. However, due to the significant resources required for the development of applications data for our products or services for new markets, we must make decisions on which markets to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular markets, products or services may not lead to the development of any viable products or services and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain markets may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. In particular, if we are unable to successfully achieve on-going adoption of our electroporation platform technology, it could slow or stop our business growth and negatively impact our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Products from our research and development programs will take time and considerable resources to develop, and may include improvements or changes to our current products, and we may not be able to complete development and commercialization of new or enhanced products on a timely basis, or at all. There can be no assurance that our research and development efforts will produce commercially viable products and solutions and before we can commercialize any new products, we will need to expend significant funds in order to, for example:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">conduct substantial research and development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in some cases, obtain necessary regulatory clearance or approval;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">further develop and scale our laboratory, engineering and manufacturing processes to accommodate different products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">source and enter into agreements with new suppliers and manufacturers; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">further develop and scale our infrastructure.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons, including failure of the product to perform as expected and failure to reliably demonstrate the advantages of the product.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Even if we are successful in developing new products, it will require us to make significant additional investments in marketing and selling resources to commercialize any such products. As a result, we may be unsuccessful in commercializing new products that we develop, which could adversely affect our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our systems are complex in design and may contain defects that are not detected until deployed by our customers, which could harm our reputation, increase our costs and reduce our sales. If our products do not perform as expected or the reliability of the technology on which our products are based is questioned, our operating results, reputation and business will suffer.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends on our ability to provide reliable, high-quality products that enable high performance cell engineering through flexible, efficient and cost-effective solutions. Our systems are complex in design and involve a highly complex and precise manufacturing process. As a result of the technological complexity of our systems, changes in our suppliers&#8217; manufacturing processes or the inadvertent use of defective materials by us or our suppliers could result in a product recall, or an adverse effect on our ability to achieve acceptable manufacturing quality and product reliability. To the extent that we do not achieve and maintain our projected quality or product reliability, our reputation, business, operating results, financial condition and customer relationships would be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customers may discover defects in our products after the products have been fully installed and operated. In addition, some of our products include components from other vendors, which may contain defects. As a result, should problems occur, it may be difficult to identify the source of the problem. If we are unable to identify and fix defects or other problems, we could experience, among other things:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">product recalls and replacement costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of customers or orders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">damage to our brand reputation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">failure to attract new customers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">diversion of development, engineering and manufacturing resources;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">regulatory actions by governmental authorities; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">legal actions by our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that customers in our target markets are likely to be particularly sensitive to product defects and errors. Our reputation and the image of our products, services and technologies in our target markets may be impaired if our products or services fail to perform as expected. If our products do not perform, or are perceived to not have performed, as expected or favorably in comparison to competitive products, our operating results, reputation, and business will suffer, and we may also be subject to legal claims arising from product limitations, errors, or inaccuracies. Any of the foregoing could have an adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Although our products are tested in accordance with industry standards prior to shipment, defects or errors could nonetheless occur. For example, our instruments or PAs could fail or our partners could use our technology improperly and blame a failure on our systems, resulting in customer complaints and significant resources dedicated to finding the cause of the failure and/or developing a solution. Our operating results depend on our ability to execute and, when necessary, improve our quality management strategy and systems and our ability to effectively train and maintain our employees with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">We provide a standard one-year warranty on sold instruments. Existing and future warranties place us at the risk of incurring future repair and/or replacement costs. Since a large portion of our revenue is derived from sales of our PAs, which can only be used when our instruments are functioning, if our instruments fail to function and our customers choose to use alternative cell engineering methods our financial condition and results of operations would suffer. In addition, even after any underlying concerns or problems are resolved, any lingering concerns in our target markets regarding our technology or any manufacturing defects or performance errors, either actual or simply perceived, in our products or services could continue to result in lost revenue, delayed market acceptance, damage to our reputation and claims against us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, application scientists, engineers, scientific personnel, and customer support staff, our business may be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Our future sales will depend, in large part, on our ability to develop and substantially expand our sales and applications scientist infrastructure, particularly as we enter into new markets, rollout new products and platforms and manage inbound interest from new customers. We sell our products through our direct sales force and field application scientists located in North America, the United Kingdom and Europe, and have field application scientists located in the Asia-Pacific region where sales are currently managed by distributors. Our sales and marketing efforts are targeted at pharmaceutical and biotechnology companies and academic institutions focused on cell engineering and drug discovery. To continue driving adoption of our products and to support our global brand, we will need to further expand our field sales and application scientist infrastructure by hiring additional, highly qualified sales representatives, field application scientists, engineers and scientific personnel and customer support staff, in addition to increasing our marketing efforts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Identifying and recruiting qualified personnel globally with sufficient industry experience and training them requires significant time, expense and attention. If we provide inadequate training, fail to increase our sales and marketing capabilities or fail to develop broad brand awareness in our target markets in a cost-effective manner, our business may be harmed. In addition, if our efforts to expand do not generate a corresponding increase in revenue or result in a decrease in our operating margin, our financial results will be adversely impacted. If we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, our highly specialized application scientists and scientific personnel work closely with researchers, clinicians and current and prospective customers to optimize and implement cell engineering methods, processes and applications to meet their specific needs. Hiring these highly skilled application scientists and scientific personnel is competitive due to the limited number of people available with the necessary scientific and technical backgrounds and ability to understand our products at a technical level, and training such individuals requires significant time, expense and attention. Furthermore, we face intense competition in the labor market for such highly skilled specialists from competitors in our industry, our customers and companies in other industries, particularly because of the recent rapid growth in the cell therapy field. To effectively support current and potential customers, we will need to hire, maintain, train and grow globally the number of our applications scientists and add to our customer support staff. If we are unable to maintain, attract, train or retain the number of qualified support personnel that our business needs, our business and prospects will suffer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to expand or leverage the number of peer-reviewed articles published using data generated through the use of our products or otherwise increase brand awareness in our target markets, the demand for our products and our business may be adversely affected.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely on a significant base of peer-reviewed publications to showcase and validate the application of our technology in academic and clinical research settings. To date, there have been multiple peer-reviewed articles published, including in prominent journals, using data generated through the use of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">technology across a wide range of key scientific research areas, including research, discovery, development, and manufacturing of next-generation, cell-based therapeutics, as well as drug discovery including protein production for biological therapeutics, viral vectors, vaccines and small molecule discovery. We believe that expanding the number and breadth of these publications, and otherwise developing and maintaining awareness of our brand in our target markets in a cost-effective, manner is critical to achieving broad acceptance of our products and attracting new customers. Such publications and other brand promotion activities may not generate customer awareness or increase revenue and, even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the customers necessary to realize a sufficient return on our brand-building efforts, or to achieve the reputation and widespread brand awareness that is critical for broad customer adoption of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to Our Regulatory Environment and Our Industry</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">Changes in tariffs or other government trade policies may materially adversely affect our business and results of operations, including by reducing demand for our products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The imposition of tariffs and trade restrictions as a result of international trade disputes or changes in trade policies may adversely affect our sales and profitability. For example, in 2018 and 2019, the U.S. government imposed and proposed, among other actions, new or higher tariffs on specified imported products originating from China in response to what it characterized as unfair trade practices, and China responded by imposing and proposing new or higher tariffs on specified U.S. products. There can be no assurance that a broader trade agreement will be successfully negotiated between the United States and China to reduce or eliminate these tariffs. These tariffs, and the related geopolitical uncertainty between the United States and China, may cause decreased demand for our products or increase cost of components used in our products, which could have a material adverse effect on our business and results of operations. For example, certain of our foreign customers may respond to the imposition of tariffs or threat of tariffs on products we produce by delaying purchase orders or purchasing products from our competitors. Ongoing international trade disputes and changes in trade policies could also impact economic activity and lead to a general contraction of customer demand. In addition, tariffs on components that we may import from China or other nations will adversely affect our profitability unless we are able to exclude such components from the tariffs or we raise prices for our products, which may result in our products becoming less attractive relative to products offered by our competitors. Future actions or escalations by either the United States or China that affect trade relations may also negatively affect our business, or that of our suppliers or customers, and we cannot provide any assurances as to whether such actions will occur or the form that they may take. To the extent that our sales or profitability are negatively affected by any such tariffs or other trade actions, our business and results of operations may be materially adversely affected.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">We are subject to governmental export controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Exports of our products are subject to export controls and sanctions laws and regulations imposed by the U.S. government and administered by the U.S. Departments of State, Commerce, and Treasury. U.S. export control laws may require a license or other authorization to export products to certain destinations and end users. In addition, U.S. economic sanctions laws include restrictions or prohibitions on the sale or supply of certain products to U.S. embargoed or sanctioned countries, governments, persons and entities. Obtaining export licenses can be difficult, costly and time-consuming and we may not always be successful in obtaining necessary export licenses, and our failure to obtain required export approval for our products or limitations on our ability to export or sell our products imposed by export control or sanctions laws may harm our revenues and adversely affect our business, financial condition, and results of operations. Noncompliance with these laws could have negative consequences, including government investigations, penalties and reputational harm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The regulatory framework for the collection, use, safeguarding, retention, disclosure, transfer and other processing of personal data worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. We are, and will increasingly become as we seek to expand our business, subject to numerous foreign laws, regulations, rules and standards, as well as associated industry standards, policies and contractual or other obligations, relating to the collection, use, retention, security, disclosure, transfer and other processing of personal data in the jurisdictions in which we operate, collectively, Data Protection Requirements. If we fail, or are perceived to have failed, to address or comply with any such Data Protection Requirements, this could result in enforcement actions against us that could include investigations, fines, penalties, audits and inspections, additional reporting requirements and/or oversight, temporary or permanent bans on all or some processing of personal data or orders to destroy or not use personal data. Further, individuals or other relevant stakeholders could bring a variety of claims against us for our actual or perceived failure to comply with the Data Protection Requirements. Any of these events could have a material adverse effect on our reputation, business, or financial condition, and could lead to a loss of actual or prospective customers, collaborators or partners; interrupt or stop clinical trials; result in an inability to process personal data or to operate in certain jurisdictions; limit our ability to develop or commercialize our products; or require us to revise or restructure our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For example, the European Union&#8217;s General Data Protection Regulation, or GDPR, applies to any processing operations carried out in the context of the activities of an establishment in the EEA, as well as to any other processing operations relating to the offering of goods or services to individuals in the EEA and/or the monitoring of individuals&#8217; behavior in the EEA. Also, notwithstanding the United Kingdom&#8217;s withdrawal from the EU, by operation of the so called &#8220;UK GDPR&#8221; &#8203;(i.e., the GDPR as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended), or UK GDPR, the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of the activities of an establishment in the United Kingdom and any other processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of individuals&#8217; behavior in the United Kingdom. Therefore, reference to the GDPR herein also refers to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, the GDPR provides that EEA Member States may introduce specific requirements related to the processing of &#8220;special categories of personal data&#8221;, including the personal data related to health and genetic information, which we may process in connection with clinical trials or otherwise; as well as personal data related to criminal offences or convictions. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. This fact may lead to greater divergence on the law that applies to the processing of such personal data across the EEA and/or United Kingdom, which may increase our costs and overall compliance risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The GDPR itself imposes stringent data privacy and security requirements on both processors and controllers of personal data, including personal data related to health and genetic information, which we may process in connection with clinical trials. In particular, the GDPR imposes several requirements relating to ensuring there is a lawful basis for processing personal data, extends the rights of individuals to whom the personal data relates, materially expands the definition of what is expressly noted to constitute personal data (including expanding the relevant definition to capture expressly the &#8216;pseudonymized&#8217; or key-coded data that is commonly processed in a clinical trial-related context), requires additional disclosures about how personal data is to be used, imposes limitations on retention of personal data, imposes strict rules on the transfer of personal data out of the EEA to most third countries, creates mandatory data breach notification requirements in certain circumstances and establishes onerous new obligations on service providers, or processors, who process personal data simply on behalf of others.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">A particular issue presented by certain European data protection laws, including the GDPR, is that they generally restrict transfers of personal data from Europe, including the EEA, the United Kingdom </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">and Switzerland, to the United States and most other countries unless specific safeguards to protect the transferred personal data have been implemented. A July&#160;2020 decision of the European Union&#8217;s highest court, and subsequent regulatory guidance, have made complying with these requirements even more challenging&#8201;&#8212;&#8201;particularly in respect of transfers of personal data to the United States. Certain previously available safeguards have been invalidated, and reliance on alternative and commonly used safeguards may be complex or not possible in certain circumstances, following a recent ruling of the Court of Justice of the European Union and subsequent regulatory guidance. If we are unable to implement a valid solution for personal data transfers from Europe, we will face increased exposure to regulatory actions, substantial fines and injunctions. Inability to import/export personal data from Europe may also: restrict our activities in Europe; limit our ability to collaborate with partners as well as other service providers, contractors and other companies in Europe; and/or require us to increase our processing capabilities within Europe at significant expense or otherwise cause us to change the geographical location or segregation of our relevant systems and operations&#8201;&#8212;&#8201;any or all of which could adversely affect our operations or financial results. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Following the United Kingdom&#8217;s withdrawal from the EU on January&#160;31, 2020 and end of the post-Brexit transition period on December&#160;31, 2020, as noted above, the United Kingdom has introduced the UK GDPR which currently makes the privacy regimes of the EEA and United Kingdom similar, though it is possible that either the EU, and consequently those further states that make up the remainder of the EEA, or United Kingdom could elect to change their approach and create differences in legal requirements and regulation in this area. This could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially duplicative and/or divergent enforcement actions for the same violations. Furthermore, under the post-Brexit Trade and Cooperation Agreement between the EU and the United Kingdom, the United Kingdom and EU have agreed that personal data transfers to the United Kingdom from EEA Member States will not be treated as &#8216;restricted transfers&#8217; to a non-EEA country for an initial period of up to six&#160;months from the end of the post-Brexit transition period. If the European Commission does not adopt an &#8216;adequacy decision&#8217; in respect of the United Kingdom during this period, from that point onwards the United Kingdom will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of personal data from the EEA to the United Kingdom will require a valid &#8216;transfer mechanism&#8217; (such as entry into the then-current form of the European Commission-issued Standard Contractual Clauses). In general terms, the relationship between the United Kingdom and the EEA in relation to certain aspects of data protection law remains unclear, and there will now be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">While we have taken steps to comply with the GDPR and implementing legislation in applicable Member States, and the UK GDPR and Data Protection Act 2018 in the United Kingdom, we cannot assure you that our efforts to achieve and remain in compliance have been and/or will continue to be, fully successful.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EEA Member States/the United Kingdom may result in fines of up to &euro;20,000,000 / &#163;17,500,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. In addition to administrative fines, a wide variety of other potential enforcement powers are available to competent authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by non-compliant actors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All of these evolving compliance and operational requirements may require us to modify our data processing practices and policies, which in turn could distract management or divert resources from other initiatives and projects and may interrupt or delay our development activities. Any failure or perceived failure by us to comply with any applicable laws and regulations relating to data privacy and security could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign anti-corruption and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are subject to anti-corruption and anti-money laundering laws and regulations, including Foreign Corrupt Practices Act, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct or may in the future conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other third-party collaborators from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from persons in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to selling our products internationally directly through our sales teams, we currently engage third parties outside of the United States, and may engage additional third parties outside of the United States, to sell our products internationally and to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other third-party collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our customers who use our platform and we, if we develop a product, may be exposed to broadly applicable U.S. federal and state healthcare laws and regulations, including those relating to kickbacks and false claims, transparency, and health information privacy and security law. Failure to comply with such laws and regulations may result in substantial penalties.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our customers who use our platform and we, if we develop a product, may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell, and distribute our products. Such laws include federal and state anti-kickback laws, false claims laws, transparency laws, and health information privacy and security laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Violations of such laws may result in substantial criminal, civil and administrative penalties, including imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and significant fines, monetary penalties, forfeiture, disgorgement and damages, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, including the proposed modification to some of the aforementioned laws. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the healthcare industry. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or the implementation of new laws affecting the healthcare industry. Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any of our products successfully, and our customers and collaborators&#8217; ability to commercialize their products successfully, will depend in part on the extent to which coverage and adequate reimbursement for these products and will be available from third-party payors. As such, cost containment reform efforts may result in an adverse effect on our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">Our business is subject to environmental regulation and regulations relating to the protection of health and safety matters that could result in compliance costs. Any violation or liability under environmental laws or health and safety regulations could harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We are subject to environmental and safety laws and regulations governing the use, storage and disposal of hazardous substances or wastes and imposing liability for the cleanup of contamination from these substances. We handle hazardous substances in our manufacturing processes, and we could be liable for any improper use, storage, or disposal of such substances. We cannot completely eliminate the risk of contamination or injury from hazardous substances or wastes, and, in the event of such an incident, we could be held liable for any damages that result. In addition, we may be required to incur significant additional costs to comply with environmental laws and regulations in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The Occupational Safety and Health Act of 1970, or OSHA, establishes certain employer responsibilities, including maintenance of a workplace free of recognized hazards likely to cause death or serious injury, compliance with standards promulgated by the Occupational Safety and Health Administration and various record keeping, disclosure and procedural requirements. Various OSHA standards may apply to our operations. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with OSHA and other state and local laws and regulations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The failure to comply with these regulations could result in fines by government authorities and payment of damages to private litigants, which could harm our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">Our FDA Master File, and equivalent Technical Files in foreign jurisdictions, are an important part of our strategic offering which allows our partners to expedite their cellular therapies into and through the clinic. Delays in filing or obtaining (as applicable in a given jurisdiction), or our inability to obtain or retain, acceptance of such filings in individual countries could negatively impact the progress of our partners if they intend to run clinical trials in such countries, and as a result, could negatively affect our reputation and revenues or require disclosure of confidential information to our partners. Further, changes that we are required to make from time to time, or changes to regulations or negative data or adverse events for our partners, could impact references to our FDA Master File and Technical Files by our partners.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Providing our customers with an established regulatory path for use of our technology in the development of their therapeutics is an important value we provide to our customers. We have established and maintained an FDA Master File and equivalent Technical Files in certain other countries to provide that regulatory path. We may be unable in a timely manner, or at all, to provide similar filings in all countries where our customers desire to perform clinical trials, and regulators may refuse to accept such filings or may change their approach to such filings in a manner that weakens our ability to support our customers. If regulators at any point find that such filings have not been sufficiently maintained, or are insufficient to support clinical trials or drug approvals, as a result we may need to disclose confidential information to our partners to allow them to include such information in their filings. In addition, while we believe our FDA Master File and equivalent Technical Files have the potential to create certain efficiencies and reduce certain regulatory development risks for our customers, there is no guarantee that referencing our FDA Master File or Technical File, as applicable, will result in success in customers&#8217; submissions seeking authorization for clinical trials or marketing authorization. We cannot be certain that the FDA or foreign regulators will not require audits of and information on our ExPERT systems used in the clinic as our partners advance their cellular therapies from preclinical through clinical development toward marketing approval. Such additional information requests and audits of our facilities could result in delays in the development and potential regulatory approval of our partners&#8217; cellular therapy product candidates, affecting timing of milestone payments and our future ability to enter into new SPL agreements. Failure to adequately respond to any such regulatory requests could result in the regulator preventing our electroporation system from being utilized for a partner&#8217;s cellular therapy. This could result in our partners not utilizing our ExPERT system for their other clinical programs and negatively impact our ability to enter into partnership agreements with other cellular therapy developers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to Our Financial Position and Capital Requirements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may need additional funding beyond the proceeds of this offering and may be unable to raise capital when needed, which would force us to delay, reduce, eliminate or abandon our commercialization efforts or product development programs.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We cannot be certain that our anticipated cash flow from operations will be sufficient to meet all of our cash requirements or our growth plan. We intend to continue to make investments to support our business growth and may require additional funds to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand the commercialization of our products and execute on our growth strategy;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">fund our operations and product development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">finance the expansion into new international markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">expand our manufacturing capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">defend, in litigation or otherwise, any claims that we infringe, misappropriate or otherwise violate third-party patents or other intellectual property rights;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">commercialize our new products, if any such products receive regulatory clearance or approval for commercial sale; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">acquire companies and in-license products or intellectual property.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the net proceeds from this offering, together with our existing cash balances and cash receipts generated from sales of our products, will be sufficient to meet our anticipated cash requirements for the foreseeable future. However, we may need additional funding sooner than expected and our business and future funding requirements can change unpredictably due to a variety of factors, including acquisitions, which could affect our funding needs or cash flows from operations. We may be unable to raise additional funds in a timely manner or on terms that are acceptable to us. If we do not have, or are not able to obtain, sufficient funds, we may have to delay the further development or commercialization of our products. We also may have to reduce marketing, customer support or other resources devoted to our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our results of operations and liquidity needs could be materially and adversely affected by market fluctuations and economic downturn.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our results of operations and liquidity could be materially and adversely affected by economic conditions generally, both in the United States and elsewhere around the world. Domestic and international equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international economic policies, conditions and concerns. In the event the markets continue to remain volatile, our results of operations and liquidity could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions, some of which may not be federally insured. If economic instability were to occur, we cannot be certain that we will not experience losses on these cash and cash equivalents.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the level of demand for any of our products, which may vary significantly;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the timing and cost of, and level of investment in, research, development, manufacturing, regulatory approval and commercialization activities relating to our products, which may change from time to time;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the size, seasonality and customer mix of the cell engineering market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the start, milestone attainment and completion of programs in which our platform is utilized;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">sales and marketing efforts and expenses;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the rate at which we grow our sales force and the speed at which newly-hired salespeople become effective;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the productivity of our sales force;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">positive or negative coverage in the media or publications of our products or competitive products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms of our arrangements with our suppliers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the degree of competition in our industry and any change in the competitive landscape of our industry, including the introduction of new products or enhancements or technologies by us or others in the cell engineering market and competition-related pricing pressures;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in governmental regulations or in the status of our regulatory approvals or applications;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future accounting pronouncements or changes in our accounting policies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disruptions to our business and operations or to the business and operations of our suppliers, distributors, and other third parties with whom we conduct business resulting from the COVID-19 pandemic or other widespread health crises;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future global financial crises and economic downturns, including those caused by widespread public health crises; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our ability to use our net operating losses, business tax credits and similar tax attributes to offset future taxable income or taxes may be subject to certain limitations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, we had U.S. federal and state net operating loss carryforwards of $57.8 million and $43.0 million, respectively, and federal research credit carryforwards of $0.9 million. Under current law, U.S. federal net operating losses incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax&#160;years beginning after December&#160;31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally is defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and we may experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, including pursuant to this offering, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. Similar provisions of state law also may apply to limit the use of our state net operating loss carryforwards. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to Our Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide could adversely affect our business and the businesses of our partners. The COVID-19 pandemic has had and could continue to have an adverse impact on our business, operations, and the markets and communities in which we, our partners, and customers operate.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected, by, among other things, disrupting the research </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">and development activities of our customers, disrupting the development of our collaboration partners&#8217; product candidates, disrupting our ability to enter into new collaborations with potential partners in a timely manner, causing disruptions in the operations of our third-party manufacturing organizations upon whom we rely for the production and supply of our products, and causing other disruptions to our operations. The COVID-19 pandemic has caused general business disruption worldwide. As a result of the COVID-19 pandemic, we temporarily closed our headquarters and other offices, and our employees and contractors who are able to perform their duties remotely continue to do so. We have also implemented travel restrictions and other significant changes in how we operate our business. The operations of our partners and customers have likewise been altered. While the duration and extent of the COVID-19 pandemic depends on future developments and potential resurgences that cannot be accurately predicted at this time, such as the extent and effectiveness of containment actions and available vaccines, the pandemic has had an adverse effect on the global economy and the ultimate societal and economic impact of the COVID-19 pandemic remains unknown. The potential impact and duration of the COVID-19 pandemic on the global economy and our business are difficult to assess or predict. Potential impacts, some of which we have already experienced, include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our customer prospects and our existing customers may experience slowdowns in their businesses, and our academic institution customers may experience decreases in government funding of research and development, which in turn may result in reduced demand for our products, lengthening of sales cycles, loss of customers, difficulties in collections, and inaccurate inventory forecasting;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">limitations on our business operations by local, state, provincial and/or federal governments that could impact our ability to sell products to customers, and visit customers for process optimization of their cellular therapies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">delays in negotiations with partners and potential partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in receiving supplies from the third parties we rely on to manufacture components to our products, which may impair our ability to sell our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in installation of our products for our customers and partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">interruption of or delays in the shipments of purchased products to customers or to our distribution partners;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">decreased employee productivity and morale, with increased employee attrition and risk of a cyberattack resulting from our employees working from home;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">disruptions and significant costs to our growth planning, such as for facilities and international expansion;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">costs in fully returning to work from our facilities around the world, including changes to the workplace, such as space planning, food service and amenities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">legal liability for safe workplace claims;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of critical vendors or third-party partners, which may go out of business; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continued cancellation of in-person marketing events, including industry conferences, and prolonged delays in our ability to reschedule or conduct in-person marketing events and other sales and marketing activities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The impact of any of the foregoing, individually or collectively, could adversely affect our business, financial condition, and results of operations. Moreover, to the extent the COVID-19 pandemic adversely affects our business, financial condition, and results of operations, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of information security could adversely affect our business, results of operations and financial condition.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of information (including but not limited to, confidential information, employee data, customer information, personal data and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our information. The size and complexity of our information security systems, and those of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">third-party vendors with whom we contract (and the large amounts of information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicious attacks by third parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cyberattacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyberattacks also could include phishing attempts or e-mail fraud to cause unauthorized payments or information to be transmitted to an unintended recipient, or to permit unauthorized access to systems. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any cyberattack or security incident that leads to unauthorized access, acquisition, use or disclosure of personal or proprietary information could harm our reputation, cause us not to comply with U.S. federal and/or state, or non-U.S., data breach notification laws, or our contractual obligations, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we have cyber-insurance coverage that may cover certain events described above, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of information, including confidential information, employee data, customer information, personal information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We are highly dependent on our senior management team and key personnel and our business could be harmed if we are unable to attract and retain personnel necessary for our success.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are highly dependent on our senior management team and key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales, marketing, scientific and technical professionals, and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales, marketing, scientific and technical professionals could result in lower than expected sales and delays in product development. If we are not successful in attracting and retaining highly qualified personnel, it would have a negative impact on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued, and will in the future issue, equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, they may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Many of the other cell engineering or therapeutic development companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities, better chances for career advancement and higher compensation. Some of these characteristics are more appealing to high-quality candidates than what we can offer. Further, if we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, job candidates and existing employees often consider the value of the equity awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are a public company or for other reasons, it may harm our ability to recruit and retain highly skilled employees. Many of our employees have become or will soon become vested in a substantial amount of their equity awards. Our employees may be more likely to leave us if the equity they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the lock-up agreements described herein.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees as we expand our business and operations. If we fail to attract new personnel or fail to retain and motivate our current personnel, it will negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We have increased the size of our organization and expect to further increase it in the future, and we may experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of March&#160;31, 2021, we had 65 full-time employees. As our sales and marketing strategies develop and as we transition into operating as a public company on a U.S. exchange, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">improving our operational, financial and management controls, reporting systems and procedures.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have experienced growth and anticipate further growth in our business operations both inside and outside the United States. This future growth could strain our organizational, administrative and operational infrastructure, including quality control, operational, finance, customer service and sales organization management. We expect to continue to increase our headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, engineers, technical personnel and sales and marketing staff and improve and maintain our products to properly manage our growth. Rapid expansion in personnel could mean that less experienced people develop, market and sell our products, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our employees, our business may be harmed. We may not be able to maintain the quality or expected turnaround times of our products or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely, efficient and effective manner could adversely affect our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our officers, employees, independent contractors, consultants and commercial partners may engage in misconduct or activities that are improper under other laws and regulations, or make significant errors, which would create liability for us.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to the risk that our officers, employees, independent contractors, consultants, commercial partners, suppliers, and third-party distributors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, which could result in regulatory sanctions and serious harm to our reputation. While we have programs in place to address this conduct, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, including without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, and the curtailment or restructuring of our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our existing products and limit commercialization of any products that we may develop.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The marketing, sale and use of our products could lead to the filing of product liability claims where someone may allege that our products identified inaccurate or incomplete information or otherwise failed to perform as designed. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability claim could result in substantial damages and be costly and time-consuming for us to defend. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">substantial litigation costs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">distraction of management&#8217;s attention from our primary business;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the inability to commercialize our products or new products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">decreased demand for our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">damage to our business reputation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">product recalls or withdrawals from the market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">loss of sales; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">termination of existing agreements by our partners and potential partners failing to partner with us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain product liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability claims. Any product liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We may not be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future and these efforts may not have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also harm our reputation with customers, which could negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If our customers fail to safely and appropriately use our products, or if we are unable to train our customers on the safe and appropriate use of our products, our reputation may be negatively impacted and we may be unable to achieve our expected sales, growth or profitability.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">An important part of our sales process includes training our customers on how to safely and appropriately use our products. If our customers are not properly trained, they may misuse or ineffectively use our products. Any improper use of our products may result in unsatisfactory outcomes, negative publicity or lawsuits against us, any of which could harm our reputation and affect future product sales. Even if our products are used improperly by customers, we may face reputational damage if our products are associated with negative outcomes or injuries. Damage to our reputation could make it more difficult for us to sell our products and enter into new partnerships. Accordingly, if our customers fail to safely and appropriately use our products or if we are unable to train our customers on the safe and appropriate use of our products, our reputation may be negatively impacted and we may be unable to achieve our expected sales, growth or profitability.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Litigation and other legal proceedings may harm our business.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">While we have never been involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal or state regulatory investigations, securities class actions and other legal proceedings or investigations, we may become involved in such legal proceedings which could have a negative impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could harm our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our products, even if the regulatory or legal action is unfounded or not material to our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our operations (including our manufacturing operations) and the operations of our distribution partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and pandemics, including the COVID-19 pandemic, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. Our ability to obtain components for our products could be disrupted if the operations of our suppliers were affected by a man-made or natural disaster or other business interruption, including interruptions related to the COVID-19 pandemic. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We manufacture our ExPERT instruments at our manufacturing facilities located in Maryland, and we rely on various suppliers in the United States. Should our manufacturing facilities or the facilities of our suppliers be damaged or destroyed by natural or man-made disasters, such as earthquakes, fires or other events, or should events such as political unrest unfold, it could take&#160;months to relocate or rebuild, during which time our manufacturing and the operations of our suppliers would cease or be delayed and our products may be unavailable. The inability to perform our manufacturing activities, combined with our limited inventory of materials and components and manufactured products, or the inability of our suppliers to continue their operations, may cause us to be unable to meet customer demand or harm our reputation, and we may be unable to reestablish relationships with such customers in the future. Consequently, a catastrophic event or business interruption at our manufacturing facilities or at our suppliers&#8217; facilities could harm our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We do not carry insurance for all categories of risk that our business may encounter. Although we have general and product liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could negatively affect our business, financial condition and results of operations. We do not carry specific hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. Although we carry cyber insurance, the coverage may not be sufficient to cover our losses in the event of a security </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">incident that results in any data loss, deletion or destruction; unauthorized access to, or acquisition, disclosure or exposure of information; or compromise related to the security, confidentiality, integrity or availability of information technology, software, services, communications or data.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We also expect that operating as a public company in the United States will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">The majority of our operations are currently conducted at a single location and any disruption at our facility could negatively impact our operations and increase our expenses.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our headquarters in Maryland contains most of our corporate and administrative functions, the majority of our research, and all of our in-house manufacturing, inventory and distribution functions. A natural or other disaster, such as a fire or flood, could cause substantial delays in our operations, damage or destroy our manufacturing equipment or inventory, and cause us to incur additional expenses. The insurance we maintain against fires, floods and other natural disasters may not be adequate to cover our losses in any particular case. With or without insurance, damage to our manufacturing facility or our other property, or to any of our suppliers, due to fire, flood or other natural disaster or casualty event may have a material adverse effect on our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may face exposure to foreign currency exchange rate fluctuations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro and the British pound. We expect our non-U.S. operations to continue to grow in the near term and we are continually monitoring our foreign currency exposure to determine if we should consider a hedging program. Today, our non-U.S. contracts are generally denominated in U.S. dollars, while our non-U.S. operating expenses are often denominated in local currencies. Additionally, as we expand our non-U.S. operations, a larger portion of our operating expenses may be denominated in local currencies. Therefore, increases in the value of the U.S. dollar and decreases in the value of foreign currencies could result in the dollar equivalent of our revenue being lower, which would negatively affect our reported results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to our Intellectual Property</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Our ability to compete and the success of our business could be jeopardized if we are unable to protect our intellectual property adequately.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our success depends to a degree upon the protection of our proprietary technology and obtaining, maintaining and enforcing our intellectual property and other proprietary rights. We rely on a combination of trade secrets, patents, copyrights, trademarks and contractual provisions with employees, contract manufacturers, consultants, customers and other third parties to establish and protect our intellectual property rights, all of which offer only limited protection. Other parties may not comply with the terms of their agreements with us, and we may not be able to enforce our rights adequately against these parties.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although we enter into confidentiality, assignments of proprietary rights and license agreements, as appropriate, with our employees and third parties, including our contract manufacturers, contract engineering firms, and generally control access to and distribution of our technologies, documentation and other proprietary information, we cannot be certain that the steps we take to prevent unauthorized use of our intellectual property rights are sufficient to prevent their misappropriation, particularly in foreign countries where laws or law enforcement practices may not protect our intellectual property rights as fully as in the United States. In addition, we rely on trade secrets and know-how to protect certain of our technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets and know-how are difficult to protect, as trade secrets do not protect against independent development of a technology by third parties. Although we use reasonable efforts to protect our trade secrets and know-how, our employees and third parties to whom our trade secrets </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">and know-how are disclosed may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If competitors are able to use our technology, our ability to compete effectively could be harmed. For example, if a competitor were to gain use of certain of our proprietary technology, it might be able to develop and manufacture similarly designed solutions at a reduced cost, which would result in a decrease in demand for our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Furthermore, we have adopted a strategy of seeking limited patent protection both in the United States and in foreign countries with respect to the technologies used in or relating to our products. Although we generally apply for patents in those countries where we expect to have material sales of our patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. We do not know whether any of our pending patent applications will result in the issuance of patents or whether the examination process will require us to narrow our claims, and even if patents are issued, they may be contested, circumvented, modified, revoked, found to be unenforceable, or invalidated over the course of our business. Moreover, the rights granted under any issued patents may not provide us with proprietary protection, barriers to entry or competitive advantages, and, as with any technology, competitors may be able to develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies and we may not be able to obtain licenses on reasonable terms, if at all, thereby causing great harm to our business. Additionally, the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the United States Patent and Trademark Office, or the USPTO, or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or patent applications, in our licensed patents or patent applications or in third-party patents. Moreover, patents have a limited term, and certain of our patents have recently or will expire in the near future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We rely on our trademarks, trade names, and brand names to distinguish our products from the products of our competitors and have registered or applied to register many of these trademarks. We cannot assure you that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources to the advertising and marketing of new brands.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Legal proceedings to assert our intellectual property rights could be costly and could impair our operations.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Even in those instances where we have determined that another party is breaching our intellectual property and other proprietary rights, enforcing our legal rights with respect to such breach may be expensive and difficult. We may need to engage in litigation to enforce or defend our intellectual property and other proprietary rights, which could result in substantial costs and diversion of management resources. Further, many of our current and potential competitors are substantially larger than we are and have the ability to dedicate substantially greater resources to defending any claims by us that they have breached our intellectual property rights. If we are unsuccessful in enforcing our intellectual property rights, it could have a material adverse effect on our business, results of operations and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We may be sued by third parties for alleged infringement of their proprietary rights, which could be costly, time-consuming and limit our ability to use certain technologies in the future or to develop future products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We may be subject to claims that our technologies infringe upon the intellectual property or other proprietary rights of third parties. Any claims, even those without merit, could be time-consuming and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">expensive, and could divert our management&#8217;s attention away from the execution of our business plan. Moreover, any settlement or adverse judgment resulting from the claim could require us to pay substantial amounts or obtain a license to continue to use the technology that is the subject of the claim, or otherwise restrict or prohibit our use of the technology. There can be no assurance that we would be able to obtain a license from the third party asserting the claim on commercially reasonable terms, if at all, that we would be able to develop alternative technology on a timely basis, if at all, or that we would be able to obtain a license to use a suitable alternative technology to permit us to continue offering, and our customers to continue using, our affected product.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also harm our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">We may be obligated to disclose our proprietary technology to our customers, which may limit our ability to protect our intellectual property.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Certain customer agreements contain provisions permitting the customer to become a party to, or a beneficiary of, a technology escrow agreement under which we place proprietary know-how and source code for our products in escrow with a third party. Under these escrow agreements, the know-how and source code to the applicable product may be released to the customer, typically for its use to further develop, maintain, modify and enhance the product, upon the occurrence of specified events, such as our filing for bankruptcy and breaching our representations, warranties or covenants of our agreements with our customers. Disclosing this know-how and source code may limit the intellectual property protection we can obtain or maintain for that know-how or source code or the products embodying or containing that know-how or source code and may facilitate intellectual property infringement claims against us. Each of these could harm our business, results of operations and financial condition.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risks Related to This Offering and Our Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">There has been no prior market for our common stock in the United States and an active trading market for our common stock may not develop in the United States.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for shares of our common stock in the United States. However, since 2016, our common stock has traded on AIM under the symbol &#8220;MXCT,&#8221; as well as other symbols, of which &#8220;MXCN&#8221; is currently active, and following this offering will continue to trade on AIM. We cannot predict when or whether investor interest in our common stock might lead to an increase in its market price or the development of a more active trading market. The U.S. initial public offering price for our common stock was determined through negotiations with the underwriters based on a number of factors, including the historic trading prices of our common stock on AIM, that might not be indicative of prices that will prevail in the trading market for our common stock in the United States. While our common stock has been approved for listing on the Nasdaq Global Select Market, an active trading market for our shares in the United States may never develop or be sustained following this offering. If an active market for our common stock does not develop, it may be difficult to sell shares purchased in this offering without depressing the market price for the shares, or at all.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of listed companies. Stock prices of many newly public companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business, financial condition and results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Upon the completion of this offering, our common stock will be traded on two separate stock markets and investors seeking to take advantage of price differences between such markets may create unexpected volatility in our share price; in addition, investors may not be able to easily move shares for trading between such markets.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our shares of common stock are already admitted to and traded on AIM and have been approved for listing on The Nasdaq Global Select Market. Price levels for our common stock may fluctuate significantly on either market, independent of our common stock price on the other market. Investors could seek to sell or buy our common stock to take advantage of any price differences between the two markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected volatility in both our common stock prices on either exchange and the volumes of shares of our common stock available for trading on either exchange. In addition, holders of common stock on either market will not be immediately able to transfer such common stock for trading on the other market without effecting necessary procedures with our transfer agent. This could result in time delays and additional cost for our stockholders. Further, if we are unable to continue to meet the regulatory requirements for admission to AIM or listing on the Nasdaq Global Select Market, we may lose our admission to AIM or listing on the Nasdaq Global Select Market, which could impair the liquidity of shares of our common stock. Investors whose source of funds for the purchase of shares of our common stock is denominated in a currency other than U.S. Dollars may also be adversely affected by fluctuations in the exchange rate between such currency and the U.S. Dollar.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Securities traded on AIM may carry a higher risk than securities traded on other exchanges, which may impact the value of your investment.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our shares of common stock are currently traded on AIM. Investment in equities traded on AIM is sometimes perceived to carry a higher risk than an investment in equities quoted on exchanges with more stringent listing requirements, such as the main market of the London Stock Exchange, New York Stock Exchange or Nasdaq. This is because AIM is less heavily regulated, imposes less stringent corporate governance and ongoing reporting requirements than those other exchanges. In addition, AIM requires only half-yearly, rather than quarterly, financial reporting. You should be aware that the value of our shares of common stock may be influenced by many factors, some of which may be specific to us and some of which may affect AIM companies generally, including the depth and liquidity of the market, our performance, a large or small volume of trading in our shares of common stock, legislative changes and general economic, political or regulatory conditions, and that the prices may be volatile and subject to extensive fluctuations. Therefore, the current market price of our shares of common stock may not reflect the underlying value of our company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">The price of our common stock is likely to be volatile and may fluctuate due to factors beyond our control.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The market price of our common stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">actual or anticipated fluctuations in our financial condition or results of operations;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">variance in our financial performance from expectations of securities analysts;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in our projected operating and financial results;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements by us or our competitors of significant business developments, acquisitions, or new offerings;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements by our partners on clinical development delays for products being enabled by our technology;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">announcements or concerns regarding real or perceived safety or efficacy issues with our products or similar products of our competitors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">adoption of new regulations applicable to our industry or the expectations concerning future regulatory developments;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our involvement in litigation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">future sales of our common stock by us or our stockholders, as well as the anticipation of lock-up releases;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in senior management or key personnel;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the trading volume of our common stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the anticipated future size and growth rate of our market; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">general economic and market conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Broad market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may also negatively impact the market price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and our trading volume could decline.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If no or too few securities or industry analysts commence coverage of us, the trading price for our common stock could be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, the price of our common stock could decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause the price of our common stock and trading volume to decline</font><font style="font-style:italic;">.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a U.S.-listed public company, and our management and board of directors will be required to devote substantial time to new compliance initiatives and corporate governance practices.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">As a U.S.-listed public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company or as a company with shares traded only on AIM. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. In addition, our shares of common stock are currently traded on AIM and will continue to be subject to AIM&#8217;s admission and compliance requirements, which differ in many respects from the requirements of the Nasdaq Global Select Market and U.S. securities rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our management, board of directors and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our management and board of directors. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Future sales of our common stock in the public market could cause our share price to fall.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Sales of a substantial number of shares of our common stock in the public market after this offering, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Upon the closing of this offering, we will have 98,189,559 shares of common stock outstanding, assuming no exercise of outstanding options or the underwriters&#8217; option to purchase additional shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act of 1933, or the Securities Act, as amended, except for any shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. A total of 1,487,486 shares of common stock outstanding immediately after this offering, or 1.5%, will be restricted as a result of securities laws, lock-up agreements or other contractual restrictions that restrict transfers for 90&#160;days after the date of this prospectus. Of the remaining shares outstanding, 96,372,073 shares will remain freely tradeable and 330,000 shares will become freely tradeable after the distribution compliance period pursuant to Regulation&#160;S under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated and William Blair &amp; Company, L.L.C. may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements with the underwriters prior to expiration of the lock-up period. See &#8220;Shares Eligible for Future Sale.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We intend to file a registration statement on Form S-8 under the Securities Act to register shares for issuance under our equity incentive plans, including our Long-Term Incentive Plan, or LTIP, 2021 Equity Incentive Plan and employee stock purchase plan. Each of these plans provides for automatic increases in the shares reserved for issuance under the plan which could result in additional dilution to our stockholders. Once we register these shares, they can be freely sold in the public market upon issuance and vesting, subject to any lock-up restrictions of the holder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Because we do not expect to pay dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have never declared or paid any dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The decision to pay future dividends to stockholders will be at the discretion of our board of directors after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. Accordingly, investors cannot rely on dividend income from our common stock and any returns on an investment in our common stock will likely depend entirely upon any future appreciation in the price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If you purchase common stock in this offering, you will suffer immediate dilution of your investment.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">The initial public offering price of our common stock is substantially higher than the net tangible book value per share. Therefore, if you purchase common stock in this offering, you will pay a price per share that substantially exceeds the book value of our tangible assets, after subtracting our liabilities, after this offering. Based on the initial public offering price of $13.00 per share, you will experience immediate dilution of $10.54 per share, representing the difference between our net tangible book value per share after giving effect to this offering and the initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately 55.3% of the aggregate price paid by all purchasers of our common stock in the last five years but will own only approximately 19.6% of the shares of our common stock purchased in the last five years. To the extent options are exercised, you will incur further dilution. See the section of this prospectus titled &#8220;Dilution&#8221; for more information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Provisions in our governing documents will require disclosure of information about stockholders that would not otherwise be required to be disclosed under applicable U.S. state or federal laws.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>

          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">In accordance with the AIM Rules for Companies published by the London Stock Exchange, or the AIM Rules, we are required to disclose information regarding the legal and beneficial owners of three&#160;percent or more of our outstanding common stock. In order to allow us to comply with the AIM Rules, our certificate of incorporation contains a provision requiring any legal or beneficial owner of three&#160;percent or more of the voting power attributable to our outstanding common stock to notify us of his, her or its holdings, as well as of any change in his, her or its legal or beneficial ownership above three&#160;percent of our outstanding common stock, which increases or decreases his, her or its holding through any single&#160;percentage. Comparatively, none of the U.S. state or federal laws that will be applicable to us after the offering or the rules of Securities and Exchange Commission, or the SEC, or the Nasdaq Global Select Market require stockholders to report this beneficial ownership information to us or us to disclose this information to the public or a regulatory body. We are required to make this information public in the United Kingdom under the AIM Rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. We intend to use the net proceeds from this offering to: (i)&#160;continue making investments in research and development efforts; (ii)&#160;continue making investments </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">in building our business development, sales and applications teams and marketing our products to new and existing partners in attractive global markets, as well as for general corporate purposes, including working capital, operating expenses and capital expenditures; (iii)&#160;further invest to in-source and automate manufacturing to support our cell therapy customers; (iv)&#160;scale our process development capabilities via investment in laboratory space, equipment and addition of scientific resources; and (v)&#160;commercialize our VLX Large-Scale Transfection System under the ExPERT family of products to facilitate potential expansion into adjacent markets. The failure by our management to apply these funds effectively could result in financial losses that could have an adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; will make our common stock less attractive to investors.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section&#160;107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We will remain an emerging growth company until the earliest of: (1)&#160;the last day of the fiscal year following the fifth anniversary of this offering; (2)&#160;the last day of the first fiscal year in which our annual gross revenue is $1.07&#160;billion or more; (3)&#160;the date on which we have, during the previous rolling three-year period, issued more than $1&#160;billion in non-convertible debt securities; and (4)&#160;the last day of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700&#160;million as of June&#160;30 of such fiscal year.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations may not be as comparable to the results of operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. We could be an &#8220;emerging growth company&#8221; for up to five&#160;years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Provisions in our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, as they will be in effect upon the completion of this offering, and provisions of Delaware law applicable to us, may have the effect of delaying or preventing a change of control or changes in our management. Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws will include provisions that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, or our chief executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">establish that our board of directors is divided into three classes, with each class serving three-year staggered terms;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">prohibit cumulative voting in the election of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that our directors may be removed (i)&#160;with or without cause, upon the vote of at least 50% of the outstanding shares of voting stock or (ii)&#160;with cause, by the affirmative vote or consent of at least two-thirds of the other members of our board of directors; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three&#160;years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our fifteenth amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America as the exclusive forums for substantially all disputes between us and our stockholders, which will restrict our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, or employees.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:268pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any derivative action or proceeding brought on our behalf;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a breach of a fiduciary duty;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our fifteenth amended and restated certificate of incorporation, or our amended and restated bylaws; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any action asserting a claim against us that is governed by the internal affairs doctrine.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The provisions would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Securities Exchange Act of 1934, as amended. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our fifteenth amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees. If a court were to find either choice of forum provision contained in our fifteenth amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could seriously harm our business.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This prospectus contains forward-looking statements about us and our industry that involve substantial risks, uncertainties, and assumptions, including those described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expected future growth and the success of our business model;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the potential payments we may receive pursuant to our SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share and achieve and maintain industry leadership;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the rate and degree of market acceptance of our products within the cell engineering market;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the expected future growth of our manufacturing capabilities and sales, support and marketing capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to expand our customer base and enter into additional SPLs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to accurately forecast and manufacture appropriate quantities of our products to meet commercial demand;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding development of the cell therapy market, including projected growth in adoption of non-viral delivery approaches and gene editing manipulation technologies;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to maintain our FDA Master File and Technical Files;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our research and development for any future products, including our intention to introduce new instruments and PAs and move into new applications;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the development, regulatory approval, and commercialization of competing products and our ability to compete with the companies that develop and sell such products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to retain and hire senior management and key personnel;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">regulatory developments in the United States and foreign countries;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to develop and maintain our corporate infrastructure, including our internal controls;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our financial performance and capital requirements;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our use of the net proceeds from this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:396pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The forward-looking statements made in this prospectus relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this prospectus to reflect events or circumstances after the date of this prospectus or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission, or SEC, as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMIAO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:354pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MARKET, INDUSTRY AND OTHER DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This prospectus contains estimates, projections and other information concerning our industry, our business and the markets for our products. Some market data and statistical information contained in this prospectus are also based on management&#8217;s estimates and calculations, which are derived from our review and interpretation of independent sources and our internal research and knowledge of our market. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to these estimates. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These and other factors could cause results to differ materially from those expressed in the projections and estimates made by independent third parties and us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Unless otherwise expressly stated, we obtained industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:190pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">USE OF PROCEEDS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">We estimate that we will receive net proceeds from this offering of approximately $160.2 million (or approximately $184.7 million if the underwriters exercise their option to purchase additional shares of our common stock from us in full) based on a public offering price of $13.00 per share of common stock, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The principal purposes of this offering are to obtain additional capital to increase our financial flexibility, to support our operations and growth, to create a public market for our common stock in the United States and to enable access to the U.S. public equity markets for us and our stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">approximately $20 million to $30 million for research and development initiatives, including commercialization of the VLX platform under the ExPERT umbrella and introducing next-generation versions of our ExPERT platform;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">approximately $20 million to $30 million to expand our manufacturing capabilities and invest in manufacturing automation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">approximately $10 million to $20 million to expand our sales and marketing, business development, and field application scientist teams; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the remainder for working capital and general corporate purposes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We may also use a portion of the net proceeds from this offering for the acquisition of businesses, technologies, services or other assets that we believe are complementary to our own. However, we do not currently have agreements or commitments to enter into any acquisitions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth of our business and our potential acquisition activities. Based on our current plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:562pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">DIVIDEND POLICY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate declaring or paying any cash dividends in the foreseeable future. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:139pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">CAPITALIZATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth our cash and cash equivalents and capitalization as of March&#160;31, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">on an actual basis; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">on an as adjusted basis, giving effect to our receipt of estimated net proceeds of $160.2&#160;million from the sale of 13,500,000 shares of common stock that we are offering at a public offering price of $13.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Cash and cash equivalents are not components of our total capitalization. You should read this table together with the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included elsewhere in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <table style="width:456pt;height:166pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:313.09pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">March&#160;31, 2021 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:313.09pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Actual </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">As Adjusted </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:313.09pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">78,703,700</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:51pt; text-align:right; white-space:nowrap;">238,918,700 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:313.09pt;text-align:left;">
                <font style="letter-spacing:-0.025pt;">Stockholders&#8217; equity: </font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.167pt 0pt 0.833pt 0pt; width:313.09pt;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">Common stock, $0.01 par value, 200,000,000 authorized, </font>
                  <br >
                  <font style="letter-spacing:-0.025pt;">84,689,559 shares issued and outstanding, actual; 400,000,000 </font>
                  <br >
                  <font style="letter-spacing:-0.025pt;">shares authorized, 98,189,559 shares issued and outstanding, as </font>
                  <br >
                  <font style="letter-spacing:-0.025pt;">adjusted </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">846,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">981,900</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:313.09pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">182,766,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">342,846,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:313.09pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:51pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:313.09pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">81,285,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:51pt; text-align:right; white-space:nowrap;">241,500,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:313.09pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:-0.025pt;">Total capitalization </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">81,285,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:51pt; text-align:right; white-space:nowrap;">241,500,600</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on 84,689,559 shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">12,071,923 shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our LTIP with a weighted average exercise price of $4.41 per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">4,131,667 shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">71,168 shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of &#163;1.09081 ($1.50477 based on the exchange rate of &#163;1.00 to $1.3795, the exchange rate on March 31, 2021) per share. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">DILUTION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of common stock and the as adjusted net tangible book value per share immediately after this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our net tangible book value as of March&#160;31, 2021 was $81.3 million, or $0.96 per share of common stock. Our net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the number of our shares of common stock outstanding as of March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">After giving effect to the sale by us of 13,500,000 shares of common stock in this offering at a public offering price of $13.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March&#160;31, 2021 would have been $241.5 million, or $2.46 per share. This amount represents an immediate increase in net tangible book value of $1.50 per share to our existing stockholders and an immediate dilution of $10.54 per share to new investors purchasing common stock in this offering. We determine dilution by subtracting the as adjusted net tangible book value per share after this offering from the public offering price per share paid by investors purchasing common stock in this offering. The following table illustrates this dilution on a per share basis:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <table style="width:456pt;height:83pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <tr style="line-height:9.99999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:386.43pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Public offering price per share </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">13.00 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:386.43pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:-0.025pt;">Historical net tangible book value per share as of March&#160;31, 2021 </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.96</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:386.43pt;white-space:normal;text-align:left;">
                <div style="margin-left:20pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1.50</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:386.43pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">As adjusted net tangible book value per share after giving effect to this offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">2.46</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.25pt 0pt; width:386.43pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Dilution per share to new investors in this offering </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">10.54</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">If the underwriters exercise their option to purchase additional shares of common stock from us in full, our as adjusted net tangible book value would be $2.65 per share, and the dilution in net tangible book value per share to new investors in this offering would be $10.35 per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The following table summarizes, as of March&#160;31, 2021, on the as adjusted basis described above, the number of shares of our common stock, the total consideration and the average price per share (1)&#160;paid to us by existing stockholders for shares purchased in the last five years and (2)&#160;to be paid by new investors acquiring our common stock in this offering at a public offering price of $13.00 per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>


          <table style="width:456pt;height:76.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:184.05pt;text-align:left;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Shares Purchased </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Total Consideration </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Average Price</font>
                  <br >
                  <font style="letter-spacing:-0.089pt;">Per Share </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Number </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Percent </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Amount </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Percent </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:184.05pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Existing stockholders </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">55,504,812</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">80.4<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">141,953,649</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">44.7<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.16pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2.56</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:184.05pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">New investors </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">13,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">19.6</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">175,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">55.3</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.16pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21.75pt; text-align:right; white-space:nowrap;">13.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:184.05pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">69,004,812</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">317,453,649</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.04pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.16pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:13.1pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">The number of shares of common stock that will be outstanding after this offering is based on 84,689,559 shares of common stock outstanding as of March&#160;31, 2021, and excludes:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">12,071,923 shares of common stock issuable on the exercise of outstanding stock options as of March&#160;31, 2021 under our LTIP with a weighted average exercise price of $4.41 per share;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">4,131,667 shares of common stock reserved for future issuance as of March&#160;31, 2021 under our LTIP; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">71,168 shares of common stock issuable on the exercise of an outstanding common stock warrant at an exercise price of &#163;1.09081 ($1.50477 based on the exchange rate of &#163;1.00 to $1.3795, the exchange rate on March 31, 2021) per share.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:544pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">To the extent that stock options or warrants are exercised, new stock options or other equity awards are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSCFD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">SELECTED CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The selected consolidated statement of operations data for the fiscal&#160;years ended December&#160;31, 2019 and 2020 and the selected consolidated balance sheet data as of December&#160;31, 2019 and 2020 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary consolidated statement of operations data for the three months ended March 31, 2020 and 2021 and the summary consolidated balance sheet data as of March 31, 2021 have been derived from our unaudited interim financial statements included elsewhere in this prospectus. You should read the financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results to be expected for any period in the future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:330pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:149.07pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended March 31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.111pt;">Consolidated Statement of Operations Data:</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,742,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,494,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Costs of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">2,499,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">659,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">693,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,121,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,083,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,801,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">17,601,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,244,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,077,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">7,852,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,050,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">6,088,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,776,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">3,308,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">31,541,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">8,071,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,174,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(2,988,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(6,373,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Other income (expense): </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(116,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(742,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">206,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">65,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">42,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">9,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total other income (expense) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(73,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(732,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:149.07pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:43.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(0.09<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:149.07pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Weighted-average common shares outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">56,397,524</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:43.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">81,004,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:205.52pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">As of December&#160;31,</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">As of March 31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Consolidated Balance Sheet Data:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">78,703,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Working capital(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">15,108,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,639,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">77,015,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">95,007,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">16,383,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">13,722,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">182,766,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:205.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total stockholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">81,285,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Working capital is defined as current assets less current liabilities.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</font>
          <br >
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with the section of this prospectus titled &#8220;Selected consolidated financial data&#8221; and our consolidated financial statements and related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and business strategy, include forward-looking statements that involve risks and uncertainties. As a result of many factors, our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this prospectus titled &#8220;Risk factors.&#8221; Please also see the section titled &#8220;Special note regarding forward-looking statements.&#8221;<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; portfolio of proprietary related processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of June&#160;30, 2021, we have placed more than 400 of our electroporation instruments worldwide. During the year ended December 31, 2020, we sold a total of 70 instruments and leased an additional 16 instruments to our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend on the successful further development and commercialization of our products. We generated revenue of $21.6&#160;million and $26.2&#160;million for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and incurred net losses of $12.9&#160;million and $11.8&#160;million for those same&#160;years. As of December&#160;31, 2020, we had an accumulated deficit of $95.2&#160;million. We generated revenue of $6.5 million and incurred a net loss of $7.1 million for the three months ended March 31, 2021. As of March 31, 2021, we had an accumulated deficit of $102.3 million. We expect to continue to incur net losses as we focus on growing commercial sales of our products in both the United States and international markets, including growing our sales teams, scaling our manufacturing operations, continuing research and development efforts to develop new products and further enhance </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">our existing products. Further, following the closing of this offering, we expect to incur additional costs associated with operating as a public company in the United States.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe we have an attractive, diversified revenue model with revenue generated from multiple sources including instrument leases with recurring license fees, sales of instruments and related disposables and participation in the clinical and commercial success of some of our customers through milestone and sales-based payments under agreements that we refer to as Strategic Platform Licenses, or SPLs. In addition to our ExPERT products, we previously developed CARMA, a proprietary therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies. In the first quarter of 2021, we conducted a strategic review of our CARMA activities and made the decision to cease further research and clinical development activities with respect to the CARMA platform for our own internal purposes and instead to focus on out-licensing the CARMA platform manufacturing processes and associated intellectual property to third-party customers. During the&#160;years ended December&#160;31, 2019 and 2020 and the three months ended March 31, 2021, our CARMA-related expenses were $11.7&#160;million, $11.1&#160;million and $3.9 million, respectively. As a result of our strategic decision to focus on out-licensing this platform, we will no longer incur these expenses in future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the net proceeds from this offering, together with our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future. We have based this estimate on assumptions that may prove to be wrong, however, and we could exhaust our available capital resources sooner than we expect. See &#8220;Liquidity and Capital Resources&#8221; for more information about our current capital resources.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Impact of COVID-19 on Our Business</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In December&#160;2019, a novel strain of coronavirus, which led to the disease known as COVID-19, emerged in Wuhan, Hubei Province, China. Less than four&#160;months later, in March&#160;2020, the World Health Organization declared COVID-19 a pandemic, and the virus has now spread to most other countries and regions and every state within the United States, including Maryland, where our primary offices and instrument assembly facility are located. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Impacts to our business as a result of COVID-19 have included disruptions to our manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, decreased productivity and unavailability of materials or components, limitations on our employees&#8217; and customers&#8217; ability to travel, and delays in product installations, demonstrations, trainings or shipments to and from affected countries and within the United States. In light of the uncertain and rapidly evolving situation relating to the spread of COVID-19, we have taken precautionary measures intended to minimize the risk of the virus to our employees, our customers and the communities in which we operate, including temporarily closing our offices to visitors and limiting the number of employees in our offices to those that are deemed essential for manufacturing and research purposes, as well as virtualizing, postponing or canceling customer, employee and industry events.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disruptions in our customers&#8217; operations have impacted and may continue to impact our business. For example, customers have experienced delays in the progress of their clinical programs, shutdowns or slowdowns in their research laboratory operations, cessation of equipment purchases, and closing of their facilities to outsiders, which have disrupted our ability to conduct product demonstrations that are a key part of our selling process. We are focused on navigating the challenges presented by COVID-19, which includes increased focus on inventory levels of finished goods and parts to reduce the risk of COVID-related supply constraints.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We do not yet know the net impact that the COVID-19 pandemic may have on our business and cannot guarantee that it will not be materially negative. Although we continue to monitor the situation and may adjust our current policies as more information and public health guidance become available, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">the ongoing effects of the COVID-19 pandemic and/or the precautionary measures that we or our customers have implemented or may adopt may create operational and other challenges, any of which could harm our business and results of operations. While we maintain an inventory of finished products and raw materials used in our products, a prolonged pandemic could lead to shortages and/or extended lead times for the raw materials necessary to manufacture our products. If we experience a prolonged disruption in our manufacturing, supply chains or commercial operations, or if demand for our products is significantly reduced as a result of the COVID-19 pandemic, we would expect to experience a material adverse impact on our business, financial condition, results of operations and prospects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Historically, a significant portion of our field sales, product demonstrations and user support have been conducted in person, and the marketing of our products, sourcing of potential new customers and rollout of our new products has historically been supported by our participation at industry conferences. Currently, as a result of the work and travel restrictions related to the COVID-19 pandemic, and the precautionary measures that we have adopted, substantially all of our field sales and professional services activities are being conducted remotely, which has resulted in a decrease in our travel and conference-related marketing expenditures. However, we expect these expenditures to increase in the future, which could negatively impact our financial condition and results of operations. As of the date of this prospectus, we do not yet know the extent of the negative impact of such restrictions and precautionary measures on our ability to attract new customers or retain and expand our relationships with existing customers over the near and long term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Key Factors Affecting Our Performance</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by the following factors. While each of these factors presents significant opportunities for our business, they also pose challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties, including those described in this prospectus under the heading &#8220;Risk Factors.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Sales and Leases of Instruments<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our financial performance has largely been driven by, and in the future will continue to be impacted by, the rate of sales and leases of our ExPERT family of proprietary flow electroporation instruments to existing and new customers. We currently market three versions of our instruments, the ATx, the STx, and the GTx, and we plan to introduce and market a fourth version called the VLX under the EXPERT brand. While the ATx and STx are primarily sold to end users for research and drug discovery purposes, the GTx is sold, typically to academic centers, for research or clinical use as well as leased to customers for research, clinical or commercial use. We view the demand for our instruments, whether in the form of sales or leases, as an indicator of the health of our current business and as a predictor of future instrument sale and lease revenue. As described below, we separately sell proprietary single-use disposables, which we call processing assemblies, or PAs, that are necessary for our customers to use our electroporation instruments. Therefore, depending on the number of instruments that have been sold or are under active lease, we have insight into the demand for PAs that will also translate to future revenue for us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our sales model varies based on the activity of the end customer, such as whether they are a translational research center, an academic center, a company focused on drug discovery, or a company engaged in cell therapy development, and the customer&#8217;s intended use of our platform. If our customer intends to use our platform for research or drug discovery only, we typically sell the instrument outright. Each of the ATx, STx and GTx have different prices based on the instrument&#8217;s features, with the GTx being the most expensive. When we sell an instrument, we also provide a non-exclusive license to our intellectual property for the customer to use the instrument broadly for research or drug discovery, as applicable. In the case of a sale, title to the instrument conveys to the buyer, but we retain the ownership of intellectual property rights and software and protocols loaded onto the instruments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The sales cycle for our cell engineering instruments varies widely and typically ranges from approximately six to approximately 12&#160;months, with the actual period depending on project stage, budget process, equipment prioritization and the general financial status of the customer or the market </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">in general. As a result of this lengthy and unpredictable sales cycle, we expect that we will be prone to quarterly fluctuations in our instrument sales revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For cell therapy customers who use our technology to develop engineered cells for human therapeutic use in clinical trials or, if approved by regulatory authorities, for commercial sale, we license our platform on a non-exclusive basis in exchange for an annual fee per instrument licensed. This license fee varies based on whether the instrument is being used for preclinical or clinical purposes. Once we have leased an instrument to a customer, we generally have high visibility into future lease revenue from this customer. Over the last several years, approximately 80% of our installed instruments up for annual lease renewal have been renewed by our customers, and the renewal rate for instruments under SPLs has been near 100%. It is possible, however, that our future lease revenue could be impacted by failure of the customer therapeutic candidates to progress through clinical development for reasons unrelated to the successful use of our instruments, such as drug toxicity, lack of efficacy, funding constraints, changes in development priorities, patient access limitations or regulatory challenges. For any of these reasons, a customer could determine not to renew or to enter into additional instrument leases with us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our installed base of electroporation instruments has grown from over 125 instruments as of December&#160;31, 2015 to over 400 instruments as of June&#160;30, 2021. This installed base includes both instruments sold to customers and instruments licensed for research and clinical use. Because of the size of the drug discovery market and our long history in that market, the installed base of instruments is currently weighted more heavily towards instruments sold for drug discovery and research applications. However, since each licensed instrument provides us with ongoing license revenues, the share of revenues from licensed instruments may grow as a share of our total revenue mix.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We plan to further grow our installed base of ExPERT instruments through additional sales and leases to our current customers and through the sale or lease of instruments to new cell therapy, drug discovery and academic customers. To achieve this goal, we intend to further expand our commercial infrastructure, including through the expansion of our sales force and field application scientists. We have expanded our sales force and field application scientist count over the past several&#160;years and now have over 20 dedicated field sales and application scientist professionals globally. Our candidate identification and hiring process is stringent, and there can be no assurance that we will be able to continue to recruit the high level of candidates that make up our current team.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have numerous collaborations in place with academic and commercial institutions to further expand our capabilities and supporting data in new cell engineering applications. Recent sales efforts have also focused on expanding our presence in translational academic centers, which we view as a potentially meaningful source of installed base expansion given the increased industry focus on, and government funding allocated to, cell therapy. Academic translational centers have been a strong source of cell therapy innovation and commercial spinouts in the cell therapy sector.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect revenue from instruments leased to cell therapy customers to continue to grow as those customers move their existing drug development programs into later-stage clinical trials and advance their preclinical pipeline programs into clinical development. In addition, we expect new customers to emerge and contribute to these revenues, particularly given the underlying growth in the cell therapy pipeline among companies in this industry, availability of capital to support such companies, and in particular the switch by some of these cell therapy companies away from viral approaches to non-viral approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Sales of Processing Assemblies<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to instrument sales, our current and future revenue is dependent on sales of our proprietary PAs, as well as the sale of our proprietary electroporation buffer solution, for use with our instruments. We sell PAs that are intended either to support research use or use in current good manufacturing practices, or cGMP, clinical research applications. The PAs differ in terms of their volume capacities and the associated numbers of cells that can be processed in each electroporation sequence with a particular PA, as well as the number of transfection experiments that can be performed in a single electroporation process. Our PA pricing varies based on the volume of cells processed and the number of transfections per PA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect that as our installed instrument base grows, our sales of PAs and electroporation buffer solutions will grow accordingly, especially as cell therapy programs continue to progress through the clinic and potentially become commercial-stage, thereby increasing the number of PAs needed by customers. We are also developing and intend to launch new PAs that target previously unserved subsegments across the bioprocessing and cell therapy markets, which could further increase our PA sales. However, both the number of PAs used per instrument, as well as the specific PA used, is highly variable across our customer base and depends on several factors, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the purpose for which the customer is using the platform;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the relative pricing of our PAs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">progression of cell therapy products through preclinical and clinical development;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">whether the cell therapy customer uses a centralized or decentralized manufacturing process;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the customer&#8217;s target indication, which can result in variations in patient numbers needed for clinical trials; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">whether the cells to be processed using our platform are patient-derived, donor-derived or cell line-derived.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">With considerable variability of processes, even within the same indication, such as is the case for allogeneic genetically-modified cell therapies, such as chimeric antigen receptor T cells, or CAR-Ts, and the nascency of the cell therapy industry, we expect that it may take several&#160;years for us to gain visibility into how these factors will impact our PA revenue over time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We continuously re-evaluate our PA portfolio based on customer needs and have introduced, and intend to continue to introduce, new PAs and improvements to existing PAs. In 2019, we launched the first multi-well PAs for the ExPERT platform. Compared to single-well, multi-well PAs allow users to run multiple samples concurrently, which enables scientists to complete more experiments per run, leading to shorter overall processing time and lower per transfection cost. Introduction of new PAs, however, introduces additional uncertainty. Some new PAs may fail to be used in line with our expectations when they are launched. While we also price PAs based on the value provided to the customer, introduction of new PAs could cannibalize our existing PA portfolio more than we had anticipated as customers find the new products to be a better solution for their applications or workflows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Strategic Platform Licenses (SPLs)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Typically, our cell therapy customers will either purchase our ATx instrument for research purposes or obtain a research use license under lease of our GTx instrument technology in order to validate the use of our technology in their programs and to progress their preclinical work towards clinic trials. However, once a cell therapy customer using one of our ExPERT instruments advances their preclinical research to a stage where they are planning to enter clinical development, they need to enter into a licensing arrangement with us for the rights to clinical and/or commercial use of our instrument. Our customers typically negotiate the terms of those licenses during research and preclinical development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We refer to these arrangements as SPLs, the terms of which contain not only higher annual, non-exclusive license fees for the clinical use of the instrument, but also allow us to share in the economics of the customer&#8217;s programs. From 2017 through June&#160;30, 2021, we have entered into 13 SPLs with commercial cell therapy developers, and those licenses currently allow for over 75 clinical development programs in the aggregate. On average, our current SPLs allow for approximately six product candidates per license, although this average may change over time. SPLs include potential payments to us upon the customer&#8217;s achievement of specified clinical development or regulatory milestones, as well as potential sales-based payments to us, which could be payments based upon the achievement of specified sales levels and/or royalty payments that are a&#160;percentage of the customer&#8217;s net sales. The amount of each milestone payment is typically correlated in size with value-creating, pre-commercial clinical progress events or commercial sales levels.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Of the over 75 programs associated with our current SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared Investigational New Drug application, or IND. Our 13 SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments, if all product candidates allowed under those agreements were to fully progress through clinical development and obtain regulatory approval. However, our actual milestone revenue from these agreements will likely be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">considerably lower than this amount, as not all programs covered by each agreement will become and remain active programs in a customer&#8217;s development pipeline or successfully complete the clinical development process, and each agreement typically includes programs that have not been specifically identified, or for which a candidate may never be identified or developed by the customer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our strategy is to capitalize on the growth in the number of cell therapy developers by entering into new SPLs. We announced six such agreements in 2019, three in 2020 and two so far in 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the year ended December 31, 2020, one cell therapy company with which we have entered into an SPL accounted for 15% of our total revenue, and our six largest such customers accounted for an aggregate of approximately 40% of our total revenue for the year through a combination of instrument license fees, milestones realized and processing assembly revenue.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our future milestone revenue under our SPLs will depend in large part on the clinical and regulatory achievements of our customers. Generally, pre-commercial milestone payments become larger as programs move through the clinic. We rely in part on our customers&#8217; public disclosures around regulatory timelines to forecast our receipt of pre-commercial milestone payments. While we expect our forecasting ability to improve over time as more of our customers&#8217; programs advance through the clinic and the number of clinical programs covered by our licenses expands, given the early nature of the cell therapy clinical market, we expect our realization of pre-commercial milestones to be somewhat unpredictable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the potential for sales-based payments once a customer&#8217;s product is approved and in commercial use is unknown and variable based on a number of factors, including inherent clinical risk, potential changes in the customer&#8217;s strategy, the designated indication and its impact on the potential number of patients to be served and the competitive products available to patients, product pricing and reimbursement structures, our customer&#8217;s commercial manufacturing plans and the inherent unknowns in adoption of next-generation cell therapies relative to other modalities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Gross Margins<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have historically generated overall gross margins of approximately 89% over the past several years, although our margins depend on our revenue mix from instruments, PAs and potential milestones under SPLs. We price our instruments at a premium given what we believe to be the broad benefits of our platform, and the limited availability of alternative, clinically validated non-viral delivery approaches. However, the market for non-viral delivery is highly competitive, and introduction of a GMP-grade platform by a competitor that delivers similar performance across a similar diversity of cell types could negatively impact our business and lead to increased price pressure that negatively impacts our gross margins. In addition, part of our growth strategy is to expand into new regional markets, which could require the use of distributors and/or our participation in more competitive environments, which could impact our ability to price our instruments at a premium and could negatively impact our ability to enter into SPLs on terms similar to those currently in effect.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We expect our gross margins to benefit from realization of the economics from our SPL agreements described above, to the extent that such milestones grow to be a significant proportion of overall revenues, as there is no cost of goods sold associated with such revenue. However, realization of these potential milestone revenues is uncertain.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Key Business Metrics</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to revenue, we regularly review several key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. These key metrics include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the number of cumulative instruments that we have placed with our customers, either by sale or lease, which we refer to as our installed base and consider to be an indication of our traction within the non-viral delivery market and indicative of the future recurring revenue generated from those instruments, including disposables and annual license fees;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the number of active SPLs that we have entered into with cell therapy developers, as well as the total number of our customers&#8217; clinical programs, whether active or contemplated, that are </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">covered by such active SPLs and the&#160;percentage of those clinical programs that are under an active IND application (or foreign equivalent), meaning that the customer is cleared to commence clinical trials;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate potential pre-commercial milestone payments under active SPLs, representing the maximum potential milestone payments to us if all programs covered by each SPL were to achieve regulatory approval;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of potential programs licensed for clinical use, whether active or contemplated, that are covered by only our SPLs; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the aggregate number of programs licensed for clinical use and covered by our SPLs that are currently in the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">With respect to the numbers of programs under license, in many cases we make estimates of such programs based on our contract terms with our customers and our knowledge about our customers&#8217; clinical progression of their programs. We rely, in part, on our customers&#8217; public disclosures around regulatory timelines to forecast our receipt of pre-commercial milestone payments. However, it is possible that some programs may have become dormant or inactive without our knowledge, some new programs may be identified and some programs may progress further in clinical development without our knowledge if the customer has not made a public announcement. While we expect our forecasting ability to improve over time as more of our customers&#8217; programs move through the clinic and the number of clinical programs covered by our licenses expands, given the early nature of the cell therapy clinical market, we expect our realization of pre-commercial milestones to be somewhat unpredictable. This number may fluctuate due to the success of our commercial partners. Additionally, the addition of a large multi-product (program) SPL may dilute the&#160;percentage of commercial programs currently in the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of the dates presented, our key metrics described above were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:109pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252.51pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:59.16pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">As of June&#160;30,</font>
                <br >
                <font style="letter-spacing:-0.089pt;">2021</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:59.16pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:59.16pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020* </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:252.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Installed base of instruments (sold or leased) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;320 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;400 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;400 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Number of active SPLs </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">8 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">12</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">13 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:252.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed clinical programs (SPLs only) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;55 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;75 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:252.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Total number of licensed clinical programs under SPLs currently in the clinic </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;5% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;15% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;15% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:252.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total potential pre-commercial milestones under SPLs </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;$650&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;$950&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:59.16pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&gt;$950&#160;million</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.2pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7.7pt; width:456pt; line-height:10pt;font-size:8pt;">
          <font style="letter-spacing:-0.02pt;">* Amounts presented as of December&#160;31, 2020 give effect to one SPL entered into and additional INDs cleared in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Components of Our Results of Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We generate revenue principally from the sale of instruments, single-use PAs and buffer, and from the lease of instruments to our customers. Our SPLs also include associated clinical progress milestones and sales-based payments to us, in addition to annual lease payments. Sales of instruments and disposables under contracts with customers are classified as product sales in our consolidated financial statements. Revenue from instrument leases, including payments that we may receive from our customers based on their achievement of specified clinical development or commercialization milestones, are classified as leased elements in our consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our business and revenue growth strategy consists of the sale or lease of instruments and the sale of disposables. We record revenue from the sale of instruments or PAs upon the shipment to a customer. Instrument leases are typically invoiced annually at the start of each instrument license period and are accounted for as monthly revenue over the lease term with the expectation of continuing customer renewals of their instrument leases. As our customers achieve clinical progress milestones and/or sales-based payment milestones, we recognize the full value of the milestone as revenue. In addition, as customers use instruments they have either purchased or leased, they typically replenish </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">their supplies of disposables through recurring purchases. Although customers are not contractually obligated to renew their instrument leases or to purchase additional disposables and may decide not to do so solely at their own discretion, leased instruments and disposables revenue streams have historically formed an important component of our future revenues, and we believe they provide insight into our future performance. We consider these sales and lease revenue streams to be recurring revenues.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In order to evaluate how our sales are trending across key markets, as well as the contribution of program economics from our SPLs, we separately analyze revenue derived from our cell therapy customers and drug discovery customers, as well as the performance-based milestone revenues we recognize under our SPLs. Cell therapy includes revenue from instruments sold, annual license fees for instruments under lease, and sales of our proprietary disposables. Drug discovery includes revenue from instruments sold, sales of our proprietary disposables and, occasionally, instruments leased, in each case under contracts with drug discovery customers. Program-related revenue includes pre-commercial milestones earned and recognized as revenue during the period. Once SPL customers achieve regulatory approval for and commercialize their products, in nearly all cases we will also be entitled to receive sales-based payments which may be milestone payments upon achievement of specified levels of net sales and/or royalties expressed as a&#160;percentage of net sales. We have not received any commercial payments from our SPL customers to date, and we do not expect to receive any such payments in the near term. As our customers progress their programs and achieve additional milestones, our SPL program revenue is expected to constitute a growing portion of our total revenues in future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We also offer our customers extended warranty and service plans. Our extended warranty and service plans are offered for periods beyond the standard no-fee, one-year warranty that customers who purchase instruments receive. These extended warranty and service plans generally have fixed fees and terms ranging from one additional year to four additional&#160;years and include an annual calibration. We recognize revenue from the sale of extended warranty and service plans over the respective coverage period, which approximates the service effort provided by us. Warranties are typically not a material revenue stream for us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Product Sales<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue from contracts with customers includes revenue from the sale of instruments, PAs and buffer. Customers purchase an ATx, STx or GTx depending upon their intended use and all customers purchase PAs for use with our instruments. Commercial customers may not use a purchased instrument for clinical or commercial processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect product sales revenue to increase in future periods as our market grows and we are able to generate recurring PA sales.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Leased Elements<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue from leased elements consists of revenue from the leasing of instruments to customers (typically the GTx). Our leases of instruments to customers consist of fixed license/lease payments and variable milestone payments that are dependent on our customer&#39;s achievement of clinical milestones. Typically, instrument leases that provide for clinical or commercial use also include sales-based milestone payments (and/or sales-based royalties in some cases) upon the commercialization of the customer&#39;s product. Under our instrument lease arrangements we lease our instruments to customers and provide associated software licenses to allow customers non-exclusive use of our technology for research and/or specific clinical programs, typically along with rights for commercial use upon approval of the customer&#39;s products. We also provide to our clinical use licensees scientific and regulatory support to help them improve process optimization and facilitate their regulatory submission process.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We expect leased elements revenue to increase in future periods as our market grows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Cost of Goods Sold<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cost of goods sold primarily consists of costs for raw material parts, contract manufacturer costs, salaries, overhead and other direct costs related to sales recognized as revenue in the period. Cost of goods sold associated with instrument lease revenue consists of leased equipment depreciation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect that our cost of goods sold will increase or decrease primarily to the extent that our instrument and disposables revenue increases and decreases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Gross Profit and Gross Margin<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Gross profit is calculated as revenue less cost of goods sold. Gross profit margin is gross profit expressed as a&#160;percentage of revenue. Our gross profit in future periods will depend on a variety of factors, including sales mix among instruments, disposables and milestones, the specific mix among types of instruments or disposables, the proportion of revenues associated with instrument leases as opposed to sales, the share of revenues composed of milestones, changes in the costs to produce our various products, the launch of new products or changes in existing products, our cost structure for manufacturing including changes in production volumes, and the pricing of our products which may be impacted by market conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Operating Expenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Research and Development<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Research and development expenses consist primarily of costs incurred for our research activities related to advancing our technology and development of applications for our technology, including research into specific applications and associated data development, process development, product development (e.g. development of instruments and disposables, including hardware and software engineering) and design and other costs not directly charged to inventory or cost of goods sold, such as supply chain development and design and management of quality systems.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These expenses include employee-related costs, such as salaries, benefits, incentive compensation, stock-based compensation, and travel, as well as consultant services, facilities, and other expenses, laboratory supplies and materials expenses for employees and contractors engaged in research and development. We expense research and development costs as incurred in the period in which the underlying activity is undertaken.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We previously developed CARMA, our proprietary platform technology for the development of non-viral, human messenger RNA, or mRNA-based, chimeric antigen receptor, or CAR, or T-cell receptor, or TCR, redirected immune cell therapies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the first quarter of 2021, we conducted a strategic review of our CARMA activities and made the decision to cease further pre-clinical and clinical activities with respect to the CARMA platform and associated candidates (MCY-M11 and other identified targets) for our own internal purposes and instead to focus on out-licensing the CARMA platform manufacturing processes and associated intellectual property to third-party customers. For periods through the first half of 2021, our research and development expenses include costs associated with developing the CARMA platform principally for a clinical trial that has concluded. As a result of our strategic decision to focus on out-licensing this platform, we will no longer incur significant CARMA-related expenses after the first half of 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe that our continued investment in research and development is essential to our long-term competitive position. We expect to continue to incur substantial research and development expenses as we invest in research and development to support our customers, develop new uses for our existing technology and develop improved and/or new offerings to our customers and partners. As a result, we expect that our research and development expenses, excluding CARMA-related expenses, will continue to increase in absolute dollars in future periods and vary from period to period as a&#160;percentage of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Sales and Marketing<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our sales and marketing expenses consist primarily of salaries, commissions and other variable compensation, benefits, stock-based compensation and travel costs for employees within our commercial sales and marketing functions, as well as third-party costs associated with our marketing activities. We expect our sales and marketing expenses to increase in future periods as we expand our commercial sales, marketing and business development teams, increase our presence globally, and increase marketing activities to drive awareness and adoption of our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">General and Administrative<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">General and administrative expenses primarily consist of salaries, benefits, stock-based compensation and travel costs for employees in our executive, accounting and finance, legal, corporate </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:42.62pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">development, human resources, and office administration functions as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs, facilities and allocated overhead expenses and costs associated with being an AIM listed public company such as director fees, broker fees, investor relations consultants and insurance costs. We expect that our general and administrative expenses will continue to increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company listed on two exchanges, including insurance (particularly directors and officers insurance), costs to comply with the rules and regulations applicable to companies listed on a U.S. securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the SEC and stock exchange listing standards, public relations and professional services. We expect these expenses to vary from period to period as a&#160;percentage of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Other Income (Expense)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest Expense<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest expense consists primarily of interest related to borrowings under credit facility agreements. For the&#160;years ended December&#160;31, 2019 and 2020 and the three months ended March 31, 2020 and 2021, we had a $5.0&#160;million outstanding term loan, or the Term Loan, under the MidCap Credit Agreement (as defined below). As of March&#160;31, 2021, we repaid the Term Loan in full prior to maturity as allowed by and in accordance with the terms of the MidCap Credit Agreement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Other Income (Expense), Net<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We classify our outstanding warrant for the purchase of shares of our common stock as a liability on our consolidated balance sheets since the warrant&#8217;s strike price is in a currency other than our functional currency. The warrant liability is initially recorded at fair value at the date of issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liability are recognized as a component of other income (expense). Other income (expense), net also includes interest earned on cash balances in our cash accounts and interest earned on money market funds, commercial paper and corporate bonds as well as miscellaneous income unrelated to our core operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Provision for Income Taxes<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We did not recognize a benefit for the net operating losses we incurred for the&#160;years ended December&#160;31, 2019 and 2020. As of December&#160;31, 2020, we had U.S. net operating loss carryforwards of $57.8&#160;million, which may be available to offset future taxable income and begin to expire in 2025, as well as net operating losses in the various states in which we file. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date since, due to our history of net losses, we have determined that it is not currently more likely than not that our net deferred tax assets are recoverable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The use of our net operating loss carryforwards may have been restricted by changes in our ownership and may be further restricted as a result of future changes in our ownership.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Results of Operations</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended March&#160;31, 2020 and 2021<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The results of operations presented below should be reviewed in conjunction with the condensed consolidated interim financial statements and notes included elsewhere in the prospectus. The following tables set forth our results of operations for the periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:258pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:371.99pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:371.99pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,742</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">6,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">659</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">693</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,083</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">5,802</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Operating expenses </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">6,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">1,777</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">3,308</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">8,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">12,175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(2,988<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(6,373<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Other income (expense) </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(116<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(742<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(733<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:371.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">(3,062<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(7,106<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:120pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.56pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:315.56pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.56pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Revenue </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.56pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Product sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">3,195</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">4,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">881</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">28<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.56pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Leased elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,426</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,256</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(170<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.56pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">121</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">163</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:10.5pt; text-align:right; white-space:nowrap;">35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:315.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">5,742</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">6,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">753</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:10.5pt; text-align:right; white-space:nowrap;">13<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue increased by $0.8&#160;million, or 13%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. Product sales accounted for 56% and 63% of our total revenue for the three&#160;months ended March&#160;31, 2020 and 2021, respectively, and leased elements revenue accounted for 42% and 35% of our total revenue for the three&#160;months ended March&#160;31, 2020 and 2021, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table provides additional details regarding the sources of our revenue for the&#160;periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:105pt;margin-top:10.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:305.98pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:305.98pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:305.98pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Cell therapy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">3,190</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">4,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,539</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">48<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:305.98pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Drug discovery </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,762</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:305.98pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Program-related </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(748<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:12.75pt; text-align:right; white-space:nowrap;">(99<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:305.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">5,742</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.95pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">6,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">753</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">13<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Our overall increase in revenues was primarily driven by growth in sales and leases of instruments and sales of disposables to cell therapy customers. Instrument sales, leased instruments and disposable sales increased in part due to continued high levels of capital invested in companies operating in our target markets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-size:10pt;">Costs of Goods Sold<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:3.99999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:313.67pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:313.67pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:313.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;659</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;693</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.9pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Costs of goods sold increased by $34,000, or 5%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The increase was primarily driven by higher sales of instruments and disposables. Costs of goods sold did not increase at the same rate as revenue growth because of the impact of growth in leased instruments, which have minimal associated cost of goods sold.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-size:10pt;">Operating Expenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">Research and Development<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:298.53pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:298.53pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:298.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;4,245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;6,078</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;1,833</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">43<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.89pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Research and development expenses increased by $1.8&#160;million, or 43%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The increase was primarily driven by $1.7&#160;million in costs associated with cessation of CARMA operations, partially offset by $0.4&#160;million decrease in on-going CARMA activities, and a $0.5&#160;million increase in compensation expenses associated with headcount increases and stock-based compensation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">Sales and Marketing<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.44pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:304.44pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:304.44pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and Marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;2,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;2,789</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">36<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.9pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Sales and marketing expenses increased by $0.7&#160;million, or 36%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The increase was primarily driven by increased compensation expense as a result of headcount increases, commissions on sales, and stock-based compensation which added $0.9&#160;million to sales and marketing costs, partially offset by COVID-19 driven reductions in travel and marketing expenses of $0.2&#160;million. As travel and in-person restrictions instituted due to COVID-19 begin to recede, we expect travel and marketing expenses to increase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">General and Administrative<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:298.53pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:298.53pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:298.53pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;1,777</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;3,308</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8199;1,532</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">86<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.99pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">General and administrative expense increased by $1.5&#160;million, or 86%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The increase was primarily driven by increased compensation expense associated with headcount increases, salary increases, and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">stock-based compensation which added $1.1&#160;million within the general and administrative function and $0.3&#160;million in public company and legal expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Interest and Other Income (Expense)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Income<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.34pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:306.34pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:306.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.28pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8199;(34<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(77<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other income decreased by $34,000, or 77%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The decrease was primarily driven by a lower average balance of short-term investments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Expense<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.11pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:304.11pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:304.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;116</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;742</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8199;626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">538<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other expense increased by $0.6&#160;million, or 538%, from the three&#160;months ended March&#160;31, 2020 to the three&#160;months ended March&#160;31, 2021. The increase was primarily driven by the termination fees associated with repayment before maturity of the Term Loan and the fair value change of common stock warrants, partially offset by the lower interest expenses due to a lower average loan balance associated with the early repayment of debt in 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2019 and 2020<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in the prospectus. The following tables set forth our results of operations for the periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:257.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:359.1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:3pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">21,621</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">26,169</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">2,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">2,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">19,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">23,402</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Operating expenses </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">17,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">17,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">7,852</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">8,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">6,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">8,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">31,542</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">34,459</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(12,420<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(11,057<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Other income (expense) </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(681<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">(826<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">475</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">760</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:359.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">(12,895<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">(11,816<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:120pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.09pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Revenue </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Products sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">12,918</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">14,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,932</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">15<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Leased elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">8,364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">10,717</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,354</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:10.5pt; text-align:right; white-space:nowrap;">77</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:304.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">21,621</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">26,169</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">4,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:10.5pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue increased by $4.5&#160;million, or 21%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. Product sales accounted for 60% and 57% of our total revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively, and leased elements revenue accounted for 39% and 41% of our total revenue for the&#160;years ended December&#160;31, 2019 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table provides additional details regarding the sources of our revenue for the&#160;years presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:105pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:304.09pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Cell therapy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">11,868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">15,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">3,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Drug discovery </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">7,321</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">7,143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(178<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:304.09pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Program-related </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">2,432</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">3,257</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">825</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:10.5pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:304.09pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">21,621</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">26,169</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">4,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:10.5pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our overall increase in revenue primarily was driven by growth among cell therapy customers in the number of instruments and disposables that we sold, new leased instrument placements, and recurring revenues from existing instrument leases, as well as growth in the number of clinical milestone events that our SPL customers achieved that resulted in payments to us. Instrument sales and leases and disposable sales increased in part due to continued high levels of capital invested in companies operating in our target markets. Milestones increased due to the clinical progress of our SPL&#160;customers. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Costs of Goods Sold<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.56pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:315.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cost of goods sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">268</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">11<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.31pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Costs of goods sold increased by $0.3&#160;million, or 11%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by higher sales of instruments and disposables. Cost of goods sold did not increase at the same rate as revenue growth because of the growth in milestone payments, which have no associated cost of goods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Operating Expenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Research and Development<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:308.45pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:1pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:308.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">143</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Research and development expenses increased by $0.1&#160;million, or 1%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense associated with field application scientist headcount increases and applications development headcount increases which combined to add $1.4&#160;million to research and development costs, offset by reduced expenses associated with our CARMA activities of $1.1&#160;million and reduced travel expenses of $0.3&#160;million during 2020 due to the impact of the COVID-19 pandemic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Sales and Marketing<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:319.56pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:319.56pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:319.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and Marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">7,852</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,329</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.97pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">477</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Sales and marketing expenses increased by $0.5&#160;million, or 6%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense as a result of headcount increases, commissions on sales, and stock-based compensation which added $1.8&#160;million to sales and marketing costs, partially offset by COVID-19 driven reductions in travel and marketing expenses of $1.3&#160;million. As travel and in-person restrictions instituted due to COVID-19 begin to recede, we expect travel and marketing expenses to increase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">General and Administrative<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.2pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:315.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">6,088</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">8,386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2,298</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">38<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">General and administrative expense increased by $2.3&#160;million, or 38%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by increased compensation expense associated with headcount increases, salary increases, and stock-based compensation which added $1.5&#160;million within the general and administrative function as well as $0.6&#160;million of expenses associated with capital raising activities that were not eligible to be capitalized. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Interest and Other Income (Expense)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Income<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:320.48pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:320.48pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.86pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(140<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">(68<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other income decreased by $0.1&#160;million, or 68%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The decrease was primarily driven by declining interest income due to lower market rates in 2020 on our short-term investments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Interest and Other Expense<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;height:59.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:320.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:320.48pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:320.48pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">681</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.93pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">826</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">145</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">21<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Interest and other expense increased by $0.1&#160;million, or 21%, from the year ended December&#160;31, 2019 to the year ended December&#160;31, 2020. The increase was primarily driven by the fair value change of common stock warrants, partially offset by fees associated with an early prepayment of debt in 2019 and the lower interest expenses due to a lower average loan balance associated with an early repayment of debt in 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:55.15pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Since our inception, we have experienced losses and negative cash flows from operations. For the year ended December&#160;31, 2020 and the three months ended March 31, 2021, we incurred a net loss of $11.8&#160;million and $7.1 million, respectively. As of March 31, 2021, we had an accumulated deficit of $102.3&#160;million. To date, we have funded our operations primarily with proceeds from sales of common stock, borrowings under loan agreements and from revenues associated with sales and leasing of our products to customers. As of March 31, 2021, we had cash and cash equivalents and short-term investments of $78.7&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We expect to incur additional operating losses in the future as we continue to invest in expanding our business through growing our sales and marketing efforts, continued research and development, product development and expanding our product offerings. Based on our current business plan, we believe the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Our future funding requirements will depend on many factors, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">market acceptance of our products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost and timing of establishing additional sales, marketing and distribution capabilities;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the cost of our research and development activities and successful development of data supporting use of our products for new applications, and timely launch of new features and products;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our ability to enter into additional SPLs and licenses for clinical use of our platform in the future;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">changes in the amount of capital available to existing and emerging customers in our target markets;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the effect of competing technological and market developments; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the level of our selling, general and administrative expenses.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">If we are unable to execute on our business plan and adequately fund operations, or if the business plan requires a level of spending in excess of cash resources, we will have to seek additional equity or debt financing. If additional financings are required from outside sources, we may not be able to raise such capital on terms acceptable to us or at all. To the extent that we raise additional capital through the sale of equity or debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures or declaring dividends. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. If we are unable to raise additional capital when desired, we may have to delay development or commercialization of future products. We also may have to reduce marketing, customer support or other resources devoted to our existing products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Cash Flows<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes our uses and sources of cash for the periods presented:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:120pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">March 31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:272.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:272.42pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:272.42pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Net cash provided by (used in): </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">(8,803<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(8,782<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(5,498<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(4,642<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:272.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">455</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:28.5pt; text-align:right; white-space:nowrap;">(16,578<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(208<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">15,692</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:272.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">12,311</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">28,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">48,899</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:272.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:25.5pt; text-align:right; white-space:nowrap;">3,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:28.5pt; text-align:right; white-space:nowrap;">3,544</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">(5,706<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">59,949</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.6pt; width:456pt; line-height:12pt;font-style:italic;">Operating Activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the three months ended March 31, 2021 was $4.6 million, and consisted primarily of our net loss of $7.1 million, offset in part by net non-cash expenses of $2.0&#160;million, including stock-based compensation of $1.3 million, warranty liability fair value adjustments of $0.3 million, and depreciation and amortization expenses of $0.3 million. We also had net cash inflows of $0.5 million due to net changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of an increase in deferred revenue of $1.2 million, a decrease in accounts receivable of $0.9 million, partially offset by a $1.4 million decrease in accounts payable and accrued expenses, and a $0.3 million increase in inventory.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the three months ended March 31, 2020 was $5.5&#160;million, and consisted primarily of our net loss of $3.1 million, offset in part by non-cash expenses of $0.8&#160;million, including stock-based compensation of $0.5 million. and depreciation and amortization expenses of $0.2&#160;million. We also had net cash outflows of $3.2 million due to changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of a decrease in accounts payable and accrued expenses of $2.7 million, an increase in accounts receivable of $0.7&#160;million and an increase in inventory of $0.5 million, partially offset by a $0.4 million increase in deferred revenue and a $0.1 million increase in the net effect of our right-of-use assets and lease liabilities.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the year ended December&#160;31, 2020 was $8.8&#160;million, and consisted primarily of our net loss of $11.8&#160;million, offset in part by net non-cash expenses of $3.9&#160;million, including stock-based compensation of $2.5&#160;million and depreciation and amortization expenses of $1.0&#160;million. We also had net cash outflows of $0.9&#160;million due to net changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of an increase in deferred revenue of $1.6&#160;million and an increase in accounts payable and accrued expenses of $0.4&#160;million, partially offset by a $1.8&#160;million increase in accounts receivable, a $0.9&#160;million increase in inventory, a $0.2&#160;million increase in other current and non-current assets and a $0.1&#160;million increase in the net effect of our right-of-use assets and lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Net cash used in operating activities for the year ended December&#160;31, 2019 was $8.8&#160;million, and consisted primarily of our net loss of $12.9&#160;million, offset in part non-cash expenses of $2.5&#160;million, including stock-based compensation of $1.8&#160;million and depreciation and amortization expenses of $0.6&#160;million. We also had net cash inflows of $1.6&#160;million due to changes in our operating assets and liabilities. Net changes in our operating assets and liabilities consisted primarily of a decrease in accounts receivable of $1.6&#160;million, an increase in accounts payable and accrued expenses of $1.2&#160;million, an increase in deferred revenue of $0.8&#160;million and a $0.5&#160;million increase in the net effect of our right-of-use assets and lease liabilities, partially offset by a $1.9&#160;million increase in inventory and a $0.7&#160;million increase in other current and non-current liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Investing Activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by investing activities during the three months ended March 31, 2021 was $15.7&#160;million, which was primarily attributable to maturities of marketable securities of $16.0 million, partially offset by purchases of property and equipment of $0.3 million.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash used in investing activities during the three months ended March 31, 2020 was $0.2 million, which was primarily attributable to purchases of property and equipment of $0.7 million, partially offset by net purchases and maturities of marketable securities of $0.5 million.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash used in investing activities during the year ended December&#160;31, 2020 was $16.6&#160;million, which was primarily attributable to net purchases of marketable securities of $14.5&#160;million and purchases of property and equipment of $2.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by investing activities during the year ended December&#160;31, 2019 was $0.5&#160;million, which was primarily attributable to net purchases and maturities of marketable securities of $1.7&#160;million, partially offset by purchases of property and equipment of $1.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Financing activities<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by financing activities during the three months ended March 31, 2021 was $48.9&#160;million, which was primarily attributable to net proceeds from our issuance of common stock of $51.8&#160;million and proceeds of $2.0 million from the exercise of stock options, partially offset by the repayment of the Term Loan of $4.9 million.</font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">There was no financing activity during the three months ended March 31, 2020.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by financing activities during the year ended December&#160;31, 2020 was $28.9&#160;million, which was primarily attributable to net proceeds from issuance of common stock of $28.6&#160;million, proceeds from the PPP loan (as defined below) in the amount of $1.4&#160;million and the proceeds of $0.4&#160;million from the exercise of stock options, partially offset by the repayment of the PPP loan of $1.4&#160;million and lease principal payments of $0.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Cash provided by financing activities during the year ended December&#160;31, 2019 was $12.3&#160;million, which was primarily attributable to net proceeds from issuance of common stock of $12.3&#160;million, proceeds from borrowing under our MidCap Credit Agreement of $5.0&#160;million and the proceeds of $0.1&#160;million from the exercise of stock options, partially offset by the repayment of our previously outstanding borrowing under the MidCap Credit Agreement of $5.1&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Long-Term Debt<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, we entered into a Credit and Security Agreement, or the MidCap Credit Agreement, with MidCap Financial Trust, or MidCap. The MidCap Credit Agreement provided for a $5.0&#160;million Term Loan maturing on November&#160;1, 2024. The Term Loan provided for (i)&#160;an interest rate of one-month Libor plus 6.5% with a 1.5% Libor floor, (ii)&#160;monthly interest payments, (iii)&#160;30 monthly principal payments of approximately $0.2&#160;million beginning June&#160;2022 and (iv)&#160;a 3% final payment fee. The Term Loan was secured by a lien on substantially all of our assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In conjunction with our entry into the MidCap Credit Agreement, we issued MidCap a warrant to purchase 71,168 shares of common stock at a price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. In connection with the MidCap Credit Agreement, we also incurred expenses of $47,300. As of December&#160;31, 2020, the Term Loan had an outstanding principal balance of $5.0&#160;million and $0.1&#160;million of unamortized debt discount. On March&#160;12, 2021, we repaid all amounts outstanding under the Term Loan and terminated all remaining obligations under the MidCap Credit Agreement and incurred fees of approximately $0.3 million associated with early repayment. The unamortized debt discounts and fees were expensed and recorded as interest expense. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, we received a loan, or the PPP loan, from Silicon Valley Bank in the amount of $1.4&#160;million under the U.S. Small Business Administration&#8217;s Paycheck Protection Program, or PPP. The PPP was established as part of the U.S. Coronavirus Aid, Relief, and Economic Security (CARES) Act and provided for potential forgiveness of the loan upon our meeting certain conditions as to the use of the proceeds. The loan provided for interest at 1% and a maturity date of April&#160;2022. In May&#160;2020, we repaid the PPP loan in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Contractual Obligations and Commitments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our contractual obligations and commitments as of December&#160;31, 2020 consisted of operating lease obligations, finance lease obligations and debt obligations under the MidCap Credit Agreement. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, operating lease obligations included $2.0&#160;million in payments due under our lease of office and laboratory space under operating lease agreements that expire in October&#160;2023. As of December&#160;31, 2020, our finance lease obligations consisted of $0.3&#160;million in payments due for our lease of laboratory equipment under a finance lease that expires in April&#160;2023. As of December&#160;31, 2020, debt obligations included the contractually required principal and interest payments payable under our MidCap Credit Agreement, under which borrowings bore interest at a variable rate. On March&#160;12, 2021, we repaid all amounts outstanding under the MidCap Credit Agreement in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">On May 27, 2021, we entered into an operating lease for up to 67,326 square feet of new office space. The lease for new office space consists of three phases with phase 1 estimated to commence in January 2022, and the lease of all phases is estimated to expire on June 30, 2035. We and the landlord both have a one-time right to terminate phase 3 of the lease associated with 13,543 square feet during a defined time window. We will design and construct the leasehold improvements with the approval of the landlord. The landlord will reimburse us for costs of property improvements up to amounts specified in the lease. The total incremental non-cancellable lease payments under the new lease agreements are approximately $24.5 million through the lease terms.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Purchase orders or contracts for the purchase of supplies and other goods and services are based on our current procurement or development needs and are generally fulfilled by our vendors within short time horizons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Qualitative and Quantitative Disclosures About Market Risk</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Interest Rate Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to market risk for changes in interest rates related primarily to balances of our cash and cash equivalents and marketable securities. As of March&#160;31, 2021, we had cash and cash equivalents of $78.7&#160;million, which consisted primarily of money market funds and bank deposits. The primary objective of our investment is to preserve principal and provide liquidity. As of March&#160;31, 2021, we had money market funds of $31.2 million and did not hold short-term marketable securities. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. A 10% change in the level of market interest rates would not have a material effect on our business, financial condition or results of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, we entered into the Term Loan with MidCap, which carried a fixed interest rate of 6.5% per annum plus one-month Libor with a 1.5% Libor floor. We repaid the Term Loan in full in March&#160;2021 and no longer have any variable-rate indebtedness.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Foreign Currency Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are exposed to financial risks as a result of exchange rate fluctuations between the U.S. dollar and certain foreign currencies and the volatility of these rates. In the normal course of business, we earn revenue primarily denominated in U.S. Dollars as well as in Euros and British Pounds. We incur expenses primarily in U.S. Dollars as well as in Euros, British Pounds and other currencies. Our reporting currency is the U.S. Dollar. We hold our cash primarily in U.S. Dollars as well as in Euros and British Pounds. We do not expect that foreign currency gains or losses will have a material effect on our financial position or results of operations in the foreseeable future. We have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to managing risks relating to fluctuations in currency exchange rates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Inflation Risk<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Our operations may be subject to inflation in the future principally through the costs of components and raw materials associated with our instruments and disposables and the cost of labor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Critical Accounting Policies and Significant Judgments and Estimates</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have prepared our consolidated financial statements in accordance with generally accepted accounting principles in the United States. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements included elsewhere in this prospectus, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Revenue Recognition<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We derive revenue from two primary sources, product sales, which is comprised primarily of instrument and disposables revenue, and leased elements, which is comprised of revenue associated with instrument leases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For revenue generated pursuant to contracts with customers, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our arrangements, we perform the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the assessment of the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when, or as, we satisfy each performance obligation. At contract inception, we assess the goods or services promised within each contract, determine which goods or services are performance obligations and assess whether each promised good or service is distinct.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We enter into instrument lease and licensing arrangements that are accounted for using lease accounting rather than accounted for as pursuant to contracts with customers. Under these arrangements, we license to third parties rights to use our products and embedded software. The terms of these arrangements typically include payment to us of one or more of the following: instrument lease fees, and clinical progress milestones and may, under the terms of existing agreements, include regulatory and/or sales milestone payments and/or royalties. Revenue from instrument leases is recognized ratably over the determined contractual term of the lease agreement and revenue from associated milestones is recognized when each specific milestone event is achieved by the customer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In some product sale arrangements, products and services have been sold together representing distinct performance obligations. In such arrangements we allocate the sale price to the various performance obligations in the arrangement on a relative standalone selling price basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The standalone selling price is the price at which an entity would sell a promised good or service separately to a customer. We estimate the standalone selling price of each of the identified performance obligations in our customer contracts, maximizing the use of observable inputs. Our process for determining standalone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. We believe that this method results in an estimate that represents the price we would charge for the product offerings if they were sold separately.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are primarily directly paid by customers as pass-through costs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Amounts received under lease arrangements prior to revenue recognition are recorded as deferred revenue in our consolidated balance sheets. Amounts expected to be recognized as revenue within the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">12&#160;months following the balance sheet date are classified as current portion of deferred revenue in our consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as other liabilities in our consolidated balance sheets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Stock-based Compensation<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain an incentive compensation plan under which stock options are granted primarily to employees, consultants and non-employee directors. We measure stock-based compensation expense on the date of grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We record forfeitures as they occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We estimate the fair value of stock options granted to our employees and directors based on the closing price of our common stock on the AIM, a market operated by the London Stock Exchange, on the grant date, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions include expected volatility using publicly traded peer group companies&#8217; common stock, expected dividend yield, risk-free rate of interest and the expected term using the simplified method.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Warrants to Purchase Common Stock<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In connection with our Term Loan, we issued a stock purchase warrant to purchase 71,168 shares of common stock. Because the exercise price is denominated in British pounds, we record a liability for the fair value of the warrant at the end of each reporting period, with changes between periods reported in our consolidated statements of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The fair value of the stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to such unobservable inputs identified above may change the embedded conversion options&#8217; fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our annual consolidated financial statements and interim condensed consolidated financial statements appearing in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Emerging Growth Company Status</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section&#160;107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the delayed adoption of new and revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As an EGC, we may also take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we are presenting only two&#160;years of audited financial statements and only two&#160;years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will avail ourselves of the exemption from providing an auditor&#8217;s attestation report on our internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:484pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we are providing reduced disclosure about our executive compensation arrangements; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">we will not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We will remain an EGC until the earliest of (i)&#160;December&#160;31, 2026, which is the last day of the fiscal year in which the fifth anniversary of this offering occurs, (ii)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more, (iii)&#160;the date on which we have issued more than $1&#160;billion in non-convertible debt during the previous rolling three-year period, or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">BUSINESS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Mission</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe in the vast potential of next-generation cell therapies to have a meaningful impact on the millions of patients worldwide who, despite medical advancement, live with unmet medical needs across a variety of diseases. Our aim is to be the premier cell engineering platform technology to support the development of advanced therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Overview</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty&#160;years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have sought to leverage or repurpose cell functions and/or machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has led to a revolution in biological research and resulted in numerous biological discoveries. Living human cells can also be engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">, or outside the body, where they are repaired or reprogrammed to fight disease. In this case, the engineered cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. Over the past few&#160;years, the success of multiple U.S. Food and Drug Administration, or FDA, approved cell therapies providing long-lasting amelioration of symptoms or presence of disease has catalyzed tremendous investment&#8201;&#8212;&#8201;leading to exponential growth in cell-based therapies being evaluated for therapeutic applications. According to the Alliance for Regenerative Medicine, the combination of gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the American Society of Gene and Cell Therapy, or ASGCT, there are now more than 3,400 gene, cell and RNA therapies in development globally, with gene therapy including genetically-modified chimeric antigen receptor T cells, or CAR-Ts, accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx, STx and GTx; portfolio of proprietary related processing assemblies, or disposables; and software protocols. We have garnered meaningful expertise in cell engineering via our internal research and development efforts as well as our customer-focused commercial approach, which includes a growing application scientist team. The platform is also supported by a robust intellectual property portfolio with 50 granted U.S. and foreign patents and 76&#160;pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the U.S. National Institutes of Health, or NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. As of June 30, 2021, we have placed more than 400 of our electroporation instruments worldwide. During the year ended December 31, 2020, we sold a total of 70 instruments to our customers and leased an additional 16 instruments to our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe our ExPERT platform offers a compelling value proposition to our academic and biopharmaceutical customers due to: (i)&#160;the ability to use our technology to deliver almost any molecule into almost any cell type, including hard-to-transfect human primary cells, while maintaining high cell viability and function: (ii)&#160;the capacity to introduce larger and more diverse payloads compared to other intracellular delivery technologies, such as viral vectors; and (iii)&#160;the flexibility to scale up from research to current good manufacturing practices, or cGMP, manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe our ExPERT intracellular delivery platform provides value across numerous applications in the life sciences market, including the research, discovery, development, and manufacturing of next-generation, cell-based therapeutics, as well as in biomanufacturing, such as transient protein production for drug discovery and manufacturing of other proteins, including biological therapeutics, viral vectors and vaccines and small molecule drug discovery.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT technology platform is being used in the clinic to support the development of next-generation cell therapy approaches to treat human disease. Following the successful clinical development leading to FDA approvals of CAR-T cell therapies in blood-based cancer, developers have focused on improving efficacy, lowering the cost of manufacturing and/or expanding engineered cell therapies into new indications, such as solid tumors. To address these goals, the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy industry has trended towards developing more complex therapies that require sophisticated engineering and gene manipulation as well as the use of different starting cell types.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Often as a product candidate moves from preclinical research to clinical trials and then commercial scale up, drug developers must transition to different technologies, which can create significant financial, technical, and regulatory burdens for customers and lead to significant timeline delays due to re-optimization requirements. We believe that our ExPERT platform enables our customers to engineer cells safely, efficiently, and with high reproducibility, cell viability and potency throughout the stages of product development and commercialization. This ability to use a single platform provides significant cost and time savings for our customers and accelerates the delivery of new treatments to patients.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we are committed to continued research and development investments in technology and scientific innovation to maintain our market leadership position. For example, we intend to introduce new instruments and processing assemblies, or PAs, under the ExPERT brand that allow us to meet the evolving needs of customers and move into new applications to better serve high growth segments of the cell therapy market, including allogeneic CAR-T, engineered stem cells for inherited disorders, engineered primary cells for treatment of solid tumors and development of personalized neoantigen approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe we are well positioned in this market given the manufacturing supply constraints and payload size limitations of other delivery methods, such as viral vectors. Given our value proposition in non-viral delivery, we have established strategic relationships, in the form of Strategic Platform Licenses, or SPLs, with a growing number of leading cell therapy developers as they work to bring next-generation cell therapies into and through the clinic and advance those candidates to potential commercialization. These SPLs provide us with the ability to secure downstream program-related pre-commercial milestones and, in most cases, commercial sales-based payments. In addition, from our SPL customers, we receive both annual research and clinical license fees as well as payments from sales of our proprietary disposables as recurring revenue streams. Given growth in the cell therapy pipeline and increased investment in the space, we estimate that the number of potential SPLs for us will increase from approximately 50 today, based on our estimate of the companies that are currently developing engineered cell therapies, to almost 140 by 2026, based on our estimates of growth in the cell therapy pipeline, growth in the number of therapeutic delivery entrants into the market and ongoing shift to non-viral delivery. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have entered into 13 SPLs with commercial cell therapy developers since January&#160;1, 2017, of which 12 have been publicly announced as shown in the table below.</font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;height:287.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;min-height:38.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.167pt 0pt; width:169pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Partner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.167pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Therapeutic Indication </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Date Announced </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 4.167pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Most Advanced </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Stage of </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Clinical </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Development* </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31.25pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">CRISPR/Casebia Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:192pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.025pt;">Hemoglobin-related diseases and severe combined immunodeficiency (SCID) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">March&#160;14, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.917pt 0pt 2.833pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1/2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">CRISPR Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Immuno-oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;9, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Precision Biosciences </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November 14, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1/2</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Kite Pharma (now Gilead) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology (CAR-T)</font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">March 1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Preclinical </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Editas Medicine </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:192pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:-0.025pt;">Sickle cell disease and beta-thalassemia; Immuno-oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">October&#160;7, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1/2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">VOR Biopharma </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">November&#160;21, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1/2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">KSQ Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">December&#160;4, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Preclinical </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Allogene Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology (CAR-T) </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">March&#160;24, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1/2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Caribou Biosciences </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">May&#160;7, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Apeiron Biologics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">July&#160;8, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1b </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Myeloid Therapeutics </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">January&#160;11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Phase 1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:21pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:169pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Celularity </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:192pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Oncology </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">May 25, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Preclinical</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Includes only product candidates that have been publicly disclosed by the customer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to SPLs, we provide some customers, which could be academic institutions or commercial entities, with access to our instruments through licenses for research-only purposes, without the rights or ability to produce material for clinical use, or for use in the clinical evaluation and development of a therapeutic product intended for human use. We refer to these agreements as research licenses and clinical licenses, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Under these SPLs and other license agreements with our customers, in exchange for an annual license fee per instrument, we provide our customers with non-exclusive access to our:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">cGMP-compatible platform, which enables early-optimization and scale-up from preclinical research into clinical development using our intellectual property portfolio;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">FDA Master File and Technical Files, which may accelerate and streamline development and reduce regulatory risk in the creation and development of our partners&#8217; therapeutic drug candidates;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">experienced commercial team of sales personnel and application scientists who work directly with our customers to solve cell engineering problems; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">continuous know-how and cell engineering process improvements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Of the over 75 clinical program licenses associated with our existing SPLs, more than 15% are in the clinic, meaning they have at least an FDA-cleared investigational new drug application, or IND. An IND is a request for authorization from the FDA to administer an investigational new drug to humans. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. Clinical trials then involve the administration of the investigational product to human subjects under the supervision of qualified investigators and are </font>
        </div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. In Phase&#160;1, the investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and excretion of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In Phase&#160;2, the investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials. In Phase&#160;3, the investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a biologics license application, or BLA, requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our 13 SPLs have the potential to generate over $950&#160;million in pre-commercial milestone payments if all of the licensed programs were to achieve regulatory approvals. In addition, under the SPLs, we typically have the potential to receive significant, sales-based commercial payments for approved products. However, as described above, clinical development involves a lengthy and expensive process with an uncertain outcome, and therefore our customers may never receive FDA or other regulatory approval for their product candidates covered by their SPL agreements with us, in which case we will not receive this amount of pre-commercial milestone payments or the sales-based commercial payments or royalties contemplated by our agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10.1pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-org_prog4c.jpg" alt="[MISSING IMAGE: tm2113965d2-org_prog4c.jpg]" height="122" width="551" >
        </div>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our current strategic partners have demonstrated success progressing next-generation cell therapies through the clinic, which has provided growing validation supporting our ability to facilitate complex cell engineering in a clinical setting. Further, our platform is supported by an FDA Master File. A Master File is a submission to the FDA with confidential detailed information about our products, methods, processes and data, which can be referenced by our customers to support their own regulatory filings, which we believe has the potential to reduce certain risks and challenges in connection with our customers&#8217; regulatory submissions and development timelines. Outside of the United States, similar Technical Files are in place or being pursued to support our customers&#8217; regulatory processes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the year ended December 31, 2020, one cell therapy company with which we have entered into an SPL accounted for 15% of our total revenue, and our six largest such customers accounted for an aggregate of approximately 40% of our total revenue for the year through a combination of instrument license fees, milestones realized and processing assembly revenue. As the number of SPL customers </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">increases, the portion of our total revenue derived from any one or a limited number of SPL customers will decline accordingly.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We aim to build a large, diversified portfolio of SPLs that enable us to participate in the economics of the near-term and long-term success of our partners&#8217; drug candidates. We estimate that the total addressable market opportunity for our ExPERT platform, based on the potential for current SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies as described in more detail under &#8220;&#8212;&#160;Our Market Opportunity.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Competitive Strengths</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe our industry leadership position and continued growth will be driven by the following competitive strengths:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Our proprietary technology platform unlocks the significant potential of advanced therapeutics</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We have built our ExPERT platform to advance the growing demands for non-viral delivery and next-generation cell and gene engineering approaches. Our platform technology enables delivery of almost any molecule into almost any cell type. We believe our platform leads the industry in performance (measured by consistency, efficiency, viability, flexibility, and scale). Our platform is further supported by a robust intellectual property portfolio with 50 issued U.S. and foreign patents and 76 pending patent applications worldwide.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Comprehensive, high-performance transfection platform</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We believe our ExPERT platform offers a unique value proposition given the flexibility to scale up from research to cGMP manufacturing on a single platform&#8201;&#8212;&#8201;enabling the engineering of cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less. Our long-term internal engineering expertise is supplemented by our customer focused approach&#8201;&#8212;&#8201;with a growing application scientist team working with our customers across increasingly diverse applications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Positioned as a leader in the large and growing next-generation cell therapy market with the ability to capitalize on rising demand for non-viral approaches.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We believe we are well positioned to capture increased market share within the large and growing next-generation cell therapy market. Since the FDA approved the first engineered CAR-T cell therapies to treat cancer in 2017, the number of cell therapy candidates being evaluated pre-clinically and clinically has grown exponentially. We expect growth to continue given the remaining high unmet medical need in cancer and other chronic conditions and predict increased investments in cell therapy product development across a variety of human diseases. We expect to grow our market share given the high performance of our platform and regulatory support through our FDA Master File as well as the ongoing shift to non-viral delivery as the industry has trended towards developing advanced cell-based therapies with complex engineering strategies to improve efficacy, reduce time to patient treatment and expand into new indications.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Innovative partnership business model focused on value creation and shared success</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our SPLs allow us to participate in the value creation of our customers&#8217; programs via pre-commercial milestones and in nearly all cases commercial sales-based payments. We intend to continue to build a portfolio of strategic partnerships with cell therapy developers, which provide us with a growing, diversified source of potential downstream revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to the high performance and flexibility of the ExPERT platform, we believe our partnership model further reduces clinical risk and development timelines for our cell therapy partners. By entering into an SPL with us, for example, our partners gain access to our FDA Master File to support their IND-enabling studies and potentially shorten clinical development. Our FDA Master File was originally established in 2002 and has been continuously updated as platform improvements are implemented to support different applications and cell types. The FDA Master File and equivalent Technical Files in other countries can be referenced by our partners to support their own regulatory submissions with the goal of accelerating regulatory submissions processes for our partners. To date, our FDA Master File and Technical Files have been referenced by our customers in over 30 clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">First-mover advantage has yielded broad-based adoption, with commercial model supported by top-tier customers.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model is supported by more than 20&#160;years of investment and experience and has enabled us to cultivate long-standing and collaborative relationships with our significant and growing customer base. From leading commercial cell therapy drug developers and top biopharmaceutical companies to top academic and government research institutions, including the NIH, our customers have extensively validated our technology. We believe the features and performance of our platform have led to sustained customer engagement. Our existing customer base includes large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue. We now have 13 SPLs with commercial cell therapy developers, which together provide licenses for over 75 programs, of which currently more than 15% have advanced into clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Recurring revenue model provides high visibility, with drivers of potential long-term upside.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our business model enables us to generate substantial revenue from five sources: sales of instruments and disposables to new customers; additional sales of instruments and disposables to our existing installed base; annual instrument license fees from cell therapy customers; pre-commercial milestones under SPLs; and potential commercial sales-based payments under SPLs. We generate high recurring revenue from our ExPERT instrumentation licenses and disposable sales, which provides visibility into future near-term revenue. Over the last three&#160;years, annual renewals of instrument licenses were greater than 80% on average&#8201;&#8212;&#8201;and for our SPLs were near 100%. In addition to recurring revenue, we have the potential to receive meaningful pre-commercial and commercial payments under SPLs if our customers are successful in advancing programs through the clinic and into the commercial stage. In aggregate, we have the potential to receive over $950&#160;million in pre-commercial milestone payments under our current SPLs, if all of the programs were to receive regulatory approvals.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Founder-led leadership team and workforce with deep domain knowledge.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our management team combines strong and broad subject matter expertise with a demonstrated history of commercial and operational execution. Moreover, our workforce has deep domain knowledge across a range of scientific, engineering, regulatory and business disciplines. We have supplemented our diverse technical experience by assembling a deep operational team with expertise in manufacturing, legal, sales, marketing, customer service and finance. We believe the team we have assembled with talent from multiple disciplines and a science- and customer-focused culture represents a significant competitive advantage for us. As of March&#160;31, 2021, of our 65 full-time employees, 45 have advanced degrees, including 19 with Ph.D. degrees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Growth Strategies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The key elements of our growth strategy include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Establish ExPERT as the standard of non-viral delivery technology in the rapidly growing cell therapy market</font><font style="font-weight:bold;letter-spacing:-0.111pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We are committed to continued investment in technology and scientific innovation to maintain our market leadership position. We believe that the adaptability of, and continuous improvement in, our single-use disposable product portfolio via recent product launches exemplifies our partnership with our customers to meet varying processing volume requirements, for example. We plan to further invest in our current platform and potentially introduce new instruments and PAs that allow us to meet the evolving needs of customers and move into new applications to better serve high-growth segments of the cell therapy market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Drive customer adoption and accelerate revenue growth through execution and expansion of our strategic marketing initiatives</font><font style="font-weight:bold;letter-spacing:-0.111pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We aim to accelerate our revenue growth by investing in our sales and application scientist teams to fuel growth in our underlying ExPERT platform and foster and develop new customer and SPL opportunities. We also see opportunity for geographic expansion, particularly in Asia, and the potential to further penetrate non-commercial customer accounts, including translational academic centers globally, which </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">we believe will represent &#8220;hotspots&#8221; driving innovation that favor non-viral extracellular delivery technology. Finally, we expect to continue to cultivate academic collaborations and grow our application scientist team to gain exposure to and experience with up and coming cell and gene engineering approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Increase our number of SPLs</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;We plan to continue to pursue SPLs with target customers, including leading biopharmaceutical companies focused on cell therapies. We believe that there are a substantial number of potential SPL opportunities in the market and have seen a commensurate increase in our SPL discussions over the past several&#160;years. Given growth in the cell therapy pipeline and increased investment in the space, we estimate that the number of potential SPLs for us will increase from approximately 50 today, based on our estimate of the companies that are currently developing engineered cell therapies, to almost 140 by 2026, based on our estimates of growth in the cell therapy pipeline, growth in the number of therapeutic delivery entrants into the market and ongoing shift to non-viral delivery. We plan to aggressively pursue these opportunities and establish new SPLs by increasing business development activities and demonstrating our technological advantages over alternative methods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Commercialize our VLX Large-Scale Transfection System under the ExPERT brand to expand our capabilities into additional attractive market verticals, including large-scale bioprocessing and cell therapy applications</font><font style="font-weight:bold;letter-spacing:-0.111pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our VLX Large-Scale Transfection System provides the ability to transfect up to approximately 200&#160;billion cells, or ten times the number of cells and/or volume of the GTx/STx, in less than 30 minutes. The VLX has been sold to a limited number of customers for specific large-scale applications in a first generation design. We plan to align the current design of the VLX with the design, capabilities and branding of our ExPERT instruments, as well as make specific product enhancements that would be unique to the VLX. As part of this initiative, the VLX will be rebranded under the ExPERT brand as the &#8220;VLx.&#8221; We believe that improving the design of the VLX and commercializing it under the ExPERT brand with an updated state-of-the art design, adding an on-board user interface, and developing associated cGMP compatible large-scale disposables and software protocols, would allow us to enter into large-scale bioprocessing applications including viral vector production in suspension cell cultures and rapid production of proteins, including monoclonal antibodies&#8201;&#8212;&#8201;as well as facilitate further scale up in allogeneic (or donor-derived) cell therapy approaches.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Enhance manufacturing and research and development capabilities by investing in capacity as well as automation and process development.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We intend to expand our manufacturing infrastructure. We plan to invest in our capacity to support increased demand for our instruments and disposables as our customers move further through the clinic and toward commercialization. We also plan to invest in the automation and final assembly of our PAs for greater control and for enhanced flexibility as our partners expand the use of our technology. Additionally, we plan to expand our research and development capabilities by investing in process development via expanding laboratory space, increasing capital investment in laboratory equipment and supplies and growing our scientific team&#8201;&#8212;&#8201;to continue to align our capabilities with the requirements of our customers and potentially support new product development.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Opportunistically pursue strategic investments, partnerships and acquisitions</font><font style="font-weight:bold;letter-spacing:-0.111pt;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our revenue growth to date has been organically driven by the addition of customers to our growing installed base of ExPERT users and expansion of our product offerings to those customers. We may consider opportunistic investments, partnerships and acquisitions that we believe will complement our product platform, allowing us to enter new markets and applications to enhance our growth profile. We also intend to establish new industry partnerships, enabling us to remain at the forefront of cell engineering trends and continue to collaborate with customers to accelerate the development and commercialization of new medicines.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Technology Platform</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The foundation of our technology is our proprietary and patented Flow Electroporation platform, which we have developed and optimized over more than 20&#160;years. Electroporation, or electro-permeabilization, leverages the fundamental properties of cell membranes, the ability to create </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">reversible permeability in the presence of an electric charge, as a universal method to introduce foreign molecules, or transfect, eukaryotic cells. Electroporation can be applied to almost any eukaryotic cell type to deliver a broad range of molecules, including DNA, mRNA, siRNA and proteins. Our patented Flow Electroporation platform is fully scalable and can support small-scale research and development through to large-scale cell engineering for development of commercial therapeutics.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.81pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pht_expert4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_expert4clr.jpg]" height="145" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our technology platform is marketed under the ExPERT brand. The value of our ExPERT brand starts with Efficiency&#8201;&#8212;&#8201;with high delivery </font><font style="font-weight:bold;letter-spacing:-0.111pt;">Efficiency</font><font style="letter-spacing:-0.025pt;">, users can achieve </font><font style="font-weight:bold;letter-spacing:-0.111pt;">Potency</font><font style="letter-spacing:-0.025pt;">, with high Potency, users improve their chances of therapeutic </font><font style="font-weight:bold;letter-spacing:-0.111pt;">Efficacy</font><font style="letter-spacing:-0.025pt;">, and if this can be repeated, </font><font style="font-weight:bold;letter-spacing:-0.111pt;">Reproducibly</font><font style="letter-spacing:-0.025pt;"> from patient to patient, users have a successful </font><font style="font-weight:bold;letter-spacing:-0.111pt;">Therapy</font><font style="letter-spacing:-0.025pt;">. By delivering high efficiency at any scale, the ExPERT platform is designed to improve our customer&#8217;s ability to achieve the required therapeutic index, enabling accelerated, cost-efficient translation of complex cellular therapies from research to the clinic.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform consists of three instruments, the ATx, STx and GTx, which use a broad range of PAs, or disposables, of different volumes to enable scalable electroporation from tens of thousands to billions of cells to facilitate the translation of complex cellular therapies from concept to the clinic, in support of the intended therapeutic commercialization.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our ExPERT family of instruments and disposables supports scale-up for cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="position:relative;margin-top:4pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-pht_scale4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_scale4c.jpg]" height="151" width="568" >
        </div>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Overview of our ExPERT platform</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our Flow Electroporation Technology was designed to meet the stringent demands of clinical use&#8201;&#8212;&#8201;namely, the ability to safely and reproducibly modify a broad range of primary human cells with high efficiency, low cytotoxicity, and at the scale required to enable the treatment of patients across a diverse range of diseases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We believe the current ExPERT instrument family represents the next generation of our clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality and ease of use, the ExPERT platform delivers the high-end performance that we believe is essential to enabling the next wave of biological and cellular therapeutics. The combination of the ExPERT instruments, associated disposables and universal electroporation buffer, provides researchers, production scientists, and cGMP facilities with a solution to transfect cells with high efficiency, viability and consistency, which are the three attributes that are consistently ranked by our customers as the top requirements when choosing a cellular or gene engineering platform for clinical use. We believe our ExPERT platform is seen as a critical enabling technology by many of the leading cell therapy companies, helping them to achieve their program goals </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">and milestones expeditiously. Our instruments are sold or licensed for research use and licensed for clinical use, while the associated disposables and electroporation buffer are sold to support preclinical research and development work and are compatible for integration into cGMP manufacturing environments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe that the following four components of our platform have allowed us to successfully address the increasing complexity of cellular engineering approaches in the industry:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Instrument design;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Electroporation and cell handling protocols;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">PAs (disposables); and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Universal electroporation buffer formulation (consumables).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, we have implemented a global scientific and regulatory support strategy for our customers that is designed to accelerate clinical development and streamline the regulatory submission process, thereby potentially saving time and reducing cost and development risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe several factors differentiate our ExPERT platform and will continue to be significant drivers of customer adoption, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">High performance electroporation</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our range of ExPERT instruments can be used to transfect almost any cell type, including hard-to-transfect human primary cells and induced Pluripotent Stem Cells, or iPSCs. Transfection efficiency using our platform has consistently been at least 90% for most cell types (using mRNA) with minimal disturbance to the cell, resulting in high cell viability of at least 90%. This performance is documented by multiple peer-reviewed publications demonstrating that transfecting cells using our platform does not significantly alter the cell phenotype, natural expression of cell surface receptors or proliferative capacity.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Scalability</font><font style="font-style:italic;">.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our Flow Electroporation Technology can engineer cells ranging from tens of thousands of cells to tens of billions of cells in a single transfection run in 30 minutes or less, without requiring costly re-optimization or sacrificing performance on scale-up. We offer a range of PAs to support preclinical research and development work and manufacturing in cGMP environments, which allows customers to seamlessly scale-up in a sterile process format that can be integrated into their workflow.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Flexibility to deliver larger and more diverse payloads.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;While adeno-associated virus, or AAV, lentivirus and other vectors have increasingly been used in </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> and </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> gene therapies, viral vectors carry inherent capacity limitations. For example, the most commonly used Cas9 nuclease, spCas9, and a sgRNA are approximately 4.2 kilobase, or kb, in size, but a single AAV only allows for approximately 4.5 kb to be packaged within it, making it difficult to include other elements (e.g., multiple sgRNAs if multiple edits are required or DNA templates if correction is the goal) to ensure the delivery of the required elements into the cells and meet desired gene-editing objectives. A kb is a unit of measurement in molecular biology equal to 1,000 base pairs of DNA or RNA. Our platform enables larger molecules to be delivered into the cells (or multiple different molecules to be co-loaded into cells). For comparison, we are able to deliver large molecules, including CRISPR RNPs which can be 40 nanometers or higher in diameter.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Designed for Clinical Use.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The ExPERT GTx platform has been specifically designed for use in a cGMP clean room setting for manufacturing of cell therapies intended for use in patients. The platform integrates features such as electronic documentation and electronic signatures designed to be consistent with the FDA expectations under 21 CFR Part&#160;11, (which may be critical to the regulatory compliance process for certain customers) and networking capability for automated transfer of electronic batch records of manufacturing runs to a centralized data management solution. As part of our global regulatory strategy, our customers have access to our FDA Master File or equivalent Technical Files with the regulatory agencies in the countries where they will seek to conduct clinical trials, potentially streamlining the regulatory submission process and helping to reduce time and cost of clinical trials.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Industry Background</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The promise of cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The field of cell therapy has emerged as one of the fastest growing and most promising treatment modalities to address a host of human diseases. In 2017, the FDA approved the first </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> CAR-T cell therapies, Kymriah and Yescarta, developed and commercialized by Novartis and Kite Pharma (now Gilead), respectively, offering a potentially transformative option to a cohort of relapsed and refractory hematological cancer patients who had previously exhausted all other therapies. The success of these therapies has catalyzed significant investment in advanced cell therapies. According to the Alliance for Regenerative Medicine, gene, cell, and tissue-based therapeutic developers raised an aggregate of $19.9&#160;billion in 2020, up from $13.3&#160;billion in 2018. According to the ASGCT, there are now more than 3,400 gene, cell and RNA therapies in development globally, with gene therapy including genetically-modified CAR-Ts accounting for 53% of those candidates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe there are several key factors driving the meaningful investment and subsequent explosion in gene and cell therapy trials globally, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">success of multiple FDA-approved cell therapies providing long-lasting amelioration of symptoms or even cure of disease;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">numerous advancements in various cell engineering systems, such as the discovery and adaption of targeted gene editing systems including CRISPR, and development of next-generation intracellular delivery approaches;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">improved understanding of how to monitor and manage impacts of adverse events (including immune response to delivery vectors) as clinicians have gained more experience in treating patients with currently approved gene and cell therapies; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">successful demonstration of proof-of-concept efficacy of next-generation </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> and </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> gene and cell therapy-based approaches as these therapies have begun to be explored in humans.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As a result of these advancements in the industry, cellular engineering programs that deliver genetically modified cells capable of treating complex human diseases are rapidly increasing in number and complexity.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Background on cell therapy<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cells represent the smallest discrete unit of life and are the building blocks of all living organisms, from single cell organisms&#8201;&#8212;&#8201;such as amoebas&#8201;&#8212;&#8201;to organisms as complex as humans, which are made up of over 30 trillion cells. Eukaryotic cells are characterized by three basic components: (i)&#160;the cell membrane, which controls movement of molecules into and out of the cell, (ii)&#160;a nucleus, which typically houses the cell&#8217;s DNA and is where RNA synthesis occurs, and (iii)&#160;the cytoplasm, or the fluid inside the cell.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">With increased knowledge of cell complexity and systems biology in the scientific community, researchers have been able to engineer, or manipulate, cells in order to leverage or repurpose cell functions and/or machinery. The ability to deliver foreign molecules into living cells&#8201;&#8212;&#8201;either isolated from an organism (</font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">), within an organism (</font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;">), or to cells outside of their normal biological context, such as those grown in culture (</font><font style="font-style:italic;">in vitro</font><font style="letter-spacing:-0.025pt;">)&#8201;&#8212;&#8201;has led to a revolution in biological research and resulted in numerous biological discoveries. Cell therapy is generally used to refer to </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> manipulation of cells for therapeutic purposes. Living human cells are engineered outside the body (</font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;">) where they are repaired or reprogrammed to fight disease. In this case, the cell itself is the drug.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Both academic and commercial research has focused on novel strategies to improve efficacy, reduce time to treatment, and expand the use of cell therapies into new indications. Given the level of investment, the field is evolving rapidly to next-generation approaches with increasing complexity. For example:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Development of off-the-shelf therapies.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Efforts have focused on using allogeneic donor cells or cell lines to develop &#8220;off-the shelf&#8221; approaches for CAR-T therapies. Use of donor cells versus autologous patient cells could potentially improve time to treatment, lower cost of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:22pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">treatment, and improve therapeutic efficacy by using healthy cells as a starting point, but may require &#8220;knock-out&#8221; or &#8220;knock-down&#8221; of additional genes to prevent patients from rejecting donor cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Use of next-generation chimeric receptors or engineered TCRs to expand the cell therapy toolbox.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Next-generation synthetic receptors or engineered T-cell receptors, or TCRs, have been developed and introduced into cells to improve antigen recognition and reduce the potential for antigen escape (the ability to recognize multiple antigens). Engineered TCRs, for example, enable cells to recognize intracellular proteins.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Knocking out or knocking down expression of certain genes to improve efficacy</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;A promising strategy for next-generation therapies include &#8220;knocking out&#8221; or &#8220;knocking down&#8221; genes to improve the efficacy of cell therapies. For example, cancer cells have evolved to overexpress programmed death-ligand 1, which binds to programmed cell death protein 1, or PD1, on T-cells and helps evade recognition. Therefore, knocking out the PD1 &#8220;checkpoint&#8221; on T-cells could increase the ability for engineered T-cells to recognize the cancer cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Use of other primary cell types</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Focus of cell therapy in immuno-oncology applications has expanded to include other immune effector cells beyond T-cells (including NK cells, T-regs and gamma delta T-cells). Similarly, the treatment of complex genetic diseases using gene correction of stem cells, such as hematopoietic stem cells, or HSCs, and their derivatives and iPSCs will also require correction of multiple mutations with increasing fidelity and improved efficiency.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Driving towards personalized cell therapy</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Another promising approach is neo-antigen-based therapies, where T-cells are engineered to target each patient&#8217;s highly specific protein expression signatures identified on their cancer cells. To achieve this, multiple unique T-cell receptors directed against the patient&#8217;s own tumor antigens are identified, cloned and inserted back into the patient&#8217;s own T-cells for reinfusion. Such neoantigen T-cell receptor engineered-T-cell approaches hold promise for the future of personalized cellular immunotherapies and could fundamentally change the cancer treatment paradigm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition, the availability of gene editing systems such as CRISPR, which allows scientists to directly alter DNA and RNA at targeted locations, has meaningfully accelerated technological advancements in cell therapy. For instance, several triple edited </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies have now entered clinical trials and some companies have demonstrated proof-of-concept with as many as six edits to a single cell. These are just a few examples of the increasing complexity of the cellular engineering required to deliver the next generation of cell therapies that show great promise for treating previously untreatable diseases. We believe that our ExPERT platform can address each of these next-generation approaches because of our ability to facilitate the evolving complexities described above.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Approaches to intracellular delivery<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At a high level, there are two methods of introducing molecules into cells: carrier (or biological) based (e.g., the use of engineered viruses, vesicles, nanocarriers and nanoparticles) and membrane-disruption based or physical approaches, such as electroporation. Both of these approaches seek to introduce &#8220;cargo&#8221; into the cell interior without damaging the cell or producing an unintended impact to cell function. Carrier-based approaches serve to package the cargo to prevent it from degradation while simultaneously gaining access to the cell in order to deliver the intended cargo. Physical approaches seek to disrupt the cell membrane, which facilitates passage of molecules across the cell membrane, or involve direct penetration of the membrane.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The type of molecules that scientists can now introduce into cells&#8201;&#8212;&#8201;also referred to as payload&#8201;&#8212;&#8201;is highly diverse. Each payload type carries unique challenges including size variability, shape, architecture, and chemical properties, which has led to an increase in the number of strategies available for intracellular delivery of molecules. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:7.61000000000001pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The following chart compares the advantages and disadvantages of viral-mediated transfection and electroporation:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5.31pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:72pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Transfection </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Method </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:84pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:60pt;white-space:nowrap;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.1pt;">Biological</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:72pt;white-space:nowrap;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.1pt;">Virus mediated</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Delivery via a viral vector, often known as &#8220;transduction&#8221; </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.8pt;">
                <font style="letter-spacing:-0.022pt;">High efficiency</font>
              </div>
              <div style="margin-top:6pt; text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Easy to use (simplicity of infection)</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Effective on dissociated cells</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.07pt 0pt 2.99pt 0pt; width:108pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Labor intensive, time consuming and significant facilities cost</font>
              </div>
              <div style="margin-top:6pt; text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Insertional mutagenesis, immunogenicity, and cytotoxicity </font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Packaging capacity limitations </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.77pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:9pt;">
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:60pt;white-space:nowrap;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.1pt;">Physical</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:72pt;white-space:nowrap;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.1pt;">Traditional </font>
                <br >
                <font style="letter-spacing:-0.1pt;">electroporation</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center; line-height:10.78pt;">
                <font style="letter-spacing:-0.022pt;">Electrical pulses to produce electrically induced membrane permeability to allow for payload delivery </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:84pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.022pt;">Easy to perform</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">All cell types</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">High transfection efficiency</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.33pt 0pt 0.5pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.022pt;">Potential for low cell viability</font>
              </div>
              <div style="margin-top:6pt; text-align:center;">
                <font style="letter-spacing:-0.022pt;">Instrument investment</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">For gene and cell therapies, engineered viral vectors have historically been the most common delivery technique. Viral-mediated gene delivery uses the inherent capacity for viruses to infect human (or other) cells and inject DNA that the virus carries into cells. Commonly used viral methods of gene transfer include retrovirus, lentivirus, adenovirus, adeno-associated virus, the herpes virus and the Epstein-Barr virus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">There are several reasons why early approaches have utilized viral vectors, including that:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses are widespread in humans&#8201;&#8212;&#8201;more than 200 are known to cause disease in humans&#8201;&#8212;&#8201;and are naturally efficient at delivery of genetic information into targeted cells;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses can be easily engineered to deliver the genetic material of interest, can be engineered to not self-replicate, and in the case of some viruses (such as lentivirus and wild-type AAVs), integrate their DNA into the host genome, thereby driving sustainable expression of the gene of interest; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">viruses were one of the first methods used in early gene therapy trials, with the first generation of lentiviral vectors created in the mid-1990s.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">Traditionally, first-generation approaches modified T-cells with a virus-mediated chimeric antigen receptor, or CAR. For example, Kymriah and Yescarta use lentivirus and retrovirus, respectively, for delivery of the CAR construct. While viral vectors, in particular lentivirus, have formed the bulk of delivery methods for such early cell therapies, AAV has become the viral vector of choice, particularly for </font><font style="font-style:italic;">in vivo</font><font style="letter-spacing:-0.025pt;"> gene therapy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The following chart compares the advantages and disadvantages of the major viral vectors used in gene therapy:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;min-height:111.18pt;margin-top:10.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Viral Vector </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Genetic </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Material </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Insert </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capacity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Host Range </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.089pt;">Adenovirus</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">dsDNA </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">&lt; 7.5 kb </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Broad host range; infective for many cell types </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">No integration </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.197pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">No integration </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Large range of cell types </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Relative insert capacity constraints </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">High transduction efficiency </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.447pt 0pt 1.563pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">May initiate strong inflammatory response </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:231.61pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Viral Vector </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Genetic </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Material </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Insert </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capacity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:57.5pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Host Range </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Advantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Disadvantages </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.089pt;">AAV</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">ssDNA </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">&lt; 5kb </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Broad host range; infective for many cell types </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Chromosomal integration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.197pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Small packaging capacity </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Nonimmunogenic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Immune response </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Nonpathogenic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.503pt 0pt 2.107pt 0pt; width:108pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Slow expression onset </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.089pt;">Retrovirus</font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">RNA </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">8 kb </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Broad host range </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Long-term expression </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.02pt;">Transduces only dividing cells </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Persistent gene transfer with dividing cells </font>
              </div>
            </td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="padding:0pt;background:#CCCCCC; width:6pt;">&#8203;</td>
            <td style="background:#CCCCCC;padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Integration might induce oncogenesis in some applications </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.089pt;">Lentivirus</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:36pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">RNA </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:41pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">8 kb </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:57.5pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Ecotropic, amphotropic </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Long-term expression </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Exposure to replication competent lentiviruses </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:96pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Does not require cell division for proviral integration </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.02pt;">Random integration could cause insertional mutagenesis </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:57.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 1.573pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Low cytotoxicity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 1.573pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.02pt;">Mobilization of the vector by endogenous retroviruses in the genomes of patients</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:15.5pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">As the cell therapy market continues to evolve, more complex approaches are being deployed to improve efficacy, reduce time to patient and expand the application of cell therapy to additional indications. Use of viral vectors carry several challenges, however, especially given the increase in complexity of these &#8220;next-generation&#8221; </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy approaches, such as:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Viral payload limitations</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Many methods of gene manipulation require insertion of relatively large molecules, including proteins such as CAS9 RNP for CRISPR or plasmids. Viral vectors, particularly AAV, have fundamental payload capacity limitations, curtailing their utility for complex engineering systems. Additionally, the industry has continued to shift to using complexed molecules including combination of proteins and mRNA which cannot be delivered by viral means.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">The picture below shows the size ranges of various kinds of molecules that can be inserted into cells.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-pht_cellul4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_cellul4c.jpg]" height="317" width="578" >
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Concerns around toxicity</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Given viruses used in gene therapy by default infect human cells, there continue to be questions around the safety profile associated with viruses. In </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:50.93pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">particular, there are concerns over the potential for random integration of lentivirus and the widespread presence of neutralizing antibodies against many AAV serotypes used in gene therapies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.111pt;">Costs and time to market</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Concerns exist regarding viral vector manufacturing capacity and the cost associated with viral development and manufacturing. According to BioPlan&#160;Associates, a market research firm, lead times at contract manufacturing organizations are averaging 18&#160;months to obtain a cGMP viral manufacturing slot and six to nine&#160;months for requisite viral safety testing. Additional bottlenecks arise from demand for viral approaches, which has led to subsequent demand for cGMP plasmids. The ongoing COVID-19 pandemic has further exacerbated demand, particularly for adenovirus, and suspension cells, which are difficult to engineer at high volume. Concurrently, regulatory scrutiny and product characterization requirements are increasing as more gene and cell therapy products reach the clinic, as noted by the FDA&#8217;s revised guidelines for viral vector analytics in early 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Novel intracellular delivery approaches are needed to support the increased complexity of the burgeoning cell therapy pipeline. Characteristics include reducing immunogenicity risk of viral vectors, the need to drive high efficiency of multi-molecule delivery while maintaining high cell viability and potency, reducing the risk of potential genotoxicity of multiplex editing (potential for translocations), the need to deliver a large number of molecules at scale, the ability to deliver to a large number of cell types in a time efficient matter, and the need to manufacture in a cGMP environment&#8201;&#8212;&#8201;all at a manageable cost.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Electroporation as a mechanism of non-viral delivery</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Electroporation background<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">In order to understand electroporation, it is important to understand the make-up of the cell membrane. The cell membrane is a phospholipid bilayer, which is a thin membrane made up of two layers of lipid molecules forming a continuous cell membrane around the cytoplasm and acting as a stable barrier between the intracellular and extracellular environment. The lipid membrane is fluid&#8201;&#8212;&#8201;meaning individual molecules (including lipids and proteins) are free to rotate and move laterally and transversely, which is a critical property and determined by the composition of the lipid and the cell&#8217;s thermal environment. The membrane is also selectively permeable, allowing the cell to control and maintain its internal composition, with the typical arrangement of the cellular membrane designed to impede the movement or passage of molecules into or out of the cell.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Applying electric fields above a certain threshold induces membranes to become more permeable. A key discovery in the use of electroporation to drive reversible permeability of cell membranes was the use of electric pulses&#8201;&#8212;&#8201;applying fields of adequate strength but for short durations&#8201;&#8212;&#8201; which allows the membrane to return to its normal state or reseal, and thus permeabilization is transient. If the pulse is too strong or too long, the membrane does not reseal, leading to cell death. The length of time that the membrane remains permeable is dependent on various factors, including temperature, ionic content and the presence and distribution of proteins.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">While the precise molecular mechanism of electrically-induced membrane permeability has not been fully elucidated (with a number of theories proposed), experiments and mathematical modeling have provided insights into the potential physical-chemical mechanism of cell electroporation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Overview of the electroporation process<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic shows the steps involved in the electroporation process:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-pht_electro4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_electro4c.jpg]" height="422" width="578" >
        </div>
        <table style="width:456pt;height:140.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:17.33pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Step </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:426.67pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">1</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Polarization of the cell membrane occurs when electrical pulses are applied to cells suspended between two electrodes, creating an electric field. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">2</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">The application of electrical pulses and the resulting transmembrane voltage induce the formation of openings in the cellular membrane. The size distribution of these openings depends on the intensity of the applied electric field and duration of cell exposure. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">3</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">These openings allow the entry of macromolecules such as RNA, DNA or proteins (such as Cas9/guide RNA complexes) through the cell membrane and into the cytoplasm of the cell. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:17.33pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">4</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:426.67pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">The effects of electroporation on the cellular membrane are reversible. Once the electric field is removed, the membrane has the capacity to reseal, trapping the molecules that passed across the membrane within the cytoplasm.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:3.7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Development of our proprietary flow electroporation platform<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The majority of commercial electroporation systems employ static electroporation. Generally, electroporation platforms consist of two flat plate electrodes, which are attached to the opposite sides of a cuvette (or chamber). A suspension of cells is added, in addition, to the molecule or molecules to be introduced into the cells. Electrodes are connected to electronic circuity that is able to deliver electric pulses of specified duration applied one or more times to the electrodes and thus to the cell suspension in the cuvette/chamber.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Static electroporation is limited to small volumes (typically less than 1 mL), making its use in cell therapy limited primarily to early research and development. This has proven to be a bottleneck when the goal is to scale electroporation to clinical or commercial therapeutic applications where electroporation of large volumes of cell suspension is required. Maintenance of sterility is important to applications of electroporation for large volumes, and given the limited volume of cells that could be electroporated per cuvette, electroporation of large volumes of cell suspension would require multiple cuvettes using static electroporation, making it impractical outside of early, small-scale research and development experiments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:45.15pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Since pioneering the development and commercialization of Flow Electroporation over 20&#160;years ago, we have focused on optimizing our Flow Electroporation platform, specifically for </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> applications. Flow Electroporation involves the continuous pumping of batches of a fixed volume of cells from a larger cell suspension from a sample bag into an electroporation chamber housed within our PA. Once the electroporation of the cells is completed, the electroporated cells are pumped to a collection bag and the next batch of cells to be electroporated enters the chamber. This process is repeated until the complete volume of cell suspension has been electroporated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The key benefit of Flow Electroporation is that a large volume of cells can be electroporated, all in a closed, sterile system&#8201;&#8212;&#8201;facilitating the use of electroporation for therapeutic applications without sacrificing the viability and function of the transfected cells. The ability to electroporate cells in a closed system facilitates automating and maintaining a sterile environment for the engineering and manufacturing of larger cell volumes. Examples of applications benefiting from such scale are autologous CAR-T therapies, future allogeneic approaches using iPSCs, and manufacturing of transiently produced protein using Chinese hamster ovary or human embryonic kidney cells within the bioproduction or rapid vaccine production market segments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Market Opportunity</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The challenges of viral delivery methods and increase in complexity of next-generation cell therapies have driven increased adoption of non-viral delivery technologies, such as electroporation. We believe our ExPERT technology is well positioned as a non-viral delivery platform in the cell therapy market. Originally developed in 1999 for the cell therapy market, we have systematically designed and improved to deliver any molecule, into any cell at any scale, with high efficiency and under cGMP conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT platform is now the delivery backbone for a number of next-generation cell therapy programs that are in the clinic, including:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">CRISPR Therapeutics&#8217; CTX-001 for transfusion-dependent &beta;-thalassemia and severe sickle cell disease.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">VOR Biopharma&#8217;s VOR33, an eHSC therapy candidate for the treatment of Acute Myeloid Leukemia that received IND clearance in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Allogene&#8217;s Allogeneic CAR-T for cancer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Caribou&#8217;s CRISPR gene-edited allogeneic T-cell therapy program.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Editas Therapeutics&#8217; EDIT-301, an </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> gene editing cell medicine in development for the treatment of sickle cell disease that received IND clearance in January&#160;2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Precision BioSciences&#8217; lead program, PBCAR0191, a novel CD19-targeted allogeneic CAR-T therapy candidate to treat relapsed/refractory Non-Hodgkin&#8217;s lymphoma and B-cell acute lymphoblastic leukemia, and PBCAR269A, a BCMA targeted genome edited allogeneic CAR-T therapy candidate for multiple myeloma.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">While many legacy cell therapy approaches use viral delivery approaches, we believe these developers will increasingly adopt non-viral approaches. We believe we currently have the largest market share supporting customers using non-viral delivery approaches for engineered cell therapies to treat immune-oncology and inherited disorders. As shown in the graphic below, we estimate that we have captured approximately 40% to 55% of U.S. clinical programs utilizing non-viral delivery and we expect to increase our share over time as more preclinical programs reach the IND-enabling phase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:110.37pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-pc_clinical4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pc_clinical4clr.jpg]" height="326" width="548" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Based on the current pipeline of engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy candidates in development for immuno-oncology and inherited genetic disorders, we estimate that our total addressable market opportunity for our ExPERT platform, based on the potential for SPLs, was approximately $9&#160;billion in 2020. We expect this market to grow to over $24&#160;billion by 2026 driven by growth in the </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapy pipeline and a shift to use of non-viral delivery technologies. We calculate these market opportunities using our internal estimates of risk-adjusted potential aggregate revenue potential from SPLs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We estimate there are currently almost 700 genetically modified </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies in various phases of development that we would consider our current addressable market, which is engineered cell therapy focused on oncology and inherited disorders. Based on historical growth rates of the cell therapy landscape and ongoing investment, we expect the number of </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies to at least double over the next five&#160;years. We believe approximately 40% of current therapies are using non-viral delivery technologies. Given the benefits of non-viral approaches relative to viral delivery vectors, we expect the utilization of non-viral strategies to continue growing to approximately 60% of the total market by 2026. We expect this ongoing shift to non-viral strategies to be driven by increased adoption of gene manipulation technologies, such as CRISPR based gene editing approaches, the increased complexity of </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> therapies in the pipeline, as well as the high cost, payload limitations, and current manufacturing capacity constraints of viral approaches and advances in non-viral engineering technologies. These estimates are shown in more detail in the graphic below, which also identifies the programs that we consider to be part of our potential pipeline in terms of estimating our total addressable market:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:30.68pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-org_genet4c.jpg" alt="[MISSING IMAGE: tm2113965d2-org_genet4c.jpg]" height="404" width="558" >
        </div>
        <div style="text-indent:20pt; margin-top:14.69pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We have a diverse portfolio of clinical partners and licensees that mirror the overall next-generation engineered </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies. While difficult to predict given uncertainty around regulatory approvals and clinical risk, according to Evaluate Pharma, a provider of commercial intelligence and predictive analytics to the pharmaceutical industry, the first next-generation </font><font style="font-style:italic;">ex vivo</font><font style="letter-spacing:-0.025pt;"> cell therapies using non-viral approaches could be approved in the United States as early as 2023.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our platform&#8217;s ability to engineer a diversity of cell types (including CAR-T, chimeric antigen receptor Natural Killer cells, or CAR-NK/NK, T cell receptor, or TCR, and stem cells) and cell sources (autologous and allogeneic) enhances our opportunity by potentially providing for SPL revenues regardless of which approaches advance in the coming&#160;years. Additionally, our instruments and platform are well validated, having been used in over 30 clinical trials to date and having been involved in the development of drugs to treat a variety of indications spanning from hematological malignancies to solid tumors to inherited genetic disorders. We believe that the increasing number of publications highlighting the performance of our platform compared to other electroporation and transfection approaches will help to drive acceptance of our products in the cellular engineering market segments.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic depicts the variety of cell types, cell sources and target indications within the cell therapy market, as well as those represented in our cell therapy customers&#8217; current programs, which we believe to be in line with the overall market. For purposes of the graphic, all clinical gene modified cell therapies across therapeutic areas, such as oncology, inherited disorders and immune disorders, using both viral and non-viral delivery have been included, while other regenerative medicine programs that do not entail genetic modification to obtain a cell-based therapeutic product, such as tissue engineering, immune or stem cell therapies, that are not genetically modified have been excluded.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-pc_celltype4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pc_celltype4c.jpg]" height="232" width="597" >
        </div>
        <div style="margin-top:17.4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Agreements with Customers</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In addition to sales of our instruments, as part of our business model we enter into the following types of Instrument license agreements with our customers:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Research Licenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Research licenses are agreements we have entered into with customers (which could be academic institutions or commercial entities), which provide access to use our instruments for pre-clinical research-only purposes, without the rights or ability to produce material for use in the clinic. Research licenses provide the customer with the ability to use the platform for research in exchange for a non-refundable, annual lease payment of typically $150,000 per instrument per year. We have entered into many research licenses to-date, either as (i)&#160;stand-alone research license agreements, (ii)&#160;research and clinical license agreements that do not have associated commercial rights or (iii)&#160;under an SPL, which allows a customer to use the instrument for clinical development and potential commercial sale of a therapeutic product. Research licenses under a stand-alone research license agreement (as well as instruments purchased for research use) could represent opportunities for future SPLs.</font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Clinical Licenses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Clinical licenses are agreements with academic institutions or commercial entities, that provide access to use our instruments in the clinical evaluation and development of a therapeutic product intended for human use. A clinical license provides the customer with the ability to use the platform for production of clinical material for human clinical use, as well as access to our application scientist team, all in exchange for an annual lease payment that typically approximates $250,000 per instrument per year. Similar to a research license, in a clinical license, we retain the title to the instrument. Academic clinical licenses can represent opportunities for future SPLs to the extent that commercial entities seek and obtain rights to such programs from the academic institution.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Strategic Platform Licenses (SPLs)<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">SPLs are agreements with commercial therapeutic developers who are developing therapeutics intended for human use in clinical development or for commercial sale. As is the case with all of our clinical licenses, we retain title to the licensed instrument and associated intellectual property.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The SPL provides access to our platform for broad preclinical research, clinical evaluation and commercial use for a specific field of use, access to our FDA Master File (via the Letter of Authorization process) and/or Technical Files outside of the United States, and access to our application scientists. We typically provide our SPL customers with access to any updates we make to our platform, access to platform intellectual property that we develop during the term of the SPL, as well as pricing certainty for the programs associated with the SPL.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our customer relationships may evolve to an SPL after the customer&#8217;s drug candidate optimization and verification process nears completion and the clinical process development stage begins. Specifically, if a customer wishes to use our products in the clinical phase of process development, they will need </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:256.29pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">to enter into an SPL, as a customer must obtain clinical rights to perform clinical process development, including for engineering runs. Customer discussion for an SPL can take place any time during our engagement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our SPL customers typically pay an annual license fee of $150,000 per instrument per year for a research license (for preclinical use) or $250,000 per instrument per year for a clinical license (for clinical or commercial use). Partners also purchase associated single-use disposables and consumables as needed. Our SPL partners also commit to pay precommercial milestone payments for each therapeutic licensed under the agreement and produced using our platform, as they achieve key pre-commercial clinical development events (including for example, IND filing, dosing of an agreed number of patients in a Phase&#160;1 clinical trial, initiating a pivotal clinical trial, and BLA approvals in specified regions). Precommercial milestone payments, expressed in U.S. dollars, typically range from mid-six figures at IND filing to mid-seven figures for BLA approval milestones.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Almost all of our SPLs also include a commitment to pay us post-approval sales-based payments for commercialized therapeutics. These payments can be structured as royalties and/or milestone-based payments and vary across our SPL customers. From a revenue perspective, sales based-payments for therapeutics are incremental to any instrument leases and/or disposables or consumables sales. Our revenues associated with a program under an SPL vary with the size of the target indication for the therapeutic, pricing of the therapeutic, the specifics of the therapeutic including the enablement we provide and the specifics of the negotiation for each SPL.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We view our ability to sign SPLs as a key measure of our success in partnering with leading therapeutic developers in the clinic and supports the high performance of our platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our SPLs and research and clinical licenses may be terminated at the option of our customers at any time. Annual instrument lease fees are non-refundable and customers may not use our instruments or process assemblies after terminating their agreement with us. We retain title to the leased instrument in each of our licenses. Upon a contract termination, our customers would be responsible for any further clinical studies or data development that regulators may require to allow a change in their cell engineering methodology. To date, none of our SPL licensees has ever terminated their contract with us. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following graphic is an example of typical single-product revenues from a representative SPL:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2113965d2-pht_typical4clr.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_typical4clr.jpg]" height="463" width="596" >
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Our Products</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The ExPERT instrument family was designed to provide a single unifying technology that can be used from concept to clinic, with both the research and clinical versions of the instrument incorporating the same underlying technology and protocols. Our customers have a choice of three different instrument versions that are standardized on the same technology to deliver the same high performance&#8201;&#8212;&#8201;the ATx, STx and GTx. Customers can start with the lower to medium scale research instrument (ATx) and then scale to the clinical version (GTx), without the need for re-optimization and re-validation. The STx provides the same scale as the GTx but is used for drug discovery applications, not for human therapeutic use, and is not covered by our FDA Master File or our Technical Files.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We believe these systems will also be supportive of the commercial marketing of our partners&#8217; therapeutic products which we enable. By allowing our customers to perform their research and process optimization on a research platform and seamlessly scale to a clinically validated, cGMP environment and 21 CFR Part&#160;11 compatible clinical platforms, significant time and cost savings can be realized.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All of our instruments were designed to provide customers with the key features required for a scalable high-end, high-performance transfection solution. Each of our ExPERT instruments are benchtop with the same small footprint and have integrated touch screens with an intuitive Graphical User Interface, or GUI, designed for simple training and operation. To support use in the cGMP suite for clinical manufacturing, our GTx ExPERT software is network capable to enable upload of electronic batch records to a local shared drive and has a software intermediary to facilitate integration and automated data transfer to cloud-based data management solutions. We have integrated hardware and software design solutions, manufactured under cGMP, that are tailored for use in cGMP manufacturing of clinical product for advanced cellular therapies. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following chart summarizes the features of the three ExPERT instruments:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="min-height:90pt;white-space:normal;text-align:right;vertical-align:top;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0pt 0pt; width:427pt;">
              <div style="position:relative;text-align:right;">
                <img src="tm2113965d2-pht_expsca4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_expsca4c.jpg]" height="109" width="364" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:17pt;white-space:nowrap;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:335.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:118pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Features </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:103pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">ExPERT ATx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:103pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">ExPERT STx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">ExPERT GTx </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:31.75pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Main Use </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Research </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Research/</font>&#8203;<br ><font style="letter-spacing:-0.025pt;">Development </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Clinical </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Market segment </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">General Research </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Protein Production </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">Cellular Therapy </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Scale (cells) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 700&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 20&#160;billion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,000 to 20&#160;billion </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Designed for Use in cGMP Suite </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Benchtop </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Touchscreen </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Static electroporation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Flow electroporation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:24pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 6pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Barcode reader </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:103pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 6pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Designed to Align with 21 CFR Part&#160;11 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:36pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:118pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:-0.025pt;">FDA Master File and Technical Files </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.667pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:27.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 5.333pt 0pt; width:118pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Network capable </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:103pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:8pt 0pt 5.333pt 0pt; width:96pt;">
              <div style="text-align:center;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">&#10003;</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:2.61pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT ATx: Research focused, static electroporation for small to medium scale transfection<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:171pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d2-pht_atx4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_atx4c.jpg]" height="153" width="159" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Our ExPERT ATx static electroporation instrument is a research focused, high performance electroporation platform for small to medium scale transfection. The ATx instrument delivers high efficiency and viability at research scale and can utilize our range of PAs capable of transfecting from 75&#160;thousand up to 700&#160;million cells. Additionally, our ATx instrument is compatible with all of our static PAs, which can also be used on our GTx instrument, allowing for a seamless transition to our clinical cGMP-compatible platform. The ATx is designed and used by our customers for early design of experiment and process optimization at small scale to minimize cell acquisition and reagent costs. Once optimized for the biological function with smaller numbers of cells, the process can be replicated and scaled before being transferred to the clinical platform (GTx) for eventual manufacturing in the cGMP suite or to </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:300pt;">
              <font style="letter-spacing:-0.025pt;">the STx platform for drug discovery.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.91pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT STx: Flow Electroporation for protein production and drug development<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:4.99999999999994pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:297pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d2-pht_stx4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_stx4c.jpg]" height="172" width="159" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Our ExPERT STx, which is used in the field of protein production as well as other drug discovery applications, also incorporates our proprietary Flow Electroporation Technology for high yield transient expression of complex proteins, viral vectors, vaccines and biologics. Our STx instrument has high efficiency and can rapidly transfect from 75&#160;thousand up to 20&#160;billion cells. When combined with flexible media strategies, the STx allows for substantial improvement in yields of high-quality, transiently expressed proteins while enabling reduced media costs. </font>
              </div>
              <div style="margin-top:6pt; line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">Another key application area for the STx is expression of therapeutic targets for cell-based assays. Traditionally, drug screening has been performed using stable cell lines because conventional transfection technologies, such as lipofection, may induce changes to membrane composition, which does not offer the consistency and scalability that are critical for sensitive, high throughput screens. By enabling high efficiency transfection of multiple plasmids simultaneously into billions of cells, the STx provides drug developers with the ability to express complex, multi-subunit proteins, such as ion channels, in physiologically relevant cells. The high viability of our transfected cells leads to robust assay responses on multiple platforms, including automated electrophysiology and high content screening technologies. Moreover, precise control over loading efficiency gives assay developers the ability to &#8220;dial in&#8221; optimal assay windows.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:2.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">ExPERT GTx: Flow Electroporation for large scale transfection in therapeutic applications<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="min-height:225pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:144pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d2-pht_gtx4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_gtx4c.jpg]" height="177" width="159" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300pt;text-align:left;">
              <div style="line-height:12pt;">
                <font style="letter-spacing:-0.025pt;">The ExPERT GTx incorporates our proprietary Flow Electroporation Technology for use in the cGMP manufacturing of cellular therapies for use in the clinic. By incorporating the Flow Electroporation Technology, larger volumes of up to 20&#160;billion cells can be electroporated within 15 to 20 minutes. With a processing potential that ranges from 75,000 to 20&#160;billion cells on a cGMP, 21 CFR Part&#160;11 compatible system, the GTx represents a platform for clinical electroporation at large scale. </font>
              </div>
              <div style="margin-top:6pt; line-height:12.0000000000001pt;">
                <font style="letter-spacing:-0.025pt;">The GTx integrates several design features that are critical for use in a cGMP setting, such as barcode reading capability to maintain positive identification of patient samples, 21 CFR Part&#160;11 compatible software and networking capability for automated uploading of electronic batch records to either a central server or to a cloud-based data management platform. The GTx offers the potential for closed sample processing, on a system compatible with integration into cGMP manufacturing environments, and that has an established regulatory path supported by our FDA Master File and Technical Files.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:2.81pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">VLX: Designed for extremely large volume cell-engineering<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The VLX Large-Scale Transfection System is a cGMP compliant instrument specifically designed for extremely large volume cell-engineering. Using proprietary Flow Electroporation Technology, the VLX supports the ability to transfect up to 200&#160;billion cells in less than 30 minutes&#8201;&#8212;&#8201;10 times the capacity of the STx. This system is designed for the rapid and large-scale production of recombinant proteins, monoclonal antibodies, viral vectors, vaccines, virus-like particles, or VLPs, and allogeneic cell therapies. We intend to introduce the VLX under the ExPERT umbrella, to be rebranded as VLx, to provide our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">customers with an easier to use system that incorporates the benefits of the ExPERT platform. We expect that the short-term development costs associated with the VLX to VLx product development will require limited investment and will be completed by the end of 2021. In parallel, we plan to expand functionality of the VLx into new applications, such as large-scale bioprocessing. We expect that additional investment will be needed to build out process development capabilities, manufacturing capacity and the addition of large-scale bioprocessing-specific field resources. We estimate that these initiatives could cost approximately $20&#160;million to $30&#160;million in the aggregate over the next several&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Disposables&#8201;&#8212;&#8201;Processing Assemblies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our range of disposable processing assemblies, or PAs, is an important differentiator for us. We are not aware of any other company with the breadth and diversity of volume ranges and designs to enable high efficiency electroporation in single-well and multi-well formats, for use in both the research and clinical settings. We view the PA design as one of the key contributors to the high efficiency and viability of the ExPERT platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have designed a range of PAs, that are specially designed to hold and electroporate the chosen quantity of cells. Each PA contains two electrodes, between which a medical grade gasket is sandwiched that has a unique well design consistent with the processing volume required and to allow maximum retrieval of cells. We have designed a unique range of PA&#8217;s capable of electroporating cell volumes from small to large scale, in single and multi-well formats, for both research and clinical use. Cells are placed into the well or wells and the PA is then inserted into the instrument for processing. The instrument touch screen allows the operator to select the desired cell protocol that encodes the electroporation parameters, select the type of PA to be used and enter any sample specific information. Once the sample information has been entered, the operator will touch the &#8220;Start Processing&#8221; icon on the user interface and the sample will be rapidly processed. Larger volumes of cells are accommodated by larger capacity PAs and a set of simple software commands through the intuitive GUI.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our ExPERT system uses two PA designs&#8201;&#8212;&#8201;a static cuvette used for smaller cell volume requirements (from 75,000 cells up to 200&#160;million cells) and a cartridge that is used for both static and Flow Electroporation for larger cell volumes (700&#160;million up to tens of billions of cells). The Flow Electroporation PA (CL-2) allows for processing of cellular volumes ranging from 10 mL to 100 mL and up to tens of billions of cells. The CL-2 consists of two bags and associated tubing, made from medical grade materials, that are connected to the electroporation cartridge. Users will transfer their cells and loading molecules to the sample bag, and the pump on either the GTx or STx instrument pumps a fixed volume of cells into the cartridge chamber where they are electroporated. Once the electroporation is complete, the cells are pumped to the collection bag and the chamber is filled with the next volume of cells for electroporation. This process is repeated until the entire sample volume is processed. The maximum volume of 100 mL of cells can be processed in approximately 15-20 minutes. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our two ExPERT PA designs are shown in the pictures below:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="white-space:normal;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d1-pht_cuvette4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-pht_cuvette4clr.jpg]" height="97" width="155" >
              </div>
              <div style="margin-top:5pt; text-align:center; line-height:12pt;font-style:italic;">ExPERT cuvette design <br >(Static Processing Assembly)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;vertical-align:top;">
              <div style="position:relative;text-align:center;">
                <img src="tm2113965d2-pht_flowas4c.jpg" alt="[MISSING IMAGE: tm2113965d2-pht_flowas4c.jpg]" height="160" width="245" >
              </div>
              <div style="margin-top:0.85pt; text-align:center; line-height:12pt;font-style:italic;">ExPERT Flow Electroporation design<br >(Flow Processing Assembly)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have conducted extensive end-user research over the last several&#160;years to continue to improve the design of the PAs and the range of products available. As a result, we launched the ExPERT cuvette shown above in 2020 based on customer feedback, which incorporated a new design to improve </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">handling and ease of use. Under this new design, two new volume offerings have been launched, the R-1000 that can process up to 1 mL, or 200&#160;million cells, and the R-50x3, which is a 3-well cuvette capable of processing up to 10&#160;million cells in each well. The multi-well cuvettes reduce manual handling and improve productivity in the lab. By enabling three samples to be processed in the same cuvette, a more efficient process can be achieved by users. We expect to launch an additional multi-well cuvette in the second half of 2021, and the new ExPERT PA design will also be rolled out across the entire range of cuvettes.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following matrix shows our full line of currently available PAs and their respective specifications and features, including the ExPERT instruments with which they can be used:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.8pt; text-align:center; width:456pt;">
          <img src="tm2113965d1-tbl_patype4clr.jpg" alt="[MISSING IMAGE: tm2113965d1-tbl_patype4clr.jpg]" height="303" width="608" >
        </div>
        <div style="text-indent:20pt; margin-top:12.6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We are committed to continuing to strategically invest in improvements in the PA design and range of products to ensure that customers have solutions that address all of their volume and use requirements, in both the research and clinical settings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Supporting Products<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our proprietary electroporation buffer, a balanced salt solution that protects cells during transfection, is formulated for use with all our instrument platforms and PAs. This consumable is used for all cell types, eliminating the need to change buffers as users switch protocols, cell types or scale up. The buffer is made in a cGMP facility, is fully chemically defined and is free of human or animal components, and is tested to meet technical, sterility and endotoxin specifications. This buffer formulation is a key contributing factor, in combination with instrument and PA design features, to the flexibility, high efficiency and viability that can be achieved by customers across the broad range of cell types processed using our platform.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Sales and Marketing</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We follow a direct sales model in North America, United Kingdom, and Europe, while also selling through third-party distributors in some regions in Europe and Asia. As of March&#160;31, 2021, we have over 20 field sales and application scientists located in the United States, the United Kingdom, and several regions in Europe and Asia. Since the commercial launch of our first Flow Electroporation instrument, the installed base of our instruments has grown to more than 400 instruments globally.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our sales force and field application scientists and international partners inform our current and potential customers of current product offerings, new target applications and advances in our technologies and products. As our primary point of contact in the marketplace, our field teams focus on delivering a consistent marketing message and high level of customer support, while also attempting to help us better understand the evolving market and customer needs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We intend to expand our sales, support, and marketing efforts in regions, such as the Asia-Pacific region, with a significant number of large pharmaceutical and biopharmaceutical companies. We currently use distributors in countries in these regions, such as in China and Japan, and continuously assess the need for direct sales and local support personnel to supplement our distributors&#8217; resources. As we expand into a new geography, we generally rely initially on third-party distributors until we are able to recruit a direct sales force, field application scientists and business development resources in the country or region. We currently estimate that over the next five&#160;years we will invest up to $20&#160;million for these expansion initiatives in Asia and to a lesser extent in Europe.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our business model is focused on identifying new applications in cell engineering to enable our customers to develop better medicines and maximize use across our customers&#8217; value chains. This is enabled through customer partnerships that allows us to further understand the critical applications for our technology and inform our future developments and market expansion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Research and Development</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Investment in research and development is at the core of our business strategy. Members of our research and development team specialize in many functional areas including molecular biology, cellular biology, physics, gene editing, cell culture, protein manufacturing, algorithms, mechanical engineering, cell handling processes, electroporation algorithm development and customer technical support.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our research and development teams are aligned into two teams, applications and instrumentation. The application team is responsible for developing data on key applications, including improving approaches to cell handling and cell culture; designing, developing and enhancing electroporation protocols; developing and enhancing cell engineering applications, and performing product testing and quality assurance activities. The instrumentation engineering team focuses on developing and improving electroporation instrument and PA disposables to meet our partners&#8217; large range of needs from research to commercialization in a GMP environment. The research and development functional teams work together as a core team, following a stage gate process to develop, qualify and launch new products to market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Other research and development activities include customer technical support such as lab cell processing techniques, instrumentation training and application support. Most of our research and development operations are conducted in our Maryland facility.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have made substantial investments in product and technology development since our inception. Research and development expense totaled $17.7&#160;million in the year ended December&#160;31, 2020 and $6.1 million in the three&#160;months ended March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Although our CARMA pre-clinical and clinical development will be concluded in the first half of 2021, we expect our research and development expenses outside of CARMA to increase significantly for the foreseeable future as we develop data supporting the use of our products in various applications and continue to enhance our existing products as well as develop new products for our current and new markets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Manufacturing and Supply</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We design our single use PA disposables and conduct final functional testing in our Maryland facility. In addition, we design, develop and manufacture the ExPERT instruments in-house. Our in-house manufacturing and design function is certified as ISO 9001 compliant and our manufacturing facility is located at our headquarters in Maryland. This facility includes approximately 1,000 square feet of production assembly space, plus ancillary machine shop and design spaces. Inventory is held in our Maryland facility in a 2,500 square foot controlled-access shipping, receiving and storage space.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Instruments<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our range of ExPERT instruments are manufactured, tested and shipped from our Maryland facility under cGMP. Several custom components of our ExPERT instruments are fabricated by third-party suppliers. The assembly of technology-sensitive components and the final assembly is completed in-house. Currently, our Maryland manufacturing facility can support the production of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">ExPERT instruments in excess of current demand, and we will continue to obtain the space and staffing necessary to meet customer demand for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Processing Assemblies<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our family of ExPERT instruments incorporate a broad range of proprietary single use PAs that are specially designed to meet the needs of our customers for cell volume, single- or multi-well configuration, static or flow processing. These PAs are only available from us and are designed for use only with our instruments. Accordingly, our range of PAs are designed, developed, tested and shipped from our Maryland facility. We currently outsource manufacturing of components and final clean-room disposables assembly to third parties. We plan to move the cleanroom assembly activities in-house in order to enhance operational control over quality, expand capacity, enable automation implementation and improve other areas of operations. In-addition, in-house manufacturing would be expected to allow research and development to more rapidly develop new products and enhancements when manufacturing and research and development are in the same facility. We currently plan to design and construct a new facility in the first half of 2022 that would include new cleanroom space for assembly of processing assemblies. We expect that staffing, manufacturing process development and initial validation would begin thereafter. We will seek to establish commercial scale production capacity by the end of 2022 and full initial capacity during 2023. In aggregate, we expect to invest approximately $20&#160;million to $30&#160;million to expand our manufacturing and automation efforts over the next five years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Supply<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For both instrument and PA manufacturing, we regularly assess our supply chain to ensure availability of components, our ability to respond to customer demand for our products and to qualify multiple suppliers. We have relationships with several custom parts manufacturers and electronics suppliers that can provide components for our instruments, including components currently provided by a single source. Approximately 47% of our inventory held at December 31, 2020 was purchased from one supplier. The single source suppliers are chosen for their business stability and scalability to minimize risk. If a single source supplier has a part or process that is time-consuming to transfer to another supplier, we will hold enough inventory of that part to allow adequate time for technical transfer and qualification. Our ongoing strategy is to maintain adequate levels of inventories at all times and to qualify at least two suppliers for critical quality components, and we plan to continue the diversification of our supply chain as we scale. This inventory strategy was designed to minimize supply chain risk and as a result we are currently able to ship on demand and to date have never had a backorder for a product.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Competition</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The life sciences market is highly competitive and dynamic, reflecting rapid technological evolution and continually evolving customer requirements. There are other companies, both established and early-stage, that have or are developing electroporation and other non-viral delivery technologies that could be applicable to both bioprocessing and cell engineering. These companies include Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc. and Harvard Biosciences Inc. (BTX) as well as several other smaller companies, including spinouts from academic labs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Some of these companies may have substantially greater financial and other resources than us, including larger research and development staff or more established sales forces. Other competitors are in the process of developing novel technologies for the life sciences market which may lead to products that rival or replace our products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For further discussion of the risks we face as a result of competition, see &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Business and Growth Strategy&#8201;&#8212;&#8201;We may be unable to compete successfully against our existing or future competitors.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Intellectual Property</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our intellectual property strategy has been, and still is, to obtain patent protection in relevant jurisdictions over our instruments, methods utilizing our instruments, as well as design patents over the ExPERT system. As part of this strategy, we have focused on obtaining protection for our non-viral delivery platform to the extent possible, particularly in the United States and other key jurisdictions of commercial value. As of May&#160;4, 2021, we have 50 granted U.S. and foreign patents, including in foreign </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">jurisdictions such as Australia, Canada, Japan, China, South Korea and certain countries in Europe, as well as 76 pending patent applications worldwide. The main focus of our patent coverage protects our Flow Electroporation, processing chambers/disposables, control and process elements, and methods of using our non-viral delivery platform. Our patent portfolio provides protection over our instruments and related methods through at least 2028 and over our electroporation applications and methods through 2034. We are also working to secure design protection of the ExPERT system, which has the potential to provide protection through at least 2036.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to our granted patents and filed applications, we maintain and protect a number of different trade secrets related to our cell processing technology and other core technology areas, such as improvements made to protocols, pulsing patterns, proprietary buffer and formulations developed by us. Our&#160;years of accumulated know-how and the technical expertise of our employees provide us with a competitive advantage. We use our know-how and technical expertise to optimize and update our proprietary methods and protocols, such as cell handling and preparation techniques unique to different cells and target molecules, which we confidentially share with our customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain the confidentiality of our trade secrets, know-how and proprietary methods and protocols to protect our intellectual property from competitors. One key element of this protection is our FDA Master File and Technical Files described in more detail below, which allow us to submit to the regulator confidential detailed information about our ExPERT system and disposables. The relevant submission can be referenced by our customers or licensees to support their own regulatory filings without the need for us to disclose the confidential information contained in the FDA Master File and Technical Files.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We also seek to protect our brand through procurement of trademark rights. As of May&#160;4, 2021, we owned 13 registered trademarks in the United States, 79 registered foreign trademarks and 15 pending U.S. trademark applications. Our registered trademarks and pending trademark applications include trademarks for MaxCyte, CARMA, a stylized version of ExPERT and our logo. In order to supplement protection of our brand, we have also registered several internet domain names.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Government Regulation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The FDA and similar governmental authorities regulate, among other things, the research, development, testing, manufacturing, clearance, approval, labeling, storage, recordkeeping, advertising, promotion, marketing, distribution, post-market monitoring and reporting, and import and export of technologies including biological drug products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our biopharmaceutical and life sciences customers are subject to extensive regulations by the FDA and equivalent regulatory authorities in other countries, regarding the conduct of preclinical studies and clinical trials, in the manufacture of product candidates and products for use in humans (i.e., &#8220;Good Manufacturing Practice&#8221; laws and regulations) and the marketing authorization and commercialization of biological drug products.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The activities of sponsors, applicants and manufacturers are subject to regulation of those jurisdictions where the research or manufacturing occur, and also jurisdictions for which applications are planned or have been made and the product is intended to be marketed.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Although we are not engaged in directly regulated activities, our customers will generally assess our products for sufficiency in meeting their regulatory needs, and may impose rigorous quality or other regulatory compliance requirements on us as their supplier through supplier qualification processes and customer contracts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have established a quality management system (under ISO 9001:2015 standards) which is designed to respond to customer expectations and needs and support customer adherence to applicable regulatory requirements. The technologies we offer for potential use by customers in a cGMP environment are produced under this ISO 9001:2015 quality management system.</font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Master and Technical Files to Support Customer Regulatory Submissions<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our core business is focused on developing our proprietary and patented electroporation technology platform is used by our customers in research and development applications as well as for manufacture </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">of commercial cell therapies. In order to support our customers&#8217; use of our platform, we have voluntarily submitted a Master File to the FDA, Center for Biologics Evaluation and Research and Technical Files to comparable regulatory authorities in other jurisdictions, including Canada, Japan, the United Kingdom and Austria, and provide nonexclusive Letters of Authorization to the Master or Technical Files under contractual agreements with our customers. We are also in discussions with regulatory authorities in Australia, Germany, Thailand and China with respect to submitting technical files for our electroporation technology platform. In this way, the regulatory body may review information on our platform in the context of its utilization by our partners in regulated products, for example, as described in our customers&#8217; Investigational New Drug applications. We continuously update the Master and Technical Files in order to support the regulatory activities of our customers. The FDA and regulators in other countries allow Master and Technical Files, but they do not approve them.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">U.S. Healthcare Laws and Reform<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the United States, there are federal and state healthcare laws that constrain the business or financial arrangements and relationships through which our customers who use our platform and we, if we develop a product, research, sell, market and distribute products. Such laws include federal and state anti-kickback laws, false claims laws, transparency laws and health information privacy and security laws. Violations of these laws can lead to significant administrative, civil and criminal penalties, including sanctions, damages, disgorgement, monetary fines, possible exclusion from participation in government healthcare programs such as Medicare and Medicaid, imprisonment, additional reporting requirements and/or oversight obligations, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care, including the proposed modification to some of the aforementioned laws. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the healthcare industry. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or the implementation of new laws affecting the healthcare industry. Similarly, a significant trend in the healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any of our products successfully, and our customers and collaborators&#8217; ability to commercialize their products successfully, will depend in part on the extent to which coverage and adequate reimbursement for these products and will be available from third-party payors. As such, cost containment reform efforts may result in an adverse effect on our operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">The Foreign Corrupt Practices Act<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Data Privacy and Security Laws and Regulations<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The collection, use, transfer, disclosure, retention, security and other processing of personal data (including, without limitation, clinical trial data and other data concerning health) may be subject to independent and overlapping data security and privacy regulatory frameworks in the various jurisdictions in which we operate. These frameworks are evolving and may impose potentially conflicting obligations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For example, in the European Economic Area, or EEA, the processing of personal data is principally governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR applies to any processing operations carried out in the context of an establishment in the EEA as well as any processing operations relating to the offering of goods or services to individuals in the EEA and/or the monitoring of their behavior in the EEA. Further notwithstanding the United Kingdom&#8217;s withdrawal from </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">the European Union, by operation of the so-called &#8220;UK GDPR&#8221; &#8203;(i.e., the GDPR as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended), the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of an establishment in the United Kingdom and any processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of their behavior in the United Kingdom. Therefore, reference to the GDPR herein, also refers to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise. In addition, the GDPR provides that EEA member states may introduce specific requirements related to the processing of &#8220;special categories of personal data&#8221;, including the personal data related to health and genetic information, which we may process in connection with clinical trials or otherwise; as well as personal data related to criminal offenses or convictions. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. This fact may lead to greater divergence on the law that applies to the processing of such categories of personal data across the EEA and/or United Kingdom.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The GDPR enhances data protection obligations for controllers of personal data (such as clinical trial sponsors), including stringent requirements relating to the consent of data subjects in certain circumstances, expanded disclosures about how personal data is used, requirements to respect enhanced data subject rights in certain circumstances, requirements to conduct privacy impact assessments for &#8216;high risk&#8217; processing, limitations on retention of personal data, mandatory data breach notification and &#8216;privacy by design&#8217; requirements. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA or United Kingdom to countries that have not been judged to ensure an adequate level of protection for personal data, like the United States. Such transfers of personal data require the implementation and maintenance of a valid &#8220;transfer mechanism.&#8221; Following a recent ruling of the Court of Justice of the European Union, and subsequent regulatory guidance, certain previously available transfer mechanisms have been invalidated, and reliance on alternative transfer mechanisms may be complex or not possible in certain circumstances, for example, in many cases, such transfer mechanisms may need to be supplemented with additional, often onerous, technical, organizational and/or contractual measures.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply with the requirements of the GDPR and related national laws may result in fines up to 20&#160;million euros/17.5&#160;million pounds sterling or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. In addition to administrative fines, a wide variety of other potential enforcement powers are available to competent supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by non-compliant actors&#8201;&#8212;&#8201;including permitting authorities to require destruction of improperly gathered or used personal data. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Additionally, following the United Kingdom&#8217;s withdrawal from the European Union on January&#160;31, 2020 and end of the post-Brexit transition period on December&#160;31, 2020, as noted above, the United Kingdom has introduced the UK GDPR which currently makes the privacy regimes of the EEA and United Kingdom similar, though it is possible that either the European Union, and consequently those further states that make up the remainder of the EEA, or United Kingdom could elect to change their approach and create differences in legal requirements and regulation in this area. Furthermore, under the post-Brexit Trade and Cooperation Agreement between the European Union and the United Kingdom, the United Kingdom and European Union have agreed that personal data transfers to the United Kingdom from EEA Member States will not be treated as &#8216;restricted transfers&#8217; to a non-EEA country for an initial period of up to four&#160;months from the end of the post-Brexit transition period, plus a potential further two&#160;months thereafter. If the European Commission does not adopt an &#8216;adequacy decision&#8217; in respect of the United Kingdom during this period, from that point onwards the United Kingdom will be an &#8216;inadequate third country&#8217; under the GDPR and transfers of personal data from the EEA to the United Kingdom will require a valid transfer mechanism (such as entry into the then-current form of the European Commission-issued Standard Contractual Clauses).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Given the breadth and depth of changes in relevant data protection obligations and regulatory frameworks, achieving and maintaining compliance with applicable data protection laws and regulations </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:180pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">such as the GDPR and UK GDPR will require significant time, resources and expense, and we may be required to put in place new or additional mechanisms to ensure compliance with current, evolving and new data protection requirements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Failure to comply, or perception of a failure to comply with any of these laws, regulations, rules and standards could result in enforcement actions against us, including fines, public censure, claims for damages by affected individuals, damage to our reputation, and loss of goodwill, any of which could have a material adverse effect on our business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Legal Proceedings</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We are not subject to any material legal proceedings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Facilities</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our corporate headquarters, where our primary research and development, instrument design, development and manufacture, applications lab and distribution, sales, marketing and general and administrative activities are housed, are located in Gaithersburg, Maryland.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our headquarters facility consists of approximately 26,000 square feet of office and laboratory space under leases, which expire in October&#160;2023.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">On May 27, 2021, we entered into an operating lease, or the Operating Lease, for up to 67,326 square feet of new office space located in Rockville, Maryland. The Operating Lease consists of three phases of area expansion, with phase 1 estimated to commence on January 1, 2022. The Operating Lease will expire on June 30, 2035. We believe that our facilities, once phase 1 of the Operating Lease is effective, will meet our current and future anticipated needs for the foreseeable future.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Employees and Human Capital</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of March&#160;31, 2021, we had 65 full-time employees, 45 of which have advanced degrees, including 19 with Ph.D. degrees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">None of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MANAGEMENT</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information for our executive officers and directors, including their ages as of June&#160;1, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:257.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.089pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:216pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:192pt;">Executive Officers:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler........................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">President, Chief Executive Officer and Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amanda Murphy....................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">44 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Ron Holtz................................................. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">63 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Senior Vice President and Chief Accounting Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Thomas M. Ross...................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:216pt;white-space:normal;">
              <font style="letter-spacing:-0.025pt;">Executive Vice President, Global Sales and Marketing </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Maher Masoud......................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">46 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Executive Vice President and General Counsel </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">Non-Employee Directors:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:24pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:216pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD.......................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">79 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Chairman</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Yasir Al-Wakeel</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">39</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Will Brooke............................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">65 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD............................. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Rekha Hemrajani..................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">52</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Stanley C. Erck........................................ </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">73 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">John Johnston.......................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">62 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Art Mandell............................................... </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:216pt;">
              <font style="letter-spacing:-0.025pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.41pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Executive Officers</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;font-weight:bold;">Doug Doerfler</font><font style="letter-spacing:-0.025pt;"> has served as our president and chief executive officer and on our board of directors since July&#160;1998. Prior to cofounding MaxCyte in 1998, Mr.&#160;Doerfler served as president and chief executive officer and as a director of Immunicon Corporation. Prior to joining Immunicon, Mr.&#160;Doerfler held executive positions at life sciences company Life Technologies Corporation (now Thermo Fisher). Mr.&#160;Doerfler currently serves as chair emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization. Mr.&#160;Doerfler received his B.S. in finance from the University of Baltimore School of Business. We believe that Mr.&#160;Doerfler&#8217;s life science and cell therapy industry knowledge and public company management experience qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;font-weight:bold;">Amanda L. Murphy</font><font style="letter-spacing:-0.025pt;"> has served as our chief financial officer since September&#160;2020. Before joining MaxCyte, Ms.&#160;Murphy served as a managing director of BTIG, LLC from 2018 to 2020 where she covered cell and gene therapy as an equity research analyst. Prior to BTIG, she was a partner and healthcare equity research analyst at William Blair &amp; Company from 2006 to 2018, focused on covering enabling tools and services in the life sciences. Ms.&#160;Murphy received a B.S. in biology from Boston College and an M.B.A. in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Ron Holtz</font><font style="letter-spacing:-0.025pt;"> has served as our senior vice president and chief accounting officer since September&#160;2020 and served as our chief financial officer from 2005 to September&#160;2020. He also served on our board of directors from 2016 to July 2021. From 2000 to 2004, Mr.&#160;Holtz served as chief financial officer of B2eMarkets Inc., an e-sourcing and performance management provider. Mr.&#160;Holtz served as chief financial officer of RWD Technologies from 1996 to 1999 and previously spent time in Ernst &amp; Young LLP&#8217;s Financial Advisory Services Group. Mr.&#160;Holtz received his B.S. in mathematics from the University of Wisconsin, an M.B.A. from the University of Maryland and is a certified public accountant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Thomas M. Ross</font><font style="letter-spacing:-0.025pt;"> has served as our executive vice president of global sales and marketing since September&#160;2014. Prior to joining MaxCyte, Mr.&#160;Ross was senior vice president of commercial operations </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">at OpGen from 2012 to 2014. Mr.&#160;Ross also served as chief commercial officer at Predictive BioScience and vice president of North America medical diagnostics sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr.&#160;Ross held several senior leadership roles in manufacturing operations at Life Technologies Corporation and Cambrex. Mr.&#160;Ross received his B.A. in business administration from The Citadel.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Maher Masoud</font><font style="letter-spacing:-0.025pt;"> has served as our executive vice president and general counsel since January&#160;2020 and previously as our vice president of legal from May&#160;2017 to January&#160;2020. From July&#160;2015 to May&#160;2017, Mr.&#160;Masoud served as assistant general counsel and corporate secretary for Wellstat Management Company and previously served as co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors. Previously, Mr.&#160;Masoud was a corporate attorney at Human Genome Sciences, Inc. from 2006 until 2012. Mr.&#160;Masoud received his J.D. from Michigan State University College of Law and a B.S. in cell and molecular biology genetics from the University of Maryland. Mr.&#160;Masoud is a member of the Maryland state bar.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Non-Employee Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">J. Stark Thompson, PhD</font><font style="letter-spacing:-0.025pt;"> has served as the chairman of our board of directors since January&#160;2001. Dr.&#160;Thompson has nearly five decades of corporate leadership and business management experience, dating back to when he joined the DuPont Company in 1967, where he spent more than 20&#160;years. From 1988 until 2000, Dr.&#160;Thompson served as president, chief executive officer and board member of Life Technologies, Inc. Dr.&#160;Thompson has served on and led various boards of directors, including for companies such as Gene Logic, Inc. and Luminex Corporation. Dr.&#160;Thompson received his B.S. in Chemistry from Muskingum University and his M.Sc. and Ph.D. in physiological chemistry from The Ohio State University. We believe Dr.&#160;Thompson&#8217;s extensive experience in business operations qualifies him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Yasir Al-Wakeel, BM BCh</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since June&#160;2021. Dr.&#160;Al-Wakeel has served as Chief Financial Officer and Head of Corporate Development of Kronos Bio, Inc. since August&#160;2020. Prior to joining Kronos Bio, Dr.&#160;Al-Wakeel served as the Chief Financial Officer of Neon Therapeutics, Inc. from July&#160;2017 to May&#160;2020. Previously, Dr.&#160;Al-Wakeel served as the Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, Inc. from August&#160;2015 until July&#160;2017. Dr.&#160;Al-Wakeel previously served in various capacities at Credit Suisse, an investment banking firm, from 2008 to 2015. While at Credit Suisse, Dr.&#160;Al-Wakeel was Director of Healthcare Investment Banking, focused on biotechnology, and, prior to that role, he was an Equity Research Analyst covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr.&#160;Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr.&#160;Al-Wakeel received his BM BCh (Doctor of Medicine and Surgery) from Oxford University and his M.A. in theology from Cambridge University. We believe that Dr.&#160;Al-Wakeel&#8217;s significant scientific and finance background qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Will Brooke</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since March&#160;2004. Mr.&#160;Brooke is a limited partner of Harbert Management Corporation, or HMC, which he co-founded in 1993, most recently serving as EVP and Managing Partner of its venture capital funds family from July&#160;2003 to December&#160;2014. Mr.&#160;Brooke has been advising and investing in early-stage and growth companies for more than 30&#160;years, and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc. and Emageon Corporation. Since December&#160;2018 he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr.&#160;Brooke practiced law for a decade. Mr.&#160;Brooke received a B.S. in Business Management and a J.D. from the University of Alabama. We believe Mr.&#160;Brooke&#8217;s extensive business experience and deep financial knowledge qualifies him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Richard Douglas, PhD</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since February 2018. Dr. Douglas formerly served as the senior vice president of corporate development of Genzyme Corporation where he worked from 1989 until 2011 when Genzyme was acquired by Sanofi. Prior to joining Genzyme, Dr.&#160;Douglas served in science and corporate development capacities at Integrated Genetics prior to its acquisition by Genzyme in 1989. Since 2011 Dr. Douglas has served as an adviser to RedSky Partners, a biotechnology-focused advisory firm and also as executive director of Labyrinth Choir, Inc. He is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">chairman of the board of directors of AldeyraTherapeutics which he joined in 2016 and has been a board member of Novavax, Inc. since 2010. He has a B.S. in chemistry from the University of Michigan, where he now serves as chair of the National Advisory Board for the Office of Technology Transfer, and a Ph.D. in biochemistry from the University of California, Berkeley. We believe that Dr. Douglas&#39;s significant business experience and scientific background qualify him to serve on our board of directors.</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Stanley C. Erck</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since March&#160;2005. Mr.&#160;Erck has served as president and chief executive officer of Novavax, Inc. since April&#160;2011 and as a director of Novavax since June&#160;2009. Mr.&#160;Erck previously served as executive chairman of Novavax from February&#160;2010 to April&#160;2011 and interim chief financial officer from November&#160;2017 to March&#160;2018. From 2000 to 2008, Mr.&#160;Erck served as president and chief executive officer of Iomai Corporation, a developer of vaccines and immune system therapies, which was acquired in 2008 by Intercell AG. He also previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme and Baxter International. Mr.&#160;Erck also served on the board of directors of BioCryst Pharmaceuticals from December&#160;2008 to December&#160;2018. Mr.&#160;Erck currently serves on the board of directors of MDBio Foundation. Mr.&#160;Erck received a B.S. in economics from the University of Illinois and an M.B.A. from the University of Chicago. We believe Ms.&#160;Erck&#8217;s public company board experience and extensive knowledge and experience in biotechnology qualify him to serve on our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Rekha Hemrajani</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since June&#160;2021. Ms.&#160;Hemrajani has served as Chief Executive Officer and Director of Jiya Acquisition Corporation since August&#160;2020. She previously served as President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, from January&#160;2020 to April&#160;2020. From March&#160;2019 to September&#160;2019, Ms.&#160;Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March&#160;2016 to March&#160;2019, she served as Chief Operating Officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company. Ms.&#160;Hemrajani currently serves as a director of the publicly held company ALX Oncology Holdings, Inc. and previously served as a director of Adverum Biotechnologies, Inc. and Aravive,&#160;Inc. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. We believe Ms.&#160;Hemrajani is qualified to serve on our board of directors due to her executive and financial experience at multiple companies in the biopharmaceutical and biotechnology industries.</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">John Johnston</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since January&#160;2016. Mr.&#160;Johnston previously served on the board of directors of Midatech Pharma from December&#160;2014 to February&#160;2019, Flow Group from August&#160;2013 to October&#160;2017, Action Hotels from December&#160;2013 to December&#160;2018 and Constellation Healthcare Technologies from December&#160;2014 to January&#160;2017. From August&#160;2011 to April&#160;2013 Mr.&#160;Johnston served as managing director of institutional sales at Nomura Code, and from 2008 to 2011, he was director of sales and trading at Seymour Pierce. In 2003, Mr.&#160;Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. Mr.&#160;Johnston began his investment career at the Royal Bank of Scotland and previously held positions at Legg Mason Investors and Murray Johnston. Mr.&#160;Johnston received his B.A. in commerce from Abertay University and his M.B.A. from the University of Dundee. We believe Mr.&#160;Johnston&#8217;s executive leadership and operational experience qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;">Art Mandell</font><font style="letter-spacing:-0.025pt;"> has served on our board of directors since May&#160;2006. Mr.&#160;Mandell served as president and chief operating officer of Prestwick Pharmaceuticals, Inc. from October&#160;2005 to August&#160;2007. Prior to Prestwick, Mr.&#160;Mandell was president and chief executive officer and a director of Cellective Therapeutics, Inc. from 2004 to 2005, when it was acquired by Astra Zeneca/MedImmune. Before Cellective, Mr.&#160;Mandell served as president and chief executive officer and director of Stemron Corporation from 2001 to 2003, and as senior vice president and chief business officer of Human Genome Sciences, Inc. from 1997 to 2001. Mr.&#160;Mandell began his healthcare career at Syntex Pharmaceutical Corporation. Mr.&#160;Mandell received his B.S. from San Jose State University and his M.B.A. from Santa Clara University. We believe Mr.&#160;Mandell&#8217;s extensive knowledge and experience in both pharmaceuticals and biotechnology qualify him to serve on our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Family Relationships</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">There are no family relationships among any of our directors or executive officers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Composition of Our Board of Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our business and affairs are managed under the direction of our board of directors. We currently have nine directors. Our board of directors may establish the authorized number of directors from time to time by resolution. In accordance with our fifteenth amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms. Each director serves until the election and qualification of successor directors at the annual meeting of stockholders, or until the director&#8217;s earlier removal, resignation or death. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;I directors are Doug Doerfler, Yasir Al-Wakeel and Rekha Hemrajani, whose terms will expire at our 2022 annual meeting of stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;II directors are Art Mandell and Stanley Erck, whose terms will expire at our 2023 annual meeting of stockholders; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the Class&#160;III directors are Will Brooke, John Johnston, J. Stark Thompson and Richard Douglas, PhD, whose terms will expire at our 2021 annual meeting of stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Director Independence</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">In connection with this offering, our common stock has been approved for listing on the Nasdaq Global Select Market. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors within a specified period following the completion of this offering. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Audit committee members must also satisfy the independence criteria set forth in Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (i)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (ii)&#160;be an affiliated person of the listed company or any of its subsidiaries. We intend to satisfy the audit committee independence requirements of Rule&#160;10A-3 as of the completion of this offering. Additionally, compensation committee members must not have a relationship with us that is material to the director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning her or his background, employment and affiliations, our board of directors has determined that none of our directors to be serving upon the listing of our common stock on Nasdaq, other than Mr. Doerfler, has any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the Nasdaq listing standards. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director and the transactions described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Committees of Our Board of Directors</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. Upon completion of this offering, copies of each charter will be posted on our website at www.maxcyte.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of such website address in this prospectus is an inactive textual reference only.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Audit Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our audit committee consists of Yasir Al-Wakeel, Will Brooke, John Johnston and Art Mandell. Our board of directors has determined that each member of the audit committee satisfies the independence requirements under Nasdaq listing standards and Rule&#160;10A-3(b)(1) of the Exchange Act of 1934, as amended, or the Exchange Act. The chair of our audit committee is Mr.&#160;Brooke, whom our board of directors has determined is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our board of directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the corporate finance sector.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">helping our board of directors oversee our corporate accounting and financial reporting processes;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing related person transactions;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">approving or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our audit committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Compensation Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our compensation committee consists of J.&#160;Stark Thompson, Will Brooke, Stan Erck and Rekha Hemrajani. The chair of our compensation committee is Dr.&#160;Thompson. Our board of directors has determined that each member of the compensation committee is independent under the Nasdaq listing standards and a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, non-executive directors and other senior management, as appropriate. Specific responsibilities of our compensation committee include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and approving the compensation of our chief executive officer, other executive officers and senior management;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing, evaluating and recommending to our board of directors the succession plans for our executive officers;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and recommending to our board of directors the compensation paid to our non-executive directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">administering our equity incentive plans and other benefit programs;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections and any other compensatory arrangements for our executive officers and other senior management; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our compensation committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">Our nominating and corporate governance committee consists of Art Mandell, Stan Erck and Richard Douglas. The chair of our nominating and corporate governance committee is Mr.&#160;Mandell. Our board of directors has determined that each member of the nominating and corporate governance committee is independent under the Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Specific responsibilities of our nominating and corporate governance committee will include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">considering and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">instituting plans or programs for the continuing education of our board of directors and orientation of new directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our nominating and corporate governance committee will operate under a written charter, to be effective prior to the completion of this offering, that satisfies the applicable Nasdaq listing standards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Code of Conduct</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">We have adopted a Code of Conduct that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Conduct will be posted on our website at www.maxcyte.com. We intend to disclose on our website any future amendments of our Code of Conduct or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions or our directors from provisions in the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:-0.025pt;">None of the members of the compensation committee are currently, or have been at any time, one of our officers or employees. None of our executive officers currently serve, or have served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Non-Employee Director Compensation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have historically provided our non-employee directors with an annual cash retainer as well as additional annual retainers for service as chair of the board and service as chair or member of the board&#8217;s committees. The fees for committee service are in addition to the annual cash retainer for board service.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:129.5pt;margin-top:8.00000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.667pt 0pt; width:159.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-right:1pt;letter-spacing:-0.089pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:36.66pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.667pt 0pt; width:130.54pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;letter-spacing:-0.089pt;">(January&#160;1, 2020&#8201;&#8211;&#8201;March&#160;31, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.667pt 0pt; width:102.96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 Annual Cash Retainer</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-left:14pt;padding-right:14pt;letter-spacing:-0.089pt;">(As of April&#160;1, 2021) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Board of Directors</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$67,500 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$80,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$40,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$40,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Audit Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$15,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$20,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$8,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$10,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:159.84pt;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Compensation Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$12,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$14,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$6,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$6,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:159.84pt;white-space:normal;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Nominating &amp; Corporate Governance Committee</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$8,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$10,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.84pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.66pt;">
              <font style="letter-spacing:-0.025pt;">Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:130.54pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:102.96pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">$5,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:5.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition to annual cash retainers, our non-employee directors have been granted options to purchase shares of our common stock under our LTIP. From time to time, our non-employee directors are also reimbursed upon request for out-of-pocket expenses incurred in connection with their attendance at meetings of our board of directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2020 Director Compensation Table<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information regarding the compensation earned for service on our board of directors in 2020 by our non-employee directors. Doug Doerfler, our President and Chief Executive Officer, and Ron Holtz, our Senior Vice President and Chief Accounting Officer, were also members of our board of directors but did not receive any additional compensation for service as directors during the year.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:110.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.667pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-right:1pt;letter-spacing:-0.089pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.667pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Fees Earned or</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Paid in</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Cash</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-left:24pt;padding-right:24pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.667pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Awards(1)(2)</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-left:19pt;padding-right:19pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.667pt 0pt; width:36.12pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-left:3pt;padding-right:3pt;letter-spacing:-0.089pt;">Total ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">79,500 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">102,406 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">61,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">83,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">40,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">62,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">46,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">68,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">48,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">70,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:278.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:57.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">56,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:48.13pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">22,906 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">78,906</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">This column reflects the full grant date fair value of options granted during the year measured pursuant to Financial Accounting Standard Board Accounting Standards Codification Topic 718, or ASC 718, the basis for computing stock-based compensation in our financial statements. The assumptions we used in valuing options are described in Note 2 to our financial statements included elsewhere in this prospectus.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">The following table provides information regarding the aggregate number of option awards granted to our non-employee directors that were outstanding as of December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:396pt;height:83.5pt;margin-left:30pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 1.25pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;letter-spacing:-0.089pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">241,333 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Will Brooke </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">142,500 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">94,700 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stanley Erck </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">265,067 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">John Johnston </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">108,417 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:347.88pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Art Mandell </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:36.12pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">122,000</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our named executive officers, or NEOs, for the fiscal year ended December&#160;31, 2020, consisting of our principal executive officer and the next two most highly compensated executive officers serving as of December 31, 2020, were:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Doug Doerfler, our president and chief executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Amanda L. Murphy, our chief financial officer; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Brad Calvin, our former chief commercial officer.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">2020 Summary Compensation Table</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents all of the compensation awarded to or earned by or paid to our named executive officers for the fiscal year ended December&#160;31, 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:137.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Salary</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Awards</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:12pt;padding-right:12pt;letter-spacing:-0.089pt;">($)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Non-Equity </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Incentive Plan&#160;</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Compensation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:18pt;padding-right:18pt;letter-spacing:-0.089pt;">($)(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Compensation</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:18pt;padding-right:18pt;letter-spacing:-0.089pt;">($)(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:17pt;padding-right:17pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">518,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">332,263</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">356,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,223,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:169.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">President, Chief Executive Officer and Director</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Amanda L. Murphy(4) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">125,758</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,425,826</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">222,466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">4,245</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,778,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="margin-left:10pt;">Chief Financial Officer</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Brad Calvin(5) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">371,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">368,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">334,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">17,516</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,092,089</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:169.51pt;text-align:left;">
              <div style="margin-left:10pt;">Former Chief Commercial Officer</div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Amounts reported represent the aggregate grant date fair value of the stock options granted to our named executive officers during fiscal year 2020 under our LTIP, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in the notes to our audited financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer upon the exercise of the options or the sale of the underlying shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents amounts paid pursuant to our annual incentive compensation program, described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of matching contributions under our 401(k) plan paid by us during 2020 and de minimis incentives provided to all employees based on company-wide sales performance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Ms. Murphy began serving as our chief financial officer in September 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Mr. Calvin ceased serving as an executive officer in May 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:11.72pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Narrative to the Summary Compensation Table</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Performance-Based Bonuses<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Each of our executive officers is eligible to receive performance bonus under our annual incentive compensation program.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2020 annual incentive compensation program, each of our named executive officers was eligible to receive a cash incentive payment equal to (1)&#160;his or her target incentive, as a&#160;percentage of annual base salary, multiplied by (2)&#160;the&#160;percentage achievement of certain 2020 corporate goals established by our compensation committee in its sole discretion, subject to the named executive officer remaining employed by us through the payment date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Mr.&#160;Doerfler&#8217;s target incentive was set at 55% of his annual base salary, Ms.&#160;Murphy&#8217;s at 40% of her annual base salary, and Mr.&#160;Calvin&#8217;s at 60% of his annual base salary. The corporate goals used for purposes of the 2020 annual incentive compensation program included revenue, EBITDA, and targets </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">related to our CARMA program and licensing. Our compensation committee determined that the&#160;percentage achievement of the applicable corporate goals was 125% for Mr.&#160;Doerfler and Ms.&#160;Murphy, and 135% for Mr.&#160;Calvin. As a result, our compensation committee approved a cash incentive payment for each named executive officer in the amounts reflected above in the &#8220;Non-Equity Incentive Plan&#160;Compensation&#8221; column of the Summary Compensation Table. Each named executive&#8217;s cash incentive payment for 2020 was paid in the first quarter of 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Outstanding Equity Awards as of December&#160;31, 2020</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents estimated information regarding outstanding equity awards held by our named executive officers as of December&#160;31, 2020. See &#8220;&#8212; Equity Incentive Plans&#8201;&#8212;&#8201;Long-Term Incentive Plan&#8221; below for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:247pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:178.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="13">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Options</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Exercisable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Options</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Unexercisable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Exercise</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">Price (</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:7pt;padding-right:7pt;letter-spacing:-0.089pt;">($)(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.583pt 0pt 2.167pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Expiration</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.089pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Doug Doerfler </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1,145,080 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">N/A </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">0.04 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">11/11/2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">296,000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">&#8212;</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">0.82 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.12 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">6/13/2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">252,833 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">43,167(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.31 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/14/2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">178,833 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">117,167(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.32 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/18/2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">170,712 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">219,488(4) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.78 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3/4/2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">89,421 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">300,779(5) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.36 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.86 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1/20/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Amanda L. Murphy </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">71,875 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1,078,125(6) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">4.51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">9/8/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:178.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Brad Calvin </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">166,667 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">33,333(7) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.50 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.42 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/14/2027 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">75,521 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">49,479(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.32 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7/18/2028 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">54,687 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">70,313(4) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.78 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">2.43 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3/4/2029 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">28,646 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">96,354(5) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.36 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1.86 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">1/20/2030 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:178.38pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:47pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">7,813 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:56.67pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">117,187(8) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.33pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">3.30 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:32.61pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">4.51 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:50.01pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.025pt;">9/15/2030</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:-0.025pt;">Option exercise prices have historically been expressed in British pounds, other than the option for 1,145,080 shares granted to Mr.&#160;Doerfler as indicated above, and are equal to the closing price of our common stock on the AIM on the date of grant. Conversions to U.S. dollars are provided for convenience using an exchange rate of &#163;1.00 = $1.3662, which was the rate published by the U.S. Federal Reserve as of December&#160;31, 2020. Following this offering, option exercise prices for future grants will be expressed in U.S. dollars based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;14, 2017. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;18, 2018. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on March 4, 2019. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on January&#160;20, 2020. The </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on September&#160;8, 2020. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on July&#160;14, 2017. The shares underlying this option vest, as follows: 1/16</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:-0.019pt;">th</font><font style="letter-spacing:-0.025pt;"> of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents an option to purchase shares of our common stock granted on September 15, 2020. The shares underlying this option vest, as follows: 1/16th of the shares vested 90 calendar days following the grant date and the remainder vests monthly in 45 monthly installments thereafter, subject to the applicable holder&#8217;s continued service to our company through the applicable vesting date.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Employment Arrangements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Severance Agreements<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have entered into severance agreements with each of the NEOs in connection with his or her employment with us, which sets forth the terms and conditions of his or her specified payments and benefits in connection with a termination of employment in certain circumstances. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the NEOs will focus their full time and attention on the requirements of the business rather than the potential implications of a qualifying employment termination or change in control for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the NEOs, rather than negotiating severance at the time that an NEO&#8217;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because they encourage our NEOs to stay focused on the business in those circumstances, rather than focusing on the potential implications of the termination of employment for them personally. The material terms of the severance agreements we have entered into with our NEOs are summarized below. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Doug Doerfler<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated July 20, 2021, setting forth the terms of Mr. Doerfler&#8217;s severance eligibility. Under Mr. Doerfler&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he resigns for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurs on the date of or within 24 months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr. Doerfler will be eligible to receive (i) payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 18 months following his departure (less applicable tax withholdings), (ii) 75% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 18 months, (iii) COBRA premium coverage for up to 18 months, and (iv) full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr. Doerfler must sign and not revoke a release agreement in a form presented by us.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Under Mr. Doerfler&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause,&#8221; or if he resigns for &#8220;good reason,&#8221; and if such termination or resignation occurs at any time prior to a &#8220;change of control,&#8221; then Mr. Doerfler will be eligible to receive (i) payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 12 months following his departure (less any amounts paid to Mr. Doerfler during such 12 month period </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii) COBRA premium coverage for up to 12 months, and (iii) if the termination or resignation occurs within 180 days prior to a &#8220;change of control,&#8221; then Mr. Doerfler shall also receive full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr. Doerfler must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Amanda Murphy<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated January&#160;21, 2021, setting forth the terms of Ms.&#160;Murphy&#8217;s severance eligibility. Under Ms.&#160;Murphy&#8217;s severance agreement, if she is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if she resigns for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurs on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Ms.&#160;Murphy will be eligible to receive (i)&#160;payment of her monthly base salary (calculated as her total base salary during the 12 month period prior to her date of termination divided by 12) for the 9&#160;months following her departure (less applicable tax withholdings), (ii)&#160;75% of her &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to her outstanding stock options. As a condition to receiving the foregoing severance benefits, Ms.&#160;Murphy must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Under Ms.&#160;Murphy&#8217;s severance agreement, if she is terminated by us other than for &#8220;cause,&#8221; or if she resigns for &#8220;good reason,&#8221; and if such termination or resignation occurs at any time prior to a &#8220;change of control,&#8221; then Ms.&#160;Murphy will be eligible to receive (i)&#160;payment of her monthly base salary (calculated as her total base salary during the 12 month period prior to her date of termination divided by 12) for the 9&#160;months following her departure (less any amounts paid to Ms.&#160;Murphy during such 9 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to 9&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Ms.&#160;Murphy shall also receive full acceleration of the vesting of the unvested shares subject to her outstanding stock options. As a condition to receiving the foregoing severance benefits, Ms.&#160;Murphy must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Brad Calvin<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We entered into a severance agreement dated January&#160;11, 2021, setting forth the terms of Mr.&#160;Calvin&#8217;s severance eligibility. Under Mr.&#160;Calvin&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause&#8221; &#8203;(as defined in the severance agreement), or if he resigns for &#8220;good reason&#8221; &#8203;(as defined in the severance agreement), and if such termination or resignation occurs on the date of or within 24&#160;months following a &#8220;change of control&#8221; &#8203;(as defined in the severance agreement), then Mr.&#160;Calvin will be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 9&#160;months following his departure (less applicable tax withholdings), (ii)&#160;75% of his &#8220;target bonus&#8221; &#8203;(as defined in the severance agreement) (less applicable tax withholdings) paid in monthly installments over 9&#160;months, (iii)&#160;COBRA premium coverage for up to 9&#160;months, and (iv)&#160;full acceleration of the vesting of the unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr.&#160;Calvin must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Under Mr.&#160;Calvin&#8217;s severance agreement, if he is terminated by us other than for &#8220;cause,&#8221; or if he resigns for &#8220;good reason,&#8221; and if such termination or resignation occurs at any time prior to a &#8220;change of control,&#8221; then Mr.&#160;Calvin will be eligible to receive (i)&#160;payment of his monthly base salary (calculated as his total base salary during the 12 month period prior to his date of termination divided by 12) for the 9&#160;months following his departure (less any amounts paid to Mr.&#160;Calvin during such 9 month period under our Short Term or Long Term Disability Plan, and less applicable tax withholdings), (ii)&#160;COBRA premium coverage for up to 9&#160;months, and (iii)&#160;if the termination or resignation occurs within 180&#160;days prior to a &#8220;change of control,&#8221; then Mr.&#160;Calvin shall also receive full acceleration of the vesting of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">unvested shares subject to his outstanding stock options. As a condition to receiving the foregoing severance benefits, Mr.&#160;Calvin must sign and not revoke a release agreement in a form presented by us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Health and Welfare and Retirement Benefits</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, disability and life insurance plans, in each case on the same basis as all of our other employees. We do not provide perquisites or personal benefits to our named executive officers other than those provided generally to all employees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">401(k) Plan<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We maintain a tax-qualified retirement plan, the 401(k) Plan, that provides eligible employees in the United States with an opportunity to save for retirement on a tax-advantaged basis. Under the 401(k) Plan, we may provide matching and other discretionary contributions. We currently match employee contributions equal to 50% of the salary deferral contributions, with a maximum company contribution of 3% of the employee&#8217;s eligible compensation. All contributions, including employer matching and discretionary contributions, vest based upon the number of years of service of the recipient employee, from 0% for employees with less than one year of service to 100% for employees with at least four years of service. Pre-tax contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) Plan is intended to qualify under Sections&#160;401(a) and 501(a) of the Internal Revenue Code, or Code.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Equity Incentive Plans</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Long-Term Incentive Plan<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our Board of Directors adopted our Long-Term Incentive Plan, or our LTIP, in 2000. Our LTIP was amended and restated on May&#160;17, 2016. No further awards will be granted under our LTIP after the effectiveness of our 2021 Equity Incentive Plan, or our 2021 Plan, however, any awards outstanding under our LTIP will continue to be governed by their existing terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our LTIP provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, performance awards, restricted stock and incentive shares. ISOs may be granted only to our employees and to any of our affiliate&#8217;s employees. All other awards may be granted to our employees, directors, consultants, or independent contractors or those of our affiliates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Authorized Shares</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;As of December&#160;31, 2020, an aggregate of 4,175,737 shares of our common stock were reserved for issuance under our LTIP and stock options to purchase 7,609,667 shares of our common stock were outstanding under our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Plan&#160;Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors or one or more committees or persons appointed by our board of directors may administer our LTIP (in each case, the administrator). Subject to the terms of the LTIP, the administrator has the power to, among other things, determine who will be granted awards and the terms and conditions of such awards, and interpret, prescribe, amend and make all other determinations it deems necessary or advisable for the administration of our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Stock Options</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock options have been granted under our LTIP. The administrator determines the terms and conditions of stock options, including, but not limited to, the number of shares subject to the stock option, the exercise price of the stock option, and the time(s) at which the stock option may become exercisable. The exercise price of stock options granted under our LTIP generally cannot be less than 100% of the fair market value of a share of our common stock on the grant date. The term of a stock option may not exceed ten&#160;years from the grant date. With respect to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term of an incentive stock option granted to such participant must not exceed five&#160;years from the grant date and the per share exercise price cannot be less than 110% of the fair market value of a share of our common stock on the grant date. Subject to the terms of the LTIP and as provided for in an individual award agreement, the exercise price of a stock option may be paid by (i)&#160;a net exercise arrangement; (ii)&#160;a cashless exercise or same day sale; (iii)&#160;the tender of shares of our common stock previously owned by the participant; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">or (iv)&#160;a partial payment may be made by delivery of a promissory note to us. In the event a participant&#8217;s employment with us is terminated for any reason other than by us for cause (as defined in each individual award agreement), the administrator may extend the exercise period of any options held by such participant; provided however, that such extended post-termination exercise period may not extend beyond the earlier of (A)&#160;the seventh anniversary of such termination, or (B)&#160;the tenth anniversary of the date the stock option is granted.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event any change is made to our common stock, such as by reason of any stock split, stock dividend, or recapitalization, appropriate adjustments shall be made to (i)&#160;the maximum number and class of securities issuable under the plan, (ii)&#160;the number and class of securities subject to outstanding awards, and (iii)&#160;the exercise price of each outstanding option.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exchange Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event of an exchange transaction (as defined in the LTIP), our board of directors may take such actions as it deems necessary, including, without limitation (i)&#160;accelerating the vesting of outstanding options, either in whole or in part; or (ii)&#160;if, as part of the exchange transaction, our stockholders are receiving stock of the acquiring company as consideration, converting outstanding options in whole or in part into options to purchase shares of the acquiring company</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors may amend, alter or terminate the LTIP at any time. However, our board of directors will obtain stockholder approval of any amendment to the LTIP if necessary to comply with applicable laws, and will obtain the approval of each affected participant if such amendment, alteration or termination would adversely affect such participants rights under their award. As noted above, no further awards will be granted under our LTIP after the effectiveness of our 2021 Plan; however, awards outstanding under our LTIP will continue to be governed by their existing terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">2021 Equity Incentive Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors intends to adopt our 2021 Plan, subject to the approval of our stockholders, following this offering. Our 2021 Plan will not become effective unless and until it has been approved by our stockholders, and no grants will be made under our 2021 Plan prior to its effectiveness. Once our 2021 Plan becomes effective, no further grants will be made under our LTIP.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our 2021 Plan will provide for the grant of ISOs within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Authorized Shares</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Initially, the maximum number of shares of our common stock that may be issued under our 2021 Plan after it becomes effective will not exceed a number of shares of our common stock, equal to the sum of (a)&#160;any shares that remain available for the issuance of awards under our LTIP as of immediately prior to the time our 2021 Plan becomes effective, (b) a number of new shares that in combination with the shares in clause (a) will not exceed 4,000,000 and (c)&#160;any shares of our common stock subject to outstanding stock options or other stock awards granted under our LTIP that, on or after our 2021 Plan becomes effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. As of July&#160;26, 2021, the maximum number of shares represented by clause (c) is approximately 12,310,515 shares. In addition, the number of shares of our common stock reserved for issuance under our 2021 Plan, if approved, will automatically increase on January&#160;1st of each year for a period of ten&#160;years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, in an amount equal to (1) 5% of the total number of shares of our common stock outstanding on December&#160;31 of the immediately preceding year, or (2)&#160;a lesser number of shares determined by our board of directors no later than December 31 of the immediately preceding year. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2021 Plan will be equal to three multiplied by the share reserve.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares will not reduce the number of shares available for issuance under our 2021 Plan. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax withholding obligation will not reduce the number of shares available for issuance under our 2021 Plan. If any shares of our common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of a stock award; or (iii)&#160;to satisfy a tax withholding obligation in connection with a stock award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under our 2021 Plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Plan&#160;Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee of our board of directors, will administer our 2021 Plan. Our board of directors may delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to receive specified stock awards; and (ii)&#160;determine the number of shares subject to such stock awards. Under our 2021 Plan, our board of directors will have the authority to determine stock award recipients, the types of stock awards to be granted, grant dates, the number of shares subject to each stock award, the fair market value of our common stock and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, our board of directors also generally will have the authority to effect, with the consent of any materially adversely affected participant and subject to the approval of our stockholders as may be required, (i)&#160;the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right; (ii)&#160;the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration; or (iii)&#160;any other action that is treated as a repricing under generally accepted accounting principles.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Stock Options</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted under stock option agreements adopted by the administrator. The administrator will determine the exercise price for stock options, within the terms and conditions of our 2021 Plan, except the exercise price of a stock option generally will not be less than 100% of the fair market value of our common stock on the date of grant. Options granted under our 2021 Plan will vest at the rate specified in the stock option agreement as will be determined by the administrator.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The administrator will determine the term of stock options granted under our 2021 Plan, up to a maximum of 10&#160;years. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three&#160;months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18&#160;months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the administrator and may include (i)&#160;cash, check, bank draft or money order; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;the tender of shares of our common stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration approved by the administrator.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Unless the administrator provides otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Tax Limitations on ISOs</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five&#160;years from the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Restricted Stock Unit Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Restricted Stock Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Restricted stock awards are granted under restricted stock award agreements adopted by the administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The administrator will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Stock Appreciation Rights</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted under stock appreciation right agreements adopted by the administrator. The administrator will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under our 2021 Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the administrator. Stock appreciation rights may be settled in cash or shares of our common stock or in any other form of payment as determined by our board of directors and specified in the stock appreciation right agreement.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The administrator will determine the term of stock appreciation rights granted under our 2021 Plan, up to a maximum of 10&#160;years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three&#160;months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12&#160;months in the event of disability and 18&#160;months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. In no event may a stock appreciation right be exercised beyond the expiration of its term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Performance Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our 2021 Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The performance goals may be based on any measure of performance selected by our board of directors. The performance goals may be based on company-wide performance or performance of one or more business&#160;units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our board of directors at the time the performance award is granted, our board will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (i)&#160;to exclude restructuring or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Other Stock Awards</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The administrator will be permitted to grant other awards based in whole or in part by reference to our common stock. The administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Non-Employee Director Compensation Limit</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including awards granted and cash fees paid by us to such non-employee director, will not exceed $900,000 in total value, except such amount will increase to $1,400,000 for the first year for newly appointed or elected non-employee directors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (i)&#160;the class and maximum number of shares reserved for issuance under our 2021 Plan, (ii)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&#160;the class and maximum number of shares that may be issued on the exercise of ISOs, and (iv)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Corporate Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under our 2021 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&#160;with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such stock awards that are held by persons other than current participants will terminate if not exercised (if </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the stock award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate transaction may apply to such payment to the same extent and in the same manner as such provisions apply to the holders of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, a &#8220;corporate transaction&#8221; is generally the consummation of (i)&#160;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Change in Control</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Stock awards granted under our 2021 Plan may be subject to acceleration of vesting and exercisability upon or after a change in control (as defined below) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our 2021 Plan, a &#8220;change in control&#8221; is generally (i)&#160;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (ii)&#160;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction; (iii)&#160;stockholder approval of a complete dissolution or liquidation; (iv)&#160;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction; or (v)&#160;when a majority of our board of directors becomes comprised of individuals who were not serving on our board of directors on the date of the underwriting agreement related to this offering, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Plan&#160;Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2021 Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the effective date of our 2021 Plan. No stock awards may be granted under our 2021 Plan while it is suspended or after it is terminated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">2021 Employee Stock Purchase Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our board of directors intends to adopt our employee stock purchase plan, or our ESPP, subject to the approval of our stockholders, following this offering. The purpose of our ESPP will be to secure the services of new employees, to retain the services of existing employees and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. If approved, our ESPP will include two components. One component will be designed to allow eligible U.S. employees to purchase our common stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the United States while complying with applicable foreign laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Share Reserve</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our ESPP will authorize the issuance of up to 1% of the shares of common stock outstanding as of immediately following this offering under purchase rights that may be granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January&#160;1 of each year for a period of ten&#160;years, beginning on January&#160;1, 2022 and continuing through January&#160;1, 2031, by the lesser of (i) 1% of the total number of shares of our common stock outstanding on December&#160;31 of the immediately preceding year; and (ii)&#160;a number of shares equal to 3% of the shares of common stock outstanding as of immediately following this offering, except before our date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i)&#160;and (ii).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Administration</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors will administer our ESPP and may delegate its authority to administer our ESPP to our compensation committee. Our ESPP will be implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under our ESPP, our board of directors will be permitted to specify offerings with durations of not more than 27&#160;months and to specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. Our ESPP will provide that an offering may be terminated under certain circumstances.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Payroll Deductions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, will be eligible to participate in our ESPP and to contribute, normally through payroll deductions, up to 15% of their earnings (as defined in our ESPP) for the purchase of our common stock under our ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in our ESPP at a price per share equal to the lesser of (i)&#160;85% of the fair market value of a share of our common stock on the first day of an offering; or (ii)&#160;85% of the fair market value of a share of our common stock on the date of purchase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Limitations</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in our ESPP, as determined by our board of directors: (i)&#160;being customarily employed for more than 20 hours per week or (ii)&#160;being customarily employed for more than five&#160;months per calendar year. No employee will be permitted to purchase shares under our ESPP at a rate in excess of $25,000 worth of our common stock (based on the fair market value per share of our common stock at the beginning of an offering) for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under our ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&#160;424(d) of the Code.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Changes to Capital Structure</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our ESPP will provide that in the event there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our board of directors will make appropriate adjustments to: (i)&#160;the class(es) and maximum number of shares reserved under our ESPP; (ii)&#160;the class(es) and maximum number of shares by which the share reserve may increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of shares that are subject to purchase limits under ongoing offerings.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Corporate Transactions</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our ESPP will provide that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our stock under our ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days before such corporate transaction, and such purchase rights will terminate immediately after such purchase.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Under our ESPP, a &#8220;corporate transaction&#8221; is generally the consummation of (i)&#160;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Amendment or Termination</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;Our board of directors will have the authority to amend or terminate our ESPP, except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Limitations on Liability and Indemnification Matters</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation contains provisions that limit the liability of our directors to us or our stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:7.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">unlawful payments of dividends or unlawful stock repurchases or redemptions; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any transaction from which the director derived an improper personal benefit.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">If the Delaware General Corporation Law is amended after the effective date of our certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Such limitation of liability does will not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation provides for us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws that will be in effect following the completion of this offering will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and restated bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action, suit or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With certain exceptions, these agreements provide for indemnification for related expenses including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe these provisions in our fifteenth amended and restated certificate of incorporation and amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#8217; and officers&#8217; liability insurance.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The limitation of liability and indemnification provisions in our fifteenth amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:436pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for our directors, executive officers or persons controlling us, we have been informed that, in the opinion of the Securities and Exchange Commission, or SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Rule&#160;10b5-1 Sales Plans</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our directors and officers may adopt written plans, known as Rule&#160;10b5-1 plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule&#160;10b5-1 plan, a broker executes trades under parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule&#160;10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive officers may also buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they do not possess material nonpublic information, subject to compliance with the terms of our insider trading policy. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since January&#160;1, 2018 to which we were a party or will be a party, in which:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:1.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the amounts involved exceeded or will exceed $120,000; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Equity Financings</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2019 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2019, we issued and sold an aggregate of 5,908,319 shares of common stock at a purchase price of &#163;1.70 per share, for an aggregate amount of &#163;10.0&#160;million (approximately $13.3&#160;million as of the issue date). The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:41.5pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.089pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.089pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.089pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">River and Mercantile Asset Management LLP(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">662,350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,125,995</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.167pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,488,002</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">At the time of the offering River and Mercantile Asset Management LLP was a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2020 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">In May&#160;2020, we issued and sold an aggregate of 19,181,423 shares of common stock at a purchase price of &#163;1.31 per share, for an aggregate amount of &#163;25.1&#160;million (approximately $30.5&#160;million as of the issue date), or the 2020 Placement. The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:71.5pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.089pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.089pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.089pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,281,334</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,158,547</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">14,765,097</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,331,289</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,673,988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,890,378</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">River and Mercantile Asset Management LLP(3) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,152,156</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,819,324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">3,431,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P. is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">At the time of the offering River and Mercantile Asset Management LLP was a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">2021 Placement<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2021, we issued and sold an aggregate of 5,740,000 shares of common stock at a purchase price of &#163;7.00 per share, for an aggregate amount of &#163;40.2&#160;million (approximately $55.3&#160;million as of the issue date). The following table summarizes the shares of common stock purchased by related persons.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:56.5pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Stockholder </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares of </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Subscription Price</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:30pt;letter-spacing:-0.089pt;">(</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">&#163;</font><font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:30pt;letter-spacing:-0.089pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross Proceeds</font>
                <br >
                <font style="letter-spacing:-0.089pt;">to MaxCyte</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">890,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">6,230,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">8,579,931</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">330,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,310,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,184,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P. is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:11pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP is a holder of 5% or more of our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Rights to Exchange</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, in connection with the 2020 Placement, we provided Casdin and Sofinnova with certain rights to exchange their shares in certain circumstances. See the section titled &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Rights to Exchange&#8221; for additional information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Novavax Sublease</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2011, we entered into a Lease Agreement, as subsequently amended or restated, the Lease Agreement, with Novavax, Inc., or Novavax, covering the sublease of approximately 19,000 square feet of office and laboratory space. The sublease is currently set to expire in October&#160;2023. Richard Douglas, PhD, a member of our board of directors, is a member of the board of directors of Novavax and Stanley Erck, a member of our board of directors, is the chief executive officer and a director of Novavax. Under the terms of the Lease Agreement, we paid Novavax $371,600, $416,800, $623,000, $154,800 and $158,700 for the years ended December 31, 2018, 2019 and 2020 and the three months ended March 31, 2020 and 2021, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Equity Grants to Directors and Executive Officers</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">We have granted stock options to certain of our directors and executive officers. For more information regarding the stock options and stock awards granted to our directors and named executive officers, see the sections titled &#8220;Management&#8201;&#8212;&#8201;Director Compensation&#8221; and &#8220;Executive Compensation.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Indemnification Agreements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation contains provisions limiting the liability of directors, and both such amended and restated certificate of incorporation and our amended and restated bylaws that will be in effect following the completion of this offering will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which requires us to indemnify them. For more information regarding these agreements, see the section titled &#8220;Executive Compensation&#8201;&#8212; Limitations on Liability and Indemnification Matters.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Policies and Procedures for Transactions with Related Persons</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">We have adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">The related person transactions policy also covers related party transactions under the AIM Rules, which contains a different definition of a related party to the definition of a related person set out above for U.S. purposes. The AIM Rules require that any transaction with a related party (pursuant to the definition in the AIM Rules) that exceeds 5% in any of the class tests set out in the AIM Rules, taking into account certain provisions relating to aggregation of transactions, should be announced without delay as soon as the terms of the transaction are agreed, and that the announcement should include certain specified information including a statement that our directors (with the exception of any director who is involved in the transaction as a related party) consider, having consulted with our nominated adviser for AIM, that the terms of the transaction are fair and reasonable insofar as our shareholders are concerned.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">PRINCIPAL STOCKHOLDERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table sets forth information with respect to the beneficial ownership of our shares as of June&#160;1, 2021 by:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each named executive officer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each of our directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our directors and executive officers as a group; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">each person or entity known by us to own beneficially more than 5% of our common stock (by number or by voting power).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Applicable&#160;percentage ownership before this offering is based on 84,719,345 shares of common stock outstanding as of June&#160;1, 2021. Applicable&#160;percentage ownership after this offering is based on 98,189,559 shares of common stock outstanding immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares of common stock from us. In computing the number of shares beneficially owned by a person and the&#160;percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60&#160;days of June&#160;1, 2021. However, except as described above, we did not deem such shares outstanding for the purpose of computing the&#160;percentage ownership of any other person.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;MaxCyte, Inc. 22 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <table style="width:456pt;height:284.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:11.665pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Percentage of Shares</font>
                  <br >
                  <font style="letter-spacing:-0.089pt;">Beneficially Owned </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Number of Shares </font>
                  <br >
                  <font style="letter-spacing:-0.089pt;">Beneficially Owned </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Before </font>
                  <br >
                  <font style="letter-spacing:-0.089pt;">Offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.089pt;">After </font>
                  <br >
                  <font style="letter-spacing:-0.089pt;">Offering </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 1.5pt 0pt; width:286.58pt;text-align:left;">
                <font style="border-bottom:1px solid #000000;letter-spacing:-0.111pt;">Name of Beneficial Owner</font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <font style="letter-spacing:-0.111pt;">5% Stockholders:</font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Casdin Partners Master Fund, L.P.(1) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,171,334</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14.4<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">12.4<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Sofinnova Crossover I SLP(2) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,661,289</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.5</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.7</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <font style="letter-spacing:-0.111pt;">Directors and Named Executive Officers:</font>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Doug Doerfler(3) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,266,219</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.6</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.3</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">J. Stark Thompson, PhD(4) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">288,255</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Yasir Al-Wakeel </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Ron Holtz(5) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">946,443</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.1</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.0</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Will Brooke(6) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">117,906</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Richard Douglas, PhD(7) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">60,714</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Stanley Erck(8) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">478,822</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Rekha Hemrajani </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">John Johnston(9) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">195,004</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Art Mandell(10) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">462,488</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Amanda Murphy(11) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">239,583</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:2.5pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Brad Calvin(12) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">435,417</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:1.167pt 0pt 0.5pt 0pt; width:286.58pt;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.025pt;">All directors and current executive officers as a group </font>
                  <br >
                  <font style="letter-spacing:-0.025pt;">(11 persons)(13) </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:23.33pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,490,851</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.7</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.59pt;width:0pt;">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5.0</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Represents beneficial ownership of less than 1%.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:160pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(1)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Casdin Capital, LLC is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC is the general partner of Casdin Partners Master Fund&#160;L.P. Eli Casdin is the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. As such, each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin may be deemed to beneficially own the securities held by Casdin Partners Master Fund, L.P. by virtue of their shared voting and investment control over Casdin Partners Master Fund, L.P. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr.&#160;Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The address of these persons and entities is 1350&#160;Avenue of the Americas, Suite 2600, New York, NY 10019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">The securities are held by Sofinnova Crossover I SLP, or Sofinnova Crossover. Sofinnova Partners SAS is the management company of Sofinnova Crossover and has voting and investment control over the securities. The address of Sofinnova Crossover is 7-11, boulevard Haussmann 75009 Paris, France.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 433,197 shares of common stock and (ii) 1,833,022 shares of common stock issuable upon the exercise of options exercisable as of July 31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 110,918 shares of common stock and (ii) 177,337 shares of common stock issuable upon the exercise of options exercisable as of July 31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 150,251 shares of common stock and (ii) 796,192 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 50,302 shares of common stock and (ii) 67,604 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of 60,714 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 247,751 shares of common stock and (ii) 231,071 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 120,583 shares of common stock and (ii) 74,421 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(10)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 374,484 shares of common stock and (ii) 88,004 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of 239,583 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of 435,417&#160;shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:-0.025pt;">Consists of (i) 1,487,486 shares of common stock and (ii) 3,567,948 shares of common stock issuable upon the exercise of options granted under our LTIP exercisable as of July 31, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">General</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation authorizes us to issue up to 400,000,000 shares of common stock, $0.01 par value per share, and 5,000,000 shares of preferred stock, $0.01 par value per share, all of which shares of preferred stock are undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">As of March 31, 2021, we had 84,689,559 shares of common stock outstanding, held of record by 280 stockholders.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Voting Rights<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Each holder of common stock is entitled to one vote for each share of common stock held by such holder on all matters submitted to a vote of the stockholders. In all matters, other than the election of directors and except as otherwise required by law, our amended and restated certificate or bylaws, including any provisions requiring a separate vote of a class or series of our shares, the affirmative vote of a majority of the voting power of the shares present or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. Our amended and restated bylaws provide that stockholders representing a majority of the voting power of our issued and outstanding capital stock, present in person, by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. The affirmative vote of holders of at least 75% of the voting power of all of the then-outstanding shares of capital stock, entitled to vote and voting together as a single class, is required to amend certain provisions of our fifteenth amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws and the certificate, the voting rights of our common stock, removal of directors, director liability and indemnification, vacancies on our board, special meetings, annual meetings, stockholder notices, actions by written consent and exclusive forum. Unless otherwise required by law or the fifteenth amended and restated certificate of incorporation, the amended and restated bylaws provide that the election of directors shall be decided by a plurality of the votes cast at a meeting of stockholders by the holders of stock entitled to vote in the election.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Dividends<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose. Dividends may be paid in cash, in property or in shares of our common stock. See the section titled &#8220;Dividend Policy&#8221;.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Liquidation<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Rights and Preferences<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Holders of our common stock have no conversion, subscription or other rights, and there are no redemption, sinking fund provisions or pre-emptive rights applicable to our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Fully Paid and Nonassessable<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All outstanding shares of our common stock are fully paid and non-assessable, and the shares of common stock to be issued upon completion of this offering will be fully paid and non-assessable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Preferred Stock</font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Upon the closing of this offering, our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 5,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action. Upon the closing of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Warrants</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with a credit facility we issued the lender a warrant to purchase 71,168 shares of common stock at an exercise price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. The warrant is classified as a liability as its strike price is in a currency other than our functional currency. The warrant is recorded at fair value at the end of each reporting period with changes from the prior balance sheet date recorded on the consolidated statements of operations. See Note 6 to our financial statements included in this prospectus for more information.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stock Options</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of March 31, 2021, 5,732,382 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average exercise price of $1.95 per share based on exchange rates as of March 31, 2021. For additional information regarding terms of our equity incentive plans, see the section titled &#8220;Executive and Director Compensation&#8201;&#8212;&#8201;Equity Incentive Plans.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Rights to Exchange</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, we entered into subscription agreements with investors Casdin Capital, LLC and Sofinnova Crossover I SLP, which provides Casdin and Sofinnova with certain rights. Under these agreements, in the event of a U.S. listing, we must take all necessary steps, including without limitation any additional filings with the SEC necessary, to allow each of our holders of common stock who elects to do so, to exchange their common stock listed on AIM for securities listed on such U.S. exchange, and we shall advise and instruct Casdin and/or Sofinnova how to convert their common stock traded on AIM and take delivery of the underlying U.S. exchange traded common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Anti-Takeover Provisions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws to be in Effect Following this Offering<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, each which are currently in effect or will be in effect following this offering, will:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that our board of directors will be classified into three classes of directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent in lieu thereof;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that special meetings of our stockholders may be called at any time, for any purpose or purposes, only by the chairperson of our board of directors, our chief executive officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">provide that our directors may be removed (i) with or without cause, upon the vote of at least 50% of the outstanding shares of voting stock or (ii) with cause, by the affirmative vote or consent of at least two-thirds of the other members of our board of directors; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The amendment of any of these provisions would require approval by the holders of at least 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Following this offering, we will be subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, subject to certain exceptions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Choice of Forum<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Our fifteenth amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our fifteenth amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The provisions would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act of 1934, as amended.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, our fifteenth amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. Stockholders cannot waive compliance with U.S. federal securities laws and the rules and regulations thereunder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11.42pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Limitations of Liability and Indemnification</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">See the section titled &#8220;Executive Compensation&#8201;&#8212;&#8201;Limitations on Liability and Indemnification Matters.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11.41pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Exchange Listing</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:-0.025pt;">Our common stock is currently traded on AIM, a market operated by the London Stock Exchange, under the trading symbols &#8220;MXCT&#8221; and &#8220;MXCN&#8221;. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#8220;MXCT.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:576pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.111pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">On the completion of this offering, the transfer agent for our common stock will be Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150&#160;Royall Street, Canton, Massachusetts 02021. Our UK registrar is Link Asset Services Limited. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <font style="letter-spacing:-0.025pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">SHARES ELIGIBLE FOR FUTURE SALE</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:-0.025pt;">Prior to this offering, there has been no public market for our common stock in the United States. Future sales of substantial amounts of our common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to raise equity capital.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
            <font style="letter-spacing:-0.025pt;">Based on our shares outstanding as of March&#160;31, 2021, on the completion of this offering and assuming no exercise of the underwriters&#8217; option to purchase additional shares, a total of 98,189,559 shares of common stock will be outstanding. Of these shares, all of the common stock sold in this offering by us, plus any shares sold by exercise of the underwriters&#8217; option to purchase additional common stock from us, will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by &#8220;affiliates,&#8221; as that term is defined in Rule&#160;144 under the Securities Act, or Rule&#160;144.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The remaining shares of common stock will be, and shares of common stock subject to stock options will be on issuance, &#8220;restricted securities,&#8221; as that term is defined in Rule&#160;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or Rule&#160;701 under the Securities Act, or Rule&#160;701, which are summarized below. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule&#160;904 of Regulation&#160;S under the Securities Act.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Subject to the lock-up agreements described below and the provisions of Rule&#160;144, Rule&#160;701 or Regulation&#160;S under the Securities Act (including any applicable distribution compliance period for shares sold pursuant to Regulation&#160;S under the Securities Act), as well as our insider trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Rule&#160;144</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In general, under Rule&#160;144 as currently in effect, once we have been subject to public company reporting requirements of Section&#160;13 or 15(d) of the Exchange Act for at least 90&#160;days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation or notice provisions of Rule&#160;144, subject to compliance with the public information requirements of Rule&#160;144. To be an eligible stockholder under Rule&#160;144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90&#160;days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six&#160;months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule&#160;144, subject to the expiration of the lock-up agreements described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In general, under Rule&#160;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below, subject, in the case of restricted securities, to such shares having been beneficially owned for at least six&#160;months. Beginning 90&#160;days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">1% of the common stock then outstanding, which will equal approximately 982,000 shares immediately after this offering, assuming no exercise of the underwriters&#8217; option to purchase additional shares of common stock from us; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:-0.025pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:1.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:-0.025pt;">the average weekly trading volume of our common stock on the Nasdaq Global Select Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Sales under Rule&#160;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:280pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Rule&#160;701</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Rule&#160;701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90&#160;days, to sell these shares in reliance on Rule&#160;144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule&#160;144. Rule&#160;701 also permits affiliates of our company to sell their Rule&#160;701 shares under Rule&#160;144 without complying with the holding period requirements of Rule&#160;144. All holders of Rule&#160;701 shares, however, are required by that rule to wait until 90&#160;days after the date of this prospectus before selling those shares under Rule&#160;701, subject to the expiration of the lock-up agreements described below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Form S-8 Registration Statements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We intend to file one or more registration statements on Form S-8 under the Securities Act with the SEC to register the offer and sale of shares of our common stock to be issued under our LTIP and, if and when approved by stockholders, the 2021 Plan and ESPP. These registration statements will become effective immediately on filing. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described below, and Rule&#160;144 limitations applicable to affiliates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Lock-Up Arrangements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We and all of our directors and executive officers, representing the holders of approximately 1.5 million shares of our common stock, have agreed with the underwriters that, until 90&#160;days after the date of this prospectus, we and they will not, without the prior written consent of Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated and William Blair &amp; Company, L.L.C., offer, sell, assign, transfer, pledge, contract to sell, lend or otherwise dispose of any shares of common stock, or securities convertible into or exercisable or exchangeable for common stock. These agreements are described in the section titled &#8220;Underwriting.&#8221; Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated and William Blair &amp; Company, L.L.C. may, in their sole discretion, release any of the securities subject to these lock-up agreements at any time. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following summary describes the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired in this offering by Non-U.S. Holders (as defined below). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address non-U.S., state and local tax consequences that may be relevant to Non-U.S. Holders in light of their particular circumstances, and does not address U.S. federal tax consequences other than income taxes. For example, it does not address estate and gift taxes, the alternative minimum tax, the Medicare contribution tax on net investment income, or the application of special tax accounting rules under Section&#160;451(b). Special rules different from those described below may apply to certain Non-U.S. Holders that are subject to special treatment under the Code, such as banks, regulated investment companies real estate investment trusts, financial institutions, insurance companies, tax-exempt organizations, tax-qualified retirement plans, governmental organizations, broker-dealers and traders in securities or currencies, certain former citizens or long-term residents of the United States, &#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof, or the District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security,&#8221; or integrated investment or other risk reduction strategy, persons deemed to sell our common stock under the constructive sale provisions of the Code, persons who acquire our common stock through the exercise of an option or otherwise as compensation, &#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, and partnerships and other pass-through entities or arrangements and investors in such pass-through entities or arrangements. Such Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. If a partnership (including any entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Partnerships holding our common stock and partners in such partnerships should consult their own tax advisors regarding the tax consequences of the ownership and disposition of our common stock. Furthermore, the discussion below is based upon the provisions of the Code and U.S. Treasury Regulations, rulings and judicial decisions thereunder, each as of the date hereof, and such authorities may be repealed, revoked, or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the Non-U.S. Holder holds our common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income, gift, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local or non-U.S. tax consequences, or under any applicable income tax treaty.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is a beneficial owner of common stock that is neither a U.S. Holder nor a partnership (or other entity treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or formation). A &#8220;U.S. Holder&#8221; means a beneficial owner of our common stock that is for U.S. federal income tax purposes any of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an individual who is a citizen or resident of the United States;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a trust if it (1)&#160;is subject to the primary supervision of a court within the United States and one or more United States persons (within the meaning of Section&#160;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Distributions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As described in the section titled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock to a Non-U.S. Holder, such distributions, to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide us or our paying agent with a properly executed IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the case of entities), or other appropriate form, certifying the Non-U.S. Holder&#8217;s entitlement to benefits under that treaty. We do not intend to adjust our withholding unless such certificates are provided to us or our paying agent before the payment of dividends and are updated as may be required by the IRS. In the case of a Non-U.S. Holder that is an entity, U.S. Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder&#8217;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#8217;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and you do not timely provide the required certification, you may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We generally are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us or our paying agent (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the Non-U.S. Holder&#8217;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount distributed, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Gain on Disposition of Our Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Subject to the discussions below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&#160;the gain is effectively connected with a trade or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States), (b)&#160;the Non-U.S. Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c)&#160;we are or have been a &#8220;United States real property holding corporation&#8221; within the meaning of Code Section&#160;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder&#8217;s holding period in our common stock. In general, we would be a United States real property holding corporation if the fair market value of our U.S. real property interests equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business. We believe that we have not been and we are not, and do not anticipate becoming, a United States real property holding corporation. Even if we are treated as a United States real property holding corporation, gain realized by a Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&#160;the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (i)&#160;the five-year period preceding the disposition or (ii)&#160;the holder&#8217;s holding period in our common stock and (2)&#160;our common stock is &#8220;regularly traded,&#8221; as defined by applicable U.S. Treasury Regulations, on an established securities market. There can be no assurance that our common stock will qualify or continue to qualify as regularly traded on an established securities market. If any gain on your disposition is taxable because we are a United States real property holding corporation and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner as gain that is effectively connected with the conduct of a U.S. trade or business (subject to the provisions under an applicable income tax treaty), except that the branch profits tax generally will not apply.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">If you are a Non-U.S. Holder described in (a)&#160;above, you will be required to pay tax on a net income basis at the U.S. federal income tax rates applicable to U.S. Holders, and corporate Non-U.S. Holders described in (a)&#160;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are a Non-U.S. Holder described in (b)&#160;above, you will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which gain may be offset by certain U.S.-source capital losses (even though you are not considered a resident of the United States), provided that the you have timely filed U.S. federal income tax returns with respect to such losses. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Information Reporting Requirements and Backup Withholding</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Generally, we must report annually to the IRS and to each Non-U.S. Holder the amount of distributions paid, the name and address of the recipient, and the amount, if any, of tax withheld. These information reporting requirements apply even if withholding was not required because the dividends were effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States or withholding was reduced by an applicable income tax treaty. Under applicable income tax treaties or other agreements, the IRS may make its reports available to the tax authorities in the Non-U.S. Holder&#8217;s country of residence or country in which the Non-U.S. Holder was established.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Dividends paid to a Non-U.S. Holder that is not an exempt recipient generally will be subject to backup withholding, currently at a rate of 24%, unless the Non-U.S. Holder certifies to the payor as to its foreign status, which certification may generally be made on an applicable IRS Form W-8.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Proceeds from the sale or other disposition of common stock by a Non-U.S. Holder effected by or through a U.S. office of a broker generally will be subject to information reporting and backup withholding, currently at a rate of 24%, unless the Non-U.S. Holder certifies to the withholding agent under penalties of perjury as to, among other things, its name, address and status as a Non-U.S. Holder or otherwise establishes an exemption. Payment of disposition proceeds effected outside the United States by or through a non-U.S. office of a non-U.S. broker generally will not be subject to information reporting or backup withholding if the payment is not received in the United States. Information reporting, but generally not backup withholding, will apply to such a payment if the broker has certain connections </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">with the United States unless the broker has documentary evidence in its records that the beneficial owner thereof is a Non-U.S. Holder and specified conditions are met or an exemption is otherwise established.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Backup withholding is not an additional tax. Any amount withheld under the backup withholding rules from a payment to a Non-U.S. Holder that results in an overpayment of taxes generally will be refunded, or credited against the holder&#8217;s U.S. federal income tax liability, if any, provided that the required information is timely furnished to the IRS</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Foreign Accounts</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Sections&#160;1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments paid to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a federal withholding tax of 30% on certain payments to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">FATCA withholding currently applies to payments of dividends. The U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a disposition of our common stock. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW.</font><font style="font-weight:normal;letter-spacing:-0.025pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">UNDERWRITING</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We and the underwriters for the offering named below have entered into an underwriting agreement with respect to the common stock being offered. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. are the representatives of the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <table style="width:456pt;height:99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="padding:0pt 0pt 2.5pt 0pt; width:384.61pt;">
                <div style="white-space:nowrap;">
                  <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Underwriter </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">Number of Shares </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:384.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,995,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Stifel, Nicolaus &amp; Company, Incorporated. </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">3,915,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">William Blair &amp; Company, L.L.C </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,835,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:384.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="text-transform:uppercase;letter-spacing:-0.025pt;">BTIG, LLC</font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,080,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:384.61pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Stephens Inc. </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">675,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 2.25pt 0pt; width:384.61pt;text-align:left;">
                <div style="margin-left:40pt;">
                  <font style="letter-spacing:-0.025pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:19.38pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">13,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:12.21pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the option to purchase additional shares described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments the underwriters may be required to make in respect thereof.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Option to Purchase Additional Shares.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;We have granted to the underwriters an option to purchase up to 2,025,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. This option is exercisable for a period of 30&#160;days. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Discounts and Commissions.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The following table shows the public offering price, underwriting discounts and commissions and proceeds, before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $3.0 million and are payable by us. We have agreed to reimburse the underwriters for up to $30,000 for their Financial Industry Regulatory Authority, or FINRA counsel fee. In accordance with FINRA Rule&#160;5110, this reimbursed fee is deemed underwriting compensation for this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <table style="width:456pt;height:67pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:270.7pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.245pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:3.245pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Total </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:270.7pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Per Share </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">Without Option </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.089pt;">With Option </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:270.7pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Public offering price </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">13.00</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">175,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">201,825,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270.7pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Underwriting discounts and commissions </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">0.91</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,285,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">14,127,750</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270.7pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:-0.025pt;">Proceeds, before expenses, to the Company </font>
                </div>
              </td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt; width:1pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">12.09</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">163,215,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">187,697,250</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:7.1pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the cover of this prospectus. The underwriters may offer the shares of common stock </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">to securities dealers at the public offering price less a concession not in excess of $0.546 per share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Discretionary Accounts.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares to any accounts over which they have discretionary authority.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Market Information.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Our shares of common stock are admitted to trading on AIM, a market operated by the London Stock Exchange, under the symbols &#8220;MXCT&#8221; and &#8220;MXCN.&#8221; However, prior to this offering, there has been no public market for our shares or any of our other securities on any U.S. national securities exchange. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the history of, and prospects for, our company and the industry in which we compete;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">our past and present financial information;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the trading price of our common stock on AIM;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future revenues;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the present state of our development; and</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:-0.025pt;">Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#8220;MXCT.&#8221;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
          </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Stabilization.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares. The underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Stock Market, in the over-the-counter market or otherwise and, if commenced, may be discontinued at any time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Stabilization transactions will also need to comply with U.K. and European laws, in particular the Market Abuse Regulation (Regulation (EU) 596/2014).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Passive Market Making.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the Nasdaq Stock Market in accordance with Rule&#160;103 of Regulation&#160;M under the Securities Exchange Act of 1934, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, such bid must then be lowered when specified purchase limits are exceeded. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Lock-Up Agreements.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Pursuant to certain &#8220;lock-up&#8221; agreements, we and our executive officers, directors and certain other stockholders, have agreed, subject to certain exceptions, not to and will not cause or direct any of its affiliates to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into, or announce the intention to enter into any swap, hedge or similar agreement or arrangement (including, without limitation, the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) that transfers, is designed to transfer or reasonably could be expected to transfer (whether by the stockholder or someone other than the stockholder) that transfers, in whole or in part, directly or indirectly the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C., for a period of 90&#160;days after the date of the pricing of the offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or, in some instances, acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. The exceptions permit us, among other things and subject to restrictions, to: (i)&#160;issue common stock or options pursuant to employee benefit plans, (ii)&#160;issue common stock upon exercise of outstanding options or warrants, (iii)&#160;issue securities in connection with acquisitions or similar transactions, and (iv)&#160;file registration statements on Form S-8. The exceptions permit parties to the &#8220;lock-up&#8221; agreements, among other things and subject to restrictions, to: (a)&#160;make certain gifts or transfers by will or intestate succession upon the death of the party, (b)&#160;if the party is a corporation, partnership, limited liability company or other business entity, make transfers to any shareholders, partners, members of, or owners of similar equity interests in, the party, or to an affiliate of the party, if such transfer is not for value, and (c)&#160;if the party is a corporation, partnership, limited liability company or other business entity, make transfers in connection with the sale or transfer of all of the party&#8217;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the party&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by the &#8220;lock-up&#8221; agreement. In addition, the lock-up provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C., in their sole discretion, may release our common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. When determining whether or not to release our common stock and other securities from lock-up agreements, Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. will consider, among other factors, the holder&#8217;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time of the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, and William Blair &amp; Company, L.L.C. shall provide us with notice of the impending release or waiver at least three business days before the effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of shares on our behalf or on behalf of the underwriters.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Electronic Offer, Sale and Distribution of Shares.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Other Relationships.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Selling Restrictions</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Canada</font><font style="letter-spacing:-0.025pt;">.&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 </font><font style="font-style:italic;">Prospectus Exemptions</font><font style="letter-spacing:-0.025pt;"> or subsection 73.3(1) of the </font><font style="font-style:italic;">Securities Act</font><font style="letter-spacing:-0.025pt;"> (Ontario), and are permitted clients, as defined in National Instrument 31-103 </font><font style="font-style:italic;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font><font style="letter-spacing:-0.025pt;">. Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Pursuant to section 3A.3 of National Instrument 33-105 </font><font style="font-style:italic;">Underwriting Conflicts</font><font style="letter-spacing:-0.025pt;"> (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Switzerland.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">European Economic Area.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area (each, a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that shares may be offered to the public in that Relevant State at any time:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 the Prospectus Regulation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">provided that no such offer of shares shall require the Issuer or any underwriter to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Issuer that it is a &#8220;qualified investor&#8221; within the meaning of Article&#160;2(e) of the Prospectus Regulation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">United Kingdom.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to any legal entity which is a qualified investor as defined under Article&#160;2 of the UK Prospectus Regulation;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:8.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article&#160;2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">in any other circumstances falling within Section&#160;86 of the Financial Services and Markets Authority, or FSMA,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&#160;85 of the FSMA or supplement a prospectus pursuant to Article&#160;23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">to decide to purchase or subscribe for any shares and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; &#8203;(as defined in the U.K. Prospectus Regulation) (i)&#160;who have professional experience in matters relating to investments falling within Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the &#8220;Order,&#8221; and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article&#160;49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. Any person in the United Kingdom who is not a relevant person must not act on or rely upon this document or any of its contents.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Hong Kong.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.&#160;32) of Hong Kong) (the &#8220;CO&#8221;), or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules made thereunder.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Singapore.</font><font style="letter-spacing:-0.025pt;"> Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:7.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to an institutional investor (as defined in Section&#160;4A of the Securities and Futures Act (Chapter&#160;289) of Singapore, as modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&#160;274 of the SFA;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.31pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:7.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to a relevant person (as defined in Section&#160;275(2) of the SFA) pursuant to Section&#160;275(1) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions specified in Section&#160;275 of the SFA; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">C.</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Where the shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">A.</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">B.</font>
          <br >
        </div>
        <div style=" margin-top:7.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (however described) in that trust shall not be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:58pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">transferred within six&#160;months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&#160;275 of the SFA except:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(i)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(ii)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">where no consideration is or will be given for the transfer;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(iii)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">where the transfer is by operation of law;</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(iv)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">as specified in Section&#160;276(7) of the SFA; or</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">(v)</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">as specified in Regulation&#160;37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations&#160;2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Singapore SFA Product Classification&#8201;&#8212;&#8201;In connection with Section&#160;309B of the SFA and the CMP Regulations&#160;2018, unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&#160;309A(1) of the SFA), that the shares are &#8220;prescribed capital markets products&#8221; &#8203;(as defined in the CMP Regulations&#160;2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Israel.</font><font style="letter-spacing:-0.025pt;">&nbsp;&nbsp;&nbsp;In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&#160;15 of the Israeli Securities Law, 5728-1968, including, inter alia, if: (i)&#160;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#8220;Addressed Investors&#8221;); or (ii)&#160;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, subject to certain conditions (the &#8220;Qualified Investors&#8221;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&#160;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968; (ii)&#160;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 regarding Qualified Investors is applicable to it; (iii)&#160;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&#160;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968: (a)&#160;for its own account; (b)&#160;for investment purposes only; and (c)&#160;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968; and (v)&#160;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:198pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">LEGAL MATTERS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, Reston, Virginia. Certain legal matters in connection with this offering will be passed upon for the underwriters by DLA Piper LLP (US), New York, New York.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">EXPERTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The consolidated financial statements of MaxCyte, Inc. as of and for the&#160;years ended December&#160;31, 2019 and 2020 are included herein and in the registration statement in reliance upon the report of CohnReznick LLP, independent registered public accounting firm included herein and in the registration statement, and upon the authority of said firm as experts in accounting and auditing.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">On the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at www.sec.gov.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We also maintain a website at www.maxcyte.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="TOC3">&#8203;</a><a name="fIFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:331.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MAXCYTE, INC. AND SUBSIDIARY</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:115.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:431pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:24pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.111pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Audited Financial Statements for the Years Ended December&#160;31, 2020 and 2019</font>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR"><font style="letter-spacing:-0.025pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tROIR">F-2</a></font> <a href="#tROIR"></a></td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCBS"><font style="letter-spacing:-0.025pt;">Consolidated Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCBS">F-3</a></font> <a href="#tCBS"></a></td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOO"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOO">F-4</a></font> <a href="#tCSOO"></a></td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOC">F-5</a></font> <a href="#tCSOC"></a></td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC1"><font style="letter-spacing:-0.025pt;">Consolidated Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#tCSOC1">F-6</a></font> <a href="#tCSOC1"></a></td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fNOTS"><font style="letter-spacing:-0.025pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fNOTS">F-7</a></font>
            </td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:97pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:431pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.111pt;">Unaudited Interim Financial Statements as of March&#160;31, 2021 and for the Three Months Ended March&#160;31, 2021 and 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fCCI"><font style="letter-spacing:-0.025pt;">Condensed Consolidated Interim Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fCCI">F-21</a></font> <a href="#fCCI"></a></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fCCSO"><font style="letter-spacing:-0.025pt;">Condensed Consolidated Interim Statements of Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fCCSO">F-22</a></font> <a href="#fCCSO"></a></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fCCSC"><font style="letter-spacing:-0.025pt;">Condensed Consolidated Interim Statements of Changes in Stockholders&#8217; Equity </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fCCSC">F-23</a></font> <a href="#fCCSC"></a></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fCCSE"><font style="letter-spacing:-0.025pt;">Condensed Consolidated Interim Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fCCSE">F-24</a></font> <a href="#fCCSE"></a></td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:431pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#fNOFS"><font style="letter-spacing:-0.025pt;">Notes to Condensed Consolidated Interim Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:-0.025pt;"><a href="#fNOFS">F-25</a></font>
            </td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:94pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Board of Directors and Stockholders</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte, Inc.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Opinion on the Consolidated Financial Statements</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have audited the accompanying consolidated balance sheets of MaxCyte, Inc. and Subsidiary (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, and the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for the&#160;years then ended and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for the&#160;years then ended in conformity with accounting principles generally accepted in the United States of America.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Basis for Opinion</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">/s/ CohnReznick LLP</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">We have served as the Company&#8217;s auditor since 2018.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Tysons, Virginia </font> <br ><font style="letter-spacing:-0.025pt;">April&#160;20, 2021</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:25pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Consolidated Balance Sheets</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:530pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:321.98pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Current assets:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments, at amortized cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">16,007,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,497,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,171,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,701,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">1,003,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">797,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">45,253,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">24,452,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,280,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,728,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,253,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">218,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Liabilities and stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Current liabilities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">890,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,089,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,308,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">3,551,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">572,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">508,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">4,843,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">3,193,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">11,614,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">9,343,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Note payable, net of discount and deferred fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,917,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,895,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,234,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,807,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">788,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">338,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">16,383,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Commitments and contingencies (Note 9)</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:321.98pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Common stock, $0.01 par; 200,000,000 shares authorized, 77,382,473 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and 57,403,583 shares issued and outstanding at December&#160;31, 2020 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and 2019, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:321.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Liabilities and stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">29,985,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:275pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Consolidated Statements of Operations </font>
          <br >
          <font style="letter-spacing:-0.111pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:268pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Revenue</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Costs of goods sold</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">2,767,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">2,499,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Gross profit</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">23,401,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">19,121,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">17,744,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">17,601,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">8,328,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">7,852,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">8,385,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">6,088,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">34,458,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">31,541,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,056,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,420,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Other income (expense):</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(825,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(681,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">65,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">206,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total other income (expense)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(759,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(475,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Basic and diluted net loss per common share</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(0.23<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Weighted average common shares outstanding, basic and diluted</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">69,464,751</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">56,397,524</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:246pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity </font>
          <br >
          <font style="letter-spacing:-0.111pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:141pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:155.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:155.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance January&#160;1, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,332,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">513,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">82,279,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(70,510,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,281,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:155.95pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Issuance of stock in public </font>
                <br >
                <font style="letter-spacing:-0.025pt;">offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,908,319</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">59,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,271,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">12,330,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:155.95pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">162,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">1,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">131,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">132,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:155.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:141pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance January&#160;1, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:150.39pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Issuance of stock in public offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">19,181,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">191,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">28,375,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">28,567,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:150.39pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">797,467</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">393,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">401,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:51pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:150.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">77,382,473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:51pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc.</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Consolidated Statements of Cash Flows </font>
          <br >
          <font style="letter-spacing:-0.111pt;">For the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:587.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from operating activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(11,816,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(12,895,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Depreciation and amortization on property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,047,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">613,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net book value of consigned equipment sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">79,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Loss on disposal of fixed assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">25,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Fair value adjustment of liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">366,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">14,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Bad debt (recovery) expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(117,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">54,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of discounts on short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(3,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(32,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Noncash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">21,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">51,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Changes in operating assets and liabilities: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,810,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,592,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(890,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,890,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(205,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">66,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">525,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">474,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance lease </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">83,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(33,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts payable, accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">391,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,160,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(508,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">68,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,649,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">795,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(58,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(655,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(8,782,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(8,802,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from investing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(22,505,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(7,424,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Maturities of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">8,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">9,149,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(2,072,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,271,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash (used in) provided by investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(16,578,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">454,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from financing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net proceeds from sale of common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">28,567,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">12,330,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Borrowings under notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,440,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">4,953,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(1,440,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(5,105,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceed from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">401,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">132,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on finance leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(63,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">28,904,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">12,310,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,544,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">3,962,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">11,248,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, end of year </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:7.5pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Supplemental cash flow information:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash paid for interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">421,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">669,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Supplemental noncash information:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment purchases included in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">70,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">399,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Issuance of warrant in conjunction with debt transaction </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">60,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">See accompanying notes to the consolidated financial statements.<font style="font-style:normal;letter-spacing:-0.025pt;"> </font><br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="fNOTS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">1.</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Organization and Description of Business</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte, Inc. (the &#8220;Company&#8221; or &#8220;MaxCyte&#8221;) was incorporated as a majority owned subsidiary of EntreMed, Inc. (&#8220;EntreMed&#8221;) on July&#160;31, 1998, under the laws and provisions of the state of Delaware and commenced operations on July&#160;1, 1999. In November&#160;2002, MaxCyte was recapitalized and EntreMed was no longer deemed to control the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte is a global life sciences company focused on advancing the discovery, development and commercialization of next-generation cell therapies. MaxCyte leverages its proprietary cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy, including gene editing and immuno-oncology, as well as in drug discovery and development and biomanufacturing. The Company licenses and sells its instruments and technology and sells its consumables to developers of cell therapies and to pharmaceutical and biotechnology companies for use in drug discovery and development and biomanufacturing. In early 2020, the Company established a wholly owned subsidiary, CARMA Cell Therapies, Inc. (&#8220;CCTI&#8221;), as part of its development of CARMA, MaxCyte&#8217;s proprietary, mRNA-based, clinical-stage, immuno-oncology cell therapy.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The COVID-19 pandemic has disrupted economic markets and the economic impact, duration and spread of related effects is uncertain at this time and difficult to predict. As a result, it is not possible to ascertain the overall future impact of COVID-19 on the Company&#8217;s business and, depending upon the extent and severity of such effects, including, but not limited to potential slowdowns in customer operations, extension of sales cycles, shrinkage in customer capital budgets or delays in customers&#8217; clinical trials, the pandemic could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows. In 2020, the Company made adjustments to its operating, sales and marketing practices to mitigate the effects of COVID-19 restrictions which reduced planned spending, particularly on travel and marketing expenditures. In addition, COVID-19 restrictions may have delayed or slowed the research activities of some existing and prospective customers. It is not possible to quantify the impact of COVID-19 on the Company&#8217;s revenues and expenses in 2020 or its expected impact on future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:8.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Summary of Significant Accounting Policies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Basis of Presentation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Use of Estimates</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, revenue recognition, stock-based compensation, allowance for doubtful accounts, allowance for inventory obsolescence, accruals for contingent liabilities, accruals for clinical trials, deferred taxes and valuation allowance, and the depreciable lives of fixed assets. Actual results could differ from those estimates.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Principles of Consolidation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, CCTI. All significant intercompany balances have been eliminated in consolidation.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Concentration</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, one customer represented 15% of revenue, in part due to certain one-time milestone events. During the year ended December&#160;31, 2019, one customer represented 10% of revenue.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, the Company purchased approximately 47% of its inventory from a single supplier. During the year ended December&#160;31, 2019, the Company purchased approximately 56% of its inventory from a single supplier. At December&#160;31, 2020, amounts payable to three suppliers totaled 62% of total accounts payable. At December&#160;31, 2019, amounts payable to a single supplier totaled 25% of total accounts payable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Foreign Currency</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s functional currency is the US dollar; transactions denominated in foreign currencies are transacted at the exchange rate in effect at the date of each transaction. Differences in exchange rates during the period between the date a transaction denominated in foreign currency is consummated and the date on which it is either settled or at the reporting date are recognized in the consolidated statements of operations as general and administrative expense. The Company recognized an $81,800 foreign currency transaction gain and a $24,700 foreign currency transaction loss for the&#160;years ended December&#160;31, 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Fair Value</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. US GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;1&#8201;&#8212;&#8201;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;2&#8201;&#8212;&#8201;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:-0.025pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:-0.025pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See Note 6 for additional information regarding fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Cash, Cash Equivalents and Short-term Investments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Cash and cash equivalents consist of financial instruments including money market funds and commercial paper with original maturities of less than 90&#160;days. Short-term investments consist of commercial paper with original maturities greater than 90&#160;days and less than one year. All money market funds, and commercial paper are recorded at amortized cost unless they are deemed to be impaired on an other-than-temporary basis, at which time they are recorded at fair value using Level&#160;2 inputs.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s investments at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:102pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.64pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.089pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:1pt;padding-right:1pt;letter-spacing:-0.089pt;">holding gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">holding losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.089pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,996,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,998,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Corporate Debt </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:100.77pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:103.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,233,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,234,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:13pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s investments at December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.64pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.089pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">holding gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.089pt;">holding losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.089pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,037,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,037,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,399,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,399,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,497,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.01pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,498,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:103.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:103.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,934,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.01pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.55pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:40.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,934,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At times the Company&#8217;s cash balances may exceed federally insured limits and cash may also be deposited in foreign bank accounts that are not covered by federal deposit insurance. The Company does not believe that this results in any significant credit risk.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Inventory</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company sells or licenses products to customers. The Company uses the average cost method of accounting for its inventory and adjustments resulting from periodic physical inventory counts are reflected in costs of goods sold in the period of the adjustment. Inventory is carried at the lower of cost or net realizable value. Inventory consisted of the following at:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Raw materials inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;1,771,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;1,318,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Finished goods inventory </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">2,544,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">2,383,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Total Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">3,701,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company determined no allowance for obsolescence was necessary at December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Accounts Receivable</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Accounts receivable are reduced by an allowance for doubtful accounts, if needed. The allowance for doubtful accounts reflects the best estimate of probable losses determined principally on the basis of historical experience and specific allowances for known troubled accounts. All accounts or portions thereof that are deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. The Company determined no allowance was necessary at December&#160;31, 2020. The Company recorded an allowance of $117,200 at December&#160;31, 2019. This amount was subsequently collected and the allowance was reversed in the year ended December&#160;31, 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Property and Equipment</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment are stated at cost. Depreciation is computed using the straight-line method. Office equipment (principally computers) is depreciated over an estimated useful life of three&#160;years. Laboratory equipment is depreciated over an estimated useful life of five&#160;years. Furniture is depreciated over a useful life of seven&#160;years. Leasehold improvements are amortized over the shorter of the estimated lease term or useful life. Instruments represent equipment held at a customer&#8217;s site that is typically leased to customers on a short-term basis and is depreciated over an estimated useful life of five&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment include capitalized costs to develop internal-use software. Applicable costs are capitalized during the development stage of the project and include direct internal costs, third-party costs and allocated interest expenses as appropriate. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment consist of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:114pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Furniture and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;3,492,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:54.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;2,311,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">1,424,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:54.75pt; text-align:right; white-space:nowrap;">1,223,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">641,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:54.75pt; text-align:right; white-space:nowrap;">635,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software under development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:54.75pt; text-align:right; white-space:nowrap;">30,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:55.5pt; text-align:right; white-space:nowrap;">1,963,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:54.75pt; text-align:right; white-space:nowrap;">1,277,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:297.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">(2,975,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:54.75pt; text-align:right; white-space:nowrap;">(2,198,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:297.52pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:55.5pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:54.75pt; text-align:right; white-space:nowrap;">3,280,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the Company transferred $276,600 and $571,000, respectively, of instruments previously classified as inventory to property and equipment leased to customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the Company incurred depreciation and amortization expense of $1,047,700 and $613,500, respectively. Maintenance and repairs are charged to expense as incurred.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In the&#160;years ended December&#160;31, 2020 and 2019, the Company capitalized approximately $16,700 and $13,800 of interest expense related to capitalized software development projects.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Management reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. The Company recognized no impairment in either of the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Revenue Recognition</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i)&#160;identification of contracts with customers, (ii)&#160;identification of distinct performance obligations in the contract, (iii)&#160;determination of contract transaction price, (iv)&#160;allocation of contract transaction price to the performance obligations and (v)&#160;determination of revenue recognition based on timing of satisfaction of the performance obligations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In some arrangements, product and services have been sold together representing distinct performance obligations. In such arrangements the Company allocates the sale price to the various performance obligations in the arrangement on a relative selling price basis. Under this basis, the Company determines the estimated selling price of each performance obligation in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company recognizes revenue upon the satisfaction of its performance obligation (generally upon transfer of control of promised goods or services to its customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Research and Development Costs</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Research and development costs consist of independent proprietary research and development costs and the costs associated with work performed for fees from third parties. Research and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">development costs are expensed as incurred. Research costs performed for fees paid by customers are included in cost of goods sold.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stock-Based Compensation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company grants stock-based awards in exchange for employee, consultant and non-employee director services. The value of the award is recognized as expense on a straight-line basis over the requisite service period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company utilizes the Black-Scholes option pricing model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the expected volatility, expected dividend yield, risk-free rate of interest and the expected life of the award. A discussion of management&#8217;s methodology for developing each of the assumptions used in the Black-Scholes model is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Expected volatility</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not currently have sufficient history with its own common stock to determine its actual volatility. The Company has been able to identify several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated at between 49% and 55% for the year ended December&#160;31, 2020 and between 48% and 50% for the year ended December&#160;31, 2019 using the volatility of these companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Expected dividend yield</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has never declared or paid common stock dividends and has no plans to do so in the foreseeable future. Additionally, the Company&#8217;s long-term debt agreement restricts the payment of cash dividends.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Risk-free interest rate</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This approximates the US Treasury rate for the day of each option grant during the year, having a term that closely resembles the expected term of the option. The risk-free interest rate was between 0.4% and 1.7% for the year ended December&#160;31, 2020 and 1.6% and 2.6% for the year ended December&#160;31, 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Expected term</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:4pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">This is the period that the options granted are expected to remain unexercised. Options granted have a maximum term of ten&#160;years. The Company estimates the expected term of the options to be approximately six&#160;years for options with a standard four-year vesting period, using the simplified method. Over time, management intends to track estimates of the expected term of the option term so that estimates will approximate actual behavior for similar options.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Expected forfeiture rate</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:40pt; margin-top:4pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company records forfeitures as they occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Income Taxes</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more-likely-than-not that all or a portion of the deferred tax asset will not be realized.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Management uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return, as well as guidance on derecognition, classification, interest and penalties and financial statement reporting disclosures. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense. The Company has not identified any uncertain income tax positions that could have a material impact to the consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company is subject to taxation in various jurisdictions in the United States and abroad and remains subject to examination by taxing jurisdictions for 2016 and all subsequent periods. The Company had a Federal Net Operating Loss (&#8220;NOL&#8221;) carry forward of $57.8&#160;million as of December&#160;31, 2020, which was generally available as a deduction against future income for US federal corporate income tax purposes, subject to applicable carryforward limitations. As a result of the March&#160;2016 public offering of common stock and listing on the AIM market of the London Stock Exchange, the Company&#8217;s NOLs are limited on an annual basis, subject to certain carryforward provisions, pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended, as a result of a greater than 50% change in ownership that occurred in the three-year period ending at the time of the AIM listing and public offering. The Company has calculated that for the period ending December&#160;31, 2022, the cumulative limitation amount exceeds the NOLs subject to the limitation. In addition, the Company&#8217;s NOLs may also be limited as a result of ownership changes subsequent to the 2016 AIM listing. The Company has not yet calculated such subsequent limitations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Leases</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. In transactions where the Company is the lessee, at the inception of a contract, the Company determines if the arrangement is, or contains, a lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has made certain accounting policy elections for leases where it is the lessee whereby the Company (i)&#160;does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii)&#160;combines lease and non-lease elements of its operating leases. See Note 9 for additional details over leases where the Company is the lessee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All transactions where the Company is the lessor are short-term (one year or less) and have been classified as operating leases. All leases require upfront payments covering the full period of the lease and thus, there are no future payments expected to be received from existing leases. See Note 3 for details over revenue recognition related to lease agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Loss Per Share</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of Common Stock outstanding during the period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of stock options and stock purchase warrants, which has been excluded from the computation of diluted loss per share, was 12.9&#160;million and 10.4&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Recently Adopted</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">On January&#160;1, 2020, the Company adopted new guidance addressing the accounting for implementation, setup and other upfront costs paid by a customer in a cloud computing or hosting arrangement. The guidance aligns the accounting treatment of these costs incurred in a hosting arrangement treated as a service contract with the requirements for capitalization and amortization costs to develop or obtain internal-use software. The adoption did not have a material effect on the Company&#8217;s consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Unadopted</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In June&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance with respect to measuring credit losses on financial instruments, including trade receivables. The guidance eliminates the probable initial recognition threshold that was previously required prior to recognizing a credit loss on financial instruments. The credit loss estimate can now reflect an entity&#8217;s current estimate of all future expected credit losses. Under the previous guidance, an entity only considered past events and current conditions. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years. Early adoption is permitted for fiscal&#160;years beginning after December&#160;15, 2018, including interim periods within those fiscal&#160;years. The adoption of certain amendments of this guidance must be applied on a modified retrospective basis and the adoption of the remaining amendments must be applied on a prospective basis. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In August&#160;2020, the FASB issued guidance with respect to (i)&#160;accounting for convertible instruments, (ii)&#160;accounting for contracts in an entity&#8217;s own equity as derivatives and (iii)&#160;earnings per share calculations. The guidance attempts to simplify the accounting for convertible instruments by eliminating the requirement to separate embedded conversion options in certain circumstances. The guidance also provides for updated disclosure requirements for convertible instruments. The guidance further updates the criteria for determining whether a contract in an entity&#8217;s own equity can be classified as equity. Lastly, the guidance specifically addresses how to account for the effect of convertible instruments and potential cash settled instruments in calculating diluted earnings per share. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2021, including interim periods within those fiscal&#160;years. Early adoption is permitted for fiscal&#160;years beginning after December&#160;15, 2020, including interim periods within those fiscal&#160;years. The adoption of this guidance may be applied on a modified retrospective basis or a full retrospective basis. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:11.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:11.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Revenue</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is principally from the sale or lease of instruments and processing assemblies, as well as from extended warranties. In some arrangements, product and services have been sold together representing distinct performance obligations. In such arrangements the Company allocates the sale price to the various performance obligations in the arrangement on a relative selling price basis. Under this basis, the Company determines the estimated selling price of each performance obligation in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is recognized at the time control is transferred to the customer and the performance obligation is satisfied. Revenue from the sale of instruments and processing assemblies is generally recognized at the time of shipment to the customer, provided no significant vendor obligations remain and collectability is reasonably assured. Revenue from equipment leases are recognized ratably over the contractual term of the lease agreement and when specific milestones are achieved by a customer. Licensing fee revenue is recognized ratably over the license period. Revenue from fees for research services is recognized when services have been provided.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for the year ended December&#160;31, 2020 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.089pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">14,850,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">14,850,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">601,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">601,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:263.3pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">15,451,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">10,717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">26,168,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for the year ended December&#160;31, 2019 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:268.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.089pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,917,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,917,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">339,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">339,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:268.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">13,257,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">8,363,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">21,620,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Additional disclosures relating to Revenue from Contracts with Customers</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the year ended December&#160;31, 2020 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,452,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included in the beginning</font>
                <br >
                <font style="letter-spacing:-0.025pt;">balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,191,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,752,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">5,014,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the year ended December&#160;31, 2019 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,770,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:403.99pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included in the beginning </font>
                <br >
                <font style="letter-spacing:-0.025pt;">balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,435,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,117,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:403.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,452,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations with a duration greater than one year was approximately $227,500 at December&#160;31, 2020, of which the Company expects to recognize approximately $56,200 in 2021, $56,200 in 2022, $41,900 in 2023, $22,000 in 2024 and $51,200 thereafter.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the&#160;years ended December&#160;31, 2020 and 2019, the Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts or costs to fulfil contracts.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:8.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Debt</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company originally entered into a credit facility with Midcap Financial SBIC, LP (&#8220;MidCap&#8221;) in March&#160;2014. In February&#160;2019, the Company paid off the MidCap credit facility in full in accordance with its terms and conditions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, the Company entered into a new credit facility with MidCap. The credit facility provided for a $5&#160;million term loan maturing on November&#160;1, 2024. The term loan provides for (i)&#160;an interest rate of one-month Libor plus 6.5% with a 1.5% Libor floor, (ii)&#160;monthly interest payments, (iii)&#160;30 monthly principal payments of approximately $166,700 beginning June&#160;2022 and (iv)&#160;a 3% final </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">payment fee. The Company used the proceeds from the credit facility for general operating purposes. The debt is collateralized by substantially all assets of the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In conjunction with the credit facility the Company issued the lender a warrant to purchase 71,168 shares of common stock at a price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance (see Note 5). In connection with the credit facility, the Company also incurred expenses of approximately $47,300. The warrant and expenses resulted in recording a debt discount which is amortized as interest expense over the term of the loan. At December&#160;31, 2020, the term loan had an outstanding principal balance of $5&#160;million and $83,000 of unamortized debt discount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, the Company received a loan from Silicon Valley Bank in the amount of $1,440,000 under the US Small Business Administration&#8217;s Paycheck Protection Program (&#8220;PPP&#8221;). The PPP was established as part of the US Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act and provides for potential forgiveness of the loan upon the Company meeting certain conditions as to the use of the proceeds. The loan provided for interest at 1% and a maturity date of April&#160;2022. In May&#160;2020, subsequent to the Company&#8217;s 2020 equity raise (see Note 5), the Company repaid the loan in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stockholders&#8217; Equity</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In March&#160;2019, the Company completed an equity capital raise issuing approximately 5.9&#160;million shares of Common Stock at a price of &#163;1.70 (or approximately $2.25) per share. The transaction generated gross proceeds of approximately &#163;10&#160;million (or approximately $13.3&#160;million). In conjunction with the transaction, the Company incurred costs of approximately $1.0&#160;million which resulted in the Company receiving net proceeds of approximately $12.3&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In May&#160;2020, the Company completed an equity capital raise issuing 19,181,423 shares of its common stock at a price of &#163;1.31 (or approximately $1.60) per share in an unregistered offering. The transaction generated gross proceeds of approximately &#163;25.1&#160;million (or $30.5&#160;million). In conjunction with the transaction, the Company incurred costs of approximately $1.9&#160;million which resulted in the Company receiving net proceeds of approximately $28.6&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the year ended December&#160;31, 2020, the Company issued 797,467 shares of Common Stock as a result of stock option exercises, receiving gross proceeds of $401,000. During the year ended December&#160;31, 2019, the Company issued 162,500 shares of Common Stock as a result of stock option exercises, receiving gross proceeds of $132,700.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Warrant</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with the November&#160;2019 credit facility the Company issued the lender a warrant to purchase 71,168 shares of Common Stock at an exercise price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. The warrant is classified as a liability as its strike price is in a currency other than the Company&#8217;s functional currency. The warrant is recorded at fair value at the end of each reporting period with changes from the prior balance sheet date recorded on the consolidated statements of operations (see Note 6).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stock Options</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company adopted the MaxCyte, Inc. Long-Term Incentive Plan (the &#8220;Plan&#8221;) in January&#160;2016 to amend and restate the MaxCyte 2000 Long-Term Incentive Plan to provide for the awarding of (i)&#160;stock options, (ii)&#160;restricted stock, (iii)&#160;incentive shares, and (iv)&#160;performance awards to employees, officers, and Directors of the Company and to other individuals as determined by the Board of Directors. Under the Plan, as amended, the maximum number of shares of Common Stock of the Company that the Company may issue is increased by ten&#160;percent (10%) of the shares that are issued and outstanding at the time awards are made under the Plan. On December&#160;10, 2019 and October&#160;27, 2020, the Company&#8217;s Board resolved to increase the number of stock options under the Plan by 3,000,000 and 1,500,000, respectively, to provide sufficient shares to allow competitive equity compensation in its primary markets for staff and consistent with practices of comparable companies.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:35.5pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020 there were 4,175,737 awards available to be issued under the Plan.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has not issued any restricted stock, incentive shares, or performance awards under the Plan. Stock options granted under the Plan may be either incentive stock options as defined by the Internal Revenue Code or non-qualified stock options. The Board of Directors determines who will receive options under the Plan and determines the vesting period. The options can have a maximum term of no more than ten&#160;years. The exercise price of options granted under the Plan is determined by the Board of Directors and must be at least equal to the fair market value of the Common Stock of the Company on the date of grant.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A summary of stock option activity for the&#160;years ended December&#160;31, 2020 and 2019 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:197.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:197.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Exercise Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.089pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contractual Life </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Intrinsic Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at January&#160;1, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,388,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.49</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,354,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,538,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(162,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">217,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(465,215<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">2.48</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,299,285</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.63</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,471,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">3,849,448</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(797,467<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.52</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,198,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(487,036<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">2.59</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,864,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">65,576,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.25pt 0pt; width:197.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercisable at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">7,609,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:46.9pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">5.9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">43,196,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The weighted-average fair value of the options granted during the&#160;years ended December&#160;31, 2020 and 2019 was estimated to be $1.39 and $1.08, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020, total unrecognized compensation expense was $7,130,900, which will be recognized over the next 2.9&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Stock-based compensation expense for the&#160;years ended December&#160;31, 2020 and 2019 was classified as follows on the consolidated statements of operations:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:69pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.98pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,230,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">827,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">484,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">325,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">756,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">598,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.98pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,471,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,752,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:13pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Fair Value</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s consolidated balance sheets include various financial instruments (primarily cash and cash equivalents, short-term investments, accounts receivable and accounts payable) that are carried at cost, which approximates fair value due to the short-term nature of the instruments. Notes payable are reflective of fair value based on market comparable instruments with similar terms. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has an outstanding warrant originally issued in connection with the November&#160;2019 debt financing (see Note 4) that is accounted for as a liability whose fair value is determined using Level&#160;3 inputs. The following table identifies the carrying amounts of this warrant at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.23pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.79pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table identifies the carrying amounts of this warrant at December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:292.35pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:292.35pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:292.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:292.35pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0399999999999991pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the year ended December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:378.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Mark-to-market </font>
                <br >
                <font style="letter-spacing:-0.089pt;">liabilities&#8201;&#8212;&#8201;warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">366,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.07pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.79pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the year ended December&#160;31, 2019:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:78pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:378.25pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Mark-to-market </font>
                <br >
                <font style="letter-spacing:-0.089pt;">liabilities&#8201;&#8212;&#8201;warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Issuance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">60,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">14,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:378.25pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.63pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The gains and losses resulting from the changes in the fair value of the liability classified warrant are classified as other income or expense in the accompanying consolidated statements of operations. The fair value of the Common Stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to such unobservable inputs identified above may change the embedded conversion options&#8217; fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no other financial assets or liabilities measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Money market funds and commercial paper classified as held-to-maturity are measured at fair value on a non-recurring basis when they are deemed to be impaired on an other-than-temporary basis. No such fair value impairment was recognized during the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:16.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized during the&#160;years ended December&#160;31, 2020 or 2019.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">7.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Retirement Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company sponsors a defined-contribution 401(k) retirement plan covering eligible employees. Participating employees may voluntarily contribute up to limits provided by the Internal Revenue Code. The Company matches employee contributions equal to 50% of the salary deferral contributions, with a maximum Company contribution of 3% of the employees&#8217; eligible compensation. In the&#160;years ended December&#160;31, 2020 and 2019, Company matching contributions amounted to $351,500 and $277,700, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">8.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Income Taxes</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company did not recognize a provision (benefit) for income taxes in 2020 or 2019. Based on the Company&#8217;s historical operating performance, the Company has provided a full valuation allowance against its net deferred tax assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Net deferred tax assets as of December&#160;31, 2020 and 2019 are presented in the table below:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:204.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Deferred tax assets:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net operating loss carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">14,998,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">12,842,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">875,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">875,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,662,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,146,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">1,387,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">965,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">566,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">647,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accruals and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">971,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">652,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Deferred tax liabilities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">ROU asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(538,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(630,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(25,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:324.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">19,923,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">16,474,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(19,923,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(16,474,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:324.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Net deferred tax assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $57.8&#160;million as of December&#160;31, 2020 will begin to expire in various&#160;years beginning in 2025. The use of NOL carryforwards is limited on an annual basis under Internal Revenue Code Section&#160;382 when there is a change in ownership (as defined by this code section). Based on changes in Company ownership in the past, the Company believes that the use of its NOL carryforwards generated prior to the date of the change is limited on an annual basis; NOL carryforwards generated subsequent to the date of change in ownership can be used without limitation. The use of the Company&#8217;s NOL carryforwards may be restricted further if there are future changes in Company ownership. Additionally, despite the net operating loss carryforwards, the Company may have a future tax liability due to state tax requirements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:34pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Income tax expense reconciled to the tax computed at statutory rates for the&#160;years ended December&#160;31, 2020 and 2019 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:335.32pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Federal income taxes (benefit) at statutory rates </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,481,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,707,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">State income taxes (benefit), net of Federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(787,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(898,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Windfall tax benefits </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(556,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(40,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Permanent differences, rate changes and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">377,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(29,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,448,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,676,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:335.32pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Total Income Tax Expense</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">9.&nbsp;&nbsp;&nbsp;Commitments and Contingencies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Operating Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From 2009 through September&#160;2019, the Company entered into various new and amended leases for office and laboratory space. A member of the Company&#8217;s Board of Directors is the CEO and Board member of the lessor of certain of these leases for which the rent payments totaled $623,000 and $416,800 in 2020 and 2019, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All the Company&#8217;s long-term office and laboratory leases expire in October&#160;2023 and provide for annual increases to the base rent of between 3% and 5%. The current monthly base lease payment for all office and laboratory leases is approximately $56,100. In addition to base rent, the Company pays a pro-rated share of common area maintenance (&#8220;CAM&#8221;) costs for the entire building, which is adjusted annually based on actual expenses incurred. None of the Company&#8217;s current operating leases contain any renewal provisions.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">All the Company&#8217;s long-term office and laboratory leases are classified as operating leases. The Company used a discount rate of 8% in calculating its lease liability under its operating leases. The September&#160;2019 lease agreements and modifications resulted in the Company establishing approximately $2,209,200 of ROU assets and $2,247,400 of lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $1,728,300 ROU asset, a $572,500 short-term lease liability and $1,234,600 long-term lease liability related to its operating leases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In July&#160;2020, the Company commenced a one-year office lease providing for monthly payments of $2,900. The Company applied the practical expedient and consequently, no ROU asset or lease liability was recognized for this short-term lease.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the weighted average remaining lease term for the Company&#8217;s operating leases was 2.8&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Finance Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In 2020, the Company entered into a three-year laboratory equipment lease that expires in April&#160;2023. The lease provides for monthly payments of approximately $9,200 per month and includes an end of lease bargain purchase option. The lease is classified as a finance lease. The Company used a discount rate of 5.5% in calculating its lease liability under this finance lease resulting in the establishment of approximately a $301,700 ROU asset and offsetting lease liabilities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $218,300 ROU asset, a $100,000 short-term lease liability included in &#8220;Accrued expenses and other&#8221; and $142,200 long-term lease liability included in &#8216;Other liabilities&#8217; related to its finance lease. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:166.5pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">All Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Lease costs for the&#160;years ended December&#160;31, 2020 and 2019 are as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:114pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Finance lease cost </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of ROU asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">83,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest on expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">14,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">551,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">19,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Variable lease cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">289,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">217,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:350.31pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Total lease cost</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,080,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">768,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Maturities of lease liabilities as of December&#160;31, 2020 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315.27pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Operating Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Finance Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">696,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">110,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">110,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">614,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">36,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total lease payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,028,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">258,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Discount factor </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(221,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:315.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.16pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,807,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.88pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">242,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">10.&nbsp;&nbsp;&nbsp;Subsequent Events</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the consolidated financial statements were available to be issued.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In February&#160;2021, the Company completed a private placement offering of 5,740,000 shares of its Common Stock. The shares were sold at a price of &#163;7.00 (or approximately $9.64) per share generating approximately &#163;40.2&#160;million (or approximately $55.3&#160;million) of gross proceeds.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In March&#160;2021, the Company paid off, in full, all amounts due under its $5&#160;million Midcap term loan in accordance with its terms.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the first quarter of 2021, the Company elected to conclude all pre-clinical and clinical activities related to the CARMA platform which were substantially completed by March&#160;2021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:31pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Condensed Consolidated Interim Balance Sheets</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:530pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:316.42pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">(see Note 2) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Current assets:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">78,703,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">16,007,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">4,294,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,171,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">4,463,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">985,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">1,003,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total current assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">88,447,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">45,253,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">4,692,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">1,591,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,728,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">194,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">218,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">83,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total assets</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">95,007,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Liabilities and stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Current liabilities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">417,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">890,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">4,357,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,308,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, current </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">589,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">572,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">6,067,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">4,843,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total current liabilities</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">11,432,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">11,614,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Note payable, net of discount, deferred fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">4,917,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">1,080,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,234,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">1,210,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">788,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total liabilities</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">13,722,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">18,554,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Commitments and contingencies (Note 8)</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Stockholders&#8217; equity</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:316.42pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Common stock, $0.01 par; 200,000,000 shares authorized, 84,689,559 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and 77,382,473 shares issued and outstanding at March&#160;31, 2021 </font>
                <br >
                <font style="letter-spacing:-0.025pt;">and December&#160;31, 2020, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">846,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Additional paid in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">182,766,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">81,285,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:316.42pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total liabilities and stockholders&#8217; equity</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">95,007,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">51,780,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See accompanying notes to unaudited condensed consolidated interim financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:291.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Condensed Consolidated Interim Statements of Operations (Unaudited)</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:269.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330.86pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three&#160;months ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Revenue</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">6,494,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,742,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Costs of good sold</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">693,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">659,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Gross profit</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">5,801,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">5,083,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Operating expenses:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">6,077,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">4,244,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,050,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">3,308,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">1,776,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total operating expenses</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">12,174,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">8,071,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Operating loss</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(6,373,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(2,988,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Other income (expense):</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest and other expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">(742,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(116,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">9,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">42,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Total other income (expense)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(732,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(73,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Net loss</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Basic and diluted net loss per share</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(0.09<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">(0.05<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Weighted average shares outstanding, basic and diluted</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">81,004,081</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See accompanying notes to unaudited condensed consolidated interim financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:306pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Condensed Consolidated Interim Statements of Changes in </font>
          <br >
          <font style="letter-spacing:-0.111pt;">Stockholders&#8217; Equity (Unaudited)</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:99pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:144.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:144.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance at January&#160;1, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">96,433,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">(83,405,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">13,601,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144.28pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">547,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:44.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">547,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:144.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:144.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance at March&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">57,403,583</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">574,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">96,981,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:44.25pt; text-align:right; white-space:nowrap;">(86,467,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">11,087,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:129pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:143.16pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Paid-in </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:143.16pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:143.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance at January&#160;1, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">77,382,473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">773,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">127,673,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">(95,222,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">33,225,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:143.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Issuance of common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">5,740,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">57,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">51,751,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">51,808,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:143.16pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">1,319,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,319,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:143.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">1,567,086</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">15,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:51pt; text-align:right; white-space:nowrap;">2,021,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:48.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:46.5pt; text-align:right; white-space:nowrap;">2,037,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:143.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:51pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:143.16pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.111pt;">Balance at March&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">84,689,559</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">846,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:51pt; text-align:right; white-space:nowrap;">182,766,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:48.75pt; text-align:right; white-space:nowrap;">(102,327,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:46.5pt; text-align:right; white-space:nowrap;">81,285,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See accompanying notes to unaudited condensed consolidated interim financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fCCSE">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:28.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.111pt;">MaxCyte, Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</font><font style="font-weight:normal;text-transform:uppercase;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:570.5pt;margin-top:20pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330.86pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three&#160;months ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from operating activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(7,105,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(3,061,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Adjustments to reconcile net loss to cash used in operating activities: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">315,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">221,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net book value of consigned equipment sold </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Fair value adjustment for liability classified warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">347,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Loss on disposal of fixed assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,319,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">547,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Bad debt recovery </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(20,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of discounts on investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">7,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Non-cash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">5,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Changes in operating assets and liabilities: </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">877,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(697,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(287,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(525,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">17,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">128,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">137,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">128,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Right of use asset&#8201;&#8211;&#8201;finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">23,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">11,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(49,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(140,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Accounts payable, accrued expenses and other </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(1,420,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(2,667,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Operating lease liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(137,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(36,600<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,224,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">376,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">73,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">219,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(4,642,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(5,498,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from investing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(1,001,900<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Maturities of short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">16,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">1,499,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(308,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(706,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash provided by (used in) investing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">15,691,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(208,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Cash flows from financing activities:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(4,922,400<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceeds from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,037,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Principal payments on finance leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(24,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Proceeds, net from issuance of common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">51,808,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">48,899,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Net increase (decrease) in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">59,948,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(5,706,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, beginning of period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">18,755,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">15,210,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash and cash equivalents, end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">78,703,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">9,504,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <font style="letter-spacing:-0.111pt;">Supplemental cash flow information:</font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash paid for interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">416,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">104,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:330.86pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.111pt;">Supplemental disclosure of non-cash investing and financing activities:</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:330.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Property and equipment purchases included in accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">21,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">93,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">See accompanying notes to unaudited condensed consolidated interim financial statements. </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="fNOFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">1.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Organization and Description of Business</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte, Inc. (the &#8220;Company&#8221; or &#8220;MaxCyte&#8221;) was incorporated as a majority owned subsidiary of EntreMed, Inc. (&#8220;EntreMed&#8221;) on 31 July&#160;1998, under the laws and provisions of the state of Delaware and commenced operations on July&#160;1, 1999. In November&#160;2002, MaxCyte was recapitalised and EntreMed was no longer deemed to control the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">MaxCyte is a global life sciences company focused on advancing the discovery, development and commercialization of next-generation cell therapies. MaxCyte leverages its proprietary cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy, including gene editing and immuno-oncology, as well as in drug discovery and development and biomanufacturing. The Company licenses and sells its instruments and technology and sells its consumables to developers of cell therapies and to pharmaceutical and biotechnology companies for use in drug discovery and development and biomanufacturing. In early 2020, the Company established a wholly owned subsidiary, CARMA Cell Therapies, Inc. (&#8220;CCTI&#8221;), as part of its development of CARMA, MaxCyte&#8217;s proprietary, mRNA-based, clinical-stage, immuno-oncology cell therapy. In the first quarter of 2021, the Company elected to conclude all pre-clinical and clinical activities related to the CARMA platform which were substantially completed by March&#160;2021. During the three months ended March 31, 2021, the Company incurred CARMA-related operating expenses of $3.9 million, which consisted of $2.2 million of on-going CARMA expenses primarily for preclinical research and clinical activities as well as $1.7 million of winddown expenses principally consisting of severance, legal and other costs associated with the cessation of CARMA activities.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The COVID-19 pandemic has disrupted economic markets and the economic impact, duration and spread of related effects is uncertain at this time and difficult to predict. As a result, it is not possible to ascertain the overall future impact of COVID-19 on the Company&#8217;s business and, depending upon the extent and severity of such effects, including, but not limited to potential slowdowns in customer operations, extension of sales cycles, shrinkage in customer capital budgets or delays in customers&#8217; clinical trials, the pandemic could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and cash flows. In 2020, the Company made adjustments to its operating, sales and marketing practices to mitigate the effects of COVID-19 restrictions which reduced planned spending, particularly on travel and marketing expenditures. In addition, COVID-19 restrictions may have delayed or slowed the research activities of some existing and prospective customers. It is not possible to quantify the impact of COVID-19 on the Company&#8217;s revenues and expenses in the first quarter of 2021 or its expected impact on future periods.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">2.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Summary of Significant Accounting Policies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Basis of Presentation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The interim condensed consolidated balance sheet as of March&#160;31, 2021, and the interim condensed consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for the three&#160;months ended March&#160;31, 2021 and 2020 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments necessary for the fair presentation of the Company&#8217;s financial position as of March&#160;31, 2021, and the results of its operations and its cash flows for the three&#160;months ended March&#160;31, 2021 and 2020. The results of operations for the three&#160;months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, any other interim periods, or any future year or period. Certain information and footnote disclosure normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Significant Accounting Policies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s significant accounting policies are disclosed in its audited consolidated financial statements for the year ended December&#160;31, 2020 included in this prospectus and have not materially changed during the three&#160;months ended March&#160;31, 2021, except as noted below.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Concentration</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the three&#160;months ended March&#160;31, 2021 and 2020, one customer represented 18% and 22% of revenue, respectively, in part due to a one-time milestone event in 2020. As of March&#160;31, 2021 and 2020, one customer accounted for 16% and 22% of accounts receivable, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">During the three&#160;months ended March&#160;31, 2021, the Company purchased approximately 58% of its inventory from two suppliers. During the three&#160;months ended March&#160;31, 2020, the Company purchased approximately 48% of its inventory from a single supplier. At March&#160;31, 2020, amounts payable to a single supplier totaled 73% of total accounts payable.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Foreign Currency</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s functional currency is the US dollar; transactions denominated in foreign currencies are subject to currency risk. The Company recognized $19,700 and $24,300 foreign currency transaction gains for the three&#160;months ended March&#160;31, 2021 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Cash, Cash Equivalents and Short-term Investments</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s cash equivalents and short-term investments at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:111pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:103.64pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:26pt;padding-right:26pt;letter-spacing:-0.089pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.089pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="letter-spacing:-0.089pt;">holding </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.089pt;">gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="letter-spacing:-0.089pt;">holding </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.089pt;">losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.089pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">8,702,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">6,523,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Commercial Paper </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,996,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">13,998,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Corporate Debt </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:103.64pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term investments </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.27pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.27pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">2,010,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:107.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:103.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,233,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.27pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">1,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.27pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,234,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table summarizes the Company&#8217;s cash equivalents and investments at March&#160;31, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:66pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:124.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.089pt;">Description </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:76.6pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:12pt;padding-right:12pt;letter-spacing:-0.089pt;">Classification </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Amortized </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:20pt;padding-right:20pt;letter-spacing:-0.089pt;">cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="letter-spacing:-0.089pt;">holding </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:16pt;padding-right:16pt;letter-spacing:-0.089pt;">gains </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Gross </font>
                <br >
                <font style="letter-spacing:-0.089pt;">unrecognized </font>
                <br >
                <font style="letter-spacing:-0.089pt;">holding </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:13pt;padding-right:13pt;letter-spacing:-0.089pt;">losses </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:10pt;padding-right:10pt;letter-spacing:-0.089pt;">fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:124.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Money market funds </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:76.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.83pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.83pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:124.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total Investments </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:76.6pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.83pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:41.83pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">31,244,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At times the Company&#8217;s cash balances may exceed federally insured limits and cash may also be deposited in foreign bank accounts that are not covered by federal deposit insurance. The Company does not believe that this results in any significant credit risk. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Inventory</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Inventory is carried at the lower of cost or net realizable value. Inventory consisted of the following at:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:45pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Raw materials inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.69pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,045,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,771,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Finished goods inventory </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.69pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,418,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,544,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 1.75pt 0pt; width:273.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Total Inventory </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.69pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,463,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company determined no allowance for obsolescence was necessary at March&#160;31, 2021 or December&#160;31, 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Accounts Receivable</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Accounts receivable are reduced by an allowance for doubtful accounts, if needed. The Company determined no allowance was necessary at December&#160;31, 2020 and March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Property and Equipment</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment are stated at cost. Depreciation is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated lease term or useful life.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Property and equipment consist of the following:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:93pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Furniture and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">3,549,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">3,492,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Instruments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,574,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,424,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">641,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">641,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software under development </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">229,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Internal-use software </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,987,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">1,963,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:273.28pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">(3,289,800<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,975,700<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 1.75pt 0pt; width:273.28pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.36pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">4,692,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.67pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">4,546,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the&#160;year ended December&#160;31, 2020, the Company transferred $276,600 of instruments previously classified as inventory to property and equipment leased to customers. For the three&#160;months ended March&#160;31, 2021 and 2020, the Company transferred $139,800 and $87,500, respectively, of instruments previously classified as inventory to property and equipment leased to customers.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the three&#160;months ended March&#160;31, 2021 and 2020, the Company incurred depreciation and amortization expense of $315,900 and $221,700, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In the three&#160;months ended March&#160;31, 2020, the Company capitalized approximately $2,500 of interest expense related to capitalized software development projects. No interest expense was capitalized in the three&#160;months ended March&#160;31, 2021.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Deferred Offering Costs</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs (non-current) until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds received as a result of the offering. Should the equity financing to which those costs relate no longer be considered probable of being consummated, all deferred offering costs will be charged to operating expenses in the consolidated statement of operations at such time.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">As of December&#160;31, 2020 and March&#160;31, 2021, $0 and $38,000, respectively, of deferred offering costs are capitalized in other assets.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stock-Based Compensation</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company grants stock-based awards in exchange for employee, consultant and non-employee director services. The value of the award is recognized as expense on a straight-line basis over the requisite service period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing valuation model, based on the following assumptions:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:80.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three&#160;months ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">55&#8201;-&#8201;57<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">49<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Dividend yield </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">0.7&#8201;-&#8201;0.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1.2&#8201;-&#8201;1.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Expected return (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.07pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13.3pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company records forfeitures as they occur.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Income Taxes</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more-likely-than-not that all or a portion of the deferred tax asset will not be realized.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Management uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return, as well as guidance on derecognition, classification, interest and penalties and financial statement reporting disclosures. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense. The Company has not identified any uncertain income tax positions that could have a material impact to the consolidated financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company is subject to taxation in various jurisdictions in the United States and abroad and remains subject to examination by taxing jurisdictions for 2016 and all subsequent periods. The Company had a Federal Net Operating Loss (&#8220;NOL&#8221;) carry forward of $57.8&#160;million as of December&#160;31, 2020, which was generally available as a deduction against future income for US federal corporate income tax purposes, subject to applicable carryforward limitations. As a result of the March&#160;2016 public offering of common stock and listing on the AIM market of the London Stock Exchange, the Company&#8217;s NOLs are limited on an annual basis, subject to certain carryforward provisions, pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended, as a result of a greater than 50% change in ownership that occurred in the three-year period ending at the time of the AIM listing and public offering. The Company has calculated that for the period ending December&#160;31, 2022, the cumulative limitation amount exceeds the NOLs subject to the limitation. In addition, the Company&#8217;s NOLs may also be limited as a result of ownership changes subsequent to the 2016 AIM listing. The Company has not yet calculated such subsequent limitations.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company did not recognize a provision or benefit for income taxes during the three&#160;months ended March&#160;31, 2021 and 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Leases</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In transactions where the Company is the lessee, at the inception of a contract, the Company determines if the arrangement is, or contains, a lease. See Note 8 for additional details over leases where the Company is the lessee.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">All transactions where the Company is the lessor are short-term (one year or less) and have been classified as operating leases. All leases require upfront payments covering the full period of the lease and thus, there are no future payments expected to be received from existing leases. See Note 3 for details over revenue recognition related to lease agreements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Loss Per Share</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of Common Stock outstanding during the period.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of stock options and stock purchase warrants, which has been excluded from the computation of diluted loss per share, was 12.1&#160;million and 12.5&#160;million for the three&#160;months ended March&#160;31, 2021 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Recently Adopted</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In January&#160;1, 2021, the Company adopted new guidance addressing income taxes, which is intended to simplify various aspects related to the accounting for income taxes. The guidance removes certain exceptions to the general principles in ASC 740 </font><font style="font-style:italic;">Income Taxes</font><font style="letter-spacing:-0.025pt;">, and also clarifies and amends existing guidance to improve consistent application. The adoption did not have a material effect on the Company&#8217;s condensed consolidated interim financial statements.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:11.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">3.</font>
          <br >
        </div>
        <div style=" margin-top:11.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Revenue</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is principally from the sale or lease of instruments and processing assemblies, as well as from extended warranties. In some arrangements, product and services have been sold together representing distinct performance obligations. In such arrangements the Company allocates the sale price to the various performance obligations in the arrangement on a relative selling price basis. Under this basis, the Company determines the estimated selling price of each performance obligation in a manner that is consistent with that used to determine the price to sell the deliverable on a standalone basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Revenue is recognized at the time control is transferred to the customer and the performance obligation is satisfied. Revenue from the sale of instruments and processing assemblies is generally recognized at the time of shipment to the customer, provided no significant vendor obligations remain and collectability is reasonably assured. Revenue from equipment leases are recognized ratably over the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">contractual term of the lease agreement and when specific milestones are achieved by a customer. Licensing fee revenue is recognized ratably over the license period. Revenue from fees for research services is recognized when services have been provided. </font>
        </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for the three&#160;months ended March&#160;31, 2021 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:274.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.089pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,075,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">4,075,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,255,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,255,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">163,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">163,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,239,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,255,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">6,494,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Disaggregated revenue for three&#160;months ended March&#160;31, 2020 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:87pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:274.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue from </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contracts with </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Customers </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Revenue </font>
                <br >
                <font style="letter-spacing:-0.089pt;">from Lease </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Elements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Product Sales </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,195,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,195,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Leased Elements </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,426,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,426,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">120,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">120,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:274.52pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,315,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,426,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">5,742,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Additional disclosures relating to Revenue from Contracts with Customers</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the three&#160;months ended March&#160;31, 2021 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:400.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">5,014,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:400.66pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included </font>
                <br >
                <font style="letter-spacing:-0.025pt;">in the beginning balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(2,032,300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:400.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,390,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:400.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Balance at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">6,372,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Changes in deferred revenue for the three&#160;months ended March&#160;31, 2020 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:67.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:388.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">3,452,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:388.66pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.025pt;">Revenue recognized in the current period from amounts included </font>
                <br >
                <font style="letter-spacing:-0.025pt;">in the beginning balance </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:39.75pt; text-align:right; white-space:nowrap;">(1,573,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:388.66pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Current period deferrals, net of amounts recognized in the current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">1,943,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:388.66pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Balance at March&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:39.75pt; text-align:right; white-space:nowrap;">3,823,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations with a duration greater than one year at March&#160;31, 2021 was approximately $379,800, of which the Company expects to recognize approximately $75,000 in one year or less, $75,800 in one to two&#160;years, $60,800 in two to three&#160;years, and $168,200 thereafter.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">For the three&#160;months ended March&#160;31, 2021 and March&#160;31, 2020 and the year ended December&#160;31, 2020, the Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts or costs to fulfill contracts. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:10pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">4.</font>
          <br >
        </div>
        <div style=" margin-top:10pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Debt</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In November&#160;2019, the Company entered into a new credit facility with MidCap Financial SBIC, LP (&#8220;MidCap&#8221;). The credit facility provided for a $5&#160;million term loan maturing on November&#160;1, 2024. The term loan provided for (i)&#160;an interest rate of one-month Libor plus 6.5% with a 1.5% Libor floor, (ii)&#160;monthly interest payments, (iii)&#160;30 monthly principal payments of approximately $166,700 beginning June&#160;2022 and (iv)&#160;a 3% final payment fee. The Company used the proceeds from the credit facility for general operating purposes. The debt was collateralized by substantially all assets of the Company.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In conjunction with the credit facility the Company issued the lender a warrant to purchase 71,168 shares of common stock at a price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance (see Note 5). In connection with the credit facility, the Company also incurred expenses of approximately $47,300. The warrant and expenses resulted in recording a debt discount which is amortized as interest expense over the term of the loan. At December&#160;31, 2020, the term loan had an outstanding principal balance of $5&#160;million and $83,000 of unamortized debt discount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In April&#160;2020, the Company received a loan from Silicon Valley Bank in the amount of $1,440,000 under the US Small Business Administration&#8217;s Paycheck Protection Program (&#8220;PPP&#8221;). The PPP was established as part of the US Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act and provides for potential forgiveness of the loan upon the Company meeting certain conditions as to the use of the proceeds. The loan provided for interest at 1% and a maturity date of April&#160;2022. In May&#160;2020, subsequent to the Company&#8217;s 2020 equity raise (see Note 5), the Company repaid the loan in full.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">In March&#160;2021, subsequent to the Company&#8217;s 2021 equity raise (see Note 5), the Company repaid the MidCap loan in full. The Company incurred fees of approximately $260,000 associated with early repayment of the loan. The unamortized debt discounts and fees were expensed and recorded as interest expense.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">5.</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stockholders&#8217; Equity</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">During the three&#160;months ended March&#160;31, 2021, the Company completed an equity capital raise issuing 5,740,000 shares of its common stock at a price of &#163;7.00 (or approximately $9.64) per share. The transaction generated gross proceeds of approximately &#163;40.2&#160;million (or $55.3&#160;million). In conjunction with the transaction, the Company incurred costs of approximately $3.5&#160;million which resulted in the Company receiving net proceeds of approximately $51.8&#160;million.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Warrant</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">In connection with the November&#160;2019 credit facility the Company issued the lender a warrant to purchase 71,168 shares of Common Stock at an exercise price of &#163;1.09081 per share. The warrant is exercisable at any time through the tenth anniversary of issuance. The warrant is classified as a liability as its strike price is in a currency other than the Company&#8217;s functional currency. The warrant is recorded at fair value at the end of each reporting period with changes from the prior balance sheet date recorded on the consolidated condensed interim statements of operations (see Note 6).</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Stock Options</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company adopted the MaxCyte, Inc. Long-Term Incentive Plan (the &#8220;Plan&#8221;) in January&#160;2016 to amend and restate the MaxCyte 2000 Long-Term Incentive Plan to provide for the awarding of (i)&#160;stock options, (ii)&#160;restricted stock, (iii)&#160;incentive shares, and (iv)&#160;performance awards to employees, officers, and Directors of the Company and to other individuals as determined by the Board of Directors. Under the Plan, as amended, the maximum number of shares of Common Stock of the Company that the Company may issue is increased by ten&#160;percent (10%) of the shares that are issued and outstanding at the time awards are made under the Plan. On December&#160;10, 2019 and October&#160;27, 2020, the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Company&#8217;s Board resolved to increase the number of stock options under the Plan by 3,000,000 and 1,500,000, respectively, to provide sufficient shares to allow competitive equity compensation in its primary markets for staff and consistent with practices of comparable companies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020 and March&#160;31, 2021 there were 4,175,737 and 4,131,667 awards available to be issued under the Plan, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A summary of stock option activity for the three&#160;months ended March&#160;31, 2021 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:128pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:207.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted-Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contractual Life </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Intrinsic </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at January&#160;1, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">12,864,230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">2.11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">65,576,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,046,856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">14.33</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">(1,567,086<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1.29</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">15,046,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(1,272,077<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21.75pt; text-align:right; white-space:nowrap;">2.96</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:42pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,071,923</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:21.75pt; text-align:right; white-space:nowrap;">4.41</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">97,631,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:207.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercisable at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">5,732,382</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.22pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">6.3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:42pt; text-align:right; white-space:nowrap;">58,324,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:11.7pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">A summary of stock option activity for the three&#160;months ended March&#160;31, 2020 is as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:128pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:194.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Options </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Exercise Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Weighted-Average </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Contractual </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Life (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Intrinsic </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at January&#160;1, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">10,299,285</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.63</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">7.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">6,471,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">2,193,449</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.71</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:42pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Forfeited </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:42pt; text-align:right; white-space:nowrap;">(29,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">2.15</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Outstanding at March&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">12,462,950</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.56</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">6.9</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:37.5pt; text-align:right; white-space:nowrap;">6,402,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:194.2pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Exercisable at March&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:42pt; text-align:right; white-space:nowrap;">7,147,842</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.39pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:55.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:12.75pt; text-align:right; white-space:nowrap;">5.5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:37.5pt; text-align:right; white-space:nowrap;">6,320,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The weighted-average fair value of the options granted during the three&#160;months ended March&#160;31, 2021 and March&#160;31, 2020 was estimated to be $7.47 and $0.86.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">At March&#160;31, 2021, total unrecognized compensation expense was $20,457,000 which will be recognized over the next 3.4&#160;years.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">Stock-based compensation expense for the three&#160;months ended March&#160;31, 2021 and 2020 was classified as follows on the consolidated condensed interim statements of operations:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.51pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three&#160;months ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">741,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">254,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Sales and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">269,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">106,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">308,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">187,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:296.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,319,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.9pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">547,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">6.</font>
          <br >
        </div>
        <div style=" margin-top:11.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Fair Value</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company&#8217;s consolidated balance sheets include various financial instruments (primarily cash and cash equivalents, short-term investments, accounts receivable and accounts payable) that are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">carried at cost, which approximates fair value due to the short-term nature of the instruments. Notes payable are reflective of fair value based on market comparable instruments with similar terms. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company has an outstanding warrant originally issued in connection with the November&#160;2019 debt financing (see Note 4) that is accounted for as a liability whose fair value is determined using Level&#160;3 inputs. The following table identifies the carrying amounts of this warrant at December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:281.23pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:281.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.15pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:12.21pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The following table identifies the carrying amounts of this warrant at March&#160;31, 2021:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:243.86pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;1 </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;2 </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Level&#160;3 </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:243.86pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Liabilities </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:243.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Liability classified warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:243.86pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.97pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the year ended December&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:72pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:356.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Mark-to-market </font>
                <br >
                <font style="letter-spacing:-0.089pt;">liabilities &#8212;</font>
                <br >
                <font style="letter-spacing:-0.089pt;">warrant </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:356.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.87pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:356.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.87pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">366,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:356.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.87pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.11pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The following table presents the activity for those items measured at fair value on a recurring basis using Level&#160;3 inputs for the three&#160;months ended March&#160;31, 2021 and March&#160;31, 2020:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:-0.025pt;">Mark-to-market liabilities&#8201;&#8212;&#8201;warrant</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:54pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:328.6pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">March&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:328.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at prior&#160;years ended </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">441,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">74,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:328.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Change in fair value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.02pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">347,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.58pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:328.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Balance at current periods ended </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.02pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">789,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.58pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">74,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.1pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The gains and losses resulting from the changes in the fair value of the liability classified warrant are classified as other income or expense in the accompanying consolidated condensed interim statements of operations. The fair value of the Common Stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to such unobservable inputs identified above may change the embedded conversion options&#8217; fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in these unobservable inputs generally result in decreases in fair value.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no other financial assets or liabilities measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:74pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Money market funds and commercial paper classified as held-to-maturity are measured at fair value on a non-recurring basis when they are deemed to be impaired on an other-than-temporary basis. No such fair value impairment was recognized during the three&#160;months ended March&#160;31, 2021 and 2020.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company measures its long-lived assets, including property and equipment, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized during the three&#160;months ended March&#160;31, 2021 and 2020. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">7.</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Retirement Plan</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company sponsors a defined-contribution 401(k) retirement plan covering eligible employees. Participating employees may voluntarily contribute up to limits provided by the Internal Revenue Code. The Company matches employee contributions equal to 50% of the salary deferral contributions, with a maximum Company contribution of 3% of the employees&#8217; eligible compensation. In the three&#160;months ended March&#160;31, 2021 and March&#160;31, 2020, Company matching contributions amounted to $92,900 and $68,600, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">8.</font>
          <br >
        </div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Commitments and Contingencies</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Operating Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">From 2009 through September&#160;2019, the Company entered into various new and amended leases for office and laboratory space. A member of the Company&#8217;s Board of Directors is the CEO and Board member of the lessor of certain of these leases for which the rent payments totaled $158,700 and $154,800 in the three&#160;months ended March&#160;31, 2021 and 2020, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $1,728,300 ROU asset, a $572,500 short-term lease liability and $1,234,600 long-term lease liability related to its operating leases. At March&#160;31, 2021, the Company had a $1,591,000 ROU asset, a $589,600 short-term lease liability and $1,080,000 long-term lease liability related to its operating leases.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020 and March&#160;31, 2021, the weighted average remaining lease term for our operating leases was 2.8&#160;years and 2.6&#160;years, respectively.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">Finance Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">At December&#160;31, 2020, the Company had a $218,300 ROU asset, a $100,000 short-term lease liability included in &#8220;Accrued expenses and other&#8221; and $142,200 long-term lease liability included in &#8216;Other liabilities&#8217; related to its finance lease. At March&#160;31, 2021, the Company had a $194,500 ROU asset, a $101,400 short-term lease liability included in &#8220;Accrued expenses and other&#8221; and $116,300 long-term lease liability included in &#8216;Other liabilities&#8217; related to its finance lease. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:66pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">MaxCyte. Inc. </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Notes to Consolidated Condensed Interim Financial Statements (Unaudited)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style=" text-decoration:underline #000000 solid;">All Leases</font><font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Lease costs for the three&#160;months ended March&#160;31, 2021 and 2020 are as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:136.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.65pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Three&#160;months ended</font>
                <br >
                <font style="letter-spacing:-0.089pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:358.65pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.089pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:358.65pt;text-align:left;">
              <font style="letter-spacing:-0.025pt;">Finance lease cost </font>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.65pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Amortization of ROU asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">23,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.65pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:-0.025pt;">Interest on expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Operating lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">172,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">168,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:358.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Short-term lease cost </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:358.65pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Variable lease cost </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">75,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">74,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:358.65pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.111pt;">Total lease cost</font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">284,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">257,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:13pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">Maturities of lease liabilities as of March&#160;31, 2021 were as follows:</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:117.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:348.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:1pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Operating </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Leases </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.089pt;">Finance </font>
                <br >
                <font style="letter-spacing:-0.089pt;">Leases </font>
                <br >
                <font style="letter-spacing:-0.089pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Remainder of 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">523,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">83,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">717,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">110,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">614,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">36,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Total lease payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,855,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">230,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Discount factor </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(186,200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(13,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:348.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.025pt;">Present value of lease liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt; width:1pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">1,669,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">217,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:3pt double #000000;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:17pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">9.</font>
          <br >
        </div>
        <div style=" margin-top:17pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:bold;">
          <font style="letter-spacing:-0.111pt;">Subsequent Events</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events were reviewed through the date the consolidated financial statements were available to be issued.</font><font style="font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">On May&#160;27, 2021, the Company entered into an operating lease for up to 67,326 square feet of new office space. The lease for new office space consists of three phases with Phase&#160;1 estimated to commence in September&#160;2021, and the lease of all phases is estimated to expire on June&#160;30, 2035. The Company and the landlord both have a one-time right to terminate phase 3 of the lease associated with 13,543 square feet during a defined time window. The Company will design and construct the leasehold improvements with the approval of the landlord. The landlord will reimburse the Company for costs of property improvements up to amounts specified in the lease. The total incremental non-cancellable lease payments under the new lease agreements are approximately $24.5&#160;million through the lease terms.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:-0.025pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.8pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:69.33pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
            <font style="letter-spacing:-0.155pt;">13,500,000 Shares</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font>
          </div>

        <div style="margin-top:48pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:18pt;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:75.5pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 75.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #63D05A; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:17.3pt; text-align:center; width:456pt;">
          <img src="lg_maxcyte-4c.jpg" alt="[MISSING IMAGE: lg_maxcyte-4c.jpg]" height="45" width="304" >
        </div>
        <div style="margin-top:12.61pt; text-align:justify; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 12.61pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #63D05A; ">&#8203;</div>
        </div>
        <div style="margin-top:46.82pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Joint Book-Running Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-top:50pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:16pt;">
          <tr style="line-height:16pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:16pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">
              <font style="letter-spacing:-0.178pt;">Cowen </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.178pt;">Stifel </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:144pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:-0.178pt;">William Blair</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:67.23pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">Co-Managers<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <table style="width:456pt;margin-top:20.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
          <tr style="line-height:14pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Arial, Helvetica, sans-serif;font-size:14pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.155pt;">BTIG </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.155pt;">Stephens Inc.</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>

          <div style="text-indent:20pt; margin-top:44.81pt; text-align:justify; width:456pt; line-height:11.5pt;font-family:Arial, Helvetica, sans-serif;font-size:10pt;">
            <font style="letter-spacing:-0.025pt;">Through and including August&#160;23, 2021 (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in our initial public offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </font>
          </div>

        <div style="margin-top:69.62pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 69.62pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.81pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.81000000000006pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_maxcyte-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_maxcyte-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ B@.0 P$1  (1 0,1 ?_$ 0,  0 " @(# 0$
M       *"P@) 0<#!08"! $!  (" P$! 0            $" P0&!P@)!0H0
M   % P("!0(+#PT)"@83  $" P0%  8'$0@2"2$3%!4*,5)!47&1H;'1(A9X
M.6&!P3)BTB-3MM87MQ@X&O#A0H*2)'9WEUB8&5FB,T.3)54W5]CQ<K)C-)2T
M166UXH/4-74VL]-D=*35)F8G9X?72&BX23I*FA$  @$" P8"!08+! 8'"0
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M1O@S'UD?DSCOLOG:_M@#Z-3TG&HZN)QWV ^4P '^^]PU.D'5HY[Z*'D'B_;
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M)1\3;-IO7LBJ]2M=!&6D6L--1+5=&&$)=E.M2,R@_:BVXK:,4Z/834Z$B@%
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ML'7YQ_>*\VGWKK_\KZ1<?\LZ9>DFT\,QF8\T)W<'25NWC;L/%-.Y<3:N0Y<
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M\M9;7ZJRG[*=*KGFZSNM8.4N6KC&)V]RY&XEWR;:A]+(0#ZT!-^K7XGG,_\
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MHV5BYI@TE8>282T7(()NF$E&NV[Z/>MEB@9%PT>-5%6[E!4HZE.0QBF >@:
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M>G?P56\$:+KIOV4O*XIFZ)UZ9S*SC]=^[.)S'(F94WV)JWZPYCI,V2 %103
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M*&Z\G2GFCY*=N^8.4N9S*0MY/NI1]B_%<L;CW1S$8KVXO9\2CN1W.27*^_\
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M\!-LY6%VN8?>0UU;C+[; JU%>&4757A\6VS( ) ^&F13L%6Y%"&$T9'$<OC
M8R***\-_A,L(5=7L+>"P;"L[%]E6ECK']M1-G6/8ENQ%IV?:L"U380MNVW ,
M4HN&AHQDB!4F[*/CVY$B% /I2AJ(CTU0SU/L* BM^,(O:0M;E*1L T4X&V2M
MU^&++E2Z:]:PC[:R;DA),!_8Z2E@-C^H72I6TK/"#95N5<U10%KWX3[$<?C7
MDUX>NQJV(WD,[94SIEB<.7Z=R^89#E,.QZZO0 @;X.8F8E*'DX0 ?1JCVFU!
M4BO020WCMNP:N7KM4J#5FW6=.5C:\*3=NF9594V@"/"FF41'U*M;MSNW(VK:
MK.322XMX)"<XVX2N3=(13;?@L65WF>LP3V?LRY)S-<JZJLID6[92XP25.8X1
MT4NKU%N0;<3F,<&=O6ZW:L$ $1$$6Q0$1'4:^OG:O;N4[3[<R7;>225C)Y>-
MNJ^M)*MR;\;EQRG+QDSXC=X]T9SO7NG/]U9^3=_/9F=U)_4@W2U;5=BM6E"W
M'?2*J=1UR XT* YH"5QR$<U2]W82RMA.7=G=(X>NV'GK6ZXYC&8VUDXDZ]<0
MS<IC"'96EU6W(O-= $#R1@\@% /!OWK>VLOI_<V0[FRT>66HY><+M/K7,MR)
M3?B[5RW#T6UXGT9^YOW7F=3[2U+M/-2YEI>9A<M5K[-K-_$ER+P5ZU=GZ;C\
M#??7E(]CB@% * A;^,2Y?8Y6VZXSW_61%+N;TVWN6V,\K"U)UIWN$[VG5EX"
M6<E*0RG!8N1I?0N@@4B$^X.;H3U"4Z,I<2<?%%<!5S6% 6 7@P-["#JU-R6P
M"YI( D(::#<KBA)TY4467B)IM;UCY1@HY-90R:+.)DXR%D4T$BEU6DWJPZB)
MA"CVFQ;E54WD\6H,A^3B $,(CH %,(CY-  !U'7T- H"F8YW&]53?KS+]S&;
MXZ3))8[B+O6Q%AHS985H[\%&*%7%J6W*QAC'4$&M[/6KRXSEXA '$RKPZ%T
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MFJG1[TQD5'YB>F!3>E5H[3'=7L^L@7U8US]I*J(*)K(G%-9(Y%4E"_3)J)F
MZ9RCZ D.4!"A*='4NZ>6_N7@MX.Q?:WN*@7C9V7)&&K+?3R;4X'3C+VBHI*
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M@)-E,P<W$R")7#"4B9:-7<L)&.?-SE41614.DH0P&*80&H,A[J@.!'0!'IZ
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ML$TUX+C4-Y-?^J7P>3Y]<G[7N*WF;K?^S_21QSN.W\3+VU_O/T685]P@/D(
M?M/UA"N:=5 X@\J^!SW"'HD ?VH>Y4]4MWR^<A99\#CN /,+^X"G5HGIGXG
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M,&I3D,4Q1Z0&A*;3JC:CAOGE<VO \0RM_'F^S./<4<V(R81%[R\3E-FS:)E
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MW2K';'=>6U_N?4;&I9#*OGAEXY=PC*ZOV;N.=RXI0@_:Y:+FDHIMQYHN0(4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'7F7/]%F2O]'G
M^C^\_P#2Y_HL_P#5V1_TE?\ U?\ ^>?^SNNH"-2'D_\ ZLWH>3R4(1S_ /Y9
MZ$G?.U_\X/$W_P#'@_\ 6UM^:_\ G!_\E=_Z)O\ YV_:_P#BNLH1O1(?H2*
F4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2113965d2-org_prog4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-org_prog4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ :@', P$1  (1 0,1 ?_$ .   0 !!0$! 0$!
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MX1\/\RD18&P*/96J)!5"V18WV-!O\?$0G:CVBFX799#<D&)_7J\E:%.WHO\
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M_8O,?Z=?+3S9V3#)@1;9CQ0EW?(>260RQP1P^F'9HR3*=*J2RWK7CSXQ>/\
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M (DGY*Y5.;05IM3BE.*5N&^S5OO;]#Y>^/OC[1YW<T^GLOVMDN;99A-8L:%
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M6D2#RSGE2C$D29)B2)!S/<0ISF>XA3%(Y5<\A".5SE7U55YZ4HB1H(T "*
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MM.2^5'E0XSHIC9DFR)((8495<E2\V5CQ78!5DGB1BK.H/U=XX[O8D5[]<WS
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M:5Y30Y)!/<$K%<(CFK\+E1:?+P\3/QVP\Z*.?$<69)%5T8 @C4K J>H!ZCQ
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ML7,P9W14FCG<ZY)7R-$T.1&6D,MG&N% #(LH"=(]!"L,[P.]W*-IVO==GWW
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MJ'4A5K"1_"]KKUK;R'[0_@L!K6CUID2(W\.NR,\7^>]7D?Q]]>Y$9NF9%?\
M\/#_ !*RS.^CSL-N2:,O:\EE^&;E#^Y+5R5WVL_#&JZ?):]OA]OX=VP,U)_C
MW3N=K=^^YC?:S(?YO!_$K'Q]"OTW#PV?+_G^9_+56/\ =I>(G_4.[_[=9A_G
MCG'^OCN5_P!\B_F\/\2N7^XO]-_^R,O^?YG\M48?*_[>.MZ+7^-A\>->W9MC
M9#L+'\=!WY+D%K%!43:^\DV4NP2UGR8%?71/DAD-*(C6A8U?B]>BY_VY[V;[
ME[S.W-LV(;'!A22G[J-"75HPH70H9F;40J#[1/A4"_4/]%_"-IX=@Q]E]ERV
MYMF[UCXRWR<B5%A>.=I7D]61HXXTT*SRL $4'KUL9P^)OB;AOC!AOR</Y:]V
M%>Q@.S3-' [2S"M[2I2TJ%;[T#&X!OZ,?PDDD;[QOB[&"B7N/W'W3G^Z>K+J
MAV6%CZ$%^BCPUO;HTK#Q/@H\J]+EMK?IV^G;C/83C/RV-HR^9Y:+\[FZ;%R.
MOH07\T>-&WV5Z-(P]23KI6/G4_>0]=2(F>^.^TP1GOBVM)FN#V<M&M]L!JR5
M27]#'>_L1ZOEMMK)S45RHB =T1.JJZ7_ *>-P5L/<=K8^99(Y5'O#!E8_BTI
M^6H\^JG:V7-VG>5'D>.:%C[BI1T'X]4EOP'P]O,IS9*M2:V#>#(_&25 V_6^
M0RZJ@FM8N*1,;RC9$O+Y$O#Z-8^7LS"XQC#\?APXN;R$,:L>:+&O:/)!O #Z
M6\XRSV-P/FIY(KXDFP?-,JERZ0B,"1KQ^FKR,28Q]NS&.2$@MZH4B,U)?;T<
M3>/.BY-\FK.L822<R$Q):3U&CB0 2FYC)59HIP0OHE@9 ,TY/D'A#L1T/4V%
MX=K3!LAJ?'Q_M;IR2S3&,0LMHVNI]8O;4$=!9-?-M*_.PW!7V4]C2AE.* ;%
M"[NY9\:#F>WWW7,FR9\=\_\ U=!KD$*SS>;K:RF/TP$7H5LQ-ZOV7D]O]TT[
M+@P8F/E)MG3*=O3B;(;'@\O2]V642DR.+AKJ!IZU$C9&N?'O&=&:_NL;SMMW
MN>-L&YQ/9]) RVMN:>TIZ^XS2.W+<!%6T3SAQ9]=3U?8>T^3.XD]A(P[()BK
M6Y5M^X;]D[U/#D0:-G..KPL4*L&*QG1+=K:[L]PFH64AC&0/4PK=-KXSB<>Q
MI\7)]3?ADM'D*)%9656E'J0A4OZ>E8[&32;N"@E5CZ4QJ;QU\*<TS#*M<ZOS
M'(<VF7Q\(R#66*0;^OM,[M9E5IGS(R'(,0N,FQS7^5Q*F,[+\.P+ZH:K2?#^
M5M1D.L([G I<1FY!S'#Q(MPW*&.%$$BS.5*Q*&R,!%D5'E0L?3DR= ?2VI"%
MUJ TV<P<7X%GYTVU[1/+D22&)X(PZM,Q7%W-WC:1(9 H]2+#]0QZUTR MZ;$
MK!Y<F\=?M]XAL;,];9EM/,\5E8GMG(L?F6H\MKK:5!QS'MT4F%BQ^33$P2![
MEM88+93)Y[$A8S8CX'N/C,:THEYXW(.>9>WP[CB8L,JRXJ,%T%07?':34&]4
M^42!5" '5JL&)(-<,OC';7!W2?:L[,GA>'-="WJ*Q")E)%H*^B/,T+,Y<E=)
M2Y0 %:L/8&O_  4Q+3_D9.UEFTK,,\+C%76Z[!G.34;;Z@R9-L>,]C/K\3Q?
M%ZRZI\@8F(2LV$W(0Y+)"ZLCO ^*AW^ZE;@9_-LK=MO3<H1%@B5C*8T;2R>A
MF %W<JR_>#'/I&$'60P;2+5;MRVWMYA;)NDFTY#3[B856$32)K23YC 8B..-
M75_NCE#UA.P]-2I34=54[*,%\&+K6$7)*K+EQ3,XGC_BLL]+49I+EE9M6NU-
M83"E)C5EA-G-R>WSO>D+Z#;06654+':A67 G2(LD(P]F-F\UAW(X\L7JX9SW
M 9HP/N#.!]L2 (L6,?51M#F62\)TLI)ZLO;NWN1M(RH9_1SQML9*+*3_ *0N
M,Q_5M$QD:;+'HR()(Q#':==2.H76QR1*BNNG;[%'BCA&_/';RQKML4]E;:YV
MIF.NL*LX4"UM,?D37:K:[.!-CV]/,AV(1)9Y?%]Y!O8TK6*-ZO:KFIK;WKY7
MG\?Y+M,VT.J;EB0S2J2JN!Z_W756!7P1K7\#U%C8UMI]/W!MKY9PO?</?XWD
MV;<,C'A=5=HRWRWWXLZ$,/-(M[$7 L;BXK<)#^S)X 0%18VK<E8J?AUV?L%_
M^-D"\C;^O+N.1;YN+_J(?XE2$_TI=E)&U-MV1?\ \7D_RM7"+[1O@R'IV:UR
M).G3IUV/G:_A_+>\[8^_'<J+[&9$/_+P_P 2K'N/T8?3]NO^N[5DM?W9N6/[
MDM73!^U_X<5K/;B:_O6-Z=.CL^S-_I_*^Y5><F[]=S&ZG,A_F\/\2K4/H6^F
MX>&T9?\ /\S^6KW_ .[2\1/^H=W_ -NLP_SQSC_7QW*_[Y%_-X?XE??]Q?Z;
M_P#9&7_/\S^6J&OD3]N*DG;4U'@WC]C<_&*&]K<EL]C99;V=W?5&/5];.H@Q
M)126<PZDLBCF&9$A!>PDLGJY6"&0HI1X3WRRX>.[EN_-)TR,R&2)<:%$CC>1
MF60D (H\H*J7D8$(/"[%5;6/O3]$>UY?<'C?$^S>#-@;1EP94NY9<TL^1#CQ
MQ20*CDRNUY2'<10(RM,W4E8T>1-LVE=*X'H3 ZS , K$AUL-$/8V)T&2WR*W
M(-C)EY>3&,&LNPEJ-$]$:,(VM$)K!,8QNN'*N5;QS'>)-YWF35.W15%PD: ^
M6.->ME%_PL;LQ+$D^BG:WM;Q'M!Q&#AW#H/2P8O-)(UC-DS$ //.X UR/8>P
M*BA8XU6-541FO\/-G?@IE6+Q0K(G6V!;*C5P6L817VBS\I?5(C7L>BJEFP*^
MB([T^%6NZ*G9PK<%VKENW;@YM%%F1%C[DU@/_DW^'ON*I>]7'9.5]I.2<>@7
M7E96S9:1"P-Y?1<Q="#_ ,J$^/N(-B.3^/'/+."+% :3*DF''C1HXWF/(.9[
M1A  (VN(4Q2.1K6M17.<J(B=>>C;NL:EW(5%%R3T  \23[ *_-Y%%+/*L$"L
M\[L%55!+,Q-@J@=22>@ ZD]!6:\:MKK&5QJSL]<93/M==39YJN6TUG2U,>%4
MWC[:\C9! %1&DR)-3/L3H0Z3(R ]T0Y0S"&@7XWF08V:)H(,R!(,Q5#"RNQ9
MTTH8V+@ ,JK9=#:K,4*L=0DK9L_<MD.%G9NSYTN?L\KF)KR0Q*D4QEG6>,0%
MF:)Y'#.)8PFI$G22-!&V10;GS*Q?(G-UO?2:NUA9-]"?52+01:")*LH-Y?VF
M'63:*6"MLZES!'28(3FQ9"!.1KNQK5M#<<VZ$"(YD2SHT>O4%(D(5DC69=8+
M*W5=!(U+J0$7)K,(NX_(\MWRALV4^#/%D^@8FD!@1I$GGEQ)/0=8Y(K*XF52
M(I/3E=3I"FG9EG&8W&$5.)EU9D54+-0VH\9ERGSYSK8LG*,8R.U-C,0M!'G2
M&2S4D3WPB.0"F,IA,&CT'SMV[;-NQ]SDSUSH9&QBOJ :5T 121J)")"HL'?2
M2H:PTL6M>J3D?)N1;CQG'V%]BS,>/<EE&,[%W]4MDXV1*<9# KL',,6M%=H]
M;F1%0,$KV2LSOJ"PN31]5Y'#D[.CV&QV0#9 "TL9$&5<S),]TV)7XK'F.UW8
M/JRBF5TH0B2HHU=\TUBM?SA'MV+E11J^="R817'U",JH8( MBTI'S"Z@4D4D
M*QMH)N*J)^1[KM67DR0[%F1S;VDFXA&G661D:9V?6D>*K_L^0Q,LV/(JM+$I
M;UPI#5Z+/R#RZ3)/<1\%M:RKJ[&+86;FR$.V/+3+L6LZHUG-E8NZM=)K+##9
ME?6OFQC+'%(<!J/2/V/X0\3V]$&.^4CSR(57I:X]*56"@2ZK,LR22!&&HJ&-
MM=QVYO=OD$TS;C#M<\&#!,LDGFU:6^;QI8C([8QC+1R8<L&.9HW]-9&B ;TM
M+7_-V/L.L:.2FE[4M+7V%C2WHJ#*V9%WV<Z1<6\ZDLLAJJFZN\:R26D>06\$
M"5"GD0(U5L,;1-Y:8]GVB<E/VE&,ET5T+Q>GY5"(KK&S(DD8NHA+*Z"YZR$L
M:RS)YER[" F_HW.VVPRR0SB#*&1>1VFE>&3(BBFFQ\A],C9JI+#.P1#IQT"+
M6,\<SW96&X;C^/V>N\RGXO3RIT&RJYTO(*^CLPT,?-,FD1)-6*M0E9(K";9%
M9%/[BHU8L0S$&]GNI>LS:MFW'<9<N'+QDSI%5E91&SJ7,,8(8MY@PQ3&%M^=
M(IN#IK"MGY5S/CG'<3:<W9]QEV3'=TDB=IXX9%@7,R65HA'>-HSNBY#/JZ>G
MCR*$9=8MG:N7YGLR)6.DX;E5;%C2IF101RY4BR8>M7!,&HY5FV$*BJ6/8^'@
M_P!0E6(QM"5THCGHBHKWUNQ;?MVRR.$R('=E$;6 6S>O,X747;VS>FL9-P%
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M4\B0<C6,8U%<YRHB)U7F4R.D2-+(0L:@DD]  .I)/L 'C6&QQR32+#$I:5V
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MR@8)"? !R-+'V +($))\%U5$'?#B;\LX#DQ8REMPPR,F(#Q)B!UJ/:2T3.%
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MRKR9:FYF1(6+Z HXLFOLY%%<1:Z2EEX_PI1?=B2V$#//'[6JUA^?). .N?\
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MA^+P_%4I<>R\G/V/$S,P6R9($9OB2/M?POM?CJX^4=7FG%*<4K"'CGU;J''
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M-%&BQA-8QOY$3^'FG>;FY6X94F;F.TF5*Y9F8W+,QN23[R:WRP,'$VS#BV_
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M^YC9^[Y$N1EM^<[$FWL ]BJ/8HL![ *W[XGPSBO!=H38>(8&+M^TQ]1'#&J
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M9?2=RW4L"(R6)6XKMS-PWZ/:3E+"1FG(>R1H7*Q1,[#4";OZT<86ZJA!E4*
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?.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2113965d1-pht_expert4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_expert4clr.jpg
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M8I*R,W.SE'46,%#PL7*"HN)#-$1TM+5V8/%38R5%PH.C9,-4A,15I:1EQ1(
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M/8NP)3BF)Z)1')7(            \-(JRQ-/KF0)"()P
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M5ZQ1<_"N'$S[:57E3*2%)QIP5ETW/#)":X3$P!BOI>%R'S_85&UE
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M  3%$  ") B  0  !+$CDD               !PHP?TO!9PY;ON:X
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M=                 #B4XDZ3C,D<_UE7M9,9      $8HZ+BLEZ+L.Y:O
M    "6&'NHXC,/+]O-(      #!?1\3G+F^VFD          !A7I.)S1S';3
M5@                !Q*<2=)QF2-!UE7LY,9      $8HZ+B\EZ+KNY:O@
M    "6&'NGXC,/,]O,       8+Z/B<Y\WVT9           85Z3BLT<QVLU
M8                 <2G$G2<9DCG^LJ]K)C(      C%'1<7DO1==W+5\
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MU;>^I:!B9]P.TL%=5O=M;<K8?8DL])F0S?[A-OL*=H/NW3:Y+N/G,;;O$?\
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M'G5 \ZH'G5 \ZH'G5 \ZH'G5 \VJ'G5(\ZH'G5 \ZH'G5 \ZH'G5 \ZH'G5
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M60YC,',IXYI/'-9HYM-'-YPYM8#F]@.;V YM8#FU@.;6 YM8#FU@.;6 YM8
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M#,B;,^'*HQ=Q/9>9;1<\X*<EK G,G"%P!$(U0CY.\IC'@^[!@LT" .0Q5O\
M]T75L,/D]]-F0]=[N;4<-4*$^\SJ09K1 "F@*^2I8Q$< 33 F[YG !#I1K5J
M-&T_L*.]WMB&VD^>$=T_)&9?HWKWF14J59'-PJSY4*!E1?-I<5:.A",B3R2&
MIPGTS?I+/RJL(QJ/S",J;6A*E\\JW-YYK1G>3@W.W&;JF^?V 3105RG'&A;>
M;" F.)EX%9+CF565:C2K+20"K=LTA"7:Y*I&UCV"3YX1W3\D6L(7NM\-"SEV
M?946B+A3E47,<X8,@WT'7ODLQ>-9J3"W# C>7F+'&E0!%K!D*M2/6#@/=5B9
M+>)1-(\*C5.QK.S.5-QE>[7<G-"O+VZS=4WS]J[<V88-G@4,IV'D5@(@5!,A
MB0)KAL&/_E*(Q;#LA"S0PN [B,PX"K/U_ O[MK)\\([I^0Z-B&TH0LFTS*O6
ML,$;#7=Y%DGDL[JMS"25# K=W<05^Z%O<H47-,5ZF68Y2O6.-G%@VT%#L\=F
M*MBK:,;ABIOG[4Y1MN!1R[#AC")%2:,2 V"#_P"2*)Q[!RJWACX$6&HJ/UHJ
M&7:R2?IA%XYL3\A-D?2*S5U:QLAM5 I0O\MH:2\M<,%H81PJ/:K[X\!SFT 9
M<96:O 9FW')W%,DBD,=#NPVP7N=V8VT.<XA&?9LS6FFSB0A&&6O9][(#IY)#
M8TPWDV[7IK8.=!IA9-K G,Q'9.ZF29+99G%H)M 81&A3)S@T7F7]$4;(F(O=
M=PYQPVX1^RM4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4
M'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4
M'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4'6>@M4
M'6>@M4'6>@FS&R P@_2CX J:/D(3).E%2?>*9<R6(N JWD)$MH9=VU#+A)./
MM9TJ<+<B96,6X4Q[;3K3(MR&*<Y];C$[89$!-BR]0K$#&' O=KB(QI,</?7*
MKV7W:]M]5Y+A6#Q9$'R_63B 6F'-B*X4TJ.'9R*7+GDMO5FR#"-0W1"A>Y7$
M.>^8>4X_,P_H>]44YH?>"R]K'&KMEE?Y.[ V%<'?=*+L$%37M&@_09]T;67"
M-?@3L)C_ $/>O9#[W;%V]C_D[L#=QWW2CN[4>R9]QNU8O[OZ'O4?_$/O!4=@
MJ52J52J52J52J52J52J52RJ[>Q_R=L<FD*I5*I5*I-HP.^Z5#:CV;/NC:4IA
MRH[O:]7R.)&-0SYZ!6L'H%:P>@5K!Z!6L'H%:P>@5K!Z!4/>'#^PJ=+E3G3'
M/9"EI&'L E#"H&\MCYKN):RWHOXEK+>B_B6LMZ+^):RWHOXEK+>B_B6LMZ+^
M):RWHOXEK+>B_B6LMZ+^):RWHOXEK+>B_B6LMZ+^):RWHOXE#WIL/,?Q*2V4
MZTYLN%1QNQJQ:LA<N],CYK^):RWHOXEK+>B_B6LMZ+^):RWHOXEK+>B_B0FB
M<'T'R7?1.,*C:6C4A,-X>V98;19.  8EK'V"M8/0*U@] ISY5Y>]S1&!;XDT
M3# 1K1/O'V'+6/L.XEK'V'<2UC[#N):Q]AW$M8^P[B6L?8=Q+6/L.XEK'V'<
M2UC[#N):Q]AW$M8^P[B6L?8=Q+6/L.XEK'V'<2UC[#N):Q]AW$M8^P[B6L?8
M=Q+6/L.XEK'V'<2UC[#N):S]AW$L])G&80<((7*^1I/G<?:,OSCWD=WM!WLG
M_=/:,WV1[9F^T9_E\CR?.\![1E^<>\CN]H.]D_[I[1F^R/;,WVC/\OD>3YW@
M/:,OSCWD=WM!WLG_ '3VC.]D>V9WM&?Y?(U%:E7V].#)8/#O+WD%KI#L(\.U
MH5/88BF"9>'D,9&LT8,JBZ!:<. [^UH5/8:X(SIL)<LL<!:HC$0H0M\PX<>X
MN3M:=I';/]ZFM8Z;+@&X6^=B0$PV@10X<T[FUAVE9;3%/N;YS/>7N&X,A-2=
M)G8.[E[5K4#%0B8JP28E<YRY[ESW+GN6D<M(Y:1RTCUSW*FVO*X56[A42749
M5:@XW>R(6:4]M[C[N:E %Z\M>6JWKU#B'Y5ZYO)QC:6F"$G&52]Q*I+E6[A4
M.5PJMX5A]%V#193V7B/N^#Q*MW"JW<*\KA7E\*_;O-O*K$X;3/ 69>6A<MS[
M:A%Z\KA5;N%0=:(W4^V>0'&SB@G"]VLT)G)4>7!>6JWJMZ_;O-K*LW/!!VF<
M?R9.54ET5Y:\M4VE:Y5&5.,T/)+C3C367VT($D#%%5GA7E*$7*MR_:.Y659J
M>TAVUI7E*#8K,\JTO*5;E6Y>4JWKRUY2CRT72"[.P,.!&1,:[.6E)]\M9]K%
MY:\I>4JWJ-UY60JP\0([/ JTK8"#G'UG8J*ER9,US<<!#[R<"UW)$3P;JYC@
M?GE7*:2,BM$4;%-:C@V<S-YCDZ3,YP.PV2='64 RAHV6EX<2XP$$94'B;",#
MBX5:=S53 RX1I"Y(H55*JVAD3-[(C*=6-CEZ-@B51@V*$V(+BYT !7'N+ERY
MC("-('&@QLM]HMC@JX5%P:=U0P9%1':EAY^#=5DU[&=F",IFPZ4V7,>YL*@(
M4[Z, [$8X%A52C!1P(F74"1P*I1(-F"$V74@]E4=@T>O%15G:5[&<P+.LI=L
MQV@8Z5-+G& H'&LT06S+,:52MQ1-:R[2!7O0'K6=T1[0LK,.PE1L]C@;R6NM
MGD\F%>YX5>9KQRK (.\IS1$2X2XPQ85^S^FRJJOOISWNEB\9RCG6LD%>)[QZ
MUKJ#BH">;[&U9%G'_;EBA=)<;$^R=X<_P<*A@V(*8]G-&Q9PEIVD@2S9-OP%
M/GYQQGV(1@*&Q$8(R[G2PR3:A\ZU*8\R_=\Q&!C"U$QYJDLG\J5R^"%&5"7/
M/[(3Y@R?5WDV]R*9+7$;H.+P)KC6[E<-.S16GN;S"=B;+\HM'<41@V*5(Y>;
M:+PTQ_M=C4QF?SHL&CD\-2M!H#O<R=]#W_FYAMGPPRIUJR")8LVXQJP ?.*9
M[^6PS#"(QKA3!-$J/[A@93@- CP%!HJALQ-2+ACV)DK#'8G9MYEF#,6+*K'E
MY[UI._B\FJI3+)9F;3>;:AO>%3?<C^WL".*U:XE8G0%WS5$:HQ,=^"EF\ZD+
M5F-63N5)DVU^V$^;3DP+.1_:&?3N0'<4KW0P9G=ZK!' I1D:Y;IQPB8QR*5>
MA4U[AO$E!KM+6=THS'&@!.?EVD<*AY2S;PK4ML#M[L99JFT[D"CG&QA=N[:*
MD">6YG->5&%K>PJ[RW\N5&9P401<+ FMG9;4 >X%>+9'O0/)QQA1#?7N\:;R
M&[QHM=Q0&Q2IEK)WQVA ")5L\[LU*JHV80I0O+J7 &'U8U\.R95UY5Y[WC4<
M.'8$YG."$8-O&+9*HKV,BIQ*&!!L3FXU8]F.!9BZ&+S65'#L"=+YP0LD"<:Q
ML\I<G%L;ZIV!.?39J&S:-#4;M<S&-943L9^733WU&4>5"I4*E6#$"(/ 8J&!
M%4U[%5.Q0FAW,C$A%SS +W2ZTRS65EVL .2HM[!2LL5#R=EQ!/+,:5GG&,!1
MDV;<XV6(2I=%V!^9[+6JU6HKG%<XKG%4/*YY6E*IG%:5RTKEI7+2N6E<M*]:
M9ZTSUIGK3/6F>M,]:9ZHG.4)KW.WU31LP46&"@V;,ANE:9ZTSEIGK3/6F>M,
M]:9ZTSUIGK3/4)CW.;E.U]76H9Y_=6F>M,]:9ZTSUIGK3/6F>M,]:9ZTSUZ]
M[G#=VL99@H9UZTSUIGK3/6F>M,]:9ZTSUIGK3/6F>O6/+MU4U[2M5J@KG%<\
MK2%:5RHFN6E=W5IG+3/6F>M,]:9ZTSUIGK3/6F>M,]:9ZM3G%W:^!40[-3MO
M*[+A_H/_V@ ( 0,"!C\"_P#4#;GO#&Y3!0G38GZL3WE!CWC=:Z'>7[::QYR'
M:>LF-M!4%W 59SME^(T=]1:8C^J+$GUE]/D1JRFOO84YWK'[@]6,E')\*$OX
M@7,8'0,8Q&]0L[=+WR'4\VCAM^!9^33+;A8:=VR, K.2M-NOQ?<$W!N.H@#O
MKWJ8X"[PC%>[7%KVW<U0YS^Y'@)6==&4T_3C'@*-ZOM[:T-P6;/^=*S<L&;>
M#5N=W*K,ZT)<:BO5$9P5C"H=N.FC $R]2Y\MK'B,,W'NQ"UF5U7C6LRNJ\:U
MF5U7I+6975>-:S*ZOQK6975^-:S*ZKQK6975>-:S*ZKQK6975^-:S)ZKTEK,
MGJO26LRNJ]):S*ZKTEK,KJ_&M9E=7XUK,KJO&M9E=7XUK,KJO&M9E=5Z2UF5
MU7C6LRNK\:UF5U7C6LRNJ\:UF5U?C6LRNJ\:UF5U7C6LRNJ\:UF5U7C6LRNJ
M\:=>9D^6YK!'F0XT"^N'R/!/O<RL<T8SB3IMX+FR:W&O%1@K0NUT ;*'=1^)
MW/66MI$.=7W:5_K;Z?41@"?)5--I'XA<*A$O;@QQ'=3/AC@2P.Y(CAC\Z$V\
MWGEWS<H;N(S)ILM;6O=PPN8.9@WX!>MIO)P^!9J9O%0;Y)X4V>SFD=IP[#,\
MU2/,VT%#9,<&QO-/"C]78)Q!1[%':WAP_P#$[O)OFCY(;\.8>2P<H93""9+.
MG=2X[M7 -B#JE_M?AH@VM[1&N-?S@O\ 77_3 <C* $/AWPT\F)$VK<AA^MB0
M^(WIO*/,&+*HBM"[W6FZ!U.6CO+WR\#UYJR!6G5; O3<!IWT^[_0/?CQ=N3/
M-4CV>V!R;)3X?.E'S5_:Q/1^>!'<[ .P7GV3N\F^:.]\D3[53G2_N,31D&R6
M&HHL^'N,*2\8E_LKV/V]%D'#73WL*@O]=<*9_EG)B'"GWB<8SFU#P[29%3=[
MP]N3/-5W]GV&EJLXUR><@XXT_,U-F.:8XP5R30K4:TR4]WK)A@-U4]FO/LG=
MY-\T=[Y(=..CFM;#^UK0F7B[F,HCO4;)E2S&^/%$,&ZC>[Q'W8NM.CY3N=1O
MIK&"%D03KC=G?NGMI/T8^%>\SP6W?&:R8E!PJP'&LZS281LV/+>0ITWR8C_+
MM*'8IGFJ1[/L#YK@70ANJ8R[L9+=-D6O5QAAKCA4DR)TP_$#*=$#'8-=&# F
M3I$?]I!UJ%9="FUOJ7/D61>S/?G"2ZT1:JJ18#ZIU\=:K%;AW%-N]K]J;RT,
MA&B-J,#BBI5QNL!9EN=RHX71WS2KBZ83 Q#L@B3\\B+00+T)^$F/!B0[+>?9
M.[R;YH[WR1GY(C>91BO]7?#"0_FG$Z*BU&=,/[CR0G3KQHRZTXXL,*>!-N\D
M0E,$!O+_ /9=& \*%X?RG/F1[M(3#=*)8$"W%@\"S$[G8#B5KA&""$Z33**,
MU_,"A)I H;OUH2<-9W37VY,\U2/9]@+'\U<D"/@462V@HNE, >:UG QN>4',
M"L-:+ 0+VB(1%@0!6>L#.%4=EO/LG=Y-\T=[Y(A@1O\ \+;&7A;17C7NWQ&6
MZ:UM ,8.'#6K=[F!@<8#(*U8ESI8PN.%QQF",KX<+<W'2!P$+WB\N?FHUG #
M@I0N4@!DU@-EPQGC-:LN%@1I^BX98<:A>_5/WW \ 6=SS!.:*#5O4JQ(;:NF
M%OA6;9%DKZ(PH7J\@9\U45=NS/-4CV?9([%.-?/&GC!%$"J.P/9=VE#9)R)H
MP0V]Y]D[O)OFCO?(<3MH&E6ILN$W&VCA7[><PC*WPQ0;-=(:!B%/"A,O%J9.
M&7D\!6;DM#6C%L9J]RVN9E5OX?,,K(>4.^%9Y!RKULT!N0+U;1;QFOMF"AM)
MAR*0/J=FWU\\:)QHG8C]2"&R0@5#;7AC><93N\FMPV1WOD*9>X1L-C!%U^F3
M'WB92>60!N-CR5,^#3(O;+E-<TFNR:*3A-%:CVK*^#2W6!,87N=4;+39@,L7
M=Q&?<WSFWAHB/6.AN$1I4J^N%ESV"C>CMHIOQ.^/F9J:WDL:XM $<,*TSX=:
M?,NTYI+;3BXAPKI." VA^'ASF7=@!=9=9<8U#<3[]=73"9;;3@YQ=%HKKPIK
MX<YL=I,FWA\UDIDU[6ACRWFN+:8;E2ER);G/NLSZ;HD<.R9,810E2;\&2A4,
MW&&_G OY$=5^JOY$=5^HOY$=5^HOY$=5^HOY$=5^JOY$=5^JOY$=5^JOY$=5
M^JOY$=5^JOY$=5^HOY$=5^JOY$=5^JOY$=5^JOY$=5^HOY$=5^JOY$=5^JOY
M$=5^JOY$=5^JOY$=5^JOY$=5^JOY$=5^HOY$=5^JOY$=5^JOY$=5^JOY$=5^
MJOY$=5^HOY$=5^JOY$=5^JOY$=5^HOY$=5^HG2YU\SEH?0A_F4*(F'R$Z7-T
M9K3+G1/SSH,<8Q%$>56C>I[LY?9@%IT(4?1 I@!VLV?)=F[Y*YI\!R'P)]WF
M"3*8V9!Q#B21# +(A6FRAS6" V_[<,F7"- <2+$3C@8A?['XB6B8V+6 $D-!
MW81-=.T9??ASFB>*'!U3VXLAQ%&5>PR5=&F#@"76\8C!M" %0V8*=.NP$VY6
MR^Q2""XQ,#3&)P8$+]\1LL:P<AC8G?)HC@_H:"^'D5^\._ZSVQ?"R-K/TTX;
M+/!V"9;%H<G[P0!VG*3S_P#+,^^=K,$15AW4SS1_0_P[V[O^L]L?$/\ [A_Z
MY?8'[K?O#;.]O,^^[:S?-3?-']#_  [_ .P[_K/;%^IKO)/V&#P=@F$8V??;
MMG>VF??=M9H;7!-\T=KT?([KS796ICK&<:U,=8SC6ICK&<:U,=8SC6ICK&<:
MU,=8SC6ICK&<:U,=8SC5WFWJ[YIDIQ//::VD=@,\U!6FW-Q'GL_$M2=TY?XE
MJ;NG+_$M3=TY?XEJ;NG+_$M3?TY?XEJ;NG+_ !+4W=.7^):F[IR_Q+4W=.7^
M):F[IR_Q+4G=.7^):D[IR_Q+4G].7^)%WN3[7M)?XE.F7B695N;&$0< Q15M
MK+=.,#OKD7)\//9^):F[IR_Q+4W].7^):F_IR_Q+4G].7^):D_IR_P 2==_=
M2REM;V'RAB<HNVA&%&5+NH<RVXQMM%;B<:U,=8SC6ICK&<:U,=8SC367BZ6&
MN,(VVGPIS)<;9&" [Z+6W2T /_(SC6I?F,XUJ7YC.-:E^8SC6I?F,XUJ7YK.
M-:E^8SC6I?F,XUJ7YC.-:E^8SC6I?F,XUJ7YC.-:E^8SC6I?F,XUJ7YC.-:E
M^8SC6I?F,XUJ7YC.-:E^8SC6I?F,XUJ7YC.-:E^8SC6I?F,XT+M>+MF@17;:
M[O'Y'G^:.^$.T)^X/O!#<[0'MI?_ &-[1NWMAVS=_93/!\CS_-'?"':$_<'W
M@AN=H#VTO_L;VC=O;#MF[^RF>#Y'G^:.^$.T)^X/O!#<[0'MI?\ V-[1NWMA
MVS=O8S/!\C95-^&7*6^=-<VDCFBD&M>YS&OEWQC:0[OC&LD>S4T*;<9(?-OK
MF@@,!=1:%<$1+B)K*"TT'@46U;2CL5*%TN\9MX#VEU@6[,#&#H5&C#2O4Z05
MMPC(X8"HX=IAVM.V:+G*=,ER)L2ZIKH?0/E]Y6Y<6O%;'4/;NCO8^ULJ,R<0
M&A,^(2[I.==90>(^4X'RFMPMHC'"*D)\FH\(.(XB,([2HV:E$"A6R 6K/ "S
M!:-JHEM6C:M$SA*T+.$K1,X2H9IG=4<TSA5#&!$ RP1@W5$681A4@X68$PJ0
M8UK::S"H<:,FT,\'DNC72I#[H?W#(VH4T0-!WT2YLMK0K0L0W%Y' O(.\OW$
MMIE9*UZ@^LPM-8VF;>;5XA0!X<2H8P=U1Y WD! &/U5GA9+3DQ&"+ &&99B*
M*%G)1M7DGUA-<:^)2IUR/[JF.&CZRYK;,, 0Y-?U5Y/ O(X%"]RF9K)6K=V=
M$XL.TS#3;GY,&ZO5LEV$7N#*,B+H" 'T5:L880LT[NXGN;9$**1#YUJ6Z[D.
M? 6CA+L-I#_6YOWHR_61W:-^M691EE^%5RZ,B\@JIBMWJ6,S]6O@7O%U=:8H
M[)DR(S)XQ5#=*/(:!%$^KH5<O@5IE@MW$6X_JIDN66"PP"&)/?\ #(%Q: XP
MB#!'D5?50C9!.16R&PABQ(DAE C4H7Z7R,;/"A/NKP]F3:P:%'DKE +WB$NP
MJ&L53(JIB@+/ H$,X%Y 5KDPW%18+]Q!E_;+%WM#FQJ!BA>9<Q@E61B5X-QL
M^Z.F1'A5OD0W%Y' O(X%0UBA?19II(J&ZA-E$%A[/&A6 &<)4'0@4X ?MC';
MY5#8M/TCO!_RHB\2F82VF--/T?"I?+ M3"*:^<<A[]2B9S,WO_A5B[S98?E)
M'@7NS'^LQIK0^VZ/*BAFH6$&.K*@-CWN[QSDM,ODKF/&P^=Y9H&Z4[/Q+R8Q
MQ[$'5Q4UEWL 26QBZ,.Y%-O(?(-VC8Y)=SC%V%N0H0LNF8ACWX*VT.$\FR8&
MK@.19N8\CNE#UALJ&<,6[BH=:RHD5J#JU_L)42,(QH36<UXCL RM-,,!X5"O
M.5E00:^IQAPJ8V5,DL8R07DO) @+(P-=33N0PH7ADV3/<YX%F63BKI:VB-&Z
MG3YTY@DLG4FFN%0Y*+?6-:,+</=%:M-Y!/TJ]W"B9I9#YY%NT*TS8LA2WLT5
MKE^;_P P5MO-.P+O*,+Q.JW,*(922F/F3Y$N4^)@2ZUR:_)AW4RS$QY5H4M^
M>\N29=GYY%#.0W%8SIBK#M/8M?/@4LS767%C7;SA$*%NDIWK@7@CYU)]WF.!
M<(4;H!\*=+FUV*>X40VI9QKS[J3RAW$"*CM*FG=)7D0W2LP^F8LQ.H:J5%4;
M3.RY\ILIDJTYI)C7#Z)[ZS[N5(SUBC'9!R8T^;20,"!+B,XO=Y/*8RN/SR*(
M S7=7GU=Y48-@O95A"]S)C=IM60PCX.ST(.;SD)[# #C5FV8;W8G&-33WDXL
MN0<SW9G+Y=)L#ZW@5SN[#"4)\",E9"NQ?9,XS9E>%W*A%,/Q00'K!3SN9DP*
M7(N[9K[@64V+&;-%,;7*\*NEQDGU$Q@BW :3&*;*^&M;9$UXF8J#1:R07O\
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MJ^3*\F3LM2J52@JES0N8%3+!6A:J9#%$7=D5H&+0,6@:M"U:%G M#+X%H)?
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MFTZ2"E5WA[4 1':M<L=6+KC -%\-:9Z."P\BUJJ(YJT(J;##&_BENI;2(,R
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MA$ Z*]*?WJ.1WGQV(%$;JG?9XB2M!-=9C,2-V??-[YH7-!?;!JIC@G]&W?\
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M;'E*7X,?6QY2E^#'UL>4I?@QQY2E^#'!0YUQE%%D"K;XJ ])LLB3DPT-$J
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MM#;&.Z)"K3VA:*IEG1<\L=$;?I7EZOR]OI8_[?\ F_\ .Q_8/S?V<9I;U_\
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MEF0K3)?=47EHN65<=+_=]9.Q7#$UHB&.3C8SFDV.L$: 2Z=BDTA5'FP#@EJ
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MZ[_^ LZRO95'TJVO"&\JM-=-7>]1!7UN8U3JZX"U@I!(""6*Y$^"SJ>\06[
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M+*NQ;=YIB-#P>J;94Q*I47+S58W\^$)1;0,-MQ34.5*1SQ@=@+44LV":3+J
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MV/0]Q1;->3U$\SW3S/9GF>S&AWKJB_  >6Y$N#-C,L=RAMX RP (\*[1:SB
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MVOZ9G^K/F5-.V9-VS=^W;MF[=\[;MFM#IKO??$Z4)2^NV'VF1/9[7_Q?I/\
MA,;MQ1H^!0_T/FW23G_9S\O-]_\ B_2?\)C\N"-'P*'^A\VZ2<_[,OEYOO\
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MD$(72<E$.5(,K66]!_4$MZR*HS@K$R<P:U_&BXVE2L%;CE4 2F5<AQ$,3*F
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M1QKI*J&V]298BE6],YIUQ&DJ)4(()!2PAAD+&!;\C"E.3W@E"F*5)0)3TJ"
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M.=UXE:F[.W,5-H- I!)>8Q4ZME@MN#GP$_T$_P!5/]1/]1/]1/\ 53_4>!2
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M-C9]@_\ ACPF\?\  !X#?I_BO?/=Y\_Z1W_W=N)B8E2I4J5!+1EB5<QS1?\
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M?!]87W_SYF9F9F9F9F9S#/Y'^'__V@ , P$  A$#$0  $
M                       "(;(
M                     R&O
M)*0+=P            /  (                              !)9) %H,
M-18KA(!"  4) *=\ SS))))(!))))))))(B               #=%X+[*/&W
MP(@.EZ(\P:)S6;DW9"89)FA;K/1]!)-8P              #Z X?(G*W#O\
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MPVVTTDDVWVR                !#         2"F8 !"X#P 4W@
M                         &P              "X $@ %D
M                  ;/220Y@ #FI==__P A0 GZYJ F).X+:W:639;9*2]
M                 J7M!BO  &?>22<.[<GN&;2(%$P[&D(! 0!-TD$Q8
M              &N@      /       'G       #@           Y
M            UD      !A       ^H       ;           $(
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M]Z'1\[')$3XW!AVY4PQV4_,=;.'I P&=-O5-<9]Z   #J4PO?7@BF[07)F#
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M!EU_&%HCGB/8%*ARL)P=U C4218QO:V*VE-2'%6#-]7-&"/%V>Q[_P# Z)A
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M)# -T%!OAO*JE@HE8SI9KH0:]+B#LUD\Y6*QZ)Z@@P(!4=07W<S^<_4^1/Q
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MQBD,!5)4?$4I%!Z])- 5@'0N7Y5%2414=A@-LO:KMJRXE%*=;F:U".HVU93
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M58>0065P=^_Q\3?N7\S=\W[_ /LR\SZ"1F[#]:_,U^OW):W=4/T#'O#(BJP
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M*VHKM0P"+<:**NCJF6+L0(ONX[DTJ?1CX1:M*C;+HICDJ@S-KCH<*AH78CF
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ML+!*(@*(U+ 52VKTH4A>)3=(B;'(]ZEB]:YM/F6+MU !FK0JT4;1H! &")#
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M<?-7K>)\V)\V)\^)\^/"?/B?/B=WE[H\G#V_:>]3M#GQ#,Z]7D\LZ_P?_]H
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M_=_:?W?VG]W]I_=_:?W_ -I_?_:?W?VG]_\ :?W_ -I_?_:?V_VG]_\ :.*
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M!'+:<::(12M SL0(NG+Z)4DO!E( Q#? #T@4RYC0NR=PA?1KL&GZ322]\_\
MOW^#N_6=P]YW#PG=!?6H/KW#]RGD:><":4J/$/I"S"S/65U3"RLK4PI2 JUH
MT=SF"U3"W>#I'5=H)L R@6F,^2A1B1!LQNNJ=R/"SJ#W_P#(98*]'WE4Y?X&
MX/8ATY2=)2;*&0S0=!8/E/)7-]5U[9E8W>@L5?5C#N2#:BVAR/E%N?Y(X9UQ
M^XU]WD?N4=W?)S$/R7O#,^2]X;L_)S/F ^L_#6?E@IM+X#'$P3?0^HOI&RL
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M_2)(9E3T-=)96J[TW576^W2*>3;DL5YJFKRI,:80XX#5H8X069MZJYAL1%(
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M_*VF6 J<Z'VZ39&)>#9YY'..>\H]"HBAVEF%NC[STT-1#3*2U-76TR*.!?)
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M0;C'G&JNA4W?7%PU/=_6 ,Q7RSZ3^_(6OK_I%_F/IX =.!U8'SA^)U?D.WB
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M[$L:37G_ ,)0).6D/<3Z3'H7["VNFPS=(&:(MIM16L&NU<?Z853\_/SJ(6_
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MS]E/V4_92]O/V\_:SWNTZ3JPW&!ET=I<U6&TLL1)OCI_Q?HO#W\NZ(:_S.O
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M)E-B=JF>C/1E])' M=*]?I AP@CHA-9@TN4"SQK"]+HM2FQ)YW#B Q63Z?\
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MK>2N;J)]7:$-5F=:;0O1CUU^V/SO(8#$FGE&:3@!O3L41""Q$JW^5I38<C)
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MAL/@ A=+.SA43WDV8"+4=07>;RIOO_.FQPN37/$ C(Q  $F"II2VX[H;26(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2113965d2-pht_scale4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_scale4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ]@.6 P$1  (1 0,1 ?_$ 0\  0  !@,! 0
M       "!@<("0H#! 4!"P$!  (" P$! 0            $" P0%!@<("0H0
M   % P("! 4*"!,0#@@& P$" P0%  8'$0@A$C$3% E!4=*4%6%Q(C)4U!96
MUAB!P2.5EA<9"O"1H;'10E)B,U/3)"4U5=6&EUARLD-C1&1T166%M29V5SA(
M\8*2<Y.S-,0VMB<W1X?"XH.CA+1U9J+#I*9WM\8H>!$  0," P,%# 8%" @$
M!0,% 0 " Q$$$@4&(3$305&1(@=A<=$R4I)3DQ15%A>!H=(CTPBQP4*4%?!B
MHK(S1%1%\7*"PD,DU!CA<S0EH[.D1E9C-0ED=+25)O_:  P# 0 "$0,1 #\
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MB)>+D$$W3"2C))BJNS?L'K54JB*R1SIJ)F Q1$! :\1EBDAD=#,US)6DAS7
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M$XW5X/V8R,(/,YYZH_V<1!W@+HF>=H60Y.XP1$W5X-[8Z80>9SSU1_LXB#O
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M5<.4KYA_,%J">>[L='69/6 GD /C.<XQPM/>H]Q!V=9AY M:"PX J#?TBY(
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M*3>-8^/8MDS*N7CYZX(V:-6Z1=3*+N'"I2$*'$3" 59\C(HW2R$-C:"23N
MJ2>\%B;')-*(H@72N(  WDG8 .Z2KX9':=CGX07MB"TL^.+KW(8\A+ND)RQ
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MR#.9\H;<VUY'"X89K=XDBD8YH>Q['"N]KAB:>LQV)C@'-(5+9-V5C'O7AA
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MZF.V9^2M2XH"Z891-&7MJ:BY^*562(X22DH=^A(L5%4% %-9,CIL43$,'*8
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MJPETEU8HZN#,M LB@=4H*@#AGRF,7ZF?7F#PSM?T_FN=7=E)EUM>SMCCD#C
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MCY/,B^PN;^5N@?=T7GR_B*(.Y#[K .C:#9WV996^7M3\Q]:_X^3S(OL)\K=
M^[8O/E_$48=R/W68=&T.SOLQRK\O:?,C6W^/D\R+["CY6: /^6Q>?+^(H@[D
MKNM0Z-HEG_9CE7Y>U/S(UO\ X^3S(OL*/E7V?^[8O/E_$47W$WNMP_U1K/\
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MJ/@K27NVS]4WP)\!Z,]UV7JF^!1!LIVCAT;<L0?8/">]:CX)TA[ML_5-\"?
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MYW=8X5\;]K/8K+8&;-M/0&XT_)5TD+02^ G:2T#:Z(;P15T8\;JC$L$D/?\
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M:8*KG3)UB@\"AKJ/@J\<<DKL,37.=3< 2?J57.:P5>0!W=B[13%.4#%,!BF
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MY7ESWO<7/>YQJ7.<22XD[22:E<_9V=IE]K'8V$4<%E"P,9'&T,8QC11K6M:
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MB*&0U?*[N&1Q+@#Y((;_ #5>#76UVM*(E$7P1 H"8P@4H (B81    Z1$1X
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MVJ.+0;=ZP/9-V2S7=A=[/M"B\<7K/S]M/\LX2EXZ[%F*$<^C6]^WR>TI^TY
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MC&B#".CF#1(B#1DQ9-4TFS1HU03*1--,I2$(     5Z4QC(V".,!L;10 "@
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MK)P2-GVB_<.4&ZSI7J95E%-VRA6Z116/SK/B:Z!J "(^"O/<LRZZS:]CR^R
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M ^&-^R5H([H!_2NP,5;"QQ:*P,"JJ4H.11/%,3@ *B*?6\IFXEYC]5H(ZZB
M!X-*V&W]^WK-FF'=#W>'OK6=E]@>JZ&(]]C?IY.\NR%NVN)2%-;, 8A"BFF
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M,&.([]"J&3.<LI+C)R 75>")%9=TBE VQ,/HV/9-O2QV#9K'Q;=\S8MF,:T
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M%'Y+>@)QIO+=TE.WOO=KOSE;RZ<*/R6] 3C3>6[I*=O?>[7?G*WETX4?DMZ
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M%<+2[Q<92:ZE=S%$7$T?& F4>K(!"B*:TB8IM%E0]CP A=0+S&\SS_-8LRN
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M8WY4 $:T-!M9+8Z@@<W$XY#,YHY:LGMW5'> )/<!7>LS-'VKJT_YEH/TM?\
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M"N^]EM[!9=H64SW#@R(W08230 RM=$*GD&)XJ5T3M.LI[_0&:V]NTNE%J7@
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M1F.IA'4?5KI-_HS4ES<2W^936[KB1Q>][Y:DN)J7$@<_T+DH-6Y1A;#;QST
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M1*(E$2B+K*(<YA, =.GJ>"FQ%U3L>?I HTW;E.Q>0^MEK()F3<))*%, @('
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MF/9"4PHB)1U?OCF*82Z#J)4TB!H.E.'SE..>0!7K6-W9>UNPBHA"8CLY(R(
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MPOS\3)&-'D0 "\>L<$\&M$ JI6SGF6&P58PWO-QCV81-+QT*VC8]9N@Z<NY
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M9C';Q,# /+[&6=N!X= B/AUJ#O5V"C*+M[DLC'R1,8T?=>*P1&'[&BW&IS&
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M0-3C'F61:P[/88_LVV[*BUW+IA;42UBFSEV)!<N2MR:&77ZLI4P464$3"!0
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M-LJ:*%7!)03""IN5/F,)@E11;$B**3=%)N@F1%!!,B**290(FDDD4")IID*
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MK&[E/711(X?1*.ABB!@ :(JE6C=T9>$85\Q.";A,"$?L#G 5V2XEU$I@X"=
MX@/5J   < \ @8H$4UT1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1"H#"/,3CTB/XPU
M(4%?#B(%-H(A_LT"K4U7&)ATZ1]IKTCT\@CK^'4J2N(3FY?;&Z0\(_GO5JP
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M/=LW%VU:,!,7/<,EVR:>>CX. CW,K+/NQQ_:W[OLC!HHIU2"2JRG+RD(8P@
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MLL'):I+=G)F=.G85L1$XW!:Y$HZ4;_"8(ULBHPCT5AS9G*TODB+\;A,2!0C
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MARE 5%#"81\(B(CQI6IJ5(%%$,"40 .U&X?TH/$ ?IGJ4JI7&-O%'7]=FX@
M?H(>#_VE*J**#X-E]UF_X$/U6IQ**53X-E]V#_P ?JM,285!\&"^[#?\ 'B
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J=%$7-1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2113965d2-pht_cellul4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_cellul4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!] .0 P$1  (1 0,1 ?_$ 1T  0 !! ,! 0$
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MO#:=:U\M;71VE>9RIG[J1DA1$A7#PD;$,I)^WAV9U"%7?K)ILFYSE*HJ43%
M=V;8V-NW>7C';-C-=MMV@R%ND-;7D-3W-:7GB6L!+W $AI --G;LZ@[+V-X
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MLL^,#AZ_?.3@!EG3I<PG.;[8_8#H&;^WQFG/F]6M@([6-H8QC>#6,;P:UH[
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M21&CUPW422>//2,#+$%/SP.'3-X;6V'N;=[G.P]O_88_OD\A$<$=.>J5W=J
M02UNI]..FBV;NK?VU]G-:S,W ]>D^]V\8,EQ)6H&B)M74)! <[2RO#5584)_
M$IY@VT5)35'PF.2U@J)CB9C*[,N=>TQ87;3Y)DW(5&>K$TN +)#W$\MRLF;[
M!QS?!Z9;-LZ19?=^+CO.UL$3[E@/D\1CVCWZM!\RV.SJ=O*^K+B-GY62S^U=
M/+':O(\OAR-)^(GLX\5<M*^+?08BPQM1Y><?M^\(Y:8?)Q<5:=TTY^KI^2E5
M3=$XYEM./8MF!3&*4QS.G+-M'))D,91R4.G7UK[I!D9K=UYL[(X[.PL;J=';
M2#UAK?G& DGS:6N<\GDU>S8]8L;#<-M-YX[(X"9[@ULEU$?5G./)HN  !PXE
MSFM8*&KUM9@I^"M$1&6&M3,588":9H2,/.0<@TEH>6CW1 5;/HV38+.&3YFX
M3$#$52.<ARCU 1#.)9[>>UF=;W3'QW#'$.:X%KFD<PYIH01V@BJY<@G@NH6W
M-J]DEN]H+7-(<UP/(M<*@@]A!HJMGB7E3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$6/G*C05?Y.Z!V9I.PJI,TKK7E4(>861!<*]:8Y9&6JEA*GU*<Y8>
MP,FZRA"F**R)3I=0 XYNW8NZ[O9.Z[+<MH"YUM,"]@-/$B<"V6/_ "XW. )!
MH:.IP6R^H>S;+?\ LR_VE>D,9=P$,>17PY6D/ADIS[DC6N(!!+06U%5X=-,\
MB]\<*;_M!GJRVQ,3/2,9:-76\\<[96RL/%6+I[&)6&!D(]V:)DY&O29#NH64
M1.JC\L1 JJ"RB:GTWW'L_:O4K%6,F=MY)+5CXKF+4'12 . <8WM<-;6R-HV:
M(@'A2K7-!'R4VMOC>72C-9"+;MS'%>OCEM)]);-$XM+FB6-S26/=$^KH)07-
MXUTN:]S3GO\ !:XVH;SY0/=SW"3C9"'T)Z6Y%B)&3:O+%8=ASYWZ-6EEXM5P
MI*'C*^[27E#R"A0+[T0:$(90PK EQ5[2.\G;7V0W;F.8]ESE:PZVM(CCMX])
ME:' :0Z0%L0C''PW2$@ -U<Q^RKL1N[NH,FZLI(Q]MAJ3Z'.!DENI2X1/+"2
MXLC(=*9#_P J(P"XEVGV+%^Y#\X,^>"^GBYPB81<" #[<(M6'(7C7<M<VB2V
MAI"#=3-2F%S25HH,"DHO+5^664,=]+5:';I^9(04@?HJJQ;@=PT7,<42&0,!
M&_/6SM[8W,V+,%NB5L61B&F*XD-&2,'HLE>?1D;R$CJ->T#40\:G]9=^].LO
MM_)2;DV9 Z;$S.+YK6($R12'TGP1MXOB?S,307QO+BP&-P;%#E;Y#M2E,S>N
MS-7K0XMWC-R8S=TT<)#V*MG39;L60<)J%$#$. &*(" @&;GO-I2<)(VZHG<0
M1Q!!Y$$<"#V$<UL['[ZCH8I'Z9F'2YIX.:1P(<#Q!!'$&A':J[+\@(XK<YO>
M*8@!?ZN7[7_L\]:WVI*74##\2]VZWM"&5\0?&HVA&6U>1,R2$UI#/',:JL+>
M2N3PCEO3X(A3!YZCR9[!0=/$B' 2LVYE':G4.A +W'+J]W-@-G6QNLY*ULP%
M6P@@S2'LTLK4 _/=1@\M: Z#8P;FW]=BRVY"Y\!-'W#@X6\8[2^2A:7#\&S5
M(>%&TJ1N%TKJ"MZ3HD93*^7SUD^KZPSJJ14Y"SV)RFF$E-R ]ZI^]P=,"(I"
MHH#5LFD@0>Q,N=<-S;COMSY:3)WAHT]V.,&K8HP>ZQO+ES<:#4XN>15Q7;/9
MVT\=LW!Q8>P&IX[TLI%'S3.IKD?Q)XD4:VI#&!L;3I:%+6;?6Z4PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+"'G[RT7XAZ'-<*O75KO
MM[8=KA-0:(HJ"!G)K7MRZD>)UEHZ0(J@JI&,2LEG2Y"G(9QY)&Q#D473,&^>
MGVT&[QS_ *G=2B##VT+KBZE)IX=O%360>/>-0T'LJ7$$-(6Q.HF\7;,V]Z[:
MQ&XS-S,RVM(@*^)<RU\,$5' 4)(^VH& @N!49\%^ K+C^WDMU;[E&FZ>9NSG
M*EBVEN6= DPXA'T@DF TK7;AVV1&#JL&@ -RG;I-C.NT>A$6I6[1OJF_.H,F
MXG-PF 8ZQV5:C1!;,[H<!_RDP![TCCQH2[3Y7/+GNTK8'3QFVVOSFX7B_P!\
M7;B^XN7@.+"[_DH21W(V#A5H;J\C6!C&[*0  _D^W.,ER@K1O5 I.S:K,T?8
M54@+K4+ S48S-;LL8TF(>2;*%$HIN63U-5 QBB/4A^@'3, &*(& !SW+#(7V
M+NV7^.FD@O(S5KV.+7-/F(I\(Y'D5Z=_C['*VC[#)0QSV4@HYCVAS7#S@@CW
MCS!XCBM*M$:R7PG.45&TD$G,RW CEE;58C5)IQ^O*...6]Y58@EHYI5\L=<]
M#N0"06@J',H"ICJ' 5&[MR[YNOWQ]7=JW&<+6,Z@XB'5<: &B\M6C[[I IXL
M?'504I0#@YC6<'8]DG1_=5O@ Y[^G>8FTV^LEQLKMQ^]:B:^%+S;6IJ23Q:]
MS][ " ^(>(9P*N?5SA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*A6:T
M5JE0,I:;C882J5B$:G?35BL<HQA(.)9)B4IW<G+22[9@Q;$,< $ZJA2@(@'7
MQSV+6TNKZX9:64<DUU(:-8QI>]Q\C6M!)/F 7KW=Y:6%L^\OI8X;.-NI[Y'!
MC&M',N<X@- \I("Q%Y3\H6-%T+(6O1EOIUSV1<8)H_T\PA7;&X$MS5Q)LT'T
MW748UPO%22#6*,X.T<NUT(@[TB2;A<I#" [YV9LJ[S&?%MF;>>'$V\A%T]X,
M0B(:2UCR^A#BZFIC0Z714M82%Q-U-ZM;>V9MYLV/OK:7<5]&#8PQAUR^<%X:
MZ6..$/)C:*_2OTVX?I:^1M5!6G^9/(=?2\"[V5H:0>[4"*FA?NU)B$@&3Q9.
M0E0JKN4B8=.99,Y%Y"%8J2B31<&Z;LZX( 0@$(7=&7Z=[9&9D;CLHQF,U-TM
M#'R$<&ZP'N+"0'Z@PEM2W3JJ:E<<XSKMO1N*C%YMJXN+T-=JE\:.%K^\[0X1
M!LE"6:"\:VC7JTT%%1>#O,W;EK>VFG\QT6>NK8_GHI+6Z\U%0, TESN6ADY^
M"+)5F4F*RDU;S )DA?6.$9!ZDJ8AO.4*0Q_)OWIQ86EO'DMC@W=BR-WCACG/
M<T U;)H>ULA[M3*6M+&$5[HK3S=..OUO=Y=VVNI$K<;F+B1@M'2Q>##*YW!T
M'C N@;)KH(&R/9)+JTMUO%#M&A;95K(XFFE=LD#/.JW*JP5B;0LO'RB\!-H$
M(HO#S2+%PNI%2J*:I3';K@FL4I@$2]!SAJ>TN[9L;[F*2-DK-;"YI:'L/)S:
M@:FGYPJ/.NS$%Y:73I&6LL<CX7Z) US7%CQ0Z7@$Z74(.DT-#R5P9ZZ]E,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:R/BV\BY7CQPYMZ]9>.
M8ZY;8EF.GZQ)LSBFYB!L\?+25EEDEB&*NU7;4V#D$VRZ?RT'JR!P$.G4.:N@
M6T(-W=1+=EZUK\=81NNY&GD_PG,;&PCD09GQES3P<P."X$]I'>]QLGI==/L'
M.9E,E(VRA>W@6>,U[I7@CBTB".4,<.+9"PK0G\*OX<]0YCQ6W+]M5U*--?U9
MLYU[54H)Z=A('V/)PS>2/.**$+V*-:7%R3-P1L?N1=.':8* 9-,Y#]J>NO6#
M(=.I\?BL$UCLM.X7$I>-3?5VO+='OS.:YI<.+6L-*$@CIU[.G0_&=4+;)YK<
M9D;A+=IMH1&XM=ZT^,/\3API QS'!A[KW/;J!:T@P)Q3NMRX'?$*@X":?BW3
MJ>VY'1FTNT5FL9.4N5LI:I,2YD5!*HM%M^UM/L>[[LS5N;V#FZM]XW'=4^D<
MMU;,J;C'MO;;D7,F;'XK&5')Q[T#_,YX6SNG.4R?1[K;#97+Z"WR;\?=\PR2
M!\O@O?0\2P=RYCK\QAY%>YT/8'YP?F_8^WGS"*^N*YPB_)C%('4P] ^WT$?Y
MV$7Y\U/_ %WYGL'[/L^Q]G"+D#$4]@]>GY@A[0_-Z=0'"*+;OH[4&QUC.KOK
MJJ6%\8 *,H[BD$YCM#IT )AH#>4  Z!TZ+9K^+W3N+"M\/%WMQ#%\T/)9]P:
MM^HMLYG9FU-PO\7-8^UN)_GNC'B?U@H__C*Q8OB'QLAW1'C7458763'N($M[
MRGFY3?Z[T<X_D6@B'V![/#-5GZB;UN8S%)D9PT_,TQGXV-:?JK1+?I3T[MI1
M-'B;9SQ\_5*/N9'/;]13^R81<.T;Q\:R9QC!JF";5BP;)-&C=(O@5-!LV(FB
MBF7[ %* !FSYIIKB0S3N<^9QJ7.)<2?*2:DE;\@MX+:%MO;,9' T4:UH#6@>
M0 4 'F"[?G)@/3N\?M=#?:Z_:_T#X>W/&O*OH4P&#J4>H>/C^=X#_-PBYPB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBZSEXT9I&7=N4&J!! #K.%2
M(HD$P@!0,JH8I"B(CT#Q]N9-8YYTL!+O(.*CG-:*N( \Z^Q%$U *9,Y3E,4#
ME,4>XIB&#J4Q3!X&*(#X"&8D$<#S5!J*CDN1.0H")C 4 ZB(CX  ![1$1\
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M::&!:2&!^<49+7&R+M$^Y=."BV+--NZ<" )I [ QC 4ILYCZ*XYC=S2;MO\
MNX3"VTEQ*\\&Z]#FQL!Y:W$DM',Z>'&BX9ZVY)[MKQ[0QYU9S-W,=M$P<7:-
M;72O(XD,:T:7.I0:^/"JVHT"IL*#1*518L1&,I53KM2CA$.@BQKD0SAFG4
M Z^G9%^P&<3Y"[DR%_/?R_?9YGR'WWN+C]4KENPLX\?806$7WJ"%D;>S@QH:
M. X<@KNSU%[:81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%I)YR\3XRM[Y
MJ'*H+Y87GSSV#7ZS)4=ZP8+,6#I+7D\R25;6;S"ROS6%&L(KDA%$S-DY4XNR
MJ ;M3#L3TLW7+>8.ZVGZO&TVUC)*V5KB"X&XC!!C]'7]*X&0$$L 81VKI1[3
MVUHL7DL1N[QWR0Y'/6]M)$]K2V/19W,K7,D](-+K9A\,@M#W.>#4T%[6;DU>
M*#L/3&E8'C\ZVSKW9Z-<97&;&$GYB,(SL5H7K4S')F:0,E5FAZ5$-RS4F$JJ
M""\>N0@>2 '7+I/[*V.1L;[.7.1%GD;368V:F-<2Q@D:[B\//BN/A,\,5#P3
MWN#3O_%;TO\ %3XO 6.*=?XN]T-ED#7N:UKY/#<.#'1CPF_32>*X-<P@"G%P
MVOMABHN.:QL8U8QT<P:HLF#%@@BT8LV39(J#9JS:MR)H-FS=%,I$R$*4I"@
M   '3.&',EEE,LI<Z5Q))))))XDDGB23S/:NQ(FAAA$4(:V)K0 !0  <  !P
M  Y < M2_(RK<3'O,K75PMVPK+&\A&\+%A7:$T?R1:/-.63&WMZ<_LK@E6>,
M(JR%9R,J$6R/-QHRG9XM7(]"J<T;4NMWQ[,N+*SMXG;<,AUREH\5M3&9&L^D
M!<RHC\1WA/\ #KZ;.SKSO^VV/+O:VR-]<R-W6(1X<(<[PGT;*(W2?1D-D =+
MX;?%C\2GH24H<7-G:WV;M[=54I&DKR.O[O+J2R@3 3-JKT>_AXR(DY5_!3DU
M27#>R,8>049HB8R'FE%9-,JB9R"8H\B660QF(VA<W^>@]8QT1C[FF-Y#G/:P
M.8V4%A<T.-*T-*T(*ZP-LLGE^N&,Q6VIS;9:ZANF>('RQ@1M@DF<)'P$2!CC
M$UIH::BTD&@"WRZ?J=EH>J-;TFY6IU>;;4J/5ZY9;D]4=+.K/.0T*SCY2<77
M?JN)%PI)/&YU14<JJNE.[N6445$YQZLYF\M<AE[J_LH1;V<UQ(]D0H!&USB6
ML  #1I! HT!HY- % OH_@K&[QF$L\=?SNNKZWM8HY)G5+I7L8UKI"7$N)<07
M5<2XUJXDU)D?--6JIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7F
MP^.3QMW[M?:>C[QJ[5EYV966E)DJ6]"@UN8M\A#6)2Q.98OO6*@6;U]'Q\@P
M=)@F[4(#85$3$.<INP#=R_9BWEM3 X/*8S.7UK97KKELP\>1D37Q^&&=UTA:
MUSFN!JP=ZA! (K3HI[7&Q=X[CS^'RNWL=>7]BVV? [U:*2=S)#)K[[(FN<QK
MFG@\T:2"TN!I7=MPRUO8]0<4>/NM+C'IQ-MIVJZC$V>*3<(.@C+ 6,17F(\[
MEJ91JX69R"ZB:ATCG2,<HB0YRB!AZT=1LS9[AWWELUCGF2PN+Z5\;J$:H]1#
M'4/$ M (! (%*@'@NV'2_!7VV>G>%P.38(LE:XV!DK 0=,@8"]M6]TD.)!()
M!-2"1Q6C[XX?%S>VU-Q:<V7JK5%VV9"#KPVO952@5N6MLG#34?:IJ=9)S,9!
MLWLA'QK]M9A\AV<@-O,24*<Y#=G?V:]F3?&UL%M[(X7.W]M97/KGK#?'D9$U
M['1,8[0YY#7.:8^\P'50@@$5IU+]K;I]N_<6Y,5GMNXV[R%KZF;9YMHGS/8]
MLKY&ZV1M<YK'"4Z7TT5#@X@Z:[RN'U%MVLN+7'_7U\:$C[C3]34F L4<19-Q
M[NE(Z$:(.(\[A%15%99B)?*4,0QB"<@]HB7H(]8NH64Q^:WSELMBG%^.N+^:
M2-U*:FN>2'4-" [F*@&A%15=M>F6(RF Z>X7"YIH9E;7&P1RM!KI>V-H+:@D
M$M]$T)%0:$A9(9LY;Z7X.0BA1(H0IR& 2F*8 ,4Q3!T,4P#U 2F#P$/8(814
MHM>@" D4D)$E*@")40+'- !$K=FXCFX) "/1,$(]VJ@3IT[453D#H4P@*BM2
ML?\ DKMC7W&C6#_;=BUQ,75NC-:SUTUK-!BJ)\[9^0ONPJWK^C0+%Q>[-1*D
MWCV]KM34PFD9=DS9I=ZO>42^+EQ5:">"A%#D/Q"Y&:J+&;(E835JO(![LO0\
MKK[9EBI=.VF^FJ%M&8T+=Z7[RJMKGHV71CMI-1A6DC#3$E#OI!\R38.USOFH
M+0JT<#[RD<_*+A6G6UI1#<O'UW"52?:5IB#6W495JPLTTSG)J*C(=--T9(KF
M8CZG*/D5&P"FHTB7KKO%%DY42=E5*&M%\- \H..G(FE:,<L9:@Q%XW%I6A;N
MK^EIN8JKZ^5V VCKN&V :+7AFQQ%228UJT$.]!NG\MHJ#@2^G5*<54((\M%E
M=\WH#U+M[[DB?6/U(Y9\[]W-/4O5H=0BL2J[7\GS7"D6JF4[<QQ$43% 2=!
M!RK%?9A#1$49V>+BXZ-,_=*/GQF#)LS%Z]6Z>:\=BW33]0Z5  [E#]3C]D<(
MJEA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%J#^*5QHT7NU/3Z<[K
MI.4Y#WNX1NJ]4[#BK'-4J5K+&07.M(.K%,UU5-[,5J&-("<C15-QY*KHZB10
M[E2J<[]%,SF<=+D9W73H]HV-JZZNH=#)1*6BC61M?P;(^E-56U#:$^B1U)]J
MF\LK*QP>*PMC#/U-W#E8L9CIGO?$RW,A)DN)W1G6^&#4#X='G4_4&N <UT;Z
MHT[8?A?5:#UU(5JI;4T9NZ?=TJ<A=>5<?I3D=C6>&>A&(*K3RZ:]\3F6[-5D
MFF]>B)4A[4RI=")+;ER-_@NM%Q/D<6^?&;HQ<0G:^YFK:^K1/;K<= /@%FH/
M)8SGSU<7-XC;>=5?9:;86'4%UGNSIWN2Z./,.-LVQ9-N0N(GN@CC8\L;>,GT
M/B EE#J'NZ"UL<N24.VYAW4K=S5]-576R2M>U>W/,[GN:1'JMDUR[DG(V=.L
M4)"P23=:<9NT&B[9THB8J38"]W0WAM6X/3/%UCR&4N+YPFNCHL8#I$=P&CPO
M%N#&TB-S7/:Y@<"7<N"WQ8/]I7=#A=8#;&/P<3[/&M,V<OF^(;BP?*\W(M<<
MVYD#IV2,B?'+)&0V*E:'A78SAKN&U-%6FW.2DXVAWHW4KVG:?@&-1C/0;#L*
M]GML!\YI0LE/OH*0E%0 $54P[$"%3+T*'CZ\_4S;&.E$FV\%"ZY9X&F>]D=,
M_5;QB**3PF:(VR-8.8)JXZC4KW;+V:^IFX;5UKU'WU=LQ<QO?$LL-;1V46C(
M7#KF[M_6IA-<R022NH&N#:1@,%&\%>4G\.[B],5&VU>5ITM+R%RKTI 2%[F[
M5/S-^8^\V:C3WS!V&1>N#0TZQ,<JJ#ANFF)#D* @8G4HZ,[K'OXW4,\-VV&V
M@D:]L$,;(H3I-=+F,:W4P\BUQ/,\:\5OS%>R9T+QD4QFP_K^5GC<QUW?S37U
MU5P(UMDN7R!D@[',8WD!2G!8!4'DON[X6,9&Z+YP0=YVUQOA'"<5IWF9K^!D
M+6V@*8+@S2$I^]H9, F(2:K[5(A$G"'KE%T3D1;@\!(RA-U9#;&#ZKS/S^Q9
M(+3<T@U7.-F>(R^6E726KO1>UYXD'2 :N=HK0ZCC=S9OI%;LV[OJ*XN]JPT9
M;9*%CI!'%6C([M@[S"P4 +=511K0ZE1LLIG/3A5?X1O8*ORKT$[CG#<KKRY#
M:=/K\JT2,F540E("Q2T5/0RQ"&#O3=MD%"#X&* @(9QE>[ WOCYS;W>)R#9
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MW0YWCV=M+.7N>?U!WVV-NXGQ^';6S2',LH#QT:AP=,XEVMP+AQ-'=XM;M;
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MWMNC=C>J^W;4''1W3[*.:4L:PQ:HS=O:U_>?'0& 26X<X3,DCJ R0+T0%'J
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MLEZCO66<F5GD5!X&E/<5V-35'F8C5^MZ9\\C\BBU76OK[ 79UL'1#G5OT?\
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M:/UA?'6XKW28LVN7RUNI^W]Y4AK1+G,3EG3O*$?:Z(R8.IAS'Q01K)VDXE2
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M2[K\-LX+&"F5!Q9PX@V!-\DT)1.1W)R87:G046-(D>NM^5TJ"2I5"%;&34D
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M.T3$A'@"F/IEFY2^6W)\=G],?77I9( 64II1WA/X?Y)6%&@ORA=&?COU7_G
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M&/!^Y0K&R5#75*M==E$Q6C9^MW:QSL+((E.9,RK&5B[8Z8NTBJ$,43)J& !
M0^QF5YU2ZJXZY=99"^NH+QAHZ.2&)CVGG1S71!P/OA8V/LK>S)E+5E_C-O8^
MXL9!5DD5S<R,<.56O9<EKA[Q*KOU"N(O[#,/_P ?W/\ 7)X9ZO\ &#J1^M)?
MZN#\4O;_ )1O9S_=>T_K[S\X7/U">(W[#$/_ ,?W/]<F/XP=2/UI+_5P_BE?
MY1O9S_=>T_K[S\X3ZA/$;]AB'_X_N?ZY,?Q@ZD?K27^KA_%)_*-[.?[KVG]?
M>?G"L/:'$[A)J+75UVA;M-M$ZO0:U,6R?-&R5WD9'W5",5G[P&+%*RE.Z=&2
M1$"$ZE*)A^48I>I@U3"=2>JFX,Q;83'Y1QOKN=D4>ID#6ZGN#1J=X7 5/$_$
M">"T?/\ LQ>S+MK"7>X,GMBW&.LK=\TFB6\<[1&TN=I:+CB:#@.'G('%6-QO
MT9P)Y2:@J^[-:Z561J5L-+),FMG>6^(G63N#F'T%*,Y!HWM\BQ%1O(QRA04;
M.7""A0 Q%# .:IO'>?5W8^X)]M9K*UR%OIU&)L+V$/8U[2TF%KJ%K@:.:UP[
M0%I6R/9X]EOJ!MFVW9@=K1#&W0?I$LEVR1I8]T;VN NG-J'-(JU[FFE0XA6I
MR6^&?K&:IDM8-!P[FG7R&9KR#2M%F):5@+@1HB=56&!*<?OUX>8=D)VM%D5D
MVPJ]"+)]#^<EJVQ.N^?M,I%9;PE;=8>5P:Z70QDD-2 'UC:T/8/MVN:74XM/
M#2[C#KG["VP\MMFYS/2&U?B]X6T;I&6PFEEM[P,:28-,\DA@F>!2*2-S8]=&
MRLH[Q(] QBF*(E,4Y#%$0,10ADU"&#P,0Z9P*<ARB'02B " ^ YW(%'"H(I[
M]:_"OCT06FC@0X<P000>T$'B".T$ @\"MR?P^=<5OD9K^PQ>U[OM:SQNLI>.
M@(O5X[%GHK6J=6E& OH=5U7H1:.=/5ADF\@CY:[D[<&Z)" F! Z9U?ZSYR^V
M1FH;C;MICK>:_B=(^Z]6C?=&9CM+Z22!P:-)C=5K0[4XG55?3GV-ME83K7LR
M\L>H65W#?V6!N8[:+%')7$.,%I+&)(2^VMW1.D/B-N(],LKHQ&QC!&&<%N)I
M&K];ZT:&8Z^HE1I398B2;@E8K\7"G> CU\L7RS!L@N_4 >H]RQCF$?$1ZYUF
MRV>S>=E\;-7=S=2 D@RR/DTU^:'$AOO- "^E6U=B;)V-;&SV;B<=BK=P <+6
MWB@UTY:S&QID/G>7&O$E7WFD+=B81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PBT<7KBSR7=\O>0]WJ.I[&]INR#5F5)M&Q[1I[=5;W5
M?N-#QE4=?##[193LU2T*UKZ8>+0-OIL;\UI%)Z:#G)!.96:*2AK5>0.&FBQE
M+\,WE#9JI4J1N"JK;4U_,V&IL'5 E;)J.*B=/ZY?_%DTOR$WS4G)H)[%O-@Q
M&U>/M19V%LNJ]DI&/-67T: E=OV;15174WW>\JU(_#RYW[1B=MZ+OSFB-*M9
M.2FQ=FK[UOD@C>&.TZQ2."W&[B!H&XRM6J%ZJUXB=IV5Y#S=MD3K(HLH>U5K
MS"$5:K1QUW$IJ:./'DM^^DE=BKZ>U:MM^*1A-KJ:\I@[,B6[Z/DVT??PKD<6
MX-6LC%NW\>_9I6$' (K)+*$42[3 /CE7C-*\.2E#"B81,(F$3")A$PB81,(F
M$3")A%@_M?5G*EQR'K6WM7["@G.MZW"-6[W4,Y:)^MM9]4B;U.9CS(L:Y.02
MZ\J5<BK=\Z$JC==,A>A4R]^<J;>S_3YFRY]MYZRF;G)YB6WD<4<IC%6ECJNE
MCD 90AT;.#FDGF:+JQU!V#[0$W6:PZC;"S5H_8]C:-;)AY[JXMF7#@)!,S3'
M;3P.=*'-='/+1T<C&MH&#4L=>5OQ?]#<1HHD+LFA;7;;R=,U'3+1[BO-F$L5
MF91VT969Y=C/7-%7HTC(L5D4)&->R2ZQD50(U,=)4A-1VUT5S^Z;@2XJ[L9=
MO</[6R0N;V5C\(M;,V9H(+HY61@5!U4<TG<][[0F Q5A(W.8O,8_=<4AC?C[
MF%K) 0*B1EPQ\EI/;/\ M+BVFF:ZCFZ1(Q[&^3_E/\5WF!R@V%"W!SL*2U97
M:3:6MKUO0M;/G,-#U*7C%530\P]D"=DC;;"T14$IG3\3(B)S@BW03.9/.V&T
MNDNSMJ8Z2S9;MNKFXA,<\LPU.D8ZFI@'HL82/1;QX#4YQ%5U<WEU8W?O')0W
MMQ-ZM:VMPV:WBBX-AD971)4C4^5H)&MW:3I:UIHMNW"7^,*"U2BJ#S;K[E<I
M?3L6V\*!"D74 !.4AGFP*,R.DJ9--/J=5Y!IK*G-T L</4QPX=WQ[.FHOR&Q
MI #Q)M9G4^"&4^?@&RD#_P"9V+FK8GM( !F.WY&>P"[A;7X9HAQH!Q+H@3_\
MKF5NKV7:-R\O-8HI\6'+[7M(F58F<C-T7*4L&O3; @%$/7,@U_$QL%)W0*S+
MI.4' 2KQ",*Y2(!6Y%DE#'SBS;EKM7I]FA<;[#+_ "#6.:;.!L=P('G@3</=
M(R'Q&4+?"8Z4M)J\L<T!9]3[OJWUQVM-A.B8GV_BQ<M)RU_+<8Y]XR.M66$,
M4$UX+>1VEQNY66PE:VD#9HGEZS2UI"V>MZ[HU>NTX2S7"$J=?BK/84SKJDFI
MYA%M6TK)$6<IHN7!7;Q(YP45(113KW'*4PB <:9RZL+[-7=YBXC!C9;F1\49
MH"R-SR6-H"0-+2!0$@<@2%V-V/C,[A-F8G#[HNA?;DM<=;Q75P"XB>XCB8V:
M4%P:YP?('.U.:USJZG $D*]\TI;I6KOGK;Y.TDG=/V?6-%W+Q'3H[ASRU:U[
M;$-7-ZZ_5>/F4GKU6%K#FV54R+9\NU1>I HOY\BBDL1 HJ$11=\L]-\8!<0Y
M''W,]GO1]R&X[7;N?:S<"V;7((Y/1!+74%&<"XT)+.%>L.Y;/#8*^EW#!!<]
M/+2PDERA9.UEW$!1\(CC,D?%[@W0"=4A.EHK0/T17S84]>OFK%2$E(NJIK6K
ML==ZPB911DX>5G7<$FT95V#=OF3-B$O)(1D6T!Z]4)YKURAYI^GR2E[J[<VS
MCMNP2.MHV#(W4AFN9 "/%G=4O< 2=#"YSM$8X,::<>)/PKZL]8-U=5\TVYR]
MQ,W;]FTQ6%F75CM;9M&Q,- !+-H:SQ9W ODD!(TLTL;8':7[7YOV<W)5<354
MD56WQ2E6F=,;/-:9KCCL2P04KN#7U1?LH>7M#6OG:+LS1DNNF1U'O4UHID*@
M(.69GB#--N==-/Y1=G[DVP,E,S/8@0Q;QM8GMM9Y&ES6EU:M>T<'-.IU"0[0
M7%P:3P/8#HGURR73:X.V=P/N;OI5?S,-_91NHX!M/IK8\V2MTL+F-<UL[6"-
MY!TO;Z.>%NQKQ+UB5UWLNIZMU4O52QSC1.L*GLV(O%[#C$G%147K&UWV/C[!
M91:2*R*0LEGB#M=DY<H&\LW0"G5Z+[XQ=E;7C;_'RW=T9"X7<TD#HHQ?:G&>
M.(EC*@'O!I:'-!X]H'W8Z?YFXR.*$5RRS@M0QC[&.&=LKW8YS&>K32 /?Q<T
MZ2X.+7$<.PG-_-BK?Z81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$7C^WA^';<_YNYMGC_\ A[/9]+MI_P#A
M#%_]EVG^S1K\V?5@ =7=T_\ FK+?]Y7"V%?%XY;;\U-LGX??%#3?(*F<+8+E
M_9-D,=A<Q[_!P$W#ZUCM75*O3412(,MM,2I,;1L>2G"LVRS]1OU< @DDH4%5
MCI_-:Y_TAX_QW?7*_2-C6@V,1(K]"SA_DA8AJ:2Y(B98W_TTK1RB)E!$GNSC
M&3QZC\D2$VF4A1#V=   #[09X5[P+?F%;5OAR\*JEQKJV[-V.>4$QS9W;RDE
M(JS;4Y03+BLK-[A'4BO*UFE5:JMJE(R\'&U2I,O/(W22=+B!U3$ZD23112\U
MO]_9Y=8^N%Z&1<392BE (G__  E:9=!?E"Z-_'?JO_.! 9])=X?^#,M7]4W?
M^S2+\X'2/_UFVG_YMQ'_ 'E;+U[Y\U5^D9,(F$3")A$PB818AW_A-I?9-RG[
MU8W6QTYRR.DG<B6'V)8XB,*JBS;LB SC6;DC5FGY+4O4I  !-U'VCG).&ZJ[
MHP.+AQ%BVQ-I TANNVB>ZA<7'4YPJ[B3S[."ZY;R]ESICOG<UWNW.29L96]>
MUT@@R=W!%5K&QC1%'(&,&E@J&@5-2>)*T\_$1X\T_0MGUD2C.;&XB+3 V,SL
MEEL\C9WJ$E"R$8 BFM)K+.&C9RUEB 4H="&,D8?$0'.S/13>N3WA87YRS8&W
M-O-%3PHFQ-+7M?S#  2"PU/.A"^:GMI]&-M](LY@!M1]\_&Y"TNM8NKJ:[>V
M6"2'DZ9SG,:]DP :*-)8X\P5A?IVWQ^OMM:QO4N@HYB:?L"GV65113%9P:,A
M+!'R+\6J(>*KM-HW.9(O]$H !]G.4=S8R;-;<O\ $6Q#;FYLYHF$F@U/C<UM
M3V"I )[!Q75_IGN6RV9U&P.[<DPOQV-S%G<S!HU.\*&XCDD+&]KVL:YS!VN
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M'?9W"#@MLJUT^Y<=^,.YTGT/<J]+U76ONK;.PT*K+/9)[5&.R["5DBS8BX5
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M8_FJ?7EY;_LZ6G_BRH_K<Q_"7IM^J+?[N;\:G\V?M'_O;??U%C^:I]>7EO\
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MUTT>,I"!6=JG,<Y$CG:'5,90Z!E#"<>8]Z=*]K;X?ZY?L?;Y4"GCPEK7N X
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MTYM:#-8J#>&*,?8HE*0D(A9TBV>M9)J=&2B7+.0:+MG[))4ATU"CW$#KU#J
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MLX5*U8M$TP,H<YS 7J81'J.<.7=U/?74M[=.U7,TCGO=P%7/<7.-!0<22>
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M&!#6OCO;RPU-US2=<UM)_H&L;+KR#>!K-&:PM<JK"UK[,<NU$6+1(C-1N0"
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MT3OQHA([#F6S^4VT>QO=>V0\<DR<*K0P.H*-$WHF)E&D"R/$4[5Z*$^H$#J
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M]O"*,*%;YBRVG<T+(ILR--?;+BZA"F;)'366BWNGM47U520.=94BSPLS>'9
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M3JFR"1M9*HY4,$$P'C'HRRBSBP$?[3;C8)QX][2= ]2Y44^Z.(B0]BH+JR6
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M5,9B17<]"=/T98YO:(X4^117'R4A,UKX>\Q+/7,E*R]K@924D7JQW#Q_(O\
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M_9_",W'*I]K\*AF=33^J_O/Y(?A7WE[/ /R@K/U\ \/'[/V\%4<PIYM)2FY
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M?^$;<?\ NZD_J.:8[2AY+']O^ 7A=^F#CE^I$N0JM[?>4Q5;\HK<WXL=$?\
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M;><4@I&*7S0,*70^%:*NKV>&;6:/J"SDY9^3@I>R,VGIW!B*0\%(0D7)N1=
MF+5,R#VQ-"@F8X*'!03%*)2'$"4X55O/-H4MA4;9>74FLG6J0]LT?9'H1LB=
M5BZJ$@YBYY--DFU,]> U>M#E*9%,Y50 #$$P" X45P+VB%;62)J2[HY)Z;@[
M!8HUGZ=P)%XBKOJU&S;@SH$Q:(F:O+<P*"9SE44\X1(4P$.)7F5IVJ .1%N@
MK3QHY9-89THY6JFJ-T56<*HU<M@:S;75LA*KM4S.$DBNB$8RR!_-2$Z0B<0
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M9^G<=A8=W(.XM!SZKRO2B<[UDH7RP/Y@ 7J(=! <*>=49ML>HNZQ(7%&15-
M1=DL%3>NQCY JB4[5[M(Z[FF@-!; Z4(UML4NV!4I!24*7S2&,D('$K15A6T
MPJ-DCJDHY.6=EH.:L;%IZ=P)%8BOOX",E7!G0)^E2.W>69F4$SG!0X*")2B!
M#B4I16VZVK2&=8NMQ<2BY*_KY[8H^UO/=DD92/=U4>V;33:%:B[? U$/ R!%
M"J?T FR55H5:]J$#;XTV(>P:3N7_ 'QK#*GVI]]8_P!O_ ;\0;_=6[?WOE0S
M$\BLAS"GS8OX6N/GZ8-A_P";6?RJ!1D']ZN>WZ=I/]Y]H')Y5?)[WV2K@L?^
MVN%GXS/_ )U#?V9+$<C[NT*1J?\ A%W'_NZD_J.:9.TJE8_M_P  O"W_ !_Q
MQ_4@3KCL4',^\IBJWY16YOQ8Z'_Y:WGE[5#R4%,_R:>./3]EG0/^=^"R%9CT
MC[Q^LI_A_P HW8GXE-,?JYWWE6/9\*Q[4_)AI/\ VI]2_O\ :I8'V5D>?P?8
M60YORAD_Q++_ *N&^0K%O)0U5_R<]A_C]Y'?OP]D9!R3L^+ZRG.9_#OKC\4F
MZOU8Z"S).P_!]E8ZS'Y/_-/]-._/U,-LQ5//X%.=Q_#AHW]+NW?]Y4G*@Y%0
MA+_@K^(-_C[:?[VG7&$[1[NU2[L/\)_%_P#3A=_YNF;P&#S"@Y'WOLJ@5/\
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MR;TST_,_].BF>S[68CDL@./P'ZRR!2 !Y&2O4 'II. Z=?T\V?,NU8=BB&!
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M%.EP_#AHW]+NW?\ >-)S)0<BH0F/P5_$&_Q]M/\ >TZXR*]H4O;##_K/XO\
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M6_$G;+FE>OT @8!$P.>J'3Z:2]/%S]U_W/L\?!1-0K5?0_\ %W2G<.5AY>B
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MP$_*\HWF^I$W>7LZ'JG9\*CZ2TB$CKC;NOALIDB[6E[W*GEO=/F#!#=Q$3(
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MMFK-ANVU*+58.Q5M\O$M65A@9:=G6$?,0;QS/L$TG;=11!11Z@4IA%9,#2J
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M-7F:5W#L6VU1JP>JLD]2U5W.T:F50S< 1.P-5T7J;EV_)T'S7$F=T\,)AZJ
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MJ+W'PC*'.!9X3=+>]P'HG6.F_23K%[2&Z8]Y^U%:/9L*UB?)8V#F,LW":22
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MX[GVVJW<'&04Y@T%.9YKV+3:'3?(73';/W5)9YEKJQ>MPR6_?^UTW#2P1FO
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M(U8-&S%L4YS*'*W:(D01*90XF.H8J9 ZF$1$1\1SH:2YSBYQ)<34D\R5W\:
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M6CV$LR27$ 4\B:B'2J!D>O:HN")^@G23$.6^B>;O,3O^TM8'.-I>ZH96"M'
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MWDBW;OWX.S% >XR)1*'RQ#':LJ<*>?["N=KR>AW1X4I:M+%]]/)5DEU=L?T
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MLP:?_P"(57S'@_:R_P"U^8G*!(1Z@83W4JO4/#MZ!Y:?3H/Y^9#JMC_M]LX
MC_F*?9*\;O97W /O/4O?[3VUOP:^3[4+'+F1P,F)SCAL"8^>5RY(776U4F+M
M1*'MY)E;HJP6"O1ZSU9@T;*-EGR,Y,Q23AJU].=,RCI5,AA$@F#-N[>SKKG>
MS;F.YFPF.O[D,E-D\PB%DAH .('AL=I)#JT:#VKFZ]VH_"=-H\1<,&Y,OBK'
MZ.3(M$\MU)$TDOD-*F:5M6@MI5Q /!>.E7F!<8]HNEKV@:DU>Y>-CH&FZ52V
M[:<306+T,#=^[<.4DQ, ^ BB(A[0Z#XAW!9T6PEU,U^Y,CF<M$QP/A75TYT1
M(Y:F-#2?NAYZKJ$[K5G+:!S-MX["XF61I'BVMJULH!YZ7N<X#[D^:A6*SY\]
MDWKR2D7;A](2#E=Z_?.UCN'3QXZ5.NY=.EU1,JNX774,<YS")C&,(B/4<Y=M
M[>"T@9:VK&QVT; UC&@!K6M #6M X     <  N(I[B>ZGDN[E[I+F1Q<][B2
MYSG$ESG$\22222>)))*V@_!DU)8=K?$-T8O#-U#16K74[MFX/B=P$C*_5X=R
MQ9*J"4/9(VZ;BV !]D7?4?D@;.+^M>8ML1TYOVSD>+=AMO&/G/D<"?N8VO?_
M )*Y4Z(8:XS'4G'N@'T-FY]Q(?FMC:6M[#Z4KF,_RN')?T"<^>2^BR81,(F$
M3")A$PBU;_&71EUOA[;D&+!4S=&:U8O.$1[^IH5/:-1\[O*3Y1D2/10,?[ %
M*(CX!G.'LYNMV]6\=X]-9CN0ROS_ %:6GPTU +K[[43+A_1/*^!4M$EH7TKZ
M NX*\N-*T)\U5<FO67Q"WE#I+NGV_A<-3=5&MN*P*->VYY0UY:'9*0OE@DY!
M+R_=ID^G;\GI[/#/7R\O1V/*7,>1MMS?I!MQ():R6E?$#SK[*UU56&'B]H.7
M$6LN+NMF?HUUM&8J19"GA%@,?)]/1IRX+.;62.RD*5"I[>=TY]L0I7X6)U0$
M)=K453#*OC1@Q#>>,:63 D,+<JWFB/5P"@E^0)<XMS;L([)RNVZVY9AN[X8N
M"PRCN-U:S'W#W]6FGVM*\:KFG;C=Q,PL#=V.LW[AH[QC:B1L!.MVCPQ*3(/H
M] =J/IZJ<**_LTE:XF$3")A$PB81,(F$3")A$PB81,(F$6G[XN-&>R%*U1L5
MLD91I6+!.5B5,4#"#=.U-&+V/<*" =I$O5UTR74>GRUB 'B.=E_9NRT4.5R.
M$D-)+B&.5GG,)<UP'GI+7W@3V+YN?^XUM2ZO-I[>WI;M+K?'WL]K,>/=;=LC
M?&X]@&NVT5/VSVCF0M$^=N%\DCR7H_\ AW\EZUM#5->U3)R*;39.M()"(6BW
M1RD6GJK%=C*(GHD1-U>$9LC(-GI0#O17*!C !%4S#T>ZU;#O]O[BGW# PNP5
M_,7AXY1S/[SXW_-U.U.9V.;4 U:X#[>>QAUSP?4#IY9=/[V9L>^<%9MA=$X@
M&>TAI'#<0_/#&>'%.!WHY '. ;)&7;&>H?;]F<(KNHM1GQ-^356C:(_X]565
M;RMRLSN(6O(1ZR:R55KT8_;32,;(.$CB",]-OF3?HUZ"<C#S#J^6"K?S>Q_0
M78F0N<PS>E_&8\5;M>(-0H9I7-+"YH/..-KG=_D9*!NK2_3\[?;LZ[8#%;-G
MZ-X*=EQNO(NA-Z(R'"TM8Y&3:)' D-GN',C BXN%N7ODT!\)DT-?_5_T?GYW
M 7R"YKT5?"LI\A7>.,I8'Z0I)WS8]AGXCN 2F/$1<="5$%1*;[!Y>O/.W[9.
MT0]N=)/:#RD-]OIEG":FSL8HG_TW.?-3X&2LKYZCL7VM_P#;^VS>8/H=-E[Q
MI:W,9NYN8JBA,,<<%D"?,9;64M/:TM/(K9?G!:[Q)A$PB81,(F$3")A$PB81
M,(F$6&O*XP?(#KX_0'RE\/;[:+7P_D^.3M60\R@J_J$]V<HOE?\ P]R*^W_1
M<0-; 'C^:.%?D^RJK;5"_2A??'_RY7_KX#U__-TZ[+[.G7V@.#S^%3FWX/LJ
MQX\Q?7P_CX!RA:>/V/\ \S^H'M_]EBO!7E7WOLJ4:H<H7#C9U$ $-IZ^'^5P
M%W* _P T<=H]W8@' ^[M5*TT<OS)XG!U_P#@GB\'@ CXAQMO@#]C[ B&.P)Y
M?>^RJ#7CD]/H\.OLB/A_^T!]A6VR@'['V!'"AK7CYU;NIS%]SZ0\?96."W7^
M19=X]<BO:?>*5HP>@U^'7Q\SAA]@?L<O=KCX^'AX9>SX4[?@^PKV:'()&WR@
M\9?C'_)Z\];$;P_-[?'(>"ON^HK/1,7R==>/_P >8C[?_K--;F_G>.5.WW>1
M55N<ON^W>/C\YN2!NGC[!^(E,B _R0QS4Y?4^LN80Y??,3X_^]?B@_8'[//W
M5A@__1RJ#W?$5];88!JN\^@]>NN_B1@'\G96L^G\O)_A5/R*A7<Y1LVY0 ?_
M ("YZ_8'^BJ/'X0^Q]K':@Y?$JGM(Y1-M7Q_][<NP]@^WZNM \/9A7L5=N E
M%/=OC_\ 'K<_3^1PFIO\L,*$_6^ROM.')](_7N#I]-MN'K]@0_@Z*L7P^WXA
MA.VOF^R58E ,7W%KCQ]F\JV/V?\ U1B9?#[?B&%?+[NU7/K\Y?I!XN>/LM6E
MOL#]C@/R4 >GAX^./(H?MO=VA=S3Q@^CKAGXAX4KB!UZ>/\ Y$=H_:^QXY.S
MSJGFJ;7#%\O37C_Y.OAO@'_UMLW%]C\P,IIP]WE4\OOG["ZVLC$]Q:;ZCT_Z
M&<)@_P#QK[5Z]/Y89!R0\S\*MJC'**%.Z#UZDXD^( /3PYM[7$?'IT]@]?SL
MJ'W?$K^2.7WC'>/_ +YTU^_X<#_.PJ?=\2LR(.7S*)X^R;M_V_\ UD^O3>'V
M_DAA3W?456>F 6MO /$1;\O0 .@^(CSW.(?8P$/'ZGUE5X@Y1DB!U_\ BS\5
M#IX?8-S6UR8/L?9QR*4X?%]9='9)RC4>08 ("/T+_$L_FVG4XA^9[,(/LA=7
M89RC9=X=!_\ B[SC#V#]G56@/9]L!^W[,%&\OB5.VR<O9L@>O_O3E$'\D>'>
MNNG\_!'#W>10<_=Y5?UM4+Y6R1[O9<]E=/\ \AJ Z?SARHNL0P?.VN>/3_K8
MDQ\0$/ ?ATQ  /L^WDJJ.WW=JMFAG*%>U5X_^4JG#X=1]GPM9H/:'A[<!#S/
MN[5V=4F ;]Q5 /L)\> ]@A[.#_*L!]H?8$<(>WW=JVFY5@F$3")A%0;5.I5:
ML6.S+H*.D*[!2\ZLV1,0BSE*)CW#]1!(ZGR"*+$;B4HF\ $?'//:V[KJZCM6
MFCI)&L!\A<0*_!5>&XG;;6[[AX)9&PN('D:"?L+#R)YM5BZ3M1J&LJL[O%LN
MM5H%AB6))V/AXIB\NU>VA:W438)ATT7-&C78/53T55DF[GSW+ILDF0 ,=0F\
M9=D7=E;S7F4E$%G!+*QQT%SB(WP1AS&@C5K?<-H"6T:UQ)Y [4;O*TN;J*RQ
M\3I[J=D3FBH:WZ5EQ)1SCRT,MGU-#4N:!S)$G0&PMC[JK=:G]7,XN@T^S5II
M+.+E=&R%ALK&1?(+)O*]"4R'E4HL92N/RBBZ?O9 [('*)BHMGB(^;GJ28W#8
M*:6+-.DNK^*4M$,)\.,M:11\DSFEVEXXM8QFO2:N?&[NJMR6>S\,4F#;%9XZ
M6%KS/,/%D#GMKHC@8\-U1G@Z2232'"C8Y6]Y1=K"T\L=-OR4WD@P@]U41-0K
M6"Y$:OB315B9MQ4[$3;DU40ZBC(P$.'F2]=]6R1(7N=-T2 HYS<.;L=A[BB_
M2.S72XW*$5?C[EVJ,GM]3NN3O-%<:7D\&/<=+%MC;U]U&VS-^B]],ARN(!I'
MDK1FB4"M!Z[9BND\ZS6VJ,#B^-@#GJY]ER\KR1H]AH6JH8LK4I5%FO(["LRK
MF$UY:V\-)L9LU'B !@\E[M6;\,<$/+O6S48DL,^='27=K%*U4TG'V46U+R/(
M9N01Y%A(;;Q@/GC+@6>+)W@V%\-?$C8YWB^*Q@<QC27C6[W(R;OM7X_ Q&3%
MNH7W,A++>4,<'^%'5I=<,FIX4KVM\#PGO+7R.'AG\Z_A]@Z/:7:P/=8QZU;V
M%LB1O4G1M5RQ)E34T>:DT"ID:UR!5@ZRC;VLY*U%_89<L:BV>%DYA;R&K]0R
MBZF%V[%[@=#:MO"R]MK9L3);ANEMP?%FD.N0/?X1:V1D,9DJS1&-3X@ T>:#
M])[<$]WZEXMA<W3I7QVSM3[=OA0Q@LB+6>,'NC?-*(Z2!\AT1S$EQN>^WJ7V
M?37-9TVVDI@EXB%8!]?V9EH9A1VEC-(P$G*H/'YH]S\[Z:@U>NCQY"B[:R#5
MNT<D;&=%52\6/Q$&(O/6MPO9"^W=K;":/=,Z,->UM&ZAX4I+&B2NAT;GR,+Q
M&6NRR&;N,Q:"UVU&^X9<M#73BL;(6R%S'NJ[2?%B:V1QB +V2-CCD##('-C#
M66N-J:55F+1$:KHC(LS!ZOH;K76LI]LG$>CUS#78S_8A5).#I[,\[;7<I'0Z
M+<R0G9LD$5W+A4B(I)ZA?7^%SVFTNKVX 8^>43SL)=JF?%2$Z72$,C:V24G[
M=Y<QC07 GT;2PSFWFF[L;&"0O9;PN@@>&M#8(YM4PUMC!?(XQP-'VC V1[BU
MA:)TE-V-WB[> UU5I^\W=RP8O74 JT=U>-IQ))JD\:?23/R[+RJ<Z!NN4YX[
MR74T)![DV)R]3!HT.VGQ--WF)XK7&->YHD!$KIM)(/JT;#685! DJV&O RCD
MM6GW4R5PL\);S7>6+&N,9!B;!K:'-]:D>VD!H03$6NG(XMA<.*ZQXG?4"F-I
M0G:==)9T1HK8=<C'OJY IMV2:I2LM=69>3?O(N6\M8176F47C:5<$((!$I&$
M"9B?:MT?47Q7%M VOAW&ILDA)IQN(PUH<SAW1"YCHFDU]8=SQ-ON^T'Z0;-;
M7=PX#Q+;2Z*,!H/=MI2YQ8_CWG3M>V9P%/5F\K,NO*)&'K$FE1]7;&V!N9'R
MF3/13:'+"V]"2=E6!H^LTN_4^:U>HP*H' ]A]8XBU>PQ&JCE?HB.HXW8[[B]
M8[)WUG:;<-2;XOUPEHI5L;&_2R3T(I;Z&RBH,C6-JY:7E=_-M;"08G'WU[NA
MM W'A@CF#G5HZ5[SX,=OP-;G6Z)U"(G2/HTXA3_%?D-N6G6B0NU5UAKW9.P@
MMMVG["PM"TS88Z:MO'\FFU-0'>H5M\DM28V>13DTG/K72!6+1FB9JJZ347S<
M[=T[7P.29#BI[N[PUL8XHVNC#&N9'>>LBYTEXI*6$QENAIUN>X.:PAJVV=I[
MJW!BGW&9@L[+.W39)9=,AD+'RV M#;AXC-8A(/%U:W#2V-NES@7#.O2FJ;-K
M6Q[NDK#:'MP2V+L: ML+,S!X7W^>-C-0ZTHJS:91KM;J\,BLWEZ@Y! $6YA%
MH*1CG$XF ./LYE[7*6UA%;0MA-M;/C<UNK1J=<3R@MUO>XU;(VM3Z50!1<C8
M3$7.+NK^:XF=,+JY9(TNTZ@&V\$)#M#&-%'1&E!Z)%36JR!S;RW F$3")A$P
MB81,(F$3"+I24>QEH]_%R;)I)1LDR=1\A'/VZ3QB_8O$#MW;)ZT<$4;NFCI!
M0Q%4SE,10AA*8! >F9QRR0R-FA<YDK'!S7-)#FD&H((X@@\01Q!Y+%[&2-,<
M@#HW @@BH(/ @@\"".8*T3_!LY5Z]DS;4X&0^LV&M)OB_)VJ-@)-%I%P\UM>
MJUF\2='7M]_@XU@T3;[=;-6<66S.2K.BR4@N=P4R11\DG./57IYN#!87&;SR
M^5ER[LA%&V260O<8W.C$D;6R/>\OC+"[2XZ>+2=(U+BGIYO3#9;)W^U\=CX\
M8+*5Y9&S2T.:)"R1Q8QC QX?Z31JI4#4:*C4'E+K3F=\86(ULSTU#HAPOA-^
MHP^X"L(R8MULMM=<P.M56\O)'CD5Z[K6M2-GL9F#4B[PSR9<1[PAFHIJ)K>Q
MG^GVX]F])K;<8S$\=AE'PNFL&N>R)PG89(B0)-,CQ&UI>UT8IY3H%?#B-YX3
M<_42?!G&0OO,>V417C@Q\C3$\,D JS5&PO<0PM>:^0:N&_X Z>S. UR\F$3"
M+@0 ?;A%YN>?7P$(;<]XL>X>*%JKFM+-:Y!Y.6G5EL1=MM?OYU^J=S(RM2EH
M9F^>U$THZ.999B=HZ9 NH84!;)]$@[+=/O: GPEC'AMW1275K"T-CGC(,P8.
M ;(UQ DTC@'ZFNH!JU&KCUDZB>SU;YV_ES6T)H[2[F<7R02 B%SSQ<Z-S03'
MJ/$MTN;4G3I% -8U'_B]O.J?L;>-N+_3U!KH.B$?V5>ZN+,<C/S *LYC(.#A
MS.W[@$^IDTEU613CT RA.O4.4[_VBMA6]L9+)MY<7-.#!$&<>P.<YU .PD!W
MF!7%-A[-^_[BY;'>OL;>VJ-3_%+^%>):QK*DTX@$M![2.ST_<!_AU:7X"TF7
MAZ(K(VZ_W$K ]_V=8T6B4U/"P(86L/%,V9 0KU48.55%$&1#K*"HH)UUUU *
M8O5CJ!U(S?4&^9-D V''P5\&!A.EE>;G$\7R$4!=0"@HUK14+M9T\Z:8+IW8
MOAQQ=-D9]/C3OIJ=3DUH'!D8-2UH)/&KG.(!&P+./5R*F$3")A$PB81,(H[V
MYK.M[GUA?M3V])16M;$J<Y49@6_D@[;-)N/79"_CSKI+)(R<:HJ5PV4$AO*<
M)$. =2AFKX#-7FW,W:9['D"]L[ADK*UH2QP=I=2A+7 :7"O%I([5HFY,#8;I
MP%YMS* FPOK:2%]*5#9&ENIM00'MKJ8:=UP![%Y^]"A7.(&U"</>=C68A8 R
MJ[?CWR,0N-W@*+<:YZTJ<77;"HSFDH:#78H.2)$4'R2,!*#=U\GR'*W;3=4E
M]U P7\0NEKHY;H &_P >889)X9--721U87O#B"2.\9/39QU,;TJV=:8GIMN3
M^&?6".6*S+B,;DQ<7$=O/'JHR*33((XRT$ 'NB.FB3AHD?Z&J+6*]3JM$5VJ
MBN: 9(K+1BCF5>3:JB$BZ7DS*^]7[EX[>)K+/#&(8RAP @@!1[0  ZB96^O,
ME?R7M_3UMQ =1H8 6@-IH:  0&@&@''GQ7=S"XRPP^,BQ^,KZBP$LJ]TAH]Q
M>3K<7.<"7$@DGA0#@ KNS3UJB81,(F$3")A$PB81,(F$3")A$PB811IN#5U=
MW1K>UZTM!3A$VB-.T%TB4@NHQ^D<CJ+EV7F 8@/(J10373Z@)1,3H/4HB Z[
MMK/WNU\Y;9W'D>LV\E:'D]I!#V.I]J]I+3[]1Q6R.H^PL+U.V3D-C9\']&Y"
M L+FTUQ/!#XIHZU&N*1K9&UX5;0\"5Y-ML:NMFFK_8]=7-BHRF:^^51*J*1R
M-)>,,H<8V>BSGZ^?%R[4"K(F 1$H&$A^U0ARE^B^W-P8W=&'@S>+>'6LS :5
MXL=3O1O\CV'@X?"*M()_.]U&Z?[BZ7[RO=E;GB='DK.4@.H0R:*I\*XB)]**
M9M'M-214L=21KVBQH^1D(E\TE(F0?14I'KE=1\G&/',?(L'1 ,!'+%^S51=L
MW) ,/:HF<IR]1Z#FK3P074+K:Y8R6VD%',>T.:X>1S7 AP/D((6TK&^OL9>1
M9'&3S6V1@>'Q2Q/?%+&\5 ?'(PM>QPJ:.:X.%30\5/KKEQR=>PPP#C>NQS1H
MIBD/ESZK>3,F8H$,4]@;$2L2O<4/$3.S"/CU]HYLR/IGT_BNO7&8BR\>M>+-
M3/ZHDQ#X& +F6?VENO\ <XW]$2[NS7J);3NRM9+2E#6Y8T71]\S$^=8]*JJK
MJJKKJJ+KKK*N%UUE#*K+N%SG477654$RBJZZBAC'.81,<QA$1$1'-[L8V-@8
MP!L;6@ "@  %  !R    ' 4'D7"<LTMQ*Z>=[GSR/+G.<2YSGN)+G.<:ESG$
MDN<22XDDDDE3AQUT-:N1>S8?7U:*=LT.))*V6#L*="LU=!=%.0EE /\ (5=&
M!4$6B/M7=*$*/0G><FT=[[QQ^R,#+F+ZCI_1AC[992"6M\S134]WVK0?MM(/
M+71+H_G^MF_+;:&&#H[$4EO+F@+;6U:YHDDX\"\U#(6<WRN;6C ][/5[2J?
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M166MJII1R8>HKR)A<'$RP]^$J4)0:.D<JJ=/K":A M)2*$@HPAR!>+ TMET
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M -!;K;$5?VTG\GZ+@_Z>X4V] #V>&;:6YTPB81,(F$3")A$PB81,(F$7 AU
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MLD\>T6-TXF+!9IZQV \7&099>Q6BV2LY99QZWA(5FR1,Z=K>G9M$4$^U),A
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MBJST ?56<G%?G<EOWF1RQX]KRNNW%9UJ\6/I(E<EF[J]23#4]K?Z6Y(H;$B
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M.LI_81M<2&KW$'8*:P"O2%GCK8JX@=F:%TQR4H$N>4C&4>V0DG>L][PJ<HQ
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M[?HM:F.IUQ#2.NMDWC6$SZ>SPJ]=L<4\FZ'.P$LZB)J&<F170%8"B'0Q1*<
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MP7[VWGY#%^<I_ _5W]G6:^\%A^NG)_,O??JB+\H=^*3^[9P7[VWGY#%^<I_
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MA$[XTU*5&0?NHIA:H[:%'?5Q[*,DTUGL8TG&TZK&.)!FBJ4ZJ)%143*8!,4
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MB$;*KKMX:+CXINLZ4%5RLC'M$FB2KA40 55U"(@)S?T1A$<X[NKA]W=274@
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M3.!\29_/O/<> K1C=+&]UK0)&TGIY[K68F9!T@V3+)1J+,@HN"*F$4W(+CU
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M!(O:0',M.24E+OU0#VJ+KJJF^R8<XREWKNF:1TK[V4/<:G3I:./D:UH:!Y@
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MQ/=K[&W_ '?<FNY2E2=&U=,6379]#UD-=P7NVG1\=6$]8$N@1T/83JV($SV
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5$PB81,(F$3")A$PB81,(F$3"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2113965d2-pht_electro4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_electro4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"F@.2 P$1  (1 0,1 ?_$ 1(  0 " @,! 0$!
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M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B8#M3ZM;U]%9O\
M(%L09QJKZMJ-]%X7\@1Z_?Q$S_$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B)HW;VT9.C)MXZ(BUC/Y%N*B,R\1$8IKU,<@IH=.
MI7D@F!.X4S"4J91*8W< ]N:A?:=^T/SWH_13P/;/'6MS6=263.OK)PZM2RE:
MO9?E+MW&IBJ5JU;N+ VPR;V!V1A=SN^9GWJ,6E]#2A_*MX'5OY%9UTW $L00
M-NFLBC7HR1V1;D&DM8$TG<BIWN9*7=E%8Z8'#JW8)JF*"[LP'Z(-R 4@>/0
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MW+9%15E9T&)NT>Q,<ZP*^+P-U/"X*+Q@=F%UBA2^-9YB.6;XF;7C^2Q6?:S
M/CM8-1J9&O(<UW+RZ+?D/=9RQK*&K>0E673U10H*J-O*<1E5@Z!O+S*EZ!P)
M@T^UKUP=NBZ]U?;]@FN2#.'C4VK20<,F$.@O-<8FQU&D(1VHBS'C5R]J,FY
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MR<9S'!<KD_JS"J.+B-L=5>QS8:[6Z&Y[""-H/PZ'4B2%"QP!G*+,LW$G=N%
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M.4Q^4HLW9>-YJDRUHA"ID*0@ 4I"E*4I0 "E*4     \   #(/)).I\9/X
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M)W!0%4@J&(5,I(2]<^R^#X%L3F^&J3&.38]=E2 +62JA@Z(.BG0D,%T4_"=
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MS:67E;>H\.M-!]OW9NJT\Y>(-$W>XXV7WDGIB@[W1B(2>0U=?+[ 4FV2L19
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MH+%,B:2U&(C$2*G,K?J?'C1UCMK!9#YYS(EJM 9JB4YE[1+I*D1?>0;J*[>
M9D5?*EZ=IBMP((@)PS).U.$/.<Q7C.#\HGQV'W(OLU]['11]W7V2Y\3@GD,U
M:3_0CJW^2/\ 'X??UGGPU54G<F[-,2RKB1E)1XK)24B]4.X>R$@]6,Z>OGCA
M43*.';MRJ=10YA$QSF$1'J.3ER.2M:^56 M:C0 >  Z  >P >$SK+M"C8G10
M- !X #V?>]DL/H-1(4J/XD Z%+_1\/2&81G97CH9C]UA/MDK:Q6BE33ZI%#H
M)>GQ1Z  =/L>[F,9.0== 90N\W3$0!>U/\64 \/'M]ST?8RSVW]3[Y2/9,Z:
M0R9 +\0!Z>'X ??]SIE&UIE,;"?HG;%BT^@?$ /N!]X,ZO,,^"\_%6*3$!ZI
ME .G]SUSZ%AG(<^^8^^@DSE-T(7P#T]H?V!XYW)<0==9VK9^&:UG*\7H?\64
M>H#_ $? ?<RX4WGV2J2SWS05NJY#D6_%!Z![1[?'W0Z=?>R^XN2>AUE56\AC
MLBFD527 4 'KW?T0'QZ#[G3,MP,KJ.LNF/:=9I7CAN%]Q?Y 0LX[=K-M>7!P
MVJNPV@G.5DG%O7(IL+&JCU\L'-8?*@OY@@)@:F73#P4'+GS_ !2=P\*]*@'.
MJ!>H^W4#JOW''33W[3[)7Y^(O)8!0#7(0:I]WVC[C#^'0STS)*IK)IJHJ$52
M4(11-5,P'343.4#$.0Y1$IR'*/4!#P$!ZYKX00=&Z&1UX'2?IG$1B(Q$JYYQ
MUJ.@-H:JV!\ERTD>=2>5Y^F@ZC7S='Y.41 [AA$.:'O#8"4B:*EE5#_,FILI
M!R1F!'\RV;^6F>:O37,NRN%SN*WHBU$6*=&4G=UT+B_#H*[D&GSF4]:EM:L=
MVU(@3UAX3'R+\;--;6VV*5TW*0&KZJR XO(WHY5V!;!PQ<5!WWH-H/R\)KRS
MB-R[*U.YD#).WD6E/,8^T6APO;U@C'93(MTF&U^0.R=^V5!C&2YN]V:K5*ML
MNP4VK4HF\>SU'XU\CM_#YM$U1;"A:JH"H;AU.N-@X^#62R]%^9R<A]=7<@3C
MTBYJM\V[BK&=;7H5@MSV><36Q3ZN=FW<C8 -3YCXN)2!IM0,Q$M0R$9/D8B,
M1*KO:W?4%K[W_P"N2*Z?#_\ 0-??[6;"?9P/_P!669^RW_2,>>?O_$9_<[PV
MGC_K13^@<C*B^&O3_P 5&B?=_P#T@1H^[_Z!WFR/JB?_ /7G+_V-O\Y9YQ?9
MA _^(/M'W_KA/S=D]8N>=4_0_&(C$1B(Q$8B,1&(C$1B(Q$P#:OU:WKZ+37Y
M"MB(U5]6U&^BT+^0HCB#XS/\1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
MQ.^3E;K5+M,[<)9O!5>,@9-S.R[D_8DPC0:*E<K^!3F.H!#="$*4QU#B!2@)
MA !N'%8N;F\G1B<;6;<][5%:#Q9M1H/N>\G0 :DD"6OF\[CN-XC)S^7M6CC*
MJ':VP^"H%.X^TDZ>  ))T !) GD2U8O2(7>M!>2]E<LM>P>T:_(.+4O$JE=?
M-F&LS9ZA*.HDBYEF1GK-H0RQ ,J=J"AC=%13[#^AO/+RF3VKEUXU"MR]N!8H
MJ#C3S7K(*!]-#H2=#H V@ZKKJ/*3ME^&P^],"[,R63@*.3J9KRAW>37<K!VK
M!)4LJC<-2:]2?CVA6EC[3.>U_9N2*LO2;8C97X5&!BK:BQ2!:)B)6/(J=BW8
MS*2AFTH=S%/$CKD3 2ME"B43F.82)1]Z(XG+X790Q^4QS15\Q8U18Z.Z-IN+
M(1JNC@A2?K#J   6E/[1N=P/(^HS9?"Y0R;OE*DO"C6NNQ-2H6P$A]:V4L /
M@/3<6)"9[9+)I8_LQ:52FNQ3KW)IL)W(H0(Q2A)-2^)RKVP3]=58@J)D8**@
M+2F)93O,@L)D3 !5%?5RVK#PNYAZXY7)V88'&MAA39N^$4%5KKL#:=;'LJ.M
M6@8?%U*KO-YS^2[//V;<+A:N0+<RG(NXJV'><GS&NMJ*Z]*JZKQI?J5;5#H&
M?RQT'LQ+7K&E[<V#-; N:%6?N-56&-A6T@B*,9(Q;=PSM-P=J2XG%)J]A8>K
M LDW,3N<(BN<H]4>TU7ZXX'.<GV[AXW$8QR*AGULY4ZLK$&JE=GB5=[=I;7X
M3M!^MJ*/[-O*=M\+W;GYG/9@Q;&XNU*PXT1T4K?D,;/!6KKHW*A&KKYC _DR
M#!IDVH!-L-6R]GE$]8$O:15+<6 <&F IA)H#!+A7 7.[!\:+#O%#N,J4W] Q
M@\L91LLY<\ SI16><.(?R/F#9YVSZGF::;=_3=X:>T#XA"M%7!#N5*WR;1VR
M,X W^4WF?+>9_2>3J6W^7UV:E@?Q2?@,[O:E6[75WW51IRD7!E:'Z>K(%E-(
MQ()NXEE'O7\K;*L\1F47"B#IU,Q-H!<R!2!Y384%!,/G 4L5^A/'\SQ?;.5B
M\IC-14<^QD+]&9E5*K04(! 1ZMNXGJV]=!MU,W_:8Y;M_FN\L+-X7,3*N'%U
M+8*]&159GOH86 D,;*[]^T#X4\MM3Y@T['5G%'1F[^'LKL.IVR;'<^I:[?IR
MYQT4Q136DY-!C+V6O525@W1G"CEHHW:E;QTJT5(9SU6*8IA2]7;]'/=_=T]L
M>HU?#\ACU?ZM<A=CI2S,=%4LE=EJV#0 @DM94P.WX2"-V]^_MCTP[*[S])+N
MX.*R[SWEQ./EVY"(H!=PMEU-%E3%BR[5"57UL-_Q @[/*KK%82#^,=M9",?O
M(Y^S5(X9/X]VX9O&BY# HFX9NVZB:[=8AP Q3IF*8!#J Y.%U5=];4WHKU,-
M&5@&!'@00001[P=1-<,>ZVBQ<C'=J[U(*NC%64CJ"K @J1X@@@^V>L?A9=[A
ML;C%J6WWQ=V\M$C!OFSZ2?@<'LPUAI^7A(B;=G. &<.9F&CF[E1;Q\\ZHJ=1
M[\T"]3.+X[AN^>0X[B0JX"6J55?JH7K1W1=/ ([,H7\4#;[)ZC>CO,\OW!Z:
M\3RW.,S\E90P9V^M8M=ME==K'VM96B.6_'+%AXR4>8)),@?1B)Y$>4^QK[L7
M?.SW]\D951[#7JU5Z)A7RSHK:KPT'./HR,A(Q@J;RH]!LT:E%3RRE]87,=<_
M<HH<QO0SL3AN*X;M3 JXE*Q39B56,Z@:VNZ*S.S#JQ))TUUVKH@T50!Y2^I?
M/\WW#WQRE_.V6M?3GY%-=;DZ4UU6O6E:*3HH"J"=NF]RUAU9B3*#A#Q2U9MF
MEW;>6Z)V;B:)JN<=FD(Y)-!K 3+&$K[2QR*TM(J(.7RS&/3< +ALV*4ZY1*3
MS/C'(;!?4_O[GNW^2Q>U^VJJK.6SZAM8DFQ&>PUJ$4$*&;3X68D+U.G0$25Z
M,^E_;'=/#YO>O>-]U/!<5>V]  M5BUU+<_F,0S%$#:NE8!;HN[JRM"FD!KZ/
MW+5S3-FE&VL8W8,8Y>6LL"L:7&IQLXFZ)(GKZ+A=R@Z=L6Y?,3(9=1#S#& B
MIB>6:3^3/+V]MWC%HK;G'PV"U>8-GFLA&WS" " Q.A.T-H 2H.HAKAOU%1W9
MBMG9%R]MUY];->*B;/(2T-O-()8,R@:JN]EU)"N1M,T?:A6B@7#D# 2])MK*
MT.$-:5R.L)8H4W<7'K&>2L]"F:S""JC9^I)0=A16.FF E1+V")Q%42I1EZ&8
M/+\;VC;1RF.]"'.L:O?T9AM2M]4(!4*]; $]6.O0!06F/[2G)\'R_?U&5PN5
M7E.O&TI;LT9%):RVLK8"0Y>JU6(4:*-IW$N0FP'5HTE_NMV=')LD36U.YBNE
M"#&"68_K%&RGN#JM&B 6,L%?1@W@D"6\SU<2B57_  H^JY::\'N?_P!^K<J<
M+_PXXNA?=\'R_E"D6;]-/,-BZ^5IN\5^J/,E\MY/LS_X9DX->1_\77-U%?EG
MS/F_F#DM3Y>NOE"IB!D:[""&^N?*F#^RYMNOZ5O>V3%VM["KN5]6V*/@R2W8
MSBI C>0A[/8%EYE=8C=BM$0E947!-0 !9$%3 <HI=JET]=>/Y?D^U,?'XO&>
M]!G5L^S4LNJO56 @!+!WM"ZCP.T:'=JMG^S3RO!<-WSE9?-9=>*S<7<E8?14
M;1Z[[2;"P"FNJDOH1\2[SN&S1H.V%OK]?;4NA&6:35UBXOCOU.V&@G 2X4YS
M-G4++?-Y5=-VH]0C%>X$3&345,4.I"&,)"RCB/RZ<!6]]%8YP8@W5;QL\X)]
M3S --I;IN&H'O(&IA7/3@K.Y[:\7(M/;39K;;_*/F?+&PD/Y1(8N*SKM.C,0
M-54DJ)U^T\MFK[IL[6$U0;FA:))OJB!CYAHP;F5CV$ \5<VRE/QE>XB:DE-Q
M=G464:@GWHM_(4/V^<4N15Z'<=SO&\%G8W+8QHI/(6,A8Z,U@ JN7;[%1Z@H
M;71FW@:[29-WVD.6[9YGN;C<S@,Q<JY>*J6P*"46IB;\9O,UT+VUW%BFFJIY
M;-IO -@_LJ)>D&X]2%>@+*$K:V-OE)JZP:S863JON)E-!O$IHIG44%_&.XZ)
M*8CLH]AUP5)T*9,2A$7KWC\H.\$R\NCR^/;&5*7!U%@34N3T&U@SZ%#U"[3J
M0=9._P!F#+X4]@V<?@Y/F\JF8]F361M-1L %8 U.Y&2L$6#H6WKH"I$L[R#I
MLG&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$AO[0+^$'<O_8*G^O]4R3?1O\ >5Q?]9;^8MFM/VPO]V[N?^HQ?T_%GE\A
M_&5C/@D&73_UE/-_<K_NUG]6W^:9X(<3UY/'_KZ_\\3VEYY:S]0L8B,1/F>N
M"-&;MVIW>6U;+N#]B:RINQ!(RINU)NDX<*&[2^!4TSG'T%*(] S[K0V6+6/%
MB![!XG3Q) 'WR![S/EW%:%SX $^T^'T#4G[P)]T\\BEYKK6+N5L=7BI&NMIN
M(,T2V6<US3;4,@NL,NE&)6#94=[/+:QI;U%ZOY"+V4<R"!B@=)98?,(;;!>,
MRWNQ\),:\<;1CZDUID6U:=$)->.W.XVT%1N*5JA!T95^$C2S/Y#C;^XEMNR\
M5N7+6.$LLQ*L@$DNNCY X'.!/B ;+-"HT8_&9>_J.%>5[65&B9+UOY3;5J+/
M* _D'<L\+)NVY'DB1S)/[!;'CY5-XN<HJ*2DB8W3_K*P=%#:Q\]DUY?-9-].
MWR3<VW:H4;0=%T5:Z@ 0 =!77_D+X#;_ (+&MQ.&Q<>_=YZTINW,6;<0"VK-
M9:S'4GJ;;#_/;Q.Q<M$NT8B,1//][32]*7GD=5-8LW9EHC5U59NI)F'4"(VZ
MY'"5<B< $0,8E83BQ(80ZE\XX!X"/6;?3W"&'P-G(.-+,BT@'^97T'_7W_@$
MSKMRGR>/?)/1[&T'^2O3^/7\$Z355:*FBS "%\"I^Y]CH _;RIY&\ZF,JW4F
M3PI,&!2H_%#T%]STB/0/L>&87F7>,L]C22=?B"]I/ O0!\?#TCT#J.8]?:==
M)0V/T\9M1BQ @%\ #H'0>GH^P&6YVUE&[^V9&@U$>G3P\.G\GA[OCG07 G03
MKU,^X&?0/^0?OYUFPSCH9_!V8]/#I]SP'[HCG(L]\YZ??G5.&H>("  /V/3Z
M/NAG:&UZSZ5B.A\)A\K&E.4WQ0] @(=/YPRIKL(E2C_@FEK-#@8BH"4.G00Z
M]/<#KX^CW.F7?&NT.LKJVUD3]@0)3)*]2E\>X!\/0/N?R9E&#?HPE=2^AE<&
MZJL55)R/EEZ]BG4.GA_2^#T#F><5D$$3(,*T@^,O5X)[0_K4XRZ[D7"IE)JH
ML!US8O,/YBPR=*(E%-G3A3N,8[B5@2LGIQ'Q[G(_;AGO+COU;W!>BC2JUO-7
MW:6=2!]QMR_>F&<WC?*\C8H^HQWC[C=?X#J/O27^8M+5&(C$2$//ZE,KCHCS
M9-_%QL76+C7)V5=SI(!Q"%CW!GE<.2386_9&M*=((G<SR0$1DEY-)53M(E'.
MG)D +)'I;R-N!W-MI5WONQ[$4)O#[AI8-K58^1:IT0ZFL5D#4M:B!M8[]3^-
MJY#M@F]D6BF]'<OY938=U;;A;D8]1&EG_I&L7732IVV@1"T\[D:INW34_66&
MPK#6IUG$Q=GDJW6KQ":^;.)1J[AC35E:4W0>N=5.W"97R)R+2%CD12(F46[4
M0324'/N?2G/[=Y#$S'Q*LRMG>M;+*7O(4A]E;6YV1D@'0@A*$W:G>_5A(@]/
MP_#<WC)QJ9=W'"\5L:J+JL= ZE 62GB\'$8#7<6:^_9XJ3HIES0#U]&:\S:.
M<XB,1*K_ &MOU!:^^#<D2/\ ^8U^#^?-@_LX?WRS?V6_Z1CSS^_XC'[GN&/_
M .U%/Z!R,J*X:_Q4Z*^G\;^3N\V2]4/W><O_ &-O\Y9YP?9A_P!X7M']L)^;
MLGK%SSJGZ((Q$8B,1&(C$1B(Q$8B,1&(F ;5^K6]?1::_(5L1&JOJVHWO_-:
M%Z_^H(?S8B9_B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D?N4NJIK=>A=
MCZUKCMNSGK%#(!#J/%CH,UI&+DV,PU9/%B$4,BVD%& (&/VB! 4[A#H YEW8
MG/XW;/=F%S68I;$IL._0:L%=60L!TU*AMP'MTTF!^IW:^9WGV+R/;G'NJ9V1
M4/++$A2];K8JL1KHKE-I.G0'6>9"'XH<CIJ[(Z_1TWL!C.GDR1;ES+5>88UR
M.$RY6ZDB_M!V9H$L,AU$XNTW"J*J8=4A4ZE V\&1W_V9C<6>7?DL1L0)N 2U
M&L;IKM6K7S-Y\-A4,#]8#0Z>;^+Z8>H69S*\#7P_()G&P(3918E*=="[W[?*
M\L>)L5V5A]0MJ =A;_X3;TTQ<3Q+:FVS8E<?%;'A+A3J_,V5H_.HW3%=E((Q
M3)T[B9)JX Y 27(0%2 !DA.'7ML_:/J;VKW-QOS#Y./AYJ:[Z;K$J*Z'HREV
M =2-#JI.AZ-H?'(.^_1SO7L_E_E*\/+Y#CGT->1CU67J^HZJXK1FK=3J-K@:
MC0H6&NF1/_9^<C6>D([:7S+FEIE2;?F?:R2147NC"K*,X\(ZQ?-U,IG@OW#Y
M-<CF/*!GZ2!4#BEU\TJ5%3ZN=F6]SOP/S50QA4NW)) I:W5MU?F'IM"[2MG]
M&6W@-]4M7W>A/J'3V97W/\E<<HWMNPP"<E:"J;+O)'Q;BVX/4-;54(Q37>$Z
M30G!O?>YY:63/4+#KV#C(&P+#8KQ$2M5;/ISY'?I0,%'H2;%!_(EDI@Z23TZ
M"1TFS+SA.<%!236JN[/5'M/MG'K89-.9DV75CRZ'6TJF]398Q5BJ[4U*!B&9
M]H V[BM)V/Z+]\]XY5RG#R,#"JQ[3YN3790K6>6XJJ0.@=]]A46E5*I5YFY@
MVQ7UFGQ2Y)*W(*&72FQ0L7KOJ70]:D"0@&\SRA>#:U$BU8(GKX^N"\]5[?'S
M.F7P]^]E+QOZV_6>%\GMW?TJ[_?IY0/F[_YFS?\ 1,;'IEZBMRWZC_4O)?K#
M?M_H7%>OAN^8(%&S_P!9YGE^W=I-F\@.#F]-)SD4U1JMAV/!R5?KZY;-1X*;
MLC)I-EB&C:=@7J;!@L]CRQTL@J5B*R1"+QXH"4?,\U)*Q]H>J7:O<^+98^13
MA9276#RKW2MBF\FNQ=S!6W(1YFA)6S?K\.UFR/OOT6[V[,SJJDQ<CD<*S'J/
MG8M5MR+8*U6VI@B%TV6*WE;E :DUZ'?O1+2_9?\ ''8NI*QL.\[)AGE75V22
MLL8.I2Z9VTRC$U[Y=66EIR+5*"D:>15G.Q!NN!7)$TCF4(4%"=8)]<^\N&[A
MSL/BN%L6]<(VL]J'5"]GE@(C#ZVT)JS+JI) !)!FS'V:O3[N'M7CN0YON*E\
M5N1%*U46#;8$I\TFRQ#]3>;=$1M'"J2RC<-=U3?LW.*4[<U;DXI4FT%R]-(.
MZO%V.2CJBZ<G.957NB&QBJM6RRANID&RZ*'N 0"]0'&,7UH[_P 3C1QJ9-;;
M5VBUJU:X#30?&>A(_E,K-[==9F.;]G?TMS>7/+V85J;GWM2ESICDDDG\F#JJ
MDGJJ,J>Y0)..,C(Z%CF,1$,6L9%1;1M'QL<P03:LF#%FB1NT9LVJ)2(MVS9!
M,I"$( %*4   Z!D77WW9-SY&0[/D6,69F)+,Q.I))ZDD]23U)DU8V-CX>/7A
MXB)5BU($1% 5451HJJHT 50  !T \)]V=4[HQ$AQN?@EQXWI;S7JWUV6C[.Y
M(W)+R-5FEH(9_P!6(5%!690327;.G:;<A4O6"E(X,F0I3'$"% )'[:]5>\>U
MN._57'75O@KKL6U!9Y>O4A#J"!KJ=NI4$D@#4ZQ'W?Z(^G_>W+'G.7Q[J^3<
M#S'HL-7F[0 #8!J&8* N\ ,5 !)"C3)=E<=();BY>./VI8R/J3-[3)**J[)-
M11)JI, 8))M\K/E!6=+GFY1 "O72HJ*J L<YA,/AE%PG>66O?>+W?W#8^18N
M2KVDC4[/JG8HT V*=44: : #27'N/T^P6],\WL+M.JO$I?#=*%!(7S-=X\QC
MJQ\UQI:[;F(9F.IGFNCN*/)&2N:="1TKL-&PF>E9*"^K<DR@6W54$C/7-J70
M)6B1)>O7UL'9FYB].PQNI0'=6WO[LNGC?ULW)X9Q-NX;;%+GIKM%0/F[_P"9
MLW ^(&AT\[:/3#U#R>7'!IPO(CD"^T[J76I>NFYKR/(V#^6+"I'U2=0#LKD%
MPAWGI2SM(YM4K/LBOR$3#+,K;2:_.V1B:0-'-T96(?(Q\>L[B5V$JDJFV(N0
MH+,_).01,)R)V/M'U/[6[GP&N?(HPLM+'#5765UMMW$HZEF <,I!8J3H^X$:
M:$Y'WYZ-][=F<HN/7B97(X%E596_&JMN7=L LK8(A:LJX8(& W5["#KN5<C/
M[/?D431A-K?-*4&<^6#KJ:L!!4;L2HF9)=MB^0@3%Q\JB\ 0-&  R -NT_E=
M_<D%&/5[LT]T_J#YA/E?+T^:U'D>=J?R?F>&W3PM_H]VHW::-+@WH/ZA#LL=
MTC$M^=\[4X6A^9^7*C2[RO'?N\:/Z;9H=NX%)CW'W@]O/=MCD&#BJ637$#'P
MDXNYM-W@)RM,5)7Y*=H0T*R2D8]%W)FD)=9%-X"*9RH,?.,8>_RDU*SN[U0[
M6[8PDM7(HS<M[4 JHLKL8+O!=VVL0NU 2A8@L^T :;BMO[$]&>]^\^0LH?$R
MN.P*Z+2U^35;2N_RV%=:AT#.7L*BP*"%J\PDAMBMK-YQ1Y),KD>@JZ4V&K8@
M>BQ(+6MR+F"6'S!2!ZC:T435@\280Z^N>N V*7Q,<O00"]U]^]EV\8.67D\,
M8>W=UL4./;M-1/F[_P"9LW$^ /28Y;Z8^HE/+G@VX7D3R&_;\-+M4>NFX7@>
M1Y?_ *SS-@'4D:'39^^N#.^],2$()*C8-A0DM7JZNI/4F(E+0E%V#Y&8HV"N
MR2,6T7?,DXN93528K*)%0<L/($A_-!5)*Q]I^J?:?<M-O^D4X>37=8!7>Z5%
MJ][&NQ2Q"MN0@NH.Y;-VHV[6;)>^/17OKL_)ITP\C/PK<>D^;C5O>$M\I1=4
MXK4NNRP$5,RA'J\O:VX.B67>R\XW;-U8A?-E;$A9"H$ND9#P=>K$RBJQG5&<
M<\=/W4U+12Y2.8HBBRI$FR:Y2.#%!4YB%(9,QX3]=.].#YYL3A.&M3(.,[O9
M:A#5@L H1''1CH"6*DJ/A )((&Q?V:?3WN3ME<[N3N"BS$7,JKJJIL!6TJC,
MS665D!D!) 0. Y^(E0"I:W;->9M;&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$AO[0+^$#<O_ &"J?K]5,DWT<_>5Q?\
M66_F+9K3]L+_ ';NY_[/B_IV+/+W#_Y5C/\ .#+\I3S?W*_[K9_5M_$9X'\1
M_P":8_\ :*_\\3VF9Y:S]0TQ&\W^CZRK4C<MBV^MT:IQ) 4D[);)J/@(1D4W
M4" XDI-PV:)G5$.A"B;N.;P* CE=QW&<CR^6N!Q5%N3FO]5*T9W/W%4$_=]T
MI,W/PN-QVR^0NKHQ4\7L8(H^Z6($U7J/E?QIWY(O8?2^]-7[,F8U [M]#5"X
M0\O,MV:2A$E'IXENY&0%B114I16!,4@$P?&\0R\<WV7W9VW4N1SW'9F)CL=
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M;U.)<.0D/4CJ$,4%A3!(1*/QO >F1\)V7W9W)4V1P/'9F7CJ="]=3,@/CIN
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M;D5DR>^ )UL@F]X>G7TAEK]2;@G&X6-^,]CM_P!%5'_V9G5W.^W%HJ]I9C^
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MH]%KZCM7V>VND49(JX!T.JA'JF\SH5RL0 Z;'GFL[&SLAJ3;D4)0!^0S'L\
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M]$D>PL/9[&;[I\9N-B7#)Q:LA>JV5JP_YP!]P]_N'W!.^Z![P?<REE1'0 ]
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M<\ZI^B",1&(C$1B(Q$8B,1&(C$1B)@&U?JUO7T6FOR%;$1JKPUM1@]ZKPOY
MCCV1,_Q$8B,1&(C$1B)1/O'VDN_=<;CV;08&(UPM"T^[V*NQ:LC7YEQ(*,8J
M2<,VQWBR%E:HJN#))!W&*F0!'T &;<=I^AG9_.=LX',9EN<,K*Q*['"V5A0S
MJ&.T&HD#4]-2?NSR8]6/MQ>KW8_J9SO9_$8O!OQ?&\ID8]36T7M84JL*J79<
MI%+:#J0JCZ)8!P6Y#7GDCK&RW*_-:^TE8>\.ZXV3KC%VP9F8(0<')$.JD\D)
M)4SGSY)0!,!P+V@ =.OB,-^K?97$]C<_1Q?#M<^/9B+:3:RLVXV6+T*JHTT4
M>SQUZS<3[)WK-W5ZX=@YO='=U6%5R./RUF,HQD>M#6M&/:"0]EIW;K6!.[30
M#I)L9%<VCC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3II2PP<(I&(S$O&1:TU(A$0
MJ,@_:LUIB6,T=ORQ<2BX434DI([%@NL""('5%)%0X%[2&$*BG$R<D.V/6[K6
MF]RJDA%U"[F(&BKN8#<=!J0-=2)T796-C%%R+$1K7V(&8 N^A;:H)!9MJLVT
M:G12=-!(CWKGEH6G5J-MT=)2UV@9"!TM=C2-98%*U::XWEL22UE6;^NI.+1
MGA8>QQ2P2J*93OV*?8)T.XY2YGG&>F/='(9CX%J5XV4EN73ML;J<C#H7(LH&
MP/\ &];#RR2$<ZZ-H-9@?*>IW:W'8*<A78^1BM5AW%JUZ+CYN0V-7>=Y0[%L
M4BP %TZ:KJ=)&BS>T,NSE[*QM2US$L';6I<V6B39VZD+++I[@X9W^.92U'(T
M8DB4G:%ZUB9>68?$(N"ZR1.AB)G$^887I1QRUI=G9=CUF_B"2 M:'%Y:ABEV
MIWD&G)TJ?Q7:&/0GIA7)>KV52UBTX]-"KC<SUL8LRY7#7#S:B/@4K;BA[T.H
M(^'4;>K9=/;9WQ8K!;JPQL3N(8+[+W'KVMS4<QAXLZ-5N_%]3;>E+.@JHGZR
MZDZE:V*T:"J0',HN83K%.5,3DM^+P7;&)B49ME*V6C#Q+[$9F;\K3R(Q<RLC
MP"VU,+-#X+T7J=#VY_>W*W9]O'5Y:(+.0RL6IJU!.V_B7S\)]1^.AK< ZZ-T
MU/42-5WUI=M[DU)=YB]S=1V8QF.'UEK>TJE*M4=EZS;[$UY+4;;\+3Y9U$RS
M,8*;N,.VDGT4X3<0DVLF<'B*B8]HUF=@]NTKFX=6+7\%'+U5OL77=5D)?C6
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M=K@ZBY9XR^/QLJR[B+M[KF5EE<5N;;4\2%-RC+LJ4C>K%^-PB5\RS50%.L/
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M9I=5ZKM%@23=+2:D:[9QOJ:#ER=@HN@9)>=>^JU.^&CX:"25]8=/EX:28,2
M"KQ$6P*B&2]I<-^N^;IQ6*BD."VI W:'4(-;:-SN1M5!=6[GX:VW[9C7=G,C
M@^$NRU#&[80N@)(UZ%SI5?M1 =SN:;$0?%8NS4RF-_2(JQP>NM8PD:R!;9,J
MT>UVJ+I0/R 3L41=)RU3@$MA1&O7K2(<-DI)^IIZXT2:;>KB]1B0+YZ6;$U\
MCD8-^7S.4[:8:$66@OYAZ$%;7-#9"E@36@Y7$S:6W>6U^NUIJGC\?1W!R6/A
MX]:-@6%1C5%4-0?Q\['7S_E'  9K+.&SN/O1?KXAZ[;YJ16$*54*W4FTA-2S
M>MPT=#(R=CG9NSSK\D>U2:@ZE;!9)&7GYAZOY?<HX>.G#A4P]QU#&$1'5[DL
MUN1S[L]TKK>ZQG*UHE:+N).BI6JH@'L5%51[ !-Q>/PDX[!IP*VL=*:U0-8[
MV.P4 :O98S.['3JSLS'Q8DZF93E%*R,1&(E5_M;?J"U]^^2*_4:^C_-FP?V<
M/[Y9G[+?\_CSS^_XC/[G>&_VHI_]G\C*BN&O\5.BOW@1OY.[S9+U0_=YR_\
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MJ".H(/@0?;K/VSYGU&(C$1B(Q$8B,1&(C$1B)HKE!_#9O_\ <SLS]39G,N[
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M<J! 59-)]2IS%>LCJJ2+I%-&59M'S4[YB*B G IQ ;]VUS"<'S-'(7(;,5+
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MO8T/'LH>0>+ _06LE":RQY>2I[R6A(Z2N;:K+.'"CV3B*ZK$2-K]50C5Y!%
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M8X>+:26_\/KO*VVX]:J;-H!8[5 C3NCT^Q>2#97"L,/-+7$^6J@*V40N9E5
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ME^4I9O\ 97_=;?ZMO\TSP/XG_P TQOZ^O_/6>TS/+2?J'C$1B(Q$8B,1&(G
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MC$1B(Q$8B0W]H%_"#N7_ +!4_P!?ZIDF^CG[RN+_ *RW]'MFM/VPO]V_N?\
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M_4C+;#VV&=I34M J>JLXZ5; _A9F[0C\?.3?ME0:IN=:SZGF&3+_ (O&*'$
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M05>]%GKBH2#]E!F:&.82A9'B9D'EO>&*( H=T!6O<7JBV1ZB S7Q';?"=O5
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M;AM.A!\9+WCS[0K<6C'32K;=&:VYKD%@)\HR+Q5YL2N(',!3*L)N05$;,S0
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M[<G'P+3XE;N0M"YG(N2-UIQT-;: (QU&FK-WFU\U0Q\^_N55&U+Z*\WE*DT
M_P!$XR@GCN)J(T*/EVK:"6-B#30S^X9;EC9XMGTE*6=E*7_78KS,M!2&W W=
MM.':3<HJYEAW;:JU!HZTJ6P!LTBL4*U#2DBVBV7E)-Q*V3(4D6>H?;UV*:>X
MZ*63BLO1%=<7Y/&<H@"?)U6.<BVCRU!^8MKK:Q]6;5R==@_3SN.C,%_;MUZ6
M<IB:NR'*^<R45W);YRVM!CU7^8Q_T>FRQ:D*JNB 2>.1C).C$1B(Q$8B:*Y0
M?PV;_P#W,[,_4V9S+NP/[]<-^U,7\^DB;UZ_<=WC_LORGZ%?/(J;\ _]Z/\
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M .TGXL #P_H]/3T]SX<L5U^A,I6;7[DVS%PI0 G1/WO0'P>D.F6NV[64[/\
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MJTAZBIY2;I4Y  .T0" >Y\!>.YS(HKVFDOO0K3;0A5_B'EU7@6K6-=J;QJ5
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M0>X27\%"1E;AXNOPC%K%PL)&L8>'BV*)6[*-BXQLFRCV#- GQ$6K-HB1-,@
M %(4 #.9S*Q>1W#CF-9>7KSE;Q*Y4ZAT:]L7&_7O'NWU?:?'>4W462:Z\V=M
MK8\9/14@PVQKLL0=PMM-1NHB**XCZL!N_P"-T!$P6^^RRL6Y$>7LQM7>\4ZV
M)RFH7! Z%NJVKF;2+U_OG@^O)V^ V>WIUCL=CB;'5+/M1=K(GKCHY4TXI)6/
M4=+>;ZP5.9UDI[-'D5<M.UMO=>6FMH[D]JKD73.2VAMK:IXG4;6^KM=VRE4J
MU:Z"MS^IF-H>RNQ*S<:=?9UM*F?6!)VF>1 S-1N5 I#HF1._9U<CILW%?9-S
MYK/+[R0X_P#*6W\A[#?K3JALXUS-U?9E&?:OO.E-<:P:W)N?6-+CJ&\%*!.$
MI(JLY,R[Y<'"C@Y XG.L^.5]EC/AQUK&NJ7O\*3O/4'.G?'/'0>Z4->M9R&I
M]_W)NC=^Q34VWT"2GRA<*:M1=Y2E7ER)2+!=XD?UI [=0I" G&LQ17V4&TF&
MM(.U5GEN9CSIC.8,GS?DN3,GJ")D*%/[9L&HI[C[.TMWI)&T-$VFI%-(6%2!
M;,49L)! 4$77K1E0,4>9Q-?I^QKVJSI#*?;<M*Q+<J*YS%WURYK^W[AQSK%E
MUE,/>2%-A*AL_75VT>YM24<]K3].)!=DLQE&CM@HBW$AS'34.JG.LN"XZ:RN
M&H=/4RA[ NT#L6[0S:36L]QJ^NJ]J:MS,O,S<E-N0@=>U91:(K,+&_*(-&B/
MG.7)V[<BCI=PY.JL=!.L_O;O&_0^_C0@[LU)0MI%K7KXUXMWKD?8/D897U3Y
M1&/"026!KZ[ZBCYG9T[O++U]&)QT/C-,?[N+@9_LC:#_ -'%>_,\XT,XT'NC
M_=Q<#/\ 9&T)_HXKOYGC2-![A'^[BX&?[(^A/]'%=_,\:1H/<(_W<? S_9&T
M'_HXKWYGC0QH/='^[BX&?[(VA/\ 1Q7?S/&D:#W"/]W%P,_V1]"?Z.*[^9XT
MC0>X1_NXN!G^R/H3_1Q7?S/&D:#W"/\ =Q\#/]D;0?\ HXKWYGC0QH/='^[B
MX&?[(^A/]'%=_,\1H/<(_P!W%P,_V1]"?Z.*[^9XTC0>X1_NXN!O^R-H/_1Q
M7OS/'6-%]TDGK'5.M]+U)E0=34>KZZI$8XDG<=5*?#,H&"9.IF0<2TLZ0CF"
M2+<CB2E'BKA<X%[E5E#',(F$1SF<S8.(C$1B(Q$8B,1&(C$1B(Q$8B8!M7ZM
M;U]%IK\A6Q$:J^K6B_1:%_(4<1,_Q$8B,1&(C$1B)Y).5X"/)G?'[U;M_P!^
MO,]'O3K^X7#_ +.H_P P3\Z'VB@3Z[]W?M_,_/-+C/9*_4+>_P!Z\C^J=3S6
M/[1O]\<3]G)^>NGIC_PZOW.\K_M%=^B8<M/S7V;_ $8B,1&(E(_.6:J5HY2U
M*LW: UDZCJBQJT9"RFU],<GZ?*M)*;<A/S#O5O*K5$;)4Q,R\>Z;)BP=%3;-
MY!HH1=03 H!-C_37'S\+LJ_,XVW,6Z]K6=<;+XZU2J#8@R>-RF6WHP8[UU9D
M92HTTUUC]7LWCKNY15RE> ,?&QT5+,O'Y/&*N^YW;'Y;#1ZTZ-6-I'P.CDD=
M=,FUZR:[GW55JRVG'>Q=>1$NB-AA']]XP<I=50IJXU=S2J<JVLLA$<B]9V-X
MZ:@Q;.FK-\1LZ.@*Z9"&.8M%RUMG;W;MV8]:XG+/6=CK1R/&Y+^80@VFM6P,
MBL [V5G0LH;:Q( /UV-C)S^;C8XO?/XCS-[*^;QW,XJ! S#2RTU\A26*;$8)
M9M<C<- Q%R6:^S9J,1&(C$1B)61[4G;[JC:+8:VA'OJ\_N69^;[P$U.QRG1X
ME,DA:CI=H]PDD5CLHY4HAVG;O5@](9(7ISQ:YG,-GW#6G%3</=YC=$_!\3#Z
M5$R/MK%%^:;W'Y.E=?\ G'ZOX.I^Z!*=-5U< 3;CV!Z2B/AZ!Z%^#W R5N1R
M.IF5Y=GLD[J3 ]"(?$]P@!T#IX>'C]OIF'9EW4RQ7624E8A@*5,H%#IT 1]\
M>@AX>'N]<QO)N\3*%V)F\(6* "D#M\>H?8] >YZ?#++=;K*9WFS8V,  )\7Q
M#IT#W!]'B.6][-?N2D=S[/&9>W9@'3H'V_[7P92L\Z"P'4^,[1-J4/2&?!,Z
MC9[I])6OAU[? ?'W?Y?'/G</:9QJTX%M[Y?3\&<[@8U(GR*M0][IZ?<Z#]C.
M0T^@YG3NF(" _%#Q\/@SM5YVANNHF$R<8'0P@7K\'I\?>Z_8RKJ?25"/-6SD
M3W ;J7W#=?=\??\ AZAERIMTE4C#[TT+:H3N(K\7Q#K[GP"/CX#E\QKM"/=*
ME'_#(H7JO@8BW4H?&[O3Z.H![P]/3F38=_A+C39IH9 W8L0_AI%O+Q2ZK"3B
MGC:2C7S<PD<,G[%P1TR=H*%#J1=LY2*<HAZ#%S,,*Q+:S58-U; @@^!!&A'W
M")?L9E==C]4(T(^[_P#6GJ"XZ;5;;LTIKK9B"B9W-DK;,TXDD'81G:(WOB;2
MQ(3J82IL["P<IDZ^)DRE-Z#!FNW/<:W$<O?Q[#X:[#M^E#\2'[ZD??D<9^,<
M/,LQCX*QT_R3U4_?!$W9EHE'&(C$1B)C-QKS>U5>?K[DJ IR\0^8D,YC(J92
M0<*H* T>?)<ZW=PS]1BZ[%DTG22C<QR!WE$O7*SC\ML'-JRTUUKL5NC,FH!Z
MC<A#KJ-02I#:'IUE)G8RYF%;B-II96R]55M"1T.UP4;0Z$!@5)'4:2B]6;C+
M.QV%K>VWZF[%NT2S<&=4_;>W5^2MPBW3(ZS%2.G>-7%BNQFMZI'LI-!J5.$"
M37!PHJHB<0/T[MEUQK<*W$Y?!Q<C$XZQ@!=BXHX^I@PUW)R').V1:S*7)N\M
M=H 8=-=-.>Y<K$;-%/)Y>)E\E2^AIR\S)Y*Y=KZ@?JCAZ1C*02 J/80251M2
M-#/#V>\A="Z]M%;ME3V/76D-/MWE:6N''.F\7JLK%2C$$CQ>N]95^QS-E1A8
MUS'&66<SJ#5\JJ] .I^@@2,?56KCCRM&9@WX=SV5$6"K/MY&T,K:[K\AZTKW
ML&T"TLR )[->L_\ I5;R(XB_#SZ,RI:K@:S;@4\;458?5Q\>NQ[ BE=2UP5R
M7Z:Z$"P;(JDI1B(Q$8B:+Y0?PV;_ /W,[,_4V9S+NP/[]<-^U,7\^DB;UZ_<
M?WC_ ++\I^A7SR*C^"?^]$/N@(9Z2#QGYP3]5ON3V1:L^K'7'T#J'ZOQV>8G
M<'_GV=_;+OSC3]-78/\ <7A?V3A_H]<SS+1,MC$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3 -J_5K>OHM
M-?D*V(C57U:T7Z+0OY"CB)G^(C$1B(Q$8B,1/)'RP_B9WQ^]6[?]^O,]'O3K
M^X?#_L^C\V)^<_[1?[^.[OV_F?GFEQWLEOJ%O?[UY+]5*GFL?VC?[XXG[.3\
M]=/3+_AU?N=Y7_:*[]$PY:=FOLW^C$1B(Q$I8=V0DOR2V6^J6QZBO)L[=<QE
M8C6?/#:55LJ1(V35KC-.W\=ML1\QJ9K)1YBHMG9F!4F97(%,B02"3-B%PVH[
M/PJL[$R!2:*=KY'"XUE?Q+YA\K/QF3)*L-64/J^W7<==9JYW-R3?KW/NXO.H
M&8<JQ-N-W!=BW?DW"D-AYR680L5AL<(NPZ@#4=!M_A]"3TQNJRVN]:PV0TF(
MRIRIX/8.SZ!Q$EN@2DU'MB1]1W;Q]AX:S2?FQ'FE.TDD!.X:CYBRHJ$+YEA[
M_P C%Q^W:<+C,W#:A[U#T8U_*+]5&.ZW#SG>M='T(:L_"W15 )TS3TWQ,NSF
M6RN5PLX9->*=F1E4\2Y)9E&E>9QZ5LY*#JK)H5U+$D+K:1D*R;XQ$8B,1 XB
M>;+V@^P5=F<N)BO)+^="ZIAHJEL$B#U2+*N$4Y^QN/ 1#SS/9(C93IT_ZH4!
M]&3[V/@CC^V4O(TNR7:P_<'PH/N:#4?Y4D+@:/EN*%A^O:2WWO ?Q:_?GY:U
MA2D1;AV>D2^'V0#^;.W.M.IGQDOUDU:9&@!41[?0!>GVNF8CF6:DB6BUNNLD
MK7(_H4G4/AZ]/@#,>R+.LI'/2;EAV0 4H]H^Y_-T#I]G+1<VIE&[=-9G[-L
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MSCZ3#F#^IN !=B\J@_I$-;?=3XE/W2&(^XHEF[IQ_P I5EK^,"I^Z.H_@/\
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M8B,1&(C$1B(Q$8B,1&(C$1B(Q$P#:OU:WKZ+37Y"MB(U5]6M%^BT+]]@@/\
M/B)G^(C$1B(Q$8B,1/)'RP_B9WQ^]6Z_]^O,]'O3K^X?#_LZC\VL_.?]HO\
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M(62:X#U!K 1VR9-.F-JBL]D(!AT<\:]3: LCU)JA)//,E)#3=NL]0O[8IGX
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MFP&(I\4/P3>][W7^7+OCMH1*Q#TZ>$C7<F8=AQ[??_LZYD.(W65E9ZR%.R6
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MRO\ 'DQO@0\0_K5NWB'^?7F>C_IU_</A_P!G4?FQ/SG_ &BP?_?OW<?9^O\
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M'IL6VLZ6*00?<0=0?O&?%B);6U5@U1@01[P>AD7H/A'Q>K<=,1,)JMHPC9]
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M;WSC4SY5(>,6#HHS1.'O"!O_ +;/H6V#P)GUO<>TSK5Z?67(""\.T4 >O4#
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MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)P/40$
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MSN;?&V=8:EV1L*YZ8C(BKTZE6.>FGZ^R*VJ"3-A%N51320)W*.G3I0"I((D
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M:B-"5XOFBN1@6 ?5#X/*4UXZG0[$Z'QUFQ=9Z<Y2;3F:C9K[5PI*+B3I=RV
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MJSAQ6WLZY;I+>MF43*J"IQZY'75S6#2N7Q;>?C,^/R01A\1V6-@<!CMUW-O
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M>Q8(#L4GX0 !-CY:)=HQ$8B,1&(C$1B(Q$8B?R<A5"B0P 8H^D! ! ?L@("
MAG()!U'C&@/CX2.VP^*NCMDG=.INE,6,H^B)RN/96O%3AWCNLW.ZP5[V/7UT
MFZ1HX[+:,O )HV-7R >2C)=PBHN +'',LXGOCN7APM>-DLU*V)8%L^,"RJEZ
M,=P2=VN,CDXXW;*W5&"_")B7+=C]L<RS696,JWM4]9:OX":K;DOR*R!\.F2Z
M 9!V[[49E9OB,@?=^+/(?6EFF;+K:=CKW/;%NEEF4K>X9+1QZSM+:]C1JT?M
M"Y5L[H&#76O%#CK$+L:S'MY!VI(S;X# @U.)% D_C>]^T^8PJ\+F*GQ<7$QZ
MT-0(868V-7YK8U-FFXY')Y[J^0Y1 E*:;G&HD2<YZ<]R86;9E\6Z9.;E95MJ
M9&W:]&9E$XZ9CH=56GB>-#UXJA["]]FNQ&VF:&M5NU-=8^;K\Q$SNNJB^I3B
M$8S:;I>%M1.(S&_MJ_$-SR3Z-8%JMQYR[7C7Q6C+N+*3$"5)<QP'J".48.!S
MO'75Y5%E67R"Y(=D(WUGE&H+L=JLWFT\-C,A9_Z.JXLH!_&C/D7PL2ML/%KN
MQ^V1BA-0"+J^%HLV!$!"M\[W#G>9H0!;;0$9O#49[4-H[MX\RC&.C6[VVLWU
MA>N+#24%B*QE[WQM1-*HZ0X?:::+?+*&HM6<9M>1+-_<9ENU!-@E'E64(<RC
MU,;5G\)VYW90]UI6ATJ KN(T:C"QORN9RN61M.5D\C>S)B5,VKFPJ"-J&9=V
M_P!Z<WP-B8U0+Y)N_+XH.JV\EE($Q>%PRVJT4\5CJKYUM:D5"K<ZC6Q3:QJK
M>6NMR,G[VCSS>4083=D@$W)4WC=A8'-.>,8JSRU*?2#1B6Z5&)FGY&1IB/*L
MP.Z 4P4[PZ9!_-]M<OV_8M?)5%&:NM].A9!:&:M;E4MY-K(I?RGT<+UTTZS8
MCA.Y>([AK:WC+5L5;+$U&H5S40MC4L0/.J5V">:FJ;NFNO2;?RP2_1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$KN]K'NG9/'/V=?*[>.GK9\Q=FZYUJ$W3[?\G0LN%>DSV."CS28QMB92$(
M[\AH^5^*Y142#KU$/#J")2)MKGARLTAK7V@M#TQS]I/.3^J'A?KOD%K[E7 4
MK2SD=(;GM^[GFLRZDN#K4C.5U78$I^I,?EMDU=-1EVR*2YSIG04;J8C7KX2>
MVJ^?NUMO\BO954I"=:5A7:]=Y_:[YI:O:1L2X3CN2'$>JZR@+'7D7SQDO.1D
M/7-DNI=[$+-U6P2\(_9NCE.BLD )]:::_<F2<4^;^[=O^TGY 42SOXLW$"X)
M;=UWQ/-\E-63\^TN%E@UM1^12QYI)H5:;1O5FVA(*1R:CA;RVM.=&(1/XX&3
M@])=EUZ^(>(8G$_-83E24,F0%#@0PD3$P% YP >TG</@7N-X=1\ SZ4 L QT
M&OC/E]=I*C5M#T\-?HD&IC8/**;824+*\&*Y,0LFV=QT@PD-X:P<L92-=IJ-
MW+5ZQ=,5$EVKQLH)5$E"F*8IA*(9,>/P'IKCV)D4]Y7UY*$,I7CLL%6'4$$-
MJ"#X$>WJ)K=D]Y>N&179BW>FN-;BV!E96YKCBKJ=00RE-"&'B#[#H94SH%YL
M?V=O.FLZZL6NY+4G&OF3,N&5<UVYN\%?8JD[ *LPC&+N'FH=<020;R\@U9"1
M8A%ODU\D0XK>IIGR:^],;M_U9],[N6XOD$Y3N_MVH-9DC'LQGMI^)F5Z[!U)
M16?525\Q&("^81(4]-<_N_T=]5J>&[BX:S@>R^Y[RE.(<RG-KJO^!4>NZD]
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MJAR*ZGKQ[;ZP5\_Y??NJ5FT5@"-)6;;JK>^-XV2.V4D_>ZYA:G,PL59&I%Y
M*]J1)0D?L6\&L:D<U&Z<R^:>TK69C%5QDH86+98#"LF8A <3'@YW&=X"F[B"
MJ\O9>CM6=%\S*TW8]/E[CY7$\1C5;[+W WL.BG4[=?.?[4S>V[+K,\V58U.-
M957>@+>3ANX&;D(^BBSF^;OL-5:(2]2ON+:J V&S$5)52>2V107%KKS^DN]=
MTFS:]U8,0^O-%IM12A;+KO@3I*-;)JP4?<K]:4F$IL-\NX'R6+<Z*IU4A*4M
MQQ[J<[%/$<H*+:LE;[J[\G<M%UMI>N_F\QB0YIIJ+UX"*O5V#*%;J;$G+9?$
M\D,FX78N9CVXV.].(0[T5C;9A=NX.FJOEWL$OY*[78E:LKL5\+/./')]ILEL
MZJ>P'E,B=H5>P-Z!<7=4F&ZFKG^WEH^0LTYJ#65BFI1.7V#<=:5DC<MA,T:>
MK(NQ4*F;N2<(MH7[L[,LXAQG\2N19PEU1OJ%J'YE<4,M:9616B[**LBS=Y&Y
MMQ70D=59]D^T^\Z^60\?R[XU?.TVBBXU./EFRRK6V8F.[OOOMQJ]OG[5VAM=
M#T94F!U ?1F S/HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$@_[2+C==.7_"#D7QHU\]K4=;]OT5.KP;ZWK/6]
M:;N@L$-)J&F%X^.EW96AVD<H40(V5$QC  @ "(XCQE?')3V5E^?U_G%J/B+$
MZ)U)H'FAHG682.N$63BB0M)Y4:TM</$.+W 5RE4]6OQU1V+IN'C64N"*97'R
MO MW'E'%RN<./N3G7WSO=J>S*W'$>T>H?/3CE<*/&1\=H_D G==2W)W+QT"\
MY3W+1]=U!1MLP9H>!D3(LKK"4FMQEN,*B2H-:RT<HIKN%50Q.=?P?_7UFI-.
M^Q4NW&>*X)[*U#R'W':>0?&_<55V%MVO[4Y ;6LG'"V1.T(:V5CF"GK74S\9
M2K42?N[/8\S)PSEK&MCFD$TBN3D*NN;.9Q]WPGHB)U[0[@Z#X^'VQZ?>Q.)P
MKU\I3HIY0]ANBG@/ECT'X_0WQ1$OI\?#/I/K#IKU\/?/EP2A .AT\?=]/WI%
M(T?+]QO_ -<% GQC?$]3UC\3Q'XOQA$WQ?1X^.2:,C%(_NHQ_P"=ER#SB<@"
M?_J^4=?#9QW25 >TD;O[!O\ ]GWKJ*W(IMJXR>_8V=8)LVE835K48ULM);KR
M JUL/-Z.CIF/VJ#V]K,Y@_!$<GCTDMQ\7M3NOE[^('%\?7Q3(Q+7'S6-=Q"Z
M7=.GAJ/:X'MFOOK%C9N9WCV=PM'<+<YR5O,HZ!4QAY"K;0&;=C#=\7N)TT0M
M[)Z+P] ?8S3B;Z3G$1B(Q$K:]KJ64/[/7D,$5YGF@RU\=WY?7O\ DHFUZ*>6
MZB'B"81Y5!4'W$P-U\.N3'Z F@>K?$&_ZNZ_3_+^5OV?];33Z9!7VE1E'T4Y
MH8GU]N,6_JQF8_F>/\S=][6:DX"L.5CKAMQV6U?:N/[6CFUO$$AFTQ7;@XF4
M%4E'"4PC,KL'Z;-:83G".0=&3* &< <?3US(_5.[T_3U#Y=><Q^8;E!F-O*6
M4A#T!0H&4L$V;=@/XNDBKTIP_M!V^G7#OVCG]H5]N'#7R5NQLUKE75@PN9+0
MC7!]PM*@ V;B!)KPL7S+(NL-@MF@EFXH]&Y8NNW-)4' '*(BH9R^.44Q3Z^
M>/7(UR[_ $V*#Y+'Y8/KUWV4D:?1HHZZR6.(P?M%+<YYW/[4>C;\(IQLQ6W:
M^TO:PTT]W76?U;V7(I*IV=6?L>F/D)*O32DUYT+9 1^221SDTCYHJNO+\OU,
M#]W=\7IZ?#...L[0;D*%PZ>2^;-R;-'KUW[AMTT&NNNFFDJ.X*/52O@<ZSE\
MOM[]4KAW&[=3D;?*%;&S=J^FW9KKKTT\>DB][),KP..-N%P"H-S;@G#, 5Z]
M?("DT JO;U]P'15 '_G /N]<D7[1YJ/?&-LT\S]65[M/?Y^1I_!I][2:W?\
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MA0#T 7//?(OMRLA\J]BU]CEF)\2S'4D_=)UFP>/CTXF.F+CJ%HK154#P"J
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MU/(X]A2Q#H2K+X@D$@_=!(/B"1*?B.7XWG^,HYGA[DR.+R:Q958NNUT;P(U
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MTQ$P"];7UCK!F#_8NP*=1VIRB9$]IL45"'<]O7J5F@_=(+O5/BCT*D4YAZ>
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MXO<1=C;!J:P-;M+FC*'2GHE YHR?MRQV8S")!\#NX2(2=O$ $!+YZ!.X!+U
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MVJ&3:]R';W)) 0A,V9XGC\?M?AZ.%6EJ^Y-_G(215F+:R!#E<5R%!%&5BN$
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M/EY:9<R$Q*O3^:]E)5RXD9%XH/014=OWAEG3E01])CG,(CF2MG)2@JJ"I6/
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MP7=_)<1B#3$HS+5K'CHFXE%_YJD#[TVD]%.Z\_OGTC[<[MY4[N5S^'QK;VT
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MERW /C Y.%J^-XD?C)_C4>_Q'M\-QM- >H /OY'$QF<XB,1&(C$1B)6CSPU
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ML2P8 '7M]SW.GVO0&=?G&?.^?R>#ZE_!]/\ 9[W4<Y\XP'G4N8,/$.SP]WH
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M M'G%&4/$4>W%8N[S!L')3)A.UI2:KKSM\QI(.$3$5,U]\:23V<SB,1(.ZD
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MK$D@DG4RPRBUHI"-R^4(>"8CU  ]P,C[,OZDZRXW6ZZGV25M5@"E @BEX]
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M0^WI+C)ORL7XBKA*J/G*==V"P3,H5!_4I-P1-XY51+\15Q JB1\@/03=Z D
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M)&#912Y4BE;$<><"JY#"1N1OI-ZZ<KGX?+-V:U;U\33:F13^5=E97K*@A2
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M34[E1XG8I;0?2=-!.RFLW6K4#H68#7[ITFEH?D#0Y,Y$G?RO"G.)2@9^P\]
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M_+5<338E5UV[:SZ[=54MH= 3UVZ#IXS3_P#XAJ.\;+HKLY]F*R"J8"HS;+%
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MPW=)LO5TU5XFB5>,4L4 F[".(X<-33$<5PBZD55'ZR"J(N?,(LFJZ$HE$ ,
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M/3559BJD@$J 2!X3=>8S,QD*M.?QL\U_H5Q._5_;.<^R/;_R^F35SB)J#?\
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MPREM";1M<$'0*6UDI\IZI=N<]Z15=B9_&L.=XZNA,6YK2Z_#\-EP916R.$W
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M/-?Z%<3?OU_;/]K'LCVR:@CT#[G\OV\1*(^9?M$-O5;<5FUIIF195&"H,@:
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M< !_#M-X=?L]/=]P,S#CJ3J/?+YB5^$N=]F5JA?7W'1O;)1MY$WM^<<WH_>
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MB(Q$J-]KQ]5FHOWCR'ZIRN;(_9L_O#R7]@7\\D\Y/^)%^[OMO]O/^A9$K7X
M?QA:2_SK;O\ 5O<\G3UD_=ERW]73^E431O['/^\OVK_7YO\ [+SIZFL\^I[_
M ,8B,1&(C$3 -J_5K>OHM-?D*V(C5?U;48??JT+^0HA_-B#XS/\ $1B(Q$8B
M,1&(C$1B(Q$8B,1&(E;O,Q*]T^Z52Y:QJ>QG4I8H9XULEAU)5.-]9<M4*J\:
MJ$#:&_=Z1LXXIM;>QLR*+-%@R,Z*1NZ416*8.@2[Z>GC.0XZ_CN9OQ!358#7
M7E6Y]@)M!_[M@X;(+K R:N7?;JR!E(D0>HU?*86;5F\)1F^??2RV6XE?'U,O
MED:?,9V:KFE"KD5A*V("N009$^0MB<+NFA;+.O7MBV%J9A+L6,6'(KFCL9B5
ML*32:5JWR!=J=QUU&"\(^%O\M@CT*9R<W:<H]!SJK .1V[E<.!;B8C:HQ;Y#
MB,=M=2@LWTVY^5HXW>5K^*!J#(A[;YXU\[5EW78^=RN/9NVI=R//9:!M$?1T
MLHX_$)7=671=JZDZ;=P-YR2R2Z9%D3E524(51-0A@,0Y#E Q#%,7J4Q3%$!
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M8B,1&(C$1B(Q$T]R%^H7=/[JK_\ JM*9DW9?][^+_:./^=21KZR_NB[HT_\
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MQSGIIQ?)<ZUC\B]3J7?4O8B6NE5C$]6+UJK%CJ7UW$DG4RNS 9*,AAI0 _\
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M[ VK66)NK+/\+'P&T_9&;9E\!53>EZ7XX\L^=CIB.R@#8PQ4=S17M(5$LV6
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MN?&5<.G"IC*KN%3'7<KJ'55.=0YC#J[RW+<CSO(W<ORUSW\C>Y9W<ZEB?X
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M1A*<I@$IBB(#X9]U6V4V+=4Q6U2""#H01X$$=00>H,Z[J:LBIJ+U5Z74JRL
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M1 0 0[\;(NQ+TR<=BEZ,&4CQ!'A/NNQZ;!;62MBG4$>PSS*\F>-MSXBW\"*
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MT-:KHF4JG57H4 'TB'7W?A\ R]XV(?=*VJDF1-OVP4R$7Z+>@#_T@#T /P^
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MD'+9,Z*#ATFU(0JJR*1Q*4P^( /3(SY_NKN/NFVN[N/-R<VZI2J-<Y<J"=2
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M#)F48B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B:?Y"?4-NG]U=_\
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M$! >@Y]*Q5@RDAAX:3D$@ZB5B\B_9EZYV.Y=6W3+]GIZYJ%,JO#,8_NUU-N
M Q@,K!LQ35K#E8>A3+1P>K@ =QFBBAC'&0N"]0<_ 48W*J<K$'@Q/Y51_E'Z
MX^ANO\X#I,CP.X\C' JRP;J?>3\0^^?'[_7^<)4?L'2_(W0;UTCL/7-D1AV
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M<+  =(EY[N_E><)J=O)P?94A(!'\\^+G[OP^Y1,0Y#F<SD#M8[,?^0OA]_\
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MZUX[R[<2QW#I3UKKO466WX^*6LLLRZ,&L*F1E*/+2P%2S:%CL%V7ZB87,_\
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ML<L2%/Q7G@NU[^8R*\+ I?)X?)P:JQOZ+D</;:%%5MC K7RO 7'2AR18U*!
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M3XPWNQ&+\0>XOXHSL4@Z"'C\7Q]WPRH_5G;A&APL73^K7^/2??RW%^'D5?\
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M^5TKZF@HJ<C<53B0 $YA'&N0YKE^5L>SD<FZYGN>U@SDJ;+=/,?;KM#/H-Y
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K8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2113965d1-pc_clinical4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pc_clinical4clr.jpg
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M)87QXI34H.-$9,-%=18V$P$!  (! @,'!0$! 0$!   !$0 A,4%1(&%Q$#!
M4/"!D6"AL='QP>%PH(#_V@ , P$  A$#$0   >_@           !SX*'.GYY
MS2LO@MX]1ABC2^3.G@-12(&>-K"0'D)&4H?TT).F)[S(&HYZ#3DZOF1-)RRC
M9DQQFBOBPC-G,\^QOP9HAIEC\F5,*:V'],";:DA(R1@Y4FQYOJ?H]AB@60
M                        <8B8F+(N4N4R7T6J:[%<&P!*#R$]/B<\#:4L
M@QIZS<PXPF_!!2_S6<OL]IMJ<*S9<EQ41*RHC(F_AS\/](YQM.G9R:*$(X6P
M3LQAIN7R;+F#,>4.=+2WSEZ0,M8LLTU-N3G\?Z4#5HNDV.
M          !JX:1FUY,RJ3T%MG]->"=GI)$0(M ^A\3]$*)V#9<TQ+1(R?,@
MY:!]32@WQ*A)$34@!#B;%IG-([%FFQC3[DG,49PT%-]RDB]2-'W,"38N$SYS
M&-IR1%;GB-F#3HZ*'U                                 * ,Z80O<\
M9@R7 KTS9I.;O$A     *=/V6^:JETE@F&-13=(_I3!<X
M                        ,0<_#8XYKETD++P/>:;&X@(Z4<6R>@AABRPC
M'&OA;)+3=@O(XY'O.OQP .@9OX<9BTS4XOXA!ZSHB;*
M                      \9S /<38F)JV6^0P@YN ><W.-0RK2L#6LZ-%#$
M#+O+3-;"ZC?,XVEI&PYH66N=.CF\467L9DQ)S;/]+@
M                           !'36\VR  !BC*@    %<'G+/
M
M
M                             (I=([5,IQO7D@@\4NL9Q550N&6I:^5V
MN36)'IS:T6R1*;9(
M      /X4W,,6ZO9,UXUWR%@NN9# @   !8\=GVQ&/LZ;08SV&N2'Y2_H
M                                           !\^?C5[)NO6D^:-2*
MHE.-       !:T6R5NQAC;?:'&6POU^>P
M                  :\1_&]'9FP=I'LSI<         +2C&1^ANOV\=ZPC,
M                                            '@Z^CF9CO5;0F%ZY
M;:RS,_E]#<$5Q(H$         /UQ];B8AVGZ X%W7]O35
M                           "%T5DXZXITEH&RXT'Z<]*MG=A].]O]+0
M        !<,1RIU%UD]$)=:9,
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M1RIUEU4]*_=TU8     J._PVW+!,@              !_G-PQYV>6TQ(
M   #$U=?_HJS;Z32CMJP (!;;'/[E?   !R[QMJ=J[',26M<9G).Z\RZJO=6
M6^&3"HD6K=@PK@.FV]/<A;;[R37/7[YY      'YYXU'ROK-SYS]I#BZFV@
M ;BXAVHZ'Z_;Q     "H[_#;<L$R               '^<W#'G9Y;3$@
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M3<          5=)L><D=K_,K%55M  '2C7+?S:S%NQP    J._PVW+!,@
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M4@   <Q<R:Y_3XJMDXAD"O+K8_5QU_WC[T7R/B.?VR[V#;+ON;C[+%[1J:@
M 43.,/<H=I_-8  ;D8@VKZ&:_P"[X   %1W^&VY8)D  !I#E36Z+W>*@
M      ?GJJN:NF6'?+:8D       !B:NO_T59M])I1VU8    &CODAM#&X%>
M@ );DR/;L>K^LO\ >0   %%R6$^GKJ;GC\K^G'T!$ZVV8&JHM>95!]R\?Y6^
MO'T   .0.VWF!5,IQH !/;%-NR^GOJH   !4=_AMN6"9   <<MI?.&N)UA,
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MC8?#WT7NZ*T>;MI_G]=?V^.[V=-7CJBW^GKJ(W<8^  /S$,P=UM3_2H
M         :Z:/9CH333+  $CG=FWC]<=70           *7+=/6 <;]O_+&N
MY! P -V\+[=[\X(W/   %1W^&VY8)D  !QRVE\X:XG6$P )O99?;T2RCZ>JZ
M96FJI+;9'\?KJ^?WT8:LLWLZ+GZ^O[\?;\1:YQK6C).NH  _,0S!W6U/]*@
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MB+:GHCK[O"   *CO\-MRP3(  #ESD_7>(VB2@          1/-6IO:#5WT5
M          $>A%WD,WM  &NFCN8Z$TURP !))[9=XO6_5X "*'Z,,2$Q!D3\
M$()L94]1C#W$8.=ANF6R1,D!XST'I), <<=OO+.N9# 0 -V<+[=;]X(W0
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M>,*RX          !RHVC\Y>J^KGHT           (]"+O(9O:  ,%$KIHMY
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MC4@LXL0\!N4YY$N.B3G4IQL>Y_A-#0%QT-<[FN>5&T?G+U7U<]&@
M  !'H1=Y#-[0  /YPTC\FMG8MCF_  #:;T1P1<&S>.P          !6DC@>L
M&3==O=T5F"KK/[^BL]W168*NL]@V";[<8GV:    %1W^&VY8)D  !1TUQ'>,
M*RX       **<7BY^@ !RHVC\Y>J^KGHT           (]"+O(9O:   *9U;
MR1J_Y[YS  'NO%)N?ZIZV2G(-B          &!KK-J#EO5_X??3X.^C]'QW?
M?K[O!WT?H^.[8G'N<[AB.4@   !4=_AMN6"9   4=-<1WC"LN
M<J-H_.7JOJYZ-           "/0B[R&;V@  #Y='WI-Y/;-Q?'=]  _OW\W[
MZ%8,NG:#'&?XY         &"KK-J!EO5\8FJMHRU+<L356T2NUR7<3$.TG[X
M^@   !4=_AMN6"9   4=-<1WC"LN           <J-H_.7U^5WH;G8++P
M    ,7D&&]0]I[@ !'H1=Y#-[0   *WP9,]0?,?8=QR!^^WXO+T-P70NT../
M0;J]/U+N.0       !@:ZS:7Y8UEQ?'.GUCF?XK+1:EGEM42?'6[]9:/=T5F
MSF--A+ L,U     J._PVW+!,@  *.FN([QA67           .5&T?G+_ #PC
M];;2P9F@       "M=@,(=4/2S&8 $>A%WD,WM    &L'G]G&F-5,E#TU_1>
M'H_@/7C8:"8=P,DYVNZN;K^/K^@      _A74A@^M.2-?JP^>S6JV2'(6^_X
M?LIU10>"S2S9&38]VOM4EV7QOGT     5'?X;;E@F0  %'S7$7S^NL
M    "#WN(:I^.F\=I8,S0       !6NP&$.J'I9C, "/0B[R&;V@   #RT'?
MIIY9[(QR#7BZ?2O7W7+.,.Q[@ "SOGG9OK^K#^>0    !$KK&M=<A8*@E\AV
M6I;EB:JVC+4MRQ-5;?Y\=N)IZZ2=55NGB3:#)4]<     *CO\-MRP3(
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M?'=]^ON\'?1^CX[OOU]WOZ*S<3$.TV0Z*T      5'?X;;E@F0
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M!F:    /!5]7NINS^_/(  K78#"'5#TLQF          /@4;]_.N_9Q%.>
M     -BJJU8+).O%N1/)MOQ'*/TX^@    !$*ZV12X63\\_']^>S^<\?QQY>
MSKMZP2[T_':               .4_F-E.TL&9H        K78#"'5#TLQF
M         /R5E]<4S]\51]<1_G@    2#CFUOGF]/CFPOGD
M             #E/YC93M+!F:        *UV PAU0]+,9@            ?P
MC'/$&Y17ZXP7+P@]IG>$JXYG'RE/'/\ 0
M#5^W0CQ\=0       &1^N[9NX38
M
M                         #7?(.#,+66D2ZTR>](1F(
M"*\\0+Z 6O\ '.0                                     ..>WOEE6
M\B@0V#@.;NJ.KWHYQH,>;(GI,:6B:NF4.I)DP         "AOOYU,[?D#?WH
M^])^.?"5<>0NHK<L@DYL.<L"[3^EF$#)P:[E^'C,F;[@
M           T4SAIS$[K&A9\9R%N1B#:G14R)[C&$G*?+F,*;C'U
M  *W^N*5^^ -ENKFBG/P(0?@E!@RQS7DWX-/C,D4+7(*>4Q!_"A2V3H,
M                                           "C3Z&6,4?,F9%#P$^
M/T>DITV1                               (?=XO4DKQCY>WHR=-7W7#
M,MUG27/.DU,B0DC!;I%"5@            &D)&33\L4AIG">D1,&1\]!M&=%
MP                              "H);B_73(>"O=T5F"KK/N5A[:K1NT
MR?6\G96Y;IN\:/E!&_QNH
M           1RX6&,7./XNJMV3IJ^Q8].X9\=L:(L90'O(&9PGY8H
M                                             *F->2UR8&F)>Q[R
MQ2H3)F,,F1PEQYC:4       T9AF .5.-=/@.\N:?1&I[I+_ #$U/4>8\9'"
M/EL%'FRI2Q<Y!3)$!)D?<M0EX               (8<CBSR!DA.@)I*5&; E
M &9)\98AY11M&:@%U&XQN.    #3@I V6,0:SDK)@00SY\2O"VB*GL+6-QP
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MV:U'H,8"Q"FB6&9(T;;&!*L(P?HKT]Y8IERB"^26G0T
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M-($(\YA$7"2^$'))'<8W2#,$XRHAEJ<L,+FY+D20RQL>R]"(LWR[,0<B:_\
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MWB0$?6<F0W3(_P!^R1_CZLP':F6I,8[$N>K2770U3D!M.K99(+=;I9(+M;Y
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MK:QH4DO$FUY]HYI._P"KD[(![4YI*K+DEBUK]*9%DBIAD7L3962#<5+R8RQ
MM)N*(=R1>S_(V;KM++;KM;[NV7VZ7VN$;FSC9Q4MIJ-Z@#Z=MSKUK9'M=^?N
MV -FZ2#EU[&K!\^UN&N445 Y=%-(:170:L'SZD!9)U2HIYHHN/?M5' DHTL[
MEBUO_ALD+O P[=*$-6\BV<47_P#=U 'T[;G7K6S'_7BZ,HN)O5%TDBR#E\TD
MWF;DM?>K/;+-5U%-U(C#CCSPJ2EZ-L=40L#W-"K&%=RQ?3_&V3&OT&=NG.FF
MDJV<57:\2Z@#Z=MSKUKJ&Q)-%L0(.2;K99.]63AR7469]O11O7OW.^MSOK<[
MZW.^MSOJ.)ZI-]DQI]1G;ISKIK*MG%6FO$NH ^G;;4"'/%>0(E7($2KD")5R
M!$JY B5<@1*N0(E7($2KD")5R!$JY B5<@1*N0(E7($2KD")5R!$JY B5<@1
M*N0(E7($2KD")5R!$JY B5?]/:6?[]F+7?\ ALD;?&P[=*5MXD>SBBW_ +^H
M ^G;<=]5[P9_OV8O?_WVR(=K>M:L_JU^[U&67.V[A%PZ;)((76-;K=;;NV77
M:66NE[G3G9Q2AI:PZC='[&_0I?95IT1=2:Z*VS'?5>\&?[]F/*> E>W05M+(
M/W%Z[5R[8LF[FYZM8LY>C-\\\NCY!'MDM>:,8YM8X;6H1CJ'))FTOT>DEJ\H
MVM;I&D;KT8>,0JP(SLNM'H675'?5>\&?[]EBKY#S:E#?Z*=LE+<,0:D,7OT]
M2($R)V0335@&Z@%IIJTVX[ZKT>*WH\5O=C/]^TP7WAELEFN]L>V%5UM9 SO9
MHL490_01O'1<Z_4QTS(HD(A(QM1YCQ,WU('T[;COJM/"=EJCZ1W.#;HI9YBL
M@N?27J5735&_N%G^_:C+CQM]HRSW-[VHVNNBP\ILHV45\=?Y*;GRFRC;5S?I
M>V+F&5XEVS+DNI ^G;<=]5ETBT#M8]H5-.C%Z(U>/)%32@L*F@1ZF018F^+I
M6^6GW S_ '[01SNQ#:-,=^:=J+&>.Z*JMK&WEDTR:6[*-E56UC;RR:9-+=E&
MP*Q&P5U('T[;COJK^%.R;H6'3$#5,?K*J#1;<8PL:V67=UL_W[8UUOC/:/CM
MV6[1(7"2 ]53QTGQ-,FFF,O&*J>.D^)IDTTQEXP6ST+/NJ ^G;<=]5[P9_OV
MXX\\EQM+(IN$B#%1@X[,^(,AC=X]</E?\E-SY391LHKXZ_R4W/E-E&RBOCJ/
M!G#6_J@/IVW'?5>\&?[]NVZZRX<\M?-=G_BCI5)WV8@^;C&1$COE>633)I;L
MHV55;6-O+)IDTMV4;*JMK&S1%W:;TT^FG5 ?3MN.^J]H"1XR=9\BFZY%-UR*
M;KD4W7(INN13=<BFZY%-UR*;KD4W7(INN13=<BFZY%-UR*;KD4W7(INC8 P!
M;[+/]_4!"&Y.=C772W0P:U==F?OV@MHZ<N2;FU,N@0TC@5&,,V-Q!)FT'\96
M%,6+-53QTGQ-,F "L00_JP/IVW'?5>T0+T#L,^]'V6?[^ICY+ST^A12Q*PN8
MO?7=E<GQS?1X]</E45GS1XL;5?(#7CUP/:\PZL3BR;EX01;ND2*"K,I&F2:F
MO6 ?3MM>)^-[RHYKE1S7*CFN5'-<J.:Y4<URHYKE1S7*CFN5'-<J.:Y4<URH
MYKE1S7*CFN5'-<J.:Y4<URHYKE1S7*CFN5'-<J.:]M1U0+T#L,^]'V6?[^I3
M4O14&$$R""RR;=,J64(7]DN+,="!0UJ>M55;6-O+)IDTMV4;*JMK&WEDTR:6
M[*-M7"+='RR:9,:TU-JMFR#-OU@'T[N"!>@=.I!M;=8Z144V[7"5]NQ/O1]E
MG^_JF;Q9BN2)K$%.R.;5U&V[,+6*JGCI/B:9--,9>,54\=)\33)IIC+QBJGC
MI/B:9,6+;EV[=NDT;]:!].[@@7H'2Z]362T6-:.'/U<*NTFR]NJ;FQ5RHF\<
M.&5ZESEOK>K?JR:_5)HUUO<-NF?>C[+/]_<,F:(M'O\ DIN?*;*-E%?'7^2F
MY\ILHV45\=?Y*;EB*4+Z-V[=HEUP'T[N"!>@=-R*=ZGDI^=JR;76[@U\I9H@
MO>N)1NMM9-;;$F;='6T:SLUT8-=-=6#2Y3IGWH^RS_?W":8NW;5+=E&RJK:Q
MMY9-,FENRC955M8V\LFF3%,="ZC-FV'MNO ^G=P0+T#I5O7O)VN[VKJPC9=K
MQ!#5'0FCKHF0\NKR:26B9!*^^PFC?7%4:1<ZJW],]_V$>>G7GIUYZ=>>G7GI
MU:ZTLT[ANMMOM)HWM'B?$TR::8R\8JIXZ3XFF38Q=%5BBBDW1[ !].[@@7H'
M2K8O8378.']R;9519NP73?6#E[6US%UXR:2RMBJ#DC>FQ7\INV631:MUTW73
M/O1^Z)*V5L6\ILHV45\=-V1%5P%"-PS3L0#_ '&=P0+T#J;[+%+=N?>C]T/F
MB3]HS%+D4PL?5;K::::=:N]9MM;CX2R[CXG6W4RU\OB3FZW50XKIPI5Q5EEB
M=G<$"] [#/O1_P!00+T#L,^]'_4%\<#*7\LA*Y9"5RR$KED)7+(2N60E<LA*
MY9"5RR$KED)7+(2N60E<LA*Y9"5RR$KED)7+(2DXZ'24_P!;WV00(]Y[G1RO
M<Z.4(G 8V^_5\H_(^C'GY5^KS&."A$K[5F*]JS%1>!D09G_6(JN212LEJCBK
MY@Y;L[SY>UXS<6NFWZNER#9P(54\=)\33)IIC+Q@6])03^KGPUF2TMCK+1SK
M$QO#EHT*77MM\.G^B.1/2ND!Z'^KL@)J*"]T=5NCJMT=4!TUM"_Z?-8Y8X;<
MK65RM91$%:Q:_J\9Z?T2#TO]7LW!RUIO4AK>I#15<O>R_2?_V@ ( 0("!C\"
M_P#@=>0:6H;@/7I6@)&ZH>I&GE'6QO1/J"F5,>!_W4XY? *<<O@%,F8\#_NI
MY-UL[\1ZAI4V%#<4/V&GEVUIWP?UGBANZWC54.R>D*1FW"HXDU#AK/6IY%E
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MF-:1  '#; 0(C1Z7EE7KU<ZZ>UMO!L0&)RQM6<*\2>413^76CY*&>ZNN,;8
MP<^"SA9@3,3"0K\Q*$&FAF)17$DQ%=3GOBLX58GI>65>O5SKI[6V\&Q 8G+&
MU9PKQ)Y1%/Y=:/DH9[JZXQM@#!SX+.%F!,Q,)"OS$H0::&8E%<23$5U.>^*S
MA5B?:DS?>75-+/=F(NH&3ATG:&HVXMJ^3;^K1M$E\1^]T1_(=$L??9;ZY&T)
MUNP/M$KG;K:K>]->\5'9MS\FJ[,M*B.QO$5$811,\Q4Z*G$=PO%O84G"-V('
M0VBEDE;FYZN(;IJH9*1<&CM<G+ FSR:3$?P_?#G&K$G)T6KFN+;PSAJ@2(",
M8-^]JSC7B3,Z/2ZQ54W+8)<506;;MC?P5ILP*EI=Z]>K=G3VMD&PJ(Q-CC%9
MQJQ)R=%JYKBV\,X:H$B C&#?O:LXUXDS.CTNL55-RV"7%4%FV[8W\%:;,"I:
M7>O7JW9T]K9!L*B,38XQ6<:L29*43<DVK/XAL#BJDUE(&"-9KKVOY-OZM&T2
M7Q'[W1'\AT2Q]]EOKD;0IET!32@00;"#411R0,=!G-G&@V<&:=T;()2(J-#K
M36"EHFW4PT4:@G&O&O$.UWS5T*F6:XQ9A^W>%IW**U?J]0;G&Q]HF.U"<*4F
MN!$?X9BWP<HNEK\NI,-%V[J\<8B($?A%<5954WRE-[6+O-FQ9+C&L0&;'X,\
M5;54Y+2SD-8BN9F39#N$6PA'^%Q6"&3RBZ6ORZDPT7;NKQQB(@1^$5Q5E53?
M*4WM8N\V;%DN,:Q 9L?@SQ5M53DM+.0UB*YF9-D.X1;"$?X7%8(9)F&4Z/48
MJ#1C>==[HD5W0?XBN*LQ1VOY-OZM&T27Q'[W1'\A16K^3Z6"08WPFW<T:NO3
MF?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH
M\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3F?TH\S3^
MWEC1"X51OA5A%4-&G'CV3'WV6^N1M-^6'^YR^4CUP[9'3P>N QG8AIH%3BC
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MH\I35RGB$OZ:;0RLV(<4WDVXU>$1OB=:UH%H)FVRE*\ZW*,#7!1PX8$C9_\
M,='N'U_J;)[V/J]'S<.Z3]6G932>UT ]U^W:?EYC^H<VA_[ROZIC:>2O2LJ^
MB]>BL+"]Z^TMM1&XHD45.39BZK%4 !4$@8 !4.SLA,!MIV':N)"TF.,>J($8
MZ?V]AIJ7DM)?*6[^4J$ 5%Q;BJA8 0G#"->S_P"8Z)N(A&$:ZK*9[/?I[-,]
MGOT]FF>SWZ>S3/9[]/9IGL]^GLT<22DY> @X-S9.^Q]7H^;AW2?JT[*:5@T
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M"4]T],MRR#H()1-A-3UH7HU%,;J5!2:EK&&->U?+S']0YM&MOO@^K33DTO\
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M:W]5/K^PR/;J7@<<&3>2J[4/M A,0$0<OD&D1,?GU:(\IM9E6>YA=4$J4$_
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MI-&MQTC+=42HDK-JJU*NWBJ PDU]!A0S2\^1N@ON$'>(K'H#_,O_ %JMJN.
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M;#)3Y!$H;*U9)I\A?9TL6>8< !;^ND6,:UA28BM,YJ'(Q2%=N[ZNX_FR5M5
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MCL>CV@/SXTR%+:W16M4H7N8UR[53AUO11K&QN^44 KB^E!FS8@3ZH9D-D6)
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M+(Z<-J9YCGF2ILACT6-RF :O*1J\S<CFHWBG-=W:U4C(&\VKC!KO$&MB*1P
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MBI1;&"BI6045%EQT5%2*+5%3F<?A*!]V1_\ *<?A*!]V1_\ *<?A*!]V1_\
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M\Q[;M(+"<(QG#P/5$5C"W9?:$W+7E]TC'L(U>W7M=ZE[/)3)*\ 0Y6OFQC=
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MCT<8FQNC&HP8A"8T80B&G8P01-1J)_5]TR2D>)*VHY%!.CLE1B->U6JCQO\
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MP+>=.?>Y)#<=+1SYT15CP+J/%9L@G&WNL;KIJO>5>++#L*IX5"F775!C$0,
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M.(&FO1!_;_PN]W[+PV0^-C=4]?;FY,_67F\L?VV/6RUDF=LGNCZ:-G"U\0^
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MN/S9_P!,Y!^5N/S9_P!,Y!^5N/S9_P!,Y!^5N/S9_P!,Y!^5N(TV+CG*E0Y
M948GB]Z_EGCD:4+]A+-XW[",1=%147_]^$NOD,LE/#.2.51QA.'S!.VNV.62
MU5;JGO<?:[;[D#^Z^/M=M]R!_=? JR"R>DDS2O9SXXQCT"-Q7:N:<B_!;[WZ
M0#/+0JL*3E-Y+$>N[:Y_:BN9V:-X^#._^ /_ "_'P9W_ , ?^7X^#._^ /\
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M@\.R25&A0ZLL3+H]:V=XA[.@S*+=A0-2I>YN2!UG(51\_3B?+]H=O6^;F/\
MFGR_"=W+\"#7A\"W>)IOZKH=>IT39N^U.T[4\S?%)&WPS8N.\CY(N1='X.F2
M]3U&G4>SWR3E\G=]=S-.YQD%/B^<DQ[%LDM9UM)A"HN=D-*6X.Z3="Q7)17$
M(52R88CW#<:%+)%5^HG(J)IG.6I9FF#RV)B0$@/C'+)KV8E5RZ[<^>^7+E6Y
MIZ2=ZJHVO14^O5=>/,;S!' N:ZFN)W38I"OJZ=43&>(,A6.968:BTC1+*OB7
M-_'8HT*,;W<ISMNUR<'!NV\X)1;M-=O,8K-VFJ:Z:\8-B\?(B@O?+V3'L,?R
MD56+1L\*2PDZJF-+.P]?-B37B,#J$54T5'M5$XRRMSK*Y5S[45T.K&"EB2,?
MH:$5=(Z^',J:*1;WR+;^)(TQ91SF>_EL&FT;=O%U6Y-YC'E=?BQ<8@CJZ234
MTXE.8)3W]W2>TDP-_?/:!&H]'Q0"17<L3=>S#+?Q7I?9&ORB!T_0\_Q#VEHQ
MTO-YO6!Z3HN7S--I.9\'5OIXP#"?']WL->XK=>)^%Z>*>S-HEETW1^(KT76Z
M;-_-+R_3H[T<9?3XYFB46+YM86-E:5S\>996U9(O$TODQFY6WAQJP5HY7.T/
M"F<ASU46Q>WC*HH;.3#@7-;Y=PZ <2.ULW%9/EM&D!H[ $Z0>2VQ*I",<Y'B
M9W6JU=V_5)MSYB61,[+68G?T=128I0BQIS67D1@+B=%!99':,EY+.C@:,3W2
M01A_6C1>WCRJ$^RR&SIL%L"6DYUWY<W. +"C1Z>7"AI;3[PQ@91D1#%&#6J:
M.*C>:1S='-<F8^8@(5U!H.E%'IHMU765,DC)[2)71\KO:^HMHL&?'&2%31(Z
MG>)&R'\Q6;FZ+_1#@M'X;UOMK=RZ;J>LZ?PWI:N19=1R>E/UF_I]FS<+3777
MU<8)C_AW5^VMK:5G5]7T_AOAM/)MN=R.E-UG.Z?9MWBVZZZKZ.(==$S/%)5A
M8_@^!&R*H/,G=\@_D<44QQI7Q@7M[B+VM5/5Q9K.N:-+R)2V-O!QN7>0*^UM
M^AAR)0X\2,9[Y;NJ='5B.8$FGO+IIQ!EG=0UP)>&T>7&BKD33W5<*W Z03Q"
MK?6Q61Z>.QNC)RFT,]KTY3-NJG7&\DH<A2*K$E+1W%?;)&4FO+0ZP)!^2K]J
MZ;M->,EFT5[09)+QBKL;*?65-[7RY 5@1Y!>1+Z,DLD%2DCJ/<]G8OJ733C%
M,IR2XHL1'E5'57$:/=WL"&QC[*MC6+X0)<]T!LUT5LC17-8W737:G$>SNLAH
MZBNEHQ8MA:6T"!"DH1K7C6/*E2! ,A&.14VN75%X'D)L@I T!6-(*\+;0!TY
M!OU1I!V;CI">QRM714?IPM]$NZB51M$0[KJ/90S5+0!UYIEL1F=#00M.\[?H
MG'LG02*N\@>R#\H]HZ>[B6</G#NTIB5/+A,,'F#W(17\_5-=NSU_T 1ATT6-
M(FRY?3H^:Z2V%$&V-)E/DREBA,78[IN4WX*<PK>WU+83(K8B4..[QW5M(:Y/
M%)(^:G(QL8Y3H9>H<)FSFR=WRD?=7LWAN9=:G27)%CXQ2QT(M_.?J5 R)S2.
M8,,4_+&J=.R3V21^GLWAQH<>JF924:S)#XZR_ *J$B%<B3CM4UCU1&#9HBB"
MW62/M]&\,@91R&O1R=0!$0!U&]PG'CZ&D)TYG,W,[[NZJ=O$"9E]PVFBVDY*
MZ$9\.PEL)+4;B\MZP(DKIV(-BJKR;!HB=J\2,ARBQ;5U$1X1FE*"7+<CY!6A
M$P<6""5,.Y7N]#!NVM17+HU%5(LZ*_FQ9D<,J,7:]G,!(&TH7["-81F\;T71
MR(J?H>)W]B"MAJ<,09#;W$D2Y+ML>'#C!:23-F'5%VB$QY':+HG8O!:B#+FQ
M[@,?K%J+RCO<9MGP]S6+-CUF25M3.E0V/>C7%&QXVN715U_0BW5'-'8U4Y"N
MB30H1!2&A.2,]X^8QCE9S@N1%TT=Z4[/GSRKRTPR^"8KFI#Y!*$$Q_#(%I33
MZT=E)8 9'L@ ED8TI--![T5>S54\J/8VR@Y-$Q:?DU[D5K1R@6E14138\>L@
M@EV<-Y83;"PF2T0<='J;:U7JU&=O%-,%% .6[.:ZR62P;6G\0;YQ,K6S>:B;
M^I;7M0*/^$@N[Z./YPU#G2Q&9/D5_E=A7U\X:/MLJI9M6),%\ :X?46X:EHV
MB;R-Z5QQ/<_E]K^+6KR&78P*:9_-K\JQSIU5#F3YL-B39A!RF0X,69(D! 9C
M7&;RW,Y*.WZ,W*F;8_C,W"?,J?-\L\@9$SO ZE(=[5QNJ"4.)6LR)8W$$A+5
MA"-BQ '$9RB0CA=N[BIAXU6DLLBI?*7+X;95%\5'P>M3&^7-JLS *=#Z0TV=
M'Y4>+(CG*V2UST8/M(M;<>84N#55MQY*>5,3"KF]>,-5X=!QQ_M511)LI_2,
MGR+ HC/BIH4[-%1JIZ<:OI>7?Q8307OF1(\MWY?2%+C4?!K^Y!(CU\T=E(JH
M-7+-%$U\5CIL62X).ZPC--/+/)Y4+"\0Q>CR[/P>T<?%K*9Y;3K<T:N6ASYU
M2VVQ\L.+:E),9&GGEN&"2UQ>8J/1W&09.RR#E6$N\VO+F[S-^/8@6IPJQ@T\
M:8/(KBFB+DV62<FAI-+7%M3;&A(Z(KVJ9$?I9V>*RJ^T&_RG:"RNJAXY-;83
M@91"V#'8Q]T2QDPH3Q,(\;R;$VC5=6*UOZ?JRTGOKJ1)<=UT8+-\AT1-Z111
MT2%.=O6X=&5=&IW$=V^_2V5G%Z?I^4+RLQ\+M>NUZ9*^5=&20;;MYT%7(^:'
M[2_N_9RO#>1(\R+0#?:#FZ)48W4$2/R>EUY CG (\+73K_M+OA?7RJVME'C^
M6\<[2Y!D!6JMO.MU6.H8L4*QS%:!I30D54A!^TN[WV=62,!T:&^$!8$=Z[GB
MKMB>'M(O.D:EZ+9N[[N]QY48_/36'=YI854KL150,_%+N,1S47Z]C2:I]%.)
M5;9.YDWRX\MLQ/E[%:[\\X$6[P"M:5%T8KGI76\K1==J\EZ)VM5)U96/S"^!
MC>%XA&(.HS*7Y:8YA\V7C4>P^4VM/;K:93:3&FZ@KG0BQX(6M'L>]51?*KS.
M@7TJURZVH9E)-Q662;+K\F!T<V27(4I8>]K;3&WP623RAC9O KQD>B.:B^0J
MV.23,PJY>+9A85N364X\\%OF%C#AS"RXJR'N;%1]40O0@T:@0(K1IJCN*>):
MRVUV43HV156'V4.4>)D,$MC3%;<2:0L0HI(WQH N81_P!JUFJHJMXP#RZG65
MK!O,<DY)_&O(IK:TJI[VX4GL_$ ZVK94.>QF56-E'F*HR-<YC55%X\AL8I!Y
M;(A9W(RN?D3,>R'IKV2+'0R) *6BL<@R&IA8Y%GK\89L.3$>K $47QCW;LUH
M+"/>QJ&$.BLJ.%EN58]DN5T[[(4QLZ!.)5Y/E%KX7(?%0L,DTZO5.8U'.1.[
M_1+%981QR@Q)75LCG&,T<A>EE1$YX2L>PC6LEJY/>>B+ZN+*P>:<>?8,*(4V
M1(0TNH&;K$4=')</G5C&I.?HC%T3LX)5L/8@228AK"?'E-%:6W-68KQVTUH=
M]@%>N?W2:^KB"0@%Z*O:Y 4;4"E!S']7K)?4\E8KI6LUZ[]$773C3<]W?(_5
M[MR_&/<3;K]@S=HU/4WLXHYUK#ZJ5C=EXO2EZB6'H[#IRQ>HV1SB'(^(.YNT
MJ/9V^C7C+8#J<?2YT60?*F,DS1NMB2X8Z^0YQAR6FB;XH]- .$B.5ST[[G.4
MDDU1)8^37U]5/'#OLBKH=O7U4=(E?&O8%?;1H-\R+%3EMZP9UV=GHXJI=-3=
M.>CIY-#3N/8VUBRLJIDU\^5'A!LITL('R)!%WE:WG*/0>[EHC4]DO ANQYL\
MMI&KB3+(J5L\L@DOJ::268^92/%(*]PND(% [W;-NJ\'NJZ#)EWI(JQ&V]_>
MWV1VK8O8_H V^1S[JPA0"$:BN&)R,5>W:J\9MFU]'IHN29M+K.?#HCR)T"MJ
MZ6 .#"CLLIE=4R9TN6_>>218P4<Y6MV]S5? !4QFU3+-;B%&\:OU=2V2O,3J
M<;E+:++QA6DD$5$KWQFMYCM$[RZS!TL,@7V4I9UE,F3[&WM+*6K&B0]C;W$N
M?:3B,$Q&MYIG[&IHFB?T5S;PL=\Z0QT:#55@G(P]O=V4@<&HJPN7X+IL\[&J
M[1>6S<]>QJ\3 YE?7EG:XC@TC-\J'35N.#QZ2RVM#1(-3%YH07#9T(\9X:]B
MF"A0=^40CUU2KQ\U%DM*>^J9MUC\NYAUX(MS"KNBZ[D"C6DRT@&CI/8NR;&B
MJY/@Z]FM1"?"LKBYOY$B-2T-,**6SL70P]1.,U9\RNKHL."%44II$@(F;FIN
MU<B+GCBS,DIJ&F;@6'0JFOJ<>?DT+.\IMIL::H?%0SJZ1(@M>!KT<25#<).8
M'F:HKKKFU>2S*+%;8%!D^81HE6ZBI;1Z1.<*:-UI&O)#8?7"602) .$7,].B
M+I?O'3Y)>5>)/066WU'#KY%3CI48(\D,I9EK!GV)J^,9"RF5X)CHS/MB-7LX
MML=A=24M)24M]/L]H$J!Q;[K75P4DK(YW5/C07&5%$C$$J+NUU1,=)0XYEEY
M89-2S\D@T4&-1@M 8] G^'+<3GVM_75(8TJ2YG)8DIYR<QOQ>NJ)C2X]6WV3
MV&50+.SKJ6JC5T6S##I9*0+@EC[0VE'7P75UBO3O8Z1O<9JH-'Z:\88^%;7=
M:&Z'E5Q)^34T>/ A84-09#!S/Q<<B751XLTNS=$VO4P^PO*U5V/J>@RNKI,L
MG"KL9RFT@5X*2YERF*2M&,0K8]] ;<,;K$?,A1F'[-J]J:Y/9LH<LF4F&Y#)
MQW)+R+!JO#*^1$E!A2)@W2+J/*LX89!M'MB"/)8B;G"1KF*_((+*3)+UN'PH
M=AF$VCC598N-19\=TT#YS+"WK9\UWAS%DO;!!+<P/:J(O9Q6TL>P;-QG)_+?
MVIIV( +4#,K[B.$DH1T .60-M6W(5VE<J#6/W43>OSA4?CQOWA-]QB_XCKOO
M9G'EY08V^CCFS2]L*F3.NZN?;BA"AU1;!A00H%Y0.(]SA;5W&TT7C%Z#-"8]
M:U69R)=747^/U5E0.K[Z-%69'K+2JL+S).<&T -Z!D"DIH1FUXT3O\5]<'(H
M5S<3JZVN0$@T-U01)E769#+Q^06-&MR35:2OG!2.9JR7$>Y.<C&B(S@LAUP\
MJ"R.=B3 0ZJZGSYN0UG[?K:FL@UTBQN7Q/KWQ!&$BHO>[JZ R*3>\FJD77LX
MCWUEPDP%_M*_P>=4^'^+5UCM"OQ4@ W]K>SO-U^,EW?-;#-8RH@\,S0UA50
M2I4(DV]K0X^^?C\7J()='S1@:YK%<FK>WB780[:-<QV>7DW.*ZEK,?OK.;:1
M!R8X(=R.^JUF5X*5Y)#!%8Z+O&C^H<5@1OXQSQ^^IF6%_B\G*$H@X'EV,'%"
M$E2TQAVM_=S8DB#6R)CV<_E-;.:1A [6,=O@U]7</,:UZOP8YZJZ@5E]T&JS
M4Q^YL*Z+47ZQ6M57I#.96HBKZ$XOY6-S 65Y4V$6H"Z52Y!(QE]QXA##84[\
M@B@BT9;:+"*5ZQ63N>US.UO=5.,BRM\(MBVAJI5CT(7<M\EP&:L&I=A.2)7?
M#)M=L9J[1=-.*&_A&P7.J.UDQ&V,#% 2:J76U\U6\RPK\AMLLL*R]2I:_4@E
MBPB2$3N;'+MXRJX2S_S=A,NU@Y/(Z*P_S9*I(0;&T%RNDY\SIH9VOUCM*U^N
MC55>SA:LMM-/9I50KU:^MQO)[B;X/8 ?)CV72U----TB 'J5^FD?5O-V*YNN
M-R)-^PH\P!(D8OX;!M+DEZV+T2&'6AJ(,XTB7K8"1H$;SGJY4:U5:[3%;+$C
M0[$=OYF8Q@EN*R@V<296-M9_2V<>162O"[*KNHHG(YK)(^[N17#<BIQ,N;7)
M(,R,+*+3&0$KJ"[AR"VD2<:(R@B4SR6UM=V\=0N8Y\5BMDJQ7C&UO8DW()5[
MT=;66D:EM%G5=S!GU5I,((4:):T\NN#<5KRN.U=3@&W8NY5V]O'B%<VQ;'YI
M Z6E-<4,M'CTW:U][ KI[6=[L<H]KO4J_I#>H>7/@!6GLT+.JP295G"&L(R/
MEUT:&&3+D3HS>^)@QO>YZ(C6JO9Q;.P,/E_D%I$P66YV8^7()@75D2%840CS
M_,'#QS[.(>\Z6426 L@YI;B0I#=K6/(B5HY/F!'R'RU'D;ZZ3G<Z-CD:!-++
MP>TLTHY%Q45M?3.=7744"C)&:%[GGY#U>YJHN0Y%&R::]]!Y7X[DH*T-!0E!
M+L+ZPRR%,M; 24JV2LJ(-:R2T "!8I )O16<QCZ,%!YI55E02)F8MD^8ML.H
MQ2(:74AHS5>.-O/8/+L6LY#1V$EW,BUP&SN0H1D8<)$)"D6>0Q;*]-C>+S;>
MGA-%&B59YL.01+./6S*JKRBO#D#VO<@[%-6]/M8P:M+N7VO>@_.!F>V;BJ)#
MN\P73!Y+,+3"JD TEE[%FHT Q.6B5'0*[FJGQCN)LZMS)).2.KLV-DN)>#4+
MT\M2TT[E5!58VM2R%H9&1=+,LA)O.YHMJ-X-72<TFV\&C\T,7PXH)E+C0%N*
MK*,0@WQWV!:^HAE%-K9MDU(SXJQV\L>A6E5VYK+<.=DRJ5(\OYEMDS0T&-JG
ME_D/CU#5TRD;#BU(8@["/92G$2Q(5K&1'34;TZ*)86)CSPD6.2_R@"W58/"<
MAGGJXN'XW=5;/$@XG!QZ5R+"<;4T>#RGM5S&O,C6'X\NZXLY_6^:-1A=Y6V,
M:I@<BFC4X'R_,P34?#?'1)4&-&4+C\YS#V>C$1K&:4+<CM/+&JBI@EHH#>:-
M#!R"H(?V@KDY=?&G9)C0PV/+U7>A7KRT<FWMU3$JK&\LQMV*/@8>&+2X+78[
M$CV?B%Q)K;:3C^.VL:46]KI:O^)6ENRK4+'>LH!T^'#;1Y.A[@,"\AR+6958
MM87%/-F^?>&4$^O(9M*(XF%KK8AB1B]BDD(31-H.7'Z[+9U[ B>8&8X06";'
M:!Y["OJ\&N,PK;,[*>!529-]'E1V V17Q(T@+&IRFD5Q71HUOY@/;3Q)_E%E
M$JZBRL&,2I<?/H]?;EEGKL:;2U$.N0P)3H<DEB2(40DDR'L>4"Y-_P";\9JI
MD;V_&?'9@Y]Q88G'I1V"4EE(QRC\LS6]8$*BCE?+G6D^++"1S@B5VT*7OBUF
M^Z/57:1A6C38W902QY-9 FMB1,AQ(,"CR!T(IGH0PX4%X]R"(+>Q7N^9>4Q2
M=L$'F]B[IB::HA#0+R+5O>JKMVI<' B?\XYJIVIQF!STZ>$9=Y@^6L&6]\ZJ
M7;Y<X1$9;3Y?+ZIQ=ME?[Q(#;SUWZN'L;KQ.R^QA\JEI<*A8[C)G2(Q.KGVU
MG)L<AELCC*^3&='%$B@U*UFY%79N372@SJKH)650!8C=8I,KH$ZEAV%5(FVE
M9:QKB.V^GU<.0 R0G1SHP[3-:J*C7]K>*JQR2A!!6T\[+3S$R/DV=;*#75./
M4"P,)BH\4SFST+/$-[=@MZ+WC,'IIPV57XL[%<RE9972<DR^@O*]GEYDF/PI
MVP\B7C$O()MN6TF47Q2[ZYLCGMUZI&Z<7&-56.1I<BUSZ\R#VWM9]>3'4H[Z
MX6UDR959&N Y3+R 40CH[8Z ''YJ->LG9JG'G6"DQ$UGD.<VTMU)?NO:&+5)
MCY:&!0U8A)(M1VHK:G"PKN66.*/N[4*[L:ZNJXV%2+F%C6(U]'@6685>PL<R
M:ADBK&5]C%R(MODM,V;62)(1G&@ARQ:(O, 1_IQY<SQ-^8VE3BT-M;EV!W=?
MC65TN52([P9"R9*M,@QV)(J9VT+DY WB<K'(6,1KM&W(<OE1?&5\E!X1"O>I
MC/C3LDM[65:7',9#VRAC9'A08L@RA:A-7N&A$5R<81"D88;&*O!;"LRR:.9<
MT$J1>WV,0S>!T5 E39SA,J3V3FO))FK#?RV(G*35>,!P&37H:1:9116WF8J2
MZ]O3PS7)\OR;F%Y^R>5UHQD1.1SM==4U&W7C)9=1BA*G-I,P<3&O,3%[ZNK<
M=D8^">P]4W.Z6RO73[6960MPS)X7.1VJM HV.72[S=B[J7%J%_E_32F-TCV]
MN^R999;81-7*JQ*Z5%!!:NKVJ<9TUU9\X5+0B(5R7;55!L<]43H9G;HU%[./
MVE+^YS?VG'[2E_<YO[3C]I2_N<W]IQC+7-5KFTE>CFN31R*D9FJ*B]J*G'D]
M=CJKRQK:'*;>7<&I*&YR L",:AD1A&/$HX-A,1CSD1J:#7MX\O?"J;((6.87
MD!<MN;O(:"YQCG3HE<>+35-57Y!#K+6>4TB:YYR(!(XAC^&YR[>/+_-*7&+F
M5FF"7N=-)C?ATMEM84&69+D461'6M6,Z:5K2'@SF?%K\4/>G8N[CRBLA2LL'
M%Q['LAJ\HM,.JJO([ZNR3)R1+2RNO")U'DSI\&RL.H&=\:(:0-J#[=NO%;D,
M:JSRS;<^?7EA:2I>3P8(K.;3XW&-!E9/+Q:DQ+'$Q2L8U4$Y90^8086E*@MV
MBV-M6O\ -+%,DET]>B9'A>*+F%)D7AS;%D"OL*V/59*%#U[I[^R8.N1^YJM*
MJ-U:>VR?'9C+V?\ S9<PJ++PZOD%AKDDRXCDBU WQTD1_&9D9J$Z5CU?NW;4
MT3C$ZJ+6V4(TC^;-?8H^9)ARHT6OR"?#Q^."JL93Q-'!F$>-R.&]4(C6N[.Z
MO'E90ROXW)$G&;G&[*QI[JDQ;%\9Q!V+QE9S69)&\N ,R.*J-6/'C09Q72@%
M^-*+M7B9Y3%PS+;;+:^P?#W0,:MI]/8Q69AX\F51KX4<M45DF*O-Y'.6>DE=
MK@Z:OXN'XI J[6_;&W0:NZ1WAUDB%&LNO-MD14:^9!Y@Q.<]!M*YJOU9JG%9
M9^4V"9C@/F0MW5$=*9C&28?C]=!!9A;>-R-Q@1<,N*QU:IOBH9)!9#E3EZM5
M^O\ .#Q0F)Y=8W&97>96^-^#XY;6M;9UN2XU7U\<S+F#%/5 DQ'Q"*6,4HY*
MZ(T;'N<U.,E;98_DDPSO+'RN I*3'+6]FP),2OM]U9*@U<25/ANL">AY&,CL
M?'T*]B[>/(5V145H^24OG;:/IJF":[L,9BY',K+&.,5?6I,EREKX<W20R,TA
M&<PFU'Z=Z5F,;'KR+5Y)YZ>4-I7ULBKFALQ4N*1@UMKE-I5.'U=-$EE:KEZD
M8",")KBM;KVXWDKHV8543&O-CS@F624-)%FY)'KLJDG!4Y'645Y37 [>&SE[
M5Y,.09025(%%TU3+KZ#7^8UXZWRORNAMEY15P8-E?1,=O6FEV3,+J,+QF;50
M*H$E6=3+8KS#W*K6,8CG_I">;.DQX<.*)YI,N48<>-'"--SRG.5S!"$QOI<Y
M41."9O&N@2\8%%266RA!ES%&)4'W'P8L<MBV4WFM1P.5SFJNBM1>)==7%LPV
M,&/'F2*ZZQ[(<9L$ARB&""8.#DE752I$1YH[V<T;7,1[=%77W%M7Q)+33**3
M'AVP485%AR9<"+:1Q.<]C1O<2!-$3N*Y$1_;V_HP*.FC='5UD=L6%%YQY')
MS7:SG2BGD$TU]+G.7]#VH=&(6[;7OJ@RCS9\@42"4@2R P(!I)*ZO642.-3/
M (9#;&[U=HGN8_-;)=U,D40?30IDW:4VNUTCHP'Z2,FWO&+L"SZYR?H&E2'H
M($81#G*[X(PA8I"/73MT8QNO$*S@EY\*QB1YT,^U[.=%EA8>.785K"LY@B(N
MCD1R>OYETMC#BSXW-CGZ>;'%*!SXD@<N(;E'8\?-BR@L(-VFK"-1R=J?-514
M145-%1>U%1?2BIZT7@$&OB1H$&*-H8L.$ 46+&"WX(@1P-8((V^I&HB?I%:9
M+'A\NZNHE= LIO42G=3%J>I6 +IWF=$#R.K)VC8USMW>5=$XI,AEQ.;<8Z.U
M#3R^?*9T8[L4<%FWD#,R+(ZD40:?&L>K-O=TU7])9,*2U7QY<<T60QI""<X)
MQN$5K2A>,PE<QR]YKD<GJ7B[PC"JY0-? ,"GKARTT Z18I.>..>WD/"$0GD>
MHF/=RA-1&-1&(UO%I)A9!D^7WTU^.PY;+21A\&3*Q:KNV6EG050 XW58FTEE
MKN?U\8H9"C:(R\I53C")%EC,KP"ED^8]@.)E$C![)]!*MAX2S'7AI,6K:O&Z
MO?)II,@<: .4**74BG1[T1L*H]A9=?/B3L7+GMG"R3%)TOS06MD9%XA)BTM_
MXMBTXG56 )_47C(\B7^UR,1!L<CP6.+2),./Y;^8,"AA9!;8M8RJ?);:]C3,
M<C 91Q*6CIY0H[7D D(2Q*U5V#D=C5XN59@@)T>YR+%;JTL1-PRRE3Q1?+R/
M53A.JK^^KZBWD1LQ8>0?Q-A@[Y'5!:8^JM?CF;4L"[R>=Y>>SF%4YLGQ,E]B
MEJS*<F&T]74>*19DP600)L!!$J8YB/;$Z4HA#U1N364FLR"5-L+O,9D/)(61
MX)C]8;'K>HGQJ:D=<BQBW\RV$ .2*&L5^M>%P^I8Y5:T:Y+#L*!M'72'TYZ<
M$MM!#GFF"KGQ+)9L/#K:SQ=@&]/'VR0 AR9;U*0XMVU>+D1<1)%\<P_PJZ$.
M;B,2+87Z9UB=X\Z2XU_/R"\%X9'G<JQMI1)[DU:Y@7+\:^QAT%DRI%DF)SL7
MGXY+\NZ2DQC'JJ+7-L*MZ6&/SLTK&LF19#W0JK;"LV2=I5$KRO54I,=\7C,P
MVPAU4T+L9+(A9(:44S>9[6V@@4(^6$&R=6126#]7C4P$09&7MA$Q%T>ZI_-!
M)EOGYI]1OB5<3#*E;;&U:R>2ZD/L>K4*A$%\%RFYSB;V<8%)J,%%441\8\M0
MY.,UC1[<Z)'RO%[F5D10 L2/(&NQZ%,_;G*F*DSIQC<T;=6OA8*'F0\[%<P\
MUARL>CQF>7D:J9''@<2 ZPCVP@="SPMD!8S*Q$7G\Q. AD4#)$@F2XU=U\L=
MK7%3&,1B#MV1O+K658(9[,.))W-)'1T>3U2JU=6<-C1<0B!O&>4N+1V-'-JF
MJWS/J;"08EDTGB'3)?0HQ>6.QU[H'*%AN6JLXEV\O$Q=)/N/,8=Q-WXH2NLZ
M/(,>OZ_'4-.EVL_,KJ.V2L)219+8T2 3LCQG#:U0XZ^1BE["2+C^"0JIM/:>
M5T 6'6%(;_S$Z183ZO([NIZNP:2Q0U"XCIZ'V2&M?NT]Q)BI 8](YB"W\]6[
MMCM-=.4NFO'X.']TN_R/'X.']TN_R/ H:PV!0C2+O0ROTY8W/^#RV^G3B1.D
M,ED#&&I2,@5\^UF.:GJCUU7&F6$LG]8(3W?0XDU(O;$MI"""3,K1^67F6^?$
MC2E>D:1)AMQ%9  R%&[8YS41^BZ<6X*F6Z2:AL?";<;XDV(^'8])&FK&>V;'
MCJ]R1I8W*K-S4UTUU143W4ZWM)0X5;61#SITLVJ"C1(HW&.9^B*[1@V*O8BJ
MOJX""-UI.IJX]P"3X79CKB0I3U8'2T)#96]:NFJQ>;U36*CG#1JHOZ$*ALSV
MI+FQA'LH=;3XSD^22RP8Q6@/*Y..T]JX8A%<B+NT]/$Z+432NGU?*\2JK&MM
M**Y@-D(Y8Y)=+>0JZUC@D(U>6]P48_3NJON+VC@R^=:8R2O#=Q>1*'T1+6"R
MR@-YQ0LCR>?"(C_BG/1OH=HO9_0--L#LD$# B29AAQ(YIDIXHH7G(R-$C,)(
ME2'-9W!L:KWN[$37CI8E!E$FW==T5 RDBNQ*=.=-R2HO+FH5\F!EDJFBC-'Q
MZ0PB&E#+&?MYS&,7>EM:XSCU_9W,+$<BR0L(T&!R<;6EG6]"C\J;XY#5T5F1
M4T@)&UY917"C%(WXMO,XQ^9<1)LR3D+7)$B5I*>,KR@KO$92-/D%S30=4&F@
MP\]T@SE1HV/7BY,^%>(E'+P:'+82"&.=2^8!ZN/3[(TJ6"0+I7VX^K:9HB"V
MN1&O5-%)8LQ#.W14H[3)H[N@Q_69CM!)Z/(+<#?:7N1Z:2K&D8;E'-S&+'89
M%UXP0\&L)9UN5Y$.NG3&NAL; JW8_;W;I+&R[.N?U'+K^;\$C4 (W]U4+"1J
M\=/D-*:RH?:BC?>1:\ K['NHCQELZ]8%G8D"UKY@%<"6V-*:P[%42(O$EI:'
M*Y-9'M[^@3(8L*I6FD76,U5G;7-<!3W4>QYD5E0<*/=':$D@;FL>Y&O5M<^Z
MK+VH)84L7)>CL96&Q)\;'YY'L@63H9<N0\\DMH7O2%"259,:SXR.Q7,1Q,99
M574BS)XK'JG;\?CAM["KHBW_ $T.%,R"+?)%E1QHP4TL,5<\CV_*-KD=QBOM
M/&-5W5QC^+V]R%L[& QZMV2L'T9@09>4>-V<*6QZ2F-@@G2(\,K%DM$3>QN3
M7%7C>0-C8^6\B123O @-R&PH)-E!FQJ=!WIB-1LVMV(28D0:\QO>[";(\W(\
M2L0U+\#\OLJGRJ<%<;P4F62K.)+L+%39,1Q*$W3A/$'&&>>R,YRG&CVN8.ZJ
MYE=?!+35N6V>YS:)"V(L+B'FW#(E2Z^3((JD#%)TI)T.''E;=6$5JM<MG"%4
M7E)-JXE+9$B7H:\1CU60BF%I[*.M;96@D#+2O,G+*X<D3AJA!L7CS6#)H*V!
M[&U&+R\8'(E/F%LBY)8Y)51YUTZ$;D@A&D502-CA^.&%5WOWNV";Y?D/B'M.
M;)XT -^R@NO VT1<+GY48[\?7*5G.LV2:Y\=K?$6C<UR$[/@<8]=6&/1F8RE
M?*+EEE"I;N9%ZJFN<EILE=7W#)OAU .I\#%( "<AC675M"%>8FO +"1/Q^3;
M(\C;B#C\X4X5#+*]T@5%8/',F*RWK(91BE:JW>=KG-8QJHU/<67_ -8?_P#&
MOZ,;_!R/\0_]#S*_V(P7_'W/'\Y/(@W^3U<ZCR.^FTS*3(+6FB1+*MPZLL63
MY,2ME1H]NXSV#8X4QIP\L>B-3<Y5!7V4+/+2NK/+?!;OH/+S(JC#32;K+ZHD
MR=>6<V1E^'SY08Y1**/'"0T5CFJI&(NW=Y/X[DF17D2/(+YMP+I*++8L>9D$
M#&25/@7CEC@EV:'&NXG=9*Y$A"L*TK=6\Q^OFA-H9N>7L?!O%*R%E'MY/PZF
MQF7BM)%=*K_"XEQ-F9O/@E$IILRPB.;-.]PFHUJ*Y8@KS*<FBUQO)C ,CDTU
M!D-KCD>3>W1+7J;1BTLN%*C<K3O-"]C":C0N]K&MXPO"Y+\MR"M!:>9()T_$
M[:MQ_(\RAX1=-IZ?=>S+W%D" <<Z$F.C2AR9"M:OV:\1*21*R"KKH/GEY75]
M4.VRRFMLO90Y"K9%KC65'QW)+\Y8:%[0I/,\LF&9F]7HG9YNTI;.T\*@^0H+
M@=9&M[&)"%;-NLDUDDBPY81.)( $;#->BM.%$81',[.+CV?L;<H*/^;959#6
MP;*VM+N+'NY62V;"7#Q6\N;SSQ1O[-^Y&QQ-"F@FM8F$3_XRK64?(L>D^(8]
MDU[)NWYG/Z&+:+;XX"SM4\%-4\Q[S#KXZQUC/:BC'M1_&%__ +,\I_US7<0,
MAQP337-%Y,^9%M;B1KGH^L@H"1C_ (@,>CB0FY QSFHNFJH[3MX\L+D(?,'J
MK^UQ^%E5KF>>X8_%LIKLEC:S7TE,W/YJUUE%YG458:N%&D/&)6/:1R\4GDN7
M(+M<L@^9,VNN;Q+"4&^D^76/\K,(]L:S0W7,)=5,R% YN[4BN>URKV[LFSX8
ML_!DD>ZR M-:BS'#Z/RWH(^/VTNOC4UKCMOGE5&+6\J+MG'GUSY2JY7L>NC'
M+YG=!*6BF9?GGD/C-G;0RQCOQZ%DF)5@K.;"E*\D/FA9J(9^^U%>CV]NCDMJ
M/'LDR6379%Y1^9EN:-;Y)<7ECCUQBM(PU9D-5<6\Z9=5[IA)+AJQAD#S6;V-
M:Y./)?(H.49/DMGF%Q0TF2Q;:_L;>#D,7(<?G61YT&KD'/6U!*@\9A OAB!J
M%-"N(JJKH?F4&/G:Y5)L&W27-AG&&5'E>L1U[TC\8+C]IG\:+"IEB:Q4*6O;
M9I+T7F_6\>=DF!EN11[ZDRZZI\*#(R.['C].<F,15 DBHCS?#I<5)=@TC6&"
M9@""1S&]I&OI*')8_F;CV07=5/C18M_EGMKAF5RJL"39]A!FR+.]D4]H$(2&
M: ?AK.0NBC=V-3^@#*19.8\;'"8_;,OI$5)*R 5#X)FV!A)#$>4KQ15<O<8]
M>ST+Z.*QP,YR"VO!7V"EAC6)6CK)5@*A\PDQ6.#P'#ZVD;#D54NV4RQE&SGQ
MDYKFG5W-R,43-LQK8H<6S=^7R::*5YY>(S,\RTMV&R0V(SVMC5.5$M1QNG8.
M2Z.PNJF!O<ZEBW&1W%!5#CD<*Q""&:F/#;!&U1Y&S(*&[Q%&D&K'1^N PG/3
MY.J/U3B'(J<SRZ#CL9GE .1 A193JZ>2.:$3RVD63[#%)=FQ\[:%A=A@B3<S
MG-&_EN2,(&37;ZM/*3S(@ADN ;G.P:7;U;\MN7)[/M7Q*KG,"P#=B.<URZ +
MZ4P0-U=6-= C7, V-RXPFO)828^*WVZ'/::IG!9#G8OUW/5XPZ)\%XR;.* E
M7DV37T^5Y?H_#09& @15WE_U]:KA5:IC]+O^/="0G6O/9<I [UV:*IY-EDA:
M3RX3./,3J(L*==6W498N*Y/%R?H8!/+:(VHEM0LZ41[K6RA\\)AQV*1[]&K2
MY;GM7,@>7>+I;MP^-8$FW6%,-.]FG3.EQFQFBM2O9+Y7AJQ+78XNFC?1XBS,
MK[KG>8>0&?1,BQ^G'F#:O(&7<.>9,5\?Z0D!TY\99<Q0[6NZ)Z-[%ANQ7//,
MD\*OQW O$AU,.2C[VB<Q)&$>(K6X8&P$9E(00"^'.ARO#V,6;KWB.L!4%A+L
M:%;G-"S)4QA6';./D5P;(HR-Z*"3DPK5\@0U0:ZL8FCG_#6[CMS+)9]47RS\
MOP3I\R*UDN+@S)-R?"9@&1L5A-<<H9! *BA(;E 8I6(17$).D/SO)&P9,7S<
M4D&/$C;:X4JJR &?I*<'#77+YE='/)-%\2,>2JA1 <T6YC[LM+939=N3$L!!
M8Q9#'M "CC>TWLQ,$Y8$9%DV/.F<Y.8]4Y3=6#^O\SENKBSC'FXCB4;+&QAR
M%=3U0Y.4)C5C4<FK.\EH>;(E*B,64[F '\4W7XQM<3/<P7/US"))#?NAU'M
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M2N#&4#-=I8T5>*8JO@U.TT!U'S8J"TE.!@4Z\#B0)+=!0XHMJZQ?TD&_0T2
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MH$G+Q >!SJA2AU(9&SWO*"QI''9^@XO&^W847OV>0>^70GAN2U@2O2!Q[";
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MVZ'E 2[T!P'8O0\K!D\";@+F 4N:JJEZFZ\,$ *]1!@G1':"$M&5F/->M5P
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MB3N$W_S,9!EP0T(YF1153>YKR1+D3\)#FO$+4M #E;CVMQL*_%<$@C*JX\-
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M' N19K!B!-N%X@;>=C6^,*7_ -]+DNZDZYKKR@M#500 ZH'@K['![-G]T?\
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MG\O8"Z.<_P C 71SG^1\S2M8BH]F\7Q]*M=7W!_+[?C36&_,096(FT+P5T$
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MO,X"UN4E ;<'9/T#UIHS&M,#[1U/7PC^ 8ZV"T-_B&IY/EN)V3] ]::,QK3
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MA[#:'?*%V0BJFEJ([UC;UU,-CIEPA-@-Q: '!L$:'J%!XT$CQEGI8\!>P!>
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M23K;T>/@6. ;\GY81'@/ C5F01Y4'Y' VHE-P*! T3HTW!(UUH8\SYS\V#
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MT>VAY..K\H 9>Y#=<?R+]T]7& *1Y'\+^^/2&3A&]I#N"N$3YST1N[:/I?\
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M\M0)"  =WT,Q>[I2O8J &W=F.]0M]IU](WW'1SKSRU D( !W?0S%[NE*]BH
M;=V8[U"WVG7TC?<=',O+%C:>$7Z 0_HR4]$9 50B<B;')L=#V//YX>2>)0<
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M &_68HPLI$L:4G^#VBA6S"!)-)HY'R_2G__:  P# 0 "$0,1   0
M    $D@ D  $D@D$ $DD$ $ $@ $$   D$
M  D $@ @$ $@$ D$ $$  @D@@@$D@$ D$$                         $
MD@D$D@@DD@D@@ $$@$@@@$D D$$DD
M    $$ @$       $$ @
M  @$$D $$@$@@  $  @@                                       @
M$$$ @D@ D @@ D$ D
M    @
M
M                                                     SK'<=
M                                                $F#;;;;:T@
M                                             ZK;;;;;;;;+
M                                          ?;;;;;;;;;;6
M                                      $@C;;;;;;;;;;?
M                                   'FSS;;;;;;;;;;=
M                                 FVT;;;3M:;;;[,<H   @LH
M            ]MMMMMMMM*   VVVVT^VVUC#(  !M;, !:@    J?X
M         %VVVVVVVVUH  0    .E&VJC     ;K/&;=8     "
M       NVVVVVVVVM  "    4*%C.@      $];;;;      0
M    %VVVVVVVVUH  0   (V-5L         Y;;;?     "
M  NV(@7?^^VM  "   )VVV(          Z;;;.     0               %
MVS(^R3HVULDD0  %VVV*           [;;;(    "                NVP
M[VMVVVMDDE  &%GVR            +;;:8    0               %VVT[/
M0VVUH     P"IW8   #KH'[8  &3;;;    "                NVV='N2V
MVM     !  %0     5 SJ   ';;;H    0   C;;;;;;;;;;;5VVVVVVVVUH
M     P  N    #: '-P   %;;<    "   %;;;;;;;;;;;8NVVVVVVVVM
M  (  %       $      C;;?    0   K;<TS\74H;;;';;;;;;;;;H    '
M   @  $@$@@@ $$@$!;;;@   "   %;;^4SVN>$;;8               (
M$  @D@$D@DD$D$ J;;:    0   K;;RZ? %9;;;               &
M           @ C;;(   "   %;;;4 8?$S;;8                  8   D
M@D@@ D D  ';;8    0   K;;;<K;;6;;;            %;;>  "  $$DD@
M@@ @@ @ ;;;@   "   "))))))))))),            8  0  (  D@DD $$
M$$DD %;;:    0   8           (           #  "8-0X   D $ D D$
M  '3;;8   #)( #           !            8  /+!<    $DD$@@@@
M;;;>    BTGH8           (           #  #   8   @@ $ $ $  "2;
M;H   %   #'V4,H  @   !            8  &                 :0*P
M   0   89SIZ>V26637(           #      $             V#P?
M"   #%H=E#OJWJ3&!            8  %   F            "UVN(    0
M  ZJ"N+??V7R30(           #   ,   8           &%@L(    "   #
M        H  !            8   H  '@          %+P>"     0   8
M         (           #   %@  Y(         !MVNPH    "   #
M      !6VVVVVVVV8  8   !H ]RX        %F3Q%P     0   8
M    )        $  #    & :'XL       BI9BR      "   &VVVVVVVVVV
MVT(        @  8    "X7__ .      .M=KDA@     $
M 0 N   , !   P    ,=_P#_ /Y/   Y8%@L%-      "
M ( +Y+4RP @  8     :_P#_ /\ _P"X!/\ IO!X-X      !
M     $ :X!O7@ 0  ,     "S_\ _P  /_\ _P#ZVNU;       "
M        ( :R/H<0 1))8      R?_I ^_\ _P#]NP5,       !
M        $ /N+ALL 0          ;?\ %JO_ /\ _LX5@       "\
M          @   !(  "           3[_P#_ /\ _P#_ /%<     !H.L
M              0       !            ! O\ _P#_ /T@
M               "        (             (<0!*+
M             ?\ _P#_ /\ _P#_ .0
M
M                              +4               * $
M                           (V )((            _\ \2"0222  "
M                          *1"02"0           23@ " 0"2"0
M                                            " 2"0
M                     1P" "               "" """
M                  !"Q@ "2
M                .0D00 2
M                 2 22"0        7;622 00 " "
M00"0"000     " 02000"        [;P" 2 0020                 0
M     "0    0      0                                   "2  02
M" 0   1)P   " 2                                    "0"2" """
M     < 0 022"0020                                002 2 0 00
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MB80>X_9GE7:^7>P3JP$ P  '. A4"4ND9^$DV)(OJ&*L2_ SBZ<DP,8:ML"
M"P5X<'RAQVJJJG3*$T@MU(L+.1&"Q&)Y,O[:"*'&@OW3"HL.3 OH\ZH>"OGJ
M!B!D$J]1O@>H'-DH&(Q$0F'8X#$):/B8S0LYT%,N$2MYES7%#@7'MRJCH!:.
M,,9_,&8D0 FYC5E_E?3?QU'$!T826?%5F$Q@5Y:[14!^%( Z00[B[C ],Q3K
MHE8110#P2@QAJVP( +!7AP;0+.0*($&1K&K+_*^F_CJ.!*"ZK:):RQ@7YJ5(
M-47 D#KYC;"GH4O?@[XG0U(0ZE.06\R>=D*@(!'K_'[#*=7M5L59\G"##!]D
MTC%4< ")B#5P300F4LD,$NZ##@RK3TX)L!U@,-K!>]GDB1(NT]F*KV!/TK]E
M"X:*P4QSXZ7*^;VP8YWDYA'2=3G4NL#.$)F=UKSP-&'I<Z/N*XZ<.Z_4#ISQ
M;=$FF.2'1O*U89Y(T!Y-BQS]FUMZ+4Y=,QMJ.+I9:XT5CSC0>D\PV(X*FD8>
M:EV=4R-8#]PDG0I0!EM*E"5QYT*&_'#2NBD$K>\L5-3/D.8]*R ,;4S)HS/T
M3L]A\)JOMS6*'9ACUH;RX></8ZRL<S>\R^AWYYVR\<=^AUP[%D)B#2H!1#=%
MCA]/ ;--#LF<YPLY)N?#S/RF+E6H]] S8$J*$@P(C-(*F8>F.1Q&!_C1FMW1
MP ,%!<VU78D>A,X%8QUXS,4X^RS<$58([!\A4@Y6,)7=S=9-(XZ7)_@5O%5@
MM9<M I:4_#H)4[*]\/-\>Q%#KKH^.77@>%I&X<6K =B.#*Q/=9=P+B8"^IC!
M50RO8%2M:,U6]W>_Q:V9@FTU;"=XBLPARQ)QY%#?B,BW(7OJB2/6V3J@9\T>
MNIJ90QONT@'+:?2FAK#9D\^6:5#2",7ME/-W6A@4>"AEP"D#WG;F?2AY?Q'J
MB<=<5,"0\?._=RG"EU!5)C,%GL:_JW-2 Y'X#SATZ_Q ([Q1S[=$@V0EW6 7
MYF7$U-?8D+)%5+%C '91"]Q*BG(0QO98)&T7E@SISU/$1=V$;H":+] ,K&QU
M+X'NS-C^>,X:UA+T3<#G45;W4<+'FR^^NR$CVRX\:]F["$[XX=)O#-&[*36(
M*:(]W+GK:1M7OX+I$D^I"R^ ""(]/-X4JS6%>(SFH!,)"I7$6>TXE2%V +4]
MYBF)MC'5@0UA\3I3-F 2W6'Y4@%I?,XL?NFZ #X*[A>REJ5M&.4?,P Q $^7
MS2(=M<16N!%[80LJ+$!B.IM[;-($ U^5*2J1MC50^['(6G=@Q(W3_DS6(1:H
M,J:>P&$T9_'9MRTUL'2AZ/+JD<:MX::FAWE13$FY_-1A& 4-9,,Z*!C?S DY
MJS'JH54 H8*2J\6(UP$JQ,@&GX?)QF0(D W&N6<CB:WZ^VI&T%"^:]@_)'/N
MRD^R[96R[S0\(K*PT%,V)N&TD+F;\30FA$N$- O8N(Z:7=VQRD.Z.FJJ!N (
MG)T0!F[7=3L:.=69?O3==2">S,WMD73>D5V!I<.ZDN@@EQN2C6CQ;)*5+$T&
M:H)"O$8G&J&FY-0BXE1N$GV&46\I-%CD2;E=AG"M"7F,M1JC"2_9\"#=$3YD
M$9Y+K4PP\]0BK,800RV"LMF!&\7Y$Y/P,>8J8=LHI%8G?TT#A%'O8J<GLZZ6
M)FPQ6/ 6R]% R8.+E:4&VBGIUJ1LF 90"*E1).  #]",NF84Y4+@V,6%[]N5
MD?Q PD<LP#RY]44F)=L$)*))G42E= (*U\DZ5A]4HC!>2!S8 L1$9%(B^QN2
MB(%"=EM<2]QYYQ!KJI*'%I=%,'%I]XER7LW#C8 I\4OHX*!NGU:P05.!]C]Z
M&*FWIJXTO).\K7@5G S_ &4*@F5\%OT(@6IC?#K6Y6HFHQ0Z#GAP@(!HFD]@
M1GE8^H9TI4O](P8<D,[)"R045F, N;-#'H>"?1*CY*TIC$RV(!OP8#EYG3F=
M["6$^C@BP5NFAIREG!5M59.J6_Q"VO"%$\97E_)&ZS,.W,82Y$(PN*ZBVPK:
M_E2*)JK1X&3%DK'XXJHVP@:K7CM;.A@&A%P8'DCI,ED%%B.#].:G_P!''!PO
M< JQ'8IKQBBSRLSB8Z>8(TK2J?ACX!ZSXHG^+B G>SW9SMZ:,0./S4[,!D0$
MB'*2\*.0+T*SW.=]C8D2XZV0@'6X9%FBZY$2Y66?O9VC+:BA2LWC1F(83372
M,(]\'#MP"S@YS5Z,+R"?*50[/=,E[[(.*.5(O"KHC S.[-=8\F< =PHCVA/-
M?C4 L!R0TK'*_P"('@M"3-X2#K4)2R]9'WYP>RH,E5H%E.,W%,?T>A[ MH83
ML5&D1P@67YRSFXJ%S&"37RY4+MKRCZC[:869"A%R6 -\L)2@31::Y(@N2-D+
M4:F,1 O3<=;AG@),)=W3;(88UZ* 6\&R' !)"MS4#8X#6@V28U[<;WJE0*@]
MA?MS*=5P-=S,PVWZZ'0H-0UMGP%8)B()G]U[ 3V+(SLQ('T)!WZ<0 BCK#*?
ME&XDL??;(/!=I$*C8Q;<$,G"<-GB6%IAIE_6.WXN#\@"DK*2 "*A#CF,Z[%*
M$BZ?X9=6?17(8-7Z'%49+EF18S0-V>6D?@::0.,%KVSHR.TIV/FJI*IP54')
M_J#E#1J5Z#!BL<]XR]D'$A!& 8;W1;04^8(_K(5K'&@D$%#9 V3Y0^1 4)A9
M8Q[D-9&0 @4\LM0>1D>GGZ>Z<VHF-X-/8B5CLXID86FI/Z2%XRCL$S>X!NP2
M3W9#DLER90$(1J>AZ-W1>;BQB_\ X]*:J-ND9J@*-;,O0-.TB#<;NQTK0WT0
MZX35Q:[GY# 0(MU4%%99=0'56K *P60Z"A%GD8!#HW&-%%#A1G9P*)/2/&%7
M92D1:<E05O8&LB1:1,(,*"4!27TQ"59(-2D D-[%%'"1L(R)^IE H "JL -J
MKH P61A!<==#>#Q$PHB;Q25OS".#RC)A7GQ0TNFBHK';?=;_  IJ\&$FE<!7
M1&R>0NFFQ6U(@. LC""X:Z.\#B)@0""((C1'8B:1/U AN AQ_9E !5QB-2:H
M4&D30X' %H2!$W50-@ ? +-L W 64!WJ;0A46<25* U2B"3 +0=+8SSQ6!H_
MIWFL 6"B@-I78P7):7XKCBZC\+:!4E]\+4FW($X3GN GT(^ V D7^F>]R[,+
MX0!5 VAFKB+"ZKBZZZ5E^'\WS,J64*MQZ^>-SV[D*&*(MOMY$](%. )OP@"7
M6HFT1((B4SC2B?$%OBN(:Q[<WI8[U,1C05$3]+L0FB*CV):8KD/C\ 2T;,&@
M!&/:P#?,1*0.$1HY0HW>&[%^]\/(&E6)X)D(4%95,\7YT/*!9E_2K#P\M-\W
MTS]BH!QCU,?'10ZT^$+4>$<-%&LP*$*L[JS:Q-5RMLAX=; URKJI%B.5+L.8
M%3NZ)'IR8U# ":BB-32D393&H8%30$1B[1@;894NPX@5>[JD.O#FM@:Y1U4F
MP'QVIK8K>Q?L9V1-GP!JOO(I I#_ -#<W'F@5P26\#*6SJ=!*V.7-;\VM *E
MU3D-]^YWZYZJ, UI[C\6+P,:K6*+D$Q05B0U(_J@ JAC30+=)(3W$H(A!5,6
MV5/0PAMJL.) =>LBJ(B?)).0?L1N #TE7P*JJJJJJJJJJJJJJJJO<_\ L8=4
M#P"Y]1Y"_#UJ$/#9JE-OHT!V='9[E<N7+ERY<N7,M(?0,8DLNZ&74H53?YCQ
M@=A;B_A#"UG=?P=UL-[MCV'2'L9"X*VL,$*8$9"I.>TIDJ'8V$M; :J0"FE8
ME:74"! 9T$0P &!<UJL\*-Z&88 K FZW"Y$4]\SVPUH-Z#&.2[8 Q"24C;J*
M#SEA485U&1!)[#%R>TYI42!"C0>LIS ><F"XLVM2>@+6[TM2^,KAUM6X\%!.
MVQ:0')Q?F^3@%@FA)6PP*2%0[/8BGE5O0!E<$3"D->PU(W)V/NE0 <^B7@,Z
M#I9"US4MR2;ZN) QI7@#K<#K.97C##*J=-V=!"N@BE$P H,%C;IGHI\S ?N/
MP$ZR6(WCVC:D@J0%0SB+[$HM#";ME]C:"Z!+B$%HSL%?'*Z(XNC.NQPMHAH*
M][ &['%$<>^>Y5]TROVE^&P9EHHVD0N&[EF(\6N,\N(,Y:&0-:M1"53 3.
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MV[=NW;MV[=NW;_7V_6_E\& _<?>SKD!;!OJ &WG3N\^(-7'(,/(B7<J"X
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M(4 ( ,CY\:XUFW&(CE%>D7,IFG&(CA4>L7,KAB /-_CKHATZ:XUA\W -0@%
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M-916UAB 4P,/Z5T)$,F^).Y[L/3P53H"GHDQAH7I+E5LT,VM 8<#D^5#4&I
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MK+#BH-(S7&0UN';V0TJ_81VF/'Q8_P!D+C=[P>,:\@B>]-4>SA$ JP/!P?\
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M4MG@C;=9B@*QC&J@,W(Y?#DPC!\,.^- X\=R+0ZP-N\/">28G R- ZU!G?\
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M J-Y/<![0Y'-A^9(_3N>3[_<GLQ:\=B7T[EQ_B+^"(D1*?T4W0D<J"6! $T
M0G861Q'G/!Q06D_YL2O8@6T(<'UC*E[UA/\ ZF__ #W!S?_:  @! @,!/Q#_
M /!T=Q/KFV4;48HX< '2B1^_H$#Y9"\WGO\ F.G;E[;!P0<8'KMIY,]&]=RF
M!CJF1-$(Z-%Z;".[.Z=&UY?';\AU[\'>A;S.?Q#S[-_?*<?U;]'%YB/U,"L.
M<#F#NU< &3<6==E%C39@>SI+J+9T-L@8TC_5_8#IV/=[)^UMO5_>(_+@\>T,
MC>#2W<7UT'<'=JY $FXLZZ8B,>?U ^!  JKH -J] P$C>TIY4.U="99Y=^U>
MP#]--.1:OP!'K=SW!?DTM\4$+G&]*^=)VCL3+%0F *#2(Q$ZB4_3JK<M6-_N
M'VMIH."I3%$L&(KKV@(SX16+0FD@6(002+,@_K->(6'(KCE= U'Z9#:50 .Z
MOTNL7X-.#H>LW'D1ZQ56NUQU$"!I*ZM$)-B&%:NW( A5845 5M\*]  B)1'2
M(\CU,(<2J3K>@&>I+!H."R@H!N1(C_)LU^E^)* -]-I5>H'* IS-:0QVX=?4
M$J %OMW. 8Z1D**04$L/AK0#X-/4'6[=-58'#$=9;4IP\WD@F1^E/(X'Z /Y
M>!MZ#S-[+[0^Q7E;?#N$KYQ"OJYQ5-@7 *7,ICDDC5HD-GA*#54 .ZJ!]W*T
MIU>6UL?8<8K#L'Y0?SA$9=@_(!^<C6G1Y;>A]PPH-400[B*/V?&5,XH-@A25
MT*=8L@3!$QO9$ZN%L.3CP@*@" BJHFV"; 0NS5&$1$1 ]B]1&#YY1T\/IY*8
M+^50':@[UZ/T3J+XYBP%JJ4-YUVN#J%< Z^0%KY&7@%FW_#)YR?DS15EH>MN
MQ-'/;KCPD6(D1[(\?))1V>MJI=(W._P7????????????????=FB@3OW09K:3
MCM2SQ'LY(&Q"KKE7NDB1(D2)$B1(NK(&YV+DHOD"HB*T)3O'1+?=4W/'P5E:
MA!BB,4J07;E+Q#E.H@GD^P[8K;M.E#71:1FCBBTK&JG2^</L>><H\P(WRU\M
M#I*YSGGJ5SM+OKX>,\]"N-H==,-2/(#Y$0]5>>'++=M0>5Q_AO1H) IM;""M
M;6"E13VL?NI5H NB@*\&QDPZ\HF6T5AC5W#+R!5[FH+?PR:F#QPZ;%=5"[R:
M<")/Y8DMC,(H.&BH=1Q TH$3D;['M4@&G"_)T=EC3@ 2N[2NV4_0 Q'N00!(
ML$T2$AQVQ@P\WOJ+FN&.3JT9[_+S378+T-!S%MVF[8G> E&FT#OA4S2BT  ]
M0DK#&GY#]7U^"?1^3GTOL]^@B:Z. %7_ ,-O!O*_54/%>E,'E-!0KC P]@UP
MD5T5!H(M)_@BJJ@%FU'D,(7;K6Z U 2M9-K5$1-$7V%C7#4JX]KC0OJ.$\D5
MUBQ'>2OL,;$:!KNL50K8.@",I-&P"?%LN*K7:^[%&FDP&E38R Z' !HNMFML
M 5A8+MWEV#0/V'TN91E$T$@B%$HMA3HD%V&):_8H@2%RGUT$# A8)0(UH":5
M0"\EJX76**"8I @"@+ +P>U2)ZQQ.V-Z0BL@ID / (M ^CU*/(I[WF^0M]7U
M^"?1^3GTOL]^AHQM!X/+SUATU3<HG<JT!%&BH&ETTH@E"!0Z-*@%6.F]62<)
M70!Y : @&@#$-4DPR#'&&T!"I2F;#$UCA*JFBL*V8? D)2&P4@FK$SD='"(!
M.U$9TXQG20%5ET>@OH7 2QT,?7]#J<-FD<!&!(!H X [>_!.A:)I$X1[XN7&
M+]2UT]:FT,QLJLE1U.X'0 2 $]QLT,&V7LVC-N0M)/>N;Y"WU?7X)]'Y.?2^
MSWR-Z<_ECFV<$/LB&%5KM?:UT!(&X(-#HHSI@6!A-.R! (NF\N-"!L@"48*B
M6(F;];Y64XS@4@$B8J.J* N^D'D*Z0A0!&!/L<M^X=L4PGP6GG+6?%.R<:D
M9I$=-$=KECU0H[2>-Z !$2B.D1Y'J8D!T&S;D>K#L\Y='N^;Y"WU?7P *F
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M_0Y_T.7GEI7/O!_.2 A,XH![NX"8%3IR2QCA"T4\:C@Y(BH-1A4$ :%^-9)
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MD6.%H/1"/3$RJ#'O$&UU%>F#IPBK24W I0J4[Y5=Y!M2UE1:"U*2B-DP%!%
MD AQ1KFIT5UP!6I 7"-<A4E:9D,'(LI\FZ 6+&FQO#=0M(KR7PMZU%L,ZA2#
MT6J OQY&;;VVK30VJO\ +R^$]+?/?QTZOM.ON>;W[#.:X%B8JLS10(UC#T2-
M-"8;5L$8L>AD!:/ 2(ZN;6!T-HDS)<G 30A!$1!,T$P#9:AOSBD!@&+JY4#3
M9"<R%)A[K0\V5UAV(WDG.Z#B!0:RLD.D-I70@)B.DUL=/"3%$\LX&8JJTO)"
MX2I*H@*CI0K Q0^3>&W..;1)KEM;T$WX46!-OLD?<@\WX]K:@?8;\ '\^)KC
M0#Y+3[H_'N>;X%AE)2 V"CEBB/ (8J-U$KS#:H<5@  \-9D0\0#T3(!90,Q*
M)J26CIR%Q!I_($* 1YM2HH66L!?$0($"!!YG5HU(A-&6SL>)CS:>SJ7VWG63
MX\[8T^R#\B/B"MV0.X&OV1^?<\WN&K=9.Z8JL@SJ<MU/A_//////////////
M/////////Y#X^HAYQ'O.CG2;V;LZ:\-#T&*DUD%19C0K3\?:253>ED;L:Z='
M1KQ!IO5.LP[:7[=_<\WS]HX@M2G)*&=;%,@!E8'$R0'=NJQ:*L2<HK+.C@)H
M*8S/;AQ* ;3!E0L,#&%Z'&B2PMCA3))\'LDX$DI#31FO_KSA[#A4&*4BW<C?
M=#\:;U"'=4#[KG9]:FB==-''3Q)=_D(]/)UZ<'7W$P*!%H_E=W =PMT[2(ZY
M)VDXK%-X%173D]*YYD?G%=C2;/MH=G\?/(X@VGX7 NK&FN$V4QCW5 ZJK:EW
M$ZN=>?Y!\B$CDD1ZG*U_!,_+#@J+@ 1?Y#V@7SBE$2$T0A$#WC;SZT0A=;]S
MXY3\&5O!U432T%;?C8A#M+&AT3@.E!U\;G"#ZD%^_:W]NGN08\0XVT2HRI2*
MF5)5BQZ6K#L'3J<V*!S&T$I@[.;JC,28-.NJKR9Z$2PJN :,$WF^8".-!U[*
MK(7DV=;PQ]QP@1(E0(L G;* 0?G,<0W)X7T?I@ 19!%IXDO-K"A"NG "OD_&
MVF%H)"=;G9Z0Y5!-."[80$%S8UM".%A .6,'<#PJ05IYE5BF@-*>?N0GW(67
M1T*;RY%;[J.A!5VS2N@%Y<!5XX#;Y8A!5T,1*P!>7 5>.AM\O!)\O$%!("(0
MF:#H#7;4\58:.H!T12!;;6#R^,, "P:UQ0&6*G';%XSJU.5(*$#)8JZP.G<@
MH[ RIU"PW(AT456!7*G W9*I$%002"H8#=M.HU @L9+PI'!)5@.0>3I1WIS[
MKF]TT<,X*9PMCQSR^SNXIE:TG&39HM UX<%F&B<FQWJ1['4UM^:HFV4RA$BR
MP 3V*:PQXR9,F3 PQ;T88M6&"U&A>/9,F&3)G&/R$0D2830\F)F\I+&>(&>:
MQ;KJ# XVJ:^+/6W(J0#!&294+1$Q#P:N$2,;;,]JY"ZVKR"/$[!C8.VP=[>J
MD&,B+BT1,0\&KA$C&VS)0I"B.Y:,(#0B)B/Z#4HT$83)&G&X_3R%A#. U!#W
M3F]RT?AG=/ !2$0M0@T-,*"]? @$1JY.=")+(.XS&E.GH&HA@D)S$DQ#I2*B
M^K':!U%UST7R\+[#.F'&<& !"*V#U=4)KB0)_P 2@\BH>1G)G!AA['Y$((9.
M$%&:@7L>$4/'!5#@FU?00%"$1@1*;'XJ2DF(;HM)*PD'D=!M87E9M4C2P/.J
MHOLZG_)!V3-H&9 ?K0 JJ-\C+H-K"\K-JD:6!YU5%]G4_P"2#LF;0,R _6@!
M54;Y&2<,FO 25%5+L![HYO<M'YVND-W,U[8 )F0' \$70Q%5$%($).OD8P52
MP K5Y:YL"+N)%,"+S% 4/$=QW?\ GL6^RY<N7+WRY<N&.#ERXOR(0>@ 1$HC
MI$=(G)EG4F");0G=*0P"'C(TFB5@M90OJ'7_ !+IO?B)KAN)Q&/9\4FM-<0O
MHB1QS37D7^)K_L!T3+IJH <(#506O##'9\4FM-<0OHB1QS37D7^)K_L!T3+I
MJH <(#506O##$6[: >#5OXZF;W;F_0+1Q! 9!%"$@JG<+#3QLFY]Z!JB\Q!?
MI9J-;3,&S'I4#E/AW)Q:WJ.EC%,))O.JW\!Y+I3JT(,;!VV#O;U4@QD1<6B)
MB'@U<(D8VV9[5R%UM7D$>)V#&P=M@[V]5(,9$7%HB8AX-7")&-MF>U<A=;5Y
M!'B=@QOUN",%8D.;P/=O-^@6CB _ED):+2X-*1P-$=^=*U+#V*4"'PN&^\N
M!4( *J 7&Y/)AE) FB@]S%''X7C-:U1P:F.D2+-YHKM;4SJX(LG/G547V=3_
M )(.R9M S(#]: %51OD9=!M87E9M4C2P/.JHOLZG_)!V3-H&9 ?K0 JJ-\C+
MH-K"\K-JD:6 IM?7R$'%(0'(#K"BZ ;[  '8 #@)[OF^0M'2B!;D"^F)LZH?
M!=================;3$=J(P<B_O"T]\0?6J>#PLC<QJ<\Q=&A8CI$Y$Z)X
M#4NS.$*Q!E "H8T'*-402[T4D1LX&&&8X[C\']@,) ]S6%D*H(\H7@2::*0\
MFQB,HDI0C&D&;B#%7]//F;88L,JF&D"3[4!NCGIBC%K-"Q<.Z!C@@ZP;7*A(
M$+L'L^*36FN(7T1(XYIKR+_$U_V Z)F9D8BF0.&IL>I[R<WZ#:.XA2#3M/KH
M5$I(*K/M?;(60$'  *P4R!VEM)WI=I;EAO9@(<>U 1XQMMCX %8<X8<YK#R8
M#5 T3)UWOA/)=*=6A!B?*'&H 1!.GA<&WWI66LSAR)\<= 2A>DY 2KLJ%6$8
M!,A.$:+M5D7&OER9,X%F9S%RISK>+C?OB29%$6K.'DRI=6;\CDO<$9LW#[U_
M^<WN&9?.8#2%@VM@!Y<_$>?/GSY\^?/GSY\^?/GSY\^?/GSY^O;ZG]CY'Q"D
M"_+UL@41-U08,$;J=!KA #,P +(//S_NMR1\*H!E1SQ+5,20BH#(L  0X\6\
MX<Y#CWHLVC75SM@D6U(1'4&,2D%"#BC.Z#:PO*S:I&E@>=51?9U/^2#LF;0,
MR _6@!54;Y&70;6%Y6;5(TL#SJJ+[.I_R0=DS:!F0'ZT *JC?(ROA382&5WP
MTT3"BJ-Z5WNN>2(RC+J':)+9!XD'$C%/7N015U .@    #WG-\E;C-X %UA?
M65UEIB:7L#ON\>2('QN@TWYEZ>-4&A\,"D.//7BD9'9!PP0*EH$[07*\@B\=
M< !#CW/+&\7U8\H\8O XO5,&F@DW0,*((-41,2WG"K(97Y;L08[/BDUIKB%]
M$2..::\B_P 37_8#HF7350 X0&J@M>&&.SXI-::XA?1$CCFFO(O\37_8#HF7
M350 X0&J@M>&&.SXI-::XA?1$CCFFO(O\37_ & Z)D!\D .8>O)<60QU97.A
MS% 8 L ->^YODK<?JW?BZ8\>NPP01*.%5-SK>=4Y?I&$R*CT6[>?5P#S<*?*
M -2-!F=LM+SO!@H4-QB=%ARN5#%$/8YOI:MZF$PMJ^ -OY$/)8.A%K," <6X
ME0HS&!&H!"-K\3!LB(?#0I!W3C -/>(/.*]#/*SRLCT, ./;8,9 M@@6<)]/
M4]G8.VP=[>JD&,B+BT1,0\&KA$C&VS/:N0NMJ\@CQ.P8V#ML'>WJI!C(BXM$
M3$/!JX1(QMLSVKD+K:O((\3L&-@[;!WMZJ08R(N!W%0%R6]ZBQH1F3[-*99P
M J@ T>_YODK<>&*UU&\P/<F 9U+Z*O;.X2XF$'G9RH8C<.&0F5#@[3O!PNL&
M>/A6K9.:$=,F5X544M'J&33,PC)?]!N*(0""  '\"!"."";3Y0IM=@D:\)<H
M-J:3ZR9NG(%LC\AI[@20K66 ,00#X8*01TPG7/C4-O&"/#<$=#O(LI<IQU]S
MS+6\M9,0*(!J+#+0,R _6@!54;Y&70;6%Y6;5(TL#SJJ+[.I_P D'9,V@9D!
M^M "JHWR,N@VL+RLVJ1I8'G547V=3_D@[)EFY &9NI/:(A@YT#]S5     ,*
M9![_ )ODK<8Y(Y[V'"A6A$,1_E+.F%,_"+#Z0(RU-0U0Y$,E3C>O%YS+HDE
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M41$!>R(65Y]NK4XJC'O #6FLMW(__8@R=U.<:"I'@2%.;VRI1.50LI J&;
MFOTG_]H " $# P$_$/\ \'1<_($YT[G XV<F,%Z(9?)7UK.BNL>/1),\<L7V
M/!W<-@I7:*+M!*<D:P=5;ZGD+%=;U?O7\.;4&B]C8D(VAJ1%H*8#9K.Z#26;
M0Y6$!2;D YJ^978"Z&I2>F[0' TKV!\OU,H%>,.YMGWI&X@95>BXU&PCA:F@
M*:0ZHR?2T'.R] VM2LE7W5.(@4990V]K& T":)Q/7Q*LJ[$2L#N;)]Z1N"F1
M#HN!$IQ^H'1B0 "J( &U6!CHUQJVM]'L(5W8-UCIMH12@J&E ^!!NJ$!E@5H
M!MA56!+CMO+>^@B%J98MEARQ1!$-B*)Q^G2CW)?$<-A1J*JC)<$+B0R$=0-%
M?A07;; &Z6T+79#A:(0;DK&ALZ,BQ_ID\<ST:N "JH!B"8.#M +@@=$XT)YJ
M^I%050JJJJJW"Q$= C&UJK*5K<^^%8$<4P6$Q^$!2!!04"($$1H[,4C)$QFH
MC1O4 4SO ?%,'T'N/.N3]+U@30:!J%!2Q$ /((F<K!"QN^D)[8(&4(*(C1$V
M([$V.#;;^R:BGL ^'[R=F%T3PNT+1*;%B] %I/"WRHQOZ5J0>A_#*A7TU5VA
MP*;<:>7!FS9'%@>$X.":BI13@T*0*Z'<02BE)0:U=\'B-G6/C%AU(+ 6"],?
MRNNE*4@3A <+&NZXQFR/E139K&SIFN<9ICYQ0VZQ_*[Z4K" .5 QLZQ\8,.)
M$8@Q'KXU=N=?GM4$P6!1^!!#W3@GF@"@&\HHJ(EM %UXSX44BO5PIL*?9(F(
M5C*U!'78%F&:^&GS0H'Y#COR'CIK@=P,6E(]T<3%!50 .54@'*J ;<9U870H
M<@Y35OEIP4FDO"(L*B E40W@ Q41$1ZB:3Y)0I<\06 \C9.*\_!'''''''''
M''''''''4T&"%?5(?=SLX?;(18666%[>(S4Z>JWI$6<71B>Y[]^_?OW[]^[2
MAX:PJG4H"[! $,.]Y$))"\;Q@['$SCH!.C0-*XUT,WF24TP78^P"0P7CQ4#@
MMD B%'/D,C)Z%?5;87  +Y2(^M:XHH@)#0 _#@- Z:UX5*:(OX\CL'76\>&Q
M[$GJ33H#82CG0QU6;:8^Z<19H"!,T(7I"X6(]@RLDE.B$6>5$<0<P?'1M!F.
MA'C3+$K /$!V(6P/& =2ZK(D,R"&VY34E51M3-RTDL6SQ*>RV.#L1'V%;$)B
M<Q#/@&!CX I BD>&KQ3%3W7@!B] IJT":@MY=N/\>U5)&<O441&X*W<'4UX;
MEIL@( R)HNF]:I(5P46,'7BBD]=!< /5?,^WU_D_ 9,&<1HH+M %5X#">428
M< M@4("B>SW/NM^SD50DMP&%^[*602I@"8P86SP>(P%@:4F]BC="N$AD!!2!
M/M4\JW;(80MIT0L72'9("26C2!T&!$@Y3I$"OD+F    :/=H! 4;,F:BH(DS
M4=M.;'!$6$6SIC9CNLI[&6/M'0R(RM10C@^G,'[IAQ1YAPB?L[E:KKB0)'K6
MW56PBP6+F%AR+;6$U12L"J^V=([=H8&Z"HLQTET'Z1Q;L@[B<((GZ 9[?7^3
M\!DP?'JD!XPR()6PX8<!0Q+00/B%2&KLGX7'G/6*5IK'NH$- C-JA%5"JM%,
MA%1Z #14*$CA:8I$3;0A(U) .MK\Z00@4#4\PVZ)V/XL]Q-,,CT73(J%>EU:
M F%.)R3Z+74*L!)=4$8$@&@#@#H'OWH D1*(Z1'D>ID:!@$9-"4D4:!NCS#U
M1P.B[)=''COB-)"EVT7"BD*OT ,]OK_)]_DP2$["6-< !J@<$\U?4BH*H555
M55;[4V,'H8X:5,+CI'5W62FREZ@=:XP/?3Y]UM)8F($;(PHYLS+O4" /6([A
MA&@ E% 7,< 8B]3 M#B!V_\ !_?CCO%NSI>E35,P%P@[LTL % M$JGQ I @H
M*!$""(T=F(AQE2O&37!*&8?S$SV#11\035R,H1$<LTP7<[T)(1%DU#F6XP(O
M+?0F\(E;+$*A&(3 7#'IJ2;)4V$%$6+93[ /E#;*55,:?+$Q(L""I>,A);=,
M<L@F-,&63#4JYDIXCEF*OA9O<H"B+!T')VX/)\,,1(V"E\'U_D^^R830Q" *
MJN@ 57@RZQU8* BFD%XAO&>,.I4+M'+T!$@A<)V1!C0@'*\!Q3 ^%Z%!>"$9
M'=1$6K4N>E!1*-]ED53-H>,TR3QCP:F,2.FRZK P>!*("C2(GS!GL&CO0&1I
MJ%:!#9$XZ!<P Q-@IEZ>NR00K%*E#KL&\PT;EV#R*)+B&'@@7L]VAY9P)KLW
M@&JD4Y;33].B 0O5*5I,AT#20X4A*; )4%]-]6@,D@IV ..?S3CPK02"(TR!
MVGH!7?2"%%%>+P?7^3AV(%'7XA'CQX\=D0DM2F(=&W7CLP;>#<;IQ0^PD9\6
MBJ-P;AG$M#Q&XE9=FX%H+* $0( 6B",#K(!A7\.[K<,QXHTV:*I,,8, (\>
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EA-N-_K#Z3V_K.D0V4&0H.*;13R/:5*K?U<88B3H'>#TY_2G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2113965d2-org_genet4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-org_genet4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"H@.D P$1  (1 0,1 ?_$ 1<  0 !!0$! 0$!
M       &!0<("0H$ P(!"P$!  $% 0$!              $$!08'" (#"1
M  8" 0 $! L.$0@&!@ 7  (#! 4& 0<($1(3"105%E<A4Y.S==4VEM87&3'1
M(I*R<]-4U%65=I<803)2TB,T=+0UM5:V-W?7.!I1D:.4Y+=8"G%R,R28.6&!
MP4)CQ-A#9X=B)J=XJ+@J.J&Q@J*$)45&R"E*$0 ! P," P$&#1$%! 8'!0D
M 0(#$00%$@8A,0<302*35 @846%QT3)STQ055187-X&1L4)2<I*RTB.S-'24
MM-0U,U.CA#:A8L(DP8*BPV1U\.%#8R4H./%$I*6U)\25Q=562 D9_]H # ,!
M  (1 Q$ /P#OX
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MG=SS&N#:P
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M;0AJ$WD
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MLGNZ]QUY?;.S?:N[2!FMR+<2MG<B55&I+',US4C>]FN-VM%Y4M\]M>[>0_?
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MB0M<G/4CZ\D2NRP:G-U@
M
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MLR27$K45&]ZBI'&S5WRM9J>[4Y$<YTCE5$2B)L:&K3<@
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M+D,C/=37^?RERDUS<R(UBOT(K88VQL[QD<,:Z6-3T5XTTM;D^,1,Y
M
M                    IDU)%AH>6ES)97+%1C^2,@4^$S+%8M5764BJ9*?!
M,J82Z,9Z,]'3\P?:WB[>=D"+17O1M?0JJ)4^%S,EM;27"I5(V.=3T=**M/JT
M-57 GO:-8\X=B635>*!(:CNL= %LE6C9JV,+&E=6+-51.QMHQ=&'@LH2L$BH
M@X\&P191=H9=;'5(V4R-Q]2.BV7Z>XN+,^^6WN/?+HD<R-6=DJIWBN17/JUZ
MU;JX(CM+>*O0T-TH\H#!]4,Q-@?>C\?DV0]I$U\K9$F:B_G$:J,91[$TNTT<
MKFZG<$8I<_EOWA4-Q2WUQ\T7(:OD[H[W[)0T<TL;.U-81O632]SCJ>55S&KP
M<DI)X04D,+YP59#K%+U.G&<];%HV5TQGWGMS)[BBO&6[,:QSE8L:O633$Z7@
MY'MTUTTY+Z)?.H/5^VV#NO$;6FL7W,F6>QJ2)*C$CUS-AJK58Y745VK@K>5/
M3-C(U:;D       US<M^\*AN*6^N/FBY#5\G='>_9*&CFEC9VIK"-ZR:7N<=
M3RJN8U>#DE)/""DAA?."K(=8I>ITXSGK8VELKIC/O/;F3W%%>,MV8UCG*Q8U
M>LFF)TO!R/;IKIIR7T33?4'J_;;!W7B-K36+[F3+/8U)$E1B1ZYFPU5JL<KJ
M*[5P5O*GIFQD:M-R          %@.47(JF<4M%WO>]\:R,C TEDQR2&A\(YE
M9V9FI5C P$*QRX.1%$TA,22)%%C=)6R':+&P8J><9R7:&U[_ 'GN*VVYCE8R
MYN'+WSJZ6-8U7O<M.*Z6M6B?;+1J<5,2WUO'&[!VM=[JRK7OM+5K>\934][W
M-9&QM>":GN1%5>#6U<M40Q$X+\_MJ\R; IF:X<;!TIJY_39BW5#<4U9Y"QTV
MW9BK!#P)(2.=+ZYJ3',H_P#&:JZ6$7;@IDF+C)>OA,QL9OU$Z:X;8ELG89VV
MR&8;.V*6U9&UDL6ICGZW(D\BZ4THBU:VBO;6E:&O.EO5K/=2+M??.W+S&8)]
ML^6&\?*Z2&71(R/0U5MXFZG:E<E'NJC'TK15,DN9W*!AP[X_VG?,E3W=[:5B
M3J\:I6F,RC .7AK-88^ (J237CI5)'#0[_"N<91-U\%ZO3CIZ<8IL/:$F^=R
MP[<BG;;/F9([M%:KT3LV.?32CFUK2G/@9IU)WS%TYVE/NN:V==QP/B;V;7I&
MJ]I(V.NI6N1*:J^QXTH:B6_?V/EX9.S%X+[@/5C-LOSV1O;%G$-B-)G/;/TY
M+&N$XY1LD4IL]?*Q4_0]$V/FC=KO)OC;.MI\HK'WY6G9K&B.U=Q-/;ZJ^E2O
MI'/3/*OE?;)?)M;(K8:=7:)*JLT]UVKWOIHGHUIZ9M/X4\YM.<YJ!*7'6/C:
M$G*J\:1MZH5E(U3L=5>2!'*D8X448KN6,E"32;)<S)XB?H5[%0BA$EDU$B:=
MW_T\SO3S),L<OHDMYFJZ&:.NB1&TU)Q1%:]E4UM5.%45%<U45=[],^J6W.J6
M(DR.#[2*Z@<C9X)*=I$KJZ572JM<Q]':'HO&BHJ-<BM3,\8&;*
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M%AU%VG;[IQ[%A9,KVOB5R.=%)&]6N8YR(E5X(Y%HE6N:M.)DT,2,W
M          U\]X+SXB.!%.U[;I?6DELM._V64KB+&.L[:L'C#QD663,[47<P
MLT5T58INI@F"DSC/H].?F#9G3/IO/U(OKJR@NV6BVT37JKHUDU:G::41[:4Y
MUXFHNKO5BWZ3XZSR%Q9/O6W<[HT:V5(M.ENJJJK'UKRI1#/.%DBS,/$RY4LH
M%E8QA)%0,?"AD2OFJ3K"1E,%)@^4\*]&<]&.GH^8-<W$783O@5:JQZMKZ-%5
M*FUK:9+FVCN$2B2,:ZGH:D1:?4J5,?$^X
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M*ZKN1G('E)PG<:XN].[U"#Y2;#DI@J>P]/Q4@SNM:J2Y6II!^TD$BVBU0S^
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MQO;O21:5H_7!;+1>]5RI5'5-ZHYV.ISFI[O7_P [;G]^*^^O]_&H1U=U-_\
MI_VU[=9_P=R<5=(/_J<W;[1??QUH97=^]K*I6KA%);!DXIF>W:OOE'D*Q.X:
MI>-&S:RS:53FH?#_ !@KDL3(-IHJZJ'6RD=PT0/DO63*8N&^3IEKVSZ@,QD+
MW>\KRVE21E5TJL;.T:ZG+4U641>:-<Y*T53/O*JPF/O^F#\O/&WX0L;N!T3Z
M)J1)'I$]FKGH<C]2MY*YK5I5$5,1-S=XMO*B\-^[WT[IBQ1<'O[DAK*FQ$SL
MJRN&;QS5X6/>Q>M8J;,[FFCJ/:REUFD5U',HY27RP1:.#D+E<Z;A+-L#TNV]
MD=];GSN>B?)MK%7<KFP1HJ)(]R.G<RC%1RMB8J(V-JIK5S47O45KM>[DZQ[H
MQ73C:&W-M3,BW;FK&%C[F1458F-5MLU]7HK4=,]'*Z5R.[-&/5.^5'MBNTM[
M\M^[2N&G-DS_ #CAN;FI[U8/$NUJ(Z<1DA(0:Q6R#V0;U\ZMFM$LP+EAX4I%
MR*#F.1,Z:E(Z9924[,U9A]N;*ZL6-_BK;;TFW\U;1:[>9$<C7I54:K_S<;5X
MZ4D8K7KI<JLDJE4H,[NKJ#T4R.-S5WNB/<^ NIM%U JM<YBT1SDCK)*]O>ZE
MBD:Z-JN:B21Z5HLI[W.28S///NUYB+<IO(V5F:!)1SQ+K=DZ8OMRU9TT<I]<
MI3=FNW5*;'3C&>C/S!2=$HI(.G.ZX)D5LK(YFN3T%2UD14^HI7>4)-%<]5ME
M7$#D=!)+ YJIR5KKR)45/51:E_N\'Y)[VU?WE' [4NO]G6:JZWV38=*M;U4(
MM=NG$6=O8-]JUJ:2DTU&RJJA)&!+AJIU3EZ4O0QT9]$8UTRVIMW+]*=QYK)V
MD4V5M(KI897(NJ-66?:-5O'[5_?)PYF6]7MZ;JP?6G:FW\1?3P86]FLDGA:J
M:)4DOUC>CD5%7OH^]7BG ]\=R)WKQ\[X5YQ\VSLRT6K0?(>N.Y73L/85FJD1
M5)&V)FF81.+PD1-= L==*G+5EHGDZO2W=(F,3'24Q/G+M?;NYNAK=S86TAAW
M)BY4;=.8BZI&Q]Z_5W%U121SN6B<6N1%[B_:'>.ZMH^44[:&X+Z>?:>8A5UF
MR14T1.E36S33BFF:*6V8E5[US55.2I^*UR+WMR2[X*RZ?UMLNT5[C=QLA'*6
MRJW"K-V\+:9VG(J,)5M*YRBN8[UYL^R)QJQ.T*9:-B3]!2Y*;.%WM;;NU>AT
M.<RMI#+NK*R(L#WHJNC9*NIJMXIP2WC5Z+3@^1.*U0BRWCNK>GE$S[=PM[/#
MLO"Q*ES&Q41DKX4TN1W!>*W,B1JE:K'$O!*+3&P_)SDKWB?*3>%&UAS#AN%_
M'31[]W#P5@C5X]M8+JXQ,2T-"RYU59^GRTZXM)H!R[42+*MV44RPD3""RYSJ
M+96FTMI]+]GX_(Y?!R9[=.0:CGL<CE9$FEKGMX,E:Q(];6HO9N=(_4NIK41&
MX4N]]Z]8M]93%X/<<>VMG8MZL9(U6I),NM[&/JLD+WK+V;GJG:M9$S2B,<Y5
M5V3G=I<SMV2W(W=/!CDEL. W':M:-)6=USN6$S'J>5\)"/8A!Y&NW\4FDVF2
MOH>=;2;)=4F7B)2.T7*ZQBHX)B75C8> AVM8=1-JVLEC9W;FLGM7ZOS3WHY4
M<B.XMHYCHW(BZ5JQS&M175SCHIU)W-<;RR?2W>EY#DK^R:Y]O>,T_GF,<Q%:
MKF41^ICVR,<J:TI(U[G*C::S]+;C[TOF)NCD7H/1O(M]#-:]9IV=D+7<+&O7
MDZ=6ZM;YV*B*W7YZ KTU/1JED=/D$S%:M3**D8$*HLDWPMA3;&?P71[8V Q>
MY-PXMLCY86,;'$Q']J^2)CG2/8][&.T(BKWSJ)K6C7.TTTGMK<?7;J-N7,[3
MVMF71QPSO>Z6:18^QCBF>QD<;XXWR-[17-1=+:JC$17-9JKG=4=W<JN*_>;:
M'T'R&W7:-@:KWOJ"EQ;8EA6C',.CLF6I36#DGD8:/CVJ1))[NZGN&Z)"=EE)
MA-)])<E,4Q]=7NW]F[QZ2Y+<FV,?#;9C'7TKET(Y'+ V57M1VIR]ZEI*URKQ
MJ^)>ZE$VIC]S[\V'UNQ6T]X9.>[P.5QT+4[16JQ+E\*,<K=+434Z]A<U$2E(
MYDX45%6?/^1.]]Z]\<TX^:NV99:_H'057:R>V8&N'1+"V*0KD3X[E\3)CM3.
M%#O+O;HJNNB95(3"30_4QG/6RI;8]K[<V[T+=N;,6D4NY<E,K;9[ZZV->[0W
M3QIPBCDG:M%6KDKZ5VEWCNK=7E'-VA@KZ>':6)@1UW''31(Z-FM^OA7C/+%;
MN2J)1BT3G7>J.=CJ<YB-_P 7']XQWQ]5T-((^4&CN+\,\;7IB15?Q<^S5^QF
MK\BX[#/:)&F;_)QE8>8ZZ6<I,^DN>G&.GKC;4TO2WH5-N.)>RW#EY$6%:)J3
MM*LA5*_<PMDN&\%XN.']VP0]8_*.@VI,G;;7P<:I.VJZ7=E1\Z+3EKG=';/X
MIP9P)CW.5GF.,W*/EGW>=YD%LFA+3,7/7IW9C)I2CVKKMX69?-$S]E@RUVH2
M\++(X*BGG+5@H8W1Z!<4/72S@W;L_"]3L<U*20MBFI]JDB*]J+Z44R2QKQ7O
MGHB>B7'R<KZXV3OK<'2#*/6L4[YK>O!'+$J,>Y$X<9H%AE;P3O8U5>XAZ^\'
MY,\R*9WF6F="<;=G/8)O?*;KEE%4Z6(D[H?E);IZYPCFS62.*V5<.F$,V12?
M."XR<N4V..E-3'2F?QTRVEL2_P"DM_N3=5HV1UM/.KI6\)M$;(GI&QU:(KE5
M6-Y<7\TYI].KN]NH^-ZVXW:>R[YT3+NVMVMA?18.TE?,Q99&T55:Q$1[N?!G
ML53@L&Y#;1Y]=U?N73>R=J\H);E;I?;$L_8WF#GZ]B#9,UHPT6XL</#PBDA,
M)55^FPEC.H1W%N6R2ZC,Y'+0J!<HJW#;&'Z;=8L%?XK#8AF&S]DQ%A>Q^M51
MVI&.<_2U9$JW3*V1KE1'(K'J[ODM>\,[U9Z$;DQN:SV=DS^VLA(YL[)(]#45
MNE9&,9J>D3M+]4+XG-1RL5'QHU-+I_WF'*;EKK[O#.,>H^,6RW<<RV9K74[B
M'I3E0B] LEPN>VME5AG*VA%)$SE:%7:,F/AARJD)AFVZ<]!<9R+;TFV?LK)]
M,<OF]W6C726EW<HZ5.$T<45M!(K8U5:(]%5^E%2NIQ=NMF^^H&(ZOX/;VQ[U
MS(KZRM59"O&"2::[N8D=*B)56*C6:U1430WT*D Y/7[O#^Z[V'J/=NP>5$CR
MJU;LNP+Q&PJC.UQ.MP+65;-DY.3K,/"&>RC*M>&QJKE>&D8E2/\ V9@8KEF5
MOCL%KEM'&],.K^,OMOXS#,PV8M(D=#(R36]6JNELCGT:LE'(U)62(_@]%9)J
M[YMIWQENL'0S,8_<^7SS\]@KV967$3XTCC1Z(CG1L9J<V/4U7.ADB6/BQ4?&
MC.]=/N]XYB\B]-[LXF_FU['GH>'V#3VUH2JL:HV\2WMZ[ML;XA:3#=4I3N&L
MLU<$;*%*LEUDE<XZQ?TV+;T1V-M;.X#-?*NUC?/:SK&LCJZX42-VM6JG)6JB
MN3@O%.7<+MY0W4;>.V]S;?\ D5>RQV]Y;I*D3::)W+*WLT>B\T>BHU>*<%YI
MS)LXVOS@[M?B_P @MV\Q=L0N[]C[$LFO8#0-6Q8'<_5:Y>K(RMLA8VTAE2NU
M=S&M(B-:F=JQ<;GQ8H2)[)JJ3MS+$H&X;I[U7W?C-O[&LI,?BK6*9]Y)H1DC
MX6+&UBM[^1'*YRZ4D?\ G$62KVKI1JW-^?ZH=%MC9?<_4;(193,WDUO'81=H
MLD4<\C972([\W$K48U%>L4?YI4BTL<FI7);>N:*[V*^\<&W,M'G;9(O8TW13
M[AK>A6M<;I5A]57,0I:H>,.5)9*FL[%*P)R&0C%:XLU*LJF@NY)G!SDNEUN+
MHQC=U+L1VW(GXJ.Y][/O%>O:)(CNS<[EVJL:^M9$G1RHBN:Q>"+9;/:O7[+;
M,3J0W=4T>9EM??<=BD:)$Z)6=JQO!4A;(YE-,:V[FHJHUSTXJF9'$CG!OGFE
MP/O=XU%!T8G+>DKK:\=,YUT6&I*ED41BG++894'!'B+9JO6Y)5VFR5ZS9268
MJH9ZK;..C!=Z]/MN;"ZC6V/S<EPNRKA$G16)JET5<BP52BJJ2-1JO3ODC>CN
M+S8_3[JANOJ7TJN\IMZ*U3J#:JMNJ/71#VE&JVXHNI$18W*]&+WJRL<W@PU&
M\AMB\P.-.M(O<=@[V*%MW(LTQ$K67B_4+%7+8E *2+LJ+IOX/!6&:J#@L,@<
MJCILO7F$?G!5<(*JY*3*N[-L8O8^[,L_!6VRY(-KZ')'D)6/CUZ4JBU>QDJ:
MEX-<DSW\M36U6G/F\,SU$V5A(]QW>_XKC>/:,63&0R1RI'J6BI1DCX5T)17-
M=;QQ^RT.=1-6RWDAWF6PM4=V;H;D9#LH)+?7(*%K=<B5S,D%H.O6)2&DW=RO
M3:ONSN$';1CF$/X&S5RLBD[D&W;%613434U/M7I-C,SU9R6UIW2+MO&22/<E
M51[V:FI%"KTHJ*NM-3DHJM8_2K7*BINO>?6W+X#HEB=Y6S8DW7EXHXV+I161
MR*QRS3I&M45&Z%T,6K4=(S4CFHJ+8YSQV[Y77M"U9R!UMRNL&]=IVQ> E;GQ
MZG48&/J5?B[!&YD\MC/;M8XVF2C=F7LVD@1!I!JM5%<F9K'R3"HR%FZ.A.3R
M5YMK*X:+'8>%'MBO6*]TCW,=IK2)CI6JO%S%5TR.1*2-2M#%W[.\I#$8FPW=
MA<_-E<[<+&^;'O2-L4;9&ZJ:II&PN1.#9$:R!6JM8W+344#O]Y&R3'&?B1*W
M*NXJ-NDK=)/K35BR+&7)7+"YHC):9A$I6-<.V$FC&2)U$2.$5#IK$)@^,^B*
MGR;(K2#=N;AL)>WLF0-2.32K=;$F5&O5KD16JYM%5%1%15H4GE9S7MQLG;]Q
MDH?>^0?<.=+%J:_LY%@17L1[55KD:ZJ(Y%5%1*EO>7;KO+N)NDM-<QYOF0\>
MO+%-T>'F="P-21@:#KY*>K;ZQP<!ADXDY"*O#!BA"FCI [IB@]ZYRFPNXQUU
MBW/9+.D^]-P7^Q;?!-:R*.9S;Q\BOFF5CT8]]4:UT+E5VMB->K*)32W@U;/U
M"DZU[ VQC>H]UN1SI)I8&/L8XDC@MTDC=(R/2KG,G:U&=G(KF-?5474_BY.D
M71NQ3[?TII[;2L>2)4VCJW7VQ5(LALG)&GNU2B+*>/(<QU#'(S-)]GC.3&SG
M!?FY^:.5MPXM,'G[["H[6EG>30:ONNRD='J^KIJ=G[6S"[BVSCMP.9V;KZPM
M[C3]SVT3)-/U-5/J%TA9R^@
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M/CKK&X-UU;-M&W36LN)6I=L629\:*[0USE1L::G(YK-:*J.,QN\!A9EYWU/
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M &>?.6ZCA),B^,$.7/T.<^AG&?T1=O*!N()MI[:;$]CG-B=5$5%5/S-OSHO
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M%3BBHMQ)144W=TS:YG3?;['HJ/3"6**B\%14M8JHJ=Q4,FAB1FX
M
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M9M;"^-45LK4;JD95R*BT2BKMV&DCH4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#BO6^F6R&REXUJ]L@7>3+14TP*X3,=/K*$R50N2G-C(A45JT4E%J7D$
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M=5K56PYM_P!;$-'5RQJ23E^FO/F+G#'PYDR*YSC/5SZ E6*GH5%4,Z1X)
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MJB5YH$6IDP/)(
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M&J".,^ 8LUDU+(/+@X2,7]AS(.WJ")G6,9Z^#X+U_1S@0[V#?JA.:FPT>#T
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MC.57-9BD8R9A&\CU.DQ8]"QJY42R?H)EQGHQ]$/"?V:^J>OMD-AH\$@
M
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M9?$8U?RTK(RTU8'Y$SK.W&2*(I]9$N3IY+@A7)32WD$3C53,P>"0
M
M
M
M
M                            /.[=MV+9=X[6(W:MDCK+K*9S@B22>,F.
M<V<8SGJEQ@ ?8IBG*4Y<X,4Y<&*;'S,E-CIQG'_HSC( _0
M/*1ZU.[68$7(9XW11<+-\9SVB:#@RI$5#8Z.CJJ&1-C'_5 'J
M   !Y7KUK'-5WKU<C9HV)E1==3.<$2)C.,9,;.,9ST=.0!Z@
M   !Y4WK59TZ9)+D.[9$;J.D,9SUT".\*Y;&/CHZ,86P@?H_ZN0!Z@
M        >5Z]:QS5=Z]7(V:-B94774SG!$B8SC&3&SC&<]'3D >H
M        >5-ZU6=.F22Y#NV1&ZCI#&<]= CO"N6QCXZ.C&%L('Z/^KD >H
M            'E>O6L<U7>O5R-FC8F5%UU,YP1(F,XQDQLXQG/1TY 'J
M
M                        12]>XZS>PS_U@PEO,A>1(F?[3:_N9#UHH+S)
M/2(              0MC[O;!^+M?_?DR/7VI'=)H/)(             0S8G
MN)L?L<?UQ,2G,A>1,Q!(              !#(CW;7/V.J7K<V)[A"<U)F()
M            "&;$]Q-C]CC^N)B4YD+R)F()               (9$>[:Y^Q
MU2];FQ/<(3FI,Q!(             0S8GN)L?L<?UQ,2G,A>1,Q!(
M
M                   $4O7N.LWL,_\ 6#"6\R%Y$B9_M-K^YD/6B@O,D](@
M             !"V/N]L'XNU_P#?DR/7VI'=)H/)(             0S8GN)
ML?L<?UQ,2G,A>1,Q!(              !#(CW;7/V.J7K<V)[A"<U)F()
M          "&;$]Q-C]CC^N)B4YD+R)F()               (9$>[:Y^QU2
M];FQ/<(3FI,Q!(             0S8GN)L?L<?UQ,2G,A>1,Q!(
M
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MC6\Z\N!TBCF,Z]
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MXC51W!GZ7F?^(VJ?XZNXV#Y4GZAAO;KC\6$UOY&_]2S_ +1:?CSG6R..#O(
M                             M^M/R9%52%6)U2J'+C]A2SZ!39QC_W?
M\F![H@/GY0RGIY/44OU@40#RAE/3R>HI?K H@'E#*>GD]12_6!1 /*&4]/)Z
MBE^L"B >4,IZ>3U%+]8%$ \H93T\GJ*7ZP*(!Y0RGIY/44OU@40#RAE/3R>H
MI?K H@'E#*>GD]12_6!1 /*&4]/)ZBE^L"B >4,IZ>3U%+]8%$ \H93T\GJ*
M7ZP*(!Y0RGIY/44OU@40#RAE/3R>HI?K H@'E#*>GD]12_6!1 /*&4]/)ZBE
M^L"B >4,IZ>3U%+]8%$ \H93T\GJ*7ZP*(!Y0RGIY/44OU@40#RAE/3R>HI?
MK H@'E#*>GD]12_6!1 /*&4]/)ZBE^L"B >4,IZ>3U%+]8%$ \H93T\GJ*7Z
MP*(!Y0RGIY/44OU@40#RAE/3R>HI?K H@'E#*>GD]12_6!1 /*&4]/)ZBE^L
M"B >4,IZ>3U%+]8%$ \H93T\GJ*7ZP*(!Y0RGIY/44OU@40#RAE/3R>HI?K
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M#$/W+O\ 9ZX^3=U_>1_[?6'RR>C/-?MCU.G_  F#X8A^Y=_L]<?)NZ_O(_\
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M59;@             HMB_@22_<QOJBBDO_U.3[TN.*_J,/WY6A5EN
M        **T_AN9_<T3]2^%)%^N3?>L_XBXS_P!.M_OY?^ K0JRW
M    8#=Z'_<+Y%?BW6_Y_5(;"Z4_2#C?;7_HI#6'6?Z,<M[3'^GB-5'<&?I>
M9_XC:I_CJ[C8/E2?J&&]NN/Q836_D;_U+/\ M%I^/.=;(XX.\@
M                   "TSC]L+_7E?JS#Z)R(/B
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MX.\@                             "TSC]L+_7E?JS#Z)R(/B
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MJRW             !1;%_ DE^YC?5%%)?_J<GWI<<5_48?ORM"K+<
M        45I_#<S^YHGZE\*2+]<F^]9_Q%QG_IUO]_+_ ,!6A5EN
M    P&[T/^X7R*_%NM_S^J0V%TI^D'&^VO\ T4AK#K/]&.6]IC_3Q&JCN#/T
MO,_\1M4_QU=QL'RI/U##>W7'XL)K?R-_ZEG_ &BT_'G.MD<<'>0
M                    !:9Q^V%_KROU9A]$Y$'Q      $(V3L>F:BHMFV5
ML.9\GJ33HQ28L<UXNE9;Q=')*)I'<>+H-C)RSSJJ*EQU$$%5,]/Z7HZ1<<1B
M<AG<E#B,5'VN1N'Z8V:FMU.YTU/5K4Y<W.1"U9S-XO;>)GSN:E['%6T>N5^E
M[]+45$KIC:YZ\TX-:J^D8)H][KW>+A9) G(9(IUE4TB&6U;NMLB4ZA\$+E5P
MXUNDW;I8R;Z(ZABD)CT39QC&<C93NA?51K5<N*6B)7A<VBK]1$G55]1.*FI6
M^4?T7>Y&)FDJJTXVE\B<?15;9$1/3541.Z9\4B\TW955AKQK^S0EQJ%A:^&P
MMBKT@WDXJ00PH=%3L738YR86;.$CI+)&ZJJ"Q#IJ%*<IBXUCD<;?XB]DQV4A
MDM[^)U'QO:K7-7GQ1>XJ45%Y*BHJ*J*BFW\5EL9G,?%EL//%<XV9NIDD;D<Q
MR<EHJ=U%14<G-KD5JHBHJ$K%$7    +:[3V]KO2E=8VS9MA\FH"2LM?J#)_X
MIG)GMK%:7Q8V"CO!:_&2KU/PYZ?!.V.F5!+IZ5#D+Z(N^%P65W#=NL</%VUT
MR%\JMU,92.-NI[JO<U."<:(M5[B*I8]P;DPNUK)F1STW86;YXX6NT2/K)*[3
M&VD;7N34[A54TIS<J(&NW]=O=LRFC6UA[3:4+2&6QY.K^*9PG@U,D9<T$SF?
M':D82NK=M*DREX.F[.[+^F,E@GT0/P.5CP;-R/BIA9+E8&R:F<96MUJS1J[1
M*-XZE:C>XBUX"/<F%EW%)M-DU=P16C;ET6B3A Y_9M?KT]FM7\-*/5Z<U;3B
M7*%H+X6UV!M_7>K9'7L3>[#XBD-JW>.UQ0F_BF<D_'USED'+F/ANUAXR00B_
M"$&BAO"'IF[0G5Z#*XSG&,W?%X'*YJ*ZGQD7:Q65LZ>9=3&Z(FJB.?1[FJZB
MJG>LU.7N(6/,[DPNWY[*WR\W8S9"[;;6Z:)'=I.]%5K*L:Y&51%[YZM8E.+D
M+E"T%\   "VL%M_7=FV7?-/PEA\-V-K*,J\Q=Z[XIG&WB2.N;19]6G'C=W&(
M04EXR:MSFZC1TX41Z.A4I,YQC-WN<#E;/#VV>N(M.)O'R-ADU,76Z)421-*.
M5[=*JB5<UJ+]K4L=IN3"WV=O-M6LVO-V$<3YX]$B:&SHKHEUJU(W:D15HQSE
M;]LB*7*%H+X                       '.M_S!ON.XP?C+M+^*Z0.K?);_
M %_,^TVWXTQQ7Y9/]-P/M]W^) :&-=^Y5C]>>_OM48#U\^DV\]IM_P!"PVCY
M,GT/V'M]U_$2$W&F3?P             7@UU_!;[]W__ "Z(X[\HW_5-C_Y?
M_P!](<N==O\ 45G^Q?\ >R%PASR:/                    .MS7?\ 1_1?
MQ.K'\2,1^M.W?]/V/['#^C:=98[^GP>TL_%0F(O!6        !16G\-S/[FB
M?J7PI(OUR;[UG_$7&?\ IUO]_+_P%:%66X             *+8OX$DOW,;ZH
MHI+_ /4Y/O2XXK^HP_?E:%66X               HK3^&YG]S1/U+X4D7ZY-
M]ZS_ (BXS_TZW^_E_P" K0JRW            8#=Z'_<+Y%?BW6_Y_5(;"Z4
M_2#C?;7_ **0UAUG^C'+>TQ_IXC51W!GZ7F?^(VJ?XZNXV#Y4GZAAO;KC\6$
MUOY&_P#4L_[1:?CSG6R..#O(                              M,X_;"
M_P!>5^K,/HG(@^(      PB[R/\ N+<F?ZM7W\81PV+TD^DC#_MC?Q7&JNN'
MT39W]A=^,TQ4T_WFO$F#T%JJAR^-F6J<AM1T2IRM1B=*7R;S.2D93XF(?PD>
M9W!(04J5XZ0.DGD[C#9;&<9Z_4STC-L]T>WS<[GO<G![S@MI+Z:5LKKN%FAK
MI7.:]U'J]M$5%6C=2>A4U]MKKOTYM-GX_$7'O^XNXL;;POA98W#^T>V%C',;
M6-(WZE142KM+O1HI8K6]HY <'N[^D]D0%!\CK'LOEZ2V:^TK;F)DWE2U5LV>
M@XN(UP[8KY,K7)!^E$JJ)]*95F?AV#'2PK@Y!DF7L]K]1NJ#,1=77OBTL\%V
M4]W$O"6YMV/<Z=%3A(UNI$7C1^BB.TT4Q+!W^\>E/1R3.6=G[VOK[<G;6]E,
MVCH;2ZD8QELK5XQN<C%5.".9VE5:CJH90;8WSRDX@:K:N=V;8T-L3;>[=DU6
MBZD<S$0GJ74VJ5I.,E92Y3=\GG$JV<S-$IZ;<A4UCJH/ENE'!C9.L8I<-PFV
M=F;\S3F;=L<G:8/'6DDURC7>^;FY1KFMB9"Q&JC)I:K5$1S$[ZB4;5<]W%N[
M?_3;;[7[IR.(O=QY6^B@LU>Q+2TM%<U[YGW$BO17V\*(E'*K9'=[5:N5$M+7
M^:FT-+W[5Q]D<QN(/+37FRKW7=>VR"U%+4N$V5K*0N#CP&*M<#%UBP2OE51X
M.2ZJ<D=REAX5%4ABD+]$<E\NNGN&W#C+U,1@,]@\K9VTD\3[ILK[>X;$E71/
M=(QO9S/;QC1JZ:HJ*J\$7';/JCG]KYC'KG-S;;W'A;Z[CMYH[-\#+FU=,NED
MT;(I']K!&ZB2JY->E45$3BJ9 W3;'*WD)R#V]I;BW=*!IBB\>L5>'OVU+=3L
M;"FK9L.TQ!YW%6K$(Z71A6L37V'52D%%?^\IN>C)39*<I!B^/PFR=K;6L-P[
MSM[K(9+*]H^"VBE[!D4$;M':2/1%>KGNXL1.]5O<JBJ9CE-Q=0]Y;RR6U]@7
M5GB\3A>R9<7<T/OA\US*SM.RBC548C(V\)%7OD=R545$,>^5\_R1E>(L/$<H
M:=7(#8%0YB:7K<?;*:^9JU':=79WB/-$WV%B"R#N7K?C'M#IJLWJ3<_63PJ1
M-/"F44<IV3:[2@WU)/LVXEEQ<^ NY'12HJ2VTBPNU0O=I1LFG@J.8KDXT55I
MJ=AO4.\WQ<=-XK;?UM!#F;;<UE$V:%S5ANXFSMT7#&:E?%JJJ*QZ-6J:D1$=
MI;FLXWWL%/FIM71I7$5Y!5'B=';?AV^8Q/,F2YN;B\A55W$EU^T7C\L4"XPA
MDN"X-Z/2->LVQBEZ>V.Y%1_PG/G'6KUU=[V21(^B-[CJK[(VD_=^9;U2R&TT
M='\$6VW6WC$TIJ[=9G,55=S5NE/8^CQ,&M4[>[S/?O%./Y1UK96D-?-(BIVN
MP1-%>:[\<R&V4:7)SA9:0GY=VJ1M1RRAH=9I'-F2><'22(LLNGVW:DV/F\%T
M?VQO5^S+RSR-T^2>-CIDGT-MEE:S2UC42LVG6CGN>O!55K6KIHNI]O;DZ[;P
MZ>LW_8WV*LHX[>:1D#K;6Z[2!TFMTCU6D&O0K(VL3BB(YSTU:DR*E>9FPI_5
MW=W;+K+&'KAN4FXM;TW9$.NQQ)MV\5/PTRI9&5?7<KG79$S+Q9LM%S&.L5OU
M<'^BR88I!T_Q5MF=UXB\=)*F%L)Y8'HNE5<Q[>S5Z(E%[UW?(E$U5IP,UN.I
M^9O,!LO.V#(H%S^3MH;EBMU(C)&/[5L:JM6]^SO'+5R-I7C46#:W+CDGO3=.
MM^+UYUWI+67'::C*/9=C6ZE_&)8-@[.=1A)6;KT1%.5TX>(@*JFJ1NZ/GH>%
M7,4Y3*%6[)NM<)L;:.V\?E]Y6UWD<QE8W31P12]@R"W1VECW.1-;GR<7-3V-
M*I1%;5R\W#U&WSNS*8/8-W98K!865L$MS-![YDN+I6ZWQL8JHQD<54:]?9ZE
M145R.TLG+38W/UOQSD4'NC*._P"3S39I=8QTLE9H='54G457R#1/D&O%XL"=
MC1JR""A^UARX3E3*EPX*U*VR9(EM?B>F#]V,='DKENSG6?OAS5C<MRV5&JOO
M%':.S615I27C'3O-:OHJW:/-]86;)>V7$VC]^MO_ 'JUZ2L2T="KD3X15G:=
MHD2)6L/"6J:TC1E6IB_)\D.4_&[?O':G;7Y(Z Y(5;>^U:SJ>?I5-K$%3K]0
M'UR>IQD39(MG"RSAX[KK"1?I87<OL*8.0A4L)E56*IC,H=I;+W;MC*W^$Q&4
MQ-[C+*2Y9-+(^6&=(DU.C<KVHB2.:U:-92BJKJJC50P&?>_4#8^\,+C-PYS#
MYS'Y?(16DD$,4<-Q;NF<C62L:QZN6-KG)J=)6J(C=*.<CDO_ **_\RWGA_5K
MQ?\ YIS QC<OT0[:_;,C^E:9CM+Z=-W?L.*_0O-DXU$;Q
M        #G6_Y@WW'<8/QEVE_%=('5ODM_K^9]IMOQICBORR?Z;@?;[O\2 T
M,:[]RK'Z\]_?:HP'KY])MY[3;_H6&T?)D^A^P]ONOXB0FXTR;^
M   "\&NOX+??N_\ ^71''?E&_P"J;'_R_P#[Z0Y<Z[?ZBL_V+_O9"X0YY-'@
M                   '6YKO^C^B_B=6/XD8C]:=N_Z?L?V.']&TZRQW]/@]
MI9^*A,1>"L        "BM/X;F?W-$_4OA21?KDWWK/\ B+C/_3K?[^7_ ("M
M"K+<             %%L7\"27[F-]444E_\ J<GWI<<5_48?ORM"K+<
M          45I_#<S^YHGZE\*2+]<F^]9_Q%QG_IUO\ ?R_\!6A5EN
M      P&[T/^X7R*_%NM_P _JD-A=*?I!QOMK_T4AK#K/]&.6]IC_3Q&JCN#
M/TO,_P#$;5/\=7<;!\J3]0PWMUQ^+":W\C?^I9_VBT_'G.MD<<'>0
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MP>6M.KVY<[<P2,Q%W9XYL,JTTR.BB<DB-XUJQ51%X&> UH;<
M           #G6_Y@WW'<8/QEVE_%=('5ODM_K^9]IMOQICBORR?Z;@?;[O\
M2 R_[G;^X7K#\9-F?S^GQ:.M/T@W?M4'Z%A=>@7T8V7MMQ^G>;0!JDW*
M         %%0_AZ0]CH_UYX*-GZ])[6W[+BY2_TN+VU_V&E:%86T
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M53K-'%QW^   %IG'[87^O*_5F'T3D0?$
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MA-'RJE \U-Q_#4+^L#SJ,!\57GA(_6'SIV'BDWX31\JI0/-3<?PU"_K \ZC
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MZ_6\;[7-^-&7,',AS\
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MH>4G^NXGVJX_&B.;>O7ZWC?:YOQHRY@YD.?@
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MN-@^5)^H8;VZX_%A-;^1O_4L_P"T6GX\YULCC@[R
M   #DR[A7^^AR<_JPLG^]:L#M'RC_P#06(_:X_X>0X \E'Z2LY^PR?Q41UFC
MBX[_     M,X_;"_UY7ZLP^B<B#X@
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M;-&'E5'1UK<,6;8F<IMV3-U-J)(IDZI")%*4I2EQ@N/3%JU*D+S,0QZ(
M   NMK?_ +"6^NM/J%QRAY2?Z[B?:KC\:(YMZ]?K>-]KF_&C+F#F0Y^
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MCJ[C8/E2?J&&]NN/Q836_D;_ -2S_M%I^/.=;(XX.\@
M      Y,NX5_OH<G/ZL+)_O6K [1\H__ $%B/VN/^'D. /)1^DK.?L,G\5$=
M9HXN._P   M,X_;"_P!>5^K,/HG(@^(
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M5W7FO&T\SL4S'8C9.6FWUFM<XXBVS;MT^Q:(H]90F2J%P0\4<Y45W!$)X(G
MF9MB<-MZETUM+?5[V/1M@ZKHM'HVR=<5[7I+:TW<UUHV+&P$I7;<G,QC&H25
M@@F;=M(X?H92*8O0C@N"Y6.HY*HWDHX<S"3?FV9#>NY]E;>DV?BUQ?K9*3R,
M7V_A68F,65[&&B#.NHEX4:*AT$&^5>H3"F4NM@I>GJX](E$H0O%2T0D@
M  "ZVM_^PEOKK3ZA<<H>4G^NXGVJX_&B.;>O7ZWC?:YOQHRY@YD.?@
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MROU9A]$Y$'Q
M     !SK?\P;[CN,'XR[2_BND#JWR6_U_,^TVWXTQQ7Y9/\ 3<#[?=_B0&AC
M7?N58_7GO[[5& ]?/I-O/:;?]"PVCY,GT/V'M]U_$2$W&F3?P
M            76UO_P!A+?76GU"XY0\I/]=Q/M5Q^-$<V]>OUO&^US?C1ES!
MS(<_
M            !T ]V7_=R??UDV?^*JV._?)G^CE__F4WXD)OWII_IUW[2_\
M%8;#!T(;!,!N]#_N%\BOQ;K?\_JD-A=*?I!QOMK_ -%(:PZS_1CEO:8_T\1J
MH[@S]+S/_$;5/\=7<;!\J3]0PWMUQ^+":W\C?^I9_P!HM/QYSK9''!WD
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M#Q7'?:3;U(GS@JH'BN.^TFWJ1/G!50/%<=]I-O4B?."J@>*X[[2;>I$^<%5
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M3[QK1[5B?D;N_P"*LE^[3_D$? V7\5N?!/\ R1\36X/-3LGWC6CVK#Y&[O\
MBK)?NT_Y ^!LOXK<^"?^2/B:W!YJ=D^\:T>U8?(W=_Q5DOW:?\@? V7\5N?!
M/_)'Q-;@\U.R?>-:/:L/D;N_XJR7[M/^0/@;+^*W/@G_ )(^)K<'FIV3[QK1
M[5A\C=W_ !5DOW:?\@? V7\5N?!/_)'Q-;@\U.R?>-:/:L/D;N_XJR7[M/\
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M ':)^F$^F+\\ .T3],)],7YX =HGZ83Z8OSP [1/TPGTQ?G@!VB?IA/IB_/
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M7ZG1?A:'F^[E\=L?\7W,><WM+Q#(_6A]U'R\W'3S/;K]3HOPM#S?=R^.V/\
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MC_AY#@#R4?I*SG[#)_%1'6:.+CO\   +3./VPO\ 7E?JS#Z)R(/B
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M7"_S0\G_ /Q3ZI_^@S#SEM^^*XCP-Q_-CS1.FOCN<\-:_P D/)+A?YH>3_\
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M_#T\+_.=R?\ ?IJG^Q4/.<W[XIB/!7'\T/-!Z:^/9SPUK_)#_#T\+_.=R?\
M?IJG^Q4/.<W[XIB/!7'\T/-!Z:^/9SPUK_)#_#T\+_.=R?\ ?IJG^Q4/.<W[
MXIB/!7'\T/-!Z:^/9SPUK_)#_#T\+_.=R?\ ?IJG^Q4/.<W[XIB/!7'\T/-!
MZ:^/9SPUK_)#_#T\+_.=R?\ ?IJG^Q4/.<W[XIB/!7'\T/-!Z:^/9SPUK_)#
M_#T\+_.=R?\ ?IJG^Q4/.<W[XIB/!7'\T/-!Z:^/9SPUK_)#_#T\+_.=R?\
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M^O*_5F'T3D0?$
M       %#LON?F?8YUZT8"%Y'"W8_=#.^S,I^_EQ4GS*,         "^E']S
MC3ZZ[_?*@X2ZY?2/=^U0?H6''/5__7=S[7#^B:2X:B-9'1#W._\ 0?L[^M93
M^:%:'7GD\?Z8O?V__NHSJ?H/_IV\_;?^ZC-H+'W>V#\7:_\ OR9'0?VIO'ND
MT'DD             (9L3W$V/V./ZXF)3F0O(F8@D               AD1[
MMKG['5+UN;$]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@
M            $,B/=M<_8ZI>MS8GN$)S4F8@D             (9L3W$V/V.
M/ZXF)3F0O(F8@D                       .3+N%?[Z')S^K"R?[UJP.T?
M*/\ ]!8C]KC_ (>0X \E'Z2LY^PR?Q41UFCBX[_   "TSC]L+_7E?JS#Z)R(
M/B                                           H=GFC5NMV&Q%BI:
M=- 0<M-%A(!BO)SLR:+8.'V(J%C6Q%'$A+2&4.Q;()E,=58Y2EQG.<8 &MNP
M;]YN4G4A>4-OIFE&.M6[2.M,UI$Z%SCMI0U"EGS5%H=:UOWF(<MU:,GR3ARV
M68I)$)UR92*OCL,>Z-5=/&I%5YE\=O[]V&\N^H-.<>&-07ONV*A);+>6?8K>
M76KE&UM'I,L)3#N$A73*1E)B:?/?!FB)5BIIKI_LN,D-UB0B)S7D@KZ!XM9<
MB]EL7G(#7&Z:A%S>V]!UEA=6C?4#"<=L]M5&9@GLG"+5* ?FDYAM8UG\?EBY
M;&.9/PM<G98[/!LX*B<%3DHKZ/,LY9^0'-35VK(_DULNIZ3)K#!:[,V[3T6W
MN4?LRJ4^T2D;'L5$;-)OSQ#RX1I91N9XU6:)HE,94F"%.7&"RB-5=*<Q5:5+
MZ;BWAM!WMC7^@./+2D9O=NU]([;LMNV*VFGE?IFN&LFA!1K]*$A74?(2LM.S
MJIFR1#*E31,7&3ER4^3)PB)2J\@J]Q.97>.>Z;_<[5MW3>YHJK1FW=*RE;)+
MOZ1F3+4;?5+I$GEZI:85M,+.9!BNX0;JIO6QE5<-UL%^B+U^S(5.ZG(E%,DK
M+[GYGV.=>M&'DA>1PMV/W0SOLS*?OY<5)\RC "53E(MU:A:G8[!7I2'@[U'O
MI6GR4@V.V;V*,C9%:)>OXS*G09PS0D4#I=IC'5,8N>KG./1"J _E-H]QV'.H
MUFB5B<M]A7:OGJ4-7HQW*R)V<8T5?2+OP5FDJJ5JQ9H'554SC!"$+G.<X!51
M.8YGOUYK38&VK,UINLZ=8;Q:'B2KA&%K<8YDWI6B&4RN'SDK<AB,X]ME4O:N
M%C$13ZV.L;'3@%5$2J\AS/OLC5FQ]/V12H;1I5CHEE(U1?%B;)&.(UPX8.#*
M)H2#(RQ,(OX]95$Y"KH&41,=,Y<&ZQ38P147B@I0@  R7TW4+5?$X:K4NO3%
MJLDFM(XCX.!CW,G)N_!LN7;DR#-HFJL<C=J@=10W1T$(3)LYQC&<CA[K'C[[
M*]4;FQQL,D]X^*#2QC5<Y:0-5:(E5X(BJOH(E3D3JC87N2ZB3V6/BDFNWQQ:
M6,:KG+2%JK1$X\$157T$2I-:71KCL:PLZI1*S-6VR2&%3-(:!CW$B^420)E1
MPXRBW(?*35LEC)E53]5-,N.DQL8]$:DQN,R.8NVV&+@DN+Q]:,8U7.6G-:)R
M1$XJJ\$3BJFM,?CK_*W3;+&PR3W;N3&-5R\.:T3DB=U5X(G-3HQ[KC66P=4Z
MKV;6MD4^>I<X?9>'Z,=/QZS%5TP6JE?22?,CJ8[%ZS.L@HGA5$QT^T3,7IZQ
M38QV%T.PN6P."O;+,V\MM=+>ZD;(U6JK5BC1')W')5%2J*J514YHIU7T;Q&4
MPN%O+/+02V]S[[U(U[515:L;$JG<5*HJ52J514YHIL'8^[VP?B[7_P!^3(W?
M]J;@[I-!Y)             "&;$]Q-C]CC^N)B4YD+R)F()
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M$_3"?3%^> ':)^F$^F+\\ .T3],)],7YX =HGZ83Z8OSP!_<&+GYABY_Z,X
M'Z    !R9=PK_?0Y.?U863_>M6!VCY1_^@L1^UQ_P\AP!Y*/TE9S]AD_BHCK
M-'%QW^   %IG'[87^O*_5F'T3D0?$
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MYP$]]_[O^'GGMD'PU@_%$_ C'R;W'X\OA)?6'YP$]]_[O^'GGMD'PU@_%$_
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M*)^!&/DWN/QY?"2^L/S@)[[_ -W_  \\]L@^&L'XHGX$8^3>X_'E\)+ZP_.
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MTE9S]AD_BHCK-'%QW^   %IG'[87^O*_5F'T3D0?$
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M&*KM+%<C6HW2U$K7A5>/%<VF/N]L'XNU_P#?DR-O_:FTNZ30>20
M    AFQ/<38_8X_KB8E.9"\B9B"0              "&1'NVN?L=4O6YL3W"
M$YJ:[>^<_P#+=Y%?];4'^_;60VYT(^E;%?YG^#N#1_E(_0MFO\I_'6I_GH[!
M]T2G[D:_4F':6Y?ZHOWC?L' FS_Z*WVQ_P!DA L!E
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M7O[?_P!U&=3]!_\ 3MY^V_\ =1FT%C[O;!^+M?\ WY,CH/[4WCW2:#R2
M         $,V)[B;'['']<3$IS(7D3,02               0R(]VUS]CJEZ
MW-B>X0G-37;WSG_EN\BO^MJ#_?MK(;<Z$?2MBO\ ,_P=P:/\I'Z%LU_E/XZU
M/\]'8/NB4_<C7ZDP[2W+_5%^\;]@X$V?_16^V/\ LD(%@,H
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M_$#,6[J=](>9_P#,9_QU+IT@^BW ?^56_P"C0RY&"FQP
M       H=E]S\S['.O6C 0O(XO9[COR 6G9I9'1FXE4E9:14253UE=3IJ)G>
M+&(HF<L)DIR'+G&<9QG.,XR*C4WT4/%%*3^;GR$\Q&Y?R87?VC#4WT4%%'YN
M?(3S$;E_)A=_:,-3?1044?FY\A/,1N7\F%W]HPU-]%!11^;GR$\Q&Y?R87?V
MC#4WT4%%'YN?(3S$;E_)A=_:,-3?1044?FY\A/,1N7\F%W]HPU-]%!12]5,T
M%O9" :IKZ5VTBIA5UG*:NN+BF?&,N%,XSDAX;!L=.,CBCK/@LY?]0+JYL;.[
MFMEB@H^.&1[5I$Q%HYK51:+P7CP4Y,ZK83,WF];FXL[2ZE@6.&CF1/<U:1M1
M:*UJIP7@O$E/Q$;P\S6UOR=V_P!IQJOY+;G^+;_]WE_(-<?)K<7B%[X"7\DW
MW=TY3[=3-,['87"K6.J/G6SCNVK.RPDG!.W+3R5KR/A2#>4:M5EF_;)&)URX
MR7K%SCIZ<9'5703'9#&[<O(LC!-!*Z^JB2,<Q53LHTJB.1%5*HJ5Y5.F.B5A
M?8_ 7<=_#+!(Z\JB2,<Q53LV)5$<B*J5X5-CS'W>V#\7:_\ OR9&]_M3<W=)
MH/)(             0S8GN)L?L<?UQ,2G,A>1,Q!(              !#(CW
M;7/V.J7K<V)[A"<U-=O?.?\ EN\BO^MJ#_?MK(;<Z$?2MBO\S_!W!H_RD?H6
MS7^4_CK4_P ]'8/NB4_<C7ZDP[2W+_5%^\;]@X$V?_16^V/^R0@6 R@
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MG*J53N+3N%LZ?86^VYL?$X')HU,A9V$,4B-74U'L8B.H[NI5."E_QBYF
M                    4.R^Y^9]CG7K1@(7D7R9_M-K^YD/6BCPO,]'I$
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MHCK-'%QW^   %IG'[87^O*_5F'T3D0?$
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MWTQ_U]BOVI/L*9KTZ_UOC?VE/L*=6^Q/<38_8X_KB8_0-.9W&O(F8@D
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MJE(WN5%5$<O)$X'2..53L\   +3./VPO]>5^K,/HG(@^(
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M2?84S7IU_K?&_M*?84ZM]B>XFQ^QQ_7$Q^@:<SN->1,Q!(
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M5=O7.?==VC76UUV'O=7TG?[#\XQE.+._Y_[KO0,4!D)C
M             3?7WNB3_<CKZDHO^VOZHGWCOL&+[P_HKO;&?9.N7NC?Z*J)
M]=GOY^V4<7==_I6RO^6_@[<[Y\F[Z%\-_F_XZZ.GF&_:*7_1\\:A-YE5
M     !:9Q^V%_KROU9A]$Y$'Q
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M*_:D^PIFO3K_ %OC?VE/L*=6^Q/<38_8X_KB8_0-.9W&O(F8@D
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MHE45U%5W>W/XT4?BO5._"H\WQ+FM8+TN_<6[G:[Q4M13:$Q2*#M%0KV/LL'
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M;_CKHZ>8;]HI?]'SQJ$WF54         %IG'[87^O*_5F'T3D0?$
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MS<&)CP%E9VF-P3)%D6&W;I1\GW3U[J)S1$1$KQ6NENG6D,X->
M            !-]?>Z)/]R.OJ2B_[:_JB?>.^P8OO#^BN]L9]DZY>Z-_HJHG
MUV>_G[91Q=UW^E;*_P"6_@[<[Y\F[Z%\-_F_XZZ.GF&_:*7_ $?/&H3>950
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M_G!5 4&T1SY.N3:BC1<A"1KLQC&3-@I2X2-TYSG./0Q@*H%Y'!J*D^0
M           &0E7]S\5^Y2_5&'YY]4OI!RO[4OXK3A_J)_K;)?M*_80KPP$P
MP          RLX.?WM=$?CRT_>3T9WTQ_P!?8K]J3["F:].O];XW]I3["G5O
ML3W$V/V./ZXF/T#3F=QKR)F()               (9$>[:Y^QU2];FQ/<(3F
MIKM[YS_RW>17_6U!_OVUD-N="/I6Q7^9_@[@T?Y2/T+9K_*?QUJ?YZ.P?=$I
M^Y&OU)AVEN7^J+]XW[!P)L_^BM]L?]DA L!E
M                                        3?7WNB3_ '(Z^I*+_MK^
MJ)]X[[!B^\/Z*[VQGV3KE[HW^BJB?79[^?ME'%W7?Z5LK_EOX.W.^?)N^A?#
M?YO^.NCIYAOVBE_T?/&H3>950
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M?,@2T@F1SJ2(JTHO)*<>9O.V)[B;'['']<3'6:<SIQ>1,Q!(
M  !#(CW;7/V.J7K<V)[A"<U-=O?.?^6[R*_ZVH/]^VLAMSH1]*V*_P S_!W!
MH_RD?H6S7^4_CK4_ST=@^Z)3]R-?J3#M+<O]47[QOV#@39_]%;[8_P"R0@6
MR@
M     )OK[W1)_N1U]247_;7]43[QWV#%]X?T5WMC/LG7+W1O]%5$^NSW\_;*
M.+NN_P!*V5_RW\';G?/DW?0OAO\ -_QUT=/,-^T4O^CYXU";S*J
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MM-K^YD/6BB%YDGI$              (6Q]WM@_%VO_OR9'K[4CNDT'DD
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M%%X\N)TXPW[12_Z/GC4AO JH         +3./VPO]>5^K,/HG(@^(
M                                               *'9?<_,^QSKUH
MP$+R-%#KOQ=JQTBYB2:-U\HFP>K1Q%CV*QX.H1JN9L50Q<$ZN#F*3ISC'H=(
M\W"=C!),G%6,<[ZR*I\9YEB@?*B55K%7ZR5-V/$#?LOR4TRRV?.5^-K3]U8)
MZ&-%Q3ET[:$2B%TD4UL+.\86RHMA3I-CYF/T!@O3W==QO/;C<W=1,AE=,]FE
MJJJ48J(BU7CQ,6V+N:?=N ;F+B)D,KI7LTM553O51*U7CQ,H1G!F(
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M !V2?Z@O^8 .R3_4%_S !V2?Z@O^8 .R3_4%_P P _N$R%^84N/_ % #]@
M        "TSC]L+_ %Y7ZLP^B<B#X@
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MNB_^B(_VF7[*&Q\;C-L            0MC[O;!^+M?\ WY,CU]J1W2:#R2
M           $,V)[B;'['']<3$IS(7D3,02               0R(]VUS]CJ
MEZW-B>X0G-29B"0             AFQ/<38_8X_KB8E.9"\B9B"0
M      "&1'NVN?L=4O6YL3W"$YJ3,02             $,V)[B;'['']<3$I
MS(7D3,02                              6F<?MA?Z\K]68?1.1!\0
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MW5G]TJ'_ !YNO[];#3/0K_0,?[5-]E#6W1?_ $1'^TR_90V/C<9M@
M    "%L?=[8/Q=K_ ._)D>OM2.Z30>20             AFQ/<38_8X_KB8E
M.9"\B9B"0              "&1'NVN?L=4O6YL3W"$YJ3,02
M $,V)[B;'['']<3$IS(7D3,02               0R(]VUS]CJEZW-B>X0G-
M29B"0             AFQ/<38_8X_KB8E.9"\B9B"0
M           "TSC]L+_7E?JS#Z)R(/B
M                 /DN@BY14;N44G""Q#)K(+ID5153-CH,11-3!B'(;'S<
M9QG&0!_4DDD$DD$$DT4$4R)(HI$*FDDDF7!$TDDR8P1--,F,8*7&,8QC'1@
M?0 ?%PW0=(J-W2"+ENL7J*H.$B+(JDS\TJB2A3$.7/1\S.,X '[33313(DD0
MB221"IIIIE*1--,A<%(0A"XP4A"%QC&,8QT8P *-9?<_,^QSKUHP$+R.&&;]
MT\O[/2'\8*B+[]2F]J?^*I17GZI+[6[\53KZ[JS^Z5#_ (\W7]^MAIGH5_H&
M/]JF^RAK;HO_ *(C_:9?LH;'QN,VP           !"V/N]L'XNU_]^3(]?:D
M=TF@\D@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,
MB/=M<_8ZI>MS8GN$)S4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D
M               AD1[MKG['5+UN;$]PA.:DS$$@            !#-B>XFQ
M^QQ_7$Q*<R%Y$S$$@                             %IG'[87^O*_5F'
MT3D00+8^R:+J*F3.P]E6:,IU)KWB[QU8YA11*.CO&TJQ@X[P@Z2:JA?#):30
M0)T%STJ*E_0]$7'$XC)9W(1XK$0ON,C+JT1M]D[2U7NI6G)K7.7TD+5F\YB=
MMXN7-9V>.VQ4.G7*^J-;K>V-M:(O-[FM3AS5#&)GWC'!M\Z09H<G-6$6<JE2
M3.\FU(YJ4Y\]&,KOI!JU9-4L?HG54(0OZ.<#,9.E'4>-BR.P]ZK42O!FI?J(
MU55?41%4P.+K9THFD2)F>QZ.<M$U/5J?5<Y$:B>FJHAD?9]N:SIL#5+39;O7
MXVMWF>K=8IT[E\F[B;+.6_K>2["'?,?"FSTT[@N<MCD-E)0OHX-T9QD8G9X+
M,9"YGLK2VE?=VT4DDK--'1LB_M'/:M%31]LB\4] S>_W'@L7:6^0OKJ&.QNY
MHHH9-562R3?V36.;5'=I]JJ<%YU+BBTEZ        "A6:T5JEP$K:KA8(6JU
MB#:G?35BL<HRA8.)9)Y*4[N2E9)=LQ9-RF/C'74.4O3G&.GIS@5-G9W>0NF6
M5A%)/>2.HR.-JO>Y?0:UJ*JKZ2(4E_?V.+LY,ADYHK>PB;J?)(]K(V-]%SW*
MC6IZ:JA9O5/*SC?O*:>UO4FZ=?7RQ,$%G;B!@I]JK-99-S$(X?MHM;*#Y['H
M&4+@[A%-1$F3%Z38Z<=-_P WLG=NW+=MWG,?=6UJY41'O8J,JO)JN2J(Y>XU
M515IR,9V]U"V1NRZ=8[<REG=WK$55CCD17Z4YN1BT<YJ52KFHK4JE5XF0(Q<
MS$ACS8=)C[U"ZR>62,1O]B@92T0U4RJ8TN^KL*X;-)29*W3(?"4>U=NTTLJ*
M9(4RANJ7ISC.,7"/%9&7&R9B.%ZXN*5L;Y/M4D>BJUE>ZY415HE>'%2V2YK%
M0Y:+ RSQIF)H7RLAKW[HV*B.?3N-151*K2J\$JI3=I;;UMI2IK7G:UPB*-46
M[YE&K3TVHJDP3?2)S)LFICHI+'PJY.3."_0]'3@?;#8/+[BODQN$@DN;Y6JY
M&,HKM+>:\53D?#/[CP>UL<N6W#<QVF-1[6K(]51J.=P:G!%XKW#':+[Q'@_+
MR#2,9\G-4$=/5BH(&D+!B'984-T]7PB3ET&,:S)GHZ.NLJF3I]#IZ<X&53=*
MNHT$3II,/?:&I5=+-2_4:U5<OJ(BJ85;]:>E-S,V"+/8Y)'+1-4FAM?3<]&M
M;ZKE1#)&T;1U[2U:.C:+;#PZFRK)&U"A>$.,G):K)+MU7<7$Q"K<BR3EP^:H
M&43STX(8N.GK#$K+#97(-N764$DB6<+I9J)_9QM6CG.K2B(JT7NF<7^?PV+=
M:-O[F*);Z=L-O5?[65Z*K&,5*HJN1%5.XJ=TGHMA=P        H%IM=8H]>E
M;;<[#"5.KP34SZ:L5CE&4-"13,IBIY<R$G(+-V;1'M%"EP8YRXR8V,8]'.,"
MJLK*\R5TRQQ\4D][*ZC(XVJ][E]!K6HJJOJ)R*/(9"PQ-E)D<I-%;X^%NI\D
MCFL8Q/1<YRHU$KPXKSX%KM1<E=!;[5E6VG-MT;8;V#(5:7C:Y.-74M'M3J%1
M3?.8DYDI)..56/A,KGLNP,I]#@^3>@+SG=H;GVRUC\_8W-K'(M&ND8J-<O.B
M.XMU4XJVNJG&E"P;;WSL_=[I(]LY*TO98DJ]L<B*]J5IJ5G!VE5X(ZFE5X5J
M7P&.&5@            !0[+[GYGV.=>M& A>1PPS?NGE_9Z0_C!41??J4WM3
M_P 52BO/U27VMWXJG7UW5G]TJ'_'FZ_OUL-,]"O] Q_M4WV4-;=%_P#1$?[3
M+]E#8^-QFV            (6Q]WM@_%VO_OR9'K[4CNDT'DD
M (9L3W$V/V./ZXF)3F0O(F8@D               AD1[MKG['5+UN;$]PA.:
MDS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,B/
M=M<_8ZI>MS8GN$)S4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D
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M=$C5:ZBJE%HO&B]PP'I/C<AB=H,L\G#)!=)/*NA[5:ZBJE%HO<7N&>0VH;*
M           A;'W>V#\7:_\ OR9'K[4CNDT'DD             (9L3W$V/V
M./ZXF)3F0O(F8@D               AD1[MKG['5+UN;$]PA.:DS$$@
M       !#-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,B/=M<_8ZI>MS
M8GN$)S4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D
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M"\ST>D0              A;'W>V#\7:_^_)D>OM2.Z30>20
MAFQ/<38_8X_KB8E.9"\B9B"0              "&1'NVN?L=4O6YL3W"$YJ3
M,02             $,V)[B;'['']<3$IS(7D3,02               0R(]V
MUS]CJEZW-B>X0G-29B"0             AFQ/<38_8X_KB8E.9"\B9B"0
M                          "TSC]L+_7E?JS#Z)R(/B
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M52$@Z.U=88>5EJN,J@_8PT6_?]9!GG""V7*Q,DQT&,GA2$3A5>"!5[A4>/\
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MQ^QQ_7$Q*<R%Y$S$$@              $,B/=M<_8ZI>MS8GN$)S4F8@D
M          (9L3W$V/V./ZXF)3F0O(F8@D
M    M,X_;"_UY7ZLP^B<B#X@
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M8ZI>MS8GN$)S4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D
M                        M,X_;"_UY7ZLP^B<B#X@
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M[:Y^QU2];FQ/<(3FI,Q!(             0S8GN)L?L<?UQ,2G,A>1,Q!(
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MT7O7=U*&"[)@FM69RYN&N9##AKJ)ZJBIIDETQL8M>3E?7@O'O5[J4,N>YO\
MZ2]R_B- _P ?G&?^3K_6LC^RL_2&<]!/ZO?_ +,S\<Z!!UF=/
M  !#-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,B/=M<_8ZI>MS8GN$)
MS4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D               AD
M1[MKG['5+UN;$]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@
M                             %IG'[87^O*_5F'T3D0?$
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M_P#LS/QSH$'69T\             $,V)[B;'['']<3$IS(7D3,02
M       0R(]VUS]CJEZW-B>X0G-29B"0             AFQ/<38_8X_KB8E
M.9"\B9B"0              "&1'NVN?L=4O6YL3W"$YJ3,02
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M#]H?^(7;'(IS*   &Y+N;_Z2]R_B- _Q^<=%>3K_ %K(_LK/TAOOH)_5[_\
M9F?CG0(.LSIX             (9L3W$V/V./ZXF)3F0O(F8@D
M    AD1[MKG['5+UN;$]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%
MY$S$$@              $,B/=M<_8ZI>MS8GN$)S4F8@D             (9
ML3W$V/V./ZXF)3F0O(F8@D
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MT8J/:UJ(C7:JII,UV3TZLME7<]U:W,L[IXT:J/:U*46M4H9_C9IL8
M      (9L3W$V/V./ZXF)3F0O(F8@D               AD1[MKG['5+UN;$
M]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@
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M(>DL_4UON@-* >5$AZ2S]36^Z TH!Y42'I+/U-;[H#2@'E1(>DL_4UON@-*
M>5$AZ2S]36^Z TH!Y42'I+/U-;[H#2@'E1(>DL_4UON@-* >5$AZ2S]36^Z
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M]CJEZW-B>X0G-29B"0             AFQ/<38_8X_KB8E.9"\B9B"0
M                        "TSC]L+_ %Y7ZLP^B<B#X@
M                                        H=E]S\S['.O6C 0O(N-K
M::>6775!L4CA$LA/TJK33[#8ADF^'DK!,'SG""9CJ&31PNN;JER8V<%Z,=.?
MFCPO,]$U$              (6Q]WM@_%VO\ [\F1Z^U([I-!Y)
M   "&;$]Q-C]CC^N)B4YD+R)F()               (9$>[:Y^QU2];FQ/<(
M3FI,Q!(             0S8GN)L?L<?UQ,2G,A>1,Q!(              !#
M(CW;7/V.J7K<V)[A"<U)F()             "&;$]Q-C]CC^N)B4YD+R)F()
M                              +3./VPO]>5^K,/HG(@^(
M                                            *'9?<_,^QSKUHP$+
MR)?I;^AS4W]6=#_FM%#PO-?5/1<P0              A;'W>V#\7:_\ OR9'
MK[4CNDT'DD             (9L3W$V/V./ZXF)3F0O(F8@D
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M;'['']<3$IS(7D3,02               0R(]VUS]CJEZW-B>X0G-29B"0
M           AFQ/<38_8X_KB8E.9"\B9B"0
M    "TSC]L+_ %Y7ZLP^B<B#X@
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M3=&,E]B@3FIF]9?<_,^QSKUHP\A>1+]+?T.:F_JSH?\ -:*'A>:^J>BY@@
M           !"V/N]L'XNU_]^3(]?:D=TF@\D@            !#-B>XFQ^Q
MQ_7$Q*<R%Y$S$$@              $,B/=M<_8ZI>MS8GN$)S4F8@D
M       (9L3W$V/V./ZXF)3F0O(F8@D               AD1[MKG['5+UN;
M$]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@
M                 %IG'[87^O*_5F'T3D0?$
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MK[4CNDT'DD             (9L3W$V/V./ZXF)3F0O(F8@D
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MA]X6.:W7F=I012LO<+[T[5[M.B3WY"Z9G9T57=ZUM'ZD;QY53B7X&,F7
M                   !0[+[GYGV.=>M& A>1+]+?T.:F_JSH?\ -:*'A>:^
MJ>BY@@             !"V/N]L'XNU_]^3(]?:D=TF@\D@            !#
M-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,B/=M<_8ZI>MS8GN$)S4F8
M@D             (9L3W$V/V./ZXF)3F0O(F8@D               AD1[MK
MG['5+UN;$]PA.:DS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@
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M+S4]$[$              (6Q]WM@_%VO_OR9'K[4CNDT'DD
M(9L3W$V/V./ZXF)3F0O(F8@D               AD1[MKG['5+UN;$]PA.:D
MS$$@            !#-B>XFQ^QQ_7$Q*<R%Y$S$$@              $,B/=
MM<_8ZI>MS8GN$)S4F8@D             (9L3W$V/V./ZXF)3F0O(F8@D
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M&M=#%,DD:->FIL<2R-BA57.<^-B.?I<JH;$QJDW2
M   %#LON?F?8YUZT8"%Y%+:<NN*!6K8IN3O'DIBMT2F*;=.M\9+G"9<9QG&;
M+TXSC(\JUU>2DU0]'YW?$_\ XG^/'Y:M;?"4-+O0450?G=\3_P#B?X\?EJUM
M\)0TN]!15"I,^47&:1['$?R)T4^\(4PBAX'MR@.>W6,?LRI(]C8#]HH93/5P
M4O3G)O0^:+%>[EVYCKI;'(9"R@ODI6.2>)CTU)5O>.<CN**BIPXHO M%UN+;
M]C<K9WU]9PW:4[Q\T;'\>*=ZYR.XHJ4X<>X7U%[+P        &G+>6_MOU#=
M>Q8ZN75]%LF4MB+:H),8=4J+!HGA9NVP9S'+',5)1TIG&<YR;/6]'/S!4L8U
M6HJH?-56I;'\ZSD%YRI/\&5[VG'KLV>@1J4?G6<@O.5)_@RO>TX=FST!J4?G
M6<@O.5)_@RO>TX=FST!J4?G6<@O.5)_@RO>TX=FST!J4?G6<@O.5)_@RO>TX
M=FST!J4?G6<@O.5)_@RO>TX=FST!J4?G6<@O.5)_@RO>TX=FST!J4?G6<@O.
M5)_@RO>TX=FST!J4?G6<@O.5)_@RO>TX=FST!J4\C_D]O>39N&#[8<BX9ND\
MI.$#1L 4JB><XSDN3)Q)#XQTX_0S@.S9Z U*>O\ .LY!><J3_!E>]IP[-GH#
M4H_.LY!><J3_  97O:<.S9Z U*/SK.07G*D_P97O:<.S9Z U*/SK.07G*D_P
M97O:<.S9Z U*/SK.07G*D_P97O:<.S9Z U*/SK.07G*D_P &5[VG#LV>@-2C
M\ZSD%YRI/\&5[VG#LV>@-2C\ZSD%YRI/\&5[VG#LV>@-2C\ZSD%YRI/\&5[V
MG#LV>@-2E0BN4N_74I&ME]CR9T'#]F@L3$= $R=)9PFFH7!TXDIR=8ALXZ2Y
MQG'Z&1"QLIR&I3<K%59@=!&3R]G,/Y)A'&?.23LH11QE)#)DL*9*YQTE2RN?
MJX^87K9Z!3+Z!]*%4\FVWWRL7OAEONH0*>J/)MM]\K%[X9;[J 4]4>3;;[Y6
M+WPRWW4 IZH\FVWWRL7OAEONH!3U1Y-MOOE8O?#+?=0"GJCR;;??*Q>^&6^Z
M@%/5'DVV^^5B]\,M]U *>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPRWW4 IZIYW
M=0C'S99H\=SKEJN3LUD%IZ5425)G.,]4Y#.LX,7IP)J*'H\FVWWRL7OAEONH
M0*>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPRWW4 IZH\FVWWRL7OAEONH!3U1Y-
MMOOE8O?#+?=0"GJCR;;??*Q>^&6^Z@%/5'DVV^^5B]\,M]U *>J/)MM]\K%[
MX9;[J 4]4>3;;[Y6+WPRWW4 IZH\FVWWRL7OAEONH!3U3SIU",2<N':;N=(Z
M=D03<KEGI7"JY&N%,-RJGPZZ3E1PL;J]/S.MG_*)J*'H\FVWWRL7OAEONH0*
M>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPRWW4 IZH\FVWWRL7OAEONH!3U1Y-MO
MOE8O?#+?=0"GJCR;;??*Q>^&6^Z@%/5'DVV^^5B]\,M]U *>J/)MM]\K%[X9
M;[J 4]4>3;;[Y6+WPRWW4 IZIYW=0C'S99H\=SKEJN3LUD%IZ5425)G.,]4Y
M#.LX,7IP)J*'H\FVWWRL7OAEONH0*>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPR
MWW4 IZH\FVWWRL7OAEONH!3U1Y-MOOE8O?#+?=0"GJCR;;??*Q>^&6^Z@%/5
M'DVV^^5B]\,M]U *>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPRWW4 IZH\FVWWR
ML7OAEONH!3U1Y-MOOE8O?#+?=0"GJCR;;??*Q>^&6^Z@%/5'DVV^^5B]\,M]
MU *>J/)MM]\K%[X9;[J 4]4>3;;[Y6+WPRWW4 IZH\FVWWRL7OAEONH!3U1Y
M-MOOE8O?#+?=0"GJCR;;??*Q>^&6^Z@%/5(WTN? O ?&$GV?EMXL[?Q@Z\-\
M!^;V'AO:>$]7_P#:Z1/K#TBF./VPO]>5^K,/:<@?$           6^L6JZ!;
M+YKG9MBK;:3O6I/*_P"+JPJN9!)S6/+V&0K]N\%;-GB+!UXZAVQ$#^$I+=0I
M>E/J&Z<BZ6F:RECC+O#VLRLQM]V7;L1&JDG8O5\555%<FAZJJ:52O=JA9[W;
M^'R.7LL]>P-DRV.[;WM(JN18O?#$CFHB*C5UL1&KJ1U/M:+Q+@BUEX+?:[U7
M0-3L+#&:\K;:LL+7<+!?[ W:N9!T62M]I62<3\VJ:1>/%$EY)9 AC)IY(B7H
M^@(473*YK*9R6*;*S+-+!;L@8JHU-,4:*C&=ZB<&HJ\5JOHJI9L+M_#[=AF@
MPL#8(;BYDN)$17+JFE5%D>NI745RHE42C4[B(7!%K+R
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MC2?Y?\1AW3CM8[#        #0CR6_IXV?^,R_P"]VPJV>P0^2\RQH]$
M                         %5@OX;AO96/_?:(+R!T=1'\$Q?L<R_>R0HU
MYGV*B(
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MX]-LCE5!=+P<CDJJO66.==1<B4.Y)Z 3GZ9FA9?<_,^QSKUHP\A>1PA"I/F
M  &2.G_T]2_&)G_'"8X<ZR?2I-_E?T<9R%U3^D:3_+_B,.Z<=K'88
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MX_;"_P!>5^K,/:<@?$
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M4R+0+V>$'=YH4DR<N%$E"'<OG!,J8Q@F%"T$,*Y&QCB;_:PRHU?O'KS^HO\
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MT:B.M5<NE*(JJB\43N5/CK>ZQH^M6SHG'BM$7DJ^D=APQ0OP
M       !;O\ M$_]@GUB/7*4X_;"_P!>5^K,/:<@?$
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MUN,*C R^7")U%2L4):.F299G*JGA%?PR,3QDQL'QU.MCHZ<]."HB_4!&
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MN:W7V6A?07GQ]+GRY$)8,;"L*.73VFKT_4-O(M17
M%N_[1/\ V"?6(]<I3C]L+_7E?JS#VG('Q
M                           !Z6?[<:_NE#UTH+R!P.BI/D   &2.G_T]
M2_&)G_'"8X<ZR?2I-_E?T<9R%U3^D:3_ "_XC#NG':QV&        &A'DM_3
MQL_\9E_WNV%6SV"'R7F6-'H@                              JL%_#<
M-[*Q_P"^T07D#HZB/X)B_8YE^]DA1KS/L5$0
M                                                        "W?]
MHG_L$^L1ZY+C044<QC&:])C9R8V>W<XZ<YSTYST86QC'3G(54D_/B&)^U/\
M3N?LP54#Q#$_:G^G<_9@JH'B&)^U/].Y^S!50/$,3]J?Z=S]F"J@>(8G[4_T
M[G[,%5 \0Q/VI_IW/V8*J!XAB?M3_3N?LP54#Q#$_:G^G<_9@JH'B&)^U/\
M3N?LP54#Q#$_:G^G<_9@JH'B&)^U/].Y^S!50/$,3]J?Z=S]F"J@>(8G[4_T
M[G[,%5 \0Q/VI_IW/V8*J!XAB?M3_3N?LP54#Q#$_:G^G<_9@JH'B&)^U/\
M3N?LP54#Q#$_:G^G<_9@JH'B&)^U/].Y^S!50/$,3]J?Z=S]F"J@>(8G[4_T
M[G[,%5 \0Q/VI_IW/V8*J!XAB?M3_3N?LP54#Q#$_:G^G<_9@JH'B&)^U/\
M3N?LP54#Q#$_:G^G<_9@JH'B&)^U/].Y^S!50/$,3]J?Z=S]F"J@>(8G[4_T
M[G[,%5 \0Q/VI_IW/V8*J!XAB?M3_3N?LP54#Q#$_:G^G<_9@JH'B&)^U/\
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M0)J*$D$$@
M     <)__AW%7]<^(_\ #N'UP/\ P[A]<%_M6?IZQ_05_#S7]I^RI/\ L?\
MXG^3_P"R'''5CZ29?U+_ .[?VGL_[-G/_H](Y:ZD?Z^D_4__ &']I[/V#/\
MT0[,AUX=5@
M
0                 !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2113965d2-pc_celltype4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pc_celltype4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K0&_ P$1  (1 0,1 ?_$ -H   $$ P$! 0$
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MZ" 3UJDB_!=0]3(L"?2\;1LR'3Y%Z8TB.=&(E^KIC$'RYE\^\:(2,@2CS 2
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M9RZ<XHR(W;-FZ1UG#APM4)A-%!!%,IE%5E5# 4I2@)C&$  -]<_26"ZIC,Q
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M!XX2L1:)5"E#8;PVQYF)Q,STEC['MGQK5Y9W'2;I_7&;EK"691RJ1HS;HKR
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MI&JZ)IZZ;DPSLF4W4$=6(O&W, U;3[IVW]<T7<&J-J^)D8ROAJ%,B,H)$BW
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M8=MKKE+C6\WJ\Q$ZK=6C>#=5.=K<8V85-U'V$JC5!VWFE!.=X1Z8#E*(!MN
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MDKBC?$+9(PLFJ_7B4\J50]95:.(4I2E*ZD ,10=_4 '4#MZFN^X=2UY\(?\
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M:!6%S/8^GMR@H8I7'6YE#%,8#.Q3,"9:*;^]9MU[WD?%1S@Z 388\3$=2_\
MK2"S2G\VRQ\K)<7/H_Z9^@>R_3R./-DC74=S  G)F4$(W;]7B/4L([ UVEYW
MDL>D2@ZB&IRHTI1I2C2E8M=:/2\DU>9I&0ZC6;W3+$S/'S]3N$%&66MS;%00
M$[25A)AJ\C7[<QB@/0JF8NX /Q#7UAFFQY1-CNR3*;AE)!!\".(KXY&/CY<+
M8^4B28[BS*P#*1W$&X-5"_*5]V@KLG&6/./CG:'@["V][-V3C!+RQUH*<2Z!
M<.388GI90[B"EP5 YRP4FZ48+@H)&3EF"2+-:5ML^HLBLN%N ]4?(3 <1_S
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MD;I+$O=BM^DDV%R1<]M:&XL_>?>>.'Y%A'\A(RC<J:40W0^^<Q47B_)*: &
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M@8;"X@0 Y)!_*+ I#WV(D<<0R*:J3ZB?>MT'0YI-+V+ NIYZ&QR)"5Q01SZ
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M0,'=2%6_2!TL!PN>8/C5:WGC]UA=P,).Y#X"9)F;2O'-UI V \NO(OY[)%3
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MR<>X4;N43)N&RRB1R'&6H9\'5<,2PE)\*5? JP/,$'XB"+CD1>H(R,;4M$U
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M;5X[>+(-1;+J%;3YZ$^H&U]/UC.3<;^1N#4YDZ)F $'0HLD'423&>HFQ;W&
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MP50 . KUWV[M[2=JZ+C;?T.(0Z9BQA$4<^'-F/SG=KL[GBSDL>)-)N$_+3Q
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MTO4 $ W]1#<-[&?=PA=MPZAD#_37"53[6E4CPY(?_%ZI_P#?$R8UVCI.(?\
M5?4F<<N20NK<.?.1? =O,4TWQN1XO>1#AR *"$3CRS2!A(8@%*"C^ BMU0,
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M8\CM9,1V$6QUR#L(E,8 WU%6L>F&_-$D*96FY,D8/RX5,Z$=]XNKI!_/"GO
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M8+.O#JL!97!#J+#WE 6OQZ1^O&XO3)AIDZG/VHS7..S6:(DDLV.YN$))NT;
MQN;GW&8O5IC!_E7X+YTC6;B,SG6,=SCA-+W52S$[:XUF6#I4I1*Q%_8'*-4E
MW/4;I#Y=)/2&-]$#";TU3W</HWZB;=E99=.FRL<$VDQ09U(';9 9%'Z:*:O9
MM?UZ]+-TPJ\&J08>40+Q9A&,ZD_-ZI"(G/9]'(X)X7O3C9/EUQ2AF2\E*\F<
M ,&+8O6LY<YBQZFF7\!2%WL/4HJH;Z)"% 3G,( 4!$0#6K0[)WED2"*'2=2:
M0\@,:;_)\9Y#MK<I_4+86-$9I];TA(EYDYF/_P#,Y]P'$G@*C)Y2><_BYB*+
MDH?!2CKD'D0"+MV9XEO(0>-HEX!  CB8MDFT:N9Q!,RA3D3AV[M)P!3$%TW-
ML;4M;/\ N\;PUN9)]Q :9I? GJ*O.P[EC4D(>PF5E*\#T-RJ$=]?>EV+MZ!\
M;:Q;5]8X@= 9,9#WO*P!<=H$*N&L09$/&JE_('D)EKE-E*9ROEZPN+-;YTR3
M-JW02.A$0,2BHI\LK%5AR'53B82/%8P)($$QU%3G65.JX555/=/;.V=%V?H\
M>C:)$(<&.Y)/%G8_*DD;AU.UN)/  !5 4 #S_P!W;OW!OO79-?W#,9]1EL
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M?) X18Y$\A/Y/N$HA_YCH.5R+BI3VMZ&^I^[95&%I4^-B,>,V4#C1@<!U?2
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MGI9PO*3]GL\_*+G[+5'K7?RLJ_7*BW1*JX<*E(4Q@E[)R<+2<(SSE8L*)?8
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MVB8U5=8YUG;G"UADW"$7%%,<_6%>DE4&B9>L&3M,I4& RYMGU%Z%7"W 20.
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MMV>FZSJFCR>9ITSQ$\P.*GVJ;J?A%=-K&WM%U^(0ZOCQS <B19U_1=;,OL!
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MZA<S[(Z15S!GGCYBR&4Z.X%74O&4;.WW PJ]R&/7:'7C]/T0+T31NH>K?IV
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M2A09+PJQ7HXE?-()%^=N%ZI?]Z'2=_ZCKVEOL_&UB?&7#D$APX\EU#>9P#F
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MW\^E;=$S3"DS@V"= ^._F-ELQ&B0LEE5$)A6(AYIK)H2!>B05614CC'1:-V
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M"HC]-O0#;7IGN%MQZ3FYV1E-C/#TS>5T=+LC$^Y&IN"@MQMQ/"I!'&(<,JV
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M'9GZP1<27 M=1^0:U/TQS="RI\P:-DRY#*D?5UPF+I!+VM=WZK\>ZUO&LO\
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MC$TJ2+1E)9.27DB/ODY)8R*B:9GG<.8I?HIZS[U*D>R 2-,2L]YS(($"$2[
M%9,'2IDMDND7!F\@S:$6VVZ@1 4M_P"Z.VVJF_>'BTB36=..I3Y,3_57Z1%
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)1I2C2E&E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2113965d2-pht_typical4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_typical4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"Q@.2 P$1  (1 0,1 ?_$ 2   0 " @,! 0$!
M       '" 8)! 4* P(!"P$!   ' 0$               $" P0%!@@'"1
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M6_NG9?NO]A+YVCZT7.VO=/!)%2;>3 =5K14EC@ )6C&@:]H):6OYR[_=E?\
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M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(N@M/[7I?\
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M6WM&2PNN)Y!' '!H-"ZKB*TH/  5)\,.)*IS7#HY!#$POE+2ZE0* 85J>9P
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M\N^3V[(E DK9J)W4=)L4(1_TN$%K,?8ODT*ZDRJ'*=VS1F7B*SDG6 ZJ13E
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MQY8Q58XA6YM=&D-6Y;67GO;M.K%S6DG\IJR.O'NB;1S^DR<A*+ING:[3SCY
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MK%9B!09,8LZ"AWP-G#AVJ1H*+B]CUFPAO??XK=WO#B2ZK\ 2#7+AQ).)/A4
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M,4!:POD7RS?JRC@O9MSHM&@)I&^>(" ](_1R)^BIX_I^HJ0>!'^KB,_K"?\
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M$I8YT;/I-X$.!/GB*8K;GQ7_ -V'CC_L&U!_X?5[,!??Z[-_.O\ X166M?\
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MRR%+E;' -;8E9:\@1F5N*QD6(]=0>S!-)-:6TU".6.=S)6VU]+,79B*U8?R
M0#2AQ\_DC<6;XWQ!T;IK1D67*#P</RJ5%:CX%D'&[CIO:J\T[5NRI\4*#Q&U
MO;>$]PU7JR%@C4B7CZGL$VSH2TUR1W3"T5W&%=6F;\VJ/G1&0O2IQH-&*CT7
M*2@)R7EW:OTYMM).ZXF;<ASB:BK<I!R$UP' 5IC4THIK:WG9>F9D388S"6M
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MC/;==RJ%XT'9X'73GD+IS:H3JA&=H;#8;">(DXN2@4$VY$8EPD[;F,9PHX(
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%'.T/!7&H_YP0?\
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MP*-B@XM_*V.%?W&7JP=?SFC&MU@;@!1(97KER2/2)',:Z:6&*205:U[J.(/
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MV#R66U74Y3;#M&IT2.*VC$999F^<'DD55"(F(*Q$QRU9I]M%#-+#&^[:RX+
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M.B&FZW($@V+)SJZ(+4!O5G<)N 1:DDW+E)FT.4R*8"F)JC(W-TVZ/NHMFF+
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M>X4:,I->-2*"E/&M%*.^VW'D_,CD \J_,'9O=P<DXV,UU(6ZQ7&=HL;I'?\
M%!7 3K=QBJ79[$Q@[ZI LFP,E2*/F:P+BL'D@K&='&A:F[_9\0?;LO+,EU
M[/&:X@D"K:\>!]-**K.+?WR0MF=;7( J21E?A@:$T-.''U<5>KNV-V[7WOQZ
ME;/MEU!V1W7-M[%H-)VC6:R%/K^[-?U1\S;0NV(BN)I-FL8RL,BN];E(@@W2
M$60F[,IA-TXS6+:"UNPR"H!C:XM)J6./%I/C3#X5?:;/+/;ETM"0\@. H' <
M'4\\?@6P',4K],(F$3"+H+3^UZ7_ +B7_G!PAX*9:Y^UZ!_R-%_WBAE-!P7<
MX44PBK'RDV^EK&@/&$>N3W56E$T7$I?/,V:.#=G(R)RAT"4J3(%2)F >D%S$
MSTKMCM)^Y->9<7#3^R[4YWG\YPQ8SUNH2/%H*\9[V;_CV;M:2TM'#]N7S3'$
M/S6NPDD/H9F#3X/+5&O ]95SK^[N%U#*KKWI5994X])U%586*.HH<?HF.<PB
M(^B.;%WQ8V/7K*-@ 8VQ  Y 2/H%I_W8I'S;5U*64ETCM3))/$DPQ$D^DJ\V
M>)KI9,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB811IM?P59(?0FX?^^LB$4)UHW3V0](=(]41_Y<E4Y4^P?_S+^5]?
M(J59NG_(%^EA07[PB81,(F$3")A%&^VYZ#K6OY^9L<S%0$0T*P.[E9J19Q4:
MU+YS9^R</GRR#5$O@^>8P!EQ:VMU>SMMK..26X=P:QI<X^AK02?4%:WEY9V%
MNZZOI8X;5GTGR.:Q@]+G$ >LJ#'?/WA"Q?'CE^67'T7*:B:9S-]JT]XT ZA2
M& /.#.578"!0. '$%>A,P"!A 2B ;<SMMW!DCZK=%U/*1XV\H/\ FEH/HPQ\
M%H\G=GMA%*87[@TC.#3"ZA(Q_=!Y;Z<</'@5/]%VEK+:$<,OK38E&V'$E$A3
M2E'MD#;(XIC@!B 9] OW[4!.4>D/9>$,UG4=(U72)>AJUK<6L_YLT;XW? ]K
M2MNTK7-%UV'WG1+RUO+<?EP2QRM_SHW.'QK/,QZRB81,(F$3")A$PB81,(F$
M3")A%IN[YC_4/ ?NTI_[+N,B?H^M3,^GZBL@X$?ZN(S^L)_SB>0;Q4TO'\.2
MV)945),(L72H]*18QD8C4*NE&PDRG8X:/2K\2FQB+"DLNX2G8QH1H#=A,I+N
M5#E=)%(N4ZAA W281&?J2$EQ<ZI%#B<1R/EY*7(R@%!0&HP\>?I7:.X.%?R<
M3-/H>+>S$#Y?YCEG<>T<2<+YT;E:2?FE^LB=U'><6I 27[$Y.V3 "GZ0#HR
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M$BOP(^**0UD:UQ', _*L[33(D0B21")IID*FFFF4"$3(0 *0A"% "E(4H=
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MD#K#9-G;;FVGLZK6 U::SQJXSOMH//L$8M[9H1*0BY5HGU07,W I>T* E.8
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M94)"4BHUH]>@HL(G,"AS=)AZ1\.3OGGD:&2/>Y@X DD#U%2-BB8[,QK0X^(
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M[_<'3]M!5G7.K3V5)&O3UEDIIX4JYC*>2LRE KE5N"I52Z5O#>TVEW]KMC;
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MNUZS1[3)T[?-0V)5ZLVV)K\_FIE,UF^IUS7TE82EUW.M0>IG=G66!JJU'M%
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M;_PW"5]*>[__ #)V#\&_\-PE?2GN_P#\R=@_!O\ PW"5]*>[_P#S)V#\&_\
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M8C[CPE GN#HWO,JGP=B/N/"4">X.C>\RJ?!V(^X\)0)[@Z-[S*I\'8C[CPE
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M_P!UXQ2K>7R)^0/N;W\WWX36?[KQBE6\OD3\@?<WOYOOPFL_W7C%*MY?(GY
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M$3")A%6;DYQBUER;U[*438];CYZ,>="Z N$S%>1S](J@(2<4_0,D]C)% %3
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M(EHJ@Z%-:5*.I9"0U;(LG9"04I"HL5CS:<F626%\@^1%5-<I%6H(D+:;!O\
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M86*4>R527,52, #)*E,)RE$!'SK=.F[?WQW@U*"76+.RT:4A[;LNCDA)9!$
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M#5^U6L:=I=O-=:A+#&&11,=)(\B>)Q#6,#G.( )P!H 3X+'=5:0LE[[LZHZ
MFX^0I%QM7%='7SF/LT:_A)"M6B4HZD:W3L,4\:$DV!H^75(+M$Z(+@4IR]4#
M9=ZWN.TTSN_/NBV<RYL(=:,X=&YKVR1MFS'(X'*[,VN4@TX8T5EM[:E]J_8J
MVV==,?::G<;?%N6RM<QT4KX"T=1A&9N5Y&=I;FI44JM&&M]+1%1UA":&V+W8
M/(K:/**-LZL#)R:UYW75=&6FMK6%V])85[35]A(4^',SCE$VA56C,\,HHCY8
M9V41,AG2&K;AGOM8DW-I.\M*LMF/A#VM$-I)>1R!@&01R0&5U75=1SA* >F&
M<'+DW1-KVVFZ#%M'6]A:W?[^9.8W.,]]%82Q&0NZAEBN!"S*TAE6,,)+>J9!
M4L5L^;FJMAU#:G%FC633'(*U<$JKIN#J\_I?B_-W.Y&CKRQ1L""\%,2BCAC+
MVD(]4\6FT=R:S!1ZP0,**B2XN"FT?MUK>E7^BZUJ5IJ&EP]RIK]\C+O46119
MH26$/:VA;'F'4+FQAX8\C,'-R%>B]U=O:UINX-OZ3?:7K-QVDM],CBDLM+?-
M-EG:) 8WO):^7*>D&/E=&7QM.4M?G!YG=S:3O6KN27+XZG&?:NA=<WS4*3W5
M,#9H.S2\2RAS*,7D55EKV[&5CY&ZFCYA)1U'G?N)!!T5RBJ':MU0"GW7W%IN
ML[2T$#6++4]6M;\BY?&^-KB[$.D$(RN;#F80UX8UA:6.;[+PJO9/:VK:!OC<
MA=H6H:1HEYIH=:1RQRO8UE6ED1N#G:Z?*\%T9D=(UPD:[VF.I;#N9M:W_5G$
M:5KFR:#<-<61QN.Y2PP-XJLU4)Q=@Y@*:U:R8Q<\PCGZK1P+(Z::W4$A^Q$H
M"/4$ TG[P&KZ7K6^F7>D75O=V@T^)N>&1DK X/E);F8YS:BH)%:BM?%>A_=B
MT/6-O]N)++7+.YL;YVIS/Z<\3X9"TQP@.R2-:X@Y2 ZE#0@'!7&YD06XI_CO
ML%KH6*J-@V@U9LY. K5WKT'9X*R)Q[Y!>4A@BK(BO"J2[F,*J:/%P7LA?$2*
M<2D,8P:#L&YT"UW7:OW,^>+1G.+7R0O?&^/,"&OS1D/RAU,^7'(7$5( 7IG<
MVTW->;+O(]H1VTVOM:UT<4\<<L<H:X%[,DH+,Y94QYA3.&@T!)&DW9$IR5[Q
MJ4XM:*/P_OG'UKIJX0-BVMLNW5R2J]<K2$(R:0\LPI!'];@FT>Q7:-5%FD4D
M*JZSE-HD4I$&RC@>A])AVAVGAUK<HUZVU1^H0/9;6\4C9))"\ES7399'EQ!(
M#I#0!I>ZI<\,7+.N7&^>]EQM_:1VU=Z-'IES')=W4T;HHH@QH8]L&:*,-:0"
M61"KBX1M #&%ZV4]X!P%B.5>J%:WJR!U%K_9S_841;YG8,O56T;*2S)LRG$I
M9L_L%<@'M@?.I-Y)(JG[43$5%+K''K 7/(^U_<Z?96MB[UJ6_NM';:NB9 V0
MN:TDL+2UDCPP!H:0*8BM!A5>Y=XNS]MW!V\;';\.FV>O/O63/N'Q!KWM#9 \
M.DCC=(XN<YI-<#2I-:*^--UEK?77G+XOM?4BB>>/(_._N-JD#6/.OF_RKR#S
MEYD8,?+O(?+E^Q[7K=EVQ^KT=<W3YGJ&L:OJV3]JW5S<].N7JRODRYJ9LN=Q
MI6@K2E:"O +US3-"T/1,_P"QK.TM.KES]&&.+/EKES9&MS9<SLM:TS&G$K-\
MQRRJ81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?-
M7^EG_E1PB[_4_P"T" _]:_LU(Y([B@X*1,@HIA$PB81,(F$3")A$PB818[;;
M/%4NM35IFW";6+@V"SYTJJ<$R]!  J20'-X .X7.5,OYXP9D-*TVYU?48=,L
MVEUS,\- &/I/J%2?(+%ZWJ]GH.DW&L:@X,M+>,O<2:<. ]+B0T>9"\WFY-HR
MVW-B6.[2BZHDDGHDBVAS#U(^':)ILXUJFETB1(P,VY#*]4  ZQCF^>8<[_VI
MMRUVOH-OH]LT5C9[;OSGN)<]Q/$^T32O!M!X+Y7;YW?=[UW/=;@O7DB:3]&T
MG!D30&QM X"C0,U.+JNXE1?VGYX/%FQ95J.=O-.T_/!XL94SMYIVGYX/%C*F
M=O-.T_/!XL94SMYIVGYX/%C*F=O-;F^[7-UM57L>GI_[03_O<A,Y*^\$*;FL
MO[#_ %LB[O\ NID'9VHT^LS_ $$2V-9X&NI$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%$VZ_!1'@^@]9?SRF1'X
MD^=4UH:G]('Z E+\[Y_S_IY*JI5NJIX42?3#\TN%(5,+7PI=(?.$P_F!D5*N
M1A$PB81,(F$3"+!-F_M%L/\ <S?^_P!KD1Q4#P7FEX6?[Q.VO]K-^_?O*9*>
M/K*N#] >KY%Z*(W_ *$W_K9?S RJK=<[")A$PBA;D1I&O\C],7K2=IEIB"@+
MZP81\E+0 L@F&:4?-1DVD=D,BU>L@.=Q%D(;M$CAU##T>'H$-AVIN.ZVEN"V
MW%9,CENK5SG-:^N4YF.9CE(/!Q.!&*U?>FU;/>^V+O:VH22PV=XQK7/CRYVA
MKVR#+F#F\6 8@X$KOM-:PB-*ZHU[J2!D)&5A=<U*%J$7)2XMAE'S&#9),F[E
M^+)!JT%TLFD G[-,A.GYP &6VX-9GW#K=UKERUC+B[G?*YK:Y07FI#:DF@\*
MDE7FV-!MMK;>LMN6;WR6ME;,A8Y],[FQM#0790!4TQH /)0MMKB%2=O\AM&<
MC)NS6F,M&AO*_<Y!Q1HD("8\K<JNC^>@=QKF1'JG5$ [!='P!FP:'OO4=!VK
MJ6T[>&%]GJ=.H]V;.R@ ]BC@WP\05JVX^VVE;EWGI.]KJ>XCO](KTXV9.F^I
M)]NK2[Q_)<%;3-'7HJ81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(OFK_2S_
M ,J.$7?ZG_:! ?\ K7]FI')'<4'!2)D%%,(F$3")A$PB81,(F$3"+39S\Y C
M/SXZ?K#_ *T17'0C:UVYS 5Y-(E,0\68Y1 JB,>H<2K$$/ X2^?X,ZR[(;'%
MC8?:K464N[AOZ$$?1C..?R+A0M/YKEPK]Y+N2[4]2^P^D/K86K_](+3]*48&
M,GQ#"2' _EM\EK1[3YOF#.A,OFN4*?N4[3YOF#&7S2G[E.T^;Y@QE\TI^Y3M
M/F^8,9?-*?N4[3YOF#&7S2G[E.T^;Y@QE\TI^Y6Z+NTC=;5-\_VA'_>W!YR/
M]X04W-9?V#^MD7>?W4/\&ZCA3_O,_P!!$MC^> KJ9,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB811)NWP4)\/SNAVS
M_-4R(\?0GSJEE!4'H;_RH#XP]?(!53BKA5/^E%^D3\WZV04A4PLQ_20#T  ?
M5#ZV14JY>$3")A$PB81,(L$V;^T6P_W,W_O]KD1Q4#P7FEX6?[Q.VO\ :S?O
MW[RF2GCZRK@_0'J^1>BB-_Z$W_K9?S RJK=<["*&>1LS+5SCUOBPP,B[B)R!
MTSM"9A9:/7.V?Q<M%TB<?1TBR<IB51N[9/$"*IG*(&(<H"'A#+BS:U]W$QXJ
MTR-!',%P5&Y<6V\CFFC@QQ'P%:T.Y\WOMN]T"\ZMWW>;%L/8$'#ZFW;5+?:Y
M%>3E9K5F]Z!&S<8P2>.UEG;M.GVR'E&2QSB'4.H4H!U.IF9W!:P12MGM6AD1
M+F$# !S'4^,$%8W2)YI(W13N+I &N!/BUPK\1J%#D3R.WC?N]VU<SB-F6MIQ
MFF-H\EN/\5K=G,ND*E8+#QKXZLIV[S\E#I+ QE#ALJ]B"#@R8]!HP@ 811]C
M<.L[:+0'ES&^^AD;RZF($DE&BOA[+?C5$7,\FK- <?=BY[*5P)8RI/PGXEN3
MU/O?7^YY?;4'2'$HN_TILR8U->2R48K'I-[A!M6;M^C&J*'.$BP*B^3$JY>@
MIA$0Z/!FO3VLMLV-TM*2,#FX^!68BGCF+VLK5CLI](6N_EUR[1V'P\U]O+CC
M=;E5XZ<Y0ZOU^>::@]JDXY9,=HK5"X0SA));MQBY!=@LB<HF$BZ/0(AT#F6L
M+ PZ@^VO&M<1 YU.(^C4'TK'W=WU+-L]LYP!E:*\#]*A7;ZYYTSMN[R;;'&Q
M[&;,)KNO4^-JU1BCZHDF4='[!B)J?&X7:QV4T=Y:C39YK# A"R:ZX1;TG9^3
M%ZZQCGA-IC8]'CO 6=4N))S#Z) H .8KB.(\5&.^<_4GVQ#NF!0>SXU-23R-
M,#P/@LOU5S#X^:7XH4S<-LW3MO86M+)N6P:T9[/VTQ\MMZ5EE+G:&AVMA,B1
MH1A4JRO#N6Z+DQ>J@P;D,;I^?E.?3[NXOG6\<<;)A&'96\* #AYFO#FIXKRW
MAM&S/>]T1>1F=QK4\?(?(I-T_P!X+H;<>SH/4K"-VSK^UW:'DK%JLVW]66G6
M<3N*O1*(O'TUK%_9&S<;$T2CBBZ AR-USMRF.5,0(?JT;C2KJW@-P3&^-IH[
M(X.+"?!U."JPZA!-*(@'M>X5;F:6YAS;7BHFXF;]>1S_ +QBX;PV:])K_2G+
M79<3'2UQF'+B)H6OX& @'B,-%%6,J9G%M55S]@T;E,9194")$,H<I1KW]J"V
MSCMF#JR0-- ,7.).)\_-4;2X(-P^=WZ-DKN/@  L\UWWDG'R_P!PIM4>0>[-
M8,MGR2$/J._;BT[;M=:TVS*O"*K1L=1;G--BQSQ[+H)=9FF[\C,Z,8B20&6.
M5,:4VCW<4;I 8WE@J]K'ASFCFX#EXTK3T*I'J5O(]K"'M#C[)<TAKO02KUSC
M!S*PLQ%LI-U"/)*+D&#298E3,]B'+QHLW0DV950%(SI@JH"J8&#JB<@=/@S&
M-(:X.(J >'/R5\X$M(!H2.*T>\H=(\CN/5$B'\3WBO*.][2V);(76FE]9H,=
M?Q[N^[&LR_81C!9]YJ<>:*[$-RJOY:0.3L63!NH81ZYDRFV2RN;.[E(=:0-@
M8TN>[VO9:/7B3P \2L)=07-O&"+B5TKB&M;AB3^+Q)\ MQ.F*E<:'JF@4_8=
MY?;+O=?K$9'V^^2*9$G-HL1$ /+2G9$31[-LJ].<$"F*!P0*0#])ND<U^XDC
MEG?)"T,B+C1O(> 68A8^.)K)'9I ,3S*T\=X)R9D9'F%H+BRE;^6^L-<MT+Q
M+;8DN-U>MU<O-\EUZ=69V@)4:ZPD<]?V"JUQQ*B$Z,: H,Q.N1W[--(Z.P:5
M9 :?+?98'S8!O4(+6BI#J@G FF%>.%//#ZA<DWD=K65L>.;(""< 10CB!XT]
M:NKIW;VF]6!R]EIW?^V+16=!6V)C=EO-UR;F7C-9&AJ<P D12Y([<\K/-9E
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M;A=K'931WEJ--GFL,"$+)KKA%O2=GY,7KK&.>M-IC8]'CO 6=4N))S#Z) H
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MY-/\@-D6/3L77]N:QVK7:TE=OB_W=K.>UE9YND+/&\>6WP+"8!3RR%\L>(D
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MTF(EENTU%(Z_2(/!SP 7>85=.U'T S?*+S',4[4?0#%$S%.U'T Q1,Q3M1]
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M)0+5MW@VP*=4D8C4M(;';3CXJDM;G;>1D%0:1H=1",BS L]734,^5%P=8@E
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MFUITL5S',FL'%/GXLVY'BI.NN?-SFV!N;5NAIVKP:4WI11V\NHQ/E]YFM(G
MMC;;&,1QRR 97N=+(QF9QC!HT+0+?N9M'1/>-5T.XUI_6FENH=*FCA]U@O9F
MEKI7W8F=++#&2'1L;!$^3(P2.%7E:=<]S7.:]&O<B<A92(:S^JY%^=6/AIY-
MY%(*G 2M&%@0=NA;)%$X"5/SHS=*^@)EA]#.&_O,:#%I^[;37(6Y1J%J0_\
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M;<VKV2V[Q5KV.#FN!X%K@2"#S!HN#;JUN;*X?:7L<D-U&XM>Q[2Q[7#B'-<
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MJ#R%92:#AB2>9JMJ6I>ZL3:&9/3QC1 WZ68SA5!RLZ #=43 #EP91<H" ^$
M-T9I.X-_[TW4PQZ_J-S/;G$QU#(B>9BC#(R1X$MP\%Z%M?MGV^V4\3;9TJUM
MKH8"7*9)@.0FE,DH!\0'T/C5;;=&</*AJ])NX.T;K/$R$]F*1PZIR&ZW_/,/
MAZ<U$-6[N>2N'WAV\;YQ=XEW7:VJ%HEE;J[,4AA'*S$6G+QQ6\Y;(F&?@JP6
M43(H863LX$$1]B;H'Z&>D]I]L:5N_>UMH6LAYT^6.8N#'9759&YS:$<,0*KR
M7O9N_6=B]O+O<F@.C;J<,L#6E[0]M))F,=5II7V2:<CBJ::![Q;:,]P4Y9[D
MVVM6D-X\>)FT5AN@TA"1T.67F(N(B]9K2401R!5TEKY(+-52%,GVZ3;H 0,;
MI#T/<_:C1K;N3H>@:&)CMS58XY"2_,[*QSG7 :ZF%(6AP..4N\EY;L[O5K]Y
MVEW%N;<9@&Z]%EEB #,K,[V,9:ES*X@W#G-(PS!O,KJN!O.#DYR U=S=D]N6
M?6]6MVD-8UBQ46PRM;/ 5.FS-CIFUITTW?4XMO+/W$##.*Q'N'Q$VRRR*"*Y
M2IJ&'JC6[F=N=G;7UG;L.A0W<UCJ-Y(R9C9,\LK(Y;9F2',6M#WB1[6$N +B
MVI Q5OVB[K;\WCH&ZI]QW%C;ZEI5A%)!(^+IPPOD@NY,]P&A[C&PQ1ND :YS
M6M> TG!; -8\F*O3.*>O]V\E-X:@=EE6SU&7V;27$FAKVT2WGV=;LFM*9R$+
M$V"4<ECX[LS-DH\'!E6RQBIF(43YY?K&T+S4-[76W=HZ=?M+""VWF#3/&W(P
MDS%KW,:,SJYB_+1S02":+V/0=]6&F=O;/=6^=5TUPD:X/NH"X6\K^I(&B!KF
M,D><K:91'F):X@$"JK7!\^/C4[P+1FF=([!I%[X\[#T3.7:<>PS))Y,)76*<
M;4*=@Y?KBA*U]RV;U>..HP<H)+E3.!Q*!5BB.W7/;+]B]K]2W!N*UN;;=5IJ
M3(6!YHPQ.%M[0:*M>"9) 'M<144K5I6C6G=_[0=X])VQM6]M+O9E[I$D\CF-
M!>)V&[]DN-'QD"*,F-S0ZAJ11P6R[8TV^K.O;W8XLR1).OTVT3<<=9,%D2OH
MJ$?/VAE43" *I%<(%$Q1\!@\&>0Z3;Q7FJVUI-7HRW$;'4P.5SPTT/A@5[IK
M=U-8Z-=WUO03PVLKVU%1F9&YPJ/$5 P5%N%G,4][X25ODUR=N],J(J2]Q9V*
MSN2-*M7TDXFX2D##-6[3M3@K(.T6R222"/:+N5Q J9#',!<])[A;!&F]Q)=G
M[.MKB>D<19&*R/.:)KWDFGT0222:!HQ) "\E[7=S#JW:N#?>_+NUMB9)FR2F
MD48#)GQL %<7$  -;5SG8 $FBGS5_-+BSNAE;7^L]U5"T(T2 ?VJVH)'DHR2
MA:S%(BO)6!Q$34?&RRL.P3 .U<)(J))F,4HF QB@.L:SV]WIM^2"+6-.GA=<
MRMCB/LN:^1QHU@<QSFA[O!I()Q-* K<- [H]O]T17,VA:I;7#;2%TLP&9KF1
M,%72%CVM>6-\7!I P!-2%7CA'WB%*Y<V;<%><N:G4Y>IW">3U_4VLH\?S4]J
MRNM(E-;84H^<H-61DG\G(B(E2313;)B1/],$IEC[5W%[5:AL6SL+I@GG@GMV
M=>4M 8RYD+J0- )/LM;XDEQJ<*AHTOM7WHTON/?:E92.M[:YM[F06\(>YSY+
M2,,!N'N(#:.<[P#0T4;[1!<; T3FYQ,V;L(VJJ'OO7EFO@KJM6<''RYNI-.D
M"F45:UJ7701@[2Y*D0Q^SCG+HXD(8P )2F$-7U+MUOC1]*_;>IZ9=0Z90$O<
MWZ / R-!+XQ7"LC6BI XD+<M)[J=NM=UK[/:1K%E/J]2&QM?],C$B)Y CE-*
MFD;GF@)X JTV:6M_6E]CR2YS<T]A;8;<*I+46I-%ZAN4CKU/:FR(UW8I;8UL
MAP24D?,S8L+8F+6+,U<MW*:?D1%$6CE%11P918$$N@I-H]M^WNEV+^X;+^^W
M)?V[9_=H'"-L$3_HYSGC<75#FDYR"YK@&@-S.Y@BWQW8[HZSJ+.UK]-T[:6F
MW3K<7=RTR/N9F4S9!DD:&4+7 =,$,<UQ>7.R-SW6_*/F+#Z2YF17(S4Q:=N3
MC/JK8%OIFV86K2X:?V:YA*-/V&(=Q3UZD$'*/F#EFS<KHM5R LU=@55LT525
M3'&:OLS84^XMOS[3OO>- UB]@BEMGR-]ZMP^9C'!P'MM#@7M!<#1S:A[VN:5
ME]#W_P!R[;:NY[?>VG>[;FT+3[B:&[9$_P!SNC'!)(PL<X=-[FEK'.:QPS,?
M1T<;FN"Z:F\L-ZW3C3P;VHOM[1.NK5NC88Q&QT]C1TQ&IWR(3NSZ#&L:U8P5
M>L:#6V.8]J4B0.#M$14.416#I'HN+_9&VM/W?N/16V&I7=EI]KF@Z#F.,+NB
MU_4N"]\9,0<:G*'&@^BK73.X>[=4V-M/<#]2TBRU#5+W)<BY:]HN&"=T?2MF
MQQR 3%HH,Q8VI'M!7MV!R]XS:JLEKI^QMTTBGVFDP+.S6: FY$[:4CH:0/%$
M8.2-.P,K(+OC3;7L6[4%G*O;!U4QZ#='FNE[$WAK=I!?Z3I]S<65Q*8XWL;5
MKGMS9A6M&@9'5<ZC13$\%ZWK/<G8FWKZXTS6]4M+;4+6%LLL;W4>UCLF4TI5
MQ=U&4:W,XUP'%8G>.2%2OO%K8N[..6YM6%;Q,,_+"[+MJTDK0:M/,5F N"7=
MFTAY*?C/)&[PAE6ZC 7)2KI'[/J'*8;W3MI7VF;SM-N[LT^]SOD;GMX@T32,
M(=3HDO:QU2#1P?EJ"*U!"Q^J[WT[5]@7NZMDZII^2.)V2ZF+C;Q2-+:]=H8Z
M1M X5:8\U'-.6A!7-K_)&BZWXUZNV_R*W+J]H2PU*NKR>P(!V];TNY6*0B?+
MW"]!8.XQA/RS61(BJNV;IL ="@43"D4"CT4[K:6I:ONZ]T':FGWKC%.\-@>
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MNV#J\S.OJD[C%;0UH'R922YY&(BC'M/(Q-6L%"X$:V.%&ZN.-23WGR<OG(R
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M.GK&YI%"UL<<+@S,!T_:"\Y=JUOMK;FE7'O.U]S;;BGB,-IT_=M6C)!P>RW
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M%U+J[;L&C6MIZ\I>Q(!LX*\9Q-SK418F+%X5(R!7L>C*-')6#TB)S$!9'J*
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MZ=%M'6&D:C>VUDZM8XII&,J>)#6N !/B10GQ*Q.L;&V9N"^;J6N:5I]WJ#*
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M%SGO<7/<3Q+G.)))\222LS:6=II]LRRL(HX+.)H:R.-K6,8T<&M:T!K0/
M+MLH*X3")A%R=5_TJW?NJ=_WLVR5R#B5*V2J*81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB815NY3\@H?CCJB:NSLS=Q/J(+LZC$+]
M8X2DX8A2-BJI)B"HL$'"R7;G+T=0IPZ1#IS=M@[/N=Z;@BTR.HLP0Z9X_)9X
MT/#,0#E'C1>>=SM^6G;[:\VLR%KK\M+8(S^7)X5 QR@D9CX A>2.>L,O9YJ3
ML,\^<2<U,O7$C)R#H_7</'KI057#A8__ #E%5#"(CZ.?0JUL[>RMF6EJQK+:
M-H:UH&#6C  >07RKOKV[U*[DO[YYEO)GESWN-2YQ-22>9*ZCM/I^KE?*K3'D
M$[3Z?JXRICR"=I]/U<94QY!.T^GZN,J8\@G:?3]7&5,>03M/I^KC*F/()VGT
M_5QE3'D$[3Z?JXRICR"=I]/U<94QY!.T^GZN,J8\@G:?3]7&5,>03M/I^KC*
MF/()VGT_5QE3'D%Z%NY_-UM([-]+:A_WHUO./?O&"FZ+'^P?UTB[X^Z;_@S4
MO]Z'^@A6V[.>EU4F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81<=Y_T1U_
M<Z_]C-A0/!>6V#_W_P#<W[IH7]Y=<R#OI%5V_P EZOQKT.5K_%#3^M$_G0RH
M."HGBN_R*@HGW03>:E'7+QW=:G9[)\Y1XM5MT,+A)4<(@%#^=2KMJ/(Q4\,D
M9+J^3B58$@-T]<!#*]M[MU?]+ZG1I^13-7P^E4*E-U\G^CY.I7\JM/BQ5!*Y
MN3O$(OD_JG0M]><*+2A8(]WL#:+;5E4WFWL-"U!$O"1B]C=25KOIX>.E;3.J
MEC(- [=V=TY*NJ9+R=JL<,J^WTEUD^ZB%RT@Y6YBRCGGPP;6@&+N'AXD*P;-
MJ NF02=$UQ=E#JAO/$^)P'_(MF=JM5;HU;G+C<9R,K-5K,8[F;!8)EVDPB8:
M)8)&7>R,B]7,1%JT:HD$QSF$"E*'2.8:.-\KQ'&"Y[C0 <25DGO:QI>\@, J
M25IQXL\U-R<B:O-[E?<G^*5/KLAMRL4]CIEY6'[B=UY SFUIRJ5>%LEI+;T7
MKN\;9J]2=F@@.W*W77<$<$*"8>3$V"]TVWM'BW$$[GB,G/7!Q#020*<&D^UZ
M*>:P]K>S7#3,98@W.!EIB 7$ $UXN P_ +9;M?E;QLT78(6I[@W?K;7=FL)$
M5HN!M%IC8Z54:.%C-T))TR46%>,B%UR&(1XZ!%J8Q#@"G20W1AX+&\NF%]O$
M][!Q(&'_ "GR&*R<MU;0.#)GM:X^!*R%CR!T?*0<-9XW:]#D*[8MB-M20,XR
MLL8ZBIG9KV14B&E%C'R+@[=[9G4FD9!-JF8RAU Z  1R0VERUQ88W!X9G(IB
M&TKF/E13"X@+0X/;E+LH->+N7I6:/[W3(NX5_7TC9X5E=[7&34U6JJY?MTIV
M=B:X+0)Z1C(XYP<.VD0+]#R@Y $J?:EZ>CI#*8BD=&90TF)I )\ 3P^%3F1@
M>(R1G() \33BHJK?*SC;<+[#ZNJN[=<V+8-@86"3AJG#V:/?R\@TJDA-Q=C%
M!!LJH7MX9[6Y JZ)C L0K)8_4ZB9C!6?8WD<1G?&\1 BI(PQH1\-1\*I-NK9
M\@B8]ID-<*\JU^0_ NJI/,GBGLC8:NJ*%R#U1;=B$6<MD:M!7&(?R$DY9(*N
M7K:#.BX,TGW+)N@H=9-BHX.D1(XG  (;HFDT^^ABZ\L4C8N9!P]/+UJ5EY:R
M2=*.1ADY _)S]2LMEFKE5;/S<XADF:;7AY'Z?&9V"Z<,J>Q)=X512:=-IQ]6
M5$4SIN3(M#J6*,<,$O*#) N[1.DGUCE$N7W[-U#*Y_1DRLXX'#"OR&OH5K[[
M:9FMZC*NX8C'&GRX+)JORIXWW7:<MI*I;NUM8=LPBLBWD*'%6F,=V CN&356
MFF#5JFN)9&2A$FZIGS9L95=F"*O;$)V:G5IOL;R. 7,D;Q ?RB#3'A\/AS\%
M.VZMGRF!CVF4>%<<./P>*JUO;D_LK5.E]N7^LWS3VQ)VK<NJ7J"+;UN)D7+6
MAU*S7?6U;D:!L!OY^%1?:4!'69RNX73.W1*#IJ/8>Q,![ZULH9[B.)[)&-=;
ME^)^D0'',W#Z)I\1Q5K/=210OD:YCG"8-P\ 2!0X_2%?D5JMR<HN._'MQ#,]
MV;DH&M7]A(*L+&6BP,V4M)-2JF04D&T2!U)$T6DN04SNQ2!L13V)C@;P98V]
ME=W8)MHWO XT&'P\_)74UU;V]!,]K2>%2L@G]\:5JVL6VZ;#M:@1.I'K)A(,
M-CN[5#EITDTE3%3BU(R>*[,PDCR2I@(W(@=118_L2%,;P9(RUN7S>[,8\S@_
M1H:X<:A3.GA;%UG/:(N=</A4?P',/C3=-87S;M!W3K>XTO7$8YD;?*QMKCTT
M*[U$UQ9)V0JP^6UY.46;B1NHZ0(58.DR?7 ,K.T^\CG9;RQO;(\T (X^CG3R
M5-MY;/B=-&]I8T8X\/3R4=\7^;VJ]Y\6X?DC;[OK6AL63$A]I)'N,>E7M7SK
MIR4S2KV*;EW#0C25!D^9 !5P14<*N"=1,HJ$3RK>Z;/;7ILXVO<2?9PQ<.8
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M+#<P7 )@>UU.-"L51YE\47&T@THAR$U.MM(TH$"6G)W*'/(J6$5P:^YM-8'
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M)A$PB81,(O@Y<MV;9P\=K)-FK5!5RY<+G*DBW;H)F56664.($3223*)C&$0
M #I')F,?*\1Q@ND<0 !B23@ /,E2221PQNFE<&Q,:22<  !4DGP &)7E2YW<
MFW/(G;K@8EVO\7])\NA:BS,()IKF771&5F5$@$PE<21F2!# )C% K<HEZ.D>
MGOCM5LEFS=O 3M'[7NLKYG<J Y6 \FU<?\HU7S$[V]QI.X&ZW>[%W["LLT<#
M> -2,\A'-^5H\11@IQ*I#U_FZ0ST^I7C-!R3K_-TABI2@Y)U_FZ0Q4I0<DZ_
MS=(8J4H.2=?YND,5*4').O\ -TABI2@Y)U_FZ0Q4I0<DZ_S=(8J4H.2=?YND
M,5*4').O\W2&*E*#DG7^;I#%2E!R3K_-TABI2@Y)U_FZ0Q4I0<DZ_P W2&*E
M*#DO0_W/(].C]G?[53_O1K><>?>-/_U18_V#^ND7?/W3/\%ZEX?]Z'^@A6W/
M.>5U6F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81<=Y_T1U_<Z_P#8S84#
MP7EM@_\ ?_W-^Z:%_>77,@[Z15=O\EZOQKT.5K_%#3^M$_G0RH."HGBN_P B
MH+^&,4I1,80*4H"8QC" %*4 Z1$1'P  !\\<(M=/=T*J;1INW.7TR<7=@Y4[
M<MT[!N%?Z9$Z:UE-RVL].U- @=!4V<;!P+E^(@!17<RBRQ@ RG0&7U?]!)'8
M-^A!& ?-[@'//K)IZ  L?IWZ5C[L_2E>2/WK3E:/@%?6I(IS7G;-;*\S[LK7
M#![QYD'5G:3J%.E]Q3&RGE>5BY@M70\RVVJMZ.Z=.93R$LHDLN* -3..Q$YP
M3 U&0Z8V'-;&X%V*4J&!M:BN(.;A6GG15&"^=)2<0^[XUIFK3PP(IRJM0=!@
M(&+[KCB)*QD)$1TI-<[Z,G,R3&-9M'\L2(YN;*91))-XW13</R1C,PI-P5,<
M$$AZI.J7P9GY7..N3M)):+9U/*L+:T]*Q$;6C2X2 *F<?TA5P]!2?'B#Y ]X
MRVY2R&IHS;$EO!VZ>'W$[JS1:2XMJZUI".LB1JMS432>TEJU*^2>$;=9LDJ*
M97'084@S'W0NW6MH;(2& 1?D5_E,QS</RN%/'DKRW-NVXN!=9!*7_E4^A09>
M/AQ5!]42^OH;@UQOMM4<)1&FZQWQ=(M$7,OO*&D;7=71^Y9):(EYEP^ %(R-
M8P2C<%57(E[,1 #CUAZ,RD[97:G-&_&X=I[A3F[(*@<\>2L(C&VQC>S"$7@/
MH;F^9;-=@;"I%L[T_BC7*O:H*PS%5X]<AGMC9PDFTE!AD;,:DJ09)!1DJNDU
M<R"$0LJ1(Y@5['J*"7J*)F-AHHI8]#G>]I#731TJ*5I6ORK)22,?JD36D$B-
M]:>=**DM+HJL9W17,&XZPJ[)':%@N?*=_+V.(B4#VIY#-]N3M7MZA)-!N:4
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M&Z$R];+V*WF.Z2_*[('EU:84+30U\ZCUJU?+$- #<PS%H%*XUS<%?6!2UO\
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M'YAQF]*9#S3K#\PXS>E,AYKT8]S6/3HS:/\ M84_>?6LXZ^\<:[IL?\ =_\
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MV152*HLQ 7!0%$!.%6*SNYZ&&*1P<"11I((!H2#3P.'IPXJ22YMXJ]1[&D$
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MF$3")A$PB81,(F$3")A$PB81,(F$3")A%_!$"@)C" % !$1$>@  /"(B(^
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M5,,%F%=2:R6N ]T%KJ<DV4!67-(G<Q"P]562$P"(CB(Y=6E-PS,\^PXRAW
M<?I8 \J4/)9%\>GQB%U&CVAD+>)/APQ(YUPYJF>IM?LHSCGWM6X-?TZ'<[]8
M<I>?RE.O*4&P?WR%=P32=91"51F#MCRT<[C6LY)'9I-E $SE\L %,*YRFR,\
MI==V%O*X^ZF""K:^R:TK4</ 5KR\E9Q1@6]W-&![QU9:&F(I7A\)^%5@5T[L
MB>X&TNPC8.ZGUEHU2HTJ7K6Y(.F;IBMMTJW%+$N(RQ-;O&SLK*H;KCY\Q2R!
M@1<.CR KI+HG(91,;T7$+=4<RE\^ZS$%A+"UPQJ*4 R4X>%*45MT9'6#75M6
MP4%' .S \ZU^E7CYJZ-O<638?+?:D3J'07&F_P"_-1:6TE!;UWARIO-L3I[!
ME8*JXO$>SUIJ]M7K!+P=?40?'6D9%NE'-U7BA4G!2JI*J*8Z,,BL&.N)9F6L
MDCRQD317 Y?:=4 GD,<.'@KQ^:2[>(8XW3L8T.<\FF(K[+:&@YG!4PU76J)>
M>(W.&D7[=&F=3PSKO *N6 M^LZ;-3'%@NS4T]9N(J!1IC@DPT^)F<ML:FU7<
MOSA%$122=K*F;IE*;(SOEBO[:6*.21WNIJ'$"7+[537#VP#6@Q\!BK.)L;[2
M=DCV,;[P*%H.3-[.%/S2>>'BKH: >WS4?-C3E*Y*<>.,$7N';6L]EUC6>^>)
M]@FX".DJ14HQI>IAAL+5CY1B=:(E1AR>1S"[7L49 I&[8"@<W1CKH13Z;))9
MRS&WC>TN9* :$^R,KN8KB*\,2KRW,D-ZQES'$)GM(:Z,D8#'%OX^?!5.TC0Z
MALWC;W(]*OD#'VBJ2NVMR.9:OR[=-Y%2H0D;M"?9-)-BL4[=_'GD8M$5FZI3
MHN$P,FH4Q#&*-]<RR0WFI21$M>(V4(XBN48?"K6"-DMM9,D%6%[L/1F*M]L^
MHN-:<W.7$?QXK+"G6^R]U'+76#AZ/%(PZ<UMZ.V-LFNTN="+ATFZ*]A1"/9-
M452$!42E  'I$1''PR";38#=DNC;?!I)-:,+6DBI\.)5W*PQ7LPMQ1YM:BGB
MZI /IX*J._ZMP12[F.MRD&PTZG:B:GUJ\JDO&^YPNS'.^ET*^%H3=O6@A:'=
MM/,KR))MNJ)@3:@N"A"()%ZE_:OU3[1.:XR9.HZH-<N3&GE2E*>=/%6MPVQ_
M8P+<F?(*<,V;"OG6M:KT54?]I5/_ '+5_P#8EIFI2_RKOWQ^5;"SZ ] 7G8O
M]=B+AQDY$5*P-?+8&T]^1:J[-LNT41\KB)O?4%&237M4C$52\H9NCDZQ1 Q>
MGI 0'-MB>Z.]AD9@YNF@CTAA6O2-#[:1COHF^(/K<%?W9^LM=:L[QCN]5=9T
M6IZ^&S:WY=U6PITN C*RWFJ[3Z-KN1JT/)-89LS;.V,"^DEU6Q#D'LC'\'SB
M]&*@FFGTB[ZSG/ROB(J2:$N<"<>=,5?RQ1Q:C;])H;5L@-!2H %/@6M)]KAY
MKOCUMN^52M<.N<W!F/NNQ[_:92[%LFCN6<#(Q]WDIVPQ<O?'#*#ECW6*F$%&
MC)1P(S<NF#=)HD5JNW;'S F$UW'$]UQ;:F6M: */B/L@"C<10C$^ QKB"5C3
M&8[=\C!#/8YB36K9!C4XX8\O$^&&"V%4"-UE?.],A=AMZ'7VCFW=V_K#;L,%
M@K<.%J96.9W78FJ%C>JKH+OD[LQK1F\>X? H9V1!(J(JBF4H9BI731:(82\T
M;>.8:$TH&##][7&G#Q60C$4FJ"3**FV:[$8U+CCZ:854 \8M4T!AW.&^=@15
M'KOQBW#2_/9S+6U*!CUK;).DI;=-+:MBS0-#2XH^Y^KL&A4"J]02(%*!?H9=
M7L\IW#%$YQZ+9(*"N'!AX<.))5O;11C1Y) T=0LEQIC^4./H 69<B;_25^!O
M=OQS>U03B0N>U.!R568MY%LN\G#5UY45[ +!LD<ZRB<$#4Y'AQ*!6JW525$J
MIR$-3M(I!JMX2TT:R:OE6M/A\.:GN)&>X6PJ*N=%3SI2OP*6M):7U1L?O$>\
MQL6PM?5*]2<6XXNU:*/;X&-L;:+@[%QUKCFQ,X]G+MG;5KY^/&-2NSE(!UDV
MJ9!'JE$!M[FXGATFS9$]S6GJ$T-*D2&G#E4T]*K00Q2:A<ND:'$9!B*X%@K\
M*H'5-$Z=)W&VSKT?6U/<W=>-W%.>[-[!L7MM;R="W];J?35V=F=I+3;(M<K-
M;:,FJ:2Y4TVY#$ O555 ^5DNKC[3,BSNZ=6"E<*.8"<.&)))6/9!#^PW291G
MHXUIC@\@8\< **8;G%[VV+WB-OAJVWXC3]MC>,FAW^HH_F+6;W<%7%-D8^<=
M7^9T^PK,W'MC3"UY.Y3GGBJ:SXR)&Z:9R(D< >WC-K#I+7/]X$9G?FZ1:,:C
M*'U'#+]$<./DJSQ/)J!#>B7B)N7J G#&N6AY\?'XU"^T*19:+PG[UR-F;WQL
ME4'4QI9]):OXLQM\B-9:JV$:<KJ-U(WC+B#IA'2%P8)1#IVWC7KE))\@X!4C
M<X@D%S!(R74K%S6S T?[4N4N<VAIPY8@5'"G%496.CLKH.=&<6^RRN5IJ*\>
M>' \5?SDQH_4>E=Q]V>MJG7E3H3Z Y+):]8RU8A&$/,*U"5U->$I:&DI1@@@
M]ET9?S:D=T9T=51=3KG.83**";%6=S<7-O>]=[G PYJ$U%<PH:>%/!7]S!##
M-;=)H:1)3 >&4K).$]%U_#<O^\<?PM.IT5-P>Y]=Q\:]BZ]",96(AK#J&KRT
MHR8N&C1)W'QDY-(J.7":8D2<NB&4.!E $<DU*65UA9ASG%IC=6I-"0X@>L#X
M IK)D8N[DM #@\> X%H^4K*^\=G*1[G>/>O;%IR!WC<MA[^KR&IZ7?;X\U]J
MA*\UR!GIAO-[/D$R.XVR5R/8@J4L"\:/4Y==4J1$3* 7HDTALF>65DABC9$<
MQ:W,[*2!1O(_N@113ZBYF6.-S ][I!E!-&U .+N8\L:JD5,9;'KW>E<3(O9T
M5P]IEY<:XY%)35-XH-;.C,1]<-2V3V!1W'+S[&$&;.X>M%%(= K% K8[9TI[
M,%$C!DI#"_1)S";AT6>.AEI2M<<@%:>>/B%9,$C=4B$HA:_*^HCKPIAFK2OE
MAS71Z@T'IB5[J_FW?9C6=-F;K-)\XK8\M<M 1TA8DYW7LSLOW$NV,RZ;J24>
M2M.*^W7:)(JD22<=HH!>LJJ)IKBZN&ZW;1->X1CHB@.%'!M</.N*EA@A.ESR
M%K2\]4UIC45ICY44LT!C3;[R\X*QG(!K!VFMN.[3JD[H^-V$DPE8*8WR_FJN
M;93Z*930+M92^(Z^;1RI $IU2MC*JE 5"$.G0E,D5A=.M*M?[X0_+@0P Y:T
M_)S556,,DNX!<4+?=@6UX9JBO'QI19_PTKFG*KWD'>#0^DF]=CZVE3N/SBP1
M%2!FG6H:^.D;FO;&$6UCB$CV"@OC@N\01]BE(+."B!#@8A*6H/N)-'M77-2_
M,^A/$MPI7\7E15+-L+-1N!!3+E96G '&OX<UN!S7UETPB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PBY.J_Z5;OW5._[V;9*Y!Q*E;)5%,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%KB[Q_E@''G4RE9JSTB>SMA
MD)&P8%!)0\1""Y)Y]F5TE/GIJQZ*S-,2^S(NX(<.CJ](>Q=G=B?:W7A?7S2=
M%M#F?Q]M]/88".3B'GP(:1XKP'O]W-^PNV#IVFO W#?C)'P)9'7])(1R+0Y@
M\0YP*\J3AXX=N%W3I=1PY<K*N'"ZR@J++KK',HJLJH;I,=110PF,(CTB(].=
MT,8R-H8QH#&B@ X #@ OFE)))*]TLA+I'$DDFI).))\R5\>T'T?&&3>I253M
M!]'QACU)5.T'T?&&/4E4[0?1\88]253M!]'QACU)5.T'T?&&/4E4[0?1\88]
M253M!]'QACU)5.T'T?&&/4E4[0?1\88]253M!]'QACU)5.T'T?&&/4E4[0?1
M\88]253M!]'QACU)5.T'T?&&/4E4[0?1\88]257I#[EXW6T1M3TMMJ?O.K&<
M=?>._P 46/\ 8/ZZ1=__ '1_\%:E_O0_T$*W&YSPNKTPB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3"+CO/^B.O[G7_L9L*!X+RVP?\ O_[F_=-"_O+KF0=]
M(JNW^2]7XUZ'*U_BAI_6B?SH94'!43Q7?Y%06%;%US1]M4N=UWLBM1MOI-G0
M;M9^MRY%%(Z4;M7K62;I.B)*)*&(D^9)*AT&#V1 RI#-+!()H7%LC>!'@I)(
MV2L,<@!8>(7'<:OU^ZN%/O[BJQ:MRH$#,U>FV$R:OG"O5^PDCTYJ*CS@J!"-
M9$D4W!0#%,(]D7H$,B)Y1&Z(./3>02.9' _&G2C+Q)09VB@/('BORSU7KIA9
M]AW)M3X,MEVS&UV'V3**M <J72*J<9)0U=CIY!T*S1ZRBXJ8=-R)BF!#)+G*
M8# .#/,6,C+CDC)+1R)-33TD!!%&'.> ,SP*^=,!507JK@GQ!TA?5MGZJT#0
M*;?%/*O)[#'L'3AQ#^7)K(O/<TUD7CV/JOE+9PHB?S:BTZR!Q2_I8B7+J?4]
M0N8NC/*]T7+GZ:<?754(K&T@DZL4;6R<_FY>I3]2M<T?7*=H2H]:C:TG=+K9
M-C6HD:10@3=XM[HCVS65[VBBG6DIETF4ZQB]4HF#P &6DDTLV7JN+LK0T>31
MP'J5=D;(ZY !F<2?,GB56QEW>W">.V6&W6/&O5[>^DDQFDI,D*?S4WF>V!R$
MLUJ1G)J@UDR.B@L5=-@54BWZ84P']EEX=6U(P^[F9_2I2E<:<J\:>M6PT^R$
MG6$;>I6O#\7#XED>ZN$W%/D3:HN\;HT?2[Y;HALU9-;#)(/V4FNQ9+&79Q\J
MXAW\::=CVJBANS0?>4(D*<Q0*!3& 9;;4KZT88K:5S8SX>'JK6GJ4TUE:W#P
M^9C7/'C^''UK+([B[QUAZM?Z+%:7UW'4C:*46A?J8RK4<VJ=C3A(IG"PX.:V
MDD6&;'C(V.;D0,W11,F9!-0H@H0IPIF]NW/9*Z1YD97*:XBIJ<>.*G%K;AKF
M!C0QW$4P-,.'!8UHOAAQ;XTRTI/Z/TI3J#8)EL=B_L+%%_*6 T>J=%5:,;3D
M^^EI6/BG"S9,ZK5NLDW543(8Q!,4HA/<ZC>WC0RYD<]@\. ]-!05\U+!9VML
M2Z!@:X^/C\)6:5_CII"JQ>JH6O:VKD3%:/?R\IJ5BT0<%0HDA/MY)I,.X(#.
M#BDK(-IAT13KB<!!8W1T93?=W+W/<]Y+I0 []U3A7X IVV\# QK6@!GT?*O)
M=W8]70+VQV79E9915=W5*ZP>:NA]GJQI)62AX$KZ2GX%DNP<J@QDHJ&MDB:0
M\F4* *J=8IC=4W1DC)W!@A>2;8/S%O"IX'UD8*9T32XRMH)BW+F\N(^/%:.[
M=P5Y";DBIW6MKX1</M6;!O(,Z_L_FS3[9"OO.T&>2:.+=;M=Z::4AG,UF]W"
M+152.LJNV*9PY6$XI)J )-ECU.TMW"9ES</B;BV$@X'P#GUH6@_(%@WV-Q,#
M&^"%DCL'2 CAXD-I4$KT$1[%M&,&4:S(*;2/:-F+5,QS*&(V:(D;H$%0XF.<
M2I)@ B(B(_1S522XEQXDK8  !0< H@5XZ:06B9."5UM7#Q$UMM3>\HP,@X\G
M>[?5F4+$I?UB^4=89X\VV3<B<! G:% >KT>#+CWNY#@[.<PCR#]Y2F7T45'W
M>"A;E%"_-_E5K7TU6:S6N:/8KI2-B3=:C9*[:V0M36BV1R10TC66]W9,(VV)
M1IRJ%3(2=8Q;=)?K%-TE2+T=&4FS2LC="UQ$;Z9ASIPKZ*J=T;'/;(X O;6A
MY5X_"JW6/N^>%EOV<XW%9>.&M9G83V6&>DIA[%+GCY:;.N=TO+S56*[+4IF3
M>.U#+.%W3%95PJ/75$YO#EXS5=1CA]W9,\1 4 KP'('B!Z"K9VGV3Y>LZ-ID
MK7U^8X'X%*UVXV:,V-LW7VY;GK>"FMI:K%O[@;N8T@QG*^DT=.7S5HFXC'K(
MC^/:O'JZJ;9V5=NF==02D 5#]:A'>7,,+[>-Y$#_ *3? _#^)5GVT$DK9GM!
ME9P/B%FM%UCK_6=)::WHE3AZW1&(SHM:JQ;B>'3]T\Q)S]@*+9T9P"J<O,3+
MI=<IQ,4YUS^#H'HRG+-+-)UI7$RFF/C@ !\  4\<4<3.G& (\</3B?E5<ZEW
M?'"NB23^9J/'#6T%*2,]!655\TBW)G#26K4RVL,&>'.N\6\P,&$XQ0= R8^3
MLCKMTC'2,*2?5NY-6U&4!LDSRT CCX$4->>&%3BK9FGV49JR-H)(/P8CT8^
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MHUM3J,C!D=A[<A%7N]!<3E'@*!?)[N)O6]W[NNZW!=$B&25PA9X,A!I&WTY
MW,12KJFBK_V@^B&;6M']:=H/HAA/6G:#Z(83UIV@^B&$]:=H/HAA/6G:#Z(8
M3UIV@^B&$]:=H/HAA/6G:#Z(83UIV@^B&$]:=H/HAA/6G:#Z(83UIV@^B&$]
M:=H/HAA/6G:#Z(83UIV@^B&$]:=H/HAA/6O27W+ ];0VU1_[W5/WFUC..?O'
M?XIL?]W_ -=(N_OND?X+U+_>A_H(5N2SGA=7IA$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$7'>?]$=?W.O_8S84#P7EM@_]_\ W-^Z:%_>77,@[Z15=O\
M)>K\:]#E:_Q0T_K1/YT,J#@J)XKO\BH+CNW;5@U<OGSENS9,VZSMX\=K)MVK
M1JW3,LX<N7"QB)(-T$B"8YS"!2E 1$0 ,B 2:#$E"0!4\%1[97-.F-;AQN@M
M'W74>WX?;7(1EIB^R=5N45<_<>W=TNVV;K(KU"=<-8ZP"XKI2%2>@<HI"?\
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M$A0Z;JAGQ1F^0,YL:VS2==-#S49MZMZX0CI";EY5E6V%>68SAE#&6(547($
M% */5&XCL3+8>\Q!SIS.(PT"M1D+N %:X*B^Z$=WT'Y6Q=(O))ICF X\*8K*
M]X\C(6G<5MN\C]/SM%V@SHNMK9=:Q(Q$\TL]*GGM>BUWR+928J\F=)VR452
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M+J^M3>[Z3;37$U:4C874]) H/60L-K.X="V[;FZUR[M[2 "M97M96G($U=Z
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MY*T%:H^H]P\X^!+#?;2"N(K=V-4K34X&[]A+1ERV8WGHARDE)14H5PRLSYK
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MA4U;Q\.)X*[G>=D.IP"Y4%3(8Y@U7)G$I"B80(D^CE%#B!0$0*FF03&'YP%
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M5+;$5)\>;?(BD@V=V>4:SNN'CU0QB@U3O39I%GASF O6Z\JP8-"](%\H,<0
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M((Q!!Q!'!>Y7NP.13S;^E:DM,.^WE30L6#XW7,;^WTF16\EU2B(E @/VZG0
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M_ )TH_P*?&EWCGO]:_ "M_B3%7?@$Z4?X%/C2[QSW^M?@!6_Q)BKOP"=*/\
M I\:7>.>_P!:_ "M_B3%7?@$Z4?X%/C2[QSW^M?@!6_Q)BKOP"=*/\"OX;9_
M>-'*)3WMF<H]'24VOJV8H] ](=(#"" ] ABKOP"=*/\  K^_&EWCGO\ 6OP
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M?-[G'S6VO4?'^GZP8-T8V,:IKII)E%8J)0.(E\/S^DP^$<Q "S9<2K"%*!0
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MJXQ[AW7'MFSN8I58(-=0>I*+L#VFQ2T;5*J:0024257CT['.M3+D*<@G1*8
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M6Z,I+HVL<X4(H'5:RKFYL@+BLKN30M_[0[ :]H^]+^*^G@R>ZSQOE=*(.O"
MV5SV-.8$$MHZ0M:[)G(:T*/[C8]6,^/G<_J;6-N=].3+C7J=+<ZUN%=@6)[&
M<=8@9;8B=DKT^\L$$9RLW$R+15HN*?;!VG2<HEREA::U)NG?@T3]GMMHQ/U1
M<12//3_TC"#IO8&/H'8N#A7+A@:X?4[W;\>S>VIW#^U'W<KK<0&VFCC;U/\
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MZ9Y0;BU?M&2L,KQ6W/6[)N'2$@X4?S+R&MM>8*++T!HNIY2<K]X5(D&<53F
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M<6.S$C5]V[UU#5NX.O[:W]K&NZ58VTICTZPTYCVNO6ESVQ@OCC<YQF:(G@2
MM?U'-#V9 TQ9JQ9-+N+N64&J;L9FO;ZK[";BU@,D^BWAMG<?%"H/&R@%51,8
MO2 "(='6*8O3UBF ,UK32[[R.AW+<;>73'N8X8AP]WOL0>!_\AX$+7MON:W[
MINXK1V%S#J\;7L.#F'WK3C1P.(^<$<05M(V6S:L>Y1C4&:"39$_"K4SPZ:10
M(0SJ1I=-D'RX@'SU73UTHJ<?^<<XC]'/&=(D?)]X9[I"2X;AN1CR;+*T#U
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MI%&9U7"C;MVWD_4/Z'M7:5I:]O\ 3-?V9I6D:IK-Q4W=Q?.:YEJ1](]-[VM
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M2465 PE $Q#I$.>[O8NK[[[C[DL](DMHY;:^O9G&9SV@M%T]I#<D<A+JN&!
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M2$2)UU3F,/0 =)A$1\(Y-)))*\R2N+I#Q)))/AQ*EBBBA8(H6M9&. :  /'
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M !/I(Q/K7Z68L7+AJ[<,VJ[IB*IF+E9NBJX9F7*4BXM5CD,HW%8A  _4$.L
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ME7<A5GEXCZTL22<-SOFOF D&W59 DH0&KDIEDNJJ<QAO=1N)VZ["QKW!K3$
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M20.C+%12 E-^MZ@_-[36AS2'4:T9JX$G#$\CX>"J-TNT;3!QRD$5<32G #'
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M1+IGL#?/Q>_&7*JRLD[;3'Q75QU5*;Y)%N7*L?$>;X5XHFIY*FEY08>NIUC
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M9J+<F<$;R42^:R3!<[1RLS=$1>,U5FZIFSQNHDH!3")%"&*/08H@$7-<TY7
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MP]<#6']H%LX<).C*$Z$BB<3&!516>Y?!<VEK?73&AQF+9"T9<S00> \:<E+
MV6"XGM8'$@1AS,QK1Q!\3X55%=7W#7&MI?426^ML<[>$O,.*M%3<;$VQOQQL
M'8&D=R3";]NG:Z\N"]G5I#R@6\2G*W=N4F3*+3*4RCAP1#M%,I-'-,V3W6.U
MN=/+3E:S*U[!X'A7,.6)/(55C$^.,LZ[YX+P$5<^I:[F.-*'U >:N[4] U@.
M^<V/+^ZS:7;QO&ZN[J1;CL6Q"P7L,YM)]%N:T\9>4=BZUTU16$[:", L6ZP
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M6<0[*OG<^5@\54%P\?)).%B"HGTFQTVJ4="VR;TX('5:":DN)J2XX5KPIX#
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M.U'C]\[<J&554454$>J45#B(%* $+T^  SN&PT^STNT98:?$R&SC:&M8T4
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M$PB81,(F$3")A$PB81,(F$3")A$PBC_9'AA(X/\ .:O_ -_DR(_$H%8]#$Z
M >CZ'H>AX/%T9*I^:D>,#H(3Z?@^D ?6R*E7=81,(F$3")A$PB8189L']J$O
M_P!0_9-EA0/!9GA13")A$PB81,(F$3")A$PB81,(F$3")A$PBTN]Z!WJ]4XC
M0\UJ'5+B/M/(:7B$DP,@];N([5Q90&JZ,I86Z9515FE(5<R[-F8R9BF5;K*
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M+.RM(@.&2&-M/1E:%C#ATY='Z[IPNY. = '<+*+' /0ZRAC#T9164:QC!1@
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M-WR$9K9K ?%TL7R!Y/Q*B=:T^ARO<2/W+A\H"K?:/^*4[M>'!8E?B>0]O63
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MISPHLX9AT!Z75_0Y%2KG81,(F$3")A$PB810OR+_ -1>U?W%3?\ >QLKVO\
MK,?[]ORA22?R9]"_QS<[/7G*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81=E%S,M"."NX>2>QK@IB&[5DY5;B<4S@<@*@F8I52 8/Y$P"4?H
MAD6N<PYFDAPY*A<6MM>1&&ZC9)$10AP!&/D5-<!R"VD@L"*IF-M.<RANQEHI
M9PX.<Z:2)1\HAEXR0,")4@$A.T%,#"(B4>D<R]OK^I6C:"0.C'@X5'P\?C7F
M^L]HMBZN3(^W=;3'\J%^0_ 0YG_-4_U?;-@EUTV\MJV^LQ5.0A'$/"R$PGT=
M!NL84E&4><3"/5Z"@8?H^'+@]S=!LSEU6>TB/G/&WXGN_&O)-;[$0VOMZ5JD
M.7P;/1I_SFFA_P T*R=?I-UL[4KN*JEF*7LT5%DI:#DX!9N98.DJ)O/C:/0=
M*$\/6%LHNF7H_DNCH$;.Y[Y=HK$?]X:_I<!Y/GC'R$CXZKRC6-B;@T5P]X9#
M+&30.BFCD'P!V<>DM 4C1_'_ &0[ZWE;>*B.KU1 KV7;.3*%-T"(I^9_.:8"
M4!\(',0?H9YKKWWQ>P6B9F1:K+?W#33+:VT[Z^B21D4+AXU$A%.%5C8]M:F_
MZ;6,]+@:_P";F^.BSAEQH>B8@R5L;ID$@"8&4<JJ<B@@/23I771*8H#]'Q9X
MWKO_ /<!V=;YV;=T*_N7 >RZ:2.%I/F&]5P]55D(]INK^EF %/!I_&0L[BN.
M](9&34D74W,G+_3$EWB3-FI\_P"<FQ;H/"!X?UP.>,Z[]_ON7>$LT#2=&L82
M*5D$]S(#S#NK#'ZG1.'I60AVOI[*&5TCSXX@ ^H"O_.4@16LZ)#"@=C6HX%F
MYNNDX<%5>+@8! 0ZRCI185 #H_YW3GC&N_>J[[:^"VXUV6",U]FWCBA%#X>P
MP'X359.'2--@H8X6YAP)Q/PE9NBDDW*8C9%%LF<>L=-LDF@F8WA'I%-$I""/
MA]#/$]5W+N'7'E^LWUW=.<:GJRO>*GR<X@>H+(-:UF#  #R%/D7[S"**81,(
MF$3")A$PB81,(F$3")A$PB])'<M_ZA]J?[7%/WFUC.I^Q'^'+S^V_P!5&NI^
MQ'^';S^V_P!5&MR&>XKW%,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB818)L$.F+B ]&UUL/_:261'CZ$7S9%Z!('1]
M#I_,'Q9*%,[BLT:^ !#TO^7(J5<O")A$PB81,(F$3"*%^1?^HO:O[BIO^]C9
M7M?]9C_?M^4*23^3/H7^.;G9Z\Y3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%]T&KIT/5;-
MEW!O:H(J*CZB93#DKG-8*O( \\% D#B0N_CJ5<IA;R>(J5FE%_!^D1T#*OEO
M#\[]+;-%3^'Z66$VK:5;@F>YMV <<TC!\I"HON[6+"26-I\W ?*5GC'CSOB1
M5(BVTYLP#'_D5'=*L,>W'YWSW4@P;-2_/^B<,UF[[E]N;!V2]U_18I.3[VV:
M[_-,E3\"Q\VOZ%;&D]Y:M/(RLK\JSMEPUY*/3IE#5\FU(H/1VKV3@&Q"=/T5
M"'EA7('_ ,IFK7O?WLY8.RS:_8N/_5E\P^&)CQ\:QT^]=K6_T[V%W[TE_P#!
M!6=M.[_Y%.2IF4B:RS _1U@<V9IVB8#\\3$135Z>K]'H$<U:^^]-V:LC1M_/
M/_-6\I_A!JQT_<;:T(JV9\AY-8[\8"SQEW;&WG"9#N[A06!QZ.LD=Q..#D]$
M.LWASIF$ ]/HS5;[[XO;&V_U2WU2X_>Q,9_#D:L=-W3V\QM8F7#W<LH'QERS
MR/[L2652*,KN..9+]'LDX^D.9-(!Z/G%6<VF(.8.GZ/9AFK7WWV-MQ@_LW0K
MZ4^'5GBB_@MFI\!6-D[MV(;6*SF+^1>T#X0'?(L\B^[+HR20!-;.M<@M_P Y
M2+AXB(2'T>A)VI-F+_-CFK7GWW-2>/\ N_;L$3O^LO'2_$VWB^58U_=RY(]B
MQ8'><I/Q9!\JSN)[N?1C(@%D9*[31@^>=>7:,A'ZC".0+FJW7WS>XDS:6]AI
M4)YALSOX4I"QK^ZNNFN6&V'J<?\ I+.XG@IQOBQZ5*A(2_I2UAEE@^?T_P#V
M*X9CFJW7WL>\-P"UES9Q G\BV94>MQ<L<_N3NEQ)$D30? ,&'PK.XOBAQSAU
M>V::CJ:I_0E$'<XE\[H_I$V[D$/_ *G-5NOO%=Y[K,':[<,:[P9' RGH+8@X
M?"L=+OG=4KLQO)&^30T#XFK.X[3.GX=8KB)U3K:,<$Z.JX84:L-' "'SA[="
M+35Z0]'IS5KKNUW1O23<;BULAW$"]N&-_P UDC6_$L=+N7<,[LTE]=$^4KP/
M@! 6:H04(VZODT/%-^I_(]A'M$NK_*]FB7H^IFK7>X]PW[^I?7]Y-)SDGD>?
MA<XE8Z6_OISFGFE>[]T]Q^4KM"E H=!0 H>@4  /4#P9BY)IIC65[G'S)/RJ
MW<][_IDGTFJ_N4E(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O21W+
M?^H?:G^UQ3]YM8SJ?L1_AR\_MO\ 51KJ?L1_AV\_MO\ 51K<AGN*]Q3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6
M"[ \,9#A_G96OV32R(\?0GSK]L2^S+Z'@#P^AT@'_+D%$\5E[?\ D1^I^9A0
M7(PB81,(F$3")A$PBA?D7_J+VK^XJ;_O8V5[7_68_P!^WY0I)/Y,^A?XYN=G
MKSE,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M"+M6$%-RH=,7#2LD'3U>EA'NW@=(='2']KHJ>$.G*,T\%NW-.]C&\W$ ?'12
M&2-OTG 4\PLOBM1;3G#]G$ZZNCXX#T=5"MRPCTC_ "S4N8*XW?M2T!-SJ=@P
M#C6XB%/^>K-^JZ9&<LEQ"'#F]OSK/(WBMR)E5NP:ZBN*1_![*28)PR/AZ>C^
MV)A=BW^AX?9>#-6NN\O:JR);<[@TIKAQ G8X_ TD_$L?+NO;<#LLE[;AW[\'
MY*K.X_@KR<>JE(M0&D6D8.GRF0N%-%(OSO 9-A//W@#T#_4A^=FK7?WE>R5F
MXLDUQCWC_P!';W<@/^4RW<W_ )RQLV_]I0'*Z[#C^Y9([XPPCXUGC+NZ-\KG
M2!X_H3!(P_IAAG7[E5(.CY_9(PW4./3Z!\U6]^]SV@M798)-1N?..V('_P"*
M^,_$L=/W.VQ%_)NGD_>QD?PBU9VS[LZ]J=D9]LFJ-@$2]L1",EG!R%Z0Z_9F
M,*)#F /G=/0 CFK7WWT-C0FEAIFI3C]T8H_^DY8V?NOH[!_H]O.\^>5OXRL\
M9=V-'"F49#;CTJO@ZY6530.GZ8%.O-IF^D(ES5K[[[-N/]FZ ]W\[<AO\")R
MQTW=MF7_ $>R.;]T_#XFE9XP[M/3Z:0!*7?9+Q?H#K*,'=7C4A'Z(@BXK,J<
M ]+M!S5;[[ZV[Y!_W;HVFQ'_ *V2:7^"Z%8Z3NUJA;^AM(&N\R]P^ %ORK/(
MSN^^.;!(J;J,M<T<  !7D[2[25,(?\XP0Z,2ATCZ1 #-6O/OA]V;H4@BTBW/
M..WE/]+<2A8U_='<SFT:+9IYACJ_&\CXEG<5PRXW1)"D3ULP? 7P=:5D)>2.
M/\L=R^.(YJUW]Y_O/=M+3JC(P?\ T=O P_"(ZK&O[A;K>"/>0*\F,'_16=Q/
M';1D'T>;=54E+H$1_3X-H_\ Y+Y__3R.NG_DS5;KOEW<O&EL^OZAE/@UX;\&
M4 A8Y^[]S2$EU[/CR-/D"SJ+H=&@U.UA*94X=7I 15BJ[#QZ@B'SA$[1FB81
M\'HYJMUOW?-[47>LZI(UW$&ZG(^#/3XEC9-9U>9Q=+=7#G'G(_YUE8
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M/U7IW]VA_B)^1=Q-_P#+OJ3X%P_W-C['[1^JM-_NT/\ $3[';1^J]._NT/\
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M5L1::'Q!(\UCG\9-PK^6?_[G6V/X"99_\9NVWUE_\/=?^P5I_P 6NWWUA_\
M@7/_ +%2=J7F#QTWI:5*5JO8GNILR42[G%(SW)7J$ZL6Q6:-W3KRRQUF(CQ[
M)9\D'4!45#=;I H@ B&;T#N'L_=%\=-T*\Z]Z(R_+TIV>RT@$UDC8W N&%:X
M\%F-#WWM3<=Z=/T6ZZUX&%^7I3,]D$ FLD;6X$C"M?)67S=%MRJWQ7Y>:IY@
MUN[6G4[>VMXR@W=Y0)PMNAV4.Z/.L6#&17.P292TN1PP%O()]50QDS";I#JA
MT=([AO'9&L['NK>SUHP&6YMQ,SIN+AD)+16K6T-0<,?2M%V'W#T#N+975_H
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M,(F$3")A$PB81<20?-HQ@]DGAQ3:1[1R^=*%(90Q&S1$ZZYP(0#'.)4DQ'H
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M1>N5!*FW:,F:!U%#F$"D(41'P!FIV\$UU.RUMFN?<2/#6M J7.<0&M \220
M.:W6YN;>SMI+R[>V.UB8Y[WN-&M8T%SG.)X!H!)/@ M.$OW[W">.L+V,80>^
M[)6&$F$8XV9!:XB!HA3&4[,KKKR]SB+85L?I*8I31)5S%.7JIB(]&>ZP?=TW
M_+;-EDDTV*[<S,('SNZWH]F)T=?_ %E,#BN<KC[U7;*&\=!%%JTUBQ^4W++=
MG0]/MS,EIP_\UF-10+;-K#9M$W-0*MM'65C96RB72+3F*Y/L"N$D'[,ZBK=0
M#MGB+9\Q>LW:"B#ELX22<-G"1TE2$4(8H>+:OI&HZ#J4VCZM$Z'4;=^5[#0D
M'CQ!((((+7-):YI!!((*]_T/7-*W)I,&NZ),VXTJYCSQR-J X5(.! <T@@M<
MUP#FN!:X @A9YF.6556M6<O=4[?WUNGCG4V]M3V!H?R;W;K2\.R9UY7RIRDU
M2\Q22,L[<O\ ]-6#I[1NAT!FX:QLC6=#VW8;IO3 =,U*O2#7$OP%?;:6@#AX
M.*T70NX>@;BW7J>S; 7 U?2J=<O8T1FI &1P>2[$^+6JTN:>MZ3")A%7;E%R
M=UOQ%U2[W'M5"RN*DRG(:OK)U.+:2\P+Z=6409"1F]DHE S<#I#US=L E#YP
M#FT;0VCJN]M9;H6C&(7KHW/'4<6MHP5.(:XUY8+3M];XT7M[H#MQZ\)SI[96
M1D1-#WYGDAN!<P4PQQ6MIGW^'!1RY006:[OCTE5 (H]>:^B#MFQ1^>JN1A<7
MSPR9?H@FBH;T '/57_=N[BL87-.GN(' 3.J?(5B ^$A>+Q_>P[6/>&.;JC&D
M_2-NR@\SEF<?@!/DMN>LMF47<E"J^S]9V-C;:+<HPDM7+!'@L5N_9BJJV5 R
M#I)N[9NV;MNH@X;KIIKMW"1TE2%4(8H>)ZMI.HZ%J4VD:M$Z#48'Y7L=2H-*
M\02""""UP)#@002""NA-$UO2MQZ3!KFB3-N-*N69XY&UHX5(.! (((+7-< Y
MK@6N ((6=YCEE4PB81,(F$56^.O+S5/)ZR;KJVMV]M0D]"7<U O!K-#LHMJK
M.E?V".$\$JTEI([]AY16W'Z8H5 W5$@]7V0@&X;HV1K.T;73[S53 8M2M^M%
MTW%Q#*,=[=6MH:2-P%?'%:+L[N'H&^+W4[#11<"?2;KH3]1C6@OS2-]@A[LS
M:QNQ(:>&&*X/+OF9J'A12:U?=Q-K@Y@[7:2U"+)3(5C-ORRQHF1F0,Z;OYB&
M32:>1Q:H=<%#FZ_5#J] ](5-D;#UO?\ J$NFZ$8!<0P]5W5<6#+F:W AKJFK
MAA3AXJEW#[D[>[9Z9!JVXVW+K6XGZ+>BQKW9\CGXASV4%&G&IQI@J3T?OS^!
MUSM$367DULNB)R[I%DG9;Q2&[*KL7#A5-!OYVD(*?L#J-:G54#KN54 :H% 3
MK*)IE$P;_J'W>.XUA9ONV1VER6 GIQ2DR$#$Y6O8P./)H.8\&@G!>9:7]Z3M
M3J5]'922WMH)'!O4GA#8FDF@SN9)(6BO%Q;E:,7. !*W#D.14A%4CD434(4Z
M:A# <AR' #$.0Y1$IB&*/2 AX!#/#2"#0X$+HL$. <TU:5^\@HIA$PB81,(F
M$3"+YJJI()*+KJ)HHHIG5665.5-))),HG4444.($(F0@"(B(@  '2.1:TN(:
MT$N)H /%0<YK&ESB T"I)X <RHFTUO?5'(. GK7IRX1][JM>MTI2'=DARN#P
MCR?A646]DB0S]9))&8CT"2Z12O&_:-5S 84E#D ##FM>VYK.V;F.RUV!UM>2
MP-E$;J9PQY<&Y@#5KCE/LNHX85 ."U_;>Z] W?:2ZAMRY9=6$-PZ R,KD,C&
MM<[(X@![1G #VU:XURDC%2[F$6PIA%X^.8/^]+O_ /VK7+]F7.?//N'_ (YU
M;^WS?PRN$M]_XSU/^VR_PRJX9IRU-;/.Z5_WI9#_ &4VW]F:IGMO8+_'+_[!
M+_#B7L/9#_&;O[%+_#C7I:SM!=<+RO<%KW;]8]V7WD=^H,^_JURJVW[A)UZP
MQ9R)R$5($@Z0D1TU.H14A52IJF#I$HAT#G8G<33K'5^[.U--U*)LUC-8Q->Q
MWT7-SRX%<(=K-5U'0^R.]-6TF9\&I0:C,Z.1OTF.R0BHK7'%?W9%NY]UON]M
M2]X KS=O#>RL0J)DM81=?B6U5<UF:M*M4CG]E<K*/4;S;)!X+>0>FE&:C,J:
MZC5)(A$B&.TJQ[;7?<V][:-V_;FT=U*W#GN,@D9&)'","AAC:*L9TW!U0'N)
M+B UK4.[-EVAT_NV[<]T+UO2I;-C8(C&^4Q-=(22)Y7'+(\RL+*.+&M :"9?
M[Q+F5R"@YCA@\?W_ &GQUXQ[DTE4MC[-VCHRN-IFTEV%8XYW)NZE'RD@[BET
M&E=2-%&!NF^;'6:2:ZQDGAD$T,P?:_8FV;B#7F1VUGJF[K#4)((+>[>6Q]%C
M@T2.:T.!+SU,2QP#HVM#HPXN6Q=XNY&[K6YVU)+=W^C['U+3(KBYNK&,/E]X
MD:7&)KG%A C'2.4/:2V1SBV0L:Q6(X!W/9?(?4?(G6U=[P>)W$T<F:%U)LQI
M7Y]AR0U#'O';M'RR_P!7N436SR)7J#1(J"I'#UL1V5P"3U9(Z9$M8[E6&D[8
MUO2]5NMLOL7BOO,!>PV-R0 :0R1.DRT)-00QQ;EK&T@D[AVEU+6]X;>UC1;/
M=\>HQNI[I<B.1NHVC22*SQ3,CS9@!E(<]H?GRR.:0&Z\^ZFK^UZ?P!YK\BJ?
MO2V5J$HU.Y.Q\'J:.C&00;79<%H2C6V%V\A.*.3.TK)&%*W:IH>3&2ZC8IQ-
MTB)<].[RW.BWW<K0-KWVG0RW%Q/8.?<N<<Y@?>31OMBRE#&[VG$YJU<11>0=
MA+37].[2[FWCIVJW$%K:VVIM9:-:W(+EEA!*R[#ZU$C?9:&Y2*-!KX*W?=NL
M^=^\]<ZXY?;;Y7SLEJZ)K>YX6+U21H8KN]-XL]XAV%LM\HB1%@]E8>]F4(V
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M."T'7NX^_;?L-M;<EEJ5P-QWNJSQRS$C-*UL]XUC'FGT0(V#"AHT8J2=ZO\
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MD[#3K;)S=.KLG)6G7KI1[1+'(NXEJL^G*>Y5.JJ>MRKHQUV8'.H<J!RE$YQ
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M7AAS/+&TYMS_ $G-((HY5=?V-W4M+;1Y=FZE8R,L=,AM;K3[P/=8SNCB$;I
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MN2_#;9VY>;_$#DK6)VAL*+Q_\X>[*)GI.P-;;)^5R#EVG[F6,?5Y2'>=5-8
M-Y4_9=!NGHZ0\.:+M/?6D:%V^US:EW'<NU'4\O2<QK#&VC0/TA=(UPX?DL<O
M1][=N-<W)W/V[O6QEM&:5I&;K,D=()75<2.DUL3F'C^5(Q<2)X3;!)WE6T^7
ML[*:^D=-[!T>GJPM4"2L"MX4>J05(AWWG2(4K"-=+#.0KCD!,G*J*BFH3]+
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MFRJC^*?)= _/>/6 ^EFH[=W_ *-I&R-P;:N8KEU]JTF:%S6L,;1_UA,@</\
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MF=LW_=D4C9KN5CV2,,[G-&89V"I+Z-:7M9&.HYPWQYSDNK$PB81><S_BAO\
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MNS>TWWTC+FQ(H1X%I&!\L^Q'WGW:6-$_;^@1:?T1#5C7B1L8:&>R[]G@YLN
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M;6K&_<4^46G]D2DVM4;)RPKDY,;&U(QGF:<8!:^WBJXZK\6ZA6I4E$56Z+]
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MO1V2A@];W#N35-!["6K=8A?;;FOK=M@T/!;*;=CWBKFN < ZV:0:TQD:X_2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2113965d2-pht_expsca4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_expsca4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ I (B P$1  (1 0,1 ?_$ -P  0 !! (# 0
M       *!@@)"P4' 0($ P$!  (" P$!              (# 00%!@@'"1
M  4# P($ P(&"PL'#0   0(#! 4 !@<1$@@A"3$3% I!(A51%F%Q@3(C%Y&A
MM7;6MQA8>#D:L4)2<C-#)"65-C?PT6)3-#49P8*B<W6E)H8G*)BHN!$  @$"
M!0(#!00%!PD&!P    $"$0,A$@0%!C$'05$387&1(C*!H;$(P4)2<A1B@J*R
MPB-C\-&2TC/3)#1$0U.CLQ46X7.3PW2DQ/_:  P# 0 "$0,1 #\ G\4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!KQ_>&\BLZ
M8VYV\)K6Q]EB_+(@;'PC&YEM:-M2YI: ;1.47.7[RBOOPBG&.FQ5+A:1]FQZ
M3=P?<HV(B8$Q*"BF^252N<G&E/,V!5E/'LO8MG2+U<7$A(VM;K]ZY.4H&7=N
MXEFX=+&*0I2%,LJH81T  #7I42PP0=U#B'B[,7.+MJR=SV]D621S'E^]L4YF
M4M/)>8+6AI?&EFX8R+>5JQ4PRL>[H:'A4F=YK%< \33;N7"@%345.4 )4))-
MJIL6IRC"27@8T\HX6Y_)8\[O4OQ[S#>EL<=+JROS3@LN14W)7*\R-C&"XVXK
MC[EQ>KQB>/7*LP)\\-4$K0G=OJ4D&29G;42NC <KSZ4+*PK"OU47W_YB65QH
M5?+\>,%K28NQD5L/8S5?^O%P+WUJEE0IW?K!=B+H77J!-YGF_I-^N[K4D:L_
MK?O.[ZR1% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MM7#>'#^)-Q!SHWB72\%%VLZ>/<#7;,I[UF[6Z[#D DW-IIN0*5N1S;B\>@V
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MR2).YQ%:#DG8Z +I^LY5.)C*GJ4?)E5S!J2))/N'^>+JW>Q/'Y5QM).+??\
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M3[:^C(3'M9.#W'ON#<3^ZEQTY&V6PNBU+EE.,!H&=*U9EN_&]V# \B6\/?\
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M6UEMSE&/L;7X%<[-FX\UR$9/VI,^PA")E*0A"D*4H%*4A0*4I0#0"E    *
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MY@R>G9.4WK,SMJ@Y,T>):^4[;"L0XH.4]1VJ$T.&O0: ^V@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4!CM[N:*SCM==P-%!)194_$7/&Q)(AE%#:8\G3#M(
M0#&-H4!'H'@%##Z/W$5/V0J:I+-[CBYDE 06N?BT@DN)# DHLWBL^'72(H(;
M3J(D<IB< '4H'*(^(:REU*[2P^TG?5$M% * 4 H!0"@% * 4 H!0"@% * 4
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M);=AQ,O<#T"D<3$DRMN.CT7T@9%,B)550,9-!,B1!*DF0A0]QWC0"@% * 4
MH!0"@% * 4 H!0"@% ?@X<H-$C+.52(IE#43*& H?$= U'YC#IX!J(T!@XY5
M]^OC%Q>SG<>"C8XRKE*8LDY&%YS]F$MAE#1$^)?,<P#$MQ34:[EGD8D)0=*
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M802T]R,<U8-?R9PD_?2,F_N,*2Z-27O37WM)%^54$A0"@% * 4 H!0"@% *
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MF_WIC"G[K&U(Z.=(QJ,@Y?S"$8F5V=8K%!+Z9+2CA1<C1=H[544)%@DF4BI
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M!+G]$]?=MJ_N<+=K6-4<(2<XQQ?ZSC',_-Y4O!5ZO.S7%&\* 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4!ZF\!_)_=#\= 0<+L8J0'>4E!.( 93GJD]U*
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M]AUWR_Y0<EV,KCBT8SD/FV/@5,:VL5.(;93OE&-2.L19(XE9ISR:0$%),"[
MT+H !2K:=>A%UPIY&->$O3+&29&XX12_9M^_@CG<3Z$U?LJ[,UCC2,?&+SZT
M>=.2DI)@T=RR K U2<.!()CE(($.(2P27@B"<I.GB4JHRN>(4\F\",B.UCN3
M,5&L@,LTD6R#@S<\@V>%0*W!$BY13T$XG,/S &WJ,:I]#*4E]1,+]H$5-;-O
M.58H@/E8JP4G\N@_Y:[\G&$ TZ!_V<.E2B0N4P)VU2*A0"@% * 4 H!0"@%
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M)C.2TK/_ -TK6UUU^[D)KKYP#_W8U\?4"9?7_'$3_;UK+ZE+ZE1T H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@(C7>5X69 MK-%[<H[+BY>[+ OL6DG
M>@H(MU%[*N*,BV,&8JQ&^BHV])MHU-4KDY-&ZICE4-MVFJJ:=39M23CE\2-2
MKG" &^U\:7-%R5GRZ\I"C:3Z;!!.*O!(DC&*N6\8](<R2$NV6$X"T4$%3IE
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MZE""PZE[^9?+T++K9[5'<3RHT2BXSBAE1)BZ333WW#!2T0WVFV[3J [172
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:OC^#QU_YZ \]/P:_\M*>\'GI0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2113965d2-pht_atx4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_atx4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ M "Z P$1  (1 0,1 ?_$ .,  0  !@,! 0
M       $!@<("0H" P4+ 0$!  (" P$               $# @0%!@<($
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MOTHTXUDP"3;S.$:IX3C&?XI*-5DUT'D#ED*RFXQ4JB0B3K]U>E Y> D. E$
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MW3*0CG[=-TR?,W*)CHN6CMLJ51-0@B4Y# (#8:^4+B":UG?;7+'1W$;RUS7
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M",P!:ZH-%IW,,-O;OGA8UKXV%WP@"N45+?2,,>U?4.^\B _QC_9U]Y'YH_\
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MMM7Q/BFAA?4U@)DC!+B*5H*E;+="=9MN^GDII]J?J!B.90#:8</-/('%XS)
M0T]A7J[AROB+'(,GE7DM+XRQ45*$<BY2%RS(!R&<+$%,J77_ #/YLY:YRUEF
MLZ%9W-M=NC#;B25T=;A[0 )G1Q,:QDKJ'B%IRO-"&-()=V_RAY*YKY"Y>?H'
M,=]:W=DR4NM8X62@6L3B2;=LLTCY)(6$@0AXSQMJTR/;E#+S:\S7K"41<#'
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M>R8^=NG8%[.B3QR*?$$>7$Q'(#Z:XZN68.Z'@^HA<JW&+^*?8LS_ ,1/Y_\
MD/?$?Q_ZM>MU;_S5W+S_ (TG1_@V;T]"SPUY8NYI1$HB41*(E$2B)1$HB41:
MA6YIJ*6Y/7\@AQ+K#GQ@[+@ID#Q0.'#GUUL-KE"FN*O1\,,X$S36-KQ_+83B
M[H.7-ODRJ%_4#KYZA^%%DS>LP=0K%V%$1#ER#Y^RL:"J*W;<\Q^(:";JF!@
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MEBZ@KT+WC"F4>DXI%,(A8BATB*")OJE[HY@/U#Y+7IE;O 4U7Z8J9@Z3I)&
M0M8Q"B ^H>=1E:<**=RNPTHEW3S#F0.UU%E&;IXQ344,910S9!6R!3*G$3G[
MH@]("/'I *Y*^?+-';7,Q+I'V]"X[7".1\;23O(:T-KT-"KB :7-;@ [9T5
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MXPJ40M[)5,/R=,1#A^$80O7HFF<,^5^I@^,:G 1Z6'\JXR:O[UB.[A.]JM[
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MDCCQ32>.73,Z@!;J%$M^05M0QMC'P@ ]2T[EQ-!N68/I\P?FNGL^3GRJY:M
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M-QX=.H.E!^0^FK(]I[%B[=V^XJC6X@_3OFW/^<VGQOEQ2/'Z*QD(XCNU3%X
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1]-_/R\ORTWJ%SJ42B)1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2113965d2-pht_stx4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_stx4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ T #" P$1  (1 0,1 ?_$ -T  0 !! (# 0
M       *!@<("04+ @,$ 0$!  (# 0$!              $" P0%!P8($
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MJ!))R4&F]'[H3-V9CG_=H+*=/NIG&Q184XJ??KPIYU)A9>?Z1OZH$@<^23U
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M0_=1-J'2%I?[@<'80:DQ'?B^ #I31FH\WT'"Y2Z=R.W>2>\U8H=IS\A,#_\
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M' I@L( -:LN:V8?A([UE?[!^*%U[PRRS7B3PT@VQ3?>?%9.U"@591E.Q.*Y
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MSFS?;>X#'B8K(9C\,U7C[)XKCT(OD+QB@RQY2'1468-U$E1;%7BR)B(& 0^
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M[1$9K=C2TLN(<=;6AX<USN&.!H>S'+9CVS=K87-MX$HBG>X.#H)332YQ86N
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MQ[1STLG[;W$]?]8$\ EH^P^(#$9WED2(?\)CTKQMGPKV63XCV?P!;%P03 ?
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MRB(7 P@(56BL,5]9C@<0Z!1*$8J0Q^5C;^?[NC]7XL^'FXEP^@5<WU&VN ^
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MYJ;F1K1Q@&R6)FLDS%5]AF<1:*)<DPN<%$Z:3^-74"SE@MW]KMBJ(MW2?ZP
M<J:A((JKM>6'#)0?.=? /:/%7.5<*V=',9.,G&BA\.V!&-'CK!\_A$E5#E8N
MBKIMU6TM'&N+AD<Y'T<J8%4%#HG366QD$+9#@_$*-YM+2&;X/N21-JW&,YQ]
M\82/HUS%Q<G*8Y/,Y)J7\3:-)F':N$&RPNE%F_:Y(DFX2[3.$VQS#WY&OPQR
M6)S*.P6VC24CETEC> O\\8+1N6KZWS(LVR7;&9N$7921"9?/:& HMEU$$2'.
M2P6,(A:L9I4TR645PKFM?W+LU]FG&X#>(C_G_JF_LJ6Y*KOC6.N*J%3BU.XA
MSF/+/TR%3(90YU#KG["%*4!$3'$+!T\1JKA4^90#@N*V1"&E\8DV::)CK^4)
MB)%[3'\U(1-VAV"8#=0^ B _"H;@Y'"K5C!K19ZTGF>/?CTQ#-WS\6COR#G%
M%)=1-=%),&AE"%(<5%"@!KD$#B!C="A6P=.9Q6!@-:8@K+4&AHM4B*LH9RF0
MHN#N9'RO5&("JET2G***8D(4O0>TQ@ +"(CUK!@:D9K-B,S@K=,XXS(S==X!
M_*?'.Z\E.Q' M/4N+&)YI0(4ZQ1-VB-P ?&K')0%N1YW;?X@YGQWT?@O'Q)C
M)Y<P<#(.6T1"&;%PZ 0,]08Q[M8T6S5CG[B/41;NFG>=R[=)*.WGF*>4Z<]6
M^FV^6WBBLXVB1HCQ#'-> (@)6S..$KW35>PMU,:R@#FU\-F*,2A[C*3IJ["H
M(^(Z2T#X0&4!!H2[$@TU'89^4H1 _N4<F5QL(MN(LJB%NM@7W%K4P^'3KY'2
MN8W)7>NP_JRQ)1$HB41*(E$2B)1$HB41*(E$2B)1%:/=^C-8<B=>36K]MXNQ
MRK$9M+]XU<E['D:_3*8&<U!R"=G41-QQSB9!RB8JA!$0&Y#&*,$54@EIJ,U#
M ]P/VV]E\+\C<3\<61SC0DS)F1Q;8!$ 4=PAW"IA98WGR31))O&S926(DZ(1
M-E("%T@24$S<F(MIY%ML?J'YRUGM3@&1,S=+_P +9H'VBVBAM]8]M0,NY23B
MM6O+DP#LJ_0+P\>/_<CUM5ADJ.S6,T,\%BFN@9X#=$RZS@EF8NE#&74%0Q"A
MYR)26,/B8;6 /C>K4:3[Q5:G(+Z'<JFHF)"OI94UA HD28,"^ B!KD!V?Q^'
M3I4TC';7Y>50=15N&K-O'99#9,=BC+*Q4Q&2CAC)_P"89RI8UVDZ]#)=Q!\Q
MJY*EY:@ 'ZAA#Z*K7,#)*8U55J9*I).D@!.-.\ 12;MB((OUS&4.!NQ)NN#D
MRIQ,4 L"?7PMXT%6J225D!KOBERZW<_(MK'C5R$V0Z<I@LD]Q?3^?2C(R $!
M,AR2:,"6*1;%3L4EE2D*6Q2V"P4J3CQ0BBV&:R]@+W<-JD;+->*<UA+)R4IB
M/=K9[@.$%33$G>!EXU[DKR>1  &W:+/OOT[:>\>U5J.U2C_8,]DGD][;F]-P
M\@N1N8:F7=;(U RUA"X'KN6GLG?Q:G\4P&5.Y69R"1@L?C"@D,/Z8J#9-QWG
M,)_,[0#NL%1Q!&"E3U942B)1$HB41*(E$2B)1$HB41*(E$2B)1%3N68GC.=8
MY,8CF4#$Y1B^0,'$7-X_.L&TG$2L>Z(*:[1\Q=IJH.$5"CX& ;#80ZA>BD$C
M$**;S:]D3<>*[-1S/AEBY]G:\R)MD[9;73O+L0QO)==/9E%MY"2$SG^28W%Y
M#B)5$1*D<'2DHW"Q#I. #SJQEM#AB%F;*#\6:UK9%^64]Q;?^4IY-DV4<:](
M1?I&C,S+)<_R_.\G*1$@=RWX7A& *X\)[F$.S\9"PA^L-[U(!"&1I*R;UQ^3
M[;?Y=?<O.R36("I1=Q>J-&L(=4R/:'>5OD6:Y]E*29^\1 #'B3!8+V^%-.*K
MX@[%L(U?^53]LK"S(KY[*<C=UKD$HJ(9CM5#$HQ02@6X>FU+C6OI "F$!N!G
M9O&ITA5UGL6P[6_LE^U)JLB!,<X,:)FCMU3+)N-FXXYW(Y$YR%3'S%]MO\U5
M63 I+@0XB0#7, 7$1&: *-3EFM@?%OC-JL41UCQVT7KD6Y0*@.":DP#$!1 "
M]H D./8_'>6 %Z!VVL'2E HU.[2KXI(I()D213(DD0H%(DF0J:9"AX 4A  I
00#Y!TJ5"]M$2B)1$HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2113965d2-pht_gtx4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_gtx4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!# #N P$1  (1 0,1 ?_$ .L   $#! ,!
M       ("0H$!08' 0(#"P$!  (" P$               $" P0%!@<($
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M<9$-*]#Z22F+J7LCAQW&)OXYT?I+SCK#"VXZ7;\Q^+6[7.__ #;#(/I:H_\
MD7_U?E(?S9"+O[#*8MCRIA^U3[ZY?[0\7A]5]Q/![('?Z",>Q<+]GB83=(=J
M'U&S-]$\G^-2M/RR#@JK/K3C3FL *]/:Y2]H><0WR;*& /\ U<H5XO$[2ZO$
M$?0O9IQJ;I.1!3^!NDQ\6."*0W CUFB2*C=H:3P&(>/6:*E@ J$@$@1V11(N
MA#@;G)^Z(5ZNWJ2PS_,.LG"0FITW#VM<1VMTTQXBE#QJO(G=,7MM_EV7K3'0
M@:K=CG-![':@01P-:C@0JV+Z7YAE-(2SK+<==&(QGFCA9GB)XN0>J34#)PHJ
MNG:<LX*<B?GRG$@$*3\( *!1$1'%<]0;>:U-LRVF:"^,@&;6UHCD9)0 L&>D
MBM2<<25EMNGD\-V+J2Z@<=$@);!H<XR1OCJ7!YRU5H !A@ L73Z4LN:IQ::4
MMMT[",)X=W4#*IC(%\H=G>1LLX!8X%.)P$O+^*(GMS"-<D[J/MTAD+HKUID-
M<)&'3C7W<!3LQKAAD%QK>FNXQB,-EL7",4QB>-6%/>]XU[<*8U.979MTOYDT
MC\N:$>8>B:<QV-BF";!>9(@5VQRG'II1RZ%VT64+XK.*5*(E$0%02AR@ B(5
MDZ@[9+/;2EET1#.][M096CH9(Z#21D7@X\ <25>+IYN<4%U$U]J/&@8QH:9
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M&&""4EH(;66,@8URX#'(4QJF_?6@8O(KIHZ<!?(BW>Q.;MXATD82',BN; Y
MJJ0G3,<@B!XWL$0&U>5;S)%/N$\\)K"^9[@<<07$CO7J^RQRP[=!!,-,S(6
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M^P9(O96'_H'SR31KK$_UKO\ 9K&SF_;)#1K9J_O1_&7 /9-DV\])P,O'1P
MJ2*A63MFW+_C'1HYZ\6;(EXF4.0$B%U,8 N-<+OG1SGG8K1U[-;QSV\;2YW@
M/#W- Q)+*-<0!GI!H,2MNVYEVNXE$!<Z.4F@UB@/=4$CTD*_HO2F IBF Q3
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MW&XD8&T[0*9R ?;S#7.W431RW93#XG7=T#Y RT(]96"-Q^;D;P\-A])?]Y*
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MX& W[H@*8" URVP G>[1O%UQ&/2X#VKCMVI^R[@G(0O/H:2OJ.:<G'3W=_\
M+6BLB]*(BB(HB*(BB(HB*(BB(HB*(BB)I_UL68N?3QW:6 !'Y?D>U[SV !]P
M\>8")O99Z/OM19(_B\R@V\O;:I66AR2A^EDWA[U8P2_].SR%&P]ML>DEP^O5
M&]*TQ0C!.U)DT#MM8/LJ*JE."K4R?3[.-3J5@%<$2:A]0:<>/#L[:K5#G19S
MCI/PE@MP5#[TR_R54FI5P,%'*ZZ&OENH3+#<O+XN>[J+ETM\,C+P4B3W&*H
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M6<=2>P?3UE;60C3;E[[;?[<9,R<%'S3=@_SF,A<D:\I"."&429^8 # "B9K
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M3M7N<Q(_F\^A=M<PA3"[A,O4F8B.7CG*(<Z8OVTB[:)NVA#D#F 3D'E"W-8
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M?&/*OGWB']L1_7I6);8718QR(K'33%90B9S)I 8"BJ<I;D2 YOA**A@  $=
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MU< U-[+7_15VY+$_XDD^+12=Y(FFN0JA 9(CR' #E-=*75$IBF 0Y#*MTS&
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M+*F\2(G@C910JB \IP,('+XB?*H;*2'C'-8FZFD#@G^F"@>2RBXV_P!6Q(B
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M1?WB$Q^M9\_(DB0.UVW&+J",!@>'PW,9$XFC<;AVB@J-E07:J"JBS(H)VJQ
M.D-[IF !+80"I))S44 X+938>5EE%KA>+BNW7_C,X]GU4&:L4U7U:&ON(L.E
M_)I:Z#PY_OM5VY46)V:20S<BRG$'@IF4(5!"Y" ',<@?,D' D$PE*)T"OR'M
MQ, 6#7@(J%3(U6=H28 FHE'1,@N19;S"AD69;J*74$!.L7G6$I15-R@.@7T
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MCW'((?=4:BH\(<2E48+Z(6Y+\R(GQA) ! !$3-CE$-0XB9&_;34Y3H8,TM/
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2113965d1-pht_cuvette4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-pht_cuvette4clr.jpg
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M$A @,$ Q$P<A,A1!(A4C,T,T4"07"!$  @$"! $%"@D*!04!     0(#$00
M(1(%$S%!47$B$&&!D:&Q,B,4!C#!0E)B<I*B,R! \-'A@D-C<Q6RPH.3H_%3
M)"46!Q(  @$" P0(! <           $"$2$Q(@- <1(C$#!P@9$R$P1!46%"
M(/#18D,4)!,!  (" 0(%! ,! 0$      0 1(3%!46$0<8&1L3#PH<$@0-'A
M\5#_V@ , P$  A$#$0   ?OX           &!'>M<^ESU#[7FU)['%7GK>>Z
M5FJ/:X>:?4_QON>KOCO>L'S>L        .55$_0^9YS^H\FF/=\JIO9X*P]7
ME:J:J.+=1Y_5TG3K;+?WO*C_ *'F5#Z&M[?.]_Z%_P";OU8,& -@    ,'S^
M^E\SX@_T)^?V!?AE'"/GO7<NC%9T8MWH\S!W91CHR2\_79GA>O=7RWI^V_S+
MZ9K^A\[Z._"^_%J6AU+L$0Y3-S[99   P<1JF/)GM9?-#]A^,\<?7^5]%/R#
MZBF/I/.\Y_H'R]I^!Z]V_+^I;'ROKVI\UZLY\3J119SJ?XCT1:7.J 871VF'
MXEMH]5]N"83I[23RX23Q'&4*@S"/NQHGU,.'D]??EU2B/GE%$]-"FME>1PA+
MXCFFU-:0NDH,KR.8>H)+5=;PSUE"K='3"V\IAG&:#2,D2U4BN^:T>M9#8KFJ
MG.>UK=9GK#O*04AQI"6;6QOE764QZNBF3^AYB&&7-&T2_=%"T(B$%;DZ+$&=
M,'YM2S66<R@['0V%<GB*Y$DS</1G7V,Q.FG1.$.DQT1$8E#,N.^?DVU8LE*A
M[/3$+S(9,M7-KV-S8VAL;0WF'"78WB$TS<W3G!,9@V>G4Y#G,=(BH5W]$BZ,
M_(EH]!D%'E$D3<2(FG7FU(;HR!M$YEV%J,F1/,W?TY03.:^QTZG$<9A9$099
MX'GHSJ::JIF5(5D;3&RUT\.;3F$,Q.0-D++1U@)RA.7QU90?.U98Z=3F+YA:
MAFBW >=\ZTO7=/00F46E,ES=Q:\#:)( 24*]S,SDR)3T'TXPW.U1XZ;F9E6J
MXH1K-,'O?.J[PY"4FJ)$GA(N:^+5/#:) 03/>T;W=:5ENB9WS=)K8MXIG'6F
M<KYK;<5S#G%4Z6-+UT9U9:LM)/,\JJNM$#FLX6LGDUXIS+%72\2RU9K>LWO6
M7VJHED *8RUHW.^,G=*B8=D)TL,2^[YO>M(EZ?F^?_HO)2?#?56CI6Q;1OCJ
MT8R^76-I6;6SFMH62    "J<]//6.FF90E1)Y52K,<'/3.5=-=Z0AK9FI.B)
M3=-;1/9K)[QN       FAYQPO6359C/>3PJFBS :WJ[WK+K)G*=Z9RU&\@
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MQ=3W%T6\.E84\^ _#L5BK^#P5H5KR5S?DR]+%+:VL++P<=J]<G9^[CM[W<Q
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M', *#\Q((J"*$',$=!&'NMN&1J[VO1SDQ$G/4>;!5LF'*.<=XX?N:$!9B=(
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ME/A8>&WZV_T+KP.R6O\ 4KAF74M+17]@8&(8O_U/_]H # ,!  (1 Q$  !
M       "'M/,@       <)80H/(L"2    0ZH:LQXE %R  ")P&\7*/HP"/(
M!0.<#Q?*PR@5AK 4*;R-U:UB["NQ@]CTF0 ?;\H5_P"XGI<-;2Y)F=E,;)CC
MH6,)S!+#38%9)38:M@2-R7.G];YH[U$EI1B0_A@)+!$RD%%V:3#G%;[2&QMA
M Y*G(+T %O;IX_!11D_    '+DF>SO#8     #EXB0+D0       !!N$E@
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M0]$*("XHMJ$532ZD%=U<1C(.= U 4-74;#\S [>EWS8-[EU8I<NI;T^Z9E=
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M-H*R!)#& ^//VG"]1!46 I9T()3S9'^C/?"VIULE%.6V//.ELS'D ="NU7F
MR.;R%?)+\A['ZN&H ]:#MTYB!LMMO'_LXAK='?-R@B2S1C?Q N*%*XT.HG5X
M@VT9!4K/6IC/@!7IU'%H0F^6!LL!8K:(7UAUPJ <(0[)7>+E+-=;?Y@KOD^R
MACY3'JRS8)9N^CNCK&R=6H<TE>\L)+A6Q&&]#"[M)@(%=*5[0XO%#</&D@SL
MV9"QW?Q" 7HPP9.<$$L&X>6*,T&EM@.HDK32:CL8/)8SS-Z0AFVN$H83P0(N
M0A7<"M"RW6X ^OJ^?)>Y6*9U=5GG%VS)GR_BV=77YZ;@!LWT^^D"UWSTZ5WG
MFYO4L6>+UT()L447KGUU*.5U?0YOJ^#IU=I]ZGD;KKOMN"$"1P;LIT,UYT*<
MI)%<%\ZVO> =@]"D7T"-UG=_.7W671W0->I, 93#M9BO:$@6)INQ0GY@Y@"L
M&J:]ZFJ&@5T#!Z#'X79F6HH$7 [BR9P#QL"*C"R04APJ0ME4?2-HUE%?W&4L
MF$I0(;0X#XNF:]ZBBJ&YL\#JX)UVC-T'-7[[;TK+P<V8I&2 '+0:)5=1=YN"
MF%%:>MY_$N8GHZU-C&!?^2CH>Q #17EX5U#_ ,@K+!7/7]JG<''+S!,Y/M)S
MC[S$.32=G >=C V4>8VHWPM&^TU,!C)M *0$5P+BI8-4WSH_\3 -5P=/VU/O
MNY/O>4",TOKEL0M0%5-MM;FA; W4+W2OIF\P2RBX6?%\,BJ,4$*0#R@4E7%N
ML A-!M[(0"K>,,5()QS#<A8RB3:5 %:XPY5MWB$ "BT"V8 #%0 E^KL2[%LS
M7&)M7*ZKD)^%OV2/\.+I'R_-Q/\ V#7N0SU^985%,@K4L77OJ$!<'%W=2V>:
M73%X"QY7@FF0)/\ B/$>$#J,?$3N=VW@#W&'#S\\1E(MK&=UHXE*4;1.[:Q"
MO/;\FHR[+ O;HZ\7&A44M0"IHTZUFIGY.XL@:2P@6LE+(TBA_4J!FF7 X*J2
MYL,RQ\K4RNS74F5#.$Z$I>X6QL.H'%P$ %MBJ6,"DZ]W1C($[A:@O8H'>"K]
MVWUN\'O/4IOTL_7C9X*U2T+M"T49>A*!8(L<"M=3EA*C :@A1K&.TMC4$!H7
M ;; !RYEQ!EXA4!*NBW(CF-2RQ2D)L])616XKN ]%4 +1:N5<PEQL(W2R&:%
M_!"I/PFG]XC@"BCC'-9K-]J\"/G0PK-7^<_N.@=IZY"#98%!I;0%$M/]CP_B
M%6=+2\"BJ5+1@,V9;J4!8 * B<IO2A#(:@&9]?Q51DK14'HQ#('==FU40:)I
M< 1KF1=\"M0MDTU:#"FP  4"9V&&BM$<.%W'/G&G&L?EENC^?\S# T;5 )S=
MK=:'A1O*8&^AX0UT4I9"UL1S3:%MVA&K8])0ZO>@,C A4VO-P TI9K5HFJRU
M; JZY_\ /X/$"Y3=M$.:%](+W05WP?EB$+57)H#C>R !F^#S_P @I5L"G&,O
MF*K.,OCYB WJXY5_4(*;I+UTJ8@H1IA,FQX<0:\+RI8P&7%X(2K"ZO2NM44=
MM)*+<P@N8A1GB !C13S(.$72$>K"5+N;A7(AYL94^*, V5+LU8D#,YBW ,M4
MV8RQXY\H& 65>Z+AE1PJ8F1(A TIF6*5N@<.^ M,8819E3+.QH"G-P.':RIN
MZ%-9O;]&N#S$%BL B@52L7+0+9HF".QA1OG,33P%'EA%M'&S[.LR]'T9/7$&
M5\D\[&+"Z'],2B5E'\7VE/P01HM#97Y$&E3*;O7W;%<4V*+1=E@.6K*XYCUF
M;6YH.463KE "F4"Z;P ?2UF;#EC]"N"P7WA@2G=U B^0%HYXE!7![0406@.!
MK4M"V%9FF]R*]("'*%;5# 5T^H\N+<%- 2@)L!$296*&>P))"T QL0;.@]*L
M/="=H ;Z)\JFIZ&7G?NYET\L_ P#SK_1 45MS2'NX@<G'%!WNKO$3U #J0(S
M,JT0^_A$2R*W4J"X9P1H)#(^C3>D*<AY<P9+H$'6@;A0AHFVM# 6\']$04&C
MT17D1$3#*VH@;3[0%Q7I<(+MK;B%MHKAH(B$<&M#)G2[CL?/UH7YAY=<D' 6
MF9*F,0(8=RK-,6QIE@<51YI3 5K"M;$)HM!J[H%"O! &OZK&ORM,*GDDSJMN
MPO"*<D!M-DV-!1> ,LV6%,%/YL,2EI PT%2X*EL4X"C9!_:^YS*+0[/ON)S[
M>?/]?__:  @! @,!/Q#^F]2?<?@BX7W4/E@6^U9O8'_)AFNM%7NJ%?KP#UK'
M\5.UDK^YZPLJ'-G^2?B6)8-#F[[*XM_$K@I3&O8%GO&FJ=/R@7WI^N;:HC'#
M1K!H=4HH9%$A#Y"W?/P)M!KHH5T:!?>%Q#[LH]%."%52=_\ D1U'QL\K4C,]
M??\ D<CGVS#Y1LEV9?!%58WE,MJ^?:'U;[NSY"!&,;2//[9QFXH;IH*67YE_
M7% 2IB]G%XOG.'3B'1 ,44UW7Z<\0O(K[X<D8JBF<Y]G%2V$N1&/5\H/?5=K
MY$V5\EOM_P F&]O0/FJ@)%FJ*7YI^9BHM= ?F_PRL,<E3SR_!&#BP5+H:MHY
MXODE,H&J QP6M'J'E!WC).'!EN#<LHO&)2N0RH0Y!1'5L<> F#<[I*,6179]
M %U!E&HZX>\9NQ-:YG32+"J[T'PQ5FR+1HLWI29LXSUB(F% E<EVHI<"[[$,
MC>LC#D@LAEO%9LK70%VORH]D94AQ^P2(0GC1OG"WTX]Y6>F[L\;.UW=.XE$L
MV0+V8KM4<$_[:[*I@?(O@([&#?5KVB8,T6 RZ L3A&S<)6M"N]=WGUET.T@L
MVJE>F9;E29T6[N7*2D"R_!2%:G$L.+*,;.T_7&(+6XW78D#IG#M!1$&1Q0-<
MY-]X#WX(K&R^@L>S/RJS\5%;4[%_<!@"M%>:GGJ^4:_MNFM]=1"54L1!K,RX
MQ*<):J$-K*G;QK6%PU&:G4G2N6H]_EECDE.I,FR=)Q*=<QB;)\RX>J!#*+!*
M!^!2MPQ#R2G4AV(]B7:9J%,IP3O'$[3X\,>%J^OS+CF<3R\3.X_<APS9X$6H
M)JIKCP=^!LF>8 QGE-OK+\27-'K\R\QGGN<W'>(#X O?6"-.(IPN)ZS+MCX;
MW&-'@;'F:RH]R'AN/$&8N$./K\LJIJ7B&->-3=YSB5_+L>"^)DDUF7E?MAA\
M''>?$:XWX/$6'WRSGPYKF"5/B%X&YT"7L<W_ +#4OQ[^'$QQ&V!U\+67KY?M
M@Y@I\!E1C-'7_OAF8YGG.T]R>47N?N&H[EWOP-P_B/RFR:O+]PWG<;YFT#'A
MYQW#A]\S*3/@:S,&X\DJ?F?N7'?B0BRG3PJ1B=A#?7Q #6( ^7^P!=Q<P<SC
M[Z3B7.9J]97#7,2,(1P$7 GO D[:OP'J"6J//SAB4%C."I9BI>;F87B!WE@!
MK^)P[DWQAJ'?M$G$:N^(-3[Y@)?'6K0[C 9<#@W"P:.2%]2N*CNEAKI!,4XJ
M=6)9XN-%&+G2 @3.8 :/HWQTS^HJ?IX&8[EZ)S!FI6B /I5&=B$_$4]3!4\J
M(O3]_J+:44Y@'%PP48/J("G4>.!!O',YAUA]_B<1>@EAW+>6!=F!*-2@_HI>
M]3+S'RAHO:V,'5<;..+,WXG> &OZ]?O*!B/(S7/]O3CUAKC^Q__:  @! P,!
M/Q#^F#9/-J'V$]_BY4U/H_9J9EK5?Z F4RNL?.42[\?]'ZBD#WSX!C6RL67#
M['/74*%!NSS$H?:&%Z:U[&GZX+@E;8K MK)>PV5EEN4KFC]L4ICJY?G]2]IV
MXP^(E^68Q9?Y/^R[4>M5_LUA#%//_ES!F=C?O -._MUBAR51>"@/F#8:R%<W
MCYEV=T4&"RL[:ZU'^ZD:JW'?^.OI8$P%+=789K-9V:E[<G*YY:'PU5YCU'Z]
MG3*5&ME&CILS"G?Z/EZ-1; ]"*)0'7EYWQ,Y..C7OK]?,MM75Y%?>RUOG=1R
M?#;@)NGJ&,F1IW4](U4O(^0PX(7?9:?&,NCSA):\!1R==17?M<->5C'-8F-L
M!R65IC:YZ57A=1U//EG#$;G_ #Z%A+AO0 +\D=[XC!:]-9_WU)1D+LLPI1RR
MO-*.*E)LK5@%56*YR?JX:? 108&^&3#B_6\>'37X&T>NH&$.J8>[]](/NNW!
MTHV-N_.:TJJ-UCU[=>8&&#R'P,3OR(O@BA0T=L?$+;;?57YB(,%/&'$LBZP!
MZ%P&]G_DP> C"(99+1X'A=R6=U+]9<F0/54.ZO.7.@VA7.+[UOO*4-U6V\_=
M032T5%EE5^0E17FP8EF'DJ&&3W-Y@!PM]]0=SSDP)O5P=W?V3JFQ[Q$JIB!>
M4-4D>U+=,QPU4Q6)F+/.4.Y@UX"UQ"D*Q;I+.)CE+ERV+6'<SZ0K+O/QFCYS
MYB7N)4S+FW, ,PF4JL3O-RI>>T>DJX0=_#RA?,^90YB@UX667Q#A*DT?..O#
MF;0R]Y0F)L>)N7*V3"5N'39&$-9U )BYCJR^L7/:&N\I](L=YEC4TJ#:;O..
MYS.8+ANO&A7B;G.9OS@=9SG< E-ZF7L@?,<,H96:E2JG$[O@;%P5N;REO.&\
MSF,99?27+]I2;XY\/*9E==S4S#7A6?X61=S<"HK7ABS9Y^'/AECP-2LPZ^-7
MK^ D-$Y_EEF/!,>&-8,GO#<S?:$9M,3YFSK,>L\IF,)S-S0_A9X:EUF6<$9X
M!8G=?=BKN5R[_P"0G$"</ 99S+"J6<[BIBCNU[PZK[$?8E^I0Q!K3#\0<2X)
MS+ZY?5,11A70B>Q_)%O.5+Q!S PJ[XAMABEAVF5\+["M')D<&4RX(;('A?Q!
M0-ZG7TEV".$.276'<50DJUQXL15V_1Y]<?N7F($"F*&2H<Q<3)^^T4H=*&J@
MZO,R?F'Y)>]"4&6.02QHBW,6]_4&ID8]81UZPA$:J+37,+;94Q9IF*+=_P!(
C:R0[&H.*F>L8%'%SJU%MQ5W_ %Z<,"53!L7+,']LU_9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2113965d2-pht_flowas4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d2-pht_flowas4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ \ %R P$1  (1 0,1 ?_$ ,\  0 !! ,! 0
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MA'V:]:<D: : : : : : : : : : : : : : : : : : : : : : : : : :
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MC(A/0$GIJO>U-JPO.ZR>Q9].TDA:E/++>1J/R[Q!XI'>3(PRQH6^G?'RO*Y
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MNS3N:GKPBNG4BW_'N2\D6HV_BR.9WE.2SLQFO66F"MO# H,=&MZ@?3U=V!8
M[!Y.Y]O4ZY&IUU_4RK=EAL6Q=B^Y;M:>-M4BOOXD0FD))=V+-\]]R=OYAJA*
MY4L1A0M-F?M]&^!/K\OY]5IW">*H1^U:/78_'UZ_?U^.VJ<[OB21AX$>SN/.
M5QJR1S217*SO[,\,A2:.-X_8MUA(-^Q;5*0^VQW$4Z12[$Q*-9M7W&6.,6J&
M90W9K$W*_+UY+D\@\,:IEY(5Y=PZS_LURFM$S%3;JQ124,K LA:=:&>Q4T%V
MK[I]YZL\;N%9^T?1^2:[^9I>"XZW[7EEUK]LN]8/K3/-:[3^S=K'_'+%?5=Q
MGS79*1\]_*''+'BWS_AN7U8$/#_+M"+A?)XRZ008_D6(&9RW",RSNRQ*;WU^
M0P$@&\UBW?PT* ]FP\;S72^QJ*KT2Q7>\NYY=J.SI+ON6J?N73_KV,D]J'L+
M 'N _=;T[E/56 ^T?MUPY(OK$O> \AW>(XNYCDI)?5IGL4#+.\4=264+[R2(
MB,TT#N._M5D/>6Z]>E[1<ZN\ML2L1@IINL:NE&\]F*V[,:[RO?T,=3<5QOAV
M/K_4QKR7FG(^3R'^+7W:LK%H\?6'TV/CWZC:LG^E<?!I"[CYZXNNYIKM>_\
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MXN(-_C".C H;](&KD/0NQ$$O4^TO6MC T T T T T T T T T T T T T T
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M_DUCR_\ F;YMR;A^#RG-<WSWCW'<1CLW@.<3Y_ >0O)];@6>F\?>6IO*&/\
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M^+/F,_IW_P"L#6'VF*LY'Y?_ !3L0<9R[_UL^8_3_P!8(Z:=X'^[_P"*0/\
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M@2YY%F^D#'?X;_$>NWRZ:S4P5<='?^B3M]@_P'?6CH;)E=%6"?#8?#Y[?/\
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M$05:T82-0=V8_P!*21^A>21NK,?4Z]S9LV]/;5JTJ01P9SE<DYRS9<=2F@T
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M^7N-V_<0K?RG4-G)]OV-I9]Q5ZF-2R9=_=$-*,!I7=78?!1LRQ@G?<%W._\
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MRCQ*C"="BJ.T3M7?YGM^0/Q4;_,#?[?7XZAM2<9.$C>6*JBXZL&@T T T T
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MQ$O_ "2 [RGKVMZC;X;O+Z#Y)N?B-595O7.!?XXY].GR-UY55^IE\
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MJ4PP[XZ<)]-]FD;=VZG8=K0Z*.EA65'?>;^BZOF4M1?=Z5%A!9+ZD^U?*XT
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M:E7] _A_..:\ZY!9UG.+7MZQJCE3A5Q+*XH_M4MV"VQ2327U UXD],- - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MQ&- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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& T T!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2113965d1-tbl_patype4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2113965d1-tbl_patype4clr.jpg
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MLP4!9RO+Z.+Z?.%("D14Q%@\;GG>/W<3U>12"@$4A0YGB]?"]ODF0L5, %(
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MA0,_QO!_1QNO7G )@*0!-01%*QN[=,  20  4GGN[;PH! 4  BD8W=^F$*
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M(LE)6!*!"*K''KK?A]>BZP%(D$4@ 09[G6AZS-1 D@ $@SK&]$WB2!2)!!)
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MKLU[SB1N_;GYRS9F_'IH_;FE7.'<NG!EM.LT7GNY;SKW3)!4>/7C5>>W(L(
M20%A"P4?GN\],$!00LD$@HW+=YZX@E20A2%!"R47EN\]<2 " $!1GW+IH'7G
MY$ ("%E8"RE'Y[O'3(A!*D$))"R35!X]+[UQ#)9(0% !,XY=-'Z\P"R0$*!(
M3-N772.O.0A1!(( 2H\.\?-]E]U@02H $!!!1<ZOFL@%A  !*T'&K]O @D@D
M@D@!92@YU?M9@D$ E802%SO-T.Q0)(4"$$@HF=7O606$$D$A823R,^SJ_P"L
ME$))%3*(0#-L:TK>04$@E8200#-LZTK4A)()4@@D*2FXW>]2W[Q]@%7E^Y91
MI;P>%GT$4(ESO.M%W@#UQF^-^=EOL^UH$BW.>>]&Z<P!\N7XDOS8L-E@T($N
M=8NB](!QI*)G7T:^@<]/J:B59F.-:;J384E-QKTUSCWEAL\K!,9YC>A=,D'R
M9?"/L579?=9]VQ"O9&9YWI&\%)1,:O.I)1Y;G9[K 7*\75-22+/DYM?EMNIR
M4J,U]^SGV 97SUJG3):UE\.7Z-EOH5.7[-GU+"T#GOAGYP<M4C._K7.^:G5?
M&J+'Z0],\O6>XO7"B1+GF=:)O!2%ZT\=],,;W*Y[Y]^:R98,ZQO1M\XH#K5R
MZ9+BTFWTQ^E?HY A<ZYZT7>5#+<7HEQZ^45F7O)Z.6_[P4F88UIVY(A73'AT
MP+%A?9+^H?JX>VP)<]QK0NF2#%>>Z[+U9Y;IV==I._+N!TYP2OFF9XWI'3 '
M0GAUV;4ZWXUG&=?ICWXW;>0,KYZU7<$5U;Y;HV;8-3"N>N7IVUZ8W+>!)E.-
MZMK$6]8..^ON-9_G7:+IC#\:Y4O9KOR[%],%H'/?'+-K/T4D\J\(]*\ZSR/>
M10B,\SK1-Y!!Z)>#+R;.90(7.N>]%Z8(!Z9:_+]=/*N;8 C.L;T7I@)1\N/(
M]M>PY-@&89UIVI* <#-E237*/.P%SWGK0NF 7YTOIDY->F7VUS[!,GF9GC>D
M=, ?/EY)Z#U'+.18!E?/6J=(!Z8XT<BN.0>PYE$&5XWJF\#B9UZ$\EY5G'/$
M\SFV%S_GO+M2][Q(    (*+G5[UD   20$HF.EZWB0 A0  *)C5[WD    #.
M\ZT/69 0H D@ HV-7G>0  )(!)Y&?8U?MY$D!"@ #-\:TC>0 !)  !FN-:5O
M(E(62  2"F\]_-^CY,LC[MGV=3F'T:Q7EK8>N,QY[NN\_7.=9=MYHW+I>>F%
M@*0%(02M&Y;O/7G"@3$4  !1>6[UUY@ I2$E8$9_SWH'3"I$L7(*)A124?EN
M\=,Q9,114BB H\B@<NE^Z8BR8BB2H@ &<<MZ/UP!) )()E(L+FW+>D=<2L,E
M(69503(*AP[<'4Z9\>EZUG+>>JEG7T:^JS\U?NV4G-LMGW]/T,]OEI'+I>>O
M,J59ZY<8YZVSIB%(H4CEN\=,0*0*3G7I+YJ$ +1<:O/3G,L62J,%Y=-Z[82
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MH^=4W-[S^K@0!*(JC<MWKI@%$I"D4A8*/RZ7CK@ !  *0M&YZO/7F(!,I2%
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M %X<<RP 2N58NJ;R 4A2  9_SZ>BM'WS_.WAVT>S6?V/\WO_ ,K]-<_D_=*
M0>,N>YUHF\ #-<ZZ\\]=RNN/=8 ,YY]-&Z<P 7JSSU;JWC>  ,ZY[T7I@ O
MCH]RZ=TNO/[U@ S#&M-W/) !A^-Y]B]L.N)L +GO/>A=.8 2](>73LYO&A;R
M68BO9)F>-Z1TP ,RQKK_ )UW)ZX]B %RO%U3>0 .KG/=L-WZ8 $F58UJF\@%
M(  !0.?3CU]:YZ;<]]F]9?L?YK;OC_JKC\K[H  B7/,ZT3> !\^6O1<=0 #.
M>?31NG, %H.;?K%@ 2YUC6B],  M!S;]K( &8XUINY* "CYMOKDV  9[SWH7
M3  +G^;H&H0!+[$S/&](Z8 'S)?A%PL  RSGK4^F0 ,_SK0-0@ DRK&M4WD
M   #/^?3C&C;P   )DBT1&>9UHF\@!"@ !G//>C=,     (SG&]&Z8     S
M'-TW4D  D@  SW&]"W@    3'D9IG6D;R    !E?.ZIT@    $F58UJF\B98
ML   % Y[Z_\ O\URZ\I6 @)*B ""F\]W/>)J H()6(7):9RW=.N8)A4! )6
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M0J#T]0&=/4 =.T =.T =/4 =/4 =/4 =/4 =/4 =/4 =/4 =/4 ;#1.H>GJ
M.GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ .GJ "MZ@-MJ@T2+0.GJ .GJ
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M:[Y7;7I\*APUJ#"X-M>G^'5OWN)1_P!SAW5Z>XG_ *3AESM?TYPZY^_Q+?\
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M# P,# P,# P,!<F!@8&!@8&!@8&!F# P,# S!@8&!@8& @P,#,&!@8&!@8&
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M;';';';';';';';';';';';';';';';';';';'^@_P!!VQVQ_H/]!VQ_H/\
M0=L?Z#MC_0=L?Z#_ $';';';'^@_T';';';';';'^@_T';'^@[8[8[8[8[8[
M8[8_T';';'^@[8[8[8[8_P!!VQVQVQVQVQVQVQVQVQVQVQVQVQ_H.V.V.V.V
M/]!_H/\ 0?Z#MC_0=L?Z#_0=L=L?Z#_0=L?Z#MC_ $'^@_T'^@[8[8[8_]H
M" $#  $% HL2)JZD0:D4:D0:D0:D0:L0:D0:D0:D0:D0:D0:D01U+3'U(@U(
M@U(@U(@U(@U(@U(@U(@U(@U(@U(@A*4J'J1!J1!J1!J1!J1!J1!J1!J1!J1!
MJ1!J1!J1!&4I*=2(-2(-2*-2(-2(-2(-2(-2(-2(-2(-2()4U+F-2(-2(-2(
M-2(-2(-2(-2(-2(-2(-2(-2(-2('E>'U(@U(@U(@U(@U(@U(@U(@U(@U(@U(
M@U(@7%BDB:4I$SJ1!J1!J1!J1!J1!J1!J1!J1!J1!J1!J1! 4I2-2(-2(-2(
M-2(-2(-2(-2(-2(-2(-2(-2(-2()A2DC4B#4B#4B#4B#4BC4B#4B#4B#4B#4
MB#4B"FJ4NH1?S1*=.PH>C%T8<&+&(X:THX$S^QA"A1(RXDI-0HL21G(:SD)M
M,6- BP%0)29F09&D\('XL8$I,30BPHL!?@IDX*I291!0A<5<>6CRQXQ_QX0)
M68F31*3*XW@YO6A2DS'5"DIN,9_0SDIHH.$E^UB1&9QI*:EBBR4W!AKEX\(1
M)*;@G'EH\L>)_JXP):/,FF3FE1HDO'A12D9M4:')3491D:3PB=R=_;P0A45<
M>2FI8H,"-,*@2DS,B%)3<80Y.:BPL9;\>3P,V4%<-<(XLO'@!$"/$1DF<L62
MFX,*)#7"7 E9B9"DJ0K&E^91OS5";EX,TR5T*3,*E4*1**$TJ%!1-JEUJGSA
MM4U[),_L84M:$JEUPY-*929AFO4@S$.%)HF(4-6X31I5,X0/Q8R*Y=,C452_
MBB*'&DXJX;DY#A*34G4RV,?N82R/$4^+$AS"8*HDO44)\1 .)"FHT,Y>+".#
M'@2&$E^UC3XL.!/)24C!G(2R6J8)Q*X4I%FD>'D,3_5QE2*8IZXD**250I2-
M/$B9B15PYR)/+1%G<(G<G?V\*:9%4)J)+'*4N,E%3E4Z\JF)"F(T&)#B1,9?
M\>2<0<6/49>,LYTSF($@LX<+),Y(*DHCSL)9*J<NI,](RZ9A4T<54SC2_,HW
MYN),_L<.#^+B1^YPY+]KB'^MPXG<G?V^'+?CXDSQ*7YE%H54.+L-5&PU4;#5
M1L-5&PU4;#51L-5&PU4;#51L-5&PU4;#51%HE4B1=AJHV&JC8:J-AJHV&JC8
M:J-AJHV&JC8:J-AJHV"JB'1:HA&PU4;#51L-5&PU4;#51L-5&PU4;#51L-5&
MPU4;#51L-5$2BU1:=AJHV&JC8:J-AJHV&JC8:J-AJHV&JC8:J-AJHV&JB!1:
MI"C;#51L-5&PU4;#51L-5&PU8;#51L-5&PU4;#51L-5&PU4;)5-+8:J-AJHV
M&JC8:J-AJHV&JC8:J-AJHV&JC8*J-@JH50*JI,>BU2+&V&JC8:J-AJHV&JC8
M:J-AJHV&JC8:J-AJHV&JC8:J(5%JD-.PU4;#51L-5&PU4;#51L-5&PU4;#51
ML-5&PU4;#51L-5$6BU2(-AJHV&JC8:J-AJHV&JC8:J-AJHV&JC8:J-AJHV&J
MBGT6I09W_P" B# 7#9E9PF<-F1G 9_WRP(?<\#X!X%B?/*64N!]@?\?[9"!_
M\TLQ\ \?N#S%@6!@@><N6!<,\2X'VR$#_P":68^*?/*68\Y<=@9P?MD('_S2
MS'Q3YY2S'G+E_((,# P,!$#_ .TT-#0T-#> T-#0T-X;?_BLU!X@^0?(/D'R
M#Y!\/!\@^'R#Y!X/$'R#Y!\@^'P^'P^'R#Y!X/A\@^'R#Y!\/D'P^0?(/$'B
M#P?(/D'P^'P^0?(/A\/A\@\'P\'R#Y!\@^'P^'P^0?(/AX/D'R#Y!\/A\@^'
MP^'P^'P\'R#Y!\@^'P^0?#X?(/A\@\'B#X>#X?#X?#X?(/D'R#Y!X/D'R#Q!
M\@^'P^'R#Y!\@^"5]3YL#,&!A\ ^?#+^27/B?;B'S_XB>:N;0T$&A[@'S_XA
M<^)]N(?/^ S^(GF?,,# P?3%@/(?/AERRD#XA9BYY"Y&#S?;(8(%F5SQ(&/M
M]CX7W^^4\A Q]&%RR)YGS^H^H^HYX?4-#<I\^&7+B'Q"Y\3[<0^?\@^(GF?,
M-P;P3Y\,OY)<^)]N(?/^0?$3S4OM/A\/A\/A\/A\/A\/A\&OZOA\/A\/A\/A
M\/A\/@EA\/A\/A\/A\/A\/A\/@UA\/A\/A\/A\/A\/A\$OZOA\/A\/A\/A\/
MA\/A\/\ T?#X?#X?#X?#X?#X?#X4OZOA\/A\/A\/A\/A\/@EA\/A\/A\/A\/
MA\/A\/@UA\/A\/A\/A\/A\/A\(7VE]_B*[W#+BGQ$\^)_7B*[W#+EQ%<1'?7
MW_H^PF,(B[JW0DB;F5WL2#2:H@KZ%D+*6#""^]D/(CF0Y!T@KGBGGDYE]^\$
M\LG]<4DT*^@/Z R(*Y9%=[)S-B0KED+ED(,($1-/GD/)_4<PQ(/EBCOK[[Q@
ME,!J,QS#3#RLZN>+6!H:8>/*65IAIAXPTSRGDY!IAIAIAIY$\\K3#3#QY?ZY
M&F&F&F'CRJ[V1IAH>/*65ID&F&F&Y3RM,-/!X\B.\LC>8888888888888888
M88888888,C:PPPPPPPPPPPPPPPPPPPPPP1&&&&&&&&&&&&&&&&&&&&&&&&&#
M(PPPPPPPPPPPPPPPPPPPPPPP1&UAAAAAAAAAAAAAAAAAAAAAAAAANL,,,,,,
M,,,,,,,,,,,,,,,,,*(WF&&&&&&&&&&&&&&&&&&&&&"(PPPPPPPPPPPPPPPP
MPPPPPPPPP9&&&&&&&&&&&&&&&&&&&&&&&$$;Q\VAH:&XM#0TPTPW ^;<&X?4
M-P:&XER;@T-R-RF&AN+<6Y"YY6AH;E^V9IX-Q:8/FW!IX-Q;BW#ZAH:&Y&X-
M#<K<&X-#<&AH3S/GD8&9SYY&9R_A,# S*7/*S/\ ;*S.?/%@9Q&< \K S,GF
M?/!H(-!_7.?/)]P>4LI8G_!+GD+@?;$L.><^ ?!(?8'PVAH/(GFKGQ#Y\,OY
M)<^)]N(?/_B)YJ437R#Z0^D/I#Z0^D/I#Z0^D/I#Z0^D&HFOI#Z0^D/I#Z0^
MD/I#Z0^D/I#Z02R#Z0^D/I#Z0^D/I#Z0^D/I#Z0^0?2'R#Z0^D/I#Z0^D/I#
MZ0^D/I#Y!]()1-?2'TA](?2'TA](?2'TA](?2'TA](>)CZ0^D/I#Z0^D/I#Z
M0^0?2'TA](?2#437TA](?2'TA](?2'TA](?2'TA]()1!](?2'TA](?2'TA](
M?2'TA](?2'T@U$'TA](?2'TA](?2'TA](?2'TA](2HFK[W$5SX9<4^(GGQ/Z
M\17>X9<4^(COK[[G:=:'"#O:^AASZJ#O9R*YXD1,(@Z&?7(61+ 1$&?5T,!\
M\3Y8_1AL!)# SZ8IYXD&$&?5T,!Y/ZXL^C"!$T.AA95=[ F!A!A B:'0PLA<
ML?H881@V,=# 99#R$P,($& \B.^OOO=HE!2@]]7P^&M#QLR*YXM8&AX/92R%
M] 1LP:'@>0\C6@U-#0T-R)YXD; T-^K0\&Y/ZXM#0T/![*KO8$?T:'L&A[(6
M1H>#0\&A[(>1H>!!X-R([R^]Q%<^&7%/B)Y\3^O$5WN&7%/B([Q\^"W$\K0T
M-#<[<S0W!N9N<N+]@W,W*?/^&W@-X)<U<^(?/(P,S%Q3RLSESR,X'VXA\_X#
M. >1F1F1/,^9E]<"Y8?<\I\\OW/*7+)]L#X)9#R%SR%P/MB0/@'SR%B? ($/
MO@>0\2S'BGF?-O$/GPRY96_PRY\3[<0^?\@^(GFHR:TA] T@T@T@T@T@T@T@
MT@T@T@9DUI!I!I!I!I!I!I!I!I!I!I C(-(-(-(-(-(-(-(-(-(-(-(-(&9!
MI#Z!I!I!I!I!I!I!I!I!I C)K2#2#2#2'T#2#2'T#2#2#2#2#28T@T@T@T@T
M@T@T@T@T@T@T@T@9DUI!I!I!I!I!I!I!I!I#Z!I!I!I!I!I!I!I!I!I!I!I!
MI!I!I S(-(-(-(-(-(-(-(-(?0-(-(),FK[SIL=-C#####!I,@PPZ888888>
M"N?#+BGQ$\^)_7B*[W#+BGQ$=]??-1,(R82B:\37B!*(/$8>(/$'@TG0KGE9
MF+.9,S'RRD69//,9,S?URL;G5WLK&9BY92SGF9],J.^OO.F0=,$GZF7T4EW@
M*YY3,F92S$#^IY3Y9?HS*GGF/-_7*6=7>R_;*6<^>4\WVRH[Z^^9D1ODU)L4
M]]34TLZN?#+BGQ$\^)_7B*[W#+BJXB.^I)/.D'"#A!T@X0<(.)#A!P@X0<(.
M$#2372#I!T@X0<(.D'"#I!T@Z0<($@@Z0<(.D'"#A!P@X0<(.D'2#A!T@:2#
MA!P@X0<2'"#A!P@X0=(.D'2!))KA!P@Z0<(.$'"#B0X0=(.$'"#B0Z3'"#I!
MT@X0<2'"#A!T@X0<(.$'2!I)KA!P@X0<(.$'2#A!P@XD.$'2#I!P@X0<(.$'
M"#A!Q(<2'"#I!P@X0-)!P@X0<(.$'"#A!T@X0=(.$'2"4D\KG@SA'SX9?R2Y
M\3[<0^?_ !$\U<Q]@=7G84U3X\Q,PLY\\O+,7+*SBL9F+GE8T'],WVRLSGSR
M\N(P'_"3S5S#<(E-J,U%I\.9@P<Y\^&7+^07%^W$/_BIYJY\0^?#+^27/B?;
MB'S_ )!\1/-9F\\H/*#QAY0>4'E!Y0>4'E!Y0>4'E S-KR@\H/*#R@\H/*#R
M@\H/*#R@\H$HP\H/*#QAY0>4'E!Y0>,/*#R@\H/&#,P\H/*#R@\H/*#R@\H/
M*#R@\8>,$9M>4'E!Y0>,/*#R@\H/*#R@\H/*#R@TV/*#R@\H/*#R@\H/*#R@
M\H/*#R@TP:C:\H/*#R@\8>4'C#R@\H/*#R@\H$HP\H/*#R@\H/*#R@\H/*#R
M@\H/*#R@:C#R@\8>4'E!Y0>4'C#R@\H/*#R@@S>7WB^H[)#LB;GI*24N?DH9
MYU<\K&YBXI\LQY4\\S,W]<W+,KO96-S%G9F/,69'?7WDFPV&06+@CR\.')+@
M2TQG5WLA<U,S%F)T&;<QYC,BS)YY4L!FW-_7*U)%F5WLA,:H\Q9DNL,\QYC-
M)%E1WU]['Z'P5<^&7%/B)Y\3^O$5WN&7+B'Q$=Y2.TX' X' X' X' X' X'
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M87YM7\X_5+F]JG/*9T*E,QD*'>F$L4)I;93F5OD*&Q4^Z849*AFA"VPF]?\
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MF3)DR9,F3)DR9&R],F3)DR9,F3)DR*&Q1467@5S4P9@/ (F22: U: :0;<^
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M.11(AE>&!$SIB8ABD*-FXP]Z20^4:7_XROZX^ZRWUY;Y?=)_T4GZUC/=</\
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MORITHF.\H0Q?&"RL/&4&U0D"S%;ZPJ0,]_3?)6(X\!L46>L%BA_LN<VFH/\
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MC_NTN[-?5?[Y*#X [LA\+#["'<8N_P#Z=T@L/Z)5"W_^Y;4:S3,!@-?=GNF
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M&("871.4K4Q0-96K\/Z<_P"AUJ_#^G/^AUJ_#^GO^AUS##^GO^AUJ_#^GO\
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M\D5#-W+$@4MMX51QVSN&")ZJE\W>92PH$:=9,131>F(Y!N:6%#YAL@;^2RL
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MT]_I<;[I,?5?\1.@]T4^[B'K-Q[H'PU ^CDOUC>Z8/\ O IZGDO=<6?>U_\
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MX/:DA[(K5T'M20]D4X3<,8A-$YVH*'1D7JBI2\L0M$B:D8D0QOA,%1'U!O\
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M0"-UEDE :N%5"@90;,W;W[*A6JC1Y"/QQ:KAV586L'R8G)#.Y,@<JX0"U62
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M6/\ )_\ )LJTBW$RUY5"-\1&D$%%2KE427;INUF &S8F"T>]6$X_!+S$6!<
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M3BX2?9XD1F7F-3S4,M#MV<[AO.*2DDM(.3DL?MDDGQN3CRG(J"I1)WJPBOC
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MXM:EC-#1XM:EC-#1XM:EC-#2XM:EC-#2XM:EC-$2XM8;*2)CR%5F#D4 K5(
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M17214%9)-00X1$UA(F*I2CW[ MW.'/2ZGJB3W;F+BD>5HQAA3F9/.6,FKFZ
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M0P9]#<(HARY ,]P;10W_ )U$223(DFF0J:::90(1-,@72)D*6PI4R%"P #(
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M&Z1+&&QY:,+$+%H7/;.,^84Z50  RK#M#%"Z5[_69ECW;QZ&?S*SG+L*7#-
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MJYB)D!6VK)"1KKSQG\##5*&8TW3-4N#89R1)3OK77D_M=&1I,+T-<$G$YM!
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MFNKC2%LA+LE8F"J'>98*NJS")W=,LQ@"7@.P#*0A7;;,KH8D0+YB8#L0E>4
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M4E=3\'K0S,,$&<8?02X$E?:@->&C9O2W@! <@X3,7U@4U%65+WOTJ.QQHS^
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MXQE1EDC,"^%:512,)FK)1JI$:Z5-6!AQK+V?I:A2^9@$X(!:)%-@13&=8$
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MZ"@(H& HINQF)0X%:LB!%(X- -/ON) QE6R?-= 3 ,$JMBVU)'>E6*)9%/X
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M94J5*B9=O#JI4J5*E2I4J5*\*-2O"I3*E2O"I4J;YSE4J5*E2I4J5*E>#0]
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M&PFF=MX8'BK.Z+A;KY[NL-RQ ("I$:"8L P*@8@-!8.NBM*WRV1L XC<[,&
M@94$OXY1NGWMMUSEK\Y%NT^UD8T-,==<YJ.^G!:$"O?Q@-T7*-'8]J_9LXR^
M8U%J)+! 9@B!::-6H!.6QC,//JW<4)9Q&FA[+87=!69&3.9?"7><Z& IP?P]
M"F%56S,5D%Q8EB]FKFX'V9,Q'#?9^&M7(B?JHDV9)9P=C?V=DY>B#%:_%750
M9<H""7<J,=K+B*J]<HP *D-8T10'V>]&%!6-2_2DVB,_#+.#L>WD",M4J/\
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M8Z "Q:-DKQ\5*ASG\9.6[7(+.]Y!'J-7N3B$2**(4"6ABF4NDQ4+-"48UL&
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MTK$D-UID%@CH2O<DUPCI.CI%=YJ<?LD*B=)L4-2N5(@:X*XC^&B$M\YC ZM
MMRF="%'J*WSDT7!R-U]+ZGYH0)N9GLC/FAL-OB[MP\()OBZ;-JPV$S0[&PAX
M38LB!(#G#*IK8LD:47DH0?SJBBZ5#EAYI?>0^WFK].EZ7E*%/W9L= 4#J_@!
M,0)1@@@M:H7MEE],DO/A%A9@$P:V?/+( HNBJRMW@>?_ -!,% 7#Q891*H+(
M!T-CVK][.%@2"</;4;'0XFG$+-(S%.[O@ B@B54']W%8#.0M+2R8$I10] 1Y
MZQ\6FBJI?3&S]\O%1L;U%B89N3%U$Q:<0R"E"V(BSX@LDH%7N'!*C*, \_\
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MH8EOP(-;6,&FA2\@S?2#C.G0*9KM4M4(::2$)A4;7D0+QBE0(-+ B"6,!CW
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M -G?V=IH;;ABB)-.(X2(C.]:PC<,+MT#:]OX1AY[-G.7L7'1SP8]YX^/'/\
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MY3%TT&E/0&7)HO;J=RNA+#;1J4NF3;]Q>PS8K%P:K3@<T;57H% 9:U8MU.!
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M+9F9E_\ ::QU_P#A,^''_P LU@C6W !25\"GB"1K9@*2DI*2GB 64\"GB%/
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M4A=L/:>),!BE?N&@P82RC&9W<+G&ZE7"!V&\[[!T)W88.)-8!%PTA5IYGO"
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MQAP)3 VO[VCC=(M_C@O&V&T6TBX&FT_S\FC-7O"KS->8)+B:ID%776/P. *
M19IS5,J4BS4*N=FW\TM[6IM6[;PVE77:U;0IM_UM6U7#;U[2WM&FU:;;_/R:
M,U?'.S4S_P %H?RO#PK_ )S^OP5L4_E@?R_QX5^+1E.%UG49U&=5G49UF=9.
MHG49U&=1G49UF7^6=1G49U&=1G49U&=9G49U&=1G491<\)U&=1G59U&=1.HS
MJ,ZK.HSJ,ZC.JRF9=)U&=1G49UF=1G49U&=1G69U6=5CS:SJ,ZS.HSJLZC.H
MSJ,ZC.HSJ)UF=9FOMUG49UF=1G49U&=1G49U&=9G69U&//9=Y9UF=1G43JLZ
MC.JG49U&=1G49U&47+I.HG49U$ZC.LSJ,ZS.LSJ,ZC.HSJ,XDQUF=5G69U&=
M9G49U6=1G49UF=1BR5UGOH% :R\%7YS5C)+(G:*S)=N)H&5A?J6%L58."PM%
MT_!J[19C3:T]FS7A5%NU[#9U@+@E+QLZ.V86TVO[VTT.NUK=YKLB[([.GLV\
M"_!>QIA>R%:-8^+X>\GOID'2#IU6JZ@WF7N,OH!NBQ:8$35G6> 7"FJHR3\#
M4[[-2!=&>^UH[/[M8^<]XBMUVM'9M%<_LZ;6CM9ZX^,O8T:?D"@[N>WJ=]EB
M .FV2:.S9)V4^O2(MM=K3M&\ Z;7O)[[POEX)J!,.L=O5_)HW-=BI7CP\7PT
M=GY%C^#AL_U^74V'\'M-DVV:=S7\GOHRFS6=Q[SO/>=Y[R_,]Y?F>\OS/>7Y
MGO+\SWE^9[R_,]Y?F2_,]XRFR=Y[SO);F>\MS/>7YGO+<SWEN9+\R7YGO+\R
M=Y[Q*<FDOS/>=Y[R_,]Y?F>\OS/>7YGO+\R7YGO.\E^9[R_,]Y?F>\2C)I.\
M]Y?F>\OS/>7YGO.\E^9[R_,]YWGO+\R7YGO+\SWC%K)?F>\OS/>=Y[SO/>7Y
MGO+\SWG>2W,]YWGO+\SWG>>\OS/>6QLUE^9[R_,]Y?F>\OS/>7YGO+\SWEN9
M[SO/>=Y[R_,]Y?F>\OS(RVR6YGO.XE^9[R_,]Y?F>\OS/>7YGO+\SWE^9[R_
M,]Y?F>\2G)I+\SWE^9.\]Y?F>\OS/>7YDOS)?F>\OS/>6YGO+\SWEN9[QL9-
M)?F2_,]Y?F>\OS/>7YGO+\SWE^9.\]Y;F>\OS/>7YGO%&LUFOW\+U=2T2O\
MEM38OPO;X.VSC_D/Z_Z8T_+_ !^#&QHS5[S5<SJI>_)B0- Y-:,73@QU65B@
M&KXV0139RS'?7\D%RJ+=K0[5,<8VGAM'-%OM^,!=(GGVOZVA+%-#3\<%P*SM
M&T)C1@VG^;1Q.D6]G1[S4[^ C0S*&X/]12XZ$1>BW)42Q$ZS6K_L!(HF:SKM
MZVR--RS:T.T*&V\/R#0VD(MZ_D<#\D--Q:MHVBA6WP=MI':T>\U>_P#TQH_E
MX/\ I/[VJ_!9_&?E?Y^31F7.OB^2>2>7P^6>6=IL9YO#Y9Y/#Y=E?+/+#'&F
MR'EGEGE\'DGDGEGECS3R^'RSRSRSM)?*3R3R>'RPY)Y=A>6>2>78WD\/L\/D
MGEGD\/EGEGEGEGEGE\+SZ[&\OA\G@\L\D\G@\D\L\L\G@\G@\D\GA\L\D\LZ
MJ\'DGEGD\/DGDGDGEGDGEAGS3__:  P# 0 "$0,1   0!))Z:)%)( 1)/1))
M1#0/^Q)L:D);1)(+)A).*1P )*A!)3AH)06)1)!0"[(S]")+)HOZI.9,Z!!0
MD!BO>!D)$GM!!)(WQ1#),20 !R$,1;!>*$.T!.37.L0!7)VS1841$.\"(*/&
M]"1@)PWY(L1,>FQ1I"KAL)K!<]+)6)1X@(-^T8!#!/)6*C-M1"GFQ0:7LVU)
ME(4DD*^),IU7;)*GW! ?!?>I)3)(3T*.A;94O?[W;3>XEN7:1,EL3:;42??;
ML22';+95=0?+23#(\:S;3?*<3B7'U@     $ @@4  @$   $P D   I
M! D  @ H   @ H D @   @  $&H     ! 6M$@ @"/@Z$(#,D3 E$.(B(% :
M(#0%HC  %   A)M ' %@ <&H     ! #;)@ @31LC @&AM) E$F?8 % >0%H
M$(   > H B(1 " D@@D"QD X  ! (#-  @@J@:!@'S\F E%4E" % VH$@$H0
M  K ( #'? $ !E  "3P'<  ! P,>H @6M_[!0&-2[ M 7JOX% RQ/@%@4@ 1
M H @=; % %L@ &4@@@  ! #G^( @GHD9 0"61. U ?B8P% ;2P8$( I6- (
M,B! $  ,@@&H     ! \]Q( @BV$1$@!#,M U$,(  % @G@(%HGC9H @ +;\
M   $$, &P     $ #U4  @ $* $@ BA  D "8Y % $T" %H !R@ H A@0 $
M$G@ "@%D0L@@(@%DEEDD,/-Y;AB(D,D@@ D4DH@LO$DTE-B,DT+E (DT@9$(
M@*?M>8F@6"0EFPUT@ @@AN@DV@@ZD&PTFRD$&AD#FF $@DD!$@@ PD@D&D%8
M!_ID)"))0))!Y)))))Q)-P))X)-RR)")($T)/A)ICY(]IE\\)%)S;>)(?2'L
MJ! ))WQ)/Y),))((),1))>)/<A) ),]0\)9)KHI)GAD#L)F)))N!(,-I\])2
M))B!),I).!)(X$LT))8)*RL)'))22!+9)R"1)IA&2 )H) R2)-\U,MR2DR22
M2N5"R02B1:V2222O27>R6W222V3TY;R:22ZR632206B[S69XM:/[ >$MMTV%
MXD_1)SD\DDD*1#LD$A#\-@J0 \"(]\]%,(\.0ECDBE,D7$#NY- %,"(KN@@U
M0 $U ?AL%]F%VY()D)C/I&0D_P#N+"1'.)P* 8_P;*8)+8<0)90DD:S!#=J0
M"7B;L%"*1#*?RJ21@B:(#(5,K* *5R6 *_(49[(=83+=1902$9S(#.L&"=<D
M'=2(-X=54#9 (,!]((98AY".J8ZS*#QQ*/(Y:4PG"_4'V*ZIT*\'VFE0]0RT
ME/V@7JE/J4DU8HJMTE$@3-T 7UK H0$EI9L,E=MLL-EMLLLM,EELSE5ELDFL
MIMDLEMLDL,E(EEILDE]DDLMG=L,-EH6,B""20B3\>"2>28B22*1$QR2:"3(
M29"2C$"282=0J2<"0S429"37!23<PIY>24B3:)"2:2=("3X9ZA427"3-)B92
M3!W\ \2;78"822C 2823Q*02*W!*:22B2;,""(23*22F20!Z2:"3J$2922%=
M"(\28(<288"2$2822< "2/U;*V),0!9'IEG/81D!+]_E;1]M_P!P1 B1#3!\
MM[S6*.<:_)B3?E:2_"#1)L=B#KGCG\9#A\$;KK6'S(!G][]&N_<OG?;>6,8S
M@=5]0G_[ODXB@C_#!I36WD/?0X1%RCJ6-L]M/JG54:;:[B[8G<U1!XI<)0NW
M\@#@#9HK(A5CK:I(]M-/4<F)?HWQ Q7'/F9;T#]?>D1__P!:.7K;''(#8JFY
M(*X%."&1OS7=0%7*,\EK=3AJL.!N=_A7))W;]E.F?QDI 5!K\-2T#=EK.6IM
MWQ,@1%)NPK?"2&];)JT_M6+[YY_QIY?Z_::VY2'[<87YY'*+ YH'_3,!Z[=A
M'?C>(/Q;AF/)6)/28GDI)H;!*<$N 9Q>(*(SM;E,^UOOAA2VQ(F9Z#RIK(LJ
MT! ?!9\_!3(H1>JP9)3B (.L(UA!X&&U-)WAH&P?6Q)*.9-Z0)'J-,<2V'!E
MQ?OQ;@Q )$ %%A)48)+!NO81)H)+S*)G-@]P$?9)O%Q-<D+UM!H)SQ)IDW\Z
MVUZLQ;_V.L]]JSVA9V5-?;D4>UPT3[4$Y6 T0OR;O$], 4S6L?C:A#[049@W
M/TDLEK!<L<%MJ[;\D9O+A1\C(O0=G!,GRCE)E%-A,HB9-HN=0C>(WB?+>O(T
MU>\ ?#>N3^D4'X7V\X\(HP/7_P" 3!C_ ,*?;PB_.#E\8"TM:N2]J(Q_S$3W
MV:8Z?_;9;*'4PSG-M#\PC!E?CDH:6FWA@8P3AZA.>K.[D8 4UN4$E\__ &>\
MT,@$#?V^0%GWVSIZQP.Q@^_." O3YFQ__-$SF_P,?4 VWTK";3Q3.9;93%CA
M3243'#[07"-V!X S81 4RG2S<23R:S2*S43272R6K#8AO1-,)2-).A))Y))(
M))!)AG))H),-!)$)),<)+9))')(A))$))!)(())/AD ,@)S))C1)-I)%!))!
M)%%))\))GQ)"))P="'Q)/,)(!))+)))),)))(!"')))3))3)).I)BQ)*A)(A
M))8))N))M))@!I_1).I))9I)0))+)--))-41LD/D?DDTDDGD,DFDGQLDFPDH
MDDALDHDDDED^LDLTTF\DDDFT(Q4D$E#$$J99%"Y,E0QN$0AX$MMB&&KP\,&5
M1J?L,*G?FA"%J)=FQ#:,J)-4#M@J!BZ/AEQ081P)DM!(,$C0.H\@H0IA.I@E
M,</4C/AK7K @@(7(%!1)(F%YE$5L[DUML=2/%KI!OI-!LEK\Q(A! !I))($X
M,,E% ZL,L5@KKAAK@<GT#)<07W"TM!)< $'D %/*! @F' H8M%H$$D$AM)$'
M?@L)A-$$S".L0 @%XJ)DV93Z?2!TF_[O/Z[K?39VBS64VP];@8<S.7"_;L&K
M?_Y%JN[Z'IYK1;U.!55VVM28^$TH@:UETH'X@ 0 P-JH#>VGL2@5BS8$\>E%
M>DV"&PBQ @P6UM^/M-)#)).I(OA)%0)*))*$!)L))!9) )) 0.+Y)+.))D))
M=))!)IPI)(ALCO!)"))P)(!A)+!).Q)(())\))#A)")) )I)9).Y))D)),))
M@)N0!)(RRF/RV1V>VVV16VR26R/V6RTV>V2;667VV7V23?26VRVSFBVVT>RR
MW4T18_SF:*D?IZ71+V_9[7_W?YVV);YZ[)7C/;0_Y>97Z/Y'SSY'9>^_?_\
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M2- IXN/%[+-U>[^_$JX)*+!M>@!E(*5-!2Q^K!?0MB-TD&=>@LA>Y M BO
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M"P4J3FD$ %X&\Y318;@,1!@SOY6%+P@PQU2M3& D>*U8S3V;%@6.ZLTBKEG
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MEY7[/\1.XV-<:2X+G'398FM3?:&>E'ZIB>Y1LIT:]=80,C7VHGV<;[:(FB0
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M>H"TQE/4'PX=#PJ*&O[/3-<(9DW<)BFJ,4D'$+=L@+@08(U#!PAX&#PUO/\
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MZ4F L"% H2KER$6@ #2&LX[8&NKW=C[._!IL:9F6#=Q2$K"6MH8QYV-"AB@
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MY!T!^G8U'?:2[4BW7+SB:&FGJ:1=51MX#3H-2]CW#]I?C<KJ6G5'.N1&GEI
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MM8)ZAP+?EB9=K^I7B^-[&GA[)MNSO'5+_#7AIG;0KPO8TW3^FS5S2&R3]/\
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M'BD4$Y>(5PPGK-32[ M#3%464Z056PM7&R>]7$!FXOS>^-#UES8IF#12^O\
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M$^LGU!/JI]43ZG_8_P"9_L%:-K6-6O\ )];/J"?73ZB?4?[/KI]=/K#YG+]
MG&]@GUDNQ[)'.:ZL=)]9/K9]7_L^LE>OH$^DGUA/K"5_!/K"?6$*P2N)"O\
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MJ>&><KPKPP<(-[#,U]91L]9<OPKP'I>#F5L,X2B4E> ^U^_!+@5*ACP94X5
MB%N5-+?AXN94,1ASX;/#\Y3XT7<KP=8YE2O$Y[OZ)1XF)6;ERR_"I4J8]F>Q
M?J"T-*3$5JTY2@L-'[(1!I'=.J\$F JL25NX>?I:0#:6,P-6Y9-7K77KM.DT
M^VR1X$7UAWXP45L^\=I)MJBX%T#@0TV'2>5O^;*@6T$NHJ[F_IKF5LYXMGV6
MUB4%Q,6CWW^8%%&FS_']NT<HVCI..=DS1V0%E$=V8-7^;_N!2N7X^NK3!![:
M=.??:U=_]&RH"K@E^>WI%(N]GR$>U?J"Q## Z'[O\E(&*3V2651>ZF5<"-F"
MX+7I1P%=(5;P 4<AJW++%ZUUZS39=)I]MDFT$AFC5X[7O']0TV2#P>\K9=)J
M[OYL@*8Z3+M>RAILDYPG&&[1Q[]7:[UMK#?ALFRT8(C7;K][(U</>&UK[OZ-
M@B#KI'EXOZVL.TS&WD_4LERR62R(EDLERR4BE3$WRE)9+)9+)9+)9+)9%)[A
MEDLEDLEDLEDN7+ED4J/U99*2Y9+)9+)9+EDLB/*EDLEDN7X6$LE)9+(I4L=[
MC+)9+)97262DLEDN62R6,93M_(IQEDLEDI+)9+)9+)9$>?*2DN62R62R6$I+
M)<N.K]7Z)9+)27+)<LEDLERR>Z3 SQ*TTX;- ^%,N[85=>$P&55T\:[XKGVU
M57?#BRRQI.G]-D*3FAZO!=WB+<Q,KG?'38(KFV51W17/X+*@]+R\*N:.[Q1U
M[2JN]ATTE<T:8[H[MI5'?X+KOVG-.RH=?BIY_!'7[/&N^*YO!.9E?#3QKN\!
MW17-X+NV4%A>9GOCQ#O]D[O9X7='=X@?"LS+#.FD_]H " $# P$_$!0@ $ $
M 7@"B;J?V<[=.LW4_LW4_LW4_L!NWO-UO[.9NG6;I?V69W3O-U/["Z\-[F81
M;H$ J O 3=3^S=3^S=3^S/>Z=X[Y?N9KW3O'3W3O,.Z>LW4_L='=.\W0_L:S
M5-C/&<*L\R#Y*=SC-U/[-PO[-]/[-]/[-Y/["_=/6;J?V<[=.LHW3WE^Z>\L
M?YG]A$].$\7&7*<@)6SNG6#YW3O*MU]Y;G=.\W4_LW4_LW4_LW$_L.-NG6;J
M?V<'=.\"/DB#DETFD,;#N\9NI_9OI_9OI_9OI_9OE_9NA_8\&G>XS=3^Q7=/
M>!;I[Q,W3UAP&DBY R7=7:=9NI_9NE_8ONWO,=;IWFZG]FZG]FZG]G+W;K"O
MB[G&*[M[PIK=N\"?3'019U@4?6@: '!R.47W3WF.MV[P'=/>;J?V;K?V;J?V
M8:W3O"BMT[S<3^Q;=/>;K?V-@=UKWI=CIG!3=3^SB[YWFZG]F>]T[S=3^S<S
M^P'=/>;I?V;J?V ;I[SMNYQB>Z>\!35"+6190EY";J?V;[?V7XW3O =P]YVG
M<XS=+^S->Z=YNI_99NGO =T]XKNGO %V(A+*2Z3HRIH[YOF53VLL2@2I9H&=
M90&+U1SL_.CKW.$<4QC=+6%HULOGP2/?+#RU1F^.YNCS:+LJHTM*:2EY3'M,
M.=C/#6;OY_%W;4HB:X- +5: RLI"7DJY# ET3)<-\XK-9&A:4Z -M= 0"-6\
M,  ; RO ;K$+5]&02@Y)E'%P<"@;#R74+,U6J)D*K!0"@12!$1$<B9\._@;*
M"CP=($7MB!?5B#--=2H?]!!0L$OFANS4<0X+X4D41! ")811J+2<&N9^!-!P
M"V+2#HZEI0M?30MH%C</4R@-6%C; &UASX::2TSQQ-+TSUPP [1@@18P5I)A
M(0%L$Z#B N,:7@!*9-1Q+$2!"AM(,#5P#QTM5$D-1&K"B@(.H6Z,-)" 2J%B
M5&BNSD"H.32(*1TH-(WA&F\5</N%SJ(<=&0ILZ+H^+-!XH$, "JJ  956@,J
M@92:7IPFZU%*16AH6+P#E:INK6C2MV@;2\]S40JC(%B11E2AQ9W](:L@'*[-
M//QR-0\U% ;4+28"['"&+,G@Z0:^G\^P$[U.P+7 +9"TNE+DB%:K4!5WXR@D
MH(HD2HPK+]IX"1EBP9Q"7ZB*K=>:(J9):&FJJ(Y1M:!D@U.4>HX"P4@Y$1$:
M1*2Q\'!C99$9)*E*P!S5K@&JU*Z9[!QK=@5%LV@H89@<]JT:6U@=:$L"4#.!
M26.$AI<&#"+FYZZ2Z&E 5%DNPJ#H"XT4N@Z'A.JZ@XY^.4YX](WPUB6[\*^S
M%CH6!FA<'U2""!.(? S0AT><+*)9HN !H4YQSJUH"EPT:;IM275D5EQ\'4O3
MQ"9KK.L;X:P4S9)H&Z]<Y@+4IR$0DIHPU,DOCRY8E/E<>HH*HLQ99ND$<CL]
M04AD4(C2(XE>+AF"\3?.T3:[PUIX,-% ;PD%I<%:&*:B\39J7<$FQ2<*@8L
M6B4JKAUJ01,-C3F%*K5MW/(J@5[(,4P+@34(S5C*0YHX JI0"/UO*8"BB\J+
M'-'.YCK. R7@*50*)<OP;F_^?QM,U+6E-!L\"#1CR,R_ J3@5F@LR^4.2V-P
MQUJZ4('EU7)/&D9FP2)F,8#5 JG9T0)=15UL]=IJ0#>@,5<(\O%$82I:H%H
MP7*OM%3PPK'AJ=XARRU>,KRKPJX!!%!1H )!WF6M$C3 7$;0F-TB, 511@]#
M4':8:=.640E8H4J"K.0P0L-*'IM3U+!:E*"T@<_"]'J?N>U2#GKX50F@-BP&
M9[5"4/<HZP2**68EV3+G**R&=6ME%>"8D4,Z4,:,%<$8"Z*5N C4PU5U2C"9
M,JW"K34%+\)#HN$T,XP44<8V+IXLT'B=1:HLSH^A/9S5A]@L2KC(A5Y J/\
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M']DKP&IQN*]YJ>'67*QB:QJ_/3O$%+CW.<2;,NAKSA>G7D'Z/ ('")4]L_;
MN9=8G*=YMUUEF[Q]M+XM<+C45L-WB[-%QE[W,6NK?GOY2FRS+>0<O<EVS*3M
M+^6_<<!"_!YPU/89]8_$^N9]8SZQ^(IQZ#\1_P QGU3'3*.S/I&<OT'XF/\
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MJ7Z>$53D)R/6GV?^033PFYWA7R)L8_V_\A_O>!V3U(L:]6<GPG>B=_ _MO\
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M%W=@VOK3@'K3[*?91)QZTP7[T^R9]M/MH<*+YS[J6:^M.9ZT^^GV43Q[T?\
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M17??J ?'\)N7PFY_"5;K]2W+W=)???R.YOY.Y[N4P]/K\0@%;U^)O_P@[O\
M?\11WWM-S^$W/X1T-]Y3<_A.1ONTW/X3<_A/H_A!B-=.//M-[^$WI^);??R;
MG\)N?PF3YOB/V7Q M]^I]'\)O/PFY_"7:[[M$!TCSYO2<STWXG(OW<IN?PF]
M_";W\)N?PFY/Q+;[^3E;[M-W^$W+X14, QF_<FMZOW#I'+*KWQ+V@:BBTQ%X
M0:AB:^%Q;AAN8+O,>%$QR\,3&B9F.4$-)KS\%Z)^Y<QRF.7@*&_!QF(HZR^'
M#PUQX"YCQ[)CE,=+F)CAXJ@G.+P91,3'ACE%N7BO''+P9*.LQ!#28\,<ICI+
M$F.4&M)K&J4F*.OACE,2B8BWK,=/"^$QRE\I2W;POA,>..4QTES$Q,2ZTG!V
M_M\+.4:?#$HE7IDG9,<H-3$]Y/</W$ 19?\ )DMY?6/!FOY,,LP&88>*TVAA
M&<>%8DE>HBCEAK!8&#0NM+XUQKOG;U^^RBH@.+\#G_D6V]GV/]V=8.8.-2HK
MKQ?YOK'9K78?O9,X-9KMP/??[@+ELLQWCKLB8+ %/^?]]M.LU=@UCO=MHP.#
MG.4-V_3Q:X/@Z36YWLHJ-8 'QT//?ZBVWLTI[3AL@6#'SKCWY=OWM:SM_;X]
M? %H,VQ##0WJ6+3??^[4>Z00;Y12VP]-_P"C,$+L3U@HV !W%F-[&!06P'3X
M 8!CB1$-90%<,UI?3IRZ2MKW6RU!J(\Z'#99[/\ NTX!UV@O$TKD?W9&F."Z
M-KWD==G0='$17JE.O#8-8_O_ #9&I?:71FOWV6 :Q58QM<7;:=AQV_T?V^)[
M^%U!0>&.[MP&SJF>3*9F4RI3PE,IE,IE,IF2KG*94;6Z93*F93*93*94+Y?]
ME,IE,IE2F5,RF4RI3+>B)QE,IY2F5*F93*93*9I7SC:RF5*93*E+,Z2F4\I3
M ;TAN=I3*94IE,MKPE,J5X5$:EE=X4E,I@+WE,IE,J4\I3*9H93*93*9GE*9
M3*93*93*85IZ?VRF5X4REB5*93*93*9[R*^IFWKKQ]Y?*>\OB#U9?+ZI?+ZF
M7R>J7R'O+Y/4R^3U2_\ 0R^0]67R'O+Y3WBM@7WE\AZL'D]3+Y?4R^0]67R>
MIE\I[R^0]Y?*>\OD/>7R>IE\GJBNH<V67RGO+Y27RDOE/5E\GJ9?)ZF7R>IE
M\I+Y?5+Y8OD]3+XCU,5"A58UE\GJ9?(>K%Y/4Q;:0/)ZI?\ H9]@R^7U,OE]
M4OD/5E\GJBM@7YR^3U,OE/5E\AZLOE/>7R>IE\L7R>IE\AZLOD/5E\I[R^7U
M,OD/5BTT,N;K+Y#U9?+ZF7R>J7R^IE\A[R^7U,O@/4R^3U,OD]4OD]4OD]3+
MHX*\XKX'F9?(>K+Y#WE\I[Q>(]3!X ]67RQ=]#WB\GJ8/+ZF+QGJ9?*>K!X2
MG=Y,O@/4P>3U,7EB^4E\OJ9?*>\'E]3+Y?4R^0]6#R>IE\OJ8O)ZF+A31C+I
MG_9?*>\OE]3+Y/5+Y?4R^0ONR^7U,OE]3+Y8OD]3+Y?4P>3U,=5#+&76?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
